<SEC-DOCUMENT>0001193125-21-227369.txt : 20210728
<SEC-HEADER>0001193125-21-227369.hdr.sgml : 20210728
<ACCEPTANCE-DATETIME>20210728160228
ACCESSION NUMBER:		0001193125-21-227369
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		29
FILED AS OF DATE:		20210728
DATE AS OF CHANGE:		20210728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Candel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001841387
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				522214851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257444
		FILM NUMBER:		211122525

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		617-916-5445

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Candel Therapeutics, Inic.
		DATE OF NAME CHANGE:	20210120
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d120909d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Filed pursuant to rule 424(b)(4) <BR> Registration No. 333-257444 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>9,000,000&nbsp;Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g66n88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>COMMON STOCK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are offering 9,000,000 shares of common stock in this
offering. This is our initial public offering of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our shares. The initial public
offering price is $8.00 per share. Our common stock has been approved for listing on The Nasdaq Global Market under the symbol &#147;CADL.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an
&#147;emerging growth company&#148; under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and for future filings. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#toc120909_50a">Risk Factors</A>&#148; beginning on page&nbsp;10 of this prospectus.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Neither the Securities and Exchange Commission nor any state securities commission approved or disapproved of the securities that may be offered under this
prospectus, nor have any of these organizations determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,040,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,960,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">We refer you to &#147;Underwriting&#148; beginning on page 184 for additional information regarding underwriting
compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Delivery of the shares of common stock will be made on or about July 29, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have granted the underwriters an option for a period of 30 days to purchase up to an additional 1,350,000 shares of our common stock. If the underwriters exercise
the option in full, the total underwriting discounts and commissions payable by us will be $5.8&nbsp;million, and the total proceeds to us, before expenses, will be $77.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Joint Book-Running Managers </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Credit&nbsp;Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>BMO&nbsp;Capital&nbsp;Markets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>UBS&nbsp;Investment&nbsp;Bank</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The date of this prospectus is July 26, 2021 </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_50a">RISK FACTORS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_10">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_12">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_13">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_15">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_16">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_18">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_19">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_20">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_21">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_22">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc120909_23">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through and including August 20, 2021 (25 days after the commencement of this offering), all dealers effecting
transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and
with respect to their unsold allotments or subscriptions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not, and the underwriters have not, authorized anyone to provide any information or to make any
representation other than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in
jurisdictions where it is lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or
any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For investors
outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the
United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus
outside the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The market data and certain other statistical information used throughout this prospectus are based on independent industry
publications, governmental publications, reports by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys, and studies generally indicate that their
information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this prospectus, and we believe that these
sources are reliable; however, we have not independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in
particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled &#147;Risk Factors&#148; and
elsewhere in this prospectus. Some data are also based on our good faith estimates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains forward-looking statements that are subject to a
number of risks and uncertainties, many of which are beyond our control. See &#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Trademarks and Trade Names </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We own or have rights to various trademarks,
service marks and trade names, including our company name, that we use in connection with the operation of our business. This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their
respective owners. Our use or display of third parties&#146; trademarks, service marks, trade names or products in this prospectus is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for
convenience, the trademarks, service marks and trade names referred to in this prospectus may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, TM or SM symbols, but the omission of such references is not intended to,
and should not be construed to, indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">ii </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your
investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes included elsewhere in this prospectus. You should also consider, among
other things, the matters described under &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case appearing elsewhere in this prospectus. Unless the context
otherwise requires, the terms &#147;Candel,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company,&#148; &#147;the Company,&#148; &#147;the Registrant&#148; and &#147;our business&#148; in this prospectus refer to Candel
Therapeutics, Inc. </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a late clinical stage
biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor
<FONT STYLE="white-space:nowrap">neo-antigens</FONT> and creating a <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> microenvironment at the site of injection. Our approach combines an <FONT STYLE="white-space:nowrap">in-depth</FONT>
knowledge of viral immunotherapy with extensive clinical experience across a wide range of indications. Based on the broad range of data that we have generated from our preclinical models and clinical trials using our approach, we have observed what
we believe to be systemic immune response against locally injected tumors and their distant metastases. We have established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV)
constructs. In our clinical results to date from <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> our lead product candidate from our adenovirus platform, and <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> our lead product candidate from our HSV
platform, we have observed that these candidates may have the potential to address significant unmet patient need and improve clinical outcomes in novel indications across broader patient populations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced product candidate, <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> is an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> adenovirus product candidate combined with the prodrug valacyclovir that has generated promising clinical activity across a range of solid tumor
indications, including our lead indication of prostate cancer. We are currently conducting, as part of our most advanced <FONT STYLE="white-space:nowrap">CAN-2409</FONT> program, a Phase 3 clinical trial in the United States under a Special Protocol
Assessment, or SPA, with the FDA for <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in combination with the prodrug valacyclovir in patients with newly diagnosed localized prostate cancer who have an intermediate or high-risk for progression. We
expect to complete enrollment for this trial in the third quarter of 2021 with a final data readout in 2024. We are also evaluating <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in newly diagnosed high-grade glioma. The FDA has granted CAN-2409
Fast Track designation for use in this setting in combination with standard of care surgery and chemoradiation. We intend to initiate a potential registrational Phase 3 trial in this indication in the first half of 2022. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we are advancing development of our HSV platform product candidates for different solid tumor indications. Our lead HSV product candidate, <FONT
STYLE="white-space:nowrap">CAN-3110,</FONT> is currently in an ongoing investigator-initiated Phase&nbsp;1 clinical trial in our initial target indication of recurrent high-grade glioma, and we expect to report additional biomarker results in the
fourth quarter of 2021. We are also designing novel candidates based on our HSV platform for the treatment of solid tumors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our oncolytic viral immunotherapy
approach utilizes intratumoral administration of genetically engineered viruses to selectively induce tumor cell death and elicit an innate and adaptive anti-tumor immune response. Local delivery enables us to achieve these effects while aiming to
minimize systemic toxicity. The immune cells induced by these viral immunotherapies are believed to target patients&#146; specific tumor antigens, potentially improving responses in immunologically &#147;hot&#148; tumors while at the same time
infiltrating the tumor microenvironment, transforming non-inflamed &#147;cold&#148; tumors with limited immune response into &#147;hot&#148; tumors. Data from our clinical studies in patients with cancer have shown increases in the expression of
immune checkpoints <FONT STYLE="white-space:nowrap">PD-1,</FONT> <FONT STYLE="white-space:nowrap">PD-L1</FONT> and <FONT STYLE="white-space:nowrap">CTLA-4</FONT> following treatment with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> supporting
the evaluation of combinations with immune checkpoint inhibitors (ICI) such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> that, typically, are only efficacious in patients with immunologically
&#147;hot&#148; tumors. While our product candidates are administered directly into the </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
tumor, we have observed systemic immune response in our preclinical studies and clinical trials that may indicate the potential of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT
STYLE="white-space:nowrap">CAN-3110</FONT> to induce systemic immune response against distal, uninjected tumors, also known as an &#147;abscopal&#148; effect. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
believe oncolytic viral immunotherapy is among the most promising cancer treatment modalities today. Treatment with oncolytic viral immunotherapy has already been clinically validated through talimogene laherparepvec (Imlygic, Amgen), the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> intratumoral oncolytic virus. Our goal is to further improve patient outcomes from oncolytic viral immunotherapies by selecting the optimal vector, specific transgenes and clinical indications for each
tumor type while optimizing product candidate attributes, such as high-titer formulation, intratumoral administration, and storage conditions that could potentially lower logistical barriers for patients and clinicians. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have an advanced pipeline comprised of six ongoing clinical trials based on our two lead product candidates. In addition, we own exclusive development and commercial
rights for our product candidates in major territories including the United States, Europe and Asia. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pipeline is set forth below: </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g15d66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Corporate History and Our Team </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the combination of our predecessor company, Advantagene, Inc. (Advantagene), with the HSV discovery platform assets acquired from Periphagen, Inc.
(Periphagen), a company focused on engineering HSV as a gene therapy vector, we formally changed our name to Candel Therapeutics, Inc. in December 2020. Advantagene was built on a strong scientific foundation and developed <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> over years of research and development. In December 2019, Advantagene acquired substantially all the assets of Periphagen and in September 2020, licensed <FONT STYLE="white-space:nowrap">CAN-3110</FONT>
from Mass General Brigham (formerly known as The Brigham and Women&#146;s Hospital). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded and are now led by a team of renowned drug developers,
oncolytic viral immunotherapy experts, oncologists, immunologists and biotech business leaders. We are backed by a group of leading institutional life science investors, including PBM Capital, Northpond Ventures and Sands Capital Ventures. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strengths </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe
our experience and capabilities in oncolytic viral immunotherapy will bring significant benefit to cancer patients who are underserved by the current standard of care, particularly in prostate and brain cancer. We believe our key strengths are: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Deep clinical and development experience in innovative oncolytic viral immunotherapy.</P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Two potentially registrational trials for our <FONT STYLE="white-space:nowrap">CAN-2409</FONT> programs in localized
prostate and high-grade glioma, indications with significant unmet need supported by encouraging Phase 1/2 data. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Two oncolytic viral immunotherapy platforms provide versatility and optionality to pursue a range of solid tumor
indications. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Attractive commercial profile and ownership of our programs. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Commercial scale manufacturing strategy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Strategy </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our goal is to develop
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> oncolytic viral immunotherapies to transform the lives of cancer patients. We plan to rapidly develop and commercialize our two lead product candidates, <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> for the treatment of a broad range of solid tumor indications, while continuing to build our pipeline through our discovery platform<I>. </I>Key
elements of our strategy include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Advance the late stage development of, and seek regulatory approval for, our lead product candidate, <FONT
STYLE="white-space:nowrap">CAN-2409,</FONT> in newly diagnosed, localized prostate cancer. </I> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Advance the development of, and seek regulatory approval for, <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in both
monotherapy and combination therapy for </I><I>high-grade glioma</I><I>. </I> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Advance the clinical development of <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> an oncolytic HSV with
tumor-specific enhanced replication potency. </I> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Expand the development of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in other solid tumor indications, including
non-small cell lung cancer (NSCLC) and pancreatic cancer. </I> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Leverage our HSV oncolytic viral immunotherapy platform to develop additional HSV product candidates. </I>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Complete our planned cGMP manufacturing facility. </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Develop strategic partnerships to maximize the value of our current and future product candidates.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from
product sales. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for
the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Even if we consummate this offering, we will need to raise substantial additional funding. If we are unable to raise
capital when needed, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our business is dependent on the success of our lead product candidate, <FONT STYLE="white-space:nowrap">CAN-2409,</FONT>
as well as <FONT STYLE="white-space:nowrap">CAN-3110</FONT> and any other product candidates that we advance into the clinic. All of our product candidates will require additional development before we may be able to seek regulatory approval for and
launch a product commercially. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our
product candidates, which would prevent or delay development, regulatory approval, and commercialization. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the
time and cost of product candidate development. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Negative developments in the field of immuno-oncology and virus-based therapies could damage public perception of any of
our product candidates and negatively affect our business. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or
prevent regulatory approval. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We face substantial competition, which may result in others discovering, developing or commercializing product candidates
before or more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Even if <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> <FONT STYLE="white-space:nowrap">CAN-3110</FONT> or any future
product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense and limit how we manufacture and market our products.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Achieving commercial scale for our manufacturing operations in our new facility or at third-party manufacturers may result
in further delays or expenses, and we may not experience the anticipated operating efficiencies. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If, in the future, we are unable to establish sales and marketing and patient support capabilities or enter into
agreements with third parties to sell and market our current or future product candidates, we may not be successful in commercializing our current or future product candidates if and when they are approved, and we may not be able to generate any
revenue. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which began in late 2019 and has spread worldwide may
affect our ability to complete our ongoing clinical trials and initiate and complete other preclinical studies, planned clinical trials or future clinical trials, disrupt regulatory activities, disrupt our manufacturing and supply chain or have
other adverse effects on our business and operations. In addition, this pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business,
operations and ability to raise capital. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have completed and may in the future complete related party transactions that were not and may not be conducted on an
arm&#146;s length basis. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our rights to develop and commercialize any product candidates are subject and may in the future be subject, in part, to
the terms and conditions of licenses granted to us by third parties. If we fail to comply with our obligations under our current or future intellectual property license agreements or otherwise experience disruptions to our business relationships
with our current or any future licensors, we could lose intellectual property rights that are important to our business. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate History and
Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were incorporated under the laws of the State of Delaware in June 2003. Our principal executive office is located at 117 Kendrick St, Suite 450,
Needham, Massachusetts 02494, and our telephone number is (617) <FONT STYLE="white-space:nowrap">916-5445.</FONT> Our website address is <I>www.</I><I>candeltx.com. </I>We do not incorporate the information on or accessible through our website into
this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an emerging growth
company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">being permitted to only disclose two years of audited financial statements in addition to any required unaudited interim
financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden
parachute arrangements not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may take advantage of these exemptions until the fifth anniversary of our initial public offering or such earlier time that we are no longer
an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;the last
day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the
last day of the fiscal year in which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, which means the market value of our common stock that is held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this
prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. We are in the process of evaluating the benefits of relying on other exemptions and
reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation, providing an auditor&#146;s attestation report on our system
of internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or
revised accounting standards at the same time that they become applicable to other public emerging growth companies that have not elected to avail themselves of this exemption. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#145;&#145;smaller reporting company&#146;&#146; as defined in the Securities Exchange Act of 1934, or the Exchange Act. We may continue to be a smaller
reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $250&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenues are more
than $100&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $700&nbsp;million
measured on the last business day of our second fiscal quarter. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>9,000,000 shares (or 10,350,000 shares if the underwriters exercise their option to purchase additional shares in full) </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock to be outstanding immediately after this offering </P></TD>
<TD>27,798,454 shares (or 29,148,454 shares if the underwriters exercise their option to purchase additional shares in full) </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Underwriters&#146; option to purchase additional shares </P></TD>
<TD>We have granted the underwriters an option exercisable for 30 days after the date of this prospectus, to purchase up to 1,350,000 additional shares from us. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of Proceeds </P></TD>
<TD>We estimate that the net proceeds from the sale of shares of our common stock in this offering will be approximately $63.2&nbsp;million, or $73.2&nbsp;million if the underwriters exercise in full their option to purchase additional shares, based
on the initial public offering price of $8.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering, together with our existing cash
and cash equivalents, to fund patient enrollment for our Phase 3 clinical trial of CAN-2409 in high-grade glioma through the first quarter of 2023; the development, construction and qualification of our manufacturing facility and the development of
commercial manufacturing capabilities at third-party contract manufacturers through the first quarter of 2023; our Phase 3 clinical trial of CAN-2409 for newly diagnosed prostate cancer in patients who have an intermediate- or high-risk for
progression; the development of CAN-2409 and CAN-3110 in other clinical trials currently in process or contemplated; the remaining proceeds for general corporate purposes, which may include the continued expansion of our HSV platform technology,
hiring of additional personnel and consultants, capital expenditures and the costs of operating as a public company. See &#147;Use of Proceeds&#148; for additional information. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk Factors </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Directed Share Program </P></TD>
<TD>At our request, the underwriters have reserved up to 5% of the shares offered by this prospectus for sale at the initial public offering price in a directed share program for our directors, officers, employees and related persons. The number of
shares of common stock available for sale to the general public in the offering will be reduced to the extent these persons purchase the directed shares in the program. Any directed shares not so purchased will be offered by the underwriters to the
general public on the same terms as the other shares. Directed shares purchased in the program will not be subject to a lock-up restriction, with the exception of directed shares purchased by our directors and officers, which will be subject to a
180-day lock-up restriction. See &#147;Underwriting&#148; for additional information. </TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Nasdaq Global Market symbol </P></TD>
<TD>&#147;CADL&#148; </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on 18,798,454 shares of our common stock
outstanding as of June 30, 2021 after giving effect to the conversion of our preferred stock into 7,066,565 shares of common stock immediately prior to completion of this offering and excludes: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,079,006 shares of common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2021 under
our 2015 Stock Plan, or the 2015 Plan, at a weighted average exercise price of $1.60 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">78,307 shares of common stock reserved and available for future issuance under the 2015 Plan, as of March&nbsp;31, 2021,
which will cease to be available for issuance at the time that our 2021 Stock Option and Incentive Plan, or the 2021 Plan, becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">7,524,262 shares of common stock reserved and available for future issuance upon exercise of the outstanding warrants, as
of June 30, 2021, at a weighted average exercise price of $6.69 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">2,054,000 shares of our common stock that will become available for future issuance under the 2021 Plan, which will become
effective in connection with the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">293,000 shares of common stock that will become available for future issuance under our 2021 Employee Stock Purchase Plan,
or ESPP, which will become effective in connection with the completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise indicated, all information in this
prospectus assumes or gives effect to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 7,066,565
shares of our common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no exercise of the outstanding warrants described above; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no exercise by the underwriters of their option to purchase up to an additional 1,350,000 shares of our common stock in
this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-2.4579</FONT></FONT> reverse split of our
common stock and a proportionate adjustment in the ratio at which our preferred stock is convertible into our common stock, which will become effective prior to the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws,
which will occur immediately prior to the completion of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should read the following summary consolidated financial data together with our consolidated financial statements and the related notes appearing at the end of
this prospectus and the &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. We have derived the statement of
operations data for the years ended December&nbsp;31, 2019 and 2020 and the consolidated balance sheet data as of December&nbsp;31, 2020 from our audited consolidated financial statements appearing elsewhere in this prospectus. The summary unaudited
condensed consolidated statement of operations data for the three months ended March 31, 2020 and 2021 and the summary unaudited condensed consolidated balance sheet data as of March 31, 2021 have been derived from our unaudited condensed
consolidated financial statements included elsewhere in this prospectus, which have been prepared on the same basis as the audited financial statements. Our historical results are not necessarily indicative of results that should be expected in any
future period. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED<BR>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Research and development service revenue, related party</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>125</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Research and development</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B></B>6,607</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>General and administrative </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>2,555</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>9,162</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B></B>13,935</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(9,037</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B></B>(13,810</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Grant income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Interest, dividend and investment income (expense), net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,070</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Change in fair value of warrant liability</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss and new loss attributable to common stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(8,240</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss per share attributable to common stockholders, basic and diluted (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Weighted-average shares of common stock outstanding, basic and diluted (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>11,533,718</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,615,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,614,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,647,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Pro forma net loss per share attributable to common stockholders, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>$</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(0.95</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Pro forma weighted-average shares of common stock outstanding, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,681,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,714,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">See Note 16 to our audited consolidated financial statements appearing elsewhere in this prospectus for details on the
calculation of basic and diluted net loss per share attributable to common stockholders. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;MARCH&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>(IN&nbsp;THOUSANDS)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA<BR>AS&nbsp;ADJUSTED&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>29,152</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>29,152</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>92,484</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Working capital&nbsp;(3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>23,973</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,094<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,531<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,766<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Convertible preferred stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,060<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Accumulated deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,649<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,649<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,649<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total stockholders&#146; (deficit) equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,563<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">The pro forma consolidated balance sheet data gives effect to the automatic conversion of our convertible preferred
stock into an aggregate of 7,066,565 shares of common stock upon the closing of this offering and assumes no exercise of any of our warrants outstanding upon the closing of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">The pro forma as adjusted consolidated balance sheet data gives effect to (i)&nbsp;the pro forma adjustments set forth
in footnote (1)&nbsp;above and (ii)&nbsp;to our issuance and sale of 9,000,000 shares of our common stock in this offering at the initial public offering price of $8.00 per share, after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_50a"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this
prospectus, including our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; before deciding whether to invest in our common stock. The
occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or
part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business, Financial Position and Capital Requirements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from product sales. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We were incorporated under the laws of the State of
Delaware in June 2003. Since inception, we have focused substantially all of our efforts and financial resources on raising capital and developing our initial product candidates. To date, we have financed our operations primarily through the
issuance and sale of our convertible preferred stock to outside investors in private equity financings. From our inception through June 30, 2021, we raised an aggregate of $66.1 million of gross proceeds from such transactions. As of March&nbsp;31,
2021, our cash and cash equivalents and investments were $29.2 million. We have incurred net losses in each year since our inception, and we had an accumulated deficit of $48.6 million as of March&nbsp;31, 2021. For the three months ended
March&nbsp;31, 2021 and for the years ended December&nbsp;31, 2020 and December&nbsp;31, 2019, we reported net losses of $4.5&nbsp;million, $17.7&nbsp;million and $8.2 million, respectively. We have no products approved for commercial sale and
therefore have never generated any revenue from product sales, and we do not expect to do so in the foreseeable future. We have not obtained regulatory approvals for any of our product candidates, and even if our clinical development efforts result
in positive data, our product candidates may not receive regulatory approval or be successfully introduced and marketed at prices that would permit us to operate profitably. We expect to continue to incur significant expenses and operating losses
over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#146; deficit and working capital. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs and from general and administrative
costs associated with our operations. We expect our research and development expenses to significantly increase in connection with the commencement and continuation of clinical trials of our product candidates. In addition, if we obtain marketing
approval for our product candidates, we will incur significant sales, marketing and manufacturing expenses. Once we are a public company, we will incur additional costs associated with operating as a public company. As a result, we expect to
continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or
when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amount of our future losses is uncertain, and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or
securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may
be difficult to predict, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any
other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to successfully enroll and retain subjects for clinical trials, and any delays caused by difficulties in such
efforts; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain marketing approval for our product candidates, and the timing and scope of any such approvals we may
receive; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the changing and volatile U.S. and global economic environments, including as a result of the COVID-19 pandemic;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and cost of, and level of investment in, research and development activities relating to our product
candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of manufacturing our product candidates, which may vary depending on the quantity of production, and the success
of achieving commercial scale manufacturing operations in our new facility or at third-party manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to attract, hire and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expenditures that we will or may incur to develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of demand for our product candidates should they receive approval, which may vary significantly;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and
existing and potential future therapeutics that compete with our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">future accounting pronouncements or changes in our accounting policies. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing
our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or
operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common
stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We
have no products approved for commercial sale and have not generated any revenue from product sales. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to become profitable depends upon our
ability to generate revenue. To date, we have not generated any revenue from our product candidates, and we do not expect to generate any revenue from the sale of products in the near future. We do not expect to generate significant revenue unless
and until we obtain marketing approval of, and begin to sell, one or more of our product candidates. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successfully complete our ongoing and planned preclinical studies and clinical trials for our oncolytic viral
immunotherapy programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">timely file and receive acceptance of our Investigational New Drug applications, or INDs, in order to commence our planned
clinical trials or future clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successfully enroll subjects in, and complete, clinical trials for our oncolytic viral immunology programs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">implement measures to help minimize the risk of COVID-19 to our employees as well as patients enrolled in our trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">timely file NDAs and receive regulatory approvals for our product candidates from the FDA and comparable foreign
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate and successfully complete all safety studies required to obtain U.S. and foreign marketing approval for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish commercial manufacturing capabilities through build out and qualification of our planned facility or make
arrangements with third-party manufacturers for clinical supply and commercial manufacturing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">launch commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintain a continued acceptable safety profile of the product candidates following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain and maintain acceptance of the product candidates, if and when approved, by patients, the medical community and
third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">position our products to effectively compete with other therapies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain and maintain favorable coverage and adequate reimbursement by third-party payors for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enforce and defend intellectual property rights and claims with respect to our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hire additional staff, including clinical, scientific and management personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our
product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we consummate this offering, we will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be forced to
delay, reduce or eliminate some of our product development programs or commercialization efforts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The development of pharmaceutical products is
capital-intensive. We are currently advancing our product candidates through clinical development across a number of potential indications. We are currently conducting a Phase 3 clinical trial for CAN-2409 in newly diagnosed localized prostate
cancer in intermediate and high-risk patients for which we expect to complete enrollment in the third quarter of 2021 and receive final data readout in 2024. Our second program using the candidate CAN-2409 is for the treatment of a type of brain
cancer called high grade glioma. We intend to initiate a potential registrational Phase 3 trial in this indication in the first half of 2022. Consequently, we expect our expenses to significantly increase in connection with our ongoing activities,
particularly as we continue our ongoing clinical trials or initiate future trials and pursue the research and development of, and seek marketing approval for, our product candidates. In addition, depending on the status of regulatory approval or, if
we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We may also need to raise additional funds sooner if we
choose to pursue additional indications and/or geographies for our product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with
operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce
or eliminate certain of our research and development programs or future commercialization efforts, and may be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our
business, financial condition and results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that the net proceeds from this offering, together with our existing cash and cash equivalents
and investments will be sufficient to fund our operations through the first quarter of 2023. However, our future capital requirements will depend on and could increase significantly as a result of many factors, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope, progress, results and costs of product discovery, preclinical and clinical development, laboratory testing and
clinical trials for the development of CAN-2409, CAN-3110, or our other potential product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of, and the costs involved in, obtaining marketing approvals for&nbsp;CAN-2409 in newly diagnosed localized
prostate cancer and high grade glioma&nbsp;as well as for CAN-3110 in our initial target indication of recurrent high-grade glioma and our other potential product candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if approved, the costs of commercialization activities for&nbsp;CAN-2409 or CAN-3110&nbsp;for any approved indications or
any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of a collaborator that we may contract with in the future, including the costs and timing of establishing product sales, marketing,
distribution and manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential additional expenses attributable to adjusting our development plans (including any supply related matters)
to the COVID-19 pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope, prioritization and number of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to establish and maintain additional collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the achievement of milestones or occurrence of other developments that trigger payments under any additional collaboration
agreements we may enter into; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future
collaboration agreements, if any; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property
rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we acquire or in-license other product candidates and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of securing manufacturing arrangements for commercial production; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the emergence of competing oncolytic viral immunotherapies as well as immuno-oncology therapies in general and other
adverse market developments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of transitioning our manufacturing operations to our new facility; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market
our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ongoing impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Identifying potential product candidates and conducting preclinical development testing and clinical trials is a time-consuming, expensive and
uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial
success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our
business objectives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our product candidates. Disruptions in the financial markets in general, and more recently due to the COVID-19 pandemic, have made equity and debt financing more difficult to obtain, and may have a material adverse effect
on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the
rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities
would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt,
limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with
collaborators or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a
material adverse effect on our business, operating results and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to obtain funding on a timely basis, we may be required to significantly
curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could
materially affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Product Development </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business is dependent on the success of our lead product candidate,&nbsp;CAN-2409,&nbsp;as well as&nbsp;CAN-3110&nbsp;and any other product candidates that we
advance into the clinic. All of our product candidates will require additional development before we may be able to seek regulatory approval for and launch a product commercially. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We expect that a substantial portion of our
efforts and expenditures over the next several years will be devoted to our&nbsp;CAN-2409&nbsp;program, which is currently our lead product candidate. We are currently conducting, as part of our most advanced CAN-2409 program, a Phase 3 clinical
trial under an SPA for CAN-2409 in patients with newly diagnosed localized prostate cancer who have an intermediate or high-risk for progression. We expect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
complete enrollment for this trial in the third quarter of 2021 with a final data readout in 2024. We are also evaluating CAN-2409 in high-grade glioma and intend to initiate a potential
registrational Phase 3 trial in this indication in the first half of 2022. Additionally, we have an ongoing investigator-initiated Phase&nbsp;1 clinical trial for CAN-3110, our most advanced product candidate from our HSV platform, in our initial
target indication of recurrent high-grade glioma and expect to report additional biomarker results in the fourth quarter of 2021. If CAN-2409 encounters safety or efficacy issues, development delays, regulatory issues or other problems, our
development plans and business would be significantly harmed. We can provide no assurance that&nbsp;CAN-2409, CAN-3110 or any other product candidates we develop will receive regulatory approval or be successfully commercialized even if we receive
regulatory approval. If we were required to discontinue development of&nbsp;CAN-2409 or CAN-3110, or if CAN-2409 or CAN-3110 do not receive regulatory approval or fail to achieve significant market acceptance, we would be delayed by many years in
our ability to achieve profitability, if ever. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, even if we obtain regulatory approval for CAN-2409, CAN-3110 or any other product candidates we
develop,&nbsp;we will still need to develop a commercial infrastructure, build out our manufacturing capabilities or develop relationships with collaborators to commercialize, establish a commercially viable pricing structure and obtain coverage and
adequate reimbursement from third-party payors, including government healthcare programs. If we, or any future collaborators, are unable to successfully commercialize CAN-2409, CAN-3110 or any other product candidates we develop,&nbsp;we may not be
able to generate sufficient revenue to continue our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our preclinical studies and clinical trials may fail to demonstrate adequately the safety and
efficacy of any of our product candidates, which would prevent or delay development, regulatory approval, and commercialization. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining
regulatory approvals for the commercial sale of our product candidates, including&nbsp;CAN-2409, CAN-3110 or any other product candidates we develop, we must demonstrate the safety and efficacy of our product candidates for use in each target
indication through lengthy, complex, and expensive preclinical studies and clinical trials. Failure can occur at any time during the preclinical study and clinical trial processes and there is a high risk of failure, so we may never succeed in
developing marketable products. Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety and efficacy necessary to obtain regulatory approval to market any of our product candidates. If the results of our ongoing
or future preclinical studies and clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are
safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such product candidates. In some instances, there can be significant variability in safety or efficacy results between
different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and
adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. While we are currently in Phase&nbsp;3 clinical trials for CAN-2409 and are in early stages of clinical development for&nbsp;CAN-3110,&nbsp;it is
likely, as is the case with many oncology therapies, that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our trials could be
suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could
also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, our product candidates have caused undesirable side effects in clinical trials related to on-target toxicity such as fever, chills and muscle aches and other
flu-like symptoms that occurred across our trials. Patients recruited in our trials experienced the following grade&nbsp;3 and grade&nbsp;4 related side effects. In our prostate cancer Phase&nbsp;2 clinical trial, one patient presented a
grade&nbsp;3 genitourinary toxicity, and one patient presented with a transient grade&nbsp;3 ALT elevation without clinical significance. In our high-grade glioma Phase&nbsp;1b/2 clinical trial, patients experienced the following adverse events: one
patient presented with grade&nbsp;4 hemiparesis and grade&nbsp;3 worsening of speech impairment; one patient presented with grade&nbsp;3 insomnia; one patient experienced grade&nbsp;3 headache; one patient experienced grade&nbsp;3 wound
complications; one patient experienced grade&nbsp;4 motor-neuropathy symptoms/signs; seven patients experienced grade&nbsp;3 transient lymphopenia; and three patients experienced grade&nbsp;3 AST/ALT alterations. In our NSCLC Phase&nbsp;1 clinical
trial, two patients experienced grade&nbsp;3 dehydration with renal insufficiency, two patients presented grade&nbsp;3 urinary retention and six patients were observed to have a grade&nbsp;4 low lymphocyte count. In our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
pancreatic cancer Phase&nbsp;1 clinical trial, two patients displayed a grade&nbsp;3 worsening of abdominal pain and one patient presented grade&nbsp;3 dehydration with increased creatinine,
three patients experienced grade&nbsp;3 or 4 increased ALT/AST, three patients experienced grade&nbsp;3 or 4 increased bilirubin, three patients experienced grade&nbsp;3 or 4 increased lipase and two patients experienced grade&nbsp;3 or 4 low
lymphocyte count. If on-target toxicity is observed at unacceptable levels, or if our product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in
which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In addition, our product candidates could cause undesirable side effects that we have not observed yet to
date. Many compounds that initially showed promise in early stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound. In addition to our ongoing clinical trials of CAN-2409 and
CAN-3110, patients have been, and may continue to be, treated with CAN-2409 and/or CAN-3110 under an expanded access or &#147;compassionate use&#148; program. To the extent the experiences of patients being treated in this program are inconsistent
with or less favorable than the results of our ongoing or planned company-sponsored trials with CAN-2409 and/or CAN-3110, it may negatively affect perceptions of CAN-2409 and/or CAN-3110, our other product candidates, or our business. In addition,
the FDA or comparable foreign regulatory authorities may require us to obtain and submit additional clinical data due to these inconsistent or unfavorable results, which could delay clinical development or marketing approval of CAN-2409 and/or
CAN-3110 or potentially our other product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interim, top line and preliminary data from our clinical trials that we announce or publish from time
to time may change as more patient data become available and are subject to regulatory audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may publish interim, top line or preliminary data from our clinical trials. We may decide to conduct an interim analysis of the data after a
certain number or percentage of patients have been enrolled, or after only a part of the full follow-up period but before completion of the trial. Similarly, we may report top line or preliminary results of primary and key secondary endpoints before
the final trial results are completed. Preliminary, top line and interim data from our clinical trials may change as more patient data or analyses become available. Preliminary, top line or interim data from our clinical trials are not necessarily
predictive of final results and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available and we issue our final clinical trial report. These data also
remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary, interim and top line data should be viewed with caution
until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh
the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to
publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our
disclosure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the interim, topline, or preliminary data that we report differ from more complete results, or if others, including regulatory authorities, disagree
with the conclusions reached, our ability to obtain marketing authorization for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Results of earlier studies and trials of our product candidates may not be predictive of future trial results. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. Product candidates in later stages of clinical
trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. As we commence new clinical trials and continue our ongoing clinical trials, issues may arise that
could suspend or terminate such clinical trials. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies or clinical
trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we cannot be certain that we will not face
similar setbacks. In addition, the results of our preclinical animal studies, including our oncology mouse studies and animal studies, may not be predictive of the results of outcomes in human clinical trials. For example, our oncology product
candidates that are in preclinical development may demonstrate different chemical and biological properties in patients than they do in laboratory animal studies or may interact with human biological systems in unforeseen or harmful ways. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, some of past, ongoing and planned clinical trials utilize and &#147;open-label&#148; study design. An &#147;open-label&#148; clinical trial is one where
both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate
and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect, as patients in open-label clinical trials are aware when they are receiving treatment.
Open-label clinical trials may be subject to a &#147;patient bias&#148; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical
studies often include the most severe sufferers and their symptoms may have improved notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing
the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate
development and subsequently obtaining regulatory approval, if at all. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have concentrated all of our research and development efforts on our CAN-2409 and
CAN-3110 product candidates, and our future success depends on the successful development of these therapeutic approaches. In particular, CAN-2409 utilizes adenoviruses to activate the innate and adaptive immune system. To our knowledge, there are
no FDA-approved products for the treatment of cancer that utilize the adenovirus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect the novel nature of our product candidates to create further challenges
in obtaining regulatory approval. Few viral immunotherapies have been approved globally or by the FDA to date. While the first viral immunotherapy, talimogene laherparepvec (Imlygic, Amgen), has received FDA approval, regulatory agencies have
reviewed relatively few viral immunotherapy product candidates such as CAN-2409 and CAN-3110. This may lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates. Further,
any viral immunotherapies that are approved may be subject to extensive post-approval regulatory requirements, including requirements pertaining to manufacturing, distribution and promotion. We may need to devote significant time and resources to
compliance with these requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety
and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often
adheres to the Advisory Committee&#146;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our product candidates are live, gene-modified viruses for which the FDA, the EMA and other comparable foreign regulatory authorities and other public
health authorities, such as the Centers of Disease Control and Prevention and hospitals involved in clinical studies, have established additional safety and contagion rules and procedures, which could establish additional hurdles for the
development, manufacture or use of our vectors. These hurdles may lead to delays in the conduct of clinical trials or in obtaining regulatory approvals for further development, manufacturing or commercialization of our product candidates. We may
also experience delays in transferring our process to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, there has been limited historical clinical trial experience for the development of products that utilize the adenovirus. Moreover, the design and conduct
of our clinical trials differs from the design and conduct of previously conducted clinical trials in this area. In particular, regulatory authorities in the United States and in other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
jurisdictions, including Europe, have not issued definitive guidance as to how to measure and demonstrate efficacy in newly diagnosed localized prostate cancer in intermediate- to high-risk
patients in combination with the standard of care. As a result, there is substantial risk that the design or outcomes of our clinical trials will not be satisfactory to support marketing approval. For example, the endpoint in our Phase 3 clinical
trial with CAN-2409 is a disease-free survival (DFS) endpoint with final results expected 24 months after last patient treated, which has not been utilized in prior trials and may not be accepted by regulators as a basis for approval despite the
existence of the SPA. Even if this type of&nbsp;novel&nbsp;endpoint&nbsp;is accepted as a basis for approval in the United States, we cannot be certain that regulators outside of the United States will accept such endpoints or will not require us to
conduct additional validation studies to support the suitability of such endpoints for approval in these jurisdictions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are developing, and in the future
may develop, other product candidates, in combination with other therapies, which exposes us to additional risks related to any prodrugs or any agents used in combination with our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our CAN-2409 product candidate is being developed to be used in combination with the prodrug valacyclovir, which is a small molecule drug marketed for treatment of
genital herpes. In the future, we may develop other product candidates to be used with one or more currently approved other therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in
combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety,
efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in
combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the FDA or comparable foreign regulatory authorities revoke their approval of these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or
supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also
evaluate our future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market any product candidate
we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. In addition, unapproved therapies face the same risks described with respect to our product candidates currently in development and
clinical trials, including the potential for serious adverse effects, delays in their clinical trials and lack of FDA approval. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Negative developments in the
field of immuno-oncology and, in particular, oncolytic viral immunotherapy, could damage public perception of any of our product candidates and negatively affect our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The commercial success of adenovirus- or oHSV-based product candidates will depend in part on public acceptance of the use of immuno-oncology, and, in particular,
oncolytic viral immunotherapy. Adverse events in clinical trials of CAN-2409, CAN-3110 or any other adenovirus- or oHSV-based product candidates which we may develop, or in clinical trials of others developing similar products and the resulting
publicity, as well as any other negative developments in the field of immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for any adenovirus- or oHSV-based product
candidates that we may develop. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of oncolytic immunotherapies is
unsafe, whether related to our therapies or those of our competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our clinical
trials. In addition, responses by national or state governments to negative public perception may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory
approval or otherwise achieve profitability. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, prospects and results of operations and may delay
or impair the development and commercialization of our product candidates or demand for any products we may develop. As a result, we may not be able to continue or may be delayed in conducting our development programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates consist of modified viruses. Adverse developments in clinical trials of other immunotherapy
products based on viruses, like oncolytic viruses, may result in a disproportionately negative effect for our technologies as compared to other products in the field of infectious disease and immuno-oncology that are not based on viruses. Future
negative developments in the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could
delay or increase the costs of obtaining marketing approval for our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Difficulty in enrolling patients could delay or prevent clinical
trials of our product candidates, and ultimately delay or prevent regulatory approval. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Identifying and qualifying patients to participate in clinical
trials of our product candidates is critical to our success. The timing of completion of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing our product candidates, and we may experience delays
in our clinical trials if we encounter difficulties in enrollment. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in
these trials as required by the FDA or comparable foreign regulatory authorities, or as needed to provide appropriate statistical power for a given trial. In particular, because we are focused on patients with brain cancer for the development
of&nbsp;CAN-2409 and CAN-3110 our ability to enroll eligible patients may be limited or enrollment may be slower than we anticipate due to the small eligible patient population. In addition, our ability to enroll patients may be significantly
delayed by the evolving COVID-19 pandemic and we are unable to predict the full extent and scope of such delays at this point. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the potentially small
target populations for our planned clinical trials, particularly in brain cancer, the eligibility criteria will further limit the pool of available trial participants as we will require that patients have specific characteristics, such as a certain
severity or stage of disease progression, to include them in a trial. Additionally, the process of finding eligible patients may prove costly. We also may not be able to identify, recruit, and enroll a sufficient number of patients to complete our
clinical trials because of the perceived risks and benefits of the product candidate under evaluation, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective
patients, the availability of genetic sequencing information for patient tumors so that we can identify patients with the targeted genetic mutations, and the patient referral practices of physicians. If patients are unwilling to participate in our
studies for any reason, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of potential products may be delayed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
enrollment of patients further depends on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the proximity of patients to clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the design of the clinical trial, including the number of site visits and invasive assessments required;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reporting of the preliminary results of any of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion;
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">factors we may not be able to control, such as the COVID-19 pandemic that may limit patient participation, hiring of
principal investigators or staff or clinical site availability. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our clinical trials will compete with other clinical trials for
product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our clinical trials may
instead opt to enroll in a clinical trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our
competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because certain of our product candidates represent a departure from more commonly used methods for cancer
treatment and because certain of our product candidates have not been tested in humans before, potential </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in any future clinical trial of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will
be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive marketing approval for our current or future product candidates, our current or future product candidates may not achieve broad market
acceptance, which would limit the revenue that we generate from their sales. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The commercial success of our current or future product candidates, if
approved by the FDA or other applicable regulatory authorities, will depend upon the awareness and acceptance of our current or future product candidates among the medical community, including physicians, patients and healthcare payors. Market
acceptance of our current or future product candidates, if approved, will depend on a number of factors, including, among others: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efficacy of our current or future product candidates as demonstrated in clinical trials, and, if required by any
applicable regulatory authority in connection with the approval for the applicable indications, to provide patients with incremental health benefits, as compared with other available medicines; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limitations or warnings contained in the labeling approved for our current or future product candidates by the FDA or
other applicable regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prevalence and severity of adverse events associated with our product candidates or those products with which they may
be co-administered in immuno-oncology and, in particular, oncolytic viral immunotherapies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the clinical indications for which our current or future product candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">availability of alternative treatments already approved or expected to be commercially launched in the near future;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential and perceived advantages of our current or future product candidates over current treatment options or
alternative treatments, including future alternative treatments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the target patient populations to try new therapies or treatment methods and of physicians to prescribe
these therapies or methods in immuno-oncology and, in particular, oncolytic viral immunotherapies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the need to dose such product candidates in combination with other therapeutic agents, and related costs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the strength of marketing and distribution support and timing of market introduction of competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicity concerning our products or competing products and treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">pricing and cost effectiveness; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effectiveness of our sales and marketing strategies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to increase awareness of our current or future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain sufficient third-party coverage or reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability or willingness of patients to pay out-of-pocket in the absence of third-party coverage; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential product liability claims. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our current or future product candidates are approved but do not achieve an adequate level of acceptance by patients, physicians and payors, we may not generate
sufficient revenue from our current or future product candidates to become or remain profitable. Before granting reimbursement approval, healthcare payors may require us to demonstrate that our current or future product candidates, in addition to
treating these target indications, also provide incremental health benefits to patients. Our efforts to educate the medical community, patient organizations and third-party payors about the benefits of our current or future product candidates may
require significant resources and may never be successful. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face substantial competition, which may result in others discovering, developing or
commercializing product candidates before or more successfully than we do. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The development and commercialization of new product candidates is highly
competitive. We face competition from major pharmaceutical, specialty pharmaceutical and biotechnology companies among others with respect to CAN-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
2409 and CAN-3110 and will face similar competition with respect to any product candidates that we may seek to develop or commercialize in the future. We compete in pharmaceutical, biotechnology
and other related markets that develop immune-oncology therapies for the treatment of cancer. There are other companies working to develop viral immunotherapies for the treatment of cancer including divisions of large pharmaceutical and
biotechnology companies of various sizes. The large pharmaceutical and biotechnology companies that have commercialized and/or are developing immuno-oncology treatments for cancer include AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Merck,
Novartis, Pfizer and Roche/Genentech. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some of the products and therapies developed by our competitors are based on scientific approaches that are the same as or
similar to our approach, including with respect to the use of viral immunotherapy with adenovirus and HSV. Other competitive products and therapies are based on entirely different approaches. We are aware that Oncorus, Replimune, Amgen, Immavir,
Fergene and IconOVir, among others, are developing viral immunotherapies that may have utility for the treatment of indications that we are targeting. Potential competitors also include academic institutions, government agencies and other public and
private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of the companies we compete against or may compete against in the future have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in concentration of even
more resources among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also
compete with us in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and enrolling subjects for our clinical trials and in acquiring technologies complementary to, or necessary for, our
programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe side effects, or are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or foreign regulatory approval for their products more
rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all our product candidates, if
approved, are likely to be their efficacy, safety, convenience and price, if required, the level of biosimilar or generic competition and the availability of reimbursement from government and other third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Government Regulation and Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not
able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize&nbsp;CAN-2409, CAN-3110&nbsp;and future product candidates as expected, and our ability to generate revenue may be materially
impaired. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to
gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. These regulatory requirements may require us to amend our clinical trial protocols, including to comply with the
protocols of any applicable SPA we receive from the FDA; conduct additional preclinical studies or clinical trials that may require regulatory or independent institutional review board, or IRB, approval; or otherwise cause delays in obtaining
approval or rejection of an application. Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which may materially harm our business,
financial condition, results of operations, stock price and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may
decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing
approval of a product candidate. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also varies depending on the product candidate, the disease or condition that the product candidate is
designed to address, and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s
clinical development and may vary among jurisdictions, and there may be varying interpretations of data obtained from preclinical studies or clinical trials, any of which may cause delays or limitations in the approval or a decision not to approve
an application. It is possible that&nbsp;CAN-2409, CAN-3110 and future product candidates will never obtain the appropriate regulatory approvals necessary for us to commence product sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we experience delays in obtaining approval, if we fail to obtain regulatory approval of&nbsp;CAN-2409, CAN-3110&nbsp;or any future product candidate or if the label
for a product candidate does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, the commercial prospects for such product candidate may be harmed and our ability to generate
revenues from that product candidate may be materially impaired. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CAN-2409, CAN-3110 or future product candidates may cause undesirable side effects or have other
properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. Serious adverse events or undesirable side
effects caused by&nbsp;CAN-2409, CAN-3110 and future product candidates could cause us, IRBs, and other reviewing entities or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the
delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. For example, if concerns are raised regarding the safety of a new therapeutic as a result of undesirable side effects identified during clinical or
preclinical testing, the FDA or comparable foreign regulatory authority may order us to cease further development, decline to approve the product candidate or issue a letter requesting additional data or information prior to making a final decision
regarding whether or not to approve the product candidate. The FDA or comparable foreign regulatory authorities, or IRBs and other reviewing entities, may also require, or we may voluntarily develop, strategies for managing adverse events during
clinical development, which could include restrictions on our enrollment criteria, the use of stopping criteria, adjustments to a study&#146;s design, or the monitoring of safety data by a data monitoring committee, among other strategies. For
example, patients enrolled in our ongoing clinical trials of&nbsp;CAN-2409 and CAN-3110 have experienced mild to moderate adverse events, consisting mainly of&nbsp;flu-like&nbsp;symptoms and injection site reactions. In response to these adverse
events, we have implemented prophylactic measures, including intravenous fluids, antiemetics and antipyretics. The FDA&#146;s or a comparable foreign regulatory authority&#146;s requests for additional data or information could also result in
substantial delays in the approval of <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> CAN-3110 and future product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, clinical trials by their
nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of a product candidate may only be uncovered when a significantly larger number of patients
are exposed to the product candidate or when patients are exposed for a longer period of time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Undesirable side effects caused by&nbsp;CAN-2409, CAN-3110 or any
future product candidates could also result in denial of regulatory approval by the FDA or comparable foreign regulatory authorities for any or all targeted indications or the inclusion of unfavorable information in our product labeling, such as
limitations on the indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for
successful commercialization, or may result in requirements for costly post-marketing testing and surveillance, or other requirements, including REMS, to monitor the safety or efficacy of the products, and in turn prevent us from commercializing and
generating revenues from the sale of&nbsp;CAN-2409, CAN-3110 and future product candidates. Any such limitations or restrictions could similarly impact any supplemental marketing approvals we may obtain for&nbsp;CAN-2409 and
CAN-3110.&nbsp;Undesirable side effects may limit the potential market for any approved products or could result in restrictions on manufacturing processes, the discontinuation of the sales and marketing of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
product, or withdrawal of product approvals. We could also be sued and held liable for harm caused to patients, or become subject to fines, injunctions or the imposition of civil or criminal
penalties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If&nbsp;CAN-2409, CAN-3110 and future product candidates are associated with serious adverse events or undesirable side effects or have properties that
are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable
from a risk-benefit perspective. The therapeutic-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially
harm our business, financial condition, results of operations, stock price and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The FDA&#146;s agreement to a Special Protocol Assessment with
respect to the study design of our Phase 3 clinical trial of CAN-2409 in newly diagnosed localized prostate cancer in intermediate and high risk patients does not guarantee any particular outcome from regulatory review, including ultimate approval,
and may not lead to a successful review or approval process. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have obtained agreement from the FDA on the design and size of our Phase 3 clinical trial
of CAN-2409 in newly diagnosed localized prostate cancer in intermediate and high risk patients in combination with the standard of care through an SPA. The FDA&#146;s SPA process is designed to facilitate the FDA&#146;s review and approval of drugs
and biologics by allowing the FDA to evaluate the proposed design and size of certain clinical or animal studies, including clinical trials that are intended to form the primary basis for determining a product candidate&#146;s efficacy. Upon
specific request by a clinical trial sponsor, the FDA will evaluate the protocol and respond to a sponsor&#146;s questions regarding protocol design and scientific and regulatory requirements. The FDA aims to complete SPA reviews within 45 days of
receipt of the request. The FDA ultimately assesses whether specific elements of the protocol design of the trial, such as entry criteria, dose selection, endpoints and/or planned analyses, are acceptable to support regulatory approval of the
product with respect to the effectiveness of the indication studied. All exchanges between the FDA and the sponsor regarding an SPA must be clearly documented in an SPA letter or the minutes of a meeting between the sponsor and the FDA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although the FDA may agree to an SPA, an SPA agreement does not guarantee approval of a product. Even if the FDA agrees to the design, execution, and analysis proposed
in protocols reviewed under the SPA process, the FDA may revoke or alter its agreement in certain circumstances. In particular, an SPA agreement is not binding on the FDA if public health concerns emerge that were unrecognized at the time of the SPA
agreement, other new scientific concerns regarding product safety or efficacy arise, the sponsor company fails to comply with the agreed upon trial protocols, or the relevant data, assumptions or information provided by the sponsor in a request for
the SPA change or are found to be false or omit relevant facts. While we have obtained an SPA agreement for our Phase 3 clinical trial, we have subsequently made minor amendments to the protocol and have not obtained an SPA amendment in connection
with the amended protocol. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, even after an SPA agreement is finalized, the SPA agreement may be modified, and such modification will be deemed binding
on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol. Generally, such modification is intended to improve the study. The FDA retains significant latitude and
discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of the SPA agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, if the FDA
revokes or alters its agreement under the SPA, or interprets the data collected from the clinical trial differently than we do, the FDA may not deem the data sufficient to support an application for regulatory approval of CAN-2409 in prostate
cancer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have obtained orphan drug designation for CAN-2409 for use in combination with an anti-herpectic prodrug for treatment of malignant brain tumors;
however, we may be unable to maintain this designation or obtain orphan drug designation for our other product candidates, and we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product
candidates, if approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of our business strategy, we sought and have received orphan drug designation for CAN-2409 for use in combination with an
anti-herpectic prodrug for treatment of malignant brain tumors; however, we may not be able to maintain this status. We may also seek additional orphan drug designations for CAN-2409 and for certain of our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
future product candidates, and we may be unsuccessful in obtaining such designations.&nbsp;Regulatory authorities in some jurisdictions, including the United States and other major markets, may
designate drugs and biologics intended to treat conditions or diseases affecting relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is intended
to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no
reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax
advantages and&nbsp;user-fee&nbsp;waivers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, in Europe, the European Commission grants orphan drug designation after receiving the opinion of the EMA
Committee for Orphan Medicinal Products on an orphan drug designation application. Orphan drug designation is intended to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or
chronically debilitating conditions affecting not more than 5 in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those
affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of
the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for
designated orphan medicines, and potential fee reductions depending on the status of the sponsor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, if a product candidate with an orphan drug designation
receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or EMA from approving another marketing application for a product that
constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be
reduced to six years if a drug or biologic no longer meets the criteria for orphan drug designation or if the drug or biologic is sufficiently profitable such that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if
any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even though we have obtained orphan drug designation for CAN-2409 for use in combination with an anti-herpectic prodrug for treatment of malignant brain tumors, and
even if we are able to obtain orphan drug exclusivity for a future product candidate, that exclusivity may not effectively protect the relevant product candidate from competition because different therapies can be approved for the same condition and
the same therapies can be approved for different conditions but used&nbsp;off-label&nbsp;for the orphan disease. Even after an orphan drug is approved, the FDA may subsequently approve another product for the same condition if the FDA concludes that
the latter product is not the same product or is clinically superior to the protected orphan drug because it is shown to be safer or more effective, or makes a major contribution to patient care. In addition, a designated orphan drug may not receive
orphan drug exclusivity if it is approved for a use that is broader than the orphan indication for which it was designated. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development
time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we have obtained orphan drug designation for CAN-2409 for use in combination with an anti-herpectic prodrug for treatment
of malignant brain tumors, we may not be able to maintain such designation; and while we may seek orphan drug designation for applicable indications for any future product candidates, we may never receive such designations. Even though we have
received such designation for CAN-2409, and may receive further such designations in the future, there is no guarantee that we will enjoy the benefits of those designations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A Fast Track designation by the FDA, even though granted for&nbsp;CAN-2409,&nbsp;or if received for any other future
product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs
for this condition, the product sponsor may apply for FDA Fast Track designation for a particular indication. We have been granted Fast Track designation for&nbsp;the use of CAN-2409 for the treatment of localized, primary prostate cancer in
combination with radiation therapy to improve the local control rate, as well as for CAN-2409 in combination with standard of care surgery and chemoradiation to improve survival in adults with newly diagnosed high grade glioma decrease recurrence
and improve disease-free survival and may seek Fast Track designation for CAN-3110 or certain of our future product candidates. However, there is no assurance that the FDA will grant this status to CAN-3110 or any of our proposed product candidates.
Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate
marketing approval by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to
grant it. Even though we have received Fast Track designation for CAN-2409 or if we do receive Fast Track designation for CAN-3110 or any other of our future product candidates, we may not experience a faster development process, review or approval
compared to conventional FDA procedures, and receiving a Fast Track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported
by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A Breakthrough Therapy designation
by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may seek Breakthrough Therapy designation for&nbsp;some or all of our future product candidates. A Breakthrough Therapy is defined as a drug or biologic
that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints. Sponsors of product candidates that have been designated as Breakthrough Therapies are eligible to receive more intensive FDA guidance on developing an efficient
drug development program, an organizational commitment involving senior managers, and eligibility for rolling review and priority review. Drugs and biologics designated as Breakthrough Therapies by the FDA may also be eligible for other expedited
approval programs, including accelerated approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one
of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate
may not result in a faster development process, review or approval compared to product candidates developed and considered for approval that have not received Breakthrough Designation and does not assure ultimate approval by the FDA. In addition,
even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we may seek Breakthrough Therapy designation for CAN-2409,
CAN-3110 or some or all of our future product candidates for the treatment of various cancers, there can be no assurance that we will receive breakthrough therapy designation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accelerated approval by the FDA, even if granted for certain of our current or future product candidates, may not lead to a faster development or regulatory
review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may seek approval of
certain of our current or future product candidates using the FDA&#146;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage
over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA may require that a sponsor of a product receiving accelerated approval perform
adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence by the sponsor. In addition, the FDA currently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive
accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate full FDA approval. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if our development efforts are successful, we may not obtain regulatory approval of&nbsp;CAN-2409, CAN-3110&nbsp;or any future product candidates in the
United States or other jurisdictions, which would prevent us from commercializing&nbsp;CAN-2409, CAN-3110&nbsp;and future product candidates. Even if we obtain regulatory approval for&nbsp;CAN-2409, CAN-3110&nbsp;and future product candidates, any
such approval may be subject to limitations, including with respect to the approved indications or patient populations, which could impair our ability to successfully commercialize&nbsp;CAN-2409, CAN-3110&nbsp;or any future product candidates.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are not permitted to market or promote or sell&nbsp;CAN-2409, CAN-3110&nbsp;or any future product candidates before we receive regulatory approval from
the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory
authorities for each therapeutic indication to establish the product candidate&#146;s safety and efficacy for that indication. Securing marketing approval also requires the submission of information about the product manufacturing process to, and
inspection of manufacturing facilities and clinical trial sites by, the regulatory authorities. If we do not receive approval from the FDA and comparable foreign regulatory authorities for any of&nbsp;CAN-2409, CAN-3110&nbsp;and future product
candidates, we will not be able to commercialize such product candidates in the United States or in other jurisdictions. If significant delays in obtaining approval for and commercializing&nbsp;CAN-2409, CAN-3110&nbsp;and future product candidates
occur in any jurisdictions, our business, financial condition, results of operations, stock price and prospects will be materially harmed. Even if&nbsp;CAN-2409, CAN-3110&nbsp;and future product candidates are approved, they may: </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">be subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution
restrictions, or other conditions of approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not be approved with label statements necessary or desirable for successful commercialization; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">contain requirements for costly post-market testing and surveillance, or other requirements, including the submission of a
Risk Evaluation and Mitigation Strategy, or REMS, to monitor the safety or efficacy of the products. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not previously submitted a Biologics
License Application, or BLA, to the FDA, or a similar marketing application to comparable foreign regulatory authorities, for&nbsp;CAN-2409, CAN-3110&nbsp;or any product candidate, and we can provide no assurance that we will ultimately be
successful in obtaining regulatory approval for claims that are necessary or desirable for successful marketing, if at all. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in product candidate
manufacturing or formulation may result in additional costs or delay. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As product candidates are developed through preclinical studies to later-stage
clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Any of
these changes could cause&nbsp;CAN-2409, CAN-3110&nbsp;or any future product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Changes in
third-party manufacturers and manufacturing processes may also require additional testing, or notification to, or approval by the FDA or a comparable foreign regulatory authority. Such changes could be further delayed due to development of
commercial scale manufacturing operations in our new facility or at third-party manufacturers. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical
trials, increase clinical trial costs, delay approval of&nbsp;CAN-2409, CAN-3110 and future product candidates and jeopardize our ability to commence product sales and generate revenue. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent
new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our
business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to
the political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disruptions at the FDA and other agencies may also slow the time necessary for new product
candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as
the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our
regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue
our operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Separately, in response to the&nbsp;COVID-19&nbsp;pandemic, on March&nbsp;10, 2020 the FDA announced its intention to postpone most inspections of
foreign manufacturing facilities and products while local, national and international conditions warrant. On March&nbsp;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing
facilities and provided guidance regarding the conduct of clinical trials,&nbsp;which the FDA continues to update. As of June&nbsp;23, 2020, the FDA noted it was continuing to ensure timely reviews of applications for medical products during
the&nbsp;COVID-19&nbsp;pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. On July 16, 2020, the FDA noted
that it is continuing to expedite oncology product development with its staff teleworking full-time. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or
an inspection of clinical sites is required, inparticular due to the COVID-19 pandemic and related travel restrictions. As of July 2020, utilizing a rating system to assist in determining when and where it is safest to conduct such inspections based
on data about the virus&#146; trajectory in a given state and locality and the rules and guidelines that are put in place by state and local governments, the FDA is either continuing to, on a&nbsp;case-by-case&nbsp;basis, conduct only mission
critical inspections, or, where possible to do so safely, resuming prioritized domestic inspections, which generally include pre-approval&nbsp;inspections. Foreign&nbsp;pre-approval&nbsp;inspections that are not deemed mission-critical remain
postponed, while those deemed mission-critical will be considered for inspection on a&nbsp;case-by-case basis. The FDA will use similar data to inform resumption of prioritized operations abroad as it becomes feasible and advisable to do so. The FDA
may not be able to maintain this pace and delays or setbacks are possible in the future. Should the FDA determine that an inspection is necessary for approval, and an inspection cannot be completed during the review cycle due to restrictions on
travel, the FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, the FDA may defer action on the application until an
inspection can be completed. In 2020, several companies announced receipt of complete response letters due to the FDA&#146;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar
restrictions or other policy measures in response to the&nbsp;COVID-19&nbsp;pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability
of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact
our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even
if&nbsp;CAN-2409, CAN-3110&nbsp;or any future product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense and limit how we manufacture
and market our products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any product candidate for which we may obtain marketing approval will be subject to extensive and ongoing requirements of and
review by the FDA and comparable foreign regulatory authorities, including requirements related to the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export,
import, advertising, marketing, and promotional activities for such product. These requirements further include submissions of safety and other post-marketing information, including manufacturing deviations and reports, registration and listing
requirements, the payment of annual fees, continued compliance with current good manufacturing practice, or cGMP, requirements relating to manufacturing, quality </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
control, quality assurance, and corresponding maintenance of records and documents, and good clinical practices, or GCPs, for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. If the FDA or comparable
foreign regulatory authorities become aware of new safety information after approval of any of&nbsp;CAN-2409, CAN-3110 and future product candidates, they may withdraw approval, issue public safety alerts, require labeling changes or establishment
of a REMS or similar strategy, impose significant restrictions on a product&#146;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Any such restrictions could
limit sales of the product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and any of our suppliers or collaborators, including our contract manufacturers, could be subject to periodic unannounced
inspections by the FDA to monitor and ensure compliance with cGMPs and other FDA regulatory requirements. Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA&nbsp;pre-approval&nbsp;for product and
manufacturing changes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, later discovery of previously unknown adverse events or that the product is less effective than previously thought or other
problems with any products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements both before and after approval, may yield various negative results, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on manufacturing, distribution, or marketing of such products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the labeling, including required additional warnings, such as boxed warnings, contraindications,
precautions, and restrictions on the approved indication or use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring
remediation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">modifications to promotional pieces; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issuance of corrective information; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to conduct post-marketing studies or other clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinical holds or termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to establish or modify a REMS or similar strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes to the way the product is administered to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">liability for harm caused to patients or subjects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reputational harm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the product becoming less competitive; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">warning or untitled letters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspension of marketing or withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications
containing warnings or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal to approve pending applications or supplements to approved applications that we submit; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recalls of products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government
contracts, exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil, criminal or administrative penalties, including imprisonment.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these events could prevent us from achieving or maintaining market acceptance of any particular product or could substantially increase
the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues from its marketing and sale. Any of these events could further have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
other material and adverse effects on our operations and business and could adversely impact our business, financial condition, results of operations, stock price and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, the FDA&#146;s policies or those of comparable foreign regulatory authorities may change and could impose extensive and ongoing regulatory requirements and
obligations on any product candidate for which we obtain marketing approval. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval that we may have obtained and be subject to regulatory enforcement action, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulatory approval by the FDA or comparable foreign regulatory authorities is limited to those specific indications and conditions for which approval has been
granted, and we may be subject to substantial fines, criminal penalties, injunctions or other enforcement actions if we are determined to be promoting the use of our products for unapproved or&nbsp;&#147;off-label&#148;&nbsp;uses, or in a manner
inconsistent with the approved labeling, resulting in damage to our reputation and business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We must comply with requirements concerning advertising and
promotion for any product candidates for which we obtain marketing approval. Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of
Justice, Department of Health and Human Services&#146; Office of Inspector General, state attorneys general, members of Congress and the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product
candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved. If we are not able to obtain FDA approval for desired uses or indications for&nbsp;CAN-2409, CAN-3110 and future product
candidates, we may not market or promote them for those indications and uses, referred to as&nbsp;off-label&nbsp;uses, and our business, financial condition, results of operations, stock price and prospects will be materially harmed. We also must
sufficiently substantiate any claims that we make for any products, including claims comparing those products to other companies&#146; products, and must abide by the FDA&#146;s strict requirements regarding the content of promotion and advertising.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Physicians may choose to prescribe products for uses that are not described in the product&#146;s labeling and for uses that differ from those tested in clinical
trials and approved by the regulatory authorities. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory authorities do,
however, restrict communications by biopharmaceutical companies concerning&nbsp;off-label&nbsp;use. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are found to have impermissibly promoted any
of&nbsp;CAN-2409, CAN-3110 and future product candidates, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those
prohibiting the promotion of&nbsp;off-label&nbsp;uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for
alleged improper promotion and has enjoined several companies from engaging in&nbsp;off-label&nbsp;promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is
changed or curtailed. In the United States, engaging in the impermissible promotion of any products, following approval, for&nbsp;off-label&nbsp;uses can also subject us to false claims and other litigation under federal and state statutes. These
include fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and
conduct our business. These restrictions could include corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and suspension and debarment from government contracts and refusal of orders
under existing government contracts. These False Claims Act lawsuits against manufacturers of drugs and biologics have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements pertaining to certain
sales practices and promoting&nbsp;off-label&nbsp;uses. In addition, False Claims Act lawsuits may expose manufacturers to&nbsp;follow-on&nbsp;claims by private payers based on fraudulent marketing practices. This growth in litigation has increased
the risk that a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded
from Medicare, Medicaid, or other federal and state healthcare programs. If we do not lawfully promote our approved products, if any, we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of
operations, stock price and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the promotion of biopharmaceutical products is subject to additional FDA requirements and restrictions
on promotional statements. If, after&nbsp;CAN-2409, CAN-3110 or any future product candidates obtains marketing approval, the FDA determines that our promotional activities violate its regulations and policies pertaining to product promotion, it
could request that we modify our promotional materials or subject us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for
recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement actions. Similarly, industry codes in foreign jurisdictions may prohibit companies from engaging
in certain promotional activities, and regulatory agencies in various countries may enforce violations of such codes with civil penalties. If we become subject to regulatory and enforcement actions, our business, financial condition, results of
operations, stock price and prospects will be materially harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to file INDs or IND amendments to commence additional clinical trials on
the timelines we expect, and even if we are able to, the FDA or a comparable foreign regulatory may not permit us to proceed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA or comparable foreign
regulatory authorities may require us to file separate INDs for additional clinical trials we plan to conduct with our current lead product candidates, CAN-2409 and CAN-3110. We may not be able to file any additional INDs required for our current
product candidates and any future product candidates on the timelines we expect. For example, we may experience manufacturing delays or other delays with IND-enabling studies, including due to the impact of the COVID-19 pandemic on suppliers, study
sites or third-party contractors and vendors on whom we depend. We may also experience delays if we are unable to access earlier data from inactive or withdrawn INDs. Moreover, we cannot be sure that submission of an IND will result in the FDA or
comparable foreign regulatory authorities allowing further clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and
implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to
existing INDs or to a new IND. Any failure to file INDs on the expected timelines to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all. There
are similar risks related to the review and authorization of our protocols and amendments by comparable foreign regulatory authorities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If approved, our
investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Patient
Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an
abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with an&nbsp;FDA-licensed&nbsp;reference biologic product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until
four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first
licensed. During this&nbsp;12-year&nbsp;period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#146;s own preclinical data and
data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#146;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact,
implementation and meaning are subject to uncertainty. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for
the&nbsp;12-year&nbsp;period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for
competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation.
Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
a way that is similar to traditional generic substitution for&nbsp;non-biologic&nbsp;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still
developing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such
biosimilars, with the attendant competitive pressure and consequences. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The size of the potential market for our product candidates is difficult to estimate
and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our current and future
target patient populations are based on our beliefs and estimates regarding the incidence or prevalence of certain types of the indications that may be addressable by our product candidates, which is derived from a variety of sources, including
scientific literature and surveys of clinics. Our projections may prove to be incorrect and the number of potential patients may turn out to be lower than expected. The total addressable market opportunity for our product candidates will ultimately
depend upon a number of factors including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access, the success of competing therapies and
product pricing and reimbursement. Further, the market opportunity for viral immunotherapies is hard to estimate given that it is an emerging field with few globally or FDA-approved therapies, none of which have yet to enjoy broad market acceptance.
Even if we obtain significant market share for our product candidates, because the potential target populations could be small, we may never achieve profitability without obtaining regulatory approval for additional indications. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare reform measures may have a material adverse effect on our business and results of operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay
marketing approval of our current or future product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in
regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&nbsp;changes to our manufacturing arrangements, (ii)&nbsp;additions or modifications to product labeling,
(iii)&nbsp;the recall or discontinuation of our products or (iv)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. More recently, however, on January 28,
2021, President Biden issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#146; access to healthcare and to consider actions that will protect and strengthen that access. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was
passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential
competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the
minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain
branded prescription drugs, and creates a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts
off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part&nbsp;D. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be
additional challenges and amendments to the ACA in the future. Various portions of the ACA are currently undergoing legal and constitutional challenges in the Fifth Circuit Court and the United States Supreme Court; the Trump Administration has
issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or
manufacturers of pharmaceuticals or medical devices; and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further
amended. We cannot predict what affect further changes to the ACA would have on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress.
A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2&nbsp;trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s
automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2%&nbsp;per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless
additional Congressional action is taken. These Medicare sequester reductions were suspended from May&nbsp;1, 2020 through March&nbsp;31, 2021 due to the COVID-19 pandemic. The American Taxpayer Relief Act of 2012 among other things, reduced
Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several
recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing
and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#146;s budget proposal for fiscal year 2021 contains further drug price control measures that
could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part&nbsp;D plans to negotiate the price of certain drugs under Medicare Part&nbsp;B, to allow some states to negotiate
drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low income patients. Additionally, the Trump administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains
additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of product
candidates paid by consumers. The HHS has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019, the Centers for
Medicare and Medicaid Services, or CMS, issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part&nbsp;B drugs beginning January&nbsp;1, 2020. This final rule codified CMS&#146;s
policy change that was effective January&nbsp;1, 2019. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part&nbsp;D
beneficiary&nbsp;out-of-pocket&nbsp;pharmacy expenses, provide an option to cap Medicare Part&nbsp;D beneficiary monthly&nbsp;out-of-pocket&nbsp;expenses, and place limits on pharmaceutical price increases. Further, the Trump administration
previously released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs,
incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. Additionally, on July&nbsp;24, 2020 and September&nbsp;13, 2020, the Trump administration announced several
executive orders related to prescription drug pricing that seek to implement several of the administration&#146;s proposals. As a result, the FDA released a final rule on September&nbsp;24, 2020, effective November&nbsp;30, 2020, providing guidance
for states to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020, the Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from
pharmaceutical manufacturers to plan sponsors under Part&nbsp;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the
point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November&nbsp;20, 2020, the CMS issued an interim final rule implementing President Trump&#146;s Most Favored Nation
executive order, which would tie Medicare Part&nbsp;B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January&nbsp;1, 2021. On December&nbsp;28, 2020, the United States
District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy
initiatives. Any new laws or regulations that result in additional reductions in Medicare and other healthcare funding could have a material adverse effect on customers for our products, if approved, and, accordingly, on our results of operations.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, on October 1, 2020, the FDA issued a final rule allowing for the importation of certain prescription drugs from Canada. FDA also issued a final
guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
foreign country and that was authorized for sale in that foreign country. The regulatory and market implications of the final rule and guidance are unknown at this time, but legislation,
regulations or policies allowing the reimportation of drugs, if enacted and implemented, could decrease the price we receive for our products and adversely affect our future revenues and prospects for profitability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, on May&nbsp;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access
certain investigational new product candidates that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical
trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its product candidates available to eligible patients as a result of the Right to Try Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug
and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect
that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand
for our current or future product candidates or additional pricing pressures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our revenue prospects could be affected by changes in healthcare spending and policy
in the U.S. and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or
payment for healthcare products and services could negatively impact our business, operations and financial condition. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative action in the United States or any other jurisdiction. It is highly possible that additional governmental action is taken to address the COVID-19 pandemic. If we or any third parties we may engage are slow or unable to adapt to
changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and
we may not achieve or sustain profitability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and
state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the
ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the demand for our current or future product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain coverage and reimbursement approval for a product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect
our future profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If, in the future, we are unable to establish sales and marketing and patient support capabilities or enter into
agreements with third parties to sell and market our current or future product candidates, we may not be successful in commercializing our current or future product candidates if and when they are approved, and we may not be able to generate any
revenue. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently have a sales or marketing infrastructure and have limited experience in the sales, marketing, patient support or distribution
of products. To achieve commercial success for any approved product candidate for which we retain sales and marketing responsibilities, we must build our sales, marketing, patient support, managerial and other non-technical capabilities or make
arrangements with third parties to perform these services. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our current or future
product candidates if and when they are approved. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are risks involved with both establishing our own sales and marketing and patient support capabilities and
entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any drug launch. If the commercial launch of a product candidate for which we
recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we
cannot retain or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Factors that may inhibit our efforts to commercialize our current or future product candidates on
our own include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to use any
future products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we enter into arrangements with third parties to perform sales, marketing, patient support and distribution services, our drug revenues or the
profitability of these drug revenues to us are likely to be lower than if we were to market and sell any current or future product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third
parties to sell and market our current or future product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources
and attention to sell and market our current or future product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in
commercializing our current or future product candidates. Further, our business, results of operations, financial condition and prospects will be materially adversely affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If any product candidate for which we receive regulatory approval does not achieve broad market acceptance among physicians, patients, healthcare payors, and the
medical community, the revenues that we generate from its sales will be limited. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if our product candidates receive regulatory approval, they may not
gain market acceptance among physicians, patients, healthcare payors, and others in the medical community. Commercial success also will depend, in large part, on the coverage and reimbursement of our product candidates by third-party payors,
including private insurance providers and government payors. The degree of market acceptance of any approved product would depend on a number of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efficacy, safety and tolerability as demonstrated in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of market introduction of such product candidate as well as competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the clinical indications for which the product is approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acceptance by physicians, major operators of cancer or neurology clinics and patients of the product as a safe, tolerable
and effective treatment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential and perceived advantages of the product candidate over alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the safety and tolerability of the product candidate in a broader patient group; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of adequate reimbursement by third party payors and government authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in regulatory requirements by government authorities for the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">relative convenience and ease of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prevalence and severity of side effects and adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effectiveness of our sales and marketing efforts; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">favorable or unfavorable publicity relating to the product or relating to the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to successfully launch and secure market acceptance of our late-stage pipeline candidate, CAN-2409 (if approved), may be impacted by the evolving COVID-19
pandemic, although we are currently unable to predict or quantify any such potential impact with any degree of certainty. If the spread of COVID-19 and the social distancing measures taken by various governments continue, any commercial launch we
may undertake may be hindered by various factors, including challenges in hiring the employees necessary to support commercialization; delays in demand due to impacts on the healthcare system and overall economy; delays in coverage decisions from
Medicare and third-party payors; restrictions on our personal interactions with physicians, hospitals, payors, and other customers; interruptions or delays in our commercial supply chain; and increases in the number of uninsured or underinsured
patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we
may not generate sufficient revenue from these products and we may not become profitable, which would have a material adverse effect on our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we
fail to develop additional product candidates, our commercial opportunity could be limited. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect initially to develop our lead product candidates,
CAN-2409 and CAN-3110. A key part of our strategy, however, is to pursue clinical development of additional product candidates. Developing, obtaining marketing approval for, and commercializing additional product candidates will require substantial
additional funding beyond the net proceeds of this offering and will be subject to the risks of failure inherent in medical product development. We cannot assure you that we will be able to successfully advance any of these additional product
candidates through the development process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we obtain approval from the FDA or comparable foreign regulatory authorities to market additional product
candidates for the treatment of solid tumors, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives. If we are
unable to successfully develop and commercialize additional product candidates our commercial opportunity may be limited and our business, financial condition, results of operations, stock price and prospects may be materially harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations,
which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we do not currently have any drugs on the market, if we begin commercializing our current or future product candidates, we will be subject to additional
healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the
recommendation and prescription of any current or future product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other
healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our current or future product candidates for which we obtain marketing approval. Restrictions
under applicable federal and state healthcare laws and regulations, include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting,
offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such
as Medicare and Medicaid. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. The term remuneration has
been interpreted broadly to include anything of value. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. On November 20, 2020, the Office of Inspector
General, or OIG, finalized further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among
clinicians, providers, and others. This rule (with exceptions) became effective January 19, 2021. We continue to evaluate what effect, if any, this rule will have on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam
actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay
money to the federal government. In addition, manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent
claims. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties. Government enforcement agencies and private whistleblowers have investigated
pharmaceutical companies for or asserted liability under the False Claims Act for a variety of alleged promotional and marketing activities, such as providing free products to customers with the expectation that the customers would bill federal
programs for the products; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for &#147;off-label&#148; uses; and submitting inflated best price information to the Medicaid Rebate
Program. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False Claims Act;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability
for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare
benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal physician payment transparency requirements, sometimes referred to as the &#147;Sunshine Act&#148; under the
ACA require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report to the Department of Health and Human Services information related
to physician payments and other transfers of value and the ownership and investment interests of such physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and their immediate family members. Effective
January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its
implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure
of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil
monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the
federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or
marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring
drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which
differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the breadth of
these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge and may not comply under one or more of such laws, regulations and guidance. Law
enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Ensuring that our future business arrangements with third parties comply with
applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales team, were to be found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or
restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could
adversely affect our ability to operate our business and our financial results. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may face potential liability if we obtain identifiable patient health
information from clinical trials sponsored by us. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Most healthcare providers, including certain research institutions from which we may obtain patient
health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not directly subject to its
requirements or penalties. However, any person may be prosecuted under HIPAA&#146;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face
substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#146;s requirements for disclosure of individually
identifiable health information. In addition, in the future, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research
collaborations, and directly from individuals (or their healthcare providers) who may enroll in patient assistance programs if we choose to implement such programs. As such, we may be subject to state laws requiring notification of affected
individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EU General Data Protection Regulation, or GDPR, also confers a private right of action on data subjects and consumer associations to lodge complaints with
supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may increase our responsibility and
liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries.
Compliance with the GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties,
litigation, and reputational harm in connection with our European activities. Further, the United Kingdom&#146;s decision to leave the European Union, referred to as Brexit, has created uncertainty with regard to data protection regulation in the
United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated now that the United Kingdom has left the European Union. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, California recently enacted and has proposed companion regulations to the California Consumer Privacy Act, or CCPA, which went into effect January&nbsp;1,
2020. The CCPA creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered
companies to provide certain disclosures to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. As of
March&nbsp;28, 2020, the California State Attorney General has proposed varying versions of companion draft regulations which are not yet finalized. Despite the delay in adopting regulations, the California State Attorney General commenced
enforcement actions against violators on July&nbsp;1, 2020. While there are currently exceptions for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact our business
activities. On August&nbsp;14, 2020, implementing regulations were finalized and became effective as of that date. While clinical trial data and information governed by HIPAA are currently exempt from the current version of the CCPA, other personal
information may be applicable and possible changes to the CCPA may broaden its scope. We continue to monitor the impact the CCPA may have on our business activities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or
those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#146; health information. Patients about whom we or our collaborators may obtain health information, as well as the providers who may
share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable
privacy and data security laws. Claims that we have violated individuals&#146; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse
publicity that could harm our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or third-party contract research organizations, or CROs, or other contractors or consultants fail to comply with
applicable federal, state/provincial or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#146; ability to develop and commercialize our therapeutic candidates and could harm
or prevent sales of any affected therapeutics that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our therapeutics. Any threatened or actual government enforcement
action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or
reputational damage. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we are subject to other state and foreign equivalents of each of the healthcare laws described above, among others, some of
which may be broader in scope and may apply regardless of the payor. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we
could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to
numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and
flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the
risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also
could incur significant costs associated with civil or criminal fines and penalties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we maintain workers&#146; compensation insurance to cover us for
costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability
or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Employee Matters, Managing Growth and General Business Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The&nbsp;COVID-19&nbsp;pandemic, which began in late 2019 and has spread worldwide, may affect our ability to complete our ongoing clinical trials and initiate
and complete other preclinical studies, planned clinical trials or future clinical trials, disrupt regulatory activities, disrupt our manufacturing and supply chain or have other adverse effects on our business and operations. In addition, this
pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business, operations and ability to raise capital. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The&nbsp;COVID-19&nbsp;pandemic, which began in December 2019 and has spread worldwide, has caused many governments to implement measures to slow the spread
of&nbsp;COVID-19&nbsp;through quarantines, travel restrictions, heightened border scrutiny and other measures. The&nbsp;COVID-19&nbsp;pandemic and government measures taken in response have also had a significant impact, both directly and
indirectly, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has
spiked, while demand for other goods and services, such as travel, has fallen. The future progression of&nbsp;the&nbsp;COVID-19&nbsp;pandemic&nbsp;and its effects on our business and operations are uncertain. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The extent to&nbsp;which&nbsp;COVID-19&nbsp;impacts&nbsp;our operations or those of the third parties on which we rely will depend on many factors, which are highly
uncertain and cannot be predicted with confidence, including the duration of the pandemic, additional or modified government actions, new information that will emerge concerning the severity and impact&nbsp;of&nbsp;COVID-19,&nbsp;and&nbsp;the
actions to contain&nbsp;the&nbsp;COVID-19&nbsp;pandemic&nbsp;or address its impact in the short and long term. Additionally, the conduct of our clinical trials, preclinical studies and manufacturing activities is dependent upon the availability of
clinical trial sites, CROs, contract development and manufacturing organization, or CDMOs, researchers and investigators, regulatory agency personnel and logistics providers, all of which may be adversely affected
by&nbsp;the&nbsp;COVID-19&nbsp;pandemic. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any negative impact that&nbsp;the&nbsp;COVID-19&nbsp;pandemic&nbsp;has on enrolling or retaining patients in our clinical
trials, the ability of our suppliers to provide materials for our product candidates, or the regulatory review process could cause delays with respect to product development activities, which could materially and adversely affect our ability to
obtain marketing approval for and to commercialize our product candidates, increase our operating expenses, affect our ability to raise additional capital, and have a material adverse effect on our financial results. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot provide assurance that some factors from&nbsp;the&nbsp;COVID-19&nbsp;pandemic&nbsp;will not further delay or otherwise adversely affect our clinical
development, research, manufacturing and business operations activities, as well as our business generally, in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and the third-party manufacturers,
CROs and academic collaborators that we engage have faced in the past and may face in the future disruptions that could affect our ability to initiate and complete preclinical studies or clinical trials, including disruptions in procuring items that
are essential for our research and development activities, such as, for example, raw materials used in the manufacture of our product candidates, laboratory supplies for our preclinical studies and clinical trials, or animals that are used for
preclinical testing, in each case, for which there may be shortages because of ongoing efforts to address&nbsp;the&nbsp;COVID-19&nbsp;pandemic.&nbsp;Three vaccines for COVID-19 have been granted Emergency Use Authorization by the FDA, and more are
likely to be authorized in the coming months. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more
difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. Additionally, the response to&nbsp;the&nbsp;COVID-19&nbsp;pandemic&nbsp;may redirect resources with
respect to regulatory and intellectual property matters in a way that would adversely impact our ability to pursue marketing approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and potential
approvals due to measures intended to&nbsp;limit&nbsp;in-person&nbsp;interactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In response to&nbsp;the&nbsp;COVID-19&nbsp;pandemic&nbsp;and in accordance with
direction from state and local governmental authorities, we have restricted access to our facility to those individuals who must perform critical research, translational medicine and laboratory support activities that must be completed on site,
limited the number of such people that can be present at our facility at any one time, and required that most of our employees work remotely. In the event that governmental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
authorities were to keep these restrictions in place for an extended period or impose further restrictions, our employees conducting research and development activities may not be able to access
our laboratory space, and our core research activities may be significantly limited or curtailed, possibly for an extended period of time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The&nbsp;COVID-19&nbsp;pandemic&nbsp;continues to rapidly evolve, and its ultimate scope, duration and effects are unknown. The extent of the impact of the disruptions
to our business, preclinical studies and clinical trials as a result of the COVID-19 pandemic&nbsp;will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the
disease, the duration of&nbsp;the&nbsp;COVID-19&nbsp;pandemic, travel restrictions and actions to contain&nbsp;the&nbsp;COVID-19&nbsp;pandemic,&nbsp;such as social distancing and quarantines or lock-downs in the United States and other countries,
business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
COVID-19 pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could adversely impact our ability to raise additional funds through public offerings or private placements and
may also impact the volatility of our stock price and trading in our stock. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could result in adverse effects on our business and operations. We cannot be
certain what the overall impact of&nbsp;the&nbsp;COVID-19&nbsp;pandemic&nbsp;will be on our business and it has the potential to adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of our executive officers, as well as the other
principal members of our management, scientific and clinical teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#147;key
person&#148; insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and
seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our
industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or
motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from
universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and
advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Our success as a public company also depends on implementing and
maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to expand our development, manufacturing and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a
result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As we seek to advance our product candidates through
clinical trials and commercialization, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities. We expect to experience significant growth in
the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs and, if any product candidate receives marketing approval, sales, marketing and distribution. To manage our
anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources
and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or
disrupt our operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The increasing use of social media platforms presents new risks and challenges. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Social media is increasingly being used to communicate about our clinical development programs and the diseases our therapeutics are being developed to treat, and we
intend to utilize appropriate social media in connection with our commercialization efforts following approval of our product candidates, if any. Social media practices in the biotechnology and biopharmaceutical industry continue to evolve and
regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against
us, along with the potential for litigation related to&nbsp;off-label&nbsp;marketing or other prohibited activities and heightened scrutiny by the FDA, the SEC and other regulators. For example, patients may use social media channels to comment on
their experience in an ongoing blinded clinical trial or to report an alleged adverse event. If such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and comply with applicable adverse
event reporting obligations or that we may not be able to defend our business or the public&#146;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our
product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. In addition, we may encounter attacks on social media regarding our
company, management, product candidates or products. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our internal computer systems, or those of our third-party CROs that we may use in the future, or other contractors or consultants, may fail or suffer security
breaches, which could result in a material disruption of our product candidates&#146; development programs. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite our implementation of security
measures, our internal computer systems, and those of our CROs that we may use in the future, information technology suppliers and other contractors and consultants are vulnerable to damage from computer viruses, cyberattacks and other unauthorized
access, natural disasters, terrorism, war, and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development
programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent
that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of any
of our product candidates could be delayed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our operations or those of the third parties upon whom we depend might be affected by the occurrence of a natural
disaster, pandemic or other catastrophic event. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We depend on our employees and consultants, CDMOs and CROs that we may use in the future, as well as
regulatory agencies and other parties, for the continued operation of our business. While we maintain disaster recovery plans, they might not adequately protect us. Despite any precautions we take for natural disasters or other catastrophic events,
these events, including terrorist attack, pandemics, hurricanes, fire, floods and ice and snowstorms, could result in significant disruptions to our research and development, preclinical studies, clinical trials, and, ultimately, commercialization
of our products. Long-term disruptions in the infrastructure caused by events, such as natural disasters, the outbreak of war, the escalation of hostilities and acts of terrorism or other &#147;acts of God,&#148; particularly involving cities in
which we have offices, manufacturing or clinical trial sites, could adversely affect our businesses. Although we carry business interruption insurance policies and typically have provisions in our contracts that protect us in certain events, our
coverage might not respond or be adequate to compensate us for all losses that may occur. Any natural disaster or catastrophic event affecting us, our CDMOs or CROs, regulatory agencies or other parties with which we are engaged could have a
significant negative impact on our operations and financial performance. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts
of fraud. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure
controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures,
no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and
that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction
disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected. <B><I> </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We and our independent registered public accounting firm have identified
material weaknesses in our internal control over financial reporting in conjunction with their audits of our financial statements for the years ended December&nbsp;31, 2019 and 2020. If we are unable to remediate these material weakness, or if we
identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely
affect our business and the market price of our common stock. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In preparation of our consolidated financial statements to meet the requirements applicable
to this offering, we and our independent registered public accounting firm identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control
over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The material weaknesses identified related to: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">the fact that we did not have sufficient finance and accounting staff with U.S. generally accepted accounting principles
technical and accounting expertise to evaluate and account for significant transactions and oversee our third-party consultants. As a result we did not design and maintain formal accounting policies, processes and controls to analyze, account for
and disclose certain complex transactions, which led to inappropriate accounting conclusions associated with stock compensation expenses; and </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">the fact that we lacked proper monitoring entity level controls and segregation of duties due to our small accounting
staff. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have implemented, and are continuing to implement, measures designed to improve internal control over financial reporting to remediate
the control deficiencies that led to the material weaknesses, including the following: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hiring an experienced Chief Financial Officer with experience serving as acting chief financial officer of a public
company and serving as an audit partner at a major accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">strengthening supervisory reviews by our financial management, and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expanding our accounting and finance team to add additional qualified accounting and finance resources, which may include
augmenting our finance team with third-party consultants that possess the required expertise to assist management with their review. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot
assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to remediate the control deficiencies that led to the material weaknesses in our internal control over financial reporting or that they
will prevent or avoid potential future material weaknesses. In addition, neither our management nor an independent registered public accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the
provisions of the Sarbanes-Oxley Act because no such evaluation has been required. Had we or our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions
of the Sarbanes-Oxley Act, additional material weaknesses may have been identified. If we are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or identify any
additional material weaknesses in the future, or otherwise fail to maintain an effective system of internal controls, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with
securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and the market price of our common stock may decline as
a result. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to maintain an effective system of internal control over financial reporting, we may not be able to
accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and
procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us
conducted in connection with Section&nbsp;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that
may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information,
which could harm our business and have a negative effect on the trading price of our stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will be required to disclose changes made in our internal controls
and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an EGC under the JOBS Act, our independent registered public accounting firm will not be
required to attest to the effectiveness of our internal control over financial reporting pursuant to Section&nbsp;404. We could be an EGC for up to five years. Our assessment of internal controls and procedures may not detect material weaknesses in
our internal control over financial reporting. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation, which could have a
negative effect on the trading price of our stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Legal and Compliance Matters </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have to limit the
commercialization of any approved products and/or our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of our product candidates in clinical trials, and the sale of any product
for which we obtain regulatory approval, exposes us to the risk of product liability claims. We face inherent risk of product liability related to the testing of our product candidates in human clinical trials, including liability relating to the
actions and negligence of our investigators, and will face an even greater risk if we commercially sell any product candidates that we may develop. For example, we may be sued if any product candidate we develop allegedly causes injury or is found
to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product,
negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. Product liability claims might be brought against us by consumers, healthcare providers or others using, administering or
selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant
financial and management resources. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">loss of revenue from decreased demand for our products and/or product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">impairment of our business reputation or financial stability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs of related litigation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">diversion of management attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inability to commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">decreases in our stock price; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiation of investigations and enforcement actions by regulators; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions, including withdrawal of marketing
approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe we have sufficient insurance coverage in place for our business operations. However, our insurance coverage may
not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a
reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include the sale of commercial products if we obtain FDA or comparable foreign regulatory approval for our product
candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing, or at all. Failure to obtain and retain sufficient product liability insurance at an acceptable
cost could prevent or inhibit the commercialization of products we develop. On occasion, large judgments have been awarded in class action lawsuits based on therapeutics that had unanticipated side effects. A successful product liability claim or
series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash, and materially harm our business, financial condition, results of operations, stock price and
prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs laws,
sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial
condition, results of operations, stock price and prospects. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our operations are subject to anti-corruption laws, including the Foreign Corrupt Practices
Act, or FCPA, and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to
government officials or other persons to obtain or retain business or gain some other business advantage. We also may participate in collaborations and relationships with third parties whose actions, if non-compliant, could potentially subject us to
liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be
administered or interpreted. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also subject to other laws and regulations governing our international operations, including regulations administered by the
government of the United States, including applicable import and export control regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as
the trade control laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws or
other legal requirements, including trade control laws. If we are not in compliance with applicable anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial
measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. Likewise, any investigation of any potential violations of these anti-corruption laws or trade
control laws by United States or other authorities could also have an adverse impact on our reputation, our business, financial condition, results of operations, stock price and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with federal and state healthcare laws, including fraud and abuse and health and other information privacy and security laws, we could face
substantial penalties and our business, financial condition, results of operations, stock price and prospects will be materially harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to
many federal and state healthcare laws, including those described in &#147;Business&#151;Government Regulation&#148; such as the federal Anti-Kickback Statute, the federal civil and criminal False Claims Acts, the civil monetary penalties statute,
the Medicaid Drug Rebate statute and other price reporting requirements, the Veterans Health Care Act of 1992, or VHCA HIPAA, the FCPA, the ACA and similar state laws. Even though we do not and will not control referrals of healthcare services or
bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws, and regulations pertaining to fraud and abuse, reimbursement programs, government procurement, and patients&#146; rights are and will be
applicable to our business. We would be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. In the European Union, the data
privacy laws are generally stricter than those which apply in the United States and include specific requirements for the collection of personal data of European Union persons or the transfer of personal data outside of the European Union to the
United States to ensure that European Union standards of data privacy will be applied to such data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or our operations, including our arrangements with physicians and other healthcare providers, some of whom receive
share options or other financial interest in the business as compensation for services provided, are found to be in violation of any federal or state healthcare law, or any other governmental laws or regulations that apply to us, we may be subject
to penalties, including civil, criminal, and administrative penalties, damages, fines, disgorgement, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in U.S.
federal or state health care programs, corporate integrity agreements, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. If any of
the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it or they may be subject to criminal, civil or administrative sanctions, including but not limited
to, exclusions from participation in government healthcare programs, which could also materially affect our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although an effective compliance program can
mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal, state and foreign privacy, data protection, security,
reimbursement, and fraud laws may prove costly. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the
operation of our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recent changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs
Act, or TCJA, which significantly reformed the Internal Revenue Code of 1986, as amended, or the Code. The TCJA, among other things, contains significant changes to corporate taxation, including reducing the corporate tax rate from a top marginal
rate of 35% to a flat rate of 21%, limiting the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), limiting the deduction for NOLs arising in taxable years beginning after December 31,
2017 to 80% of current year taxable income and elimination of NOL carrybacks for losses arising in taxable years ending after December 31, 2017 (though any such NOLs may be carried forward indefinitely), imposing a one-time taxation of offshore
earnings at reduced rates regardless of whether they are repatriated, eliminating U.S. tax on foreign earnings (subject to certain important exceptions), allowing immediate deductions for certain new investments instead of deductions for
depreciation expense over time, and modifying or repealing many business deductions and credits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of Congress&#146; response to the COVID-19 pandemic, the
Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was enacted on March 27, 2020, and COVID relief provisions were included in the Consolidated
Appropriations Act, 2021 or CAA, which was enacted on December 27, 2020. Both contain numerous tax provisions. In particular, the CARES Act retroactively and temporarily (for taxable years beginning before January 1, 2021) suspends application of
the 80%-of-income limitation on the use of NOLs, which was enacted as part of the TCJA. It also provides that NOLs arising in any taxable year beginning after December 31, 2017, and before January 1, 2021 are generally eligible to be carried back up
to five years. The CARES Act also temporarily (for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax deductibility for net interest expense by increasing the limitation from 30% to 50% of adjusted taxable income. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory guidance under the TCJA, the FFCR Act, the CARES Act and the CAA is and continues to be forthcoming, and such guidance could ultimately increase or lessen
their impact on our business and financial condition. It is also likely that Congress will enact additional legislation in connection with the COVID-19 pandemic, some of which could have an impact on us. In addition, it is uncertain if and to what
extent various states will conform to the TCJA, the FFCR Act, the Cares Act, or the CAA. We urge prospective investors in our common stock to consult with their legal and tax advisors with respect to any recently enacted tax legislation, or proposed
changes in law, and the potential tax consequences of investing in or holding our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to utilize our net operating loss carryforwards
and certain other tax attributes may be limited. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an
&#147;ownership change&#148; (generally defined as a greater than 50% change (by value) in its equity ownership by 5% stockholders over a three-year period), the corporation&#146;s ability to use its pre-change net operating loss carryforwards
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and other pre-change tax attributes to offset its post-change taxable income may be limited. As a result of our most recent private placements and other transactions that have occurred over the
past three years, we may have experienced, and, upon closing of this offering, may experience, an &#147;ownership change.&#148; We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of
December&nbsp;31, 2020, we had U.S. federal and state net operating loss carryforwards of $8.8&nbsp;million and $27.6&nbsp;million, which begin to expire in 2027 and 2032, respectively. Additionally, as of December&nbsp;31, 2019, we had U.S. federal
and state research and development tax credit carryforwards of $0.7&nbsp;million and $0.4&nbsp;million respectively, which will begin to expire in 2036 and 2028, respectively, and which could be limited if we experience an &#147;ownership
change.&#148; The reduction of the corporate tax rate under the TCJA may cause a reduction in the economic benefit of our net operating loss carryforwards and other deferred tax assets available to us. Under the TCJA, federal net operating losses
generated after December&nbsp;31, 2017 will not be subject to expiration but will not be permitted to be carried back. In addition, under the TCJA, the amount of post-2017 net operating losses that we are permitted to deduct in any taxable year is
limited to 80% of our taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself. Additionally, as of December&nbsp;31, 2020, we had a U.S. federal net operating loss carryforward of
$19.7&nbsp;million which does not expire but is limited to an annual deduction equal to 80% of annual taxable income. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the government or third-party payors
fail to provide adequate coverage, reimbursement and payment rates for our product candidates, or if health maintenance organizations or long-term care facilities choose to use therapies that are less expensive or considered a better value, our
revenue and prospects for profitability will be limited. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In both domestic and foreign markets, sales of our products will depend in part upon the
availability of coverage and reimbursement from third-party payors. Such third-party payors include government health programs such as Medicare and Medicaid, managed care providers, private health insurers, and other organizations. Coverage
decisions may depend upon clinical and economic standards that disfavor new therapeutic products when more established or lower cost therapeutic alternatives are already available or subsequently become available, even if our products are alone in a
class. If reimbursement is not available, or is available only to limited levels, our product candidates may be competitively disadvantaged, and we may not be able to successfully commercialize our product candidates. Even if coverage is provided,
the approved reimbursement amount may not be high enough to allow us to establish or maintain a market share sufficient to realize a sufficient return on our or their investments. Alternatively, securing favorable reimbursement terms may require us
to compromise pricing and prevent us from realizing an adequate margin over cost. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is significant uncertainty related to third-party payor coverage and
reimbursement of newly approved therapeutics. Marketing approvals, pricing, and reimbursement for new therapeutic products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways
that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after marketing or product
licensing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product
in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that
country. Adverse pricing limitations may hinder our ability to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval. Our ability to commercialize our product candidates will
depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Regulatory authorities
and third-party payors, such as private health insurers, and health maintenance organizations, decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the
United States and elsewhere. Several third-party payors are requiring that companies provide them with predetermined discounts from list prices, are using preferred drug lists to leverage greater discounts in competitive classes, are disregarding
therapeutic differentiators within classes, are challenging the prices charged for therapeutics, and are negotiating price concessions based on performance goals. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In
addition, in the United States, no uniform policy of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, we believe that
future coverage and reimbursement will likely be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement for our products or product candidates for which we receive regulatory
approval may not be available or adequate in either the United States or international markets, which could have a negative effect on our business, financial condition, results of operations, stock price and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming coverage is approved, the resulting reimbursement payment rates might not be adequate. If payors subject our product candidates to maximum payment amounts, or
impose limitations that make it difficult to obtain reimbursement, providers may choose to use therapies which are less expensive when compared to our product candidates. Additionally, if payors require high copayments, beneficiaries may seek
alternative therapies. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any products to the satisfaction of hospitals, other target customers and their third-party payors. Such studies might require us
to commit a significant amount of management time and financial and other resources. Our products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain
price levels sufficient to realize an appropriate return on investment in product development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, federal programs impose penalties on manufacturers of
therapeutics in the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the Consumer Price Index-Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to
raise commercial prices. A few states have also passed or are considering legislation intended to prevent significant price increases. Regulatory authorities and third-party payors have attempted to control costs by limiting coverage and the amount
of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our
customers, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us to decrease, discount, or rebate a portion of the price we, or they, might establish for products,
which could result in lower than anticipated product revenues. If the realized prices for our products, if any, decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenue and
profitability will suffer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There may also be delays in obtaining coverage and reimbursement for newly approved therapeutics, and coverage may be more limited than
the indications for which the product is approved by the FDA or comparable foreign regulatory authorities. Such delays have made it increasingly common for manufacturers to provide newly approved drugs to patients experiencing coverage delays or
disruption at no cost for a limited period in order to ensure that patients are able to access the drug. Moreover, eligibility for reimbursement does not imply that any therapeutic will be paid for in all cases or at a rate that covers our costs,
including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new therapeutics, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary, by way of
example, according to the use of the product and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost products or may be incorporated into existing payments for other
services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, third-party payors are increasingly requiring higher levels of evidence of the benefits and clinical outcomes of new technologies,
benchmarking against other therapies, seeking performance-based discounts, and challenging the prices charged. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if available, that the
reimbursement rates will be adequate. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we obtain marketing approval could have a material
adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to
new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance, and adversely affect our ability to market our products, obtain collaborators and raise capital. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system
that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws, as
well as other healthcare reform measures that may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In particular, in 2010, the ACA was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new
methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under
the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded
prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January&nbsp;1, 2019) point-of-sale
discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and provided incentives to
programs that increase the federal government&#146;s comparative effectiveness research. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since its enactment, there have been numerous judicial, administrative,
executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently undergoing legal and
constitutional challenges in the United States Supreme Court. Additionally, the Trump administration issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a
cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or
repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot predict what affect further changes to the ACA would have on our business, especially given the new presidential administration.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Legislative changes have been proposed and adopted since the ACA was enacted in 2010. These changes include, among other things, aggregate reductions to Medicare
payments to providers of up to 2% per fiscal year, which went effective on April&nbsp;1, 2013, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the CARES
Act, as well as subsequent legislation, these reductions have been suspended from May&nbsp;1, 2020 through March&nbsp;31, 2021 due to the COVID-19 pandemic. Proposed legislation, if passed, would extend this suspension until the end of the pandemic.
In addition, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to
five years. The Trump administration&#146;s budget proposal for fiscal year 2021 included a $135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for
patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap
Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part&nbsp;D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the Trump administration also
previously released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs,
incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services, or HHS, has already started the process of soliciting
feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part
B drugs beginning January&nbsp;1, 2020. However, it is unclear whether the Biden administration will challenge, reverse, revoke or otherwise modify these executive and administrative actions after January&nbsp;20, 2021. In addition, there have been
several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. On December&nbsp;27, 2018, the District Court for the District of Columbia
invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the fiscal year 2019 and 2018 reimbursement formula on specified covered outpatient drugs (SCODs). The court ruled this change was not an
&#147;adjustment&#148; which was within the Secretary&#146;s discretion to make but was instead a fundamental change in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
reimbursement calculation. However, most recently, on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#146;s decision and found that
the changes were within the Secretary&#146;s authority. On September&nbsp;14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e.,&nbsp;before the full court), but was denied on October&nbsp;16, 2020. It is unclear how these
developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;24, 2020 and September&nbsp;13, 2020, former President Trump announced several executive orders related to prescription drug pricing that seek to implement
several of the administration&#146;s proposals. In response, the FDA released a final rule on September&nbsp;24, 2020, which went into effect on November&nbsp;30, 2020, providing guidance for states to build and submit importation plans for drugs
from Canada. Further, on November&nbsp;20, 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part&nbsp;B reimbursement rates will be calculated for certain drugs and biologicals based on
the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and will
apply in all U.S. states and territories for a seven-year period beginning January&nbsp;1, 2021, and ending December&nbsp;31, 2027. The Interim Final Rule has not been finalized and is subject to revision and challenge. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, on November&nbsp;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan
sponsors under Part&nbsp;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor
for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration
may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative measures to control drug costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the state
level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and
marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that
the ACA, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased net revenue from our
biopharmaceutical products, decreased potential returns from our development efforts, and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government healthcare
programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from commercializing our products and being able to generate revenue, and we could
be prevented from or significantly delayed in achieving profitability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, there have been a number of other legislative and regulatory proposals aimed at
changing the biopharmaceutical industry. For instance, the Drug Quality and Security Act imposes obligations on manufacturers of biopharmaceutical products related to product tracking and tracing. Among the requirements of this legislation,
manufacturers are required to provide certain information regarding the product to individuals and entities to which product ownership is transferred, will be required to label products with a product identifier, and are required keep certain
records regarding the product. The transfer of information to subsequent product owners by manufacturers is also required to be done electronically. Manufacturers are also being required to verify that purchasers of the manufacturers&#146; products
are appropriately licensed. Further, manufacturers have product investigation, quarantine, disposition, and FDA, other comparable foreign regulatory authorities, and trading partner notification responsibilities related to counterfeit, diverted,
stolen, and intentionally adulterated products that would result in serious adverse health consequences of death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that
they would be reasonably likely to result in serious health consequences or death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Compliance with the federal track and trace requirements may increase our operational expenses and impose significant
administrative burdens. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on
our business, financial condition, results of operations, stock price and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees, independent contractors, consultants, commercial
partners, principal investigators or CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could have a material adverse effect on our business.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, independent contractors, consultants, commercial partners,
principal investigators, contract manufacturing organizations or CROs could include intentional, reckless, negligent, or unintentional failures to comply with FDA regulations, comply with applicable fraud and abuse laws, provide accurate information
to the FDA, properly calculate pricing information required by federal programs, report financial information or data accurately or disclose unauthorized activities to us. This misconduct could also involve the improper use or misrepresentation of
information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter this type of misconduct, and the precautions we take to detect and
prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or
regulations. Moreover, it is possible for a whistleblower to pursue a False Claims Act case against us even if the government considers the claim unmeritorious and declines to intervene, which could require us to incur costs defending against such a
claim. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, stock price
and prospects, including the imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Violations of or liabilities under environmental, health and safety laws and
regulations could subject us to fines, penalties or other costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to
numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our
operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We would incur substantial costs as a result of violations of or
liabilities under environmental requirements in connection with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. Although we generally contract with third parties for
the disposal of hazardous materials and wastes from our operations, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held
liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of
hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or
disposal of biological, hazardous or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>For certain product candidates</I></B><I>, </I><B><I>we depend</I></B><I>, </I><B><I>or will depend</I></B><I>, </I><B><I>on development and commercialization
collaborators to develop and conduct clinical trials with</I></B><I>, </I><B><I>obtain regulatory approvals for</I></B><I>,&nbsp;</I><B><I>and if approved</I></B><I>, </I><B><I>market and sell product candidates</I></B><I>.&nbsp;</I><B><I>If such
collaborators fail to perform as expected</I></B><I>, </I><B><I>the potential for us to generate future revenue from such product candidates would be significantly reduced and our business would be harmed</I></B><I>.</I><B><I> </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For certain product candidates, we depend, or will depend, on our development and commercial collaborators to develop, conduct clinical trials of, and, if approved,
commercialize product candidates. We have entered into a collaboration with Bristol-Myers Squibb Company, or BMS, and the Adult Brain Tumor Consortium, or ABTC, for a Phase 1b clinical trial in malignant glioma patients.&nbsp;We cannot provide
assurance that our collaborators will be successful in or that they will devote sufficient resources to these collaborations.&nbsp;If our current or future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
collaboration and commercialization partners do not perform in the manner we expect or fail to fulfill their responsibilities in a timely manner, or at all, if our agreements with them terminate
or if the quality or accuracy of the clinical data they obtain is compromised, the clinical development, regulatory approval and commercialization efforts related to their and our product candidates and products could be delayed or terminated and it
could become necessary for us to assume the responsibility at our own expense for the clinical development of such product candidates. Moreover, our ability to generate revenues from these collaborations and product candidates will depend on such
collaborators&#146; abilities to perform in the manner we expect or fulfill their responsibilities in a timely manner, and delays by collaborators, or caused by other collaboration contract obligations, may result in a delay of our ability to
disclose data. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our current collaborations and any future collaborations that we enter into are subject to numerous risks, including: </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to the
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not perform their obligations as expected or fail to fulfill their responsibilities in a timely manner,
or at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval
or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#146; strategic focus or available funding or external factors, such as an
acquisition, that divert resources or create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may delay preclinical studies or clinical trials, provide insufficient funding for clinical trials, stop a
preclinical study or clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators could fail to make timely regulatory submissions for a product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being
developed or commercialized under a collaboration and, consequently, may have limited ability to inform our shareholders about the status of such product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly
with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the collaborations may not result in product candidates to develop and/or preclinical studies or clinical trials conducted
as part of the collaborations may not be successful; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product candidates developed with collaborators may be viewed by our collaborators as competitive with their own product
candidates or products, which may cause collaborators to stop commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory
approval may not commit sufficient resources to the marketing and distribution of any such product candidate; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information
in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, certain collaboration and commercialization agreements provide our collaborators with rights to terminate such agreements, which rights may or may not be
subject to conditions, and which rights, if exercised, would adversely affect our product development efforts and could make it difficult for us to attract new collaborators. For example, our license agreement with The Brigham and Women&#146;s
Hospital, or BWH, may be terminated by BWH for our failure to pay, our failure to maintain proper insurance in accordance with the agreement, if we file for bankruptcy or if we remain in default for non-financial reasons following a specified cure
period to remedy the breach. In the event of the termination of any collaboration or commercialization agreement, we would likely be required to limit the size and scope of efforts for the development and commercialization of such product candidates
or products; we would likely be required to seek additional financing to fund further development or identify alternative strategic collaborations; our potential to generate future revenue from royalties and milestone payments
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
from such product candidates or products would be significantly reduced, delayed or eliminated; and it could have an adverse effect on our business and future growth prospects.&nbsp;Our rights to
recover tangible and intangible assets and intellectual property rights needed to advance a product candidate or product after termination of a collaboration may be limited by contract, and we may not be able to advance a program post-termination.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the foregoing, our current and any future collaboration agreements may not lead to development or commercialization of our product candidates in the
most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. If one
of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial communities could be adversely affected. Any failure to successfully develop or
commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If conflicts arise with our development and commercialization collaborators or licensors,&nbsp;they may act in their own self-interest, which may be adverse to
the interests of our company</I></B><I>.</I><B><I> </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may in the future experience disagreements with our development and commercialization collaborators
or licensors.&nbsp;Conflicts may arise in our collaboration and license arrangements with third parties due to one or more of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disputes with respect to milestone, royalty and other payments that are believed due under the applicable agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disagreements with respect to the ownership of intellectual property rights or scope of licenses; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disagreements with respect to the scope of any reporting obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disagreements with respect to contract interpretation or the preferred course of development; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">unwillingness on the part of a collaborator to keep us informed regarding the progress of its development and
commercialization activities, or to permit public disclosure of these activities; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disputes with respect to a collaborator&#146;s or our development or commercialization efforts with respect to our
products and product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Conflicts with our development and commercialization collaborators or licensors could materially adversely
affect our business, financial condition or results of operations and future growth prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We rely on third parties, including independent clinical
investigators and CROs to conduct and sponsor some of the clinical trials of our product candidates</I></B><I>.&nbsp;</I><B><I>Any failure by a third party to meet its obligations with respect to the clinical development of our product candidates
may delay or impair our ability to obtain regulatory approval for our product candidates</I></B><I>.</I><B><I> </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have relied upon and plan to continue to
rely upon third parties, including independent clinical investigators, academic partners, medical institutions, regulatory affairs consultants and third-party CROs, to conduct our preclinical studies and clinical trials, including in some instances
sponsoring such clinical trials, and to engage with regulatory authorities and monitor and manage data for our ongoing preclinical and clinical programs.&nbsp;While we have, or will have, agreements governing the activities of such third parties, we
will control only certain aspects of their activities and have limited influence over their actual performance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these third parties may terminate their
engagements with us under certain circumstances.&nbsp;We may not be able to enter into alternative arrangements or do so on commercially reasonable terms.&nbsp;In addition, there is a natural transition period when a new contract research
organization begins work.&nbsp;As a result, delays would likely occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol and legal,
regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities.&nbsp;We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations
and guidelines enforced by the FDA, the Competent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Authorities of the Member States of the EEA and comparable foreign regulatory authorities for all of our products in clinical development.&nbsp;Regulatory authorities enforce these GCP
requirements through periodic inspections of trial sponsors, principal investigators and trial sites.&nbsp;If we fail to exercise adequate oversight over any of our academic partners or CROs or if we or any of our academic partners or CROs do not
successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory
requirements, or for any other reasons, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications.&nbsp;We cannot assure you that upon a regulatory inspection of us, our academic partners or our CROs or other third parties performing services in connection with our clinical trials, such regulatory authority
will determine that any of our clinical trials complies with GCP regulations.&nbsp;In addition, our clinical trials must be conducted with product produced under applicable cGMP regulations.&nbsp;Our failure to comply with these regulations may
require us to repeat clinical trials, which would delay the regulatory approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, the third parties conducting clinical trials on our behalf
are not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs.&nbsp;These contractors
may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our
clinical programs.&nbsp;If these third parties, including clinical investigators, do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated
protocols, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates.&nbsp;If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product
candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, with respect to investigator-sponsored trials that are being or may be conducted, we do not control the design or conduct of these trials,
and it is possible that the FDA or EMA will not view these investigator-sponsored trials as providing adequate support for future clinical trials or market approval, whether controlled by us or third parties, for any one or more reasons, including
elements of the design or execution of the trials or safety concerns or other trial results.&nbsp;We expect that such arrangements will provide us certain information rights with respect to the investigator-sponsored trials, including the ability to
obtain a license to obtain access to use and reference the data, including for our own regulatory submissions, resulting from the investigator-sponsored trials.&nbsp;However, we do not have control over the timing and reporting of the data from
investigator-sponsored trials, nor do we own the data from the investigator-sponsored trials.&nbsp;If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be
further delayed or prevented from advancing further clinical development.&nbsp;Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be
inadequate compared to the firsthand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely
affected.&nbsp;Additionally, the FDA or EMA may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored trials, or our interpretation of preclinical,
manufacturing or clinical data from these investigator-sponsored trials.&nbsp;If so, the FDA or EMA may require us to obtain and submit additional preclinical, manufacturing, or clinical data. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the manufacturers upon which we may rely fail to produce our product candidates in the volumes that we require on a timely basis, or fail to comply with
stringent regulations applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, our product candidates and may lose potential revenues. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to develop commercial manufacturing capabilities at our facility in Needham, Massachusetts and at third-party manufacturers. We may rely on third-party
contract manufacturers to manufacture our clinical trial product supplies and for commercial scale manufacturing. We also expect to continue to rely on third-party contractors for certain portions of our manufacturing process in the event our
manufacturing facility is complete and fully operational. There can be no assurance that our clinical development will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In particular, any
replacement of our contract manufacturer could require significant effort and expertise because there may be a limited number of qualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
replacements. Any delays in obtaining adequate supplies of our product candidates that meet the necessary quality standards, including delays caused by the COVID-19 pandemic, may delay our
development or commercialization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not succeed in our efforts to establish manufacturing relationships or other alternative arrangements for any of our
product candidates or programs. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that are both
capable of manufacturing and filling our viral product for us and willing to do so. If our existing third-party manufacturers, or the third parties that we engage in the future, should cease to work with us, we likely would experience delays in
obtaining sufficient quantities of our product candidates for us to meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. If for any reason we are unable to obtain adequate supplies of our
product candidates or the therapeutic substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively. Further, even if we do establish such collaborations or arrangements, our
third-party manufacturers may breach, terminate, or not renew these agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any problems or delays we experience in preparing for commercial scale
manufacturing of a product candidate or component may result in a delay in product development timelines and FDA or comparable foreign regulatory authority approval of the product candidate or may impair our ability to manufacture commercial
quantities or such quantities at an acceptable cost and quality, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and may materially harm our business, financial
condition, results of operations, stock price and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The manufacture of biopharmaceutical products requires significant expertise and capital investment,
including the development of advanced manufacturing techniques and process controls. Manufacturers of therapeutics often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with
production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign
regulations. Our contract manufacturers may not perform as agreed. If our manufacturers were to encounter these or other difficulties, our ability to provide product candidates to patients in our clinical trials could be jeopardized. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Contract manufacturers of our product candidates may be unable to comply with our specifications, applicable cGMP requirements or other FDA, state or foreign regulatory
requirements. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product
testing. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure or maintain
regulatory approval for their manufacturing facilities. Any such deviations may also require remedial measures that may be costly and/or time consuming for us or a third party to implement and that may include the temporary or permanent suspension
of a clinical trial or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. Any delays in obtaining products or product candidates
that comply with the applicable regulatory requirements may result in delays to clinical trials, product approvals, and commercialization. It may also require that we conduct additional studies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we are ultimately responsible for the manufacturing of our product candidates and therapeutic substances, other than through our contractual arrangements, we have
little control over our manufacturers&#146; compliance with these regulations and standards. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws
any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any new manufacturers
would need to either obtain or develop the necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take substantial time and investment. We must also receive FDA approval for the use of any new manufacturers for
commercial supply. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A failure to comply with the applicable regulatory requirements, including periodic regulatory inspections, may result in regulatory enforcement
actions against our manufacturers or us (including fines and civil and criminal penalties, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
including imprisonment) suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical
trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product candidate, refusal to permit the import or export of the products, product seizure, detention, or recall, operating
restrictions, suits under the civil False Claims Act, corporate integrity agreements, consent decrees, withdrawal of product approval, environmental or safety incidents and other liabilities. If the safety of any quantities supplied is compromised
due to our manufacturers&#146; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any failure or refusal to supply our product candidates or components for our product candidates that we may develop could delay, prevent or impair our clinical
development or commercialization efforts. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and
processes could be significant. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have completed and may in the future complete related party transactions that were not and may not be conducted on an
arm&#146;s length basis. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have in the past and continue to be party to certain transactions with certain entities affiliated with Estuardo
Aguilar-Cordova, our founder and Chief Scientific Officer, and Laura Aguilar, our Chief Medical Officer. For instance, we have entered into an exclusive license agreement with Ventagen, LLC (Ventagen), an entity owned in part (49.5%), though not
managed, by Estuardo Aguilar-Cordova and Laura Aguilar, for the use of worldwide patent rights and know-how owned or controlled by us which cover applicable technology utilizing the delivery method of the herpes derived TK protein to tumors or other
tissues via a viral vector. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2008, we entered into an operating lease agreement with a term through December 31, 2022 with Ellka Holdings, LLC, or Ellka,
for the space in which we operated in Auburndale, MA. In May 2016, we entered into a second lease agreement with Ellka for living space for employees, also in Auburndale, MA. We entered into a second lease for this space on July 26, 2018, which
expired on July 31, 2019. Ellka was originally established in 2007 as an LLC for the purpose of acquiring and managing investment properties owned by Laura Aguilar and Estuardo Aguilar-Cordova and their children&#146;s trusts. Ellka is owned and
operated by Laura Aguilar and Estuardo Aguilar Cordova and members of their immediate family. Although we believe that these transactions were conducted on an arm&#146;s length basis, it is possible that the terms were less favorable to us than they
might have been in a transaction with an unrelated party. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2021, Estuardo Aguilar-Cordova and Laura Aguilar beneficially owned
7,986,577&nbsp;shares of our common stock, or approximately 42.5% of our total outstanding capital stock as of such date. Accordingly, they will continue to have significant influence over all business decisions, including with respect to such
matters as amendments to our charter, other fundamental corporate transactions, such as mergers, asset sales, and the sale of the Company, and otherwise will be able to influence our business and affairs. In connection with this offering, we intend
to adopt a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of related-person transactions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The transition of our manufacturing operations to our new facility and to a third-party contract manufacturer may result in further delays or expenses, and we may
not experience the anticipated operating efficiencies. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have commissioned and are in the process of the build-out of and have successfully completed our
first two tech transfers at, our approximately 2,600 square foot manufacturing facility that is part of our corporate headquarters in Needham, Massachusetts at which we intend to operate our own manufacturing facility in order to secure supplies for
pivotal studies. This facility is intended to give us control over key aspects of the supply chain for our products and product candidates. We may not experience the anticipated operating efficiencies as we commence manufacturing operations at the
new facility and we may also use contract manufacturers for our products and product candidates to ensure adequate supply. Any such delays may disrupt or delay the supply of our product candidates if we have not maintained a sufficient backup supply
of our product candidates through third-party manufacturers. Moreover, changing manufacturing facilities may also require that we conduct additional studies, make notifications to the regulatory authorities, make additional filings to the regulatory
authorities, and obtain regulatory authority approval for the new facilities, which may be delayed or which we may never receive. We will further need to comply with the FDA&#146;s and applicable foreign regulatory authorities&#146; cGMP
requirements for the production of our product candidates for clinical trials and, if approved, commercial supply, and will be subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
FDA and comparable foreign regulatory authority inspection. These requirements include the qualification and validation of our manufacturing equipment and processes. We may not be able to develop
or acquire the internal expertise and resources necessary for compliance with these requirements. If we fail to achieve the operating efficiencies that we anticipate, our manufacturing and operating costs may be greater than expected, which could
have a material adverse impact on our operating results. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In operating our own manufacturing facility, we may be forced to devote greater resources and management
time than anticipated, particularly in areas relating to operations, quality, regulatory, facilities and information technology. If we experience unanticipated employee turnover in any of these areas, we may not be able to effectively manage our
ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate from the new facility, which may negatively affect our product development timeline. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any such problems could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and may materially harm
our business, financial condition, results of operations, stock price and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our reliance on third parties requires us to share our trade
secrets</I></B><I>, </I><B><I>which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed</I></B><I>.</I><B><I> </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we rely on third parties to manufacture our product candidates, and because we collaborate with various organizations and academic institutions on the
development of our product candidates, we must, at times, share trade secrets with them.&nbsp;We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements,
collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information.&nbsp;These agreements typically limit
the rights of the third parties to use or disclose our confidential information, such as trade secrets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the contractual provisions employed when working
with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used
in violation of these agreements.&nbsp;Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive
position and may have a material adverse effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, these agreements typically restrict the ability of our collaborators, advisors,
employees and consultants to publish data potentially relating to our trade secrets.&nbsp;Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in
order to secure our intellectual property rights arising from the collaboration.&nbsp;In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties.&nbsp;Despite our efforts
to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or
otherwise protected rights at the time of publication.&nbsp;A competitor&#146;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Intellectual Property </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our rights to develop and
commercialize certain of our product candidates are subject and may in the future be subject, in part, to the terms and conditions of licenses granted to us by third parties. If we fail to comply with our obligations under our current or future
intellectual property license agreements or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are and expect to continue to be reliant upon third-party licensors for certain patent and other intellectual property rights that are important or necessary to the
development of some of our technology and product candidates. For example, we rely on licenses from BWH and Periphagen to certain patent rights. These license agreements impose, and we expect that any future license agreement will impose, specified
diligence, milestone </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
payment, royalty, commercialization, development and other obligations on us and require us to meet development timelines, or to exercise diligent or commercially reasonable efforts to develop
and commercialize licensed products, in order to maintain the licenses. For more information on the terms of these license agreements, see &#147;Business&#151;Intellectual Property&#151;License Agreements.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, our licensors have, or may in the future have, the right to terminate a license if we materially breach the agreement and fail to cure such breach within a
specified period or in the event we undergo certain bankruptcy events. In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license
agreements. If our license agreements are terminated, we may lose our rights to develop and commercialize certain of our product candidates and technology, lose patent protection, experience significant delays in the development and
commercialization of certain of our product candidates and technology, and incur liability for damages. If <FONT STYLE="white-space:nowrap">these&nbsp;in-licenses&nbsp;are</FONT> terminated, or if the underlying intellectual property fails to
provide the intended exclusivity, our competitors or other third parties could have the freedom to seek regulatory approval of, and to market, products and technologies identical or competitive to ours and we may be required to cease our development
and commercialization of certain of our product candidates and technology. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a
manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and
to compete with any product candidates we may develop and our technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our or our licensors&#146; ability to obtain, maintain and defend intellectual property and to enforce intellectual
property rights against third parties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which our technology, product candidates and processes infringe, misappropriate or otherwise violate the
intellectual property of the licensor that is not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sublicensing of patent and other intellectual property rights under our license agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our diligence, development, regulatory, commercialization, financial or other obligations under the license agreement and
what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our current or future licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our license agreements are, and future license agreements are likely to be, complex, and certain provisions in such agreements may be susceptible to
multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our
diligence, development, regulatory, commercialization, financial or other obligations under the relevant agreement. In addition, if disputes over intellectual property that we have licensed or any other dispute related to our license agreements
prevent or impair our ability to maintain our current license agreements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and technology. Any of the foregoing could have a
material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">License agreements we may enter into in the future may <FONT
STYLE="white-space:nowrap">be&nbsp;non-exclusive.&nbsp;Accordingly,</FONT> third parties may also <FONT STYLE="white-space:nowrap">obtain&nbsp;non-exclusive&nbsp;licenses</FONT> from such licensors with respect to the intellectual property licensed
to us under such license agreements. Accordingly, these license agreements may not provide us with exclusive rights to use such licensed patent and other intellectual property rights, or may not provide us with exclusive rights to use such patent
and other intellectual property rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and any product candidates we may develop in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, some of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent and other intellectual property rights may in the future be subject to third-party
interests such <FONT STYLE="white-space:nowrap">as&nbsp;co-ownership.&nbsp;If</FONT> we are unable to obtain an exclusive license to such <FONT STYLE="white-space:nowrap">third-party&nbsp;co-owners&#146;</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
interest, in such patent and other intellectual property rights, such <FONT STYLE="white-space:nowrap">third-party&nbsp;co-owners&nbsp;may</FONT> be able to license their rights to other third
parties, including our competitors, and our competitors could market competing products and technology. We or our licensors may need the cooperation of any <FONT STYLE="white-space:nowrap">such&nbsp;co-owners&nbsp;of</FONT> our licensed patent and
other intellectual property rights in order to enforce them against third parties, and such cooperation may not be provided to us or our licensors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally,
we may not have complete control over the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. It is possible that our licensors&#146; filing, prosecution and
maintenance of the licensed patents and patent applications, enforcement of patents against infringers or defense of such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them
ourselves, and accordingly, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail
to file, prosecute, maintain, enforce and defend such patents and patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of
our technology and any product candidates we may develop that are the subject of such licensed rights could be adversely affected and we may not be able to prevent competitors or other third parties from making, using and selling competing products.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, our owned <FONT STYLE="white-space:nowrap">and&nbsp;in-licensed&nbsp;patent</FONT> rights may be subject to a reservation of rights by one or more
third parties. When new technologies are developed with government funding, in order to secure ownership of patent rights related to the technologies, the recipient of such funding is required to comply with certain government regulations, including
timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. A failure to meet these obligations may lead to a loss of rights or the unenforceability of relevant patents or
patent applications. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary
rights and technology, and we may not be able to ensure their protection. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business will depend in large part on obtaining and maintaining patent,
trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, synthetic intermediates, formulations, combination therapies, methods used to manufacture them and methods of treatment,
as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we
have rights under valid and enforceable patents that cover these activities and whether a court would issue an injunctive remedy. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of
the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely
affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a
reasonable cost or in a timely manner. In addition, we may not pursue, obtain, or maintain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before
it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or
license to third parties and are reliant on our licensors or licensees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The strength of patents in the biotechnology and biopharmaceutical field involves complex
legal and scientific questions and can be uncertain. The patent applications that we own <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;may</FONT> fail to result in issued patents with claims that cover our product candidates or uses
thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held
unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our technology, including our product candidates, or prevent others from designing around our claims. If the breadth or
strength of protection provided by the patent applications and patents we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be certain that we were the first to file any patent application related to our technology and directed to our product candidates, and, if we were not, we may
be precluded from obtaining patent protection for our technology, including our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be certain that we are the first to invent the
inventions covered by pending patent applications and patents, and, if we are not, we may be subject to priority disputes. Furthermore, for United States applications in which all claims are entitled to a priority date before March&nbsp;16, 2013, an
interference proceeding can be provoked by a third-party or instituted by the United States Patent and Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications
and patents. Similarly, for United States applications in which at least one claim is not entitled to a priority date before March&nbsp;16, 2013, derivation proceedings can be instituted to determine whether the subject matter of a patent claim was
derived from a prior inventor&#146;s disclosure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent
applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent or patent application claim. There also may be prior art of which we are aware, but which we do not believe affects the
validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable
or that even if found valid and enforceable, would adequately protect our product candidates, or would be found by a court to be infringed by a competitor&#146;s technology or product. We may analyze patents or patent applications of our competitors
that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts
or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our
patents or other intellectual property rights, or will design around the claims of patents that may issue that cover our products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recent or future patent reform
legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act, or America Invents Act, enacted in
2013, the United States moved from a &#147;first to invent&#148; to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;&#147;first-to-file&#148;&nbsp;system.</FONT></FONT> Under <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;&#147;first-to-file&#148;&nbsp;system,</FONT></FONT> assuming the other requirements for patentability are met, the first inventor to file&nbsp;a patent application generally will be entitled to a patent on the
invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted,
redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act and many of the
substantive changes to patent law, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;&#147;first-to-file&#148;&nbsp;provisions,</FONT></FONT> only became effective in March 2013. In addition, the courts have yet to
address many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or
permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may be able to make or use compounds that are similar to the compositions of our product candidates but that are
not covered by the claims of our patents or those of our licensors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that our pending patent applications will not result in issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that there are prior public disclosures that could invalidate our or our licensors&#146; patents, as the
case may be, or parts of our or their patents; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that others may circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue
with claims covering our products or technology similar to ours; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the laws of foreign countries may not protect our or our licensors&#146;, as the case may be, proprietary rights to the
same extent as the laws of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the claims of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents or patent applications, if
and when issued, may not cover our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued
patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inventors of our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on
which they are named as inventors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">co-owners</FONT> of certain of our patent applications may become involved with, or
license or assign the <FONT STYLE="white-space:nowrap">co-owned</FONT> applications to competitors , or become hostile to us or the patents or patent applications on which they are named as <FONT STYLE="white-space:nowrap">co-owners;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent applications omit
individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may
develop adjacent or competing products to ours that are outside the scope of our patents; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not develop additional proprietary technologies for which we can obtain patent protection; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#146; patents or
other exclusive rights; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may enter into license or other collaboration agreements in the future that may impose certain obligations on us. If we fail to comply with our obligations
under such future agreements with third parties, we could lose license rights that may be important to our future business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with our efforts
to expand our pipeline of product candidates, we may enter into certain licenses or other collaboration agreements in the future pertaining to the <FONT STYLE="white-space:nowrap">in-license</FONT> of rights to additional candidates. Such agreements
may impose various diligence, milestone payment, royalty, insurance or other obligations on us. If we fail to comply with these obligations, our licensor or collaboration partners may have the right to terminate the relevant agreement, in which
event we would not be able to develop or market the products covered by such licensed intellectual property. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, disputes may arise regarding intellectual
property subject to a licensing agreement, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sublicensing of patent and other rights under our collaborative development relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the agreements under which we currently license intellectual property or technology from third parties are
complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant
intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations,
and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and
commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may have limited control over the maintenance and prosecution of these <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent
applications, or any other intellectual property that may be related to our <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. For example, we cannot be certain that such activities by any future licensors have been or will
be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement
proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#146; infringement proceeding or defense activities may be less
vigorous than had we conducted them ourselves. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position
would be harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to patent protection, we rely heavily <FONT STYLE="white-space:nowrap">upon&nbsp;know-how&nbsp;and</FONT> trade secret
protection, as well <FONT STYLE="white-space:nowrap">as&nbsp;non-disclosure&nbsp;agreements</FONT> and invention assignment agreements with our employees, consultants and third-parties, to protect our confidential and proprietary information,
especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such
measures may not, for example, in the case of misappropriation of a trade secret by an employee or third-party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or
consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed
or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. For
example, our clinical development strategy includes the testing of live tissue samples, and our techniques for preserving and testing these samples are proprietary and confidential. If one or more third parties obtain or are otherwise able to
replicate these techniques, an important feature and differentiator of our clinical development strategy will become available to potential competitors. If any of our confidential or proprietary information, such as our trade secrets, were to be
disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, courts
outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other
resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially
equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Thus, we may not be able to
meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or
consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#146;s relationship with us
is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned
business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
technological security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides guidance on our
expectations, and our advice for best practices, in protecting our trade secrets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third-party claims of intellectual property infringement may prevent or
delay our product discovery and development efforts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part on our ability to develop, manufacture, market and sell our
product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and
biopharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation,<I></I><I>&nbsp;inter partes</I>&nbsp;review, post grant review, and reexamination proceedings before the USPTO or
oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or
proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates.
As the biotechnology and biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to
industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk
that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a third-party claims that we infringe its
intellectual property rights, we may face a number of issues, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to
litigate and may divert our management&#146;s attention from our core business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology
at issue infringes on or violates the third-party&#146;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#146;s attorneys&#146; fees; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our
proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if a license is available from a third-party, we may have to pay substantial royalties, upfront fees and other amounts,
and/or grant cross-licenses to intellectual property rights for our products and any license that is available may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to the same
intellectual property; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require
substantial monetary expenditures and time. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some of our competitors may be able to sustain the costs of complex patent litigation more
effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds
necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop from our use of the tissue
samples or other biological materials, which they provide to us, or otherwise arising from the collaboration. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We collaborate with several institutions,
universities, medical centers, physicians and researchers in scientific matters and expect to continue to enter into additional collaboration agreements. In certain cases, we do not have written agreements with these collaborators, or the written
agreements we have do not cover intellectual property </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
rights. Also, we rely on numerous third parties to provide us with tissue samples and biological materials that we use to conduct our research activities and develop our product candidates. If we
cannot successfully negotiate sufficient ownership and commercial rights to any inventions that result from our use of a third-party collaborator&#146;s materials, or if disputes arise with respect to the intellectual property developed with the use
of a collaborator&#146;s samples, or data developed in a collaborator&#146;s study, we may be limited in our ability to capitalize on the market potential of these inventions or developments. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third parties may assert that we are employing their proprietary technology without authorization. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There may be third-party patents of which we are currently unaware with claims to compositions of matter, materials, formulations, methods of manufacture or methods for
treatment that encompass the composition, use or manufacture of our product candidates. There may be currently pending patent applications of which we are currently unaware which may later result in issued patents that our product candidates or
their use or manufacture may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patent were held by a court of competent jurisdiction to cover
our product candidates, intermediates used in the manufacture of our product candidates or our materials generally, aspects of our formulations or methods of use, the holders of any such patent may be able to block our ability to develop and
commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at
all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our
business. Even if we obtain a license, it may <FONT STYLE="white-space:nowrap">be&nbsp;non-exclusive,&nbsp;thereby</FONT> giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection
provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and
commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim
of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which
may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of
litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that
event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third parties may assert
that our employees or consultants have wrongfully used or disclosed confidential information, misappropriated trade secrets, or are in breach of <FONT STYLE="white-space:nowrap">non-competition</FONT> or
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreements with our competitors. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is common in the biotechnology and biopharmaceutical
industries, we employ individuals who were previously employed at universities or other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, and
although we try to ensure that our employees and consultants do not use the proprietary information <FONT STYLE="white-space:nowrap">or&nbsp;know-how&nbsp;of</FONT> others in their work for us, we may be subject to claims that we or our employees,
consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. We may also be subject to claims
that we caused an employee to breach the terms of their <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, or that we or these individuals have, inadvertently or otherwise,
used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor or other party. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to
paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur
significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common
stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such
litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the
initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may
depend in part on our ability to <FONT STYLE="white-space:nowrap">acquire,&nbsp;in-license&nbsp;or</FONT> use these proprietary rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates may
also require specific formulations to work effectively and efficiently and these rights may be held by others. We may develop products containing our compounds <FONT STYLE="white-space:nowrap">and&nbsp;pre-existing&nbsp;biopharmaceutical</FONT>
compounds. We may be unable to acquire <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;any</FONT> compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or
important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such
third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such
alternatives, which may not be feasible. Even if we are able to obtain a license, it may <FONT STYLE="white-space:nowrap">be&nbsp;non-exclusive,&nbsp;thereby</FONT> giving our competitors access to the same technologies licensed to us. In that
event, we may be required to expend significant time and resources to develop or license replacement technology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we sometimes collaborate with
academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#146;s
rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer
the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights
we have, we may have to abandon development of such program and our business and financial condition could suffer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The licensing and acquisition of third-party
intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may
consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization
capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors may infringe our patents or the patents of our current or future licensors. To counter infringement or unauthorized use, we may be required to
file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using
the technology at issue on the grounds that our patents do not cover the technology in question or for other reasons. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held
unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee
resources from our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may choose to challenge the patentability of claims in a third-party&#146;s U.S. patent by requesting that the USPTO
review the patent claims in an<I></I><I><FONT STYLE="white-space:nowrap">&nbsp;ex-parte</FONT></I><FONT STYLE="white-space:nowrap">&nbsp;re-examination,</FONT><I></I><I>&nbsp;inter partes</I>&nbsp;review or post-grant review proceedings. These
proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#146;s patent in patent opposition proceedings in the European Patent Office, or EPO, or other foreign patent office. The costs of these
opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent
may be infringed by our product candidates or proprietary technologies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, because some patent applications in the United States may be maintained in
secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18&nbsp;months after filing, and publications in the scientific literature often lag behind actual
discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned <FONT STYLE="white-space:nowrap">and&nbsp;in-licensed&nbsp;issued</FONT> patents or our pending applications, or that we or, if
applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over
our owned <FONT STYLE="white-space:nowrap">and&nbsp;in-licensed&nbsp;patent</FONT> applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on
inventions similar to those owned by <FONT STYLE="white-space:nowrap">or&nbsp;in-licensed&nbsp;to</FONT> us, we or, in the case <FONT STYLE="white-space:nowrap">of&nbsp;in-licensed&nbsp;technology,</FONT> the licensor may have to participate in an
interference or derivation proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference or derivation proceeding involving a U.S. patent application on
inventions owned by <FONT STYLE="white-space:nowrap">or&nbsp;in-licensed&nbsp;to</FONT> us, we may incur substantial costs, divert management&#146;s time and expend other resources, even if we are successful. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with
respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from
the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our competitors
gain access to the same technology. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not
be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors
perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining our patent
protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated
<FONT STYLE="white-space:nowrap">for&nbsp;non-compliance&nbsp;with</FONT> these requirements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance fees on any issued patent are due to be
paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions
during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or
patent application include, but are not limited to, failure to respond to official actions within prescribed time <FONT STYLE="white-space:nowrap">limits,&nbsp;non-payment&nbsp;of</FONT> fees and failure to properly legalize and submit formal
documents. In certain circumstances, even inadvertent noncompliance events may permanently and irrevocably jeopardize patent rights. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on
our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any patents, if issued patents covering our product candidates could be found invalid or unenforceable if challenged
in court or the USPTO. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or one of our licensors initiate legal proceedings against a third-party to enforce a patent covering one of our product
candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or
unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad,
even outside the context of litigation. Such mechanisms <FONT STYLE="white-space:nowrap">include&nbsp;re-examination,&nbsp;inter</FONT> partes review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g.,&nbsp;opposition
proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With
respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion
of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a
material adverse impact on our business and our ability to commercialize or license our technology and product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Likewise, our current licensed patents
covering our companion technologies, licensed from BWH and from Periphagen are expected to expire in 2036 and in 2069, respectively, without taking into account any possible patent term adjustments or extensions. Our earliest patents may expire
before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration
of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects. We own pending patent applications covering our proprietary technologies or our product candidates that if
issued as patents are expected to expire from 2037 through 2040, without taking into account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of these
patent applications. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect our products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the
uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March&nbsp;16, 2013, in the United&nbsp;States, the
first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On March&nbsp;16, 2013, under the Leahy-Smith America Invents Act, or the America
Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the
patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March&nbsp;16, 2013, but before us could therefore be awarded a patent
covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States
and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&nbsp;file any patent application related to our product candidates or
(ii)&nbsp;invent any of the inventions claimed in our or our licensor&#146;s patents or patent applications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The America Invents Act also includes a number of
significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to
attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would
not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned
or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the patent positions of companies in the development and commercialization of biopharmaceuticals are particularly uncertain. Recent U.S. Supreme Court
rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and
enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on
our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have limited foreign intellectual property
rights and may not be able to protect our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have limited intellectual property rights outside the
United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less
extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent
third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in
jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the
United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of, and may require a compulsory license to, patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical
products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to
challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could
provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&nbsp;years from its
earliest <FONT STYLE="white-space:nowrap">U.S.&nbsp;non-provisional&nbsp;filing</FONT> date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited.
Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from
commercializing products similar or identical to ours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our
business may be materially harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may
develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension
term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval, only one
patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence
during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time
period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products
following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our trademarks
and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to
protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based
on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Common Stock and
This Offering </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our
common stock in this offering. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our stock price is likely to be volatile. The stock market in general and the market for biopharmaceutical companies in
particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the initial public offering
price. The market price for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">results of clinical trials of our product candidates or those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">commencement or termination of collaboration, licensing or similar arrangements for our development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements by our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or
capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of expenses related to any of our product candidates or clinical development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or setbacks related to drugs that are co-administered with any of our product candidates, such as checkpoint
inhibitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expiration of market stand-off or lock-up agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general economic, industry and market conditions and overall fluctuations in the financial markets in the United States
and abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, COVID-19 has been spreading rapidly around the world since December 2019 and has negatively affected the stock market and investor sentiment. The price of
our common stock may be disproportionately affected as investors may favor traditional profit-making industries and companies during the times of market uncertainty and instability. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>An active trading market for our common stock may not develop, and you may not be able to resell your shares at or above the initial public offering price.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has been no public market for shares of our common stock. Although we anticipate that our common stock will be approved for
listing on The Nasdaq Global Select Market, or Nasdaq, an active trading market for our shares may never develop or be sustained following this offering. The initial public offering price of our common stock will be determined through negotiations
between us and the underwriters. This initial public offering price may not be indicative of the market price of our common stock after this offering. In the absence of an active trading market for our common stock, investors may not be able to sell
their common stock at or above the initial public offering price or at the time that they would like to sell. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution
to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or current or future product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of private and public equity
offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale
of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that may materially adversely affect your rights as
a common stockholder. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt,
acquiring, selling or licensing intellectual property rights, making capital expenditures, declaring dividends, or other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to meet
certain milestones in connection with debt financing and the failure to achieve such milestones by certain dates may force us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us which
could have a material adverse effect on our business, operating results and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we raise funds through additional collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or current or future product candidates or to grant licenses on
terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, scale back or discontinue the development and commercialization of one or more of our
product candidates, delay our pursuit of potential in-licenses or acquisitions or grant rights to develop and market current or future product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering. Based on the initial public
offering price of $8.00&nbsp;per share, purchasers of common stock in this offering will experience immediate dilution of $4.95&nbsp;per share in net tangible book value of the common stock. In addition, investors purchasing common stock in this
offering will contribute 52.1% of the total amount invested by stockholders since inception but will only own 32.4% of the shares of common stock outstanding. In the past, we issued options and other securities to acquire common stock at prices
significantly below the initial public offering price. To the extent these outstanding securities are ultimately exercised, investors purchasing common stock in this offering will sustain further dilution. See &#147;Dilution&#148; for a more
detailed description of the dilution to new investors in the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an &#147;emerging growth company&#148; as defined in the JOBS Act and a &#147;smaller reporting company&#148;
as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our
common stock less attractive to investors and adversely affect the market price of our common stock. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an &#147;emerging growth company,&#148; as
defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earlier of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or
more; (ii)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years;
or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the
prior June&nbsp;30th. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies.
These exemptions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of
2002, or Section&nbsp;404; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">providing only two years of audited financial statements in addition to any required unaudited interim financial
statements and a correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval
of any golden parachute payments not previously approved. In this prospectus, we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens in this prospectus. In
particular, we have provided only two years of audited financial statements and have not included all of the executive compensation information that would be required if we were not an emerging growth company. We cannot predict whether investors
will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting
standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised
accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we no longer qualify an emerging growth company. We may take advantage of certain of the scaled disclosures
available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter,
or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal
quarter. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we are still evaluating the JOBS Act, we currently intend to take advantage of some, but not all, of the reduced regulatory and reporting
requirements that will be available to us so long as we qualify as an &#147;emerging growth company&#148; and &#147;smaller reporting company.&#148; We have elected to avail ourselves of this exemption and, therefore, we are not subject to the same
new or revised accounting standards as other public companies that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
not emerging growth companies or smaller reporting company. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or
the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. In addition, our independent registered public accounting firm will not be required to provide an
attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an &#147;emerging growth company,&#148; which may increase the risk that material weaknesses or significant deficiencies in our
internal control over financial reporting go undetected. Likewise, so long as we qualify as a &#147;smaller reporting company&#148; or an &#147;emerging growth company,&#148; we may elect not to provide you with certain information, including
certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and
securities analysts to evaluate our company. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less
active trading market for our common stock, and our stock price may be more volatile and may decline. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will incur increased costs as a result of operating
as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a
public company, and particularly after we are no longer an &#147;emerging growth company,&#148; we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting
requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In
addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the
Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas, such as &#147;say on pay&#148;
and proxy access. Emerging growth companies may implement many of these requirements over a longer period and up to five years from the pricing of this offering. We intend to take advantage of these extended transition periods but cannot guarantee
that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and
regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more
time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The
increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it
more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional
costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Section&nbsp;404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation
report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over
financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial
reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control
over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our
independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in the
financial markets due to a loss of confidence in the reliability of our financial statements. In additional, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lockup and other legal
restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Upon the closing of this offering, we will have outstanding a total of 27,798,454 shares of common stock. Of these shares, only the
shares of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable without restriction in the public market immediately following this
offering. In connection with this offering, our officers, directors and certain other stockholders, representing substantially all of our current stockholders, have agreed to be subject to a contractual lock-up with the underwriters, which will
expire 180 days after the date of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The lock-up agreements contain important exceptions that govern their applicability. The underwriters, however,
may, in their sole discretion, permit our officers, directors and other stockholders who are subject to these lock-up agreements to sell shares prior to the expiration of the lock-up agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, shares of common stock that are reserved for future issuance under our 2021 Plan and our 2021 Employee Stock Purchase Plan, each of which became effective
upon the effectiveness of the registration statement of which this prospectus forms a part, will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the&nbsp;lock-up&nbsp;agreements
and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common
stock could decline. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After this offering, the holders of 8,884,661 shares of our common stock will be entitled to rights with respect to the registration of their
shares under the Securities Act, subject to the&nbsp;180-day&nbsp;lock-up&nbsp;agreements described above. See &#147;Description of Capital Stock&#151;Registration Rights.&#148; Registration of these shares under the Securities Act would result in
such shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse
effect on the trading price of our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have broad discretion in how we use the proceeds of this offering and may not use these proceeds
effectively, which could affect our results of operations and cause our stock price to decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will have considerable discretion in the application of
the net proceeds of this offering. We intend to use the net proceeds from this offering to fund discovery and clinical development efforts as well as to further expand our manufacturing platform and capabilities, to grow our infrastructure to
support our pipeline, and to fund new and ongoing research activities, working capital and other general corporate purposes, which may include funding for the hiring of additional personnel, capital expenditures and the costs of operating as a
public company. As a result, investors will be relying upon management&#146;s judgment with only limited information about our specific intentions for the use of the balance of the net proceeds of this offering. We may use the net proceeds for
purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of
gain. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the
growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable
future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our executive officers, directors, principal stockholders and their affiliates will continue to exercise significant
influence over our company after this offering, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately following the completion of this offering, and disregarding any shares of common stock that they purchase in this offering, the existing holdings of our
executive officers, directors, principal stockholders and their affiliates will represent beneficial ownership, in the aggregate, of approximately 48.5% of our outstanding common stock with Estuardo Aguilar-Cordova and Laura Aguilar (together, both
directly and indirectly) beneficially owning approximately 28.7% of our outstanding common stock, and with entities and persons affiliated with PBM Capital beneficially owning approximately 21.7% of our outstanding common stock, assuming no exercise
of the underwriters&#146; option to acquire additional common stock in this offering, assuming we issue the number of shares of common stock as set forth on the cover page of this prospectus and without giving effect to any potential purchases by
such persons in this offering, including pursuant to the directed share program relating to this offering. In addition, Diem Nguyen, who will join our Board of Directors prior to completion of this offering, is Chief Executive Officer of Xalud
Therapeutics, Inc., which is majority-owned by PBM Capital. As a result, these stockholders, if they act together, will be able to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including
the election of directors and any merger, consolidation or sale of all or substantially all of our assets. These stockholders acquired their shares of common stock for substantially less than the price of the shares of common stock being acquired in
this offering, and these stockholders may have interests with respect to their common stock that are different from those of investors in this offering. The concentration of voting power among these stockholders may have an adverse effect on the
price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delaying, deferring or preventing a change of control of us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">impeding a merger, consolidation, takeover or other business combination involving us; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See the section of this prospectus titled &#147;Principal Stockholders&#148; for more information regarding the ownership of our outstanding
common stock by our executive officers, directors, principal stockholders and their affiliates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-takeover provisions under our charter documents and
Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws, which are to become effective upon the closing of this offering, will contain
provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board
will be elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a
meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a
resolution approved by the affirmative vote of a majority of the directors then in office; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause
and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by
stockholder action or to amend specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without
stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, because we
are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These
anti-takeover provisions and other provisions in our amended and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate
actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer, or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you
and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our
common stock to decline. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our bylaws to be effective upon the consummation of this offering designate certain courts as the sole and exclusive forum for
certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our bylaws that will become effective upon the completion of this offering provide that, unless we consent in writing to an alternative forum, the Court of Chancery of
the State of Delaware will be the sole and exclusive forum for any state law claim for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any of our
directors, officers, and employees to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and
restated bylaws or (iv)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, or
the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the
selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal
Forum Provision, as our principal office is located in Needham, Massachusetts. In addition, our amended and restated bylaws that will become effective upon the completion of this offering will provide that any person or entity purchasing or
otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal
securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may
impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts. Additionally, the forum selection clauses in our
amended and restated bylaws may limit our stockholders&#146; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors,
officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities
Act be brought in federal court were &#147;facially valid&#148; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur
additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of
Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise
choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If securities analysts do not publish research or
reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our common
stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the
trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these
analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to securities litigation, which is expensive and could divert management attention. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In particular, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly
volatile as a result of the COVID-19 pandemic. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the
future. Securities litigation against us could result in substantial costs and divert our management&#146;s attention from other business concerns, which could seriously harm our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The number of shares of our common stock outstanding may increase substantially as a result of our November 2018 issuance of warrants to purchase up to an
aggregate of 7,344,982 shares of common stock. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the November&nbsp;13, 2018 issuance of Series B Preferred Stock, we issued warrants to
purchase 3,672,491 shares of common stock for $6.81 per share to a purchaser of our Series B Preferred Stock which were immediately and remain fully exercisable upon issuance, or the Unconditional Series B Warrants. We also issued warrants for the
purchase of up to an additional 3,672,491 shares of common for $6.81 per share, or the Conditional Series&nbsp;B Warrants. As amended on July&nbsp;14, 2014, each of the Unconditional Series&nbsp;B Warrants and Conditional Series&nbsp;B Warrants
expire in November 2025. The Conditional Series B Warrants are only exercisable in the event that we achieve certain financial conditions as follows: 918,123 shares vest upon a financing event effected through the sale of our equity securities to
third parties resulting in at least $20,000,000 in gross proceeds, or a Financing Event, with a price per share of, or average market price (determined over a consecutive <FONT STYLE="white-space:nowrap">10-day</FONT> period) of, $12.47 per share;
an additional 918,123 shares vest upon a Financing Event with a price per share of, or average market price of, $13.20 per share; an additional 918,122 shares vest upon a Financing Event with a price per share of, or average market price of, $13.94
per share; and an additional 918,122 shares vest upon a Financing Event with a price per share of, or average market price of, $14.68 per share. Based on the initial public offering price of $8.00 per share, the consummation of our initial public
offering will not be a Financing Event that will result in the vesting of the Conditional Series B Warrants. The Unconditional Series&nbsp;B Warrants contain provisions allowing for cash and on a cashless exercise basis. The Conditional
Series&nbsp;B Warrants are only exercisable in connection with the first to occur of (i)&nbsp;a sale of the Company or (ii)&nbsp;the Conditional Series&nbsp;B Warrants&#146; expiration in November 2025. The Conditional Series B&nbsp;Warrants contain
provisions allowing for cash and on a cashless exercise basis in connection with a sale event, and only on a cashless exercise basis in connection with the Conditional Series&nbsp;B Warrants&#146; expiration in November 2025. The exercise of these
warrants in full, assuming vesting in full of the Conditional Series B Warrants and no net exercise, would result in an additional 7,344,982 shares of common stock outstanding, resulting in substantial dilution to shareholders who hold our common
stock. In addition, if the holders of these warrants, including PBM Capital, were to exercise such warrants in full, these holders could then have significant influence over the outcome of any shareholder vote, including the election of directors
and the approval of mergers or other business combination transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking
statements. Forward-looking statements in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and the success of preclinical studies and clinical trials of <FONT STYLE="white-space:nowrap">CAN-2409</FONT>
and <FONT STYLE="white-space:nowrap">CAN-3110</FONT> and any other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation of any clinical trials of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT
STYLE="white-space:nowrap">CAN-3110</FONT> and any other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our need to raise additional funding before we can expect to generate any revenues from product sales;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to conduct successful clinical trials or obtain regulatory approval for
<FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap">CAN-3110</FONT> or any other product candidates that we may identify or develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability of our research to generate and advance additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other
aspects of our business operations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to establish an adequate safety or efficacy profile for <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> <FONT
STYLE="white-space:nowrap">CAN-3110</FONT> or any other product candidates that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to manufacture CAN-2409, CAN-3110 or any other product candidate in conformity with our specifications and the
U.S. Food and Drug Administration&#146;s requirements and to scale up manufacturing of our product candidates to commercial scale, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the implementation of our strategic plans for our business, any product candidates we may develop and any companion
diagnostics; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our intellectual property position, including the scope of protection we are able to establish and maintain for
intellectual property rights covering our product candidates any companion diagnostics; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rate and degree of market acceptance and clinical utility for any product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to use the proceeds of this offering in ways that increase the value of your investment;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations related to the use of proceeds from this offering, and estimates of our expenses, future revenues,
capital requirements and our needs for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to maintain and establish collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential benefits with the continued existence of our license agreement with BWH; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our financial performance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to effectively manage our anticipated growth; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments relating to our competitors and our industry, including the impact of government regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified
professionals; and </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">other risks and uncertainties, including those listed under the section titled &#147;Risk Factors.&#148; In some cases, you
can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;could&#148;, &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148;
&#147;estimates,&#148; &#147;predicts,&#148; &#147;projects&#148;, &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance
on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#147;Risk Factors&#148; and
elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking
statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the registration statement, of which
this prospectus forms a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely
on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus also contains estimates,
projections and other information concerning our industry, our business, and the markets for our programs and product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently
subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from
our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.
While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and
are subject to change based on various factors, including those discussed under the section entitled &#147;Risk Factors&#148; and elsewhere in this prospectus. Some data are also based on our good faith estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $63.2&nbsp;million, or $73.2&nbsp;million if the
underwriters exercise in full their option to purchase additional shares, based on the initial public offering price of $8.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to use our net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $2.7&nbsp;million to fund of patient enrollment for our Phase&nbsp;3 clinical trial of CAN-2409 in
high-grade glioma through the first quarter of 2023; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $15.6&nbsp;million to fund the development, construction and qualification of our manufacturing facility and
the development of commercial manufacturing capabilities at third-party contract manufacturers through the first quarter of 2023; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $3.7&nbsp;million to fund our Phase&nbsp;3 clinical trial of CAN-2409 for newly diagnosed prostate cancer in
patients who have an intermediate- or high-risk for progression; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $8.3&nbsp;million to fund the development of CAN-2409 and CAN-3110 in other clinical trials currently in
process or contemplated; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the remaining proceeds for general corporate purposes, which may include the continued expansion of our HSV platform
technology, hiring of additional personnel and consultants, capital expenditures and the costs of operating as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on our
current plans, we believe that our existing cash and cash equivalents, together with the anticipated net proceeds to us from this offering, will enable us to fund our operations and capital expenditure requirements through the first quarter of 2023.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in new businesses, technology or assets.
Although we have no specific agreements, commitments or understandings with respect to any <FONT STYLE="white-space:nowrap">in-license</FONT> or acquisition, we evaluate such opportunities and engage in related discussions with other companies from
time to time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the
date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. The expected net
proceeds from this offering will not be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product
candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to the many inherent uncertainties in the development of our programs and product candidates, the amounts and timing of our actual expenditures and
the extent of our preclinical and clinical development activities may vary significantly depending on numerous factors, including the progress of our research and development efforts, the status of and results from preclinical studies and our
ongoing clinical trial or any clinical trials we may commence in the future, our ability to take advantage of expedited programs or to obtain regulatory approval for our product candidates and any other product candidates we may identify and pursue,
the timing and costs associated with the manufacture and supply of product candidates and any other product candidates we may identify and pursue for clinical development or commercialization, and any unforeseen cash needs. As a result, our
management will retain broad discretion over the allocation of the net proceeds from this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending our use of the net proceeds from this offering, we
intend to invest the net proceeds in a variety of capital preservation investments, including short-term and long-term, investment-grade, interest-bearing instruments and U.S. government securities. We cannot predict whether the proceeds invested
will yield a favorable return. Our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
management will retain broad discretion in the application of the net proceeds we receive from our initial public offering, and investors will be relying on the judgment of our management
regarding the application of the net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund the
development and growth of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on
our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash
dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and our capitalization as of March 31, 2021: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma basis to give effect to: </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the automatic conversion of 17,187,576 outstanding shares of our redeemable convertible preferred stock into an aggregate
of 7,066,565 shares of our common stock upon the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the filing and effectiveness of our amended and restated certificate of incorporation; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of 9,000,000 shares of our common stock
in this offering at the initial public offering price of $8.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us and the issuance of 58,754 shares of common stock pursuant to warrant
exercises subsequent to March 31, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table should be read together with &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations,&#148; &#147;Description of Capital Stock,&#148; and the consolidated financial statements and related notes appearing elsewhere in this prospectus. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AT MARCH&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA<BR>AS&nbsp;ADJUSTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands, except share and per&nbsp;share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.01 par value; 17,187,676 shares authorized, issued and
outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; Equity (Deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preferred stock, $0.01 par value; 17,187,676 shares authorized, issued or outstanding, actual; no shares
authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.01 par value; 75,000,000 shares authorized, 11,673,135 shares issued and outstanding,
actual; 75,000,000&nbsp;shares authorized, 18,798,454 shares issued and outstanding, pro forma; 150,000,000 shares authorized, 27,798,454 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The information set forth in the table excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,079,006 shares of our common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2021
under our 2015 Stock Plan, or the 2015 Plan, at a weighted average exercise price of $1.60 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">78,307&nbsp;shares of our common stock reserved and available for future issuance under the 2015 Plan, as of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
March&nbsp;31, 2021, which will cease to be available for issuance at the time that our 2021 Stock Option and Incentive Plan, or the 2021 Plan, becomes effective; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">7,524,262 shares of our common stock reserved and available for future issuance upon exercise of the outstanding warrants,
as of June 30, 2021 at a weighted average exercise price of $6.69 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">2,054,000&nbsp;shares of our common stock that will become available for future issuance under the 2021 Plan, which will
become effective in connection with the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">293,000 shares of common stock that will become available for future issuance under our 2021 Employee Stock Purchase Plan,
or ESPP, which will become effective in connection with the completion of this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_8"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
historical net tangible book value (deficit) as of March&nbsp;31, 2021 was $(28.4) million, or $(2.44) per share of our common stock. Our historical net tangible book value (deficit) is the amount of our total tangible assets less our total
liabilities and preferred stock, which is not included within our stockholders&#146; (deficit) equity. Historical net tangible book value per share represents historical net tangible book value (deficit) divided by the 11,673,135 shares of our
common stock outstanding as of March 31, 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pro forma net tangible book value as of March&nbsp;31, 2021 was $20.6 million, or $1.10 per share of our common
stock. Pro forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an
aggregate of 7,066,565 shares of our common stock upon the closing of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of shares outstanding as of March&nbsp;31, 2021
after giving effect to the pro forma adjustment described above. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving further effect to our issuance and sale of 9,000,000 shares of our common stock in
this offering at the initial public offering price of $8.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us and the issuance of 58,754 shares of common stock subsequent to March 31,
2021, our pro forma as adjusted net tangible book value as of March&nbsp;31, 2021 would have been $84.7&nbsp;million, or $3.05 per share. This represents an immediate increase in pro forma as adjusted net tangible book value per share of $1.95 to
existing stockholders and immediate dilution of $4.95 per share in pro forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting
pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.44)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase per share attributable to the pro forma adjustment described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value per share as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
purchasing common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per share to new investors purchasing common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise their option to purchase 1,350,000 additional shares in full, our pro forma as adjusted net tangible book value per share after this
offering would be $3.25 and the dilution in pro forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering, based on the initial public offering price of $8.00 per share, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. If any shares are issued upon exercise of outstanding options, you will experience further dilution. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes on the pro forma as adjusted basis described above, the differences between the number of shares of common stock purchased from us on an
as converted to common stock basis, the total consideration paid to us and the average price per share paid by existing stockholders and by new investors purchasing shares of common stock in this offering. The calculation below is based on the
initial public offering price of $8.00 per share, before deducting underwriting discounts and commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing common stock in this offering will pay an average
price per share substantially higher than our existing stockholders paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AVERAGE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,798,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,093,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">27,798,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">138,093,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the underwriters&#146; option to purchase
additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to 64.5% of the total number of shares of our common stock outstanding after this offering, and the number of shares of
common stock held by new investors participating in this offering would be increased to 35.5% of the total number of shares of our common stock outstanding after this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on 18,798,454 shares of common stock outstanding as of June&nbsp;30, 2021, which
includes 11,673,135 shares of our common stock outstanding as of March&nbsp;31, 2021, plus the conversion of preferred stock into 7,066,565 shares of common stock and 58,754&nbsp;shares of common stock issued subsequent to March&nbsp;31, 2021
through June&nbsp;30, 2021, and excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,079,006 shares of our common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2021
under our 2015 Stock Plan, or the 2015 Plan, at a weighted average exercise price of $1.60 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">78,307&nbsp;shares of our common stock reserved and available for future issuance under the 2015 Plan, as of March 31,
2021, which will cease to be available for issuance at the time that our 2021 Stock Option and Incentive Plan, or the 2021 Plan, becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">7,524,262 shares of our common stock reserved and available for future issuance upon exercise of the outstanding warrants
as of June&nbsp;30, 2021, at a weighted average exercise price of $6.69 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">2,054,000&nbsp;shares of our common stock that will become available for future issuance under the 2021 Plan, which will
become effective in connection with the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">293,000&nbsp;shares of common stock that will become available for future issuance under our 2021&nbsp;Employee Stock
Purchase Plan, or ESPP, which will become effective in connection with the completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that outstanding options
are exercised or shares are issued under our 2021 Plan, you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe that we have sufficient
funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities may result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our financial
statements and the related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You
should review the section titled &#147;Risk factors&#148; in this prospectus for a discussion of important factors that could cause actual results to differ materially from the results described below. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a late clinical stage biopharmaceutical company focused on
helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor
<FONT STYLE="white-space:nowrap">neo-antigens</FONT> and creating a <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> microenvironment at the site of injection. Our approach combines an <FONT STYLE="white-space:nowrap">in-depth</FONT>
knowledge of viral immunotherapy with extensive clinical experience across a wide range of indications. Based on the broad range of data that we have generated from our preclinical models and clinical trials using our approach, we have observed what
we believe to be systemic immune response against locally injected tumors and their distant metastases. We have established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV)
constructs. In our clinical results to date from <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> our lead product from our adenovirus platform, and <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> our lead product candidate from our HSV platform,
we have observed that these candidates may have the potential to address significant unmet patient need and improve clinical outcomes in novel indications across broader patient populations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our formation, we have devoted substantially all our resources to developing our oncolytic viral immunotherapy and our adenovirus platform, conducting research
and development activities, including product candidate development, recruiting skilled personnel, establishing our intellectual property portfolio, raising capital and providing general and administrative support for these operations. We have
financed our operations primarily through proceeds from the sale of convertible notes, common stock and our convertible preferred stock. As of June 30, 2021, we have raised approximately $81.3&nbsp;million through a combination of convertible notes,
common stock, convertible preferred stock financings, and government grants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were incorporated under the laws of the State of Delaware in June 2003. Our
principal executive office is located at 117 Kendrick St, Suite 450, Needham, Massachusetts 02494. On November&nbsp;30, 2020, we formally changed our name to Candel Therapeutics, Inc., previously Advantagene, Inc. Since our formation, we have
incurred significant operating losses and have not generated any revenue from the sale of products. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and
eventual commercialization of one or more of our product candidates. Our net losses were $8.2&nbsp;million, $17.7&nbsp;million and $4.5&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, and the three months ended March&nbsp;31, 2021,
respectively. As of March&nbsp;31, 2021, we had an accumulated deficit of $48.6&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will not generate revenue from product sales unless and until we
successfully complete clinical development, obtain regulatory approval for, and successfully commercialize our product candidates. The lengthy process of securing marketing approvals for new drugs requires the expenditure of substantial resources.
Any significant delay or failure to obtain regulatory approvals would materially adversely affect our product candidates development efforts and our business overall. In addition, if we obtain regulatory approval for any of our product candidates,
we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. In addition, following the closing of this offering, we expect to incur
significant additional costs associated with operating as a public company. We anticipate that our expenses will increase significantly as we: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">advance the development of our product candidate pipeline; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate and continue research and preclinical and clinical development of potential new product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expand our infrastructure and facilities to accommodate our growing employee base and ongoing development activities;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish agreements with contract research organizations, or CROs, and third-party contract manufacturing organizations,
or CMOs, in connection with our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">develop the manufacturing process and capabilities for future clinical trials and commercialization;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacture larger quantities of our product candidates for clinical development and potential commercialization;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek marketing approvals for our product candidates that successfully complete clinical trials, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain
marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">add operational, financial and management information systems and personnel, including personnel to support our research
and development programs, any future commercialization efforts and our transition to operating as a public company following the completion of this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of these anticipated expenditures, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until
such time, if ever, as we can generate significant revenue from product sales, we expect to finance our cash needs through a combination of public or private equity or debt financings and other sources, which may include collaborations, strategic
alliances and licensing arrangements with third parties. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. Our inability to raise capital as and when needed
would have a negative impact on our financial condition and our ability to pursue our business strategy. We cannot assure you that we will ever generate sufficient revenue to achieve profitability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the numerous risks and uncertainties associated with the development of therapeutics, we are unable to predict the timing or amount of increased expenses or
when or if we will be able to achieve or maintain profitability. Even if we can generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we
may be required to raise additional capital on terms that are unfavorable to us or we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Collaborations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a party to a number of license and
collaboration agreements under which we license patents, patent applications and other intellectual property to and from third parties. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Periphagen</I></B>.
On December&nbsp;9, 2019, we entered into a series of agreements, including an exclusive license agreement, a novation agreement, an equipment purchase agreement and an intellectual property assignment agreement, collectively the Periphagen
Agreements, with Periphagen, whereby we acquired certain assets and licensed certain rights (including specified patent rights and <FONT STYLE="white-space:nowrap">know-how,</FONT> or the Licensed IP Rights) of Periphagen, primarily consisting of
exclusive rights to their technology platform and a portfolio of <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> development stage virus vectors. The primary classes of assets are <FONT STYLE="white-space:nowrap">HSV-derived</FONT> assets
expressing <FONT STYLE="white-space:nowrap">neurotrophin-3</FONT> (or <FONT STYLE="white-space:nowrap">NT-3</FONT> Assets) and other <FONT STYLE="white-space:nowrap">HSV-derived</FONT> assets (Gene Transfer Neuro-Assets). Under the license
agreement, Periphagen granted us a worldwide exclusive license with the right to grant sublicenses through multiple tiers under the Licensed IP Rights to conduct research and to develop, make, have made, use, have used, offer for sale, have sold,
export and import products incorporating the Licensed IP Rights in all fields of use except the treatment, diagnosis, and prevention of nononcologic skin diseases and conditions (including use as an aesthetic). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>BWH</I></B>. On January&nbsp;20, 2018, we entered into an exclusive option agreement, or the Option Agreement, with BWH. Pursuant to the Option Agreement, we
obtained the exclusive right from BWH to negotiate a world-wide, royalty-bearing license to develop and commercialize products covered by certain BWH patents, including those patents covering <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> in the
field of gene therapy and oncolytic vector therapy for the treatment or prevention of cancerous tumors in humans or animals, as such field is further detailed in the Option Agreement, or the Licensed Field. In consideration for BWH&#146;s granting
of the exclusive option, we paid BWH a <FONT STYLE="white-space:nowrap">non-refundable</FONT> fee of $40,000. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Option Agreement, we were required to use
reasonable efforts to enter into a clinical trial agreement with BWH. We entered into such clinical trial agreement with BWH, or the BWH Clinical Trial Agreement, on June&nbsp;19, 2018. Under the BWH Clinical Trial Agreement, we have committed to
remitting financial support for the performance of a specified Phase 1 clinical trial by BWH pursuant to a protocol summary contained in the Option Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;15, 2020, we exercised our option and entered into an exclusive patent license agreement with BWH, or
the BWH License Agreement. Under the BWH License Agreement, BWH granted to us (a)&nbsp;an exclusive, royalty-bearing license under certain of BWH&#146;s patents to make, have made, use, have used, sell and have sold certain products covered by such
licensed patents, or the Licensed Products and otherwise practice processes covered by such licensed patents, or Licensed Processes; and (b)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing license under certain other of
BWH&#146;s patents to make, have made, use, have used, sell and have sold Licensed Products, but not to sell or have sold Licensed Processes. The foregoing rights are sublicensable, subject to sublicensing terms set forth in the BWH License
Agreement. In connection with executing the BWH License Agreement, we paid a license issue fee and also agreed to reimburse BWH for all reasonable fees and expenses BWH had incurred and will incur for the preparation, filing, prosecution and
maintenance of the licensed patent rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ventagen</I></B>. On March&nbsp;1, 2014, we entered into an exclusive license agreement, or the Ventagen
Agreement, with Ventagen, a related party. The Ventagen Agreement provides Ventagen an exclusive license, with rights to grant sublicense (subject to certain terms and conditions) under any worldwide patent rights and
<FONT STYLE="white-space:nowrap">know-how</FONT> owned or controlled by us during the term of the Ventagen Agreement which cover applicable technology utilizing the delivery method of the herpes derived TK protein to tumors or other tissues via a
viral vector (as further specified therein), to research, use, have used, import, have imported, export, have exported, offer for sale, have sold, sell, distribute and market certain products for the prevention or treatment of cancer in humans and
any use in animals (or the Field of Use), or the Licensed Products, for commercial sale and distribution within Mexico, Belize, Guatemala, Honduras, El Salvador, Costa Rica, Nicaragua, Panama, Colombia and Bolivia. Ventagen is 49.5% owned by certain
of our shareholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, we had cash and cash equivalents of $29.2&nbsp;million. We believe the existing cash and cash equivalents on hand
as of March&nbsp;31, 2021, together with the anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements through the first quarter of 2023. We have based this estimate on
assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;&#151;Liquidity and capital resources.&#148; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> Pandemic </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, the World Health Organization declared the outbreak of the novel coronavirus, or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> a global pandemic, or
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which continues to spread throughout the United States and worldwide. The ultimate extent of the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business,
financial condition and results of operations is highly uncertain and will depend on future developments that cannot be predicted, including new information that may emerge concerning the severity of <FONT STYLE="white-space:nowrap">COVID-19</FONT>
and actions taken by government authorities and businesses to contain or prevent the further spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> For instance, a recurrence or continuation of <FONT STYLE="white-space:nowrap">COVID-19</FONT>
cases could cause a more widespread or severe impact on commercial activity depending on where infection rates are highest. If we or any of the third parties with whom we engage were to experience any additional shutdowns or other prolonged business
disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial
condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have been carefully monitoring the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and its potential impact on our business and
have taken important steps to help ensure the safety of our employees and their families and to reduce the spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We have established a work-from-home policy for all employees, other than those
performing or supporting business-critical operations, such as certain members of our laboratory and facilities staff. For those employees, we have implemented stringent safety measures designed to comply with applicable federal, state and local
guidelines instituted in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. We have also maintained efficient communication with our partners and clinical sites as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
has progressed. We have taken these precautionary steps while maintaining business continuity so that we can continue to progress our programs. While we have experienced some delays in enrollment and site closures at certain of our third-party
clinical trial sites, these delays have not had a material impact on our development timelines for our product candidates. We will continue to monitor developments as we address the disruptions and uncertainties relating to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. See &#147;Risk Factors&#148; for a discussion of the potential adverse impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, financial condition and results of
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of our results of operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have not generated any revenue from product
sales and do not expect to generate any revenue from sales of products in the foreseeable future. We are recognizing as research and development service revenue $1.0&nbsp;million that we received in 2014 and 2015 from Ventagen for an exclusive
license to develop products for commercial sale and development within certain countries. The $1.0&nbsp;million is being recognized as revenue over the period during which we provide services under the license agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our operating expenses since inception have
consisted solely of research and development costs and general and administrative costs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses consist primarily of costs incurred for our product development activities for our two primary drug candidates, <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap">CAN-3110.</FONT> We expense research and development costs as incurred. These include the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">employee-related costs, including salaries, benefits and stock-based compensation expense, for personnel engaged in
research, development and clinical management functions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expenses incurred under agreements with third party clinical sites for the treatment and
<FONT STYLE="white-space:nowrap">follow-up</FONT> for patients enrolled in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of acquiring and manufacturing preclinical study materials, including manufacturing registration and validation
batches; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development assets that have no alternative
future use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">payments made under third-party licensing agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs incurred to develop the manufacturing process and capabilities for future clinical trials and commercialization. Our
clinical trial material for use in our existing clinical trials was manufactured in prior years; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to compliance with quality and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs of outside consultants, primarily related to regulatory; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and
insurance, and other operating costs if specifically identifiable to research and development activities. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that our research and
development expenses will continue to increase substantially for the foreseeable future and will comprise a larger percentage of our total expenses as we complete our clinical trials and commence additional clinical trials, continue to discover and
develop additional product candidates and develop and scale our <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing capabilities. Product candidates in later stages of clinical development generally have higher development costs than
those in earlier stages of clinical development, primarily due to increased scale and duration of later stage clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot determine with certainty
the duration and costs of future clinical trials of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap">CAN-3110</FONT> or any other product candidate we may develop or if, when, or to what extent we will generate
revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the
clinical development of, or obtain regulatory approval for, any of our current or future product candidates. The duration, costs, and timing of clinical trials and development of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT
STYLE="white-space:nowrap">CAN-3110</FONT> and any other product candidate we may develop will depend on a variety of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope, rate of progress, expense and results of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our successful enrollment in and completion of clinical trials, including our ability to generate positive data from any
such trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to add and retain key research and development personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the actual probability of success for our product candidates, including their safety and efficacy, early clinical data,
competition, manufacturing capability, and commercial viability; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">significant and changing government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and receipt of any marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress of the development efforts of parties with whom we may enter into collaboration agreements, and the terms and
timing of any additional collaboration agreements, license or other arrangement, including the timing of any payments thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to complete development, construction and qualification of manufacturing facility; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to manufacturing of our product candidates or to account for any future changes in our manufacturing plans;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to successfully commercialize our product candidates, if and when approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">raising additional funds necessary to complete clinical development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain third-party insurance coverage and adequate reimbursement for our product candidates,
if and when approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the acceptance of our product candidates, if approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effectively competing with other products if our product candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned
clinical trials, or to those of our manufacturers, suppliers, or other vendors resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or similar public health crisis; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to maintain a continued acceptable safety profile for our therapies following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain patents, trade secret and other intellectual property protection and regulatory
exclusivity for our product candidates, both in the United States and internationally; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A change in the outcome of any of these variables with respect to the development of a product candidate could significantly change the costs and
timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General and administrative expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative
expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development, and administrative functions. General and administrative expenses also include legal
fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and
expenses for rent and maintenance of facilities, and other operating costs that are not specifically attributable to research and development activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect
that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our continued clinical development and manufacturing activities. Following this offering, we also expect to incur increased
expenses associated with being a public company, including costs of accounting, audit, legal, regulatory, <FONT STYLE="white-space:nowrap">and&nbsp;tax-related&nbsp;services</FONT> associated with maintaining compliance with exchange listing and
Securities and Exchange Commission, or SEC, requirements; director and officer insurance costs; and investor and public relations costs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Grant income
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Grant income consists of amounts received under a grant from the National Institute of Health for development of
<FONT STYLE="white-space:nowrap">CAN-2409</FONT> for use as a therapy for pancreatic cancer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest, dividend, and investment income </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest, dividend and investment income consists of amounts earned on investment of cash equivalents and short-term investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Change in fair value of warrant liability </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have issued two warrants to PBM ADV Holdings, LLC, one of our Series&nbsp;B preferred stockholders, to purchase up to 7,344,982 shares of our common stock with an
exercise price of $6.81 per share, and a warrant to the NC Incorporated Ohio Trust, an irrevocable trust funded by us, to purchase 162,740 shares of our common stock, $0.01 par value, at an exercise price of $1.46 per share, subject to adjustments
as specified in the warrant agreement. Certain of those warrants are recorded as a liability on our balance sheet. The warrants recorded as a liability are remeasured to their fair value at each reporting date with changes in the fair value
recognized as a component of other income (expense), net in the statements of operations and comprehensive loss. We will continue to recognize changes in the fair value of the warrant liability until the warrants are exercised, expire or qualify for
equity classification. The fair value of the warrant liability is determined based on significant inputs not observable in the market. The fair value of the warrant liability uses various valuation methods, including the Monte Carlo method, the
option-pricing method, probability-weighted expected return and the hybrid method, all of which incorporate assumptions and estimates, to value the common stock warrants. The hybrid method is often used when a company is expecting a liquidity event
in the near future and is a combination of the option-pricing and probability-weighted expected return methods. Estimates and assumptions impacting the fair value measurement include the fair value per share of the underlying shares of common stock,
risk-free interest rate, expected dividend yield, expected volatility of the price of the underlying preferred stock, and the remaining contractual term of the warrants. Therefore, the fair value may not be appropriately captured by simple models.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have generated cumulative
federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within their respective carryforward periods. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, we had federal net operating loss carryforwards, or NOLs, of approximately $28.5&nbsp;million and state NOLs of approximately
$27.6&nbsp;million which may be available to offset future taxable income. Our federal NOLs include $8.8&nbsp;million available to reduce future taxable income through 2028 and approximately $19.7&nbsp;million of NOLs that do not expire and are
available to reduce future taxable income indefinitely. The state NOLs are available to offset future taxable income through 2032. As of December&nbsp;31, 2019, we also had federal and state research and development tax credit carryforwards of
$1.2&nbsp;million and $0.7&nbsp;million, respectively, which are available to offset federal and state tax liabilities through 2036 and 2028, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Realization of future tax benefits is dependent on many factors, including our ability to generate taxable income within the NOL period. Our management has evaluated
the positive and negative evidence bearing upon the realizability of our deferred tax assets, which are comprised principally of net operating loss carryforwards and certain tax credits. Management has considered our history of cumulative net losses
incurred since inception, as well as our lack of product revenue since inception, and has determined that it is more likely than not that we will not realize the benefits of its deferred tax assets. As a result, a full valuation allowance has been
established at December&nbsp;31, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in
the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as under similar state provisions. These
ownership changes may limit the amount of NOLs that can be utilized annually to offset future taxable income. In general, an ownership change, as defined under Section&nbsp;382 of the Code, or Section&nbsp;382, results from transactions increasing
the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. We have completed several financings and not yet determined if such a limitation would be placed against our NOL. We will
make such a determination prior to the utilization of any NOL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
following table summarizes our results of operations for the years ended December&nbsp;31, 2019 and 2020 and the three months ended March 31, 2020 and 2021 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE/<BR>(DECREASE)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED&nbsp;MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE/<BR>(DECREASE)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Grant income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest, dividend and investment income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Years End December 31, 2019 and 2020 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We had research and development service revenue of $125,000 for each of the years ended December&nbsp;31, 2019 and 2020. This represents the recognition as
research and development service revenue of a portion of the $1.0&nbsp;million that we received in 2014 and 2015 from Ventagen, a related party, which is being recognized over the period during which we provide the services. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our
research and development expenses for the years ended December&nbsp;31, 2019 and 2020 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE<BR>(DECREASE)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee - related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Clinical development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Occupancy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses for the year ended December&nbsp;31, 2019 were $6.6&nbsp;million, compared with $8.8&nbsp;million for the year ended December&nbsp;31,
2020 and consisted primarily of $2.8&nbsp;million and $5.3&nbsp;million, respectively, of employee-related costs, including $138,000 and $847,000, respectively, of <FONT STYLE="white-space:nowrap">non-cash</FONT> stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
compensation expense, $1.8&nbsp;million and $2.2&nbsp;million, respectively, of clinical development costs related to our clinical trial sites and the cost of treating and following up on
patients in our clinical trials and $551,000 and $812,000, respectively, of facility and occupancy related costs. The increase of $2.1&nbsp;million for the year ended December&nbsp;31, 2020, was primarily due to an increase of $2.5&nbsp;million in
employee-related costs, an increase of $334,000 in clinical development costs, an increase of $261,000 in occupancy and facility costs and an increase of $327,000 in other research costs. These increases were partially offset by the
$1.3&nbsp;million charge for in-process research and development recorded in 2019 related to the acquisition of Periphagen. The $2.5&nbsp;million increase in employee-related costs was primarily due to the increase of $709,000 in <FONT
STYLE="white-space:nowrap">non-cash</FONT> compensation expense and an increase in the research and development headcount. In the year ended December&nbsp;31, 2019, we recorded a charge of $1.3&nbsp;million for the fair value of the technology
platform, intellectual property and virus vectors acquired from Periphagen as the assets represent <FONT STYLE="white-space:nowrap">in-process</FONT> research and development with no alternative future use. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General and administrative expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes
our general and administrative expenses for the years ended December&nbsp;31, 2019 and 2020 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE<BR>(DECREASE)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Professional and consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Occupancy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $2.6&nbsp;million for the year ended December&nbsp;31, 2019 compared with $5.2&nbsp;million for the year ended
December&nbsp;31, 2020 and consisted primarily of $1.2&nbsp;million and $2.7&nbsp;million, respectively, of employee-related costs, including $262,000 and $1.3&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> stock compensation
expense, $825,000 and $2.0&nbsp;million, respectively, of professional and consulting fees and $204,000 and $256,000, respectively, of facility and other occupancy related costs. The increase of $2.6&nbsp;million was primarily due to an increase of
$1.4&nbsp;million in employee &#150; related costs as we increased our general and administrative headcount to manage growth, including an increase of $1.0&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation expense, and an
increase of $1.2&nbsp;million in professional and consulting fees. The increase in professional and consulting fees is primarily due to an increase in fees paid to personnel search firms, public relations consultants, commercial market research
firms and legal and accounting firms. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Grant income </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Grant income
was $571,000 for the year ended December&nbsp;31, 2019 compared with $624,000 for the year ended December&nbsp;31, 2020. The grant represents amounts received under a grant from the National Institutes of Health for development of <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> for use as a therapy for pancreatic cancer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest, dividend and investment income, net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest, dividend and investment income, net was $1.1&nbsp;million for the year ended December&nbsp;31, 2019 compared with $111,000 for the year ended
December&nbsp;31, 2020 and represents the earnings on our cash equivalents and short-term investments. The decrease is primarily due to a decrease in the yields earned on cash equivalents and short term investments as well as a decrease in funds
available for investment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Change in fair value of warrant liability </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The change in fair value of our warrant liability was an increase of $844,000 for the year ended December&nbsp;31, 2019 compared to an increase of $4.6&nbsp;million for
the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of three months ended March 31, 2020 and 2021 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We had research and development service revenue of $31,000
for each of the three month periods ended March&nbsp;31, 2020 and 2021. This represents the recognition as research and development service revenue of a portion of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
$1.0&nbsp;million that we received in 2014 and 2015 from Ventagen, a related party, which is being recognized over the period during which we provide the services. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our
research and development expenses for the three months ended March&nbsp;31, 2020 and 2021 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED&nbsp;MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE</B><br><B>(DECREASE)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Clinical development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Search fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Occupancy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses for the three months ended March&nbsp;31, 2020 were $1.6&nbsp;million, compared with $2.8&nbsp;million for the three months ended
March&nbsp;31, 2021 and consisted primarily of $888,000&nbsp;and $1.5&nbsp;million, respectively, of employee-related costs, including $(85,000) and $115,000, respectively, of <FONT STYLE="white-space:nowrap">non-cash</FONT> stock compensation
expense, $506,000 and $586,000, respectively, of clinical development costs related to our clinical trial sites and the cost of treating and following up on patients in our clinical trials, $0 and $202,000 respectively, of fees paid to employee
search firms and $170,000 and $129,000, respectively, of facility and occupancy related costs. The increase of $1.1&nbsp;million for the three months ended March&nbsp;31, 2021, was primarily due to an increase of $607,000 in employee-related costs,
an increase of $80,000 in clinical development costs, an increase of $202,000 in employee search costs, a decrease of $41,000 in occupancy and facility costs, and an increase of $284,000 in other research costs consisting primarily of increases in
manufacturing and regulatory expenses. The $607,000&nbsp;increase in employee-related costs was primarily due to the increase of $200,000 in non-cash compensation expense and an increase in the research and development headcount. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General and administrative expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes
our general and administrative expenses for the three months ended March&nbsp;31, 2020 and 2021 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED<BR>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE</B><br><B>(DECREASE)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Professional and consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Occupancy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $728,000 for the three months ended March&nbsp;31, 2020 compared with $1.9&nbsp;million for the three months ended
March&nbsp;31, 2021 and consisted primarily of $413,000 and $1.0&nbsp;million, respectively, of employee-related costs, including $53,000 and $316,000, respectively, of <FONT STYLE="white-space:nowrap">non-cash</FONT> stock compensation expense,
$180,000 and $749,000, respectively, of professional and consulting fees and $63,000 and $63,000, respectively, of facility and other occupancy related costs. The increase of $1.2&nbsp;million was primarily due to an increase of $618,000 in employee
&#150; related costs as we increased our general and administrative headcount to manage growth, including an increase of $263,000 in non-cash compensation expense, and an increase of $569,000 in professional and consulting fees. The increase in
professional and consulting fees is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
primarily due to an increase in fees paid to personnel search firms, public relations consultants, commercial market research firms, legal firms and accounting firms. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Grant income </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Grant income was $163,000 for the three months ended
March&nbsp;31, 2020 compared with $191,000 for the three months ended March&nbsp;31, 2021. The grant represents amounts received under a grant from the National Institutes of Health for development of <FONT STYLE="white-space:nowrap">CAN-2409</FONT>
for use as a therapy for pancreatic cancer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest, dividend and investment income, net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest, dividend and investment income, net was an expense of $72,000 for the three months ended March&nbsp;31, 2020 compared with an expense of $12,000 for the three
months ended March&nbsp;31, 2021 and represents the earnings on our cash equivalents and short-term investments net of interest expense on our outstanding debt obligations. The decrease is primarily due to a decrease in the yields earned on cash
equivalents and short term investments, a decrease in funds available for investment and a decrease in outstanding debt obligations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Change in fair value of
warrant liability </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The change in fair value of our warrant liability was a decrease in value of $455,000 for the three months ended March&nbsp;31, 2020.
There was no change in the warrant liability for the three months ended March&nbsp;31, 2021. The decrease in the warrant liability for the three months ended March 31, 2020 was due to the decline in the stock market in the first quarter 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and capital resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have not generated
any revenue from product sales and have incurred significant operating losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our product candidates. We
expect that our research and development and general and administrative costs will continue to increase significantly, including in connection with conducting clinical trials for our product candidates, developing our manufacturing capabilities and
building and qualifying our manufacturing facility to support clinical trials and commercialization and providing general and administrative support for our operations, including the cost associated with operating as a public company. As a result,
we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently have any approved products and have never generated any revenue from product sales. We have financed our operations primarily through proceeds from
government grants and from the sale of our convertible preferred stock. As of June 30, 2021, we have raised approximately $81.3&nbsp;million, including $15.2&nbsp;million of government grants and $66.1&nbsp;million from the sale of convertible
preferred stock. Our cash, cash equivalents and short-term investments totaled $29.2&nbsp;million as of March&nbsp;31, 2021. We had $0.5 million of long-term debt as of March&nbsp;31, 2021 with a maturity in November 2027. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash flows </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our sources and uses of
cash for the periods presented (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEARS ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED<BR>MARCH 31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash flows for the years ended December&nbsp;31, 2019 and 2020 and the three months ended March 31, 2020 and 2021 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating activities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities for the
year ended December&nbsp;31, 2019 was $5.2&nbsp;million, primarily consisting of a net loss of $8.2&nbsp;million as we incurred expenses associated with our clinical programs. In addition, we had <FONT STYLE="white-space:nowrap">non-cash</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
charges of $2.6&nbsp;million for the write off on in process research and development, change in the fair value of the warrant liability, stock-based compensation expense and depreciation and
amortization. Net cash used in operating activities was also impacted by $0.5&nbsp;million in changes in operating assets and liabilities, including an increase of $0.4&nbsp;million in accrued expenses, $0.3&nbsp;million in deferred rent,&nbsp;and
$13,000 in accounts payable, which were partially offset by an increase of $4,000 in prepaid expenses and a decrease of $125,000 in deferred revenue. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used
in operating activities for the year ended December 31, 2020 was $9.1 million, primarily consisting of a net loss of $17.7 million as we incurred expenses associated with our clinical programs and we increased our headcount. In addition, we had
non-cash charges of $6.8 million for the change in the fair value of the warrant liability, stock-based compensation expense and depreciation and amortization. Net cash used in operating activities was also impacted by $1.8 million in changes in
operating assets and liabilities, including an increase of $1.5&nbsp;million in accrued expenses, $0.3 million in accounts payable, $121,000 in deferred rent, and a decrease of $60,000 in prepaid expenses, which were partially offset by an increase
of $83,000 in other long term assets and a decrease of $125,000 in deferred revenue. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities for the three months ended
March&nbsp;31, 2020 was $2.2&nbsp;million, primarily consisting of a net loss of $1.8&nbsp;million and the impact of <FONT STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and amortization and
<FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense of $16,000 and <FONT STYLE="white-space:nowrap">non-cash</FONT> credits of $455,000 for a decrease in the fair value of the warrant liability and a reduction in <FONT
STYLE="white-space:nowrap">non-cash</FONT> stock compensation expense. Net cash used in operating activities was also impacted by changes in operating assets and liabilities which were insignificant. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities for the three months ended March&nbsp;31, 2021 was $5.6&nbsp;million, primarily consisting of a net loss of $4.5&nbsp;million as
we incurred expenses associated with our clinical programs and we increased our headcount, in particular our management team, and the impact of <FONT STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and amortization, <FONT
STYLE="white-space:nowrap">non-cash</FONT> stock compensation expense and <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense of $477,000. Net cash used in operating activities was also impacted by changes in operating assets and
liabilities, including an increase of $173,000 in accounts payable which was offset by a $1.3&nbsp;million decrease in accrued expenses, a $225,000 increase in prepaids and other current assets and a $277,000 increase in other long term assets. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Investing activities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities for the
year ended December&nbsp;31, 2019 was $35.7&nbsp;million, which was attributable to a net purchase of $34.7&nbsp;million in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities,
$0.8&nbsp;million for the purchase of the assets of Periphagen and $0.2&nbsp;million for purchases of fixed assets. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by investing activities for
the year ended December 31, 2020 was $38.4 million, which was attributable to a net sale of $39.9 million in available-for-sale securities and the use of $1.5 million for purchases of fixed assets. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by investing activities for the three months ended March&nbsp;31, 2020 was $19.3&nbsp;million, and consisting of the net sale of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities for the three months
ended March&nbsp;31, 2021 was $229,000, and consisted of the purchase of fixed assets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Financing activities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the year ended December&nbsp;31, 2019 was $22.0&nbsp;million, consisting of the $22.5 million of proceeds from the
issuance of our Series C convertible preferred stock and $1,000 of proceeds from exercise of stock options and the use of $0.5&nbsp;million to make payments on notes payable to our founders. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the year ended December 31, 2020 was $490,000 consisting of $460,000 received under the Paycheck Protection Program and
$30,000 of proceeds from exercise of stock options. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the three months ended March&nbsp;31, 2020 was $1,000 and
consisting of proceeds from the exercise of stock options. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the three months ended March&nbsp;31, 2021 was $112,000
and consisting of proceeds from the exercise of stock options and warrants. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect our operating expenses to increase substantially in the future in connection with our ongoing activities, particularly as we advance <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap">CAN-3110</FONT> through research and development, clinical trials, develop our manufacturing capabilities and build and qualify our manufacturing facility, as we
research and develop additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
product candidates including preclinical activities and as we prepare for marketing approval and commercialization. In addition, following the closing of this offering, we expect to incur
additional costs associated with operating as a public company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specifically, our costs and expenses will increase as we: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">advance the clinical development of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and
<FONT STYLE="white-space:nowrap">CAN-3110;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">pursue the preclinical and clinical development of other product candidates using our HSV platform; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">develop our manufacturing capabilities, including the construction and qualification of our manufacturing facility; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expand our operational, financial, and management systems and increase personnel, including personnel to support our
operations as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to fund continued development and expansion of our manufacturing capabilities, including the
construction and qualification of our manufacturing facility, which will include construction costs, equipment, software systems and the cost of engineering production runs, with proceeds from this offering and future financing transactions. These
transactions may include the issuance of additional equity or debt or the use of credit line or other bank-sponsored financing resources. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that the
anticipated net proceeds from this offering, together with our existing cash, cash equivalents, and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements through the first quarter of 2023. We have
based this estimate on assumptions that may prove to be incorrect, and we could utilize our available capital resources sooner than we currently expect. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of
the numerous risks and uncertainties associated with the research, development, and commercialization of therapeutics, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will
depend on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress, costs, and results of our clinical development and clinical trials for
<FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap">CAN-3110;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress, costs, and results of our additional research and preclinical development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to establish and maintain collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA and comparable foreign regulatory
authorities, if applicable, for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs and timing of internal process development for our manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope, progress, results, and costs of any product candidates that we may derive from our HSV platform or with
collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual
property rights and defending intellectual property-related claims; hire additional personnel in research, manufacturing, and regulatory and clinical development, as well as management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other products, product
candidates, or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and
distribution for any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product
candidates receive marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public or private
equity or debt financings and other sources, which may include </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">collaborations strategic alliances and licensing arrangements with third parties. We do not have any
committed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership
interest may be diluted, and the terms of these securities may include liquidation or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
preferences that could adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. If we raise additional funds
through other sources, such as collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, product
development, and research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce, or terminate our product
development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual obligations and commitments </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of our
contractual obligations and commitments as of March&nbsp;31, 2021: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENTS DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN<BR>1 YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1&nbsp;TO&nbsp;3&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>3&nbsp;TO&nbsp;5&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease obligation&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,489</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,378</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">651</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,489</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,378</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">651</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents future minimum lease payments under our operating leases for office and laboratory space at our Needham, Massachusetts facility (see our financial statements included elsewhere in this prospectus for
additional information on these lease agreements). </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also enter into contracts in the normal course of business with hospitals, clinics,
universities, and other third parties for clinical trials and testing and with construction contractors and process developers for the construction of our manufacturing facility. These contracts do not contain minimum purchase commitments and are
cancelable by us upon prior written notice. Payments due upon cancelation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancelation. These
payments are not included in the table above as the amount and timing of such payments are not known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical accounting policies and use of estimates </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our management&#146;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and
liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could
occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may materially differ from these estimates under different assumptions or
conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are described in more detail in the notes to our financial statements included elsewhere in this prospectus,
we believe that the following accounting policies are those most significant to the judgments and estimates used in the preparation of our consolidated financial statements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accrued Research and Development Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the process of
preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been
performed on our behalf, and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Most of our service providers invoice us in
arrears for services performed, on <FONT STYLE="white-space:nowrap">a&nbsp;pre-determined&nbsp;schedule</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts
and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to
the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">contractors and vendors working on the construction and development of our commercial-scale manufacturing facility;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinical trial sites where patients are being treated with our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">consultants providing services related to process development, regulatory and other services. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-based compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We measure stock options and other
stock-based awards granted to our employees, directors, consultants, advisors based on the fair value on the date of the grant, awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the
respective award. For stock-based awards granted to <FONT STYLE="white-space:nowrap">non-employees,</FONT> compensation expense is recognized over the vesting period which approximates the period over which services are rendered by <FONT
STYLE="white-space:nowrap">such&nbsp;non-employees.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes
option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the expected volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates
the expected term of our stock options, and our expected dividend yield. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Determination of fair value of common stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board of directors as of the
date of each option grant, with input from management, taking into consideration our most recently available third-party valuations of common stock at the time of the grants, as well as our board of directors&#146; assessment of additional objective
and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Third-party valuations, or valuation reports, were performed in accordance with the guidance
outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide,&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the December 31, 2019 valuation report prepared by a third-party, an option pricing allocation method, or OPM, was selected to allocate the total equity value
across the various securities outstanding at the time of the valuation. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the
allocation among the various holders of a company&#146;s securities changes. For the December 1, 2020 and January 1, 2021 third-party prepared valuation reports, a probability-weighted expected return method was used to determine the fair value of
the common stock. The present value of the common stock under each of these three identified scenarios was weighted based on the probability of each scenario occurring to determine the value of the common stock. These third-party valuations resulted
in a valuation of our common stock of $1.55, $3.96, $4.97 and $6.64 per share as of December&nbsp;31, 2019, December&nbsp;1, 2020, January 1, 2021 and June&nbsp;15, 2021, respectively. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to considering the results of the valuation reports, our board of directors considered various objective and subjective factors to determine the fair value
of our common stock as of each grant date, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prices at which we sold shares of convertible preferred stock and the superior rights and preferences of the
convertible preferred stock relative to our common stock at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress of our research and development programs, including the status and results of preclinical studies and
clinical trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our stage of development and commercialization and our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">external market conditions affecting the biotechnology industry and trends within that industry; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our financial position, including cash on hand, and our historical and forecasted performance and operating results;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the lack of an active public market for our common stock and our convertible preferred stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company
considering prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the analysis of IPOs and the market performance of similar companies in the biotechnology industry. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumptions underlying these valuations were highly complex and subjective and represented management&#146;s best estimates, which involved inherent uncertainties
and the application of management&#146;s judgment. As a result, if we had used different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could be materially different. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our board
of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the quoted market price of
our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent accounting pronouncements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A description of
recent accounting pronouncements that may potentially impact our financial position, results of operations, or cash flows is disclosed in Note 2 to our audited consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet arrangements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined under SEC rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and qualitative disclosures about market risk </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are exposed
to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents and short-term marketable securities, which are denominated in U.S.
dollars. We had cash, cash equivalents and short-term marketable securities of $29.2&nbsp;million, or 83.1% of our total assets, as of March&nbsp;31, 2021. Interest, dividend, and investment income earned on these assets was $177,000 for the year
ended December&nbsp;31, 2020 and $8,000 for the three months ended March 31, 2021. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. Such interest-earning instruments carry a degree of
interest rate risk; however, a change by 10% in interest rates would not have a material impact on our financial position or results of operations during the year ended December&nbsp;31, 2020 and the three months ended March&nbsp;31, 2021. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Inflation generally affects us by increasing our costs. We do not believe that inflation had a material effect on our business, financial condition or results of
operations during the years ended December 31, 2019 and 2020 and the three months ended March&nbsp;31, 2020 and 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging growth company status </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&nbsp;107 of the JOBS Act provides that an &#147;emerging growth
company,&#148; or an EGC, can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. Thus, an EGC
can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which we
remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will remain an emerging growth company until the
earliest to occur of: (1)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (2)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700.0&nbsp;million of equity
securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year
period; and (4)&nbsp;the last day of the fiscal year ending after the fifth anniversary of our initial public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a late clinical stage biopharmaceutical company focused on
helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor
<FONT STYLE="white-space:nowrap">neo-antigens</FONT> and creating a <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> microenvironment at the site of injection. Our approach combines an <FONT STYLE="white-space:nowrap">in-depth</FONT>
knowledge of viral immunotherapy with extensive clinical experience across a wide range of indications. Based on the broad range of data that we have generated from our preclinical models and clinical trials using our approach, we have observed what
we believe to be systemic immune response against locally injected tumors and their distant metastases. We have established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV)
constructs. In our clinical results to date from <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> our lead product from our adenovirus platform, and <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> our lead product candidate from our HSV platform,
we have observed that these candidates may have the potential to address significant unmet patient need and improve clinical outcomes in novel indications across broader patient populations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced product candidate, <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> is an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> adenovirus product candidate combined with the prodrug valacyclovir that has generated promising clinical activity across a range of solid tumor
indications, including our lead indication of prostate cancer. We are currently conducting, as part of our most advanced <FONT STYLE="white-space:nowrap">CAN-2409</FONT> program, a Phase 3 clinical trial in the United States under a Special Protocol
Assessment, or SPA, with the FDA for <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in patients with newly diagnosed localized prostate cancer who have an intermediate- or high-risk for progression. We expect to complete enrollment for this trial
in the third quarter of 2021 with a final data readout in 2024. We are also evaluating <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in newly diagnosed high-grade glioma. The FDA has granted CAN-2409 Fast Track designation for use in this setting
in combination with standard of care surgery and chemoradiation. We intend to initiate a potential registrational Phase 3 trial in this indication in the first half of 2022. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we are advancing development of our HSV platform product candidates for solid tumor indications. Our lead HSV product candidate, <FONT
STYLE="white-space:nowrap">CAN-3110,</FONT> is currently in an ongoing investigator-initiated Phase 1 clinical trial in our initial target indication of recurrent high-grade glioma, and we expect to report additional biomarker results in the fourth
quarter of 2021. We are also designing novel candidates based on our HSV platform for the treatment of solid tumors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our oncolytic viral immunotherapy approach
utilizes intratumoral administration of genetically engineered viruses to selectively induce tumor cell death and elicit an innate and adaptive anti-tumor immune response. Local delivery enables us to achieve these effects while aiming to minimize
systemic toxicity. The immune cells induced by these viral immunotherapies are believed to target patients&#146; specific tumor antigens, potentially improving responses in immunologically &#147;hot&#148; tumors while at the same time infiltrating
the tumor microenvironment, transforming non-inflamed &#147;cold&#148; tumors with limited immune response into &#147;hot&#148; tumors. In our data from our clinical studies in patients with cancer, we have observed increases in the expression of
immune checkpoints <FONT STYLE="white-space:nowrap">PD-1,</FONT> <FONT STYLE="white-space:nowrap">PD-L1</FONT> and <FONT STYLE="white-space:nowrap">CTLA-4</FONT> following treatment with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> supporting
the evaluation of combinations with immune checkpoint inhibitors (ICI) such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> that, typically, are only efficacious in patients with immunologically
&#147;hot&#148; tumors. While our product candidates are administered directly into the tumor, we have observed systemic immune response in our preclinical studies and clinical trials that may indicate the potential of
<FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap">CAN-3110</FONT> to induce systemic immune response against distal, uninjected tumors, also known as an &#147;abscopal&#148; effect. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe oncolytic viral immunotherapy is among the most promising cancer treatment modalities today. Treatment with oncolytic viral immunotherapy has already been
clinically validated through talimogene laherparepvec (Imlygic, Amgen), the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> intratumoral oncolytic virus. Our goal is to further improve patient outcomes from oncolytic viral immunotherapies
by selecting the optimal vector, specific transgenes and clinical indications for each tumor type while optimizing product candidate attributes, such as high-titer formulation, intratumoral administration, and storage conditions that could
potentially lower logistical barriers for patients and clinicians. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have an
advanced pipeline comprised of six ongoing clinical trials based on our two lead product candidates. In addition, we own exclusive development and commercial rights for our product candidates in major territories including the United States, Europe
and Asia. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pipeline is set forth below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g15d66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">CAN-2409,</FONT> formerly known as gene mediated cytotoxic immunotherapy, or GMCI, is our most
advanced product candidate. It is a replication deficient adenovirus that has been genetically modified to encode the enzyme thymidine kinase. This enzyme activates an orally administered prodrug, valacyclovir, a widely available, generally
well-tolerated antiviral at the site of the tumor, generating a powerful patient-specific anti-tumor immune response. We believe there are three key aspects of the mechanism of action. First, the direct, cellular killing activity is based on the
transformation of valacyclovir into a toxic nucleotide analogue that disrupts DNA synthesis and repair. This phenomenon occurs preferentially in actively dividing cancer cells, thereby providing tumor specificity. This DNA repair inhibition is also
hypothesized to be the mechanistic explanation behind the encouraging <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical activity of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in combination with radiotherapy, a treatment known
to cause DNA breaks requiring repair for continued cellular survival. Second, adenoviral capsid proteins themselves also directly trigger an immunologic response through the establishment of a proinflammatory tumor microenvironment, releasing
important cytokines such as <FONT STYLE="white-space:nowrap">GM-CSF</FONT> and <FONT STYLE="white-space:nowrap">IL-6.</FONT> We believe this contributes to the potent activation of the patient&#146;s own immune system that plays a critical role in
the <FONT STYLE="white-space:nowrap">CAN-2409</FONT> mechanism of action. Finally, the localized death of tumor cells releases numerous antigens that can be recognized by the patient&#146;s own immune system, thereby training the immune system to
target and destroy similar cancer cells that have spread to other sites in the body. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">CAN-2409</FONT> has been administered to over
700 patients with cancer to date, over 500 of whom are in ongoing, placebo-controlled randomized trials. In total, we have conducted more than 10 clinical trials with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in a range of solid tumor
indications. We have seen encouraging clinical activity and a favorable tolerability profile with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in both monotherapy and combination settings with radiotherapy, immune checkpoint inhibitor therapy,
androgen deprivation therapy (ADT), chemotherapy and surgery. Based on the totality of our clinical data generated to date, we are currently pursuing indications in prostate, brain, lung and pancreatic cancer, which we believe have the greatest
potential to address unmet need. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are conducting a Phase 3 clinical trial with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> under agreement with the FDA
through the SPA process in newly diagnosed localized prostate cancer in intermediate- and certain high-risk patients in combination with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
standard of care that comprises radiotherapy and optional ADT. Our SPA provides FDA concurrence that our key endpoints and specific critical elements of our trial design are adequate to support a
future marketing application if, among other things, we achieve the primary endpoint in the trial. The clinical trial is randomized, triple-blinded and placebo-controlled. It is targeting approximately 700 patients and is expected to be fully
enrolled in the third quarter of 2021 with final data readout anticipated in 2024. We have also received Fast Track designation by the FDA for the development of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> for the treatment of localized,
primary prostate cancer in combination with radiotherapy to improve the local control rate, decrease recurrence and improve disease-free survival. We expect that if the trial is successful and if we obtain FDA approval, <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> could be the first new FDA approved pharmacologic treatment available in over 30 years as a first line therapeutic for the over 100,000 patients who are newly diagnosed with localized prostate cancer each
year in the U.S. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also completed enrollment for a Phase 2 clinical trial with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> as monotherapy in newly
diagnosed prostate cancer patients under active surveillance. This trial has recruited 187 patients with <FONT STYLE="white-space:nowrap">low-,</FONT> intermediate- and certain high-risk localized prostate cancer. We expect to announce top line data
in 2023. We believe that this trial, if successful, could position <FONT STYLE="white-space:nowrap">CAN-2409</FONT> as a first line monotherapy treatment of patients with <FONT STYLE="white-space:nowrap">low-</FONT> and intermediate-risk prostate
cancer, thereby meaningfully expanding the addressable patient population. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also completed a Phase 1b/2 clinical trial evaluating <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> in patients with high-grade glioma. Our results demonstrated a statistically significant improvement in overall survival of approximately 3.6 months over standard of care alone (17.1 months versus 13.5
months, p=0.0417) in the overall trial population of high-grade glioma. Additionally, in a pre-specified subgroup of patients diagnosed with glioblastoma who underwent gross total surgical resection, a procedure consisting of the removal of more
than 95% of the tumor, an improvement of overall survival of approximately 8.8 months over standard of care alone was demonstrated (25.1&nbsp;months versus 16.3 months, p=0.0120). We are currently planning a Phase 3 trial in this indication and
anticipate commencement in the first half of 2022. CAN-2409 has also received Fast Track designation for use in combination with standard of care surgery and chemoradiation to improve overall survival in adults with newly diagnosed glioblastoma. We
have also received Orphan Drug designation for the use of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> for treatment of malignant brain tumors, including high-grade glioma. In addition, we have established a clinical collaboration with both
Bristol-Myers Squibb Company (BMS) and the Adult Brain Tumor Consortium (ABTC), a National Cancer Institute funded cooperative group of leading brain cancer centers that facilitates the execution of novel, early-stage trials at some of the leading
brain cancer treatment centers. This collaboration has provided support for our ongoing Phase 1 clinical trial in high-grade glioma patients, testing the combination of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and nivolumab (Opdivo, BMS). We
anticipate reporting safety and initial efficacy data from this trial in the first half of 2022. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In NSCLC, we have initiated a Phase 2 clinical trial evaluating <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> in combination with <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> checkpoint inhibitors. This open label trial is targeting enrollment of approximately 111&nbsp;patients with stage III/IV NSCLC. The
primary efficacy endpoint for this trial is response rate measured by response evaluation criteria in solid tumors (RECIST) and we expect to report safety and initial clinical activity in the first half of 2022. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our second oncolytic viral immunotherapy platform is based on a novel, next generation, genetically modified HSV that induces tumor specific oncolysis. The HSV platform
enables generation of both replication-competent and replication-deficient viral product candidates as well as capacity to clone, in the vector, up to five transgenes that will allow us to optimize our virus profile for different tumor settings. <FONT
STYLE="white-space:nowrap">CAN-3110,</FONT> our first HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue. <FONT STYLE="white-space:nowrap">CAN-3110</FONT> was
formerly known as rQNestin34.5v.2. An investigator-initiated Phase 1 clinical trial is ongoing with <FONT STYLE="white-space:nowrap">CAN-3110</FONT> in our initial target indication of recurrent high-grade glioma and we anticipate reporting
additional biomarker results in the fourth quarter of 2021. Based on the molecular targeting of <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> we believe that it could be evaluated in an expanded range of indications in the future, such as other
neurologic tumors, gastrointestinal stromal tumors, thyroid tumors and breast cancer. In addition, we are pursuing novel solid tumor discovery programs based on our HSV platform. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Corporate History and Our Team and Investors </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the
combination of our predecessor company, Advantagene, Inc. (Advantagene), with the HSV discovery platform assets acquired from Periphagen, a company focused on engineering HSV as a gene therapy vector, we formally changed our name to Candel
Therapeutics, Inc. in December 2020. Advantagene was built on a strong </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
scientific foundation and developed <FONT STYLE="white-space:nowrap">CAN-2409</FONT> over years of research and development. In December 2019, Advantagene acquired substantially all the assets of
Periphagen and in September 2020, licensed <FONT STYLE="white-space:nowrap">CAN-3110</FONT> from Mass General Brigham (formerly known as The Brigham&nbsp;and Women&#146;s Hospital). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded and are now led by a team of renowned drug developers, oncolytic viral immunotherapy experts, oncologists, immunologists and biotech business leaders.
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Paul Peter Tak, M.D., Ph.D</I>., <I>FMedSci</I>. Dr.&nbsp;Tak, our President and CEO, joined us in September 2020 and
most recently served as President and CEO of Kintai Therapeutics. Prior to his position at Kintai, he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader at GlaxoSmithKline, where he created a pipeline of
medicines in immunology and oncology. He has also trained as an internist and immunologist and served as a professor of medicine at the AMC/University of Amsterdam. Dr.&nbsp;Tak also founded the gene therapy company Arthrogen and the
immunometabolism company Sitryx. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Estuardo Aguilar-Cordova, M.D., Ph.D. </I>Dr.&nbsp;Aguilar-Cordova is our founder and Chief Scientific Officer. Prior
to starting Candel, he was deputy director of the Harvard Gene Therapy Initiative at Harvard Medical School&nbsp;and was on faculty at Baylor College of Medicine where he first became involved in viral immunotherapy in the 1990&#146;s.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Laura Aguilar, M.D., Ph.D</I>. Dr.&nbsp;Aguilar has served as our Chief Medical Officer since 2014. Before joining
Candel, she was an attending physician in pediatric oncology at the Dana Farber Cancer Institute. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Nathan Caffo</I>. Mr.&nbsp;Caffo is<I> </I>our Chief Business Officer. He was most recently the Chief Business Officer
of ALX Oncology where he played a key role in the company&#146;s initial public offering. Prior to ALX Oncology, he was the President and CEO of Presage Biosciences, a company focused on intratumoral delivery of oncology agents. To date,
Mr.&nbsp;Caffo has raised over $300&nbsp;million in equity financing over his career. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>John Canepa</I>. Mr.&nbsp;Canepa is our Chief Financial Officer. He was most recently Senior Advisor, Acting CFO at
Frequency Therapeutics, where he completed several public and private financings including the company&#146;s initial public offering. Prior to his position at Frequency Therapeutics, Mr.&nbsp;Canepa served as CFO of Agilis Pharmaceuticals and was
instrumental in its sale to PTC Therapeutics. Prior to that, he was COO and CFO of Asterand Bioscience and led its sale to a private equity group. Mr.&nbsp;Canepa was an audit partner at Arthur Andersen for 23 years where he led the firm&#146;s
worldwide life sciences practice. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are backed by a group of leading institutional life science investors, including PBM Capital, Northpond
Ventures and Sands Capital Ventures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe in the power of collective intelligence when tackling important challenges. We have therefore sought to involve
external perspectives through the formation of our Research Advisory Board that includes eminent immunologists, drug development and oncology experts. Members of the Research Advisory Board are selected based on their ability to contribute
meaningful viewpoints to Candel&#146;s internal scientific, clinical and strategic discussions in which they directly participate. There is no fixed term of service for Research Advisory Board members. Some Research Advisory Board members are
compensated as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The current members of our Research Advisory Board are as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">James Allison, Ph.D., <I>Chair of the Department of Immunology, MD Anderson Cancer Center, Director of the Parker
Institute for Cancer Research, Awardee of 2018 Nobel Prize in Physiology or Medicine</I> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Edward J. Benz, Jr., M.D., <I>President and CEO Emeritus, Dana-Farber Cancer Institute</I> </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Henry Brem, M.D., <I>Director, Department of Neurosurgery, Professor of Neurosurgery, Johns Hopkins University</I>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Roy Herbst, M.D., Ph.D., <I>Chief of Medical Oncology, Yale Cancer Center</I> </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Elizabeth Jaffee, M.D., <I>Deputy Director, Sidney Kimmel Cancer Center at Johns Hopkins University</I>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Philip Kantoff, M.D., <I>Chair, Department of Medicine, Memorial Sloan Kettering Cancer Center</I> </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Padmanee Sharma, M.D., Ph.D., <I>Professor of Genitourinary Medical Oncology and Immunology, MD Anderson Cancer Center</I>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Dr. Benz is a member of our board of directors and is compensated solely in that capacity. See
&#147;Management&#151;Director Compensation.&#148; We pay members of our Research Advisory Board that are not also members of our board of directors cash compensation in amounts equal to no more than $120,000 per year per advisor, and also grant
certain of such Research Advisory Board members options to purchase or common stock, subject to compliance with applicable conflict of interest rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our
Strengths </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe our experience and capabilities in oncolytic viral immunotherapy will bring significant benefit to cancer patients who are underserved by
the current standard of care, particularly in prostate and brain cancer. We believe our key strengths are: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Deep clinical and development experience in innovative oncolytic viral immunotherapy.</B>&nbsp;We are leveraging more
than 20 years of development history, and have deployed our lead product candidate <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in a range of oncology indications. These efforts have generated extensive clinical data in hundreds of patients and
has driven our current development focus. We continue to leverage this depth of clinical data to select new indications of interest and to efficiently execute on our clinical development strategy. We are currently developing our two product
candidates in seven clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Two potentially registrational trials for our <FONT STYLE="white-space:nowrap">CAN-2409</FONT> programs in localized
prostate and high-grade glioma, indications with significant unmet need supported by encouraging Phase 2 data.</B> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Localized prostate cancer:</I></B> Current therapeutic options for early treatment of localized prostate cancer are
limited and generally characterized by poor tolerability. A significant proportion of patients experience disease progression after receiving standard of care treatment. Based on our Phase 2 study, intermediate-risk patients receiving <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> demonstrated failure rates which were 75% lower than the outcomes reported in four large, contemporaneous clinical trials in patients with comparable disease status who were treated with similar
radiotherapy protocols, although this is limited because we have not conducted head-to-head studies. Based on the strength of this Phase 2 data, we are currently conducting a Phase 3 trial under an SPA agreement with the FDA. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>High-grade glioma:</I></B> There is presently a large unmet need in this first line patient population with current
treatment options, such as temozolomide, demonstrating an overall survival benefit of only 2.5&nbsp;months over radiotherapy alone. In our Phase 1b/2 clinical trial of patients with newly diagnosed high-grade gliomas, we compared the administration
of CAN-2409 combined with standard of care to the effects of standard of care alone. In this overall population, we demonstrated a statistically significant increase in median overall survival (mOS) of 17.1 months compared to 13.5 months observed in
the standard of care arm. We believe that the beneficial effect of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> can be further improved in the context of a precision medicine approach based on the
<FONT STYLE="white-space:nowrap">pre-specified</FONT> subgroup of patients with glioblastoma whose surgery achieved a gross total resection. In this population, <FONT STYLE="white-space:nowrap">CAN-2409</FONT> with standard of care demonstrated a
mOS of 25.1 months compared to 16.3 months in the standard of care arm. We are pursuing this precision strategy in our Phase 3 clinical trial. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Two oncolytic viral immunotherapy platforms provide versatility and </B><B>optionality to</B><B> pursue a range of
solid tumor indications.</B>&nbsp;With our clinical stage engineered adenovirus and HSV platforms, we can approach indications of interest through multiple modalities, expanding our potential to address patients in areas with high unmet need. For
example, we are currently conducting clinical trials in two different brain cancer indications with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and CAN-3110. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Attractive commercial profile and ownership of our programs.</B> We currently own development and commercialization
rights for our programs in major markets, including the U.S., Europe and Asia, allowing us to control development and seek approval in those areas as we prepare our commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Fully-integrated manufacturing strategy</B>. We expect that our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">cost-of-goods</FONT></FONT> will be substantially lower than cell- and antibody-based therapies because of our high-yield manufacturing process. We plan to manufacture our therapeutics for commercialization at our own
facility and at third-party manufacturers. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Strategy </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our goal is to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> oncolytic viral immunotherapies to transform the
lives of cancer patients. We plan to develop and commercialize our two lead product candidates, <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> for the treatment of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
a broad range of solid tumor indications, while continuing to build our pipeline through our discovery platform<I>. </I>Key elements of our strategy include the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Advance the late stage development of, and seek regulatory approval for, our lead product candidate, <FONT
STYLE="white-space:nowrap">CAN-2409,</FONT> in newly diagnosed, localized prostate cancer. </I>We are currently conducting a potentially registrational Phase 3 clinical trial in intermediate- and high-risk patients in combination with the standard
of care, radiotherapy. If approved, we believe <FONT STYLE="white-space:nowrap">CAN-2409</FONT> could be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drug for localized prostate cancer patients
with the potential to reduce disease progression and recurrence. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Advance the development of, and seek regulatory approval for, <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in both
monotherapy and combination therapy for </I><I>high-grade glioma</I><I>. </I>We have completed a Phase 2 clinical trial that showed a statistically significant overall survival benefit of approximately 8.8 months in first line glioblastoma patients
who underwent gross total resection. We plan to initiate a Phase 3 trial employing a precision medicine approach in this indication in the first half of 2022. We have also entered into a collaboration with BMS and ABTC for a Phase 1b clinical trial
in high-grade glioma patients testing the combination of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and nivolumab (Opdivo, BMS), with safety and initial efficacy data expected in the first quarter of 2022. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Advance the clinical development of <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> an oncolytic HSV with
tumor-specific enhanced replication potency. </I>An investigator-initiated Phase 1 clinical trial is ongoing in recurrent glioblastoma with additional biomarker data expected in the fourth quarter of 2021. This trial will evaluate the activity of <FONT
STYLE="white-space:nowrap">CAN-3110</FONT> in later stage disease, where we believe a replicating virus may present therapeutic advantages. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Continue to expand the development of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in other solid tumor
indications, including NSCLC and pancreatic cancer. </I>We believe we can leverage our broad clinical experience to expand the development of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in other indications.<I> </I>We have initiated a Phase 2
clinical trial in patients with NSCLC in combination with <FONT STYLE="white-space:nowrap">PD-(L)1.</FONT> We have also initiated a Phase 2 clinical trial in patients with advanced <FONT STYLE="white-space:nowrap">non-metastatic</FONT> pancreatic
adenocarcinoma. Our experience in these indications may enable us to expand in the future into other indications. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Leverage our HSV oncolytic viral immunotherapy platform to develop additional HSV product candidates. </I>Our platform
enables rapid vector engineering and generation of new candidates. Key attributes of HSV that allow targeted modifications to the virus are high capacity for genetic cargo, and the ability of our platform to generate both replication incompetent and
competent agents depending on the demands of a particular application. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Develop strategic partnerships to maximize the value of our current and future product candidates.</I> In order to
advance treatment options for a large number of patients, we may partner with other companies with complementary resources to maximize the value of our current and future product candidates. Such partnerships may allow us to pair <FONT
STYLE="white-space:nowrap">CAN-2409,</FONT> <FONT STYLE="white-space:nowrap">CAN-3110</FONT> and our future product candidates with other novel agents owned by strategic partners. Partnerships may also help realize the full potential of our product
candidates in markets where we are unlikely to pursue development or commercialization on our own. We intend to maintain significant economic interest in our product candidates and selectively consider partnership opportunities.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Complete our planned cGMP manufacturing facility</I>. We expect to develop commercial scale, fully integrated
manufacturing capabilities at our facility in Needham, Massachusetts. We will also rely on third-party contract manufacturers for clinical trial product supplies and for commercial scale manufacturing. By investing in our own manufacturing
facilities, we are positioning ourselves to leverage the off-the-shelf profile of our product candidates, by ensuring consistent and adequate commercial supply, while enabling efficient production with a low cost of goods. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Market Opportunities in Localized Prostate Cancer and High-Grade Glioma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The two indications where we have the most advanced clinical trials are localized prostate cancer and high-grade glioma. These types of cancer present substantial
market opportunities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prostate cancer is the second leading cause of cancer death among men in the U.S. The prostate cancer therapy market is estimated to be
approximately $9.9&nbsp;billion in 2019 growing to over $16.1&nbsp;billion by 2026. Although most deaths occur in patients with later stage metastatic disease, the majority of prostate cancer patients, roughly 150,000 annually in the U.S., are
initially diagnosed in the early stage of disease. Standard of care in this early, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
localized setting, leaves substantial need unaddressed. The primary interventions are surgery, radiotherapy and androgen deprivation therapy, also known as chemical castration. These treatments
have high incidence of potentially life altering side effects, including incontinence and erectile dysfunction. There is therefore a significant unmet need for a novel treatment able to forestall or prevent progression to later stages of disease
without the burdensome side effects associated with the current standard of care. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Glioblastoma is the most common form of brain cancer, comprising approximately
90% of high-grade gliomas, and has an extremely poor prognosis. Fewer than 10% of patients survive longer than 5 years, with a median overall survival of less than 15 months. The primary standard of care treatments are surgery, radiotherapy and
chemotherapy. None of these treatments offer the potential of a cure, with nearly all patients eventually succumbing to their cancer. While the annual number of drug-treatable patients with glioblastoma in the U.S. is approximately 16,000, limited
treatment options and the substantial unmet need present a significant market opportunity. One illustrative example is the agent temozolomide, which demonstrated improvement in median overall survival of less than three months compared to standard
of care, yet still generated peak annual revenue of over $1&nbsp;billion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Approach </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Conventional cancer therapies (chemotherapy, radiotherapy and surgery) often do not eradicate 100% of the tumor cells, which often leads to tumor progression or
recurrence. Deep and durable responses, therefore, are still elusive for many cancer patients. Traditionally, surgery and/or radiotherapy are used for local tumor debulking whereas chemotherapeutic agents target systemic eradication of tumor cells.
These treatment modalities, however, are often limited by toxicity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immunotherapy is a relatively new treatment modality that has expanded the anti-cancer
treatment paradigm. <FONT STYLE="white-space:nowrap">FDA-approved</FONT> immunotherapies include cytokines, cell therapies and antibodies, including checkpoint inhibitors. Much focus has been placed on harnessing the effector T cell arm of the
immune system for tumor specific immunity. Adoptive T cell therapy has shown positive results but with limited activity in solid tumors, and is not scalable for widespread use. Vaccine approaches range in complexity from peptide antigens to
autologous or allogeneic tumor cell products. The advantage of the single antigen approaches is that they can be easily manufactured and produced, however, they have the fundamental disadvantage of being potentially irrelevant for a patient&#146;s
specific tumor or immune system or easily bypassed by resistant clones. Cellular vaccines are not easily scalable and allogeneic vaccines may not bear the relevant antigens expressed by a patient&#146;s tumor. Immune checkpoint inhibitors, or ICI,
such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibodies, have transformed the treatment paradigm for
different cancer indications. However, only approximately 15 to 40% of patients overall respond to such treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are focused on the development of oncolytic
viral immunotherapy approaches, which are based on an extensive history of research. Originally, the mechanism of action of those agents was believed to be based only on the ability of the virus to induce cancer cell lysis and to resolve tumors.
Later, it was demonstrated that viral immunotherapy may induce immunogenic cell death. This effect may be enhanced by the <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> effects of the viral capsid proteins. With the dramatic emergence of
ICIs and immunotherapy as a core treatment modality, the importance of the immunostimulatory aspect of viral-mediated approaches became more widely evident. The currently understood generalized mechanism of action of oncolytic viral immunotherapies
is unique in combining both an anti-tumor cytotoxic component and an immune-stimulatory component. Together, these modalities lead to an &#147;<I><FONT STYLE="white-space:nowrap">in-situ</FONT></I> vaccination&#148; effect against the tumor. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pairing this therapeutic approach with ICI treatment is based on a strong mechanistic rationale and has shown promise in experimental models of cancer. It has been
observed that tumors that are least responsive to ICI are commonly characterized by low levels of lymphocytic infiltration and low or no <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression levels; they are referred to as &#147;cold&#148;
tumors. One of our areas of focus is the conversion of immunologically suppressed &#147;cold&#148; tumors into immunologically active &#147;hot&#148; tumors, thereby increasing their responsiveness to ICI. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specific aspects of the mechanism of action of viral immunotherapy include the following: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Direct anti-tumor cytotoxic activity. </B>Tumor specific viral mediated oncolysis is achieved by both precise delivery of the engineered virus to the tumor as well
as the virus&#146; ability to selectively replicate within a cancer cell. Various approaches have been applied in different programs to increase the specificity and potency of viral toxicity aimed at tumor cells, including genetic modifications and
use of prodrugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Broad stimulation of anti-tumor immunity. </B>The immunogenic cell death driven by oncolysis results in a potent local
and systemic immune stimulation with the increased expression of proinflammatory cytokines, chemokines and adhesion molecules. This, in turn, promotes the activation of both the innate and adaptive arms of the immune system in the presence of highly
immunogenic viral components. This broad response commonly includes recruitment and activation of antigen-presenting cells and effector immune cells to the site of the tumor. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B>Priming of the immune system against tumor antigens. </B>The lysis of cancer cells leads to the exposure of tumor-specific antigens. This early
effect, combined with intratumoral immune cell infiltration and activation, leads to antigen presentation and initiation of a local adaptive immune response targeted against a set of tumor antigens expressed by the patient&#146;s cancer cells. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B>Development of a systemic immune memory response.</B> Viral immunotherapy induces the development of a long-lasting systemic immune surveillance
against the antigens associated with the injected tumor, and consequently, tumor antigens expressed at metastatic sites. This, leads to a cytotoxic immune response against the distant tumor cells, also known as an abscopal effect. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Desirable clinical properties.</B> Viral immunotherapy has attributes that are important for a cancer therapeutic. The agents are <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> and while they have been shown to stimulate immune responses in certain patients, there is no requirement to modify them for each patient, unlike other cellular therapy approaches. The first
viral immunotherapy (Imlygic, Amgen) was approved by the FDA in 2015, providing support that additional agents in this class may have similar potential. Furthermore, safety data shown in the clinical trials and the ultimate approval of Imlygic,
supports the ability to combine viral immunotherapy with other agents due to the potential for fewer overlapping side effects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Product Candidates: Two
platforms and two clinical candidates to address diverse clinical needs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our two platforms, one based on adenovirus and the other based on HSV, provide
different and complementary sets of attributes, which allows us to utilize the product candidate that is best suited for a particular clinical application. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key
attributes across our oncolytic viral immunotherapy platforms include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Targeting a Wide Range of Cell Types.</I> Product candidates from both the HSV and adenoviral platforms can transduce a
diverse range of cell types, which we believe will allow us to address many different forms of cancer. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Off-the-Shelf</FONT></FONT> Product. </I>A
standardized product supports straightforward clinical administration, simplified manufacturing and supply chain management. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Intratumoral</I><I> Route of Administration. </I>Both of our product candidates are administered by direct injection
into the tumor site. This aims to maximize immune stimulation and minimize systemic toxicity, factors that are believed to be suboptimal with intravenous administration. For the indications that we selected, this is a straightforward procedure,
leveraging standard of care medical procedures, such as intra-prostate injection or delivery during diagnostic (bronchoscopy) or therapeutic (neurosurgery) procedures. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Cost-efficient Manufacturing. </I>Both product candidates are relatively inexpensive to manufacture, particularly when
compared to other biologic or cellular therapy treatments. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key attributes of our Adenoviral platform include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Targeting a Wide Range of Cell Types.</I> Adenoviruses can efficiently transduce cells from different lineages. This
allows us to apply this platform to many different tumor types. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Immunogenic Virus Particle.</I> The adenoviral virus particles are strong simulators of the innate immune system, a
property that contributes to immune activation at the site of administration. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>High-Titer Formulation.</I> Adenovirus can be formulated at high titers, facilitating the administration of low volume
doses sufficiently potent to induce strong activity, particularly in volume sensitive indications such as brain cancer. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Product Stability.</I> The formulation deployed in clinical trials has stability at refrigerator temperatures
(4&deg;C), supporting use at less specialized and therefore widely accessible sites such as community-based private clinics. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I><FONT STYLE="white-space:nowrap">Non-Replicating</FONT> Design</I>. Engineering the adenovirus to remove replication
ability reduces the potential for viral shedding, something which is particularly important in clinical applications such as prostate cancer. There is no need for <I>in vivo</I> amplification as the virus is highly immunogenic and can be
administered at high titers. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key Attributes of our HSV platform include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Amenable to Engineered Modifications.</I> Our knowledge of virus biology allows us to make modifications, such as those
already present in <FONT STYLE="white-space:nowrap">CAN-3110</FONT> to target certain tumor types. The tumor specific replication ability of <FONT STYLE="white-space:nowrap">CAN-3110</FONT> is regulated by the expression of ICP34.5, a gene encoding
for a protein that permits viral replication even in the presence of the interferon response that is normally able to quell viral infection. In the <FONT STYLE="white-space:nowrap">CAN-3110</FONT> construct, ICP34.5 expression is driven in gliomas,
but not in healthy brain tissue, thereby enabling replication specifically in the context of brain tumors. We believe our HSV platform will allow us to implement additional genetic modifications to leverage the use of
<FONT STYLE="white-space:nowrap">CAN-3110</FONT> in high-grade glioma and in other tumor types. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Capacity for Replication.</I> There is a strong rationale for use of a replication-competent virus that is designed to
provide potent oncolysis and <I>in vivo</I> virus amplification in high tumor volume or less anatomically accessible tumors, such as recurrent high-grade glioma. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Lower </I><I>Immunostimulatory</I><I> Potency. </I>The engineered HSV viral particle is able to persist and replicate
at the site of the tumor. This is particularly important in larger tumors formed in immune privileged, highly immunosuppressive sites; supporting the use of <FONT STYLE="white-space:nowrap">CAN-3110</FONT> in recurrent high-grade glioma.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>High Capacity for Genetic Cargos</I>. Our HSV platform allows the introduction of large genetic cargos, such as
multiple immunomodulatory genes that may further enhance the anti-tumor immune response. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Lead Product Candidate: <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the adenovirus-based <FONT STYLE="white-space:nowrap">CAN-2409</FONT> has advantageous properties
that differentiate from other viral immunotherapies. Namely, <FONT STYLE="white-space:nowrap">CAN-2409:</FONT> </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Has shown activity in a range of </I><I>solid </I><I>tumor types and in late-stage clinical trials.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Has been dosed in hundreds of patients and has shown a favorable tolerability profile.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Is engineered to be potently immunogenic but <FONT STYLE="white-space:nowrap">non-replicating</FONT> with the goal of
maximizing </I><I>the </I><I>immune response while minimizing the risk for local and systemic toxicity.</I> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Can be stored at 4</I><I>&deg;</I><I>C, facilitating the use of CAN-2409 in
<FONT STYLE="white-space:nowrap">out-patient</FONT> clinics. This aspect is particularly favorable in indications such as prostate cancer, where patients are often monitored in individual private practices. </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">CAN-2409</FONT> (international <FONT STYLE="white-space:nowrap">non-proprietary</FONT> name: aglatimagene besadenovec) is an
adenovirus-based replication-deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue. Localized injection is intended to minimize systemic
toxicities associated with systemic intravenous administration, eliminating the requirement for complex immune evasion or tumor-specific targeting mechanisms, and focuses the immune response locally against the tumor, while also activating the
desired systemic anti-tumoral response. The adenoviral construct is used as a vector to transport the thymidine kinase gene into the tumor cells at the site of injection. Thymidine kinase converts generic,
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> anti-herpes drugs, such as ganciclovir, acyclovir and valacyclovir, which we use as prodrugs, into a toxic nucleotide analogue. These agents are widely available, inexpensive and are generally
well-tolerated. Cells transduced with thymidine kinase gene undergo immunogenic cell death after exposure to these systemically administered prodrugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death
of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. This oncolytic activity is immunogenic and exposes tumor antigens that can elicit a further tumor-specific immune response. Additionally,
the virus itself stimulates a marked immune response. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">CAN-2409:</FONT> Mechanism of action - local immune
activation </U></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:4%" ALIGN="center">


<IMG SRC="g120909g29w29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines such as <FONT STYLE="white-space:nowrap">GM-CSF</FONT> and <FONT
STYLE="white-space:nowrap">IL-6</FONT> as well as chemokines, adhesion molecules and costimulatory molecules are locally upregulated, resulting in an inflamed (hot) tumor microenvironment, able to further enhance T cell activation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This local effect provides a strong mechanistic rationale for the combination of oncolytic viral immunotherapy with T&nbsp;cell checkpoint inhibitors such as <FONT
STYLE="white-space:nowrap">PD-1</FONT> or <FONT STYLE="white-space:nowrap">PD-L1</FONT> targeting antibodies. ICI agents work by unmasking the inhibitory signals provided by <FONT STYLE="white-space:nowrap">PD-L1</FONT> ligands on tumor cells when
bound to <FONT STYLE="white-space:nowrap">PD-1</FONT> receptors on T cells. By blocking this suppressive signal pharmacologically, it has been demonstrated that T cells can be unleashed to attack cancer cells and that profound clinical benefit can
be achieved, but this benefit accrues only to a minority of patients. It has been hypothesized that treatment results can be significantly improved by optimizing recognition of the specific tumor antigens by the patient&#146;s adaptive immune system
using oncolytic viral immunotherapy combined with the <FONT STYLE="white-space:nowrap">non-specific</FONT> stimulation of T cells induced by ICI treatment. It appears that a duality of signals is required: releasing the checkpoint inhibition as
described earlier, coupled with the provision of a positive, stimulatory signal to T cells. The efficient presentation of tumor specific antigens by MHC class I molecules to the immune system provides just such a specific, stimulatory signal.
Oncolytic viral immunotherapies have been shown to facilitate such cross presentation of tumor antigens and are therefore an attractive complement to <FONT STYLE="white-space:nowrap">PD-1</FONT> or <FONT STYLE="white-space:nowrap">PD-L1</FONT>
checkpoint blockade. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The immune system is highly dynamic, with continuous trafficking of different populations of immune cells throughout the body. One outcome of
this is that when T cells are locally activated against tumor-specific antigens, they can act systemically to drive an efficient immune response at sites distant from the original tumor, as is illustrated schematically in the figure above. This
abscopal effect may explain the significant effects observed at distant, uninjected sites demonstrated in experimental model of cancers. Abscopal effect has been shown with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in a mouse model of
prostate cancer. The model employed <FONT STYLE="white-space:nowrap">RM-1,</FONT> a syngeneic prostate cell line, that was implanted both in the flanks of the mice as well as systemic, via a tail vein injection to mimic metastatic disease, resulting
in the emergence of lung tumor nodules. After intratumor treatment of the flank tumor masses with either <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and systemic prodrug, alone or in combination with radiotherapy, we observed a beneficial
response in both injected and uninjected metastatic tumor. Use of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> resulted in a 38% mean reduction in tumor volume and, in the combination arm, a reduction of 61% in tumor volume. Notably, the number
of lung nodules was reduced from 20.5 in the control arm and 22.4 in the mice that received radiotherapy to 13.0 in the <FONT STYLE="white-space:nowrap">CAN-2409</FONT> arm, to 6.6 when <FONT STYLE="white-space:nowrap">CAN-2409</FONT> was combined
with radiotherapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CAN-2409 treatment teaches the immune system how to fight cancer in injected tumor and uninjected
metastases </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g01e15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The activity of CAN-2409 treatment has been shown to be dependent on CD8+ T cell involvement in mouse studies that evaluated
permutations of CAN-2409 treatment and T cell depletion. In the figure below, experimental data show that in mice bearing AKR flank xenografts that were treated with CAN-2409 and prodrug, significant tumor growth inhibition was observed. In
contrast, mice treated with the prodrug and a negative control vector showed significantly less tumor growth inhibition, providing evidence that the specific adenoviral construct of CAN-2409 is a key factor in anti-tumor activity. Moreover, when two
additional arms were treated as just described but with the addition of an antibody that depleted CD8+ T cells, very little tumor growth inhibition was observed. This supports the contention that the activity of CAN-2409 treatment is directly
dependent on CD8+ T cells. Furthermore, T cells from mice that were successfully treated with CAN-2409 and prodrug were shown to be sufficient to inhibit tumor growth when mixed with AKR tumor model cells and implanted subcutaneously in mouse
flanks. This activity was not observed with T&nbsp;cells from untreated mice, from mice that were treated with a control vector that lacked the thymidine kinase gene, or when the AKR tumor cells were xenografted alone. These data are consistent with
a T cell dependent mechanism of action of CAN-2409. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>CAN-2409 Mechanism of action &#150; T cell dependent anti-tumor activity </U></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g02y59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>CAN-2409 Mechanism of action &#150; Response to CAN-2409 treatment is </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>transferable via CD8+ T cells in mouse models of cancer </U></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g11i11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">CAN-3110</FONT> and the HSV platform technology </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">CAN-3110</FONT> is a modified HSV with specific properties that can be leveraged in diverse clinical indications. Namely, <FONT
STYLE="white-space:nowrap">CAN-3110:</FONT> </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Is engineered to provide oncolysis through tumor replication specifically in Nestin expressing cancer cells.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Has demonstrated statistically significant survival benefit in preclinical models of brain cancer.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Has demonstrated a favorable tolerability profile, not reaching a dose limiting toxicity in the dose range tested in
our Phase 1 trial. </I> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Has shown a preliminary clinical signal in a difficult to treat brain cancer population, critically defined by a highly
immunosuppressive environment. </I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Has been engineered to replicate in a range of other indications characterized by Nestin expression. </I>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Is derived from the HSV platform that also provides the potential to support expansion of our pipeline with novel
agents.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">CAN-3110</FONT> is an engineered oncolytic HSV where the expression of ICP34.5, the gene responsible
for viral replication, has been placed under the control of a tumor-specific Nestin promoter. This modification of the viral genome enables us to maintain the function of ICP34.5, an HSV protein that allows virus replication even in the presence of
a suppressive interferon response, under a strict control and only in tumor cells. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ICP34.5 is often deleted in other HSV oncolytic viruses that may be less tumor
selective with an intent of achieving favorable safety profile, but this often results in weak viruses characterized by poor replication ability and an ability to generate limited immune response. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Nestin is a cytoskeletal protein that is overexpressed in glioma cells, but it is absent in the healthy adult brain. In
<FONT STYLE="white-space:nowrap">CAN-3110,</FONT> ICP34.5 expression is controlled by the Nestin promotor enabling viral replication selectively in tumor cells. This replication-competent HSV construct provides tumor-specific cytolytic activity in
animal models, while sparing healthy cells. As set forth below, data with a tool analogue of <FONT STYLE="white-space:nowrap">CAN-3110</FONT> in a mouse model of glioma has shown survival benefit over control vectors when the agent is administered
to mice at both early and late stages of tumor growth, even after tumor implantation has led to neuropathology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CAN-3110: HSV &#147;Nestin 34.5&#148; construct
</B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g03t25.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Survival Benefit after rQNestin <FONT STYLE="white-space:nowrap">(CAN-3110</FONT> tool compound) treatment in mouse
model of high-grade glioma </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g09b98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our technology platform enables rapid HSV vector engineering and generation of new therapeutic candidates. Our platform allows rapid
and precise modifications to the virus including the insertion of high cargo capacity DNA cargo cassettes, generation of both replication incompetent and competent agents, and other attributes which provide the opportunity to optimally design HSV
technologies for specific therapeutic applications in oncolytic and immunotherapeutic indications. Our team has produced and released HSV vectors for multiple human clinical trials. Our HSV discovery platform allows us to feed and fill our pipeline,
building on our vast experience in developing oncolytic viral immunotherapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intratumoral administration </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Both CAN-2409 and CAN-3110 are intentionally administered intratumorally. We believe that directly injecting these oncolytic viral immunotherapies into a patient&#146;s
cancerous tissue helps to optimize the benefit/risk for these agents to be highly immunostimulatory at the site of the tumor, whereas systemically administered agents would need to avoid detection by the body&#146;s immune surveillance mechanisms to
avoid rapid destruction before getting to the target tumor. Intratumoral administration is straightforward and feasible in the indications that we have selected. The first FDA approved oncolytic virus, Imlygic, is intratumorally administered.
Although approved, this agent has had modest commercial success, with annual peak worldwide sales under $100M. These commercial results can be explained by a variety of factors. First, Imlygic treatment missed the endpoint of improved survival.
Second, at the time of Imlygic&#146;s approval, other successful treatments became available, such as immune check point inhibitors, and BRAF/MEK inhibitors. Third, Imlygic requires -70&deg;C storage, which necessitates specialized and expensive
equipment. CAN-2409, in contrast, is stable at 4&deg;C, which is compatible with inexpensive storage refrigerators. In summary, CAN-2409 injection is aligned with clinical practice, can be stored at regular refrigerator temperatures, and cost of
goods are expected to be low. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our <FONT STYLE="white-space:nowrap">CAN-2409</FONT> Programs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Localized Prostate Cancer </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prostate cancer is the second leading cause of
cancer deaths in men in the U.S., representing a high level of medical burden and unmet need. Approximately 200,000 men in the U.S. are diagnosed with prostate cancer annually, with more than 30,000 deaths each year. As shown in the chart below, of
the approximately 150,000 men in the U.S. who were diagnosed in 2020 before their prostate cancer had metastasized, roughly 105,000 are considered intermediate- or high-risk of progression and approximately 45,000 are considered to be <FONT
STYLE="white-space:nowrap">low-risk.</FONT> For the intermediate- and high-risk patients, the standard of care is radical prostatectomy and radiotherapy often in conjunction with androgen deprivation therapy or chemical castration. Weighing the
balance between therapeutic efficacy and side effects linked to therapy, about 10% of the intermediate-risk patients, and approximately 40% of the <FONT STYLE="white-space:nowrap">low-risk</FONT> patients decide, in consultation with their
physicians, to adopt a close monitoring approach known as active surveillance that involves periodic imaging, biomarker evaluation and biopsies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">CAN-2409</FONT> current target patient populations in localized prostate cancer
</B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g99c98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To our knowledge, the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> pharmacologic intervention indicated for newly
diagnosed localized prostate cancer is chemical castration therapy, also known as ADT. Standard of care for localized disease is primarily surgery, radiotherapy and/or ADT. Because ADT has a potentially severe side effect profile, including
impotence, hot flashes, mood changes, depression and others, these hormone treatments are reserved only for those patients that present the highest risk of localized or metastatic prostate cancer. Similarly, surgical prostatectomy can often cause
urinary dysfunction and sexual dysfunction that can last years and sometimes be permanent. Approximately one-third of men with normal baseline function will report some increase in urinary symptoms and urgency after prostatectomy and the majority of
men will experience some erectile dysfunction after treatment with either surgery or radiation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of PSA screening programs, a majority of patients are
diagnosed at early stages of disease with low grade, low volume, asymptomatic prostate cancer. Current screening methods are inadequate to definitively identify which patients are most likely to progress. As a result of these side effects, there is
a large desire to delay or prevent the need for radical treatment. As a result, many men with prostate cancer meeting the National Comprehensive Cancer Network (NCCN) guidelines for <FONT STYLE="white-space:nowrap">low-risk</FONT> prostate cancer
choose not to be treated and to undergo an intense monitoring program, known as Active Surveillance (AS), as their preferred initial course of treatment. However, within 10 years of diagnosis, between 21 and 38% of men will have developed
progressive cancer and require invasive treatments. It has been reported that 21 and 41% of patients initially under AS convert to active treatment based on progression of their disease within two and five years, and approximately 17% of men
undergoing AS choose to move to active treatments within 10 years of diagnosis, even in the absence of any evidence of progression, underscoring the level of concern around progression and the significant unmet need in this early line of treatment.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe <FONT STYLE="white-space:nowrap">CAN-2409</FONT> provides a significant commercial opportunity for therapeutic use in the newly diagnosed, localized
prostate cancer patient population, with the goal of reducing progression or recurrence of disease without significant toxicities and with a product that can be administered at outpatient facilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Clinical Experience with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> for Prostate Cancer </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have completed multiple Phase 1 clinical trials in <FONT STYLE="white-space:nowrap">non-metastatic</FONT> prostate cancer using
<FONT STYLE="white-space:nowrap">CAN-2409</FONT> as monotherapy and in combination with standard of care. The results of these trials provide evidence to support <FONT STYLE="white-space:nowrap">CAN-2409</FONT> immune activation, dosing levels and
schedules as well as a favorable tolerability profile. We have administered <FONT STYLE="white-space:nowrap">CAN-2409</FONT> to over 700 patients with localized prostate cancer to date, of which approximately 500 are in currently ongoing,
placebo-controlled randomized trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Monotherapy Activity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have observed what we believe to be a clinical response with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> as monotherapy in our Phase 1 trials. These responses
have been observed in patients with prostate cancer, including patients with newly diagnosed, localized disease, as well as those whose cancer was progressing even after radiotherapy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In newly diagnosed patients with localized prostate cancer, analysis of biopsies following monotherapy <FONT STYLE="white-space:nowrap">CAN-2409</FONT> treatment
revealed change in glandular architecture, necrosis and increased immune cell infiltration as compared to baseline biopsy. We observed in treated samples a <FONT STYLE="white-space:nowrap">4-fold</FONT> increase in the number of CD8 positive T cells
and a <FONT STYLE="white-space:nowrap">3-fold</FONT> increase in the number of CD68+ macrophages, demonstrating immune response to <FONT STYLE="white-space:nowrap">CAN-2409.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Induction of CD8+ tumor-infiltrating lymphocytes in phase 1/2 prostate cancer trial </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g22i22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In another of our Phase 1 trials, patients whose prostate cancer had progressed following radiotherapy and that presented a
persistently rising PSA level, were treated with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> as monotherapy using six dose levels, ranging from 1x10<SUP STYLE="font-size:85%; vertical-align:top">8</SUP>&#150;1x 10<SUP
STYLE="font-size:85%; vertical-align:top">11</SUP>viral particles. In 27 of the 36 patients recruited, a decrease in PSA levels was observed following a single cycle of <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> as measured by the best PSA
decrease in serial assessments within the first 3 months after treatment. PSA, while an imperfect biomarker for prostate cancer, is still widely employed for patient management in conjunction with biopsy, as rising PSA levels, and in particular PSA
doubling time are associated with disease progression. In that same trial, we observed that the PSA doubling time improved significantly (p=0.0271) from 15.9 months at baseline to 42.5 months after a single cycle of
<FONT STYLE="white-space:nowrap">CAN-2409</FONT> administration, in this treatment resistant patient population. A subset of the patients in this trial also received second or third injection courses of
<FONT STYLE="white-space:nowrap">CAN-2409.</FONT> In the majority of those patients, a decrease from <FONT STYLE="white-space:nowrap">pre-administration</FONT> PSA levels was again observed upon repeated injection. This dynamic is illustrated below
in the inset PSA graph of &#147;patient 19&#148; in this trial. The orange datapoints represent PSA levels immediately prior to <FONT STYLE="white-space:nowrap">CAN-2409</FONT> administration. After a first dose, the patient&#146;s PSA level dropped
below baseline levels for over 10 months at which point serial increases were observed, as expected in recurrent prostate cancer. Upon a second injection course of <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> a sequential drop in PSA was again
induced, indicating potentially repeated <FONT STYLE="white-space:nowrap">CAN-2409</FONT> activity even in recurrent disease subsequent to an initial response. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Best Response to First Injection (n=36) </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g98k04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in Combination Therapy </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the increasing prevalence of combination therapy for cancer patients, the ability to combine novel agents with standard of care treatments without
overlapping toxicity is of increasing importance. We believe that the favorable tolerability profile of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> demonstrated in our clinical trials is encouraging for our current and future development plans,
in combination with other agents but also as a monotherapy in lower risk patient populations that are not willing to undergo more aggressive forms of treatment. The safety data from our Phase 2 clinical trial in prostate cancer patients treated with
<FONT STYLE="white-space:nowrap">CAN-2409</FONT> in combination with standard of care are summarized in the table below. Of note is the absence of reported grade 4 treatment related adverse events and only single-patient incidence of grade 3
treatment related adverse events. It was anticipated that <FONT STYLE="white-space:nowrap">flu-like</FONT> symptoms would be evident, because <FONT STYLE="white-space:nowrap">CAN-2409</FONT> is an adenoviral gene construct known to induce a systemic
immune response. Greater than 50% of patients reported fever and/or chills often associated with viral immune activation. These symptoms, which generally manifested early and transiently, often occurred on the evening of the intratumoral
administration of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and resolved by the following morning. The rates of the gastrointestinal adverse events are consistent with those typically reported by patients undergoing radiotherapy, which is a
component of standard of care in this population. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Phase 2 prostate cancer safety data for prostate cancer patients treated with <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> in combination with standard of care </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g35d25.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Phase 2 trial data informed our agreement with the FDA under the SPA for our ongoing Phase 3 clinical trial. In our
Phase 2 clinical trial, we observed that intermediate-risk patients who received <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in combination with radiotherapy had failure rates that were 75% lower than those reported in four other
contemporaneous trials of similar patient populations as shown in the table below, although this is limited because we have not conducted head-to-head studies. Where these other clinical trials reported freedom from failure rates of between <FONT
STYLE="white-space:nowrap">75-79%,</FONT> corresponding to cumulative recurrence rates of <FONT STYLE="white-space:nowrap">21-25%,</FONT> <FONT STYLE="white-space:nowrap">CAN-2409</FONT> resulted in a 5% recurrence rate in patients with
intermediate-risk prostate cancer. The median <FONT STYLE="white-space:nowrap">follow-up</FONT> for the clinical trial of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> was 5.7 years. Similarly, results in this clinical trial also demonstrated
reduced recurrence rates in the low- and high-risk patients enrolled when compared to these other trials. Furthermore, a pathological complete response (pCR) was observed in 93% of the biopsies available at 2yrs (37%-73% in control populations). In
this trial, low-risk patients achieved a PSA of &lt; 2ng/ml in 77% of CAN-2409 treated patients versus 58% in control populations. The schema for this trial is shown below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Completed phase&nbsp;2 clinical trial of CAN-2409 combined with radiotherapy +/- androgen deprivation therapy </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g04w14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Freedom from failure in varying risk populations of localized prostate cancer </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g44i66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These were not head-to-head studies, which limits the ability to compare results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The endpoint used in our Phase 2 trial is freedom from failure (FFF), defined by the period of time between treatment and
the occurrence of a clinical or biochemical failure. Under the SPA agreement, we have selected disease-free survival (DFS) as the endpoint for our Phase 3 clinical trial. The DFS definition requires an objective detection of tumor progression. This
largely overlaps with FFF as it is often triggered by detection of an increased PSA levels (i.e., biochemical failure). We have also reanalyzed our Phase 2 data using DFS parameters, supporting the implementation of DFS as endpoint in our Phase 3
trial. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Pivotal Phase 3 Clinical Trial for Localized Prostate Cancer </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing <FONT STYLE="white-space:nowrap">CAN-2409</FONT> as a potential therapeutic option that avoids the long-term severe side effects of hormone therapy or
surgical interventions. Based on the data from our clinical trials to date, we believe that <FONT STYLE="white-space:nowrap">CAN-2409</FONT> has the potential, if approved, to be the first product candidate approved for patients with localized
prostate cancer in over 30 years. We are currently conducting a Phase 3 trial for <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> with agreement, under an SPA with the FDA for a single pivotal trial in newly diagnosed localized prostate cancer in
intermediate and high-risk patients in combination with the standard of care, radiotherapy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical trial is evaluating 711 patients, randomized 2:1.<I>
</I>Patients will receive three investigational treatment courses of <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> each consisting of four concurrent injections of transrectal ultrasound guided administration of
<FONT STYLE="white-space:nowrap">CAN-2409</FONT> followed by a course of oral valacyclovir. As illustrated schematically below, the first injection course is given at least 15 days but not more than 8 weeks before starting radiation. The second
injection course is given <FONT STYLE="white-space:nowrap">0-3</FONT> days prior to radiotherapy. The third and final injection course is delivered <FONT STYLE="white-space:nowrap">15-22</FONT> days after the second injections. A fixed dose of
valacyclovir is given for 14 days after each injection course. Standard of care external beam radiotherapy will be administered to patients throughout the course of the trial with optional ADT as determined by the treating physician. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dosing scheme for <FONT STYLE="white-space:nowrap">CAN-2409</FONT> Phase 3 prostate cancer trial </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g96s82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Trial inclusion criteria are based on patients with localized prostate cancer meeting the NCCN criteria of intermediate-risk or
patients presenting only one NCCN high-risk feature. NCCN intermediate-risk is defined as having at least one of the following: prostate serum antigen (PSA) of <FONT STYLE="white-space:nowrap">10-20</FONT> ng/ml, Gleason Score of 7, and is staged <FONT
STYLE="white-space:nowrap">T2b-T2c</FONT> via the TNM staging system. Patients may also exhibit one high-risk characteristic that may consist of a PSA of 20+ ng/ml, a Gleason Score of <FONT STYLE="white-space:nowrap">8-10,</FONT> or a cancer that is
up to stage T3a, but not more than one of these high-risk factors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our SPA agreement indicates concurrence by the FDA that specific critical elements of the design
and size of our Phase 3 trial are adequate to support future regulatory approval if, among other things, we achieve the primary endpoint in the trial. We have approximately 50 active clinical sites enrolling patients for this clinical trial, have
enrolled over 700 patients and anticipate completing enrollment in the third quarter of 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The primary endpoint for the clinical trial is DFS. Final results are
expected in 2024. This trial has been designed to have 90% power, a hazard ratio of 0.5 and an alpha of 0.05. We are assuming a 15% improvement in the active arm <FONT STYLE="white-space:nowrap">(CAN-2409)</FONT> as compared to placebo in the rate
of events measured according to the DFS definition provided above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A schema of this trial is set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Ongoing Phase 3 clinical trial of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in newly diagnosed, intermediate- and high-risk prostate cancer </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g37m21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Phase 2 Clinical Trial for Active Surveillance </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical results to date suggest that <FONT STYLE="white-space:nowrap">CAN-2409</FONT> as monotherapy may reduce the rates of biochemical failure for patients with
localized prostate cancer. In the AS setting, we will assess whether <FONT STYLE="white-space:nowrap">CAN-2409</FONT> has the potential to delay or prevent tumor progression to a later stage that demands radical treatment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Phase 2 clinical trial is a randomized, double blind, placebo-controlled study evaluating 187 patients with localized prostate cancer undergoing AS. The trial
completed enrollment in June 2019. Patients in this clinical trial were randomized 2:1, active to placebo. Patients randomized to the active arm received two investigational treatment courses of <FONT STYLE="white-space:nowrap">CAN-2409.</FONT> The
primary endpoint will assess patients&#146; risk of progression employing validated endpoints. We expect top line data from this clinical trial to be available in 2023. A schema of this trial is set forth below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Fully accrued ongoing Phase 2 clinical trial of CAN-2409 in patients with prostate cancer being managed by active surveillance </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g29h20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>High-Grade Glioma </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Glioblastoma, the most common form of high-grade glioma, is a relatively rare cancer with first-line drug treated prevalent population in the U.S. of approximately
16,113 patients. In second- and third-line this number drops to 11,642 and 6,548, respectively. Fewer than 10% of patients survive more than 5 years past their initial diagnosis. The median survival is under 15 months with the current standard of
care. Treatment in the upfront setting is surgical resection, if possible, coupled with temozolomide and/or radiotherapy. Over half of patients are candidates for maximal surgical resection and a portion succeed, achieving removal of all visible
tumor mass. This outcome is known as gross total resection. Few pharmaceutical treatment options exist for patients with high-grade glioma, with the last significant FDA approval over a decade ago. Avastin was approved in 2009, specifically for
patients with recurrent glioblastoma, and approval was granted despite the absence of a survival benefit in the registrational studies. Temozolomide was approved over 20 years ago, in 1999, with no new agent significantly supplanting its use since
then, further underscoring the profound unmet medical need in this condition. In the registrational clinical trials, temozolomide use only demonstrated <FONT STYLE="white-space:nowrap">2.5-month</FONT> overall survival benefit, yet still saw global
annual sales of over $1&nbsp;billion at its peak in 2010, shortly before generic products entered the market. The prognosis for glioblastoma that has recurred is even more dire. Patients have scarce treatment options<STRIKE></STRIKE>. Current
standard of care mainly consists of repeating first line treatment approaches or participating in a clinical trial of investigational agents. Median survival in the recurrent setting is approximately six months. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">CAN-2409</FONT> for High-Grade Glioma </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In our Phase 1b/2 clinical trial in newly diagnosed patients with high-grade gliomas, including the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> glioblastoma, <FONT STYLE="white-space:nowrap">CAN-2409</FONT> demonstrated a statistically significant increase in patient survival when combined
with current standard of care over the current standard of care alone (surgery, radiation and temozolomide). The trial compared the overall survival of 48&nbsp;enrolled patients treated at 4 clinical sites with
<FONT STYLE="white-space:nowrap">CAN-2409</FONT> plus standard of care against a matched controlled set of 134 patients enrolled at Mass General Brigham who received only standard of care. The results demonstrated that the median overall survival of
patients receiving standard of care alone was 13.5 months while patients receiving <FONT STYLE="white-space:nowrap">CAN-2409</FONT> plus standard of care was 17.1 months (p=0.0417) (left panel in the figure below). Importantly, a <FONT
STYLE="white-space:nowrap">pre-planned</FONT> analysis on a subset of patients treated surgically with gross total resection (&gt;95% of tumor removed) during surgery (18 patients compared with 44&nbsp;in the control arm), demonstrated a median
overall survival of 25.1 months in the <FONT STYLE="white-space:nowrap">CAN-2409</FONT> arm versus 16.3&nbsp;months in the standard of care group, with approximately a 50% improvement (p=0.0120) (right panel in the figure below). In this patient
population, after three years, 1 in 3 patients was alive in the <FONT STYLE="white-space:nowrap">CAN-2409</FONT> arm compared to 1 in 20 patients in the standard of care group. At the end of the study, three of the patients who received <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> were alive without progression at 43, 62.1 and 88.5 months of follow up. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Completed phase 1b/2 clinical trial of
CAN-2409 combined with standard of care in high-grade glioma </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g33i33.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">CAN-2409</FONT> +SOC </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g90h66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In our Phase 1/2 trials in high-grade glioma, CAN-2409 was generally well tolerated, with the majority of treatment-related adverse
events being Grade 1 or 2, with few reports of Grade 3 or 4 events. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Treatment Related Adverse Events from Phase 1/2 High-Grade Glioma </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g77p33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are planning a potentially registrational Phase 3 clinical trial in patients with untreated high-grade glioma. The current trial
design for this Phase 3 is an adaptive trial design, enrolling patients with glioblastoma (WHO Grade IV) intended to undergo gross total resection and standard of care chemoradiation. The primary efficacy endpoint will be overall survival, powered
to 90% with a hazard ratio of 0.65 and a type I error assumption of 2.5. We anticipate the trial to commence in the first half of 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">CAN-2409</FONT> Checkpoint Combination Therapy for High-Grade Glioma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the clinical outcomes in glioma patients treated with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and the biomarker evidence for <FONT
STYLE="white-space:nowrap">CAN-2409-mediated</FONT> immune stimulation, we performed preclinical studies to examine whether <FONT STYLE="white-space:nowrap">CAN-2409</FONT> treatment of high-grade glioma would be enhanced if combined with immune
checkpoint inhibitors to increase antitumor T cell responses. Use of either an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody or <FONT STYLE="white-space:nowrap">CAN-2409</FONT> alone resulted in <FONT
STYLE="white-space:nowrap">30%-50%</FONT> long-term survival in a murine glioma model. This percentage increased to 88% when <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> were administered together. Analysis of infiltrating T cells indicated that <FONT STYLE="white-space:nowrap">CAN-2409</FONT> increases the activation of
tumor-infiltrating CD8+ T cells, suggesting that the activity of this combination is due to a complementary biological mechanism of the two treatment modalities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
Phase 1 clinical trial for patients with newly diagnosed high-grade glioma examining the combination of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT>
nivolumab (Opdivo, BMS) in collaboration with BMS and ABTC has now completed enrollment. This is the first clinical trial to evaluate the combination of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and nivolumab in high-grade glioma patients.
Combining <FONT STYLE="white-space:nowrap">CAN-2409</FONT> with an ICI such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> may enhance anti-tumor T cell activation and expansion, with the potential for
better clinical outcome. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ongoing Phase 1 clinical trial of CAN-2409 with Opdivo in high-grade glioma </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g42e26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Oncolytic Viral Immunotherapy in High-Grade Glioma </I></B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Oncolytic viral immunotherapy is a description of a therapeutic modality that encompasses multiple different constructs and divergent pharmacologic strategies. Some
other viral approaches in high-grade glioma have previously failed, notably the investigational oncolytic viral immunotherapy agent Toca 511 that was evaluated in a Phase 2/3 trial in glioblastoma conducted by the company Tocagen. In the case of
Toca 511, we believe the similarities to CAN-2409 in glioblastoma are very limited. Toca 511 was a retroviral construct that used a different transgene, was paired with a different prodrug, and had a different development program. There are
significant differences between the programs. Of note, serotype 5 adenoviral gene constructs like CAN-2409 have been demonstrated to be highly immunogenic, whereas retroviruses are less immunogenic and therefore less likely to induce a strong innate
immune response. Critically, in the single arm Phase 1 trial of Toca 511 in glioblastoma, the data from the investigational agent was compared to a non-concurrently treated external control group that was poorly matched to the demographics of the
investigational cohort. For example, 74% of patients in the Toca 511 cohort had a Karnofsky performance score greater than 90, whereas only 51% of patients in the comparator group had such good clinical baseline status. The result was a (false)
positive comparison in the Phase 1 trial in favor of the Toca 511 treated group. Further complicating interpretation of the Phase 2/3 trial, patients received only a median of two courses of prodrug commencing 6 weeks after virus dosing. With such
significant differences between programs and in the conduct of clinical trials, we believe that such failures of other oncolytic viral immunotherapies in high-grade glioma and other indications have limited bearing on the probability of success of
the Phase 3 trial of CAN-2409 in glioblastoma. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Additional Solid Tumor Opportunities </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lung Cancer (NSCLC) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In recent years, immune checkpoint inhibitors,
specifically <FONT STYLE="white-space:nowrap">PD-1</FONT> directed agents, have transformed the treatment paradigm of NSCLC and become a backbone therapy for this indication. To date, seven immune checkpoint inhibitor products have been approved in
a number of cancer indications, and there are numerous other related drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
candidates in preclinical and clinical development. Global sales for ICIs in 2019 were approximately $23&nbsp;billion with NSCLC, accounting for between 50 and 55% of overall sales. The
commercial opportunity in NSCLC is significant. Drug treated patient populations in the US for 2020 are estimated at 75,160; 47,920 and 21,990 in first-, second- and third-line treatment, respectively. ICI use in NSCLC has become standard of care
with approximately 49% of first-line patients in the US being treated with an ICI alone or in combination with other agents. Nonetheless, the median overall survival is approximately 22 months. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To assess the potential for <FONT STYLE="white-space:nowrap">CAN-2409</FONT> to trigger immune activation and produce a &#147;hot&#148; tumor phenotype, we designed and
completed a clinical trial in patients with surgically resectable lung cancer. In this Phase 1 trial, dose escalation of intratumoral neoadjuvant <FONT STYLE="white-space:nowrap">CAN-2409</FONT> was followed by tumor resection three weeks later. The
specific goal was to obtain biological data to better understand the impact of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> on the tumor microenvironment, with a specific focus on intratumoral CD8+ T cell activation and function while assessing
effects on the systemic immune response. The effects of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> were evaluated by comparing post-injection specimens to an internal control consisting of each patient&#146;s own
<FONT STYLE="white-space:nowrap">pre-treatment</FONT> needle biopsy and blood samples, and an external cohort of matched patients who underwent standard surgical resection without <FONT STYLE="white-space:nowrap">CAN-2409.</FONT> The results showed
evidence of significant intratumoral and systemic immune activation. Selected analyses are set forth in the chart below. Analysis of peripheral blood mononuclear cells, both before and after <FONT STYLE="white-space:nowrap">CAN-2409</FONT>
administration, demonstrate a significant increase in expression of proliferation and activation markers including <FONT STYLE="white-space:nowrap">HLA-DR,</FONT> CD38 and Ki67 three weeks after <FONT STYLE="white-space:nowrap">CAN-2409</FONT>
initiation. Other relevant findings in this clinical trial included an increase in some markers of T cell activation such as <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT STYLE="white-space:nowrap">CTLA-4,</FONT> which are targets of immune
checkpoint inhibitors that have been approved for use in NSCLC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">CAN-2409</FONT> treatment stimulates local and systemic T cell
response </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g99i99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In our NSCLC Phase 1 clinical trial, two patients experienced grade&nbsp;3 dehydration with renal insufficiency, two patients
presented grade&nbsp;3 urinary retention and six patients were observed to have a grade 4 low lymphocyte count. Of significant interest, one patient, a 70 year old male with a 14.8cm stage IIIA sarcomatoid carcinoma, exhibited a nearly 50% decrease
in tumor volume at 3 weeks after CAN-2409 monotherapy treatment. Scans from this patient are shown below. Collectively, these results lead us to believe that <FONT STYLE="white-space:nowrap">CAN-2409</FONT> could provide an opportunity to improve
ICI response rates in patients with NSCLC by eliciting additional immune activation in lung cancer patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Monotherapy activity of CAN-2409 in NSCLC </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g44a52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">CAN-2409</FONT> and Checkpoint Combination Phase 2 Clinical Trial for NSCLC in Patients with
Inadequate Response to ICI </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have initiated a Phase 2 clinical trial in NSCLC patients with inadequate response to ICI that will enroll patients receiving
standard of care immune checkpoint inhibitors (plus chemotherapy if indicated) across three cohorts in combination with two courses of <FONT STYLE="white-space:nowrap">CAN-2409</FONT> plus ICI. We believe there is an opportunity to utilize <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> immune activation to improve ICI response rates with a short-term readout. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our open label Phase 2 trial will enroll 111
patients and we expect initial safety data, translational biomarkers and efficacy data to be presented in the first half of 2022. The trial schema is set forth below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Ongoing Phase 2 trial of CAN-2409 plus immune checkpoint inhibitor (ICI) and standard of care (SOC) chemotherapy for stage III/IV NSCLC Patients </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g45h32.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pancreatic Cancer </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
are currently conducting an exploratory Phase 2 clinical trial for <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in pancreatic cancer, with enrollment ongoing. We anticipate presenting interim data in 2023. In a previous Phase 1b trial, patients
with pancreatic cancer treated with <FONT STYLE="white-space:nowrap">CAN-2409</FONT> in addition to standard of care demonstrated a greater survival duration over the expected survival of the patients treated with the existing standard of care alone
in a comparison to historical trial results. Furthermore, in a number of patients where pre- and post-treatment tumor biopsies were available, a statistically significant increase in the number of CD8+ tumor infiltrating lymphocytes was observed. In
addition, the study concluded that CAN-2409 was generally well-tolerated in combination with standard of care. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CAN-2409 Induction of CD8+ tumor-infiltrating
</B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g05n11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Cancer Indications </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition to patients with prostate, brain, lung and pancreatic cancer, <FONT STYLE="white-space:nowrap">CAN-2409</FONT> has been dosed in small early-stage exploratory clinical trials in patients with ovarian cancer, malignant pleural effusion,
pediatric brain cancer and retinoblastoma, supporting the tolerability profile described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our <FONT STYLE="white-space:nowrap">CAN-3110</FONT> Program:
Recurrent Glioma </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our first <FONT STYLE="white-space:nowrap">HSV-based</FONT> program, <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> is now in a Phase 1
clinical trial in recurrent glioblastoma with additional data expected in the fourth quarter of 2021. This clinical trial is assessing <FONT STYLE="white-space:nowrap">CAN-3110</FONT> and is an open-label, single center, dose-escalation clinical
trial. The primary endpoint of this clinical trial is to analyze the safety of <FONT STYLE="white-space:nowrap">CAN-3110</FONT> use, in patients with recurrent high-grade glioma. No dose-limiting toxicities were observed in doses ranging from 1x10<SUP
STYLE="font-size:85%; vertical-align:top">6</SUP> to 1x10<SUP STYLE="font-size:85%; vertical-align:top">10</SUP> PFU in half-log increments. 30 patients have been treated in the initial dose escalation phase and 12 additional patients had been dosed
in a dose expansion phase as of April 30, 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immunohistologic studies showed persistent presence of HSV antigen and infiltration by CD8<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP> cytotoxic tumor infiltrating lymphocytes post treatment, providing support for the expected mechanism of action of CAN-3110. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Oncolytic HSV infection and CD8+ T cell infiltration after CAN-3110 treatment in patients with recurrent high-grade
glioma </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g46g30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are particularly encouraged by the clinical course of a patient who received <FONT STYLE="white-space:nowrap">CAN-3110</FONT> as a
monotherapy upon recurrence of glioblastoma. The patient was diagnosed with multicentric glioblastoma and initially treated with standard of care surgical resection followed by temozolomide and radiotherapy. The patient later recurred with two
lesions visualized on MRI. One, in the frontal region, was at the site of the initially resected mass and is labelled &#147;Secondary lesion&#148; in the MRI images below. The second, larger mass was a new lesion and is labeled as &#147;Injected
lesion&#148; in the MRI images below. The patient received <FONT STYLE="white-space:nowrap">CAN-3110</FONT> via stereotactic administration into the injected lesion. At day 56 post-injection, there was a visible decrease in the volume of both
masses. By day 112 post-injection, the volume of both masses was further reduced and the patient was able to go back to work. The patient eventually developed a third tumor and, following a stroke secondary to a diagnostic procedure, refused further
treatment, dying approximately 15 months after participation in the trial. We find this to be an encouraging case report because of the unusually favorable disease course experienced by this patient in absence of concurrent therapies. Additionally,
we have observed a median overall survival of 11.7 months in our Phase 1 trial in the first 30 patients as of the cutoff date of April 21, 2021. Given the median overall survival of 6-9 months in historical clinical trials of other investigational
agents in patients with recurrent high grade glioma, we believe this is encouraging evidence of clinical activity. We will continue to assess <FONT STYLE="white-space:nowrap">CAN-3110</FONT> in this clinical trial and anticipate reporting additional
data from this open label trial in the fourth quarter of 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Ongoing Phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g46q45.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>MRI images of patient from Phase 1 high-grade glioma trial of <FONT STYLE="white-space:nowrap">CAN-3110</FONT> with
abscopal effect </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g17h55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Clinical effect on injected and uninjected lesions. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>56 YOM, IDH wild-type, MGMT partially methylated, right frontal mesial lesion initially treated with gross total resection, chemoradiation. Recurrences at two sites.
</B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This trial is complementary to our work in the first line treatment setting of high-grade glioma with <FONT STYLE="white-space:nowrap">CAN-2409,</FONT> a <FONT
STYLE="white-space:nowrap">non-replicating</FONT> viral construct. We believe that with the larger tumor burden frequently observed in the recurrent setting and more infrequent use of surgery in this population, a replication competent viral
construct such as <FONT STYLE="white-space:nowrap">CAN-3110</FONT> may be a more appropriate approach. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Collaborations and Other Transactions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a party to a number of license and collaboration agreements under which we license patents, patent applications and other intellectual property to and from third
parties. These licenses impose various diligence and financial payment obligations on us. We expect to continue to enter into these types of license agreements in the future. We consider the following license and collaboration agreements to be
material to our business: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Periphagen</I><I>. </I>On December&nbsp;9, 2019, we entered into a series of agreements, including an exclusive license
agreement, a novation agreement, an equipment purchase agreement and an intellectual property assignment agreement, collectively the Periphagen Agreements, with Periphagen, whereby we acquired certain assets and licensed certain rights (including
specified patent rights and <FONT STYLE="white-space:nowrap">know-how,</FONT> or the Licensed IP Rights) of Periphagen, primarily consisting of exclusive rights to their technology platform and a portfolio of
<FONT STYLE="white-space:nowrap">pre-clinical,</FONT> development stage virus vectors, as well as certain physical property and equipment. The primary classes of assets are <FONT STYLE="white-space:nowrap">HSV-derived</FONT> assets expressing <FONT
STYLE="white-space:nowrap">neurotrophin-3</FONT> (or <FONT STYLE="white-space:nowrap">NT-3</FONT> Assets) and other <FONT STYLE="white-space:nowrap">HSV-derived</FONT> assets (Gene Transfer Neuro-Assets). Under the license agreement, Periphagen
granted us a worldwide exclusive license with the right to grant sublicenses through multiple tiers under the Licensed IP Rights to conduct research and to develop, make, have made, use, have used, offer for sale, have sold, export and import
products incorporating the Licensed IP Rights in all fields of use except the treatment, diagnosis, and prevention of nononcologic skin diseases and conditions (including use as an aesthetic). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">In addition, pursuant to the Periphagen Agreements, we undertook certain commitments and obligations, including the assumption of Periphagen&#146;s
outstanding loan in the principal amount of $1,000,000 with Diamyd Medical, AB. The promissory note has a contractual interest rate of 2% compounded annually, with the outstanding balance and accrued interest due upon maturity in November 2027, with
no interim installments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">In consideration for the licenses under the Periphagen Agreements, we paid Periphagen $811,000 upon signing and agreed to
make the following royalty and other payments: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B></B><FONT STYLE="white-space:nowrap">NT-3</FONT> Assets: a single digit percentage of net sales of <FONT
STYLE="white-space:nowrap">NT-3</FONT> Assets, or, if applicable, a percentage of royalties received by us in the event of a license, sublicense, assignment or other transfer to a third party for commercialization (but no greater than the original
royalty percentage we would be required to pay in the event we did not license, sublicense, assign or transfer <FONT STYLE="white-space:nowrap">NT-3</FONT> Assets); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B></B>Gene Transfer Neuro-Assets: a single digit percentage of net sales of Gene Transfer Neuro-Assets, or, if
applicable, a percentage of royalties received by us in the event of a license, sublicense, assignment or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
other transfer to a third party for commercialization to treat certain conditions and diseases (but no greater than the original royalty percentage we would be required to pay in the event we did
not license, sublicense, assign or transfer Gene Transfer Neuro-Assets); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B></B>Combination Products: a certain percentage (based on the weighted average sale price of <FONT
STYLE="white-space:nowrap">NT-3</FONT> Assets, or Gene Transfer Neuro-Assets, as applicable) of net sales of combination products; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B></B>Disposition Income: (i)&nbsp;a single digit royalty rate of certain consideration we receive for the grant of a
license, assignment or other intellectual property rights related to the <FONT STYLE="white-space:nowrap">NT-3</FONT> Assets and (ii)&nbsp;if we consummate a strategic collaboration with certain specified parties to treat non-oncolygic neurological
conditions and diseases, either 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> decile (if consummated within 18 months) or <FONT STYLE="white-space:nowrap">mid-2</FONT><SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> decile to <FONT
STYLE="white-space:nowrap">mid-3</FONT><SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> decile (if consummated thereafter) royalty rates of certain consideration we receive for the grant of a license, assignment or other intellectual property
rights related to the Gene Transfer Neuro-Assets. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">If we are required to pay royalties to a third party on any product covered
under the Periphagen Agreements, we may credit such royalty payments against the royalties owed to Periphagen in the applicable country, up to a percentage reduction in the <FONT STYLE="white-space:nowrap">mid-2</FONT><SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> decile. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The exclusive license agreement with Periphagen, or the Periphagen License Agreement,
requires us to use commercially reasonable efforts to complete a human proof of concept clinical trial of an <FONT STYLE="white-space:nowrap">NT-3</FONT> Asset, which includes certain specified clinical milestones. If we fail to use such efforts,
subject to dispute and escalation provisions in the Periphagen License Agreement, then we may submit a specified payment in lieu of satisfying such obligations. If we fail to do so, Periphagen may terminate the Periphagen License Agreement for
material breach. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The Periphagen License Agreement expires on the later of December&nbsp;9, 2069 or the end of the Royalty Term. Upon expiration, we
will have a fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to make, use, sell, offer for sale and import any products that incorporate the Licensed IP Rights. The Royalty Term
means, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the period starting on the
first commercial sale of such product in such country and concluding on the later of (i)&nbsp;expiration of patent coverage under the Licensed IP Rights or regulatory exclusivity for such product in such country; or (ii)&nbsp;the date that a certain
amount of generic competition exists in such country, provided that no Royalty Term shall exceed 30 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The Periphagen License Agreement may be
terminated (i)&nbsp;by us for convenience upon 90 days&#146; prior written notice to Periphagen, (ii)&nbsp;by Periphagen if we remain in breach of the Periphagen Agreement following a cure period to remedy the breach or (iii)&nbsp;by Periphagen if
we become bankrupt, file for bankruptcy or otherwise become insolvent or are placed in receivership. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>BWH.</I> On January&nbsp;20, 2018, we
entered into an exclusive option agreement, or the Option Agreement, with BWH. Pursuant to the Option Agreement, we obtained the exclusive right from BWH to negotiate an exclusive worldwide, royalty-bearing license to develop and commercialize
products covered by certain BWH patents, including those patents covering <FONT STYLE="white-space:nowrap">CAN-3110,</FONT> in the field of gene therapy and oncolytic vector therapy for the treatment or prevention of cancerous tumors in humans or
animals, as such field is further detailed in the Option Agreement, or the Licensed Field. In consideration for BWH&#146;s granting of the exclusive option, we paid BWH a <FONT STYLE="white-space:nowrap">non-refundable</FONT> fee of $40,000. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Under the Option Agreement, we were required to use reasonable efforts to enter into a clinical trial agreement with BWH. We entered into such clinical
trial agreement with BWH, or the BWH Clinical Trial Agreement, on June&nbsp;19, 2018. Under the BWH Clinical Trial Agreement, we have committed to remitting up to $750,000 for the performance of a specified Phase 1 clinical trial by BWH pursuant to
a protocol summary contained in the Option Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">On September&nbsp;15, 2020, we exercised our option and entered into an exclusive patent
license agreement with BWH, or the BWH License Agreement. Under the BWH License Agreement, BWH granted to us (a)&nbsp;an exclusive, royalty-bearing license under certain of BWH&#146;s patents to make, have made, use, have used, sell and have sold
certain products covered by such licensed patents, or the Licensed Products and otherwise practice processes covered by such licensed patents, or Licensed Processes; and (b)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
royalty-bearing license under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">
certain other of BWH&#146;s patents to make, have made, use, have used, sell and have sold Licensed Products, but not to sell or have sold Licensed Processes. The foregoing rights are
sublicensable, subject to sublicensing terms set forth in the BWH License Agreement. In connection with executing the BWH License Agreement, we paid a license issue fee of $100,000. We also agreed to reimburse BWH for all reasonable fees and
expenses BWH had incurred and will incur for the preparation, filing, prosecution and maintenance of the licensed patent rights, in an amount equal to $141,268. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Under the BWH License Agreement, we are required to use commercially reasonable efforts to develop and make available to the public Licensed Products in
the Licensed Field, which efforts include certain milestones detailed in the BWH License Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">Under the BWH License Agreement, prior to the
first commercial sale of the Licensed Products, we are required to pay BWH an annual license fee beginning on the fourth anniversary of the effective date. Following the first commercial sale of the Licensed Products, we are required to pay BWH an
annual minimum royalty, which amount may be credited against earned royalties starting in the fourth year following the first commercial sale. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">In
addition to such annual license fee and royalty obligations, the BWH License Agreement contains cumulative milestone payments for up to a maximum amount of $39,000,000, upon the achievement of various clinical, commercial and sales milestones of
clinical and commercial development and sales, certain of which milestones apply to development and sale of any Licensed Product as a monotherapy and certain of which milestones apply to development and sale of any Licensed Product in combination
with another therapy modality for the treatment of solid tumors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">We are required to pay royalties to BWH upon first commercial sale of the Licensed
Products, which are paid at an increasing rate as net sales increase, ranging from low single digits to high single digits. We also agreed to pay a single digit royalty rate on net sales of any products developed using certain BWH <FONT
STYLE="white-space:nowrap">know-how</FONT> but which is not covered by the licensed patent rights, or derived products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">We may reduce our royalty
obligations to BWH on any product (but not derived products) by an agreed upon percentage if we are required to pay a royalty to a third party to avoid patent infringement claims in respect of our development and commercialization of Licensed
Products. The royalty rate paid to BWH may not fall below a <FONT STYLE="white-space:nowrap">pre-specified</FONT> percentage for the sale of any product and another percentage for the sale of any derived product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Our obligation to pay royalties to BWH expires on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT>
basis on the latest of (i)&nbsp;the date upon which there ceases to be a valid claim of patent rights as further detailed in the BWH License Agreement in such country, (ii)&nbsp;expiration of statutory or regulatory exclusivity in such country and
(iii) 10 years after the first commercial sale. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The BWH License Agreement also requires us to pay a percentage of any <FONT
STYLE="white-space:nowrap">non-royalty</FONT> income attributable to the sublicense, including (i) 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> decile rates if such sublicense occurs prior to dosing the first patient in a Phase 2 trial,
(ii) 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> decile rates if such sublicense occurs after dosing the first patient in a Phase 2 trial but before approval of a BLA by the FDA (or the equivalent approval and regulatory body in another
major market country) and (iii)&nbsp;single digit rates if such sublicense occurs after approval of a BLA by the FDA (or the equivalent approval and regulatory body in another major market country). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The BWH License Agreement expires on the latest of (i)&nbsp;the 10th anniversary of the first commercial sale in the last country which has a commercial
sale, (ii)&nbsp;the date on which all relevant issued patents and filed patent applications have expired or been abandoned and (iii)&nbsp;upon the expiration of market exclusivity on the applicable product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The BWH License Agreement may be terminated by BWH (i)&nbsp;if we fail to pay any amounts owed under the terms of the agreement within a specified cure
period, (ii)&nbsp;if we fail to maintain insurance in accordance with the BWH License Agreement, (iii)&nbsp;if we file for bankruptcy, or (iv)&nbsp;if we remain in default of the BWH License Agreement for
<FONT STYLE="white-space:nowrap">non-financial</FONT> reasons following a specified cure period to remedy the breach. The BWH License Agreement may be terminated by us for convenience upon 90 days&#146; prior written notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Ventagen</I><I>. </I>On March&nbsp;1, 2014, we entered into an exclusive license agreement, or the
Ventagen Agreement, with Ventagen, LLC, or Ventagen. The Ventagen Agreement provides Ventagen an exclusive license, with rights to grant sublicenses (subject to certain terms and conditions) under any worldwide patent rights and <FONT
STYLE="white-space:nowrap">know-how</FONT> owned or controlled by us during the term of the Ventagen Agreement which cover applicable technology utilizing the delivery method of the herpes derived TK protein to tumors or other tissues via a viral
vector (as further specified therein), to research, use, have used, import, have imported, export, have exported, offer for sale, have sold, sell, distribute and market certain products for the prevention or treatment of cancer in humans and any use
in animals (or the Field of Use), or the Licensed Products, for commercial sale and distribution within Mexico, Belize, Guatemala, Honduras, El Salvador, Costa Rica, Nicaragua, Panama, Colombia and Bolivia (or the Territory). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Under the Ventagen Agreement, Ventagen agreed to use commercially reasonable efforts to develop and commercialize Licensed Products in the Territory in
the Field of Use. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Ventagen agreed to pay us $1,000,000 for research and development, which we received in 2014 and 2015, and agreed to pay us a
fixed future milestone payment of $2,500,000 upon Ventagen&#146;s achievement of a specified amount of sales of a Licensed Product, which is subject to certain reductions for our direct cost over a specified threshold. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Ventagen also agreed to purchase all of its clinical and commercial supply of Licensed Products from us required for clinical or commercial purposes at
a price of cost plus a specified increase of the wholesale price of the Licensed Products, subject to a minimum and maximum price, through the end of the Royalty Term, which is defined as the period commencing on the effective date of the Ventagen
Agreement and ending on a <FONT STYLE="white-space:nowrap">country-by-country</FONT> basis on the later of (i)&nbsp;the last expiration date of the patent rights covering a Licensed Product, (ii)&nbsp;twelve years from the receipt of marketing
authorization of the Licensed Product in the applicable country, or (iii)&nbsp;the date a generic version of a Licensed Product that is manufactured, owned or controlled by a third party is granted a market authorization. If we are unable or
unwilling to manufacture supply under the terms of the Ventagen Agreement, Ventagen has the right to manufacture its own supply and will be required to pay to us a fixed fee per dose sold by Ventagen, its affiliates, agents, sublicensee or end
users. We have also agreed to provide certain services to Ventagen related to Ventagen&#146;s development plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">The Ventagen Agreement expires on
the date of the expiration of the final Royalty Term in all countries in the Territory. The Ventagen Agreement may be terminated (i)&nbsp;by Ventagen at will upon 30 days&#146; prior written notice to us, (ii)&nbsp;by us subject to a specified
notice period if Ventagen files for bankruptcy or becomes insolvent or (iii)&nbsp;by us if Ventagen remains in material breach of the Ventagen Agreement following notice and a cure period to remedy the breach. Ventagen retains an irrevocable,
perpetual, paid up, royalty-free license, with rights of sublicense to use, have used, lease, import and export, offer to sell, sell, have sold, product, distribute and market Licensed Products in each country in the Territory after the expiration
of the Royalty Term in such country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of our current shareholders own 49.5% of the voting stock of Ventagen, but we do not hold any management position or
run the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of Ventagen. See &#147;Certain Relationships and Related Person Transactions.&#148; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Competition </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The development and commercialization of new product
candidates is highly competitive. We face competition from major pharmaceutical, specialty pharmaceutical and biotechnology companies among others with respect to <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and
<FONT STYLE="white-space:nowrap">CAN-3110</FONT> and will face similar competition with respect to any product candidates that we may seek to develop or commercialize in the future. We compete in pharmaceutical, biotechnology and other related
markets that develop immune-oncology therapies for the treatment of cancer. There are other companies working to develop viral immunotherapies for the treatment of cancer including divisions of large pharmaceutical and biotechnology companies of
various sizes. The large pharmaceutical and biotechnology companies that have commercialized and/or are developing immuno-oncology treatments for cancer include AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Inc., Merck&nbsp;&amp; Co.,
Novartis, Pfizer and Genentech, Inc. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some of the products and therapies developed by our competitors are based on scientific approaches that are the same as or
similar to our approach, including with respect to the use of viral immunotherapy with adenovirus and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
HSV. Other competitive products and therapies are based on entirely different approaches. We are aware that Oncorus, Inc., Replimune Group, Inc., Amgen Inc., ImmVira Co., Ltd., IconOVir Bio,
Inc., and FerGene, Inc., among others, are developing viral immunotherapies that may have utility for the treatment of indications that we are targeting. Potential competitors also include academic institutions, government agencies and other public
and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of the companies we compete against or may compete against in the future have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in concentration of even
more resources among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also
compete with us in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and enrolling subjects for our clinical trials and in acquiring technologies complementary to, or necessary for, our
programs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe side effects, or are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or foreign regulatory approval for their products more
rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all our product candidates, if
approved, are likely to be their efficacy, safety, convenience and price, if required, the level of biosimilar or generic competition and the availability of reimbursement from government and other third-party payors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Commercialization </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to retain significant development and
commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our product candidates on our own, or potentially with a partner, in the United States and other regions. We currently have no sales, marketing or
commercial product distribution capabilities and have no experience as a company commercializing products. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following
further advancement of our product candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization plans. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Manufacturing </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have established an operations leadership team with
extensive experience in manufacturing biologics based on viruses, including oncolytic products and gene therapy products, and in the construction, validation, approval and operation of facilities designed to manufacture biologics. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team has developed a reproducible manufacturing process for our product candidates, and we are evaluating the development of a commercial-scale biologics
manufacturing facility at our new headquarters in Needham, Massachusetts as well as using third-party contract manufacturing organizations for commercial scale manufacturing of our product candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>IP </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have obtained Orphan Drug Designation for <FONT
STYLE="white-space:nowrap">CAN-2409</FONT> for the treatment of glioblastoma, which makes the product candidate eligible for a period of orphan drug exclusivity, if approved in this indication, under certain conditions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that approval of our <FONT STYLE="white-space:nowrap">CAN-2409</FONT> and <FONT STYLE="white-space:nowrap">CAN-3110</FONT> product candidates under a BLA
will result in 12 years of data exclusivity in the United States under the ACA, 10 years of market exclusivity in Europe and significant durations in other markets, which would be complementary to any relevant patent exclusivity. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through licensing and developing our own portfolio, we have rights to one issued composition of matter patent in the United States that relates to CAN-3110, which
expires in 2036 and is exclusively licensed to us. We also own a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patent issued in the United States that relates to a method of use of CAN-2409 in combination with other agents that expires in 2034. There are also multiple patent applications in the United
States and foreign countries, that are fully or partially owned by us or are exclusively licensed to us by the inventor owners. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Government Regulation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and licensure under the
Public Health Service Act (PHS Act), and other federal, state, local and foreign statutes and regulations. The FD&amp;C Act and corresponding regulations govern, among other things, the research, development, clinical trial, testing, manufacturing,
quality control, approval, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, marketing, promotion, export and import, advertising, post-approval monitoring, and post-approval reporting involving biological
products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and we may not be
able to obtain the required regulatory approvals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, even if we obtain the required regulatory approvals for our products, pharmaceutical companies are
subject to myriad federal, state, and foreign healthcare laws, rules, and regulations governing all aspects of our operations, including, but not limited to, our relationships with healthcare professionals, healthcare institutions, distributors of
our products, and sales and marketing personnel; governmental and other third-party payor coverage and reimbursement of our products; and data privacy and security. Such laws, rules, and regulations are complex, continuously evolving, and, in many
cases, have not been subject to extensive interpretation by applicable regulatory agencies or the courts. We are required to invest significant time and financial resources in policies, procedures, processes, and systems to ensure compliance with
these laws, rules, and regulations, and our failure to do so may result in the imposition of substantial monetary or other penalties by federal or state regulatory agencies, give rise to reputational harm, or otherwise have a material adverse effect
on our results of operations and financial condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. biological products development process </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process required by the FDA before a biological product candidate may be licensed for marketing in the U.S. generally involves the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of nonclinical laboratory tests and animal studies performed in accordance with FDA&#146;s good laboratory
practices, or GLPs, requirements and applicable requirements for the humane use of laboratory animals or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an application for an investigational new drug application, or IND, which must become effective
before human clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approval of the protocol and related documentation by an IRB or ethics committee at each clinical trial site before each
trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performance of adequate and well-controlled human clinical trials according to GCPs, requirements and any additional
requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product candidate for its intended use; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparation of and submission to the FDA of a BLA for marketing approval that includes sufficient evidence of establishing
the safety, purity, and potency of the proposed biological product for its intended indication, including from results of nonclinical testing and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a determination by the FDA within 60 days of its receipt of a BLA to accept and file the application;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-license</FONT> inspection of the manufacturing
facility or facilities where the biological product is produced to assess compliance with current good manufacturing practices, or cGMPs, to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s
identity, strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA in
accordance with any applicable expedited programs or designations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">payment of user fees for FDA review of the BLA (unless a fee waiver applies); and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA review and approval, or licensure, of the BLA to permit commercial marketing of the product for particular indications
for use in the U.S. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Studies and the IND Process </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before testing any biological product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as
nonclinical studies, include laboratory evaluations of the product&#146;s biological characteristics, chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of
the preclinical tests must comply with federal regulations and requirements including GLPs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to commencing an initial clinical trial in humans with a product
candidate in the U.S., an IND must be submitted to the FDA and the FDA must allow the IND to proceed. An IND is an exemption from the FD&amp;C Act that allows an unapproved product candidate to be shipped in interstate commerce for use in an
investigational clinical trial and a request for FDA allowance that such investigational product may be administered to humans in connection with such trial. Such authorization must be secured prior to interstate shipment and administration. In
support of a request for an IND, the clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to
the FDA as part of the IND. An IND must become effective before human clinical trials may begin. Once submitted, the IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the IND on a full or partial clinical
hold within <FONT STYLE="white-space:nowrap">that&nbsp;30-day&nbsp;time</FONT> period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial or part of the study can begin. Submission of an IND
therefore may or may not result in FDA authorization to begin a clinical trial. The FDA also may impose clinical holds on a sponsor&#146;s IND at any time before or during clinical trials due to, among other considerations, unreasonable or
significant safety concerns, inability to assess safety concerns, lack of qualified investigators, a misleading or materially incomplete investigator brochure, study design deficiencies, interference with the conduct or completion of a study
designed to be adequate and well-controlled for the same or another investigational product, insufficient quantities of investigational product, lack of effectiveness, <FONT STYLE="white-space:nowrap">or&nbsp;non-compliance.&nbsp;If</FONT> the FDA
imposes a clinical hold, studies may not recommence without FDA authorization and then only under terms authorized by the FDA. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under control of the trial sponsor. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion
criteria, and the parameters and criteria to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be
submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#146;s regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent. An
IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the trial at least
annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of
a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the product candidate has been associated with unexpected serious harm to
patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or
committee, or DSMB. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the trial and may recommend halting the clinical
trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain information about
certain clinical trials must also be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials
typically are conducted in three sequential phases that may overlap or be combined: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1. The biological product candidate is initially introduced into healthy human subjects and tested for safety. In
the case of some products for severe or life-threatening diseases, especially when the product may </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. These studies are designed to test the safety, dosage tolerance,
absorption, metabolism and distribution of the biological product candidate in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2. The biological product candidate is evaluated in a limited patient population with a specific disease or
condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. Multiple Phase 2 clinical
trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3. The biological product candidate is administered to an expanded patient population to further evaluate dosage,
clinical efficacy, potency, and safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for
approval and product labeling. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2018, the FDA released a draft guidance entitled &#147;Expansion Cohorts: Use in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-In-Human</FONT></FONT> Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#148; which outlines how developers can utilize an adaptive trial design commonly
referred to as a seamless trial design in early stages of oncology biological product development (i.e., the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial) to compress the traditional
three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring
efficiency to biological product development and reduce developmental costs and time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some cases, the FDA may require, or companies may voluntarily pursue,
additional clinical trials after a product is approved to gain more information about the product. These post-approval clinical trials, sometimes referred to as Phase&nbsp;4 clinical trials, may also be made a condition to approval of the
BLA.&nbsp;Failure to exhibit due diligence with regard to conducting required Phase 4 clinical trials could result in withdrawal of approval for products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical
characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of
biological products, the Public Health Service Act, or PHS Act, emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality
batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and
tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Both the FDA and the EMA provide expedited pathways for the development of biological product candidates for treatment of rare diseases, particularly life threatening
diseases with high unmet medical need. Such biological product candidates may be eligible to proceed to registration following a single clinical trial in a limited patient population, sometimes referred to as a Phase 1/2 trial, but which may be
deemed a pivotal or registrational trial following review of the trial&#146;s design and primary endpoints by the applicable regulatory agencies. Determination of the requirements to be deemed a pivotal or registrational trial is subject to the
applicable regulatory authority&#146;s scientific judgement and these requirements may differ in the U.S. and the European Union. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During all phases of clinical
development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the
FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or<I>&nbsp;in vitro</I>&nbsp;testing that suggest a
significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar
days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial
receipt of the information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a
finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some trials also include oversight by an independent group of qualified experts organized by the clinical trial
sponsor, known as a data safety monitoring board, which provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial if it determines
that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. review and approval processes
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful the completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include results of product development, laboratory and animal studies, human
clinical trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will
accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Within 60 days following submission of the
application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may
request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review to determine if it is substantially complete before the FDA accepts it for filing. In
most cases, the submission of a BLA is subject to a substantial application user fee, although the fee may be waived under certain circumstances. Under the performance goals and policies implemented by the FDA under the Prescription Drug User Fee
Act, or PDUFA, for original BLAs, the FDA targets ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority
review. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification. This review typically takes twelve months from the date the BLA is
submitted to the FDA because the FDA has approximately two months to make a &#147;filing&#148; decision. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional
information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the submission
is accepted for filing, the FDA begins <FONT STYLE="white-space:nowrap">an&nbsp;in-depth&nbsp;substantive</FONT> review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent for
its intended use and whether the product is being manufactured in accordance with cGMP to ensure its continued safety, purity and purity. The FDA may refer applications for novel biological products or biological products that present difficult or
novel questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The
FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and
Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it
determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will
typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of
time, money and effort in the areas of training, record keeping, production and quality control. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Pediatric Research Equity Act, or PREA, a BLA or
supplement to a BLA for a novel product (e.g., new active ingredient, new indication, etc.) must contain data to assess the safety and effectiveness of the biological </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.
The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA
may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the
deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required
inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for
additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor
safety or efficacy of a product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the
indications for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings, precautions or interactions be
included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. The FDA also may condition approval on, among
other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing
requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market trials and surveillance to further assess and monitor the product&#146;s safety and effectiveness
after commercialization, and may limit further marketing of the product based on the results of these post-marketing trials. In addition, new government requirements, including those resulting from new legislation, may be established, or the
FDA&#146;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan product
designation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant orphan designation to a biological product intended to treat a rare disease or condition, which is
generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or 200,000 or more individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making a biological product
available in the U.S. for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the
therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan product designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages <FONT
STYLE="white-space:nowrap">and&nbsp;user-fee&nbsp;waivers.</FONT> If a product that has orphan product designation subsequently receives the first FDA approval for a particular active ingredient for the disease or condition for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan product exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain
approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same
biological product as defined by the FDA or if a product candidate is determined to be contained within the competitor&#146;s product for the same indication or disease. If a biological product designated as an orphan product receives marketing
approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. In addition, orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for
designation was materially defective or, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to
assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan drug status in the European Union has similar, but not identical, benefits. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expedited development and review programs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA has various
programs, including fast track designation, breakthrough therapy designation, accelerated approval and priority review, that are intended to expedite or simplify the process for the development and FDA review of drugs and biologics that are intended
for the treatment of serious or life-threatening diseases or conditions. To be eligible for fast track designation, new drugs and biological product candidates must be intended to treat a serious or life-threatening disease or condition and
demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic
may request the FDA to designate the drug or biologic as a fast track product at any time during the clinical development of the product. One benefit of fast track designation, for example, is that the FDA may consider for review sections of the
marketing application on a rolling basis before the complete application is submitted if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of
applicable user fees before the FDA may initiate a review. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the FDA&#146;s breakthrough therapy program, a sponsor may seek FDA designation of its product
candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that
it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the
benefits of fast track designation. The FDA may take other actions appropriate to expedite the development and review of the product candidate, including holding meetings with the sponsor and providing timely advice to, and interactive communication
with, the sponsor regarding the development program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A product candidate is eligible for priority review if it treats a serious or life-threatening disease or
condition and, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious disease or condition. The FDA will attempt to direct additional resources to the evaluation of
an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Under priority review, the FDA&#146;s goal is to review an application in six months once it is filed, compared to ten months
for a standard review. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, a product candidate may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious
or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing
that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint other than survival or irreversible morbidity or mortality, that is
reasonably likely to predict irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval,
the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to verify the clinical benefit in relationship to the surrogate endpoint or
ultimate outcome in relationship to the clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the
timing of the commercial launch of the product. The FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-approval requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rigorous and extensive FDA regulation of
biological products continues after approval, particularly with respect to cGMP requirements, as well as requirements relating to record keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and
advertising and promotion of the product. Manufacturers of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other
post-approval requirements applicable to biological products, include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record keeping requirements, reporting of adverse effects,
reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the
manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA
together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products,
such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Manufacturers must comply with the FDA&#146;s advertising and promotion requirements, such as those related <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">to&nbsp;direct-to-consumer&nbsp;advertising,</FONT></FONT> the prohibition on promoting products for uses or in patient populations that are not described in the product&#146;s approved labeling (known <FONT
STYLE="white-space:nowrap">as&nbsp;&#147;off-label&nbsp;use&#148;),</FONT> industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply
with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S.
requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could
include refusal to approve pending applications, withdrawal of an approval, clinical holds, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, product detentions or refusal to
permit the import or export of the product, restrictions on the marketing or manufacturing of the product, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors or other stakeholders,
debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their
establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time,
money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including
withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications
and additional labeling claims, are also subject to further FDA review and approval. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. patent term restoration and marketing exclusivity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending upon the timing, duration and specifics of the FDA approval of a biological product, some of a sponsor&#146;s U.S. patents may be eligible for limited patent
term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent
term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term restoration period is <FONT STYLE="white-space:nowrap">generally&nbsp;one-half&nbsp;the</FONT> time
between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension
and the application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The U.S. PTO, in consultation with the FDA, reviews and approves the
application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our patents, if and as applicable, to add patent life beyond its current expiration date, depending on the
expected length of the clinical trials and other factors involved in the filing of the relevant BLA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A biological product can obtain pediatric market exclusivity in the U.S. Pediatric exclusivity, if granted, adds six
months to existing exclusivity periods, including some regulatory exclusivity periods tied to patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term,
may be granted based on the voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, includes a subtitle called the
Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with,
<FONT STYLE="white-space:nowrap">an&nbsp;FDA-licensed&nbsp;reference</FONT> biological product. This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences
between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to
the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after
one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structure of
biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first
licensure of the reference product, and FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until 12 years after the date of first licensure of the reference product. &#147;First
licensure&#148; typically means the initial date the particular product at issue was licensed in the U.S. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product
if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including
a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the
biological product that does not result in a change in safety, purity, or potency. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the <FONT
STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate
implementation and impact of the BPCIA is subject to significant uncertainty. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. regulation of companion diagnostics </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates may require use of an<I>&nbsp;in vitro</I>&nbsp;diagnostic to identify appropriate patient populations. These diagnostics, often referred to as
companion diagnostics, are regulated as medical devices. In the U.S., the FD&amp;C Act and its implementing regulations and other federal and state statutes and regulations govern, among other things, medical device design and development,
preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import and post-market surveillance. Unless an exemption
applies, companion diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called
510(k) clearance, and premarket approval, or PMA approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If use of companion diagnostic is essential to safe and effective use of a drug or biologic product,
then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August&nbsp;6, 2014, the FDA issued a final guidance document addressing the development and approval
process for &#147;<I>In Vitro</I>&nbsp;Companion Diagnostic Devices.&#148; According to the guidance, for novel candidates such as our product candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be
approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate
generally will be considered an investigational device, unless it is employed for an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a
significant risk device under the FDA&#146;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and
a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides
that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products
and sponsors of<I>&nbsp;in vitro</I>&nbsp;companion diagnostic devices on issues related <FONT STYLE="white-space:nowrap">to&nbsp;co-development&nbsp;of</FONT> these products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA generally requires companion diagnostics intended to select the patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic
contemporaneously with approval of the therapeutic. The review of these<I>&nbsp;in vitro</I>&nbsp;companion diagnostics in conjunction with the review of therapeutic candidates such as those we are developing involves coordination of review by the
FDA&#146;s Center for Biologics Evaluation and Research and by the FDA&#146;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical <FONT STYLE="white-space:nowrap">and&nbsp;pre-clinical&nbsp;data</FONT>
and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s safety and
effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are also subject to an application fee. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">PMAs for certain devices must generally include the results from <FONT STYLE="white-space:nowrap">extensive&nbsp;pre-clinical&nbsp;and</FONT> adequate and
well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible
results when the same sample is tested multiple times by multiple users at multiple laboratories. In addition, as part of the PMA review, the FDA will typically inspect the manufacturer&#146;s facilities for compliance with the Quality System
Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the FDA evaluations of both the PMA
application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or a <FONT STYLE="white-space:nowrap">not-approvable</FONT> letter, which usually contains a number of conditions that must be met in order to
secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been
met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness
of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the FDA&#146;s evaluation of the PMA or manufacturing
facilities is not favorable, the FDA will issue an order denying approval of the PMA or issue a not approvable order. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to
make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment
to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA
approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and
time-consuming to generate and that can substantially delay approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After a device is placed on the market, it remains subject to significant regulatory
requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#146;s
manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling,
packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional regulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the foregoing, state and
federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws
govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous
substances, we could be liable for damages and governmental fines. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Government regulation outside of the United States </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in the U.S., we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development,
clinical trials, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products as well as authorization and approval of our
products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The requirements and
process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and
the ethical principles that have their origin in the Declaration of Helsinki. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or
withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical trials regulation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the
commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the U.S. have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of
human clinical trials. In the European Union, for example, a CTA must be submitted for each clinical trial to each country&#146;s national competent authority, or NCA, and at least one independent ethics committee, or EC, much like the FDA and an
IRB, respectively. Once the CTA is approved in accordance with a country&#146;s requirements, the corresponding clinical trial may proceed. Under the current regime (the EU Clinical Trials Directive 2001/20/EC and corresponding national laws) all
suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the EU Member State where they occurred. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. It will
overhaul the current system of approvals for clinical trials in the EU. Specifically, the new Regulation, which will be directly applicable in all Member States (meaning that no national implementing legislation in each EU Member State is required),
aims at simplifying and streamlining the approval of clinical trials in the EU. For instance, the new Regulation provides for a streamlined application procedure via a single entry point and strictly defined deadlines for the assessment of clinical
trial applications. It is expected that the new Regulation will come into effect following confirmation of full functionality of the Clinical Trials Information System, the centralized EU portal and database for clinical trials foreseen by the new
Regulation, through an independent audit, which is currently expected to occur in December 2021. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European Union drug review and approval </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the European Economic Area, or EEA, medicinal products can only be commercialized after obtaining a marketing authorization. To obtain regulatory approval of a
medicinal product in the EEA, we must submit a marketing authorization application, or MAA. A centralized marketing authorization is issued by the European Commission through the centralized procedure, based on the opinion of the Committee for
Medicinal Products for Human Use, or CHMP, of the EMA, and is valid throughout the EEA. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy
medicinal products such as (gene-therapy, somatic cell-therapy or tissue-engineered medicines), and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
diabetes, auto-immune and other immune dysfunctions, and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for
products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the
centralized procedure the maximum timeframe for the evaluation of a MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock
stops may extend the timeframe of evaluation of a MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision to
grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#146;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health
interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to the
standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
application used to submit the BLA in the U.S. is similar to that required in the European Union, although there may be certain specific requirements, for example those set out in Regulation (EC) No 1394/2007 on Advanced Therapy Medicinal Products,
covering gene therapy, somatic cell therapy and tissue-engineered medicinal products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Now that the UK (which comprises Great Britain and Northern Ireland) has left
the European Union, Great Britain will no longer be covered by centralized marketing authorizations (under the Northern Irish Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products
with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January, 1 2021. For a period of two years from January&nbsp;1, 2021, the Medicines and Healthcare products Regulatory
Agency, or MHRA, the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing
authorization. A separate application will, however, still be required. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Data and market exclusivity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EEA, upon receiving marketing authorization, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of
market exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from referencing the innovator&#146;s <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data contained in the dossier of the reference
product when applying for a generic or biosimilar marketing authorization in the EEA, during a period of eight years from the date on which the reference product was first authorized in the EEA. During the
<FONT STYLE="white-space:nowrap">additional&nbsp;two-year&nbsp;period</FONT> of market exclusivity, a generic or biosimilar marketing authorization application can be submitted, and the innovator&#146;s data may be referenced, but no generic or
biosimilar product can be marketed until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period will be extended to a maximum of eleven years if, during the first eight years of those ten years,
the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing
therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the
innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained a marketing authorization based on a MAA with a completely independent data package of pharmaceutical
tests, preclinical tests and clinical trials. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan drug designation and exclusivity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Products receiving orphan designation in the EEA can receive ten years of market exclusivity, during which time no &#147;similar medicinal product&#148; may be placed
on the market. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic
indication. An orphan product can also obtain an additional two years of market exclusivity in the European Union where an agreed Pediatric Investigation Plan for pediatric studies has been complied with. No extension to any supplementary protection
certificate can be granted on the basis of pediatric studies for orphan indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The criteria for designating an &#147;orphan medicinal product&#148; in the EEA are similar in principle to those in the
U.S. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if it meets the following criteria: (1)&nbsp;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically
debilitating condition; (2)&nbsp;either (a)&nbsp;such condition affects no more than five (5)&nbsp;in ten thousand (10,000) persons in the EEA when the application is made, or (b)&nbsp;it is unlikely that the product, without the benefits derived
from orphan status, would generate sufficient return in the European Union to justify the necessary investment in its development; and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized
for marketing in the EEA, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as
reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan drug designation must be submitted before the
application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan
drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">The&nbsp;10-year&nbsp;market</FONT> exclusivity may be reduced to six years if, at the end of the fifth year, it is established that
the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar medicinal
product for the same indication at any time if: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically
superior; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the marketing authorization holder of the authorized product consents to a second orphan medicinal product application; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the marketing authorization holder of the authorized product cannot supply enough orphan medicinal product.
</P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pediatric development </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EEA, companies
developing a new medicinal product must agree upon a Pediatric Investigation Plan, or PIP, with the EMA&#146;s pediatric committee, or PDCO, and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies (e.g.,
because the relevant disease or condition occurs only in adults). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The marketing
authorization application for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted by the PDCO of the obligation to implement some or all of
the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults, in which case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing
authorization with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval)
even where the trial results are negative. In the case of orphan medicinal products, a two year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available
when data in compliance with the PIP are developed and submitted. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-approval controls </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion
and sale of the medicinal product. These include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual
qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put
in place and documenting measures to prevent or minimize the risks associated with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may
include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited
redactions. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">All advertising and promotional activities for the product must be consistent with the approved summary of product
characteristics, or SmPC, and therefore all <FONT STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription
medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each European Union
Member State and can differ from one country to another. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Brexit and the Regulatory Framework in the United Kingdom </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2016, the electorate in the UK voted in favor of leaving the European Union (commonly referred to as &#147;Brexit&#148;). Thereafter, in March 2017, the country
formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The UK formally left the European Union on January&nbsp;31, 2020. A transition period began on February&nbsp;1, 2020, during which
European Union pharmaceutical law remained applicable to the UK, however this ended on December&nbsp;31, 2020. On December&nbsp;24, 2020, the UK and European Union entered into a Trade and Cooperation Agreement. The agreement sets out certain
procedures for approval and recognition of medical products in each jurisdiction. Since the regulatory framework in the UK covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial
sales and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the UK, as the UK
legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the UK in the long-term. The MHRA has recently published detailed guidance
for industry and organizations to follow from January&nbsp;1, 2021 now the transition period is over, which will be updated as the UK&#146;s regulatory position on medicinal products evolves over time. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and markets in other
countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product
candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care
organizations, provide coverage, and establish adequate reimbursement levels for, the product. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid
Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial
degree. No uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a
third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the
prices charged, examining the medical necessity, reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a
formulary, which might not include all of the approved products for a particular indication. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to secure coverage and reimbursement for any product that
might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, which will require additional expenditure above and beyond the costs
required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered
medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and financial condition. Additionally, a third-party payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one
payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort.
Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved products. Coverage policies and third-party payor
reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and
reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing
approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain
the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation, state and federal
anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully
soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of
an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity need not have actual
knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration
involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the civil False Claims Act. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, prohibit individuals or
entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false
statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the
federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. The FCA also permits a private
individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil False Claims
Act, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or
remuneration to a Medicare or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner, or supplier of services reimbursable by
Medicare or a state health care program, unless an exception applies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for
knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully
obstructing a criminal investigation of a healthcare offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or
services. Similar to the federal Anti-Kickback Statute, a person or entity may be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, impose, among other things, specified requirements on covered entities and their respective business associates relating to the privacy and security of individually identifiable health information including
mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business
associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal
civil actions. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare,
Medicaid, or the Children&#146;s Health Insurance Program, for certain payments and &#147;transfers of value&#148; provided to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching
hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made in the previous year to
certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that
potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Analogous state and foreign laws and regulations, including, but not limited to, state anti-kickback and false claims
laws, may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and relevant
federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; restrict marketing practices or require disclosure of marketing
expenditures and pricing information. State and foreign laws may govern the privacy and security of health information in some circumstances. These data privacy and security laws may differ from each other in significant ways and often are not <FONT
STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, which may complicate compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The scope and enforcement of each of these laws
is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of
interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that
our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any
other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as
Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT>
with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject
to similar actions, penalties and sanctions. Ensuring business arrangements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#146;s attention
from its business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Employees and Human Capital Resources </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
June 25, 2021, we had 50 employees. Of these employees, 36 perform research and development functions. None of our employees are represented by a labor union and we believe we maintain good relations with our employees. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees,
advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and
the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legal proceedings
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings
that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of
defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth certain
information about our executive officers, significant employees and directors, including their ages as of June&nbsp;21, 2021. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>POSITION(S)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><I>Executive Officers</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paul Peter Tak, M.D., Ph.D., FMedSci</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer, Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Estuardo Aguilar-Cordova, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Founder&nbsp;and Chief Scientific Officer, Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laura K. Aguilar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nathan Caffo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">John Canepa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Susan Stewart, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Regulatory Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Carrie&nbsp;S. Cox</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Edward&nbsp;J. Benz, Jr., M.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paul B. Manning<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chris Martell<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Udi Meirav, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Diem Nguyen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Alan E. Smith, Ph.D., FRS, CBE<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shaan C. Gandhi, M.D., D.Phil.<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><I>Key Employees</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Francesca Barone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Head of Research</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chris Matheny</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Development Leader</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Audit Committee. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Compensation Committee. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Nominating and Corporate Governance Committee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><U>Executive Officers </U></I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Paul Peter Tak, M.D., Ph.D.</I></B><B><I>, FMedSci</I></B>, has served as President and Chief Executive Officer of Candel since September 2020. He received his
medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his Ph.D. He has been Clinical Associate Professor of
Medicine at the University of California San Diego. Next, he served as Professor of Medicine and founding Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC). During this time,
he founded Arthrogen b.v., a biotech company focused on gene therapy. He has published extensively in peer-reviewed journals and received numerous awards. He has been elected Fellow of the Academy of Medical Sciences (U.K.). At GlaxoSmithKline he
served as Senior Vice President, Chief Immunology Officer, and Global Development Leader from 2011 to 2018. He oversaw the creation of a portfolio of new medicines for immune-mediated inflammatory diseases, cancer, infectious disease and pain,
including <FONT STYLE="white-space:nowrap">anti-OSM</FONT> antibody, anti-LAG3 antibody, <FONT STYLE="white-space:nowrap">ESM-BET</FONT> inhibitor, RIP1 kinase inhibitor,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT> antibody, anti-CCL17 antibody, Benlysta sc, gepotidacin, molibresib (BET inhibitor), belantamab mafodotin (anti-BCMA antibody-drug conjugate), and <FONT
STYLE="white-space:nowrap">NY-ESO1</FONT> SPEAR T cell therapy. He was the Chair of the Scientific Review Board, the governing body accountable for the scientific assessment of GSK&#146;s R&amp;D portfolio. From 2018 to 2020, Dr.&nbsp;Tak served as
venture partner at Flagship Pioneering and also as President and CEO of Kintai Therapeutics, a <FONT STYLE="white-space:nowrap">start-up</FONT> focused on enteric signaling networks, where he oversaw the creation of a portfolio of proprietary small
molecules called precision enteric medicines for the treatment of obesity, neurological disease, and cancer. In addition, he has served as President and CEO of Tempero Pharmaceuticals, Board Member of Galvani Bioelectronics, ViiV Healthcare, Sitryx
Therapeutics <FONT STYLE="white-space:nowrap">(co-founder),</FONT> Omega Therapeutics, Levicept, and Citryll. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Estuardo Aguilar-Cordova, M.D., Ph.D.,
</I></B>has served as our Founder and Chief Scientific Officer since September 2020 and previously served as our Chief Executive Officer from 2002 until September 2020. He has more than 30&nbsp;years of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
experience in the fields of biotherapeutics, cancer research and drug development, including serving as principal or co-investigator in more than 25 clinical trials ranging from Phase I to Phase
III. Prior to starting Candel, Dr. Aguilar-Cordova held academic positions for nearly two decades. Most recently, he was deputy director of the Harvard Gene Therapy Initiative at Harvard Medical School in Boston and was a faculty member in
Pediatrics, Hematology-Oncology at Baylor College of Medicine in Houston. He has served on numerous national oversight committees, including roles as chairman and member of the NIH Recombinant Advisory Committee (RAC), as a consultant to the FDA
Biological Response Modifiers Advisory Committee (BRMAC), and as a member of the Vaccine and Related Products Advisory Committee (VRPAC). Dr. Aguilar-Cordova has also held other appointments including president of the Latin American Gene Therapy
Society. Dr. Aguilar-Cordova has published more than 80 peer-reviewed scientific publications and book chapters, is on the editorial board of various professional journals and is an inventor on several patent applications. Dr.&nbsp;Aguilar-Cordova
has an undergraduate degree in Biology and Chemistry from California State University, Bakersfield, an M.D. Inf. from the University del Valle de Guatemala and a Ph.D. from the University of California, Davis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Laura K. Aguilar, M.D., Ph.D.</I></B><I>, </I>has served as our Chief Medical Officer since 2014 and previously served as Vice President, Clinical Research from
2006 to 2014. In her role, Dr.&nbsp;Aguilar develops clinical trial strategies and oversees clinical trial activities to move the company forward in research and development. As chief clinical lead, she works with physicians, regulatory authorities
and business partners, builds and maintains key opinion leader relationships, and advises clinical teams at study sites. Prior to joining Candel, Dr.&nbsp;Aguilar was an attending physician in Pediatric Oncology at Dana-Farber Cancer Institute and
Children&#146;s Hospital in Boston, MA from 2001 to 2009. She also served as associate director and clinical liaison for the Harvard Gene Therapy Initiative. Dr.&nbsp;Aguilar has an undergraduate degree in Biochemistry from the University of
California at Davis, and an M.D. and Ph.D. in Immunology from Baylor College of Medicine in Houston, TX. She completed her Pediatric residency and a Pediatric Hematology Oncology fellowship at Texas Children&#146;s Hospital in Houston. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nathan Caffo</I></B>, has been Candel&#146;s Chief Business Officer since September 2020. From September 2018 to September 2020, he was CBO at ALX Oncology, an
immuno-oncology company, where he played a central role in the company&#146;s financing including series B and C and debt financings totaling $120&nbsp;million, as well as the company&#146;s $186&nbsp;million initial public offering. He was also
responsible for all strategic partnering activities. Prior to ALX Oncology, from April 2009 to August 2018 he was President and CEO of Presage Biosciences, an oncology company that developed the first intratumoral microdosing platform for evaluation
of multiple oncology agents. While at Presage he led the company&#146;s partnering strategy, resulting in over $30&nbsp;million in upfront cash. Mr.&nbsp;Caffo&#146;s <FONT STYLE="white-space:nowrap">26-year</FONT> industry career has been focused
on cancer therapeutics, personalized medicine, and applications of genomic technology. Mr.&nbsp;Caffo also led drug <FONT STYLE="white-space:nowrap">in-licensing</FONT> at Perlegen Sciences, a genomic medicine
<FONT STYLE="white-space:nowrap">spin-off</FONT> of Affymetrix. Prior to that, he worked at Applied Biosystems (now Life Technologies) and its sister company Celera (now Quest Diagnostics) for 11 years in a number of technical and business roles,
including managing the company&#146;s genomics service business. Mr.&nbsp;Caffo has a B.S. in Microbiology from Pennsylvania State University. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>John
Canepa</I></B>, has been Candel&#146;s Chief Financial Officer since December 2020. Mr.&nbsp;Canepa has over 40 years of experience in the life science industry as an audit partner with a large international public accounting firm, and as a
financial executive with public and private life science companies. Prior to joining Candel, he served as Senior Advisor, Acting CFO of Frequency Therapeutics from December 2018 until November 2020. During this time, Frequency completed several
public and private financings, including its initial public offering in October 2019, and dramatically expanded its operations. Prior to joining Frequency, Mr.&nbsp;Canepa served as CFO of Agilis Biotherapeutics from December 2017 to August 2018 and
was instrumental in its sale to PTC Therapeutics in August 2018. Prior to Agilis, he was COO and CFO of Asterand Bioscience from October 2012 to August 2017 and led its sale to a private equity group in 2017. Mr.&nbsp;Canepa began his career at
Arthur Andersen&nbsp;&amp; Co. and was with the firm for 23 years. He was a partner in the Boston office technology practice and the worldwide leader of the firm&#146;s life science practice. Mr.&nbsp;Canepa received a B.A. in Economics from Denison
University and a Master&#146;s Degree in Finance from Michigan State University. John is a Trustee of Mount Auburn Hospital in Cambridge Massachusetts, where he currently serves as <FONT STYLE="white-space:nowrap">co-chair</FONT> of the board of
trustees and is on the board of the Beth Israel Lahey Health network. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Susan Stewart, J.D.</I></B>, has served as Candel&#146;s Chief Regulatory Officer since
October 2020. Ms.&nbsp;Stewart has worked for more than 28 years in biopharmaceutical regulatory affairs, with significant experience devising innovative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
strategies for novel therapeutics, overseeing regulatory submissions at various stages of product development and leading interactions with global health authorities. As an independent
consultant, she also serves as Chief Regulatory Officer at Kaleido Biosciences, and had served as senior vice president of regulatory affairs and quality at Kaleido Biosciences, senior vice president of regulatory affairs, quality, and compliance at
Tokai Pharmaceuticals and vice president, regulatory affairs at Transmolecular. She also spent 13&nbsp;years at Genzyme Corporation in regulatory and compliance roles, including serving as vice president, regulatory affairs after beginning her
career with Abbott Laboratories. She received her J.D. from Concord Law School at Purdue University Global, her LL.M. from the Maurice A. Deane School of Law at Hofstra University and her B.A. from the University of Massachusetts. She is a Fellow of
the Regulatory Affairs Professionals Society (RAPS), a Director of the Board, and holds Regulatory Affairs Certifications (RAC) for both the U.S. and Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </U></I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Carrie S. Cox</I></B> has served as a member of our board of directors since May 2021. She served as the Chairman and Chief Executive Officer of Humacyte, Inc., a
regenerative medical technology company, from 2010 until June 2018, and served as its Executive Chairman from June 2018 to May 2019. Ms. Cox previously served as EVP and President, Global Pharmaceuticals, at Schering-Plough Corporation, from 2003
until its merger with Merck &amp; Co., Inc., in November 2009. Prior to that, from 1997 to 2003, she held the role of President, Global Prescription Business at Pharmacia Corporation. Ms. Cox currently serves as a member of the Boards of Directors
of Texas Instruments Inc. (Nasdaq: TXN) and Cardinal Health (NYSE: CAH), and she has served as Chairman of Selecta Biosciences (Nasdaq: SELB) since November 2019. She is currently Chairman of Organon &amp; Co. (NYSE: OGN). Ms.&nbsp;Cox also served
on the board of directors of Celgene Corp. from 2009 until its acquisition by Bristol-Myers Squibb Co. in November 2019, on the board of directors of electroCore, Inc. (Nasdaq: ECOR) between June 2018 and March 2020, and as Chairman of the board of
directors of Array BioPharma, Inc. from August 2018 until its acquisition by Pfizer Inc. in July 2019. She received her B.S. from Massachusetts College of Pharmacy in 1981, and was a Registered Pharmacist. We believe that Ms. Cox&#146;s leadership
in the biopharmaceutical industry, including both in operating roles and as a corporate director, provide her with the appropriate set of skills to serve as a member of our board of directors. Ms. Cox has notified us that she will resign from our
board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. Ms. Cox&#146;s resignation is due to her existing professional obligations and not due to any disagreement with us or any
matters relating to our operations, policies or practices. Following her resignation from our board of directors, Ms. Cox will continue to serve as a Special Advisor to the CEO of Candel. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Edward J. Benz, Jr., M.D.</I></B>, has served as a member of our board of directors since September 2017. Dr.&nbsp;Benz is the President and CEO Emeritus of the
Dana-Farber Cancer&nbsp;Institute and a member of the Dana-Farber Cancer&nbsp;Institute Board of Directors. Dr.&nbsp;Benz is an expert in blood disorders and is board certified in both hematology and internal medicine. He is an active clinical
hematologist and a National Institutes of Health (NIH) funded researcher with a focus on the molecular basis and genetics around inherited blood disorders. From October 2000 until his retirement in October 2016, Dr.&nbsp;Benz served as President and
CEO of Dana-Faber Cancer Institute and the Richard and Susan Smith Professor of Medicine and Professor of Genetics at Harvard Medical School. Prior to his role at Dana-Farber, Dr.&nbsp;Benz served as chairman for the Department of Medicine and Sir
William Osler Professor of Medicine at Johns Hopkins University School of Medicine, as well as physician in chief at Johns Hopkins Hospital. Dr.&nbsp;Benz has also served as President of the American Society of Hematology, the Association of
American Cancer Institutes, the American Society for Clinical Investigation, the American Clinical and Climatological Society, and the Friends of the National Institute of Nursing Research. Over the course of his career, Dr.&nbsp;Benz has authored
more than 300 articles, books, reviews and abstracts and has received numerous awards. Dr.&nbsp;Benz serves on the board of directors of F-star Therapeutics, Inc. (NASDAQ: FSTX) and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), and also serves on
the board of directors of Renovacor, Inc. and serves on our Research Advisory Board. We believe Dr.&nbsp;Benz&#146;s experience in the field of hematology and blood disorders provides him with the appropriate set of skills to serve as a member of
our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Paul B. Manning</I></B> has served as a member of our board of directors since November 2018. Mr. Manning currently serves as the
Chief Executive Officer of PBM Capital Group, LLC, or PBM Capital, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Mr.&nbsp;Manning is a member of the board of
directors of Liquidia Corporation (NASDAQ: LQDA) and Taysha Gene Therapies, Inc. (NASDAQ: TSHA), and he currently serves as Chairman of the board of directors of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) He previously served on the board of
directors of Dova Pharmaceuticals, Inc., a biopharmaceutical company, from September 2016 to November 2019, and AveXis, Inc., a gene therapy company, from April 2014 to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
May&nbsp;2018. Mr.&nbsp;Manning received a B.S. in microbiology from the University of Massachusetts. We believe Mr.&nbsp;Manning&#146;s 30 years of managerial and operational experience in the
healthcare industry and as an investor in healthcare related companies provides him with the appropriate set of skills to serve as a member of our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Chris Martell</I></B> has served as a member of our board of directors since November 2018. Chris Martell is the manager of GTAM1 2012 ADV LLC and an investor at
Martell Capital. Previously, Chris was a Partner at PBM Capital in 2018. Prior to joining PBM Capital, Chris had an <FONT STYLE="white-space:nowrap">18-year</FONT> career at J.P. Morgan where he was a managing director in the Healthcare Investment
Banking and Mergers and Acquisitions groups. He led the execution of a wide range of transactions including mergers and acquisitions, spin-offs and corporate separations, initial public offerings and equity and debt financings for Medical Device,
Life Science Tool and Diagnostic, Pharmaceutical and Biotechnology companies. Chris graduated from Yale University with a B.A. in Ethics, Politics and Economics. We believe Mr.&nbsp;Martell&#146;s broad financial and investment banking experience,
financial and transactional expertise and acumen in mergers and acquisitions and complex financial transactions provides him with the appropriate set of skills to serve as a member of our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Udi Meirav, Ph.D.</I></B>, has served as a member of our board of directors since 2004. Dr.&nbsp;Meirav is the President and Founder of Boston-based EnVerid,
Inc., an energy-efficiency materials company, a role he has served in since 2010 and was previously the Chief Executive Officer of Luminus Devices, Inc., a manufacturer of high performance LEDs for solid state lighting. Dr.&nbsp;Meirav has served on
numerous boards of directors of companies involved in IT, life sciences, semiconductors and solid state lighting. He has also worked with Stata Venture Partners, an early stage venture capital fund, and with Strategic Decisions Group, a premier
consulting firm with focus on pharmaceuticals and biomedical technology. Dr.&nbsp;Meirav has a Ph.D. in Physics from the Massachusetts Institute of Technology and a Bachelor of Science degree in Mathematics and Physics from Tel Aviv University. We
believe Dr.&nbsp;Meirav&#146;s multidisciplinary background with executive experience in technology and finance provides him with the appropriate set of skills to serve as a member of our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Diem Nguyen, Ph.D., MBA</I></B>, will serve as a member of our board of directors upon the effectiveness of this registration statement. Dr.&nbsp;Nguyen is the
Chief Executive Officer and member of the board of directors of Xalud Therapeutics, a private biotechnology company, which is majority-owned by PBM Capital. Previously, Dr.&nbsp;Nguyen was the Executive Vice President of PPD, a leading global
clinical research organization providing drug development services, a position she held from April 2018 to April 2020. Since 2008, Dr.&nbsp;Nguyen has held various leadership roles at Pfizer Inc., last serving as Global President, Americas of Pfizer
Essential Health from January 2017 to March 2018. Dr.&nbsp;Nguyen is a director at Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) and Children&#146;s Hospital of Philadelphia. She received a B.A. in Chemistry with Specialization in Biochemistry and a
Ph.D. in Biochemistry and Molecular Genetics from the University of Virginia, and an MBA in General Management from the University of Virginia&#146;s Darden Graduate School of Business Administration. We believe that Dr.&nbsp;Nguyen&#146;s
managerial, commercial and medical experience in the pharmaceutical industry provides her with the appropriate set of skills to serve as a member of our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Alan E. Smith, Ph.D., FRS, CBE</I></B>, has served as a member of our board of directors since October 2015. Dr.&nbsp;Smith is the former Senior Vice President
(1989-2011) and Chief Scientific Officer of Genzyme Corporation, Cambridge, MA, a position he held from 1997 to 2011. Prior to is acquisition by Genzyme in 1989, Alan was the Vice President and Scientific Director of Integrated Genetics, a
Massachusetts start-up biotechnology company. Dr. Smith sits on the Scientific Advisory Board of Pharnext, a start-up genomics company in Paris, France, and he is on the Board of Directors of Arecor, a start-up biotechnology company in Cambridge UK.
From 2014 to 2020, he was chairman of the Board of Cambridge in America, the representative body of the University and Colleges of Cambridge in North America, and from 2016 -2019, he was chairman of Native Plant Trust, the first plant conservation
organization in the U.S. Alan has published extensively on the genetic code and protein synthesis, tumour virology, cell biology and cystic fibrosis. He holds a B.A. from Christ&#146;s College, Cambridge UK and a Ph.D. from the Laboratory of
Molecular Biology, Cambridge, England. He is a fellow of the Royal Society of London and of Christ&#146;s College. We believe Dr.&nbsp;Smith&#146;s executive experience provides him with the appropriate set of skills to serve as a member of our
board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shaan&nbsp;C. Gandhi, M.D., D.Phil.</I></B> has served as a member of our board of directors since May 2020. Dr.&nbsp;Gandhi is a
Director at Northpond Ventures, LLC (&#147;Northpond Ventures&#148;), a global science, medical and technology-focused venture capital firm, where he leads the firm&#146;s work in biotechnologies. Previously, Shaan was a Principal at the Longwood
Fund from 2018 to 2020, where he created and invested in life sciences companies, including Pyxis Oncology, a cancer immunotherapy company focused on novel modulators of the tumor microenvironment, which he
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
co-founded and served as President. He was an attending hospitalist at Massachusetts General Hospital from 2018 to 2019, where he also did his residency in internal medicine from 2015 to 2018. He
serves on the boards of directors of various private companies, including Aro Biotherapeutics, CAMP4 Therapeutics, DiCE Molecules, StrideBio, Triumvira Immunologics and Vigil Neuroscience. He holds an M.D. from Harvard Medical School; an MBA from
Harvard Business School, where he was a Baker Scholar; a D.Phil. in medical oncology from the University of Oxford, where he was a Rhodes Scholar; and a B.S. with honors in biochemistry from Case Western Reserve University. We believe that Dr.
Gandhi&#146;s financial, managerial and medical experience coupled with his substantial experience as an investor in emerging biotechnology companies provides him with the appropriate set of skills to serve as a member of the board of directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><U>Key Employees </U></I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Francesca Barone, M.D., Ph.D.</I></B> has
been Candel&#146;s Vice President, Head of Research since November 2020. Prior to that, she was our Head of Experimental Medicine since November 2020. Dr.&nbsp;Barone served as Head of Experimental Medicine at Kintai Therapeutics, Inc, a Flagship
Pioneering, Inc. company, from May 2019 through its merger into Senda Biosciences, Inc. until November 2021. Prior to that, she was a Rheumatology Consultant and Associate Professor (Reader) at University of Birmingham and at the Birmingham,
Sandwell and West Birmingham NHS Foundation Trust in UK from 2010 to May 2019. In July 2016, Dr.&nbsp;Barone was awarded an ARUK Senior Fellowship to exploit the mechanisms enabling the persistence of tertiary lymphoid structures (TLS) in inflamed
tissue and to investigate the pathogenicity of the stromal cells in TLS associated diseases. Dr.&nbsp;Barone obtained her M.D. at the University of Rome, Sapienza, and her Ph.D. in immunology at Kings College in London. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Christopher Jon Matheny, PharmD, Ph.D.</I></B> has been Candel&#146;s Vice President, Development Leader since March 2021. Prior to joining Candel,
Dr.&nbsp;Matheny worked at GlaxoSmithKline in roles of increasing responsibility in translational medicine and clinical pharmacology, most recently as the Early Development Leader on four separate immuno-oncology programs from October 2013 to March
2021. Additionally, he served as the <FONT STYLE="white-space:nowrap">Co-chair</FONT> of the Early Development Leader Community as part of the Enterprise Leadership group at GlaxoSmithKline from 2017 to 2018. He received his PharmD and Ph.D. degrees
from the University of North Carolina at Chapel Hill and completed his Pharmacy Practice Residency at the University of Kentucky Hospitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Family Relationships
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than Dr.&nbsp;Aguilar and Dr.&nbsp;Aguilar-Cordova, who are married, none of our directors or executive officers has a family relationship with another
director or executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Composition of our Board of Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors currently consists of nine members, each of whom are members pursuant to the board composition provisions of our certificate of incorporation and
our voting agreement, which agreement is described under &#147;Certain Relationships and Related Party Transactions&#148; in this prospectus. These board composition provisions will terminate upon the completion of this offering. Upon the
termination of these provisions, there will be no further contractual obligations regarding the election of our directors. Effective upon the completion of this offering, we intend to form a nominating and corporate governance committee. Our
nominating and corporate governance committee and our board of directors may consider a broad range of factors relating to the qualifications and background of director nominees, which may include diversity, which is not only limited to race, gender
or national origin, although we currently have no formal policy regarding board diversity. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is identification of persons who
will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of
the competitive landscape and professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal.
Our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the completion of this offering also provide that our directors may be removed only for cause by the affirmative vote of the
holders of at least two-thirds of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of
directors, may be filled only by vote of a majority of our directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Director independence</I>. We intend to apply to list our common stock on The Nasdaq Global Market. Under the Nasdaq
listing rules, independent directors must comprise a majority of a listed company&#146;s board of directors within twelve months from the date of listing. In addition, the Nasdaq listing rules require that, subject to specified exceptions, each
member of a listed company&#146;s audit, compensation and nominating and governance committees be independent within twelve months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those
set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule <FONT
STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a
relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the
Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (1)&nbsp;accept, directly or indirectly, any
consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In order to be
considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT> the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining
whether a director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of
compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. Our board of directors
has determined that all members of the board of directors, except for Paul Peter Tak, M.D., Ph.D., FMedSci and Estuardo Aguilar-Cordova, M.D., Ph.D., are independent directors, including for purposes of the rules of the Nasdaq Global Market and the
SEC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Staggered board</I>. In accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws that will become
effective upon the completion of this offering, our board of directors will be divided into three classes, Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, with each class serving staggered three-year terms. At each annual meeting of the
stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at
the annual meeting of stockholders to be held during the years 2022 for Class&nbsp;I directors, 2023 for Class&nbsp;II directors and 2024 for Class&nbsp;III directors. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our Class&nbsp;I directors will be Shaan&nbsp;C. Gandhi, M.D., D.Phil, Udi Meirav, Ph.D. and Alan&nbsp;E Smith, Ph.D.,
FRS, CBE; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our Class&nbsp;II directors will be Edward&nbsp;J. Benz, Jr., M.D., Paul&nbsp;B. Manning and Paul Peter Tak, M.D., Ph.D.,
FMedSci; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our Class&nbsp;III directors will be Estuardo Aguilar-Cordova, M.D., Ph.D., Chris Martell, and Diem Nguyen, Ph.D.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the completion of this
offering provide that the number of directors may be changed only by resolution of our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The division of our board of directors into three
classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Committees of our
board of directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors plans on establishing an audit committee, a compensation committee and a nominating and corporate governance
committee, each of which will operate pursuant to a charter to be adopted by our board of directors and will be effective upon completion of the offering. Following the completion of this offering, copies of each committee&#146;s charter will be
posted on the corporate governance section of our website, at <I>www.candeltx.com</I>. The inclusion of our website address in this prospectus does not incorporate by reference the information on or accessible through our website into this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Audit committee.</I> Effective upon completion of this offering, Shaan C. Gandhi, M.D., D.Phil, Chris Martell, and Udi
Meirav, Ph.D. will serve on the audit committee, which will be chaired by Chris Martell. Our board of directors has determined that each member of the audit committee is &#147;independent&#148; for audit committee purposes as that term is defined in
the rules of the SEC and the applicable Nasdaq Global Market rules, and has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board of directors has designated Chris Martell as an &#147;audit committee
financial expert,&#148; as defined under the applicable rules of the SEC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The audit committee&#146;s responsibilities include: </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing policies and procedures for the receipt, retention and treatment of accounting-related complaints and
concerns; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent registered
public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they
relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing quarterly earnings releases and scripts. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Compensation committee.</I> Effective upon completion of this offering, Paul B. Manning, Chris Martell and Alan E. Smith, Ph.D., FRS, CBE will serve on the
compensation committee, which will be chaired by Chris Martell. Our board of directors has determined that each member of the compensation committee is &#147;independent&#148; as defined in the applicable Nasdaq Global Market rules. The compensation
committee&#146;s responsibilities include: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">annually reviewing and recommending corporate goals and objectives relevant to the compensation of our Chief Executive
Officer to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and, based on
such evaluation, recommending to our board of directors for determination the compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating and assessing potential and current compensation advisors in accordance with the independence standards
identified in the applicable Nasdaq Global Market rules; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">retaining and approving the compensation of any compensation advisors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving our policies and procedures for the grant of equity-based awards; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to the board of directors with respect to director compensation; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management the compensation discussion and analysis to be included in our annual proxy
statement or Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Nominating and corporate governance committee.</I> Effective upon completion of this offering, Estuardo
Aguilar-Cordova, M.D., Ph.D., Edward&nbsp;J. Benz, Jr., M.D. and Shaan Gandhi, M.D., D.Phil will serve on the nominating and corporate governance committee, which will be chaired by Edward&nbsp;J. Benz, Jr., M.D. Our board of directors has
determined that Edward J. Benz, Jr., M.D. and Shaan Gandhi, M.D., D.Phil, satisfy the relevant independence requirements for service on the nominating and corporate governance committee set forth in the Nasdaq Global Market listing rules. Due to
being our Chief Scientific Officer, Estuardo Aguilar-Cordova, M.D., Ph.D., is not independent for purposes of nominating and corporate governance committee membership under the Nasdaq Global Market listing rules. Under the applicable Nasdaq Global
Market listing rules, we are permitted to phase-in our compliance with the independence requirements for our nominating and corporate governance committee. The phase-in periods with respect to director independence allow us to have only one
independent member on our nominating and corporate governance committee upon the listing date of our common stock, a majority of independent members on our nominating and corporate governance committee within 90 days of the listing date and a fully
independent nominating and corporate governance committee within one year of the listing date. We are taking advantage of these phase-in rules with respect to Dr. Aguilar-Cordova&#146;s service on our nominating and corporate governance committee,
and we expect that by the first anniversary of our listing on the Nasdaq Global Market, our nominating and corporate governance committee will comply with the applicable independence requirements. The nominating and corporate governance
committee&#146;s responsibilities include: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing and recommending to the board of directors criteria for board and committee membership; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with the board of directors the corporate succession plans for the Chief Executive Officer and
other key officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing and recommending to the board of directors a set of corporate governance guidelines; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the evaluation of the board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">None of the
members of our compensation committee has at any time during the prior three years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors
or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate
Governance </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to adopt a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers
responsible for financial reporting, which will be effective upon completion of this offering. Upon the completion of this offering, our code of business conduct and ethics will be available on our website at <I>www.candeltx.com</I>. The inclusion
of our website address in this prospectus does not incorporate by reference the information on or accessible through our website into this prospectus. We intend to disclose any substantive amendments to the code, or grant of any waivers from the
code for any officer or director, on our website or in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations on Liability and
Indemnification Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted by Delaware law, provisions in our amended and restated certificate of incorporation, which will become effective
immediately prior to the closing of this offering, and amended and restated bylaws, which will become effective upon the effectiveness of this registration statement, limit or eliminate the personal liability of directors for a breach of their
fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, a director exercise an informed business judgment based on all material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
information reasonably available to him or her. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director,
except for liability for: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any act related to unlawful stock repurchases, redemptions or other distributions or payments of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to seek <FONT STYLE="white-space:nowrap">non-monetary</FONT>
relief, such as injunctive relief or rescission. These provisions will not alter a director&#146;s liability under other laws, such as the federal securities laws or other state or federal laws. Our amended and restated certificate of incorporation
that will become effective immediately prior to the closing of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted by Delaware law, our amended and restated bylaws to be effective upon the effectiveness of this registration statement will provide that: </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other agents, in
connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then the liability of our
directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any officer, director, employee or other
agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our bylaws permit such indemnification. We have obtained such insurance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the indemnification that will be provided for in our amended and restated certificate of incorporation and amended and restated bylaws, we plan to enter
into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements may
require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts incurred by a director or executive officer in any action or
proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary to attract and
retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This description of the indemnification provisions of our amended and restated
certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to the registration statement of which this
prospectus forms a part. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling
persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or
threatened litigation that may result in claims for indemnification by any director or officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Leadership Structure and Board&#146;s Role in Risk
Oversight </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has no policy with respect to the combination or separation of the position of Chairman of the Board and Chief Executive
Officer. Our board of directors recognizes that no single leadership model is correct at all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
times and that, depending on the circumstances, another leadership model might be appropriate. Our board of directors, therefore, believes that it should have the flexibility to decide whether it
is best for our Company at any point in time to combine or separate the roles of Chief Executive Officer and Chairman of the Board. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Risk is inherent with every
business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including risks relating to our operations, strategic direction and intellectual property as more fully discussed under &#147;Risk
Factors&#148; in this prospectus. Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its
committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate
and functioning as designed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of
directors, as disclosed in the descriptions of each of the committees above and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a
particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or
risks, the chair of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk
oversight role, particularly with respect to risk interrelationships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future
compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our named executive officers, or NEOs, for the year ended December&nbsp;31, 2020, which consist of each person who served as our principal executive officer during 2020
and the next two most highly compensated executive officers, are: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Paul Peter Tak, M.D., Ph.D., FMedSci, our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Estuardo Aguilar-Cordova, M.D., Ph.D., our Founder, Chief Scientific Officer and former Chief Executive Officer;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Laura K. Aguilar, M.D., Ph.D., our Chief Medical Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">John Canepa, our Chief Financial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Compensation Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, the compensation of our NEOs has
consisted of a combination of base salary, cash bonuses and long-term incentive compensation in the form of stock options. Our NEOs, like all full-time employees, are eligible to participate in our health and welfare benefit plans. As we transition
from a private company to a publicly traded company, we intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. At a minimum, we expect to review executive compensation annually
with input from a compensation consultant. As part of this review process, we expect the board of directors and the compensation committee to apply our values and philosophy, while considering the compensation levels needed to ensure our executive
compensation program remains competitive. We will also review whether we are meeting our retention objectives and the potential cost of replacing a key employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2020 Summary Compensation Table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows total
compensation earned by or paid to our NEOs for services rendered to us in all capacities during the fiscal year ended December 31, 2020. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Principal Position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SALARY<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BONUS<BR>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK<BR>AWARDS<BR>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>AWARDS<BR>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NON-EQUITY<BR>INCENTIVE&nbsp;PLAN<BR>COMPENSATION<BR>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Paul Peter Tak, M.D., Ph.D., FMedSci</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">134,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">85,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2,316,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">90,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2,626,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Estuardo Aguilar-Cordova, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><I>Founder &amp; Chief Scientific Officer; Former Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Laura K. Aguilar, M.D., Ph.D. <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I></I>2020</TD>
<TD NOWRAP VALIGN="bottom"><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">John Canepa</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,230,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column reflect the first two $42,500 installments of a $170,000 total sign-on bonus pursuant to Dr. Tak&#146;s employment agreement with the Company, payable in four quarterly installments
following September 12, 2020, a $104,000 discretionary bonus paid to Dr. Aguilar-Cordova for performance in 2020, and a $75,000 sign-on bonus paid to Mr. Canepa pursuant to his employment agreement with the Company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In accordance with SEC rules, these columns reflect the aggregate grant date fair value of the option awards and stock awards granted during 2020 computed in accordance with Financial Accounting Standard Board ASC
Topic&nbsp;718 for stock-based compensation transactions, or ASC&nbsp;718. Assumptions used in the calculation of these amounts are included in Note&nbsp;11 to our financial statements included elsewhere in this prospectus. These amounts do not
reflect the actual economic value that will be realized by the named executive officer upon the vesting of stock options, the exercise of stock options, the lapse of our repurchase option on shares of restricted stock or the sale of shares of our
common stock. Dr.&nbsp;Tak was granted a performance-based stock option of 296,144 shares in 2020 and was granted an option to purchase 1,776,868 shares of common stock in connection with his employment agreement. No amount has been included in the
table above as there was no value ascribed based upon probable achievement. Assuming maximum achievement, the grant date fair value of such performance-based award to Dr.&nbsp;Tak is $395,883. Mr. Canepa was granted an option to purchase 322,710
shares of common stock in connection with his employment agreement. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cash bonuses for performance during the year ended December&nbsp;31, 2020 are not calculable as of the latest practicable date prior to the filing of this prospectus. We expect that such amounts will be determined later
in the first quarter of 2021. For more information on these bonuses, see the description of the annual performance bonuses under &#147;2020 bonuses&#148; below. <B> </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative to Summary Compensation Table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2020 salaries </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our NEOs each receive a base salary to compensate them for services rendered to our company. The base salary payable to each named executive officer is intended to
provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and responsibilities. Base salaries are reviewed annually, typically in connection with our annual performance review process, approved by our
board of directors or the compensation committee, and may be adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance, and experience. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For fiscal year 2020, the annual base salary for each of Dr. Tak, Dr.&nbsp;Aguilar-Cordova, Dr.&nbsp;Aguilar and Mr.&nbsp;Canepa were $500,000, $500,000, $395,000, and
370,000, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2020 bonuses </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the fiscal year ended
December&nbsp;31, 2020, each of the named executive officers was eligible to earn an annual cash bonus based on the achievement of certain corporate and individual performance milestones. The target annual bonus for each of Dr.&nbsp;Tak, Dr.
Aguilar-Cordova, Dr.&nbsp;Aguilar, and Mr.&nbsp;Canepa for the fiscal year ended December&nbsp;31, 2020 were 50%, 50%, 40% and 40% of annual base salary, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Equity-based compensation </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we do not have a formal policy
with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our
executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our board of directors or our
compensation committee periodically review the equity incentive compensation of our named executive officers and may grant equity incentive awards to them from time to time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2020, we granted an option to purchase 1,776,868 shares of our common stock, subject to time-based vesting and an option to purchase 296,144 shares of our common
stock, subject to performance-based vesting, to Dr.&nbsp;Tak in connection with his appointment as our President and Chief Executive Officer. In 2020, we also granted options to purchase 322,710 shares of our common stock to Mr.&nbsp;Canepa in
connection with his appointment as our Chief Financial Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Employment Agreements in Place During Fiscal Year 2020 for Our Named Executive Officers
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Paul Peter Tak, M.D., Ph.D, FMedSci. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective
September&nbsp;12, 2020, we entered into an employment agreement with Dr.&nbsp;Tak, or the Tak Employment Agreement, for the position of President and Chief Executive Officer. The Tak Employment Agreement provides for an annual base salary and an
annual bonus opportunity. Pursuant to the Tak Employment Agreement Dr.&nbsp;Tak&#146;s annual base salary will increase to $670,000 per year effective on the first anniversary of the commencement of his employment if the Company has completed an
underwritten public offering on or prior to such date. The Tak Employment Agreement provides for a signing bonus in the gross amount of $170,000, payable in four equal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
quarterly installments of $42,500 each, commencing on the first payroll date following the commencement of his employment and on each 3-month anniversary of employment following his start date,
provided that he remains employed through each date of payment. Pursuant to the Tak Employment Agreement, Dr. Tak is eligible to receive a lump sum payment of $80,000 to assist with relocation to the Greater Boston Area if and when he relocates in
2022, subject to repayment if Dr. Tak terminates his employment other than for &#147;good reason&#148; or we terminate his employment for &#147;cause&#148; (as such terms are defined in the Tak Employment Agreement) within 12 months of receipt of
the relocation assistance payment. Pursuant to the Tak Employment Agreement, we will reimburse Dr. Tak for reasonable costs related to travel to Massachusetts and temporary housing in Massachusetts, not to exceed $20,000, which amount will be
grossed up in respect of any related taxes, reasonable legal fees related to obtaining a visa, reasonable fees for independent tax and accounting advise not to exceed $10,000 per year, and reasonable legal fees related to negotiation of his
employment agreement, not to exceed $10,000. Dr. Tak is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Tak Employment Agreement, in the event that Dr. Tak&#146;s employment is terminated by us without cause or by Dr. Tak for good reason outside of the 3
month period preceding and 12 month period following the first event constituting a change in control (such period, the &#147;change in control period&#148;), subject to the execution and effectiveness of a severance and release of claims agreement
within 60 days of such termination, he will be entitled to receive (i) an amount equal to 12 months of base salary plus Dr. Tak&#146;s target bonus for the then-current year, less any payments Dr. Tak receives pursuant to his restrictive covenants
agreement with the Company, payable in installments over 12 months commencing within 60 days of termination, and (ii) subject to the Dr. Tak&#146;s timely election to continue COBRA health coverage and copayment of premium amounts at the applicable
active employees&#146; rate, we will continue to pay the share of the premiums that we would have paid to provide health insurance to Dr. Tak until the earlier of (A) 12&nbsp;months following termination or (B) Dr. Tak&#146;s eligibility for group
medical plan benefits under any other employer&#146;s group medical plan. In the event that such termination occurs during the change in control period, Dr. Tak will, subject to the execution and effectiveness of a general severance and release of
claims agreement within 60 days of such termination, be entitled to receive (x) a lump sum payment equal to 1.5 times the sum of Dr. Tak&#146;s then-current base salary (or base salary in effect immediately prior to the change in control, if
higher), plus his target bonus for the then-current year (or his target bonus in effect immediately prior to the change in control, if higher), less any payments pursuant to Dr. Tak receives pursuant to his restrictive covenants agreement with the
Company, and (y) the benefits set forth in clause (ii) of the preceding sentence but for a period of 18 months. In addition, pursuant to the Tak Employment Agreement, all equity awards held by Dr. Tak that are subject to time based vesting will
fully accelerate as of the earlier of the consummation of a &#147;change in control&#148; of the Company (as defined in the Tak Employment Agreement) or the termination of Dr. Tak&#146;s employment by the Company without cause or by Dr. Tak for good
reason. Furthermore, in the event of a change of control or Dr. Tak&#146;s termination without cause or for good reason, Dr. Tak will have no less than 12 months to exercise vested, unexpired stock options. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Estuardo Aguilar-Cordova, M.D., Ph.D. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective November 13, 2018,
we entered into an amended and restated employment agreement with Dr. Aguilar-Cordova, or the Estuardo Aguilar-Cordova Employment Agreement, for the position of President and Chief Executive Officer. Dr. (Estuardo) Aguilar-Cordova subsequently
transitioned to his current role as our Chief Scientific Officer in September 2020. The Estuardo Aguilar-Cordova Employment Agreement provides for an annual base salary and an annual target bonus opportunity. Dr. Aguilar-Cordova is eligible to
participate in the employee benefit plans available to our employees, subject to the terms of those plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Estuardo Aguilar-Cordova Employment
Agreement, in the event that Dr. Aguilar-Cordova&#146;s employment is terminated by us without &#147;cause&#148; or by Dr. Aguilar-Cordova for &#147;good reason&#148; (as such terms are defined in the Estuardo Aguilar-Cordova Employment Agreement),
subject to the execution and effectiveness of a severance and release of claims agreement, he will be entitled to receive (i) 12 months of base salary continuation, and (ii) subject to Dr.&nbsp;Aguilar-Cordova&#146;s timely election to continue
COBRA health coverage, we will pay the premiums necessary to continue Dr.&nbsp;Aguilar-Cordova&#146;s and his covered dependents&#146; health insurance coverage until the earlier of (A) 12&nbsp;months following termination or (B)
Dr.&nbsp;Aguilar-Cordova&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Laura K. Aguilar, M.D., Ph.D. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective November 13, 2018, we entered into an amended and restated employment agreement with Dr.&nbsp;Aguilar, or the Laura Aguilar Employment Agreement, for the
position of Chief Medical Officer. The Laura Aguilar Employment Agreement provides for an annual base salary an annual target bonus opportunity. Dr.&nbsp;Aguilar is eligible to participate in the employee benefit plans available to our employees,
subject to the terms of those plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Laura Aguilar Employment Agreement, in the event that Dr.&nbsp;Aguilar&#146;s employment is terminated by us
without &#147;cause&#148; or by Dr. Aguilar for &#147;good reason&#148; (as such terms are defined in the Laura Aguilar Employment Agreement), subject to the execution and effectiveness of a severance and release of claims agreement, she will be
entitled to receive (i) 12 months of base salary continuation, and (ii) subject to Dr.&nbsp;Aguilar&#146;s timely election to continue COBRA health coverage, we will pay the premiums necessary to continue Dr.&nbsp;Aguilar&#146;s and her covered
dependents&#146; health insurance coverage until the earlier of (A) 12&nbsp;months following termination or (B) Dr.&nbsp;Aguilar&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>John Canepa </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective December 1, 2020, we entered into an
employment agreement with Mr. Canepa, or the Canepa Employment Agreement, for the position of Chief Financial Officer. The Canepa Employment Agreement provides for an annual base salary and an annual target bonus opportunity. Pursuant to the Canepa
Employment Agreement Mr. Canepa received a signing bonus in the gross amount of $75,000, which is subject to repayment if Mr. Canepa voluntarily terminates his employment with the Company or if the Company terminates his employment for reasons
excluding redundancy, ill health or a transfer of the part of the business in which he works within 12 months of the commencement of his employment. Mr. Canepa is eligible to participate in the employee benefit plans available to our employees,
subject to the terms of those plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Canepa Employment Agreement, in the event that Mr. Canepa&#146;s employment is terminated by us without cause
or by Mr. Canepa for good reason, subject to the execution and effectiveness of a severance and release of claims agreement within 60 days of such termination, he will be entitled to receive (i) an amount equal to nine months of base salary plus Mr.
Canepa&#146;s target bonus for the then-current year, less any payments Mr. Canepa receives pursuant to his restrictive covenants agreement with the Company, payable in installments over 9 months commencing within 60 days of termination, and (ii)
subject to the Mr. Canepa&#146;s timely election to continue COBRA health coverage and copayment of premium amounts at the applicable active employees&#146; rate, we will continue to pay the share of the premiums that we would have paid to provide
health insurance to Mr. Canepa until the earlier of (A) nine&nbsp;months following termination or (B) Mr. Canepa&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan. Pursuant to the Canepa Employment
Agreement, all equity awards held by Mr. Canepa that are subject to time based vesting will fully accelerate if Mr. Canepa&#146;s employment is terminated by the Company without &#147;cause&#148; or by Mr. Canepa for &#147;good reason&#148; within
one month prior to or 12 months following the consummation of a &#147;change in control&#148; (as such terms are defined in the Canepa Employment Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at Fiscal Year End </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents the outstanding equity awards held by each of our named executive officers as of December&nbsp;31, 2020: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION AWARDS <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>VESTING<BR>COMMENCEMENT<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>UNEXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EQUITY<BR>INCENTIVE<BR>PLAN<BR>AWARDS:<BR>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>UNEARNED<BR>OPTIONS (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXERCISE<BR>PRICE ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXPIRATION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER<BR>OF<BR>SHARES<BR>THAT</B><br><B>HAVE</B><br><B>NOT<BR>VESTED</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARKET<BR>VALUE<BR>OF<BR>SHARES<BR>THAT<BR>HAVE<BR>NOT<BR>VESTED<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Paul Peter Tak, M.D., Ph.D., FMedSci</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/14/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332,651&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/9/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,144&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/9/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Estuardo Aguilar-Cordova, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/13/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,358&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/12/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><I>Founder&nbsp;&amp; Chief Scientific Officer; Former Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,717&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/12/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,103&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Laura K. Aguilar, M.D.,<BR>Ph.D.<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/13/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,358&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/12/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,717&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/12/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">John Canepa</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,710&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/14/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><I>Chief Financial Officer </I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of the outstanding equity awards in the table above was granted pursuant to our 2015 Stock Plan, as amended, or the 2015 Plan. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying this option vest as follows: 25% vested upon the grant date, 25% vesting on the first anniversary of the vesting commencement date, and the remainder vesting thereafter in 36 equal monthly
installments. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying this option shall vest (if at all) if a specified stock price following our initial public offering is obtained on or prior to September&nbsp;12, 2023. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying this option vest in four equal annual installments following the vesting commencement date. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying this option shall vest upon achievement of a specified clinical milestone on or prior to November&nbsp;12, 2023. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying this option vest as follows: 25% upon the grant date the remainder in three equal annual installments following the vesting commencement date. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying this option vest as follows: 35% vest on the first anniversary of the vesting commencement date, 35% vest in equal monthly installments over months 13 to 24 following the vesting commencement date,
15% vest in equal monthly installments over months 25 to 36 following the vesting commencement date, and 15% vest in equal monthly installments over months 37 to 48 following the vesting commencement date. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table provides certain information
concerning compensation for each person who served as a non-employee member of our board of directors during the year ended December&nbsp;31, 2020. Other than as set forth in the table and described more fully below, we did not pay any compensation,
make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our board of directors in 2020. During fiscal year 2020, Paul Peter Tak, M.D., Ph.D., FMedSci, our President and Chief Executive
Officer, and Estuardo Aguilar-Cordova, M.D., Ph.D., our Founder, Chief Scientific Officer, and former President and Chief Executive Officer, served as members of our board of directors and received no additional compensation for their
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">161 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
services as members of our board of directors. See the section titled &#147;Executive Compensation&#148; for more information about Dr.&nbsp;Tak&#146;s and Dr.&nbsp;Aguilar-Cordova&#146;s
compensation for fiscal year 2020. We reimburse non-employee members of our board of directors for reasonable travel and out-of-pocket expenses incurred in attending meetings of our board of directors and committees of our board of directors. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FEES&nbsp;EARNED&nbsp;OR<BR>PAID&nbsp;IN&nbsp;CASH ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK&nbsp;AWARDS<BR>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION&nbsp;AWARDS<BR>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Edward J. Benz, Jr., M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shaan C. Gandhi, M.D., D.Phil <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP> </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paul B. Manning</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chris Martell</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Udi Meirav, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Alan E. Smith, Ph.D., FRS, CBE</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In accordance with SEC rules, these columns reflect the aggregate grant date fair value of the option awards granted during 2020 computed in accordance with Financial Accounting Standard Board ASC Topic&nbsp;718 for
stock-based compensation transactions, or ASC&nbsp;718. Assumptions used in the calculation of these amounts are included in Note&nbsp;2 to our financial statements included elsewhere in this prospectus. As of December&nbsp;31, 2020, our
non-employee directors each held options to purchase shares of our common stock and stock awards as follows: Dr.&nbsp;Benz held options to purchase 52,890 shares, Mr.&nbsp;Martell held options to purchase 16,274 shares, Dr.&nbsp;Meirav held options
to purchase 99,677 shares, and Dr.&nbsp;Smith held options to purchase 20,342 shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gandhi disclaimed director compensation in connection with service on our board of directors in accordance with the standard policy of Northpond Ventures. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors intends to adopt a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, which will be effective as of the
completion of this offering, that is designed to enable us to attract and retain, on a long-term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, each director who is not an employee will be
paid cash compensation from and after the completion of this offering, as set forth below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ANNUAL<BR>RETAINER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Board of Directors</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All <FONT STYLE="white-space:nowrap">non-employee</FONT> members <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP> </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Audit Committee</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Compensation Committee</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Nominating and Corporate Governance Committee</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gandhi disclaims director compensation in connection with service on our board of directors in accordance with the standard policy of Northpond Ventures. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option to
purchase 28,480&nbsp;shares of common stock on the date of such director&#146;s election or appointment to the board of directors, which will vest monthly over three years, subject to continued service as a director. On the date of each annual
meeting of stockholders of our company, each continuing <FONT STYLE="white-space:nowrap">non-employee</FONT> director, other than a director receiving an initial equity award, will be granted a <FONT STYLE="white-space:nowrap">non-qualified</FONT>
stock option to purchase 14,240&nbsp;shares of common stock, which will vest and become fully exercisable upon the earlier to occur of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date
of grant, subject to continued service as a director through such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">162 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Compensation Risk Assessment </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program
does not encourage excessive or unnecessary risk taking. This is primarily due to the fact that our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term
strategic goals, in particular in connection with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> compensation philosophy. As a result, we do not believe that our compensation programs are
reasonably likely to have a material adverse effect on our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Compensation Plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2015 Stock Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2015 Stock Plan, or the 2015 Plan, was approved
by our board of directors and our stockholders on October&nbsp;21, 2015 and amended in November 2018, October 2020, December 2020, March 2021, April 2021 and June 2021. Under the 2015 Plan, 5,336,262 shares of common stock have been reserved for
issuance in the form of incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted stock, unrestricted stock or any combination of the foregoing. The shares issuable pursuant to awards granted under the
2015 Plan are authorized but unissued shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2015 Plan is administered by our board or at the discretion of the board, which has full power to select the
individuals to whom awards will be granted and to determine the specific terms and conditions of each award, subject to the provisions of the 2015 Plan. Pursuant to the 2015 Plan and subject to applicable law, our board of directors has delegated to
the compensation committee the power to make recommendations to the board of directors relating to management compensation, the adoption of employee benefit plans, stock option or equity incentive plans and other similar matters. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The option exercise price of each option granted under the 2015 Plan is determined by our board of directors and may not be less than the fair market value of a share
of common stock on the date of grant. The term of each option is fixed by the board and may not exceed 10 years from the date of grant. The board determines at what time or times each option may be exercised when granting the option. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2015 Plan provides that, upon the consummation of a sale event, unless provision is made in connection with the sale event for the assumption or continuation of the
awards by the successor entity or substitution of the awards with new awards of the successor entity, with appropriate adjustment, the 2015 Plan and all outstanding and unexercised options issued thereunder will terminate upon the effective time of
the sale event. We may make or provide for cash payment to holders of options equal to the difference between (i)&nbsp;the per share cash consideration in the sale event multiplied by the number of shares subject to outstanding options being
cancelled, and (ii)&nbsp;the aggregate exercise price to the holders of all vested and exercisable options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors may amend the 2015 Plan but no
such action may adversely affect the rights of an award holder without such holder&#146;s consent. Approval by our stockholders of amendments to the 2015 Plan must be obtained if required by law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, options to purchase 4,079,006&nbsp;shares of common stock were outstanding under the 2015 Plan. Our board of directors has determined not to
make any further awards under the 2015 Plan following the closing of this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Stock Option and Incentive Plan </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2021 Plan, was adopted by our board of directors on July&nbsp;10, 2021, approved by our stockholders on July&nbsp;14, 2021 and will become effective upon the date
immediately preceding the date on which the registration statement of which this prospectus is part is declared effective by the SEC. The 2021 Plan will replace the 2015 Plan as our board of directors has determined not to make additional awards
under the 2015 Plan following the closing of our initial public offering. However, the 2015 Plan will continue to govern outstanding equity awards granted thereunder. The 2021 Plan allows us to make equity-based and cash-based incentive awards to
our officers, employees, directors and consultants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have initially reserved 2,054,000 shares of our common stock for the issuance of awards under the 2021 Plan,
or the Initial Limit. The 2021 Plan provides that the number of shares reserved and available for issuance under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">163 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
2021 Plan will automatically increase on January&nbsp;1, 2022 and each January 1 thereafter, by 4% of the outstanding number of shares of our common stock on the immediately preceding
December&nbsp;31 or such lesser number of shares as determined by our compensation committee, or the Annual Increase. The number of shares reserved under the 2021 Plan subject to adjustment in the event of a stock split, stock dividend or other
change in our capitalization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares we issue under the 2021 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common
stock underlying any awards under the 2021 Plan and the 2015 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without
the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2021 Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The maximum number of shares of common stock that may be issued in the form of incentive stock options shall not exceed the Initial Limit, cumulatively increased on
January&nbsp;1, 2022 and on each January 1 thereafter by the lesser of the Annual Increase for such year or shares of common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The grant date fair value of
all awards made under our 2021 Plan and all other cash compensation paid by us to any non-employee director in any calendar year for services as a non-employee director shall not exceed $750,000; provided, however, that such amount shall be
$1,000,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 Plan will be
administered by our compensation committee. Our compensation committee has the full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to
make any combination of awards to participants, to accelerate at any time the exercisability or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2021 Plan. Persons eligible to
participate in the 2021 Plan will be those full or part-time officers, employees, non-employee directors and consultants as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and
options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on the date of grant unless the option is granted
(i) pursuant to a transaction described in, and in a manner consistent with Section 424(a) of the Code or (ii) to individuals who are not subject to U.S. income tax. The term of each option will be fixed by our compensation committee and may not
exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee
may award stock appreciation rights under the 2021 Plan subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in
our stock price over the exercise price. The exercise price of each stock appreciation right may not be less than 100% of the fair market value of our common stock on the date of grant. The term of each stock appreciation right will be fixed by our
compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each stock appreciation right may be exercised. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee may award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may
determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. Our compensation committee may also grant shares of common stock that are
free from any restrictions under the 2021 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the
recipient had held a specified number of shares of common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee may grant cash bonuses under the 2021 Plan to participants, subject to
the achievement of certain performance goals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">164 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 Plan provides that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2021 Plan, an acquirer
or successor entity may assume, continue or substitute outstanding awards under the 2021 Plan. To the extent that awards granted under the 2021 Plan are not assumed or continued or substituted by the successor entity, upon the effective time of the
sale event, such awards shall terminate. In such case, except as may be otherwise provided in the relevant award certificate, all awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the
effective time of the sale event and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a sale event in the administrator&#146;s discretion or to the
extent specified in the relevant award certificate. In the event of such termination, (i) individuals holding options and stock appreciation rights will be permitted to exercise such options and stock appreciation rights (to the extent exercisable)
within a specified period of time prior to the sale event or (ii) we may make or provide for a payment, in cash or in kind, to participants holding vested and exercisable options and stock appreciation rights equal to the difference between the per
share consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation rights and we may make or provide for a payment, in cash or in kind, to participants holding other vested awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors may amend or discontinue the 2021 Plan and our compensation committee may amend or cancel outstanding awards for purposes of satisfying changes
in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2021 Plan require the approval of our stockholders. The administrator of the 2021 Plan is
specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock appreciation rights or effect the repricing of such awards through cancellation and re-grants without stockholder consent. No
awards may be granted under the 2021 Plan after the date that is 10 years from the effective date of the 2021 Plan. No awards under the 2021 Plan have been made prior to the date of this prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Employee Stock Purchase Plan </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Employee Stock Purchase Plan,
or ESPP, was adopted by our board of directors on July&nbsp;10, 2021, approved by our stockholders on July&nbsp;14, 2021 and will become effective on the date immediately preceding the date on which the registration statement of which this
prospectus forms a part is declared effective by the SEC. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section 423 of the Code. The ESPP initially reserves and authorizes the issuance of up to
a total of 293,000 shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2022 and each January 1 thereafter through January 1,
2031, by the least of (i) 293,000 shares of our common stock, (ii)&nbsp;1% of the outstanding number of shares of common stock on the immediately preceding December&nbsp;31, or (iii)&nbsp;such lesser number of shares of common stock as determined by
the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All employees who are customarily employed by us or one of our designated subsidiaries for more than 20 hours per week and who we have employed for a period of time as
required by the administrator of the ESPP (but in no event will the required period of continuous employment be equal or greater than two years) are eligible to participate in the ESPP. However, any employee who owns&nbsp;5% or more of the total
combined voting power or value of all classes of our stock will not be eligible to purchase shares of common stock under the ESPP. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may make one or more
offerings each year to our employees to purchase shares under the ESPP. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least&nbsp;15&nbsp;business days before the applicable offering date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each employee who is a participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up to 15% of his or her eligible
compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of our common stock on the last business day of the
offering period at a price equal to&nbsp;85% of the fair market value of the shares of our common stock on the first business day or the last business day of the offering period, whichever is lower, provided that no more $25,000 worth of common
stock (or such other lesser maximum number of shares as may be established by the administrator) may be purchased by any one employee during any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">165 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
offering period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of our common stock, valued at the start of the purchase period, under the ESPP in any
calendar year. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An
employee&#146;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ESPP may
be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Senior Executive Cash Incentive Bonus Plan </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;10, 2021,
our board of directors adopted the Senior Executive Cash Incentive Bonus Plan, or the Bonus Plan. The Bonus Plan provides for annual cash bonus payments based upon the attainment of company and individual performance targets established by our
compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to our company, or the Corporate Performance Goals, as well as individual performance objectives. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee may select Corporate Performance Goals from among the following: cash flow (including, but not limited to, operating cash flow and free cash
flow); revenue; corporate revenue; earnings before interest, taxes, depreciation and amortization; net income (loss) (either before or after interest, taxes, depreciation and/or amortization); changes in the market price of our common stock;
economic value-added; development, clinical, regulatory or commercial milestones; acquisitions or strategic transactions, including collaborations, joint ventures or promotion arrangements; operating income (loss); return on capital assets, equity,
or investment; stockholder returns; return on sales; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss) per share of our common stock; bookings, new
bookings or renewals; sales or market shares; number of customers, number of new customers or customer references; operating income and/or net annual recurring revenue; or any other performance goal as selected by the compensation committee, any of
which may be measured in absolute terms, as compared to any incremental increase, in terms of growth, as compared to results of a peer group, against the market as a whole, compared to applicable market indices and/or measured on a pre-tax or
post-tax basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each executive officer who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The
bonus formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The Corporate Performance Goals will be measured at the end of each performance period after our financial reports have been
published or such other appropriate time as the compensation committee determines. If the Corporate Performance Goals and individual performance objectives are met, payments will be made as soon as practicable following the end of each performance
period, but no later than 74 days after the end of the fiscal year in which such performance period ends. Subject to the rights contained in any agreement between the executive officer and us, an executive officer must be employed by us on the bonus
payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to approve additional bonuses to executive officers in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">166 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than compensation arrangements, we describe below the transactions, and series of similar transactions, since January&nbsp;1, 2018, to which we were a party or
will be a party, in which: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amounts involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate
family of the foregoing persons, had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, we did not have a formal policy
concerning transactions with related persons. In connection with this offering, we plan to adopt a written policy, effective upon completion of this offering, that requires all future transactions between us and any director, executive officer,
holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons (as defined in Item 404 of Regulation
<FONT STYLE="white-space:nowrap">S-K)</FONT> or their affiliates, in which the amount involved is equal to or greater than $120,000, be approved in advance by our audit committee. Any request for such a transaction must first be presented to our
audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee is to consider the relevant facts and circumstances available and deemed relevant to the audit committee, including, but not
limited to, the extent of the related party&#146;s interest in the transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar
circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Private Placements of Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Series B Preferred
Stock Financing </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2018, we issued and sold an aggregate of 11,155,406 shares of Series B preferred stock at a purchase price of $2.7696 per share.
Certain investors holding convertible notes issued in 2016 used such notes to purchase our Series B preferred stock. Each share of our Series B preferred stock will convert automatically into one share of our common stock immediately prior to the
completion of this offering. The following table summarizes purchases of our Series B preferred stock by related persons: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;OF&nbsp;SERIES&nbsp;B<BR>PREFERRED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE&nbsp;PURCHASE<BR>PRICE PAID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">PBM ADV Holdings, LLC&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,026,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000,121.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Estuardo Aguilar-Cordova, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">883,181.13</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laura K. Aguilar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">161,318.12</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Estuardo Aguilar-Cordova, M.D., Ph.D., and Laura K. Aguilar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,884.00</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fred Mermelstein<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,221.00</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">PBM ADV Holdings, LLC is an affiliate of PBM Capital, and is the holder of five percent or more of our capital stock. Paul B. Manning is the Chairman and CEO of PBM Capital and is a member of our board of directors. PBM
ADV Holdings, LLC transferred 696,851 of their Series B Preferred shares to GTAM1 2012 ADV LLC in December 2018. Chris Martell was formerly a Partner at PBM Capital, is the manager of GTAM1 2012 ADV LLC, and is a member of our board of directors.
Diem Nguyen is the Chief Executive Officer of Xalud Therapeutics, Inc., which is majority-owned by PBM Capital. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate purchase price was funded by the cancellation or conversion of indebtedness (including principal and interest) under a certain convertible promissory note, issued by us to Dr.&nbsp;Estuardo Aguilar-Cordova
in January 2005. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate purchase price was funded by the cancellation or conversion of indebtedness (including principal and interest) under a certain convertible promissory note, issued by us to Dr.&nbsp;Laura&nbsp;K. Aguilar in
January 2005. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate purchase price was funded by the cancellation or conversion of indebtedness (including principal and interest) under a certain convertible promissory note, issued by us to Dr.&nbsp;Aguilar-Cordova and
Dr.&nbsp;Laura&nbsp;K. Aguilar in January 2005. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Mermelstein resigned from our board of directors in November 2018. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate purchase price was funded by the cancellation or conversion of indebtedness (including principal and interest) under certain convertible promissory notes, issued by us to Dr.&nbsp;Mermelstein in December
2015. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series B Preferred Stock Financing and the cancellation of the certain promissory notes held by Dr.&nbsp;Estuardo
Aguilar-Cordova and Dr.&nbsp;Laura&nbsp;K. Aguilar, we also agreed to pay (i)&nbsp;Dr.&nbsp;Estuardo Aguilar-Cordova $354,230.33 on November 13, 2018 and $354,230.32 on November 13, 2019, and (ii)&nbsp;Dr.&nbsp;Laura&nbsp;K. Aguilar $168,168.85 on
November 13, 2018 and $168,168.84 on November 13, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">167 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series B Preferred Stock Financing we also issued to PBM ADV Holdings, LLC two warrants to
purchase, in the aggregate, up to 7,344,982 shares of our common stock. Subsequently, PBM ADV Holdings, LLC transferred their warrant to purchase 567,028 shares of our common stock to GTAM1 2012 ADV LLC in December 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Series C Preferred Stock Financing </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, we issued and sold an
aggregate of 6,032,170 shares of Series C preferred stock at a purchase price of $3.73 per share. Each share of our Series C preferred stock will convert automatically into one share of our common stock immediately prior to the completion of this
offering. The following table summarizes purchases of our Series C preferred stock by related persons: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;OF&nbsp;SERIES&nbsp;C<BR>PREFERRED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE&nbsp;PURCHASE<BR>PRICE PAID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Northpond Ventures, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,021,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Northpond Ventures, LP is an affiliate of Northpond Ventures. Shaan Gandhi is a director at Northpond Ventures and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Stockholders </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series C preferred
stock financing, we entered into the Amended and Restated Investors&#146; Rights Agreement, or the Investors&#146; Rights Agreement, dated as of March&nbsp;19, 2020, with certain of our stockholders, including our principal stockholders and their
affiliates, the Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, dated as of March&nbsp;19, 2020, with certain of our stockholders, including our principal stockholders and their affiliates,
and the Amended and Restated Voting Agreement, dated as of March&nbsp;19, 2020, with certain of our stockholders, including our principal stockholders and their affiliates. All of the material provisions of these agreements will terminate
immediately prior to the completion of this offering, other than the provisions relating to registration rights, which will continue in effect following the completion of this offering and entitle the holders of such rights to have us register their
shares of our common stock for sale in the U.S. See &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officer and Director
Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See &#147;Executive Compensation&#148; for information regarding compensation of directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into offer letters or employment
agreements with each of our executive officers. For more information regarding our agreements with our named executive officers for the fiscal year ended December&nbsp;31, 2020, see &#147;Executive Compensation&#151;Narrative to Summary Compensation
Table&#151;Employment Arrangements with Our Named Executive Officers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into or plan to enter into indemnification agreements with each of our directors and executive officers, the form of which is attached as an exhibit to
the registration statement of which this prospectus is a part. The indemnification agreements and our amended and restated certificate of incorporation and amended and restated bylaws require us to indemnify our directors and officers to the fullest
extent permitted by Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Lease Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2008, we
entered into an operating lease agreement with a term through December 31, 2022 with Ellka, for the space in which we operated until we entered into a termination agreement, and the lease was terminated in February 2021. We also entered into a lease
for a living space for employees in Auburndale, MA, which terminated in January 2021. In May 2016, we entered into a second lease agreement with Ellka for living space for employees, also in Auburndale, MA. We entered into a second lease for this
space on July 26, 2018, which expired on July 31, 2019. Ellka was originally established in 2007 as an LLC for the purpose of acquiring and managing investment properties owned by Laura Aguilar and Estuardo Aguilar-Cordova and their children&#146;s
trusts. Ellka is owned and operated by Laura Aguilar and Estuardo Aguilar-Cordova and members of their immediate family. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">168 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We entered
into an exclusive license agreement with Ventagen LLC, or Ventagen, in March 2014, which granted Ventagen the right to develop, commercialize and distribute products in Mexico, Belize, Guatemala, Honduras, El Salvador, Costa Rica, Nicaragua, Panama,
Columbia and Bolivia, in exchange for a $1 million upfront fee and potential future milestone payment of $2.5 million. Stockholders of the Company own 49.5% of the voting stock of Ventagen, including 47% by Estuardo Aguilar-Cordova and Laura Aguilar
and trusts for the benefit of their children. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directed Share Program </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At
our request, the underwriters have reserved up to 5% of the shares offered by this prospectus for sale at the initial public offering price in a directed share program for our directors, officers, employees and related persons. See
&#147;Underwriting&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">169 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The following table presents information concerning the beneficial ownership of the shares of our common stock as of June 30, 2021, by: </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person we know to be the beneficial owner of 5% or more of our outstanding shares of our capital stock;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have determined beneficial ownership in accordance with SEC rules. The information does not necessarily indicate beneficial ownership for any other purpose. Under
these rules, a person is deemed to be a beneficial owner of our common stock if that person has a right to acquire ownership within 60&nbsp;days by the exercise of options or the conversion of our redeemable convertible preferred stock. A person is
also deemed to be a beneficial owner of our common stock if that person has or shares voting power, which includes the power to vote or direct the voting of our common stock, or investment power, which includes the power to dispose of or to direct
the disposition of such capital stock. Except in cases where community property laws apply or as indicated in the footnotes to this table, we believe that each stockholder identified in the table possesses sole voting and investment power over all
shares of common stock shown as beneficially owned by the stockholder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The percentage of beneficial ownership prior to this offering in the table below is based on
18,798,454 shares of common stock deemed to be outstanding as of June 30, 2021, assuming the conversion of all outstanding shares of redeemable convertible preferred stock into an aggregate of 7,066,565 shares of common stock immediately prior to
the completion of this offering, and the percentage of beneficial ownership after this offering in the table below is based on 27,798,454 shares of common stock assumed to be outstanding after the completion of this offering. The table below assumes
that the underwriters do not exercise their option to purchase additional shares. If the underwriters exercise their option to purchase additional shares in full, we will sell an aggregate of 10,350,000 additional shares of common stock. Shares of
common stock subject to options that are currently exercisable or exercisable within 60&nbsp;days of June 30, 2021 are considered outstanding and beneficially owned by the person holding the options for the purpose of computing the percentage
ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. The percentages of shares beneficially owned after this offering set forth below are calculated without giving
effect to any potential purchases in this offering, including pursuant to the directed share program relating to this offering. Unless otherwise indicated below, the address of each individual listed below is c/o Candel Therapeutics, Inc.,
117&nbsp;Kendrick St, Suite&nbsp;450, Needham, Massachusetts&nbsp;02494. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Address of Beneficial Owner</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;SHARES<BR>BENEFICIALLY&nbsp;OWNED<BR>BEFORE OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE&nbsp;OF<BR>SHARES<BR>BENEFICIALLY<BR>OWNED BEFORE<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE<BR>OF SHARES<BR>BENEFICIALLY<BR>OWNED&nbsp;AFTER<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL"><B>5% or Greater Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Entities affiliated with PBM Capital <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">6,777,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">30.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">21.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Northpond Ventures, LP&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">1,685,326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">9.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">EAC Descendants Irrevocable Trust&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">942,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">5.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">3.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">LKA Descendants Irrevocable Trust&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">942,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">5.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">3.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Paul Peter Tak, M.D,
Ph.D.&nbsp;FMedSci&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">444,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Estuardo Aguilar-Cordova, M.D.,
Ph.D.&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>..</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">3,138,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">16.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">11.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Laura K. Aguilar, M.D., Ph.D.&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">2,995,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">15.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">10.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">John Canepa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Carrie S. Cox&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">7,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Edward J. Benz, Jr., M.D.&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">60,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">170 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Address of Beneficial Owner</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;SHARES<BR>BENEFICIALLY&nbsp;OWNED<BR>BEFORE OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE&nbsp;OF<BR>SHARES<BR>BENEFICIALLY<BR>OWNED BEFORE<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE<BR>OF SHARES<BR>BENEFICIALLY<BR>OWNED&nbsp;AFTER<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Shaan C. Gandhi, M.D., D.Phil </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Paul B. Manning&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">6,777,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">30.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">21.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Udi Meirav, Ph.D.&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">161,722</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Alan E. Smith, Ph.D., FRS, CBE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">68,147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Chris Martell&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">599,576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">All executive officers and directors as a group (thirteen persons)<SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">14,253,836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">70.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">48.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;3,388,977 shares of common stock issuable upon conversion of our Series B Preferred Stock held by PBM ADV Holdings, LLC and (ii)&nbsp;3,388,977 shares of common stock issuable upon the exercise of
warrants held by PBM ADV Holdings, LLC. In July&nbsp;2021, PBM ADV Holdings, LLC distributed all of the shares of Series&nbsp;B convertible preferred stock it then held and its interest in the November&nbsp;2018 warrants to its beneficial owners,
including the distribution of 2,755,731 shares of Series&nbsp;B Preferred Stock and warrants to purchase 2,755,731 shares of our Common Stock to Paul&nbsp;B. Manning and entities controlled by Mr.&nbsp;Manning for no additional consideration in
accordance with the terms of its operating agreement. Under the terms of the distribution, Mr.&nbsp;Manning retains sole voting and shared dispositive power over such distributed securities through the completion of this offering, at which time
Mr.&nbsp;Manning&#146;s voting and dispositive power over the distributed shares will terminate except with respect to any shares held by Mr.&nbsp;Manning or by entities controlled by Mr.&nbsp;Manning. PBM ADV Holdings, LLC is majority owned by PBM
Capital Investments&nbsp;II, LLC, and is managed by PBM Capital. Paul&nbsp;B. Manning, a member of our board of directors, is the Chief Executive Officer of PBM Capital and has sole voting and investment power with respect to the shares held by PBM
ADV Holdings, LLC. The business address for each person and entity named in this footnote is 200&nbsp;Garrett Street, Suite&nbsp;S, Charlottesville, Virginia&nbsp;22902. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,685,768 shares of our common stock issuable upon conversion of our Series&nbsp;C Preferred Stock held by Northpond Ventures, LP (&#147;Northpond&#148;). Northpond LP is managed by Northpond Ventures GP,
LLC (&#147;Northpond LLC&#148;) and Northpond LLC may be deemed to beneficially own such shares. Michael Rubin is the managing member of Northpond LLC and may also be deemed to beneficially own such shares. The business address for each person and
entity named in this footnote is 7500 Old Georgetown Rd, Suite 850, Bethesda, MD 20814. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 942,338 shares of common stock. Stephen Scherer and Katherine Michelle Rives, as trustees, have voting and dispositive power over the shares. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 942,338 shares of common stock. Stephen Scherer and Katherine Michelle Rives, as trustees, have voting and dispositive power over the shares. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 444,217&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2021. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;853,786&nbsp;shares of common stock, (ii)&nbsp;129,738 shares of Series&nbsp;B Preferred Stock held solely by Dr.&nbsp;Aguilar-Cordova, (iii)&nbsp;32,399&nbsp;shares of Series&nbsp;B Preferred Stock
held jointly with his spouse, Laura&nbsp;K. Aguilar, M.D., Ph.D., (iv)&nbsp;2,074,942&nbsp;shares held for the benefit of Dr.&nbsp;Aguilar-Cordova by the Estuardo Aguilar-Cordova 2020 Irrevocable Trust and (v)&nbsp;47,512&nbsp;shares of common stock
issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2021. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;874,943&nbsp;shares of common stock, (ii)&nbsp;23,697&nbsp;shares of Series&nbsp;B Preferred Stock held solely by Dr.&nbsp;Aguilar, (iii)&nbsp;32,399 shares of Series&nbsp;B Preferred Stock held
jointly with her spouse, Estuardo Aguilar-Cordova, M.D., Ph.D., (iv)&nbsp;2,013,100&nbsp;shares held for the benefit of Dr.&nbsp;Aguilar by the Laura&nbsp;K. Aguilar 2020 Irrevocable Trust and (v)&nbsp;51,784 shares of common stock issuable upon the
exercise of options exercisable within 60 days after June&nbsp;30, 2021. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 7,910 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after June&nbsp;30, 2021. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 60,010 shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2021. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Paul B. Manning does not hold any shares of our common stock in his capacity as director. Paul&nbsp;B. Manning is the Chairman and CEO of PBM Capital and is a member of our board of directors. PBM Capital is an
affiliate of PBM ADV Holdings, LLC, a holder of five percent or more of our capital stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 48,822 shares of common stock and (ii) 112,900 shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2021. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 32,548 shares of common stock and (ii) 35,599 shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2021. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 32,548&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60 days after (ii)&nbsp;283,514&nbsp;shares of Series&nbsp;B Preferred Stock held by GTAM1 2012 ADV LLC, of
which Mr.&nbsp;Martell serves as Manager, and (iii)&nbsp;283,514 warrants held by GTAM1 2012 Trust, of which Mr.&nbsp;Martell serves as trustee but is not a beneficiary. Mr.&nbsp;Martell disclaims beneficial ownership over all of these interests,
except for his beneficial ownership in the 32,548&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after June&nbsp;30, 2021. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See footnotes 5 to 13. Also includes shares beneficially owned by Nathan Caffo and Susan Stewart, J.D., each of whom are executive officers but not named executive officers. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">171 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering and after giving effect to the conversion into common stock and retirement of all outstanding shares of our redeemable convertible
preferred stock, our authorized capital stock will consist of 150,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share, all of which will be undesignated, and there will be
27,798,454 shares of common stock outstanding and no shares of preferred stock outstanding. As of March&nbsp;31, 2021, we had approximately 350&nbsp;record holders of our capital stock. All of our outstanding shares of redeemable convertible
preferred stock will convert into shares of our common stock upon the completion of this offering. In addition, upon the completion of this offering, options to purchase shares of our common stock will be outstanding and 2,347,000 shares of our
common stock will be reserved for future grants under our equity incentive plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following description of our capital stock and provisions of our amended and
restated certificate of incorporation and amended and restated bylaws are summaries of material terms and provisions and are qualified by reference to our amended and restated certificate of incorporation and amended and restated bylaws, copies of
which have been filed with the SEC as exhibits to the registration statement of which this prospectus is a part. The descriptions of our common stock and preferred stock reflect amendments to our amended and restated certificate of incorporation and
amended and restated bylaws that will become effective upon the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, we will be authorized to issue one class of common stock. Holders of our common stock are entitled to one vote for each share of
common stock held of record for the election of directors and on all matters submitted to a vote of stockholders. Holders of our common stock are entitled to receive dividends ratably, if any, as may be declared by our board of directors out of
legally available funds, subject to any preferential dividend rights of any preferred stock then outstanding. The holders of our common stock do not have any cumulative voting rights. Upon our dissolution, liquidation or winding up, holders of our
common stock are entitled to share ratably in our net assets legally available after the payment of all our debts and other liabilities, subject to the preferential rights of any preferred stock then outstanding. Holders of our common stock have no
preemptive, subscription, redemption or conversion rights and no sinking fund provisions are applicable to our common stock. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the
rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. Except as described under &#147;Antitakeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of
Incorporation and Amended and Restated Bylaws&#148; below, a majority vote of the holders of common stock is generally required to take action under our amended and restated certificate of incorporation and amended and restated bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, our board of
directors will be authorized, without action by the stockholders, to designate and issue up to an aggregate of 10,000,000 shares of preferred stock in one or more series. Our board of directors can designate the rights, preferences and privileges of
the shares of each series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights
of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of
restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change in control of our company, which might harm the market
price of our common stock. See also &#147;Antitakeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws&#151;Provisions of our Amended and Restated Certificate of
Incorporation and Amended and Restated Bylaws&#151;Undesignated preferred stock&#148; below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors will make any determination to issue such
shares based on its judgment as to our company&#146;s best interests and the best interests of our stockholders. Upon the completion of this offering, we will have no shares of preferred stock outstanding and we have no current plans to issue any
shares of preferred stock following completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">172 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with
the November 13, 2018 issuance of Series&nbsp;B Preferred Stock, we issued warrants to purchase 3,672,491 shares of common stock for $6.81 per share to a purchaser of our Series B Preferred Stock which were immediately and fully exercisable upon
issuance, or the Unconditional Series&nbsp;B Warrants. We also issued warrants for the purchase of up to an additional 3,672,491&nbsp;shares of common for $6.81 per share, or the Conditional Series&nbsp;B Warrants. As amended on July&nbsp;14, 2014,
each of the Unconditional Series&nbsp;B Warrants and Conditional Series&nbsp;B Warrants expire in November 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Conditional Series B Warrants are only
exercisable in the event that we achieve certain financial conditions as follows: 918,123 shares vest upon a financing event effected through the sale of our equity securities to third parties resulting in at least $20,000,000 in gross proceeds, or
a Financing Event, with a price per share of, or average market price (determined over a consecutive 10-day period) of, $12.47 per share; an additional 918,123 shares vest upon a Financing Event with a price per share of, or average market price of,
$13.20 per share; an additional 918,122 shares vest upon a Financing Event with a price per share of, or average market price of, $13.94 per share; and an additional 918,122 shares vest upon a Financing Event with a price per share of, or average
market price of, $14.68 per share. Based on the initial public offering price of $8.00 per share, the consummation of our initial public offering will not be a Financing Event that will result in the vesting of the Conditional Series B Warrants.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Unconditional Series&nbsp;B Warrants contain provisions allowing for cash and on a cashless exercise basis. The Conditional Series&nbsp;B Warrants are only
exercisable in connection with the first to occur of (i)&nbsp;a sale of the Company or (ii)&nbsp;the Conditional Series&nbsp;B Warrants&#146; expiration in November 2025. The Conditional Series&nbsp;B Warrants contain provisions allowing for cash
and on a cashless exercise basis in connection with a sale event, and only on a cashless exercise basis in connection with the Conditional Series&nbsp;B Warrants&#146; expiration in November 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, PBM ADV Holdings, LLC and GTAM1 2012 LLC owned all of the Unconditional Series&nbsp;B Warrants and the Conditional Series&nbsp;B Warrants.
PBM ADV Holdings, LLC holds warrants to purchase, in the aggregate, 6,777,954 shares of our common stock. Such warrants, if fully exercised for cash in connection with this offering, would result in PBM ADV Holdings, LLC beneficially owning 33.4% of
our common stock. Paul&nbsp;B. Manning, a member of our board of directors, is affiliated with PBM ADV Holdings, LLC. In addition, GTAM1 2012 LLC holds warrants to purchase, in the aggregate, 567,028 shares of our common stock. Such warrants, if
fully exercised for cash in connection with this offering, would result in GTAM1 2012 LLC beneficially owning 2.8% of our common stock. Chris Martell, a member of our board of directors, is affiliated with GTAM1 2012 ADV LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, the holders of
8,884,661&nbsp;shares of our common stock, including shares issuable upon the conversion of our convertible preferred stock, or their permitted transferees, which we refer to as our registrable securities, are entitled to rights with respect to the
registration of these securities under the Securities Act. These rights are provided under the terms of the Investors&#146; Rights Agreement. The Investors&#146; Rights Agreement includes demand registration rights, short-form registration rights
and piggyback registration rights. All fees, costs and expenses incurred in connection with registrations under the Investors&#146; Rights Agreement will be borne by us, and all selling expenses, including underwriting discounts and selling
commissions, will be borne by the holders of the shares being registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Demand Registration Rights </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, the holders of our registrable securities are entitled to demand registration rights. Under the terms of the investor rights
agreement, we will be required, upon the request of holders of at least 25% of our outstanding registrable securities, to file a registration statement with an anticipated offering amount of at least $3.0&nbsp;million and use commercially reasonable
efforts to effect the registration of these shares for public resale. We are required to effect up to two registrations pursuant to this provision of the Investors&#146; Rights Agreement. A demand for registration may not be made until six months
after the effective date of the registration statement for this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">173 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Short Form Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, the holders of our registrable securities are also entitled to short form registration rights. Pursuant to the Investors&#146;
Rights Agreement, if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> upon the request of holders of at least 10% of our outstanding registrable securities to sell registrable securities with an
anticipated aggregate offering amount of at least $1.0&nbsp;million, we will be required to use our commercially reasonable efforts to effect a registration of such shares. We are required to effect up to two registrations in any twelve month period
pursuant to this provision of the Investors&#146; Rights Agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of our registrable securities are entitled to piggyback registration rights. If we register any of our securities either for our own account or for the
account of other security holders, the holders of our outstanding registrable securities are entitled to include their shares in the registration. Subject to certain exceptions contained in the Investors&#146; Rights Agreement, we and the
underwriters may limit the number of shares included in the underwritten offering if the underwriters determine that marketing factors require a limitation of the number of shares to be underwritten. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Investors&#146; Rights Agreement contains
customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to
indemnify us for material misstatements or omissions attributable to them. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The registration rights granted under the investor rights agreement will terminate upon the earlier of (i)&nbsp;a deemed liquidation event, as defined in our amended
and restated certificate of incorporation (as in effect prior to the completion of this offering) or certain other events constituting a sale of the company, (ii)&nbsp;at such time after our initial public offering when all registrable securities
could be sold under Rule 144 of the Securities Act or a similar exemption without limitation during a three-month period without registration or (iii)&nbsp;the fifth anniversary of our initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Antitakeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain provisions of the Delaware General Corporation Law and of our amended and restated certificate of incorporation and amended and restated bylaws that will become
effective upon the completion of this offering could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of
coercive takeover practices and inadequate takeover bids and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These
provisions are also designed in part to encourage anyone seeking to acquire control of us to first negotiate with our board of directors. These provisions might also have the effect of preventing changes in our management. It is possible that these
provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests. However, we believe that the advantages gained by protecting our ability to negotiate with any unsolicited and
potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could improve
their terms. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Delaware Anti-Takeover Statute </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of
this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an
&#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination
between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">174 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers,
and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors
and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or
more of the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, Section&nbsp;203 defines an interested stockholder as any entity or person
beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Provisions of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws to be in effect upon completion of this offering will include a number of
provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of
directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Board
composition and filling vacancies</I>. Our amended and restated certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our
amended and restated certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors.
Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less
than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>No written consent of stockholders</I>. Our amended and restated certificate of incorporation provides that all stockholder actions are required to be taken by a
vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the
amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Meetings of stockholders</I>. Our certificate of
incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted
upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Advance notice requirements</I>. Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for
election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the
action is to be taken. Generally, to be timely, notice must </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">175 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify
the requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Amendment to certificate of incorporation and bylaws</I>. Any amendment of our amended and restated certificate of incorporation must first be approved by a majority
of our board of directors, and if required by law or our amended and restated certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment, and a majority of the outstanding
shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than two-thirds of the outstanding
shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority vote of the directors then in office,
subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of not less than two-thirds of the outstanding shares entitled to vote on the amendment, or, if the board of directors recommends that the
stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Undesignated preferred stock</I>. Upon the completion of this offering, our amended and restated certificate of incorporation will provide for authorized shares of
preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in
the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without
stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of
incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets
available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control
of us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Choice of Forum </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
<FONT STYLE="white-space:nowrap">by-laws</FONT> provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Chancery Court does not have jurisdiction, the federal
district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a claim of breach
of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State
of Delaware or our certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (including the interpretation, validity or enforceability thereof) or (4)&nbsp;any action asserting a claim governed by the internal affairs doctrine.
Our <FONT STYLE="white-space:nowrap">by-laws</FONT> of incorporation also provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this
choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that, unless we consent in writing to the selection of an alternative forum, the federal
district courts of the United States will be the exclusive forum for any private action asserting violations by us or any of our directors or officers of the Securities Act or the Exchange Act, or the rules and regulations promulgated thereunder,
and of all suits in equity and actions at law brought to enforce any liability or duty created by those statutes or the rules and regulations under such statutes. If any action the subject matter of which is within the scope of the preceding
sentence is filed in a court other than the federal district courts of the United States, the plaintiff or plaintiffs shall be deemed by this provision of the bylaws (i)&nbsp;to have consented to removal of the action by us to the federal district
courts of the United States, in the case of an action filed in a state court, and (ii)&nbsp;to have consented to transfer of the action to the federal district courts of the United States </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">176 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We recognize that the Delaware Forum Provision in our bylaws may impose additional litigation costs on stockholders in
pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#146; ability to bring a claim in a
forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our
stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#147;facially valid&#148; under Delaware
law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum
Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach
different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The transfer agent and
registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&#146;s address is 6201 15th Avenue, Brooklyn, NY 11219, and its telephone number is (718)&nbsp;921-8200. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have applied to list our common stock on The Nasdaq Global
Market under the symbol &#147;CADL.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">177 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. Future sales of our common stock in the public market, or the availability of such shares
for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on
resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to raise equity capital
in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the number of shares of common stock outstanding as of June&nbsp;30, 2021, upon the completion of this offering, 27,798,454 shares of our
common stock will be outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable,
except that any shares held by our affiliates, as that term is defined in Rule 144 under the Securities Act, may only be sold in compliance with the limitations described below, and shares of our common stock are restricted shares of common stock
subject to time-based vesting terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, a person who
has beneficially owned restricted stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days
preceding, a sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the
time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of
either of the following: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1% of the number of shares then outstanding, which will equal approximately 278,000 shares immediately after this offering
assuming no exercise of the underwriters&#146; option to purchase additional shares, based on the number of shares outstanding as of March 31, 2021; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks preceding
the filing of a notice on Form 144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided, in each case, that are subject to the Exchange Act periodic reporting
requirements for at least 90 days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice provisions of Rule 144.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rule 701 under the Securities Act, as in effect on the date
of this prospectus, permits resales of shares in reliance upon Rule 144 but without compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers or directors who purchased
shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the effectiveness of the registration statement of which
this prospectus forms a part before selling their shares. However, substantially all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and under &#147;Underwriting&#148; included elsewhere
in this prospectus and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection
with this offering, we, each of our directors and executive officers, and holders of substantially all of the shares of our outstanding stock have agreed with the underwriters that for a period of 180 days following the date of this prospectus,
subject to certain exceptions, we will not offer, sell, assign, transfer, pledge, contract to sell or otherwise dispose of or hedge any shares of our common stock or any securities convertible into or exchangeable for shares of our common stock. The
underwriters may, in their sole discretion, at any time, release all or any portion of the shares from the restrictions in this agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">178 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the completion of this offering, certain of our officers, directors and other employees may adopt written plans, known as Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under these <FONT
STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a broker may execute trades pursuant to parameters established by the officer or director when entering into the plan, without further direction from such officer or director. Such sales would
not commence until the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by such officer or director in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, certain holders of
our securities will be entitled to various rights with respect to registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction
under the Securities Act immediately upon the effectiveness of the registration statement.&nbsp;See the section entitled &#147;Description of Capital Stock&#151;Registration rights&#148; appearing elsewhere in this prospectus for more information.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to file one or more registration
statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after
the date of this prospectus and will automatically become effective upon filing with the SEC. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting
restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrants </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 7,344,982 shares of common stock issuable under the Unconditional Series&nbsp;B Warrants and Conditional Series&nbsp;B Warrants may be available for sale in the
open market once issued, subject to resale restrictions under Rule&nbsp;144 for certain affiliates of ours that may hold such warrants at the time of such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">179 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion is a summary of material U.S. federal income tax considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as
defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. For purposes of this discussion, a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation or any other organization taxable as a corporation for U.S. federal income tax purposes that is created or
organized in or under laws other than the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an estate the income of which is not subject to U.S. federal income tax on a net income basis; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust (1) that (a)&nbsp;has not made an election to be treated as a U.S. person under applicable U.S. Treasury
regulations and (b)&nbsp;either (i) is not subject to the primary supervision of a court within the United States or (ii)&nbsp;is not subject to the substantial control of one or more U.S. persons or (2)&nbsp;the income of which is not subject to
U.S. federal income tax on a net income basis. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion does not address the tax treatment of partnerships or other entities or
arrangements that are treated as pass-through entities for U.S. federal income tax purposes or persons that hold their shares of common stock through partnerships or such other pass-through entities. The tax treatment of a partner in a partnership
or other entity or arrangement that is treated as a pass-through entity for U.S. federal income tax purposes generally will depend upon the status of the partner and the activities of the partnership. A partner in a partnership or an investor in any
other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as
applicable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion is based on current provisions of the Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S. Treasury
regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect.
Any such change or differing interpretation could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. We have not sought and will not seek any rulings from the Internal Revenue
Service, or the IRS, regarding the matters discussed below. There can be no assurance that the IRS, will not challenge one or more of the tax consequences described herein. We assume in this discussion that a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code, which is generally property held for investment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it address any aspects of any U.S. federal tax other than the income tax, U.S. state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, the alternative minimum tax, or the Medicare tax on net investment income. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">180 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other
integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our
common stock should consult their tax advisors with respect to the U.S. federal, state, local, estate and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions on Our Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in the &#147;Dividend
Policy&#148; section above, we do not intend to pay any dividends in cash or property on our common stock in the foreseeable future. Distributions of cash or property, if any, on shares of our common stock generally will constitute dividends for
U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess
will be treated as a return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s adjusted tax basis in the shares of common stock. Any remaining excess will be treated as capital gain, subject to
the tax treatment described below in &#147;Gain on Sale or Other Taxable Disposition of Our Common Stock.&#148; Any such distributions will also be subject to the discussion below under the section titled &#147;Withholding and Information Reporting
Requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion in the following two paragraphs in this section, dividends paid to a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by an applicable income tax treaty
between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Dividends that are treated as effectively connected with a trade or business conducted by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification and disclosure
requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected
income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower rate as specified by an
applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of
shares of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or a successor form) to the applicable withholding agent and satisfy applicable certification and other
requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that
is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may generally obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to
the discussion below under &#147;Withholding and Information Reporting Requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income tax on any gain recognized upon
such holder&#146;s sale, exchange or other taxable disposition of shares of our common stock unless: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a
U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on Our Common Stock&#148; also may apply; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">181 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such
lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income
tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market, within the meaning of the
relevant provisions of the Code, and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the five-year period
ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. If we are determined to be a U.S. real property holding corporation and the foregoing exception does not
apply, then the non-U.S. holder generally will be taxed on its net gain derived from the sale or other taxable disposition at the U.S. federal income tax rates applicable to United States persons (as defined in the Code). Generally, a corporation is
a &#147;U.S. real property holding corporation&#148; only if the fair market value of its &#147;U.S. real property interests&#148; (as defined in the Code and applicable U.S. Treasury regulations) equals or exceeds 50% of the sum of the fair market
value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a &#147;U.S. real property holding corporation&#148;
for U.S. federal income tax purposes, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Backup Withholding and Information Reporting </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We must
report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on shares of our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable
rate with respect to dividends on shares of our common stock. Generally, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will comply with such procedures if it provides a properly executed IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable IRS Form <FONT STYLE="white-space:nowrap">W-8),</FONT> or otherwise meets documentary
evidence requirements for establishing that it is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, or otherwise establishes an exemption. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of
U.S. federal income tax, as described above in &#147;Distributions on Our Common Stock,&#148; generally will be exempt from U.S. backup withholding. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information
reporting and backup withholding will generally apply to the proceeds of a disposition of shares of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.,</FONT> unless the holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information
reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or
operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the
information reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated
under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded
or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Withholding and Information Reporting Requirements&#151;FATCA </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Foreign
Account Tax Compliance Act, or FATCA, generally imposes a U.S. federal withholding tax at a rate of 30% on payments of dividends on our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">182 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
&#147;foreign financial institution,&#148; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a
&#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise excepted under FATCA. Such withholding may also apply to payments of gross proceeds of
sales or other dispositions of shares of our common stock, although under proposed U.S. Treasury regulations (the preamble to which specifies that taxpayers, including withholding agents, are generally permitted to rely on them pending
finalization), no withholding will apply to payments of gross proceeds. If withholding under FATCA is required on any payment related to our common stock, under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be
eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph.
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our shares of common
stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">183 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement, dated July 26, 2021, among us and Jefferies LLC, Credit Suisse Securities (USA) LLC, BMO
Capital Markets Corp. and UBS Securities LLC, as the representatives of the underwriters in this offering named below, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from
us, the respective number of shares of common stock shown opposite its name below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,430,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">BMO Capital Markets Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">UBS Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,170,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of
their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable
laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the
liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise
discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have
advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a
concession not in excess of $0.336 per share of common stock. After the offering, the initial public offering price, concession and reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to
be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">184 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the
underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,040,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,796,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,960,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,004,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$3,800,000. We have also agreed to pay the filing fees incident to, and the fees and disbursements of counsel for the underwriters in connection with, the required review by the Financial Industry Regulatory Authority, Inc. in an amount up to
$40,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Determination of Offering Price </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there
has not been a public market for our common stock. Consequently, the initial public offering price for our common stock will be determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations
will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other
factors deemed relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We offer no assurances that the initial public offering price will correspond to the price at which the common stock will trade in the
public market subsequent to the offering or that an active trading market for the common stock will develop and continue after the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have submitted an application to list our common stock on The Nasdaq Global Market under the trading symbol &#147;CADL.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the underwriters an
option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of 1,350,000 shares from us at the public offering price set forth on the cover page of this prospectus, less
underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter&#146;s initial
purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and holders of
all or substantially all our outstanding capital stock and other securities have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-l(h)</FONT> under the Securities Exchange Act of 1934, as amended; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities
exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">185 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus
without the prior written consent of the representatives.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after
the close of trading of the common stock on and including the 180<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
representatives may, together in their sole discretion and at any time or from time to time before the termination of the <FONT STYLE="white-space:nowrap">180-day</FONT> period release all or any portion of the securities subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters and any of our stockholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale
of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, pursuant to Regulation M under the Securities Exchange Act of 1934, as amended, certain persons participating in the offering may
engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of
the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares of our common stock in this
offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares
to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase
additional shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close
out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the
open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is a bid for the purchase of shares of common
stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short
position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our
common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement
permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and
therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor any of the underwriters make any representation or prediction as to the
direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at
any time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our common stock on The Nasdaq Global Market in accordance with Rule&nbsp;103
of Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess
of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">186 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
prospectus in electronic format may be made available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective
investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for
online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site
maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directed Share Program </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At our request, the underwriters have reserved for
sale at the initial public offering price up to 5% of the shares offered by this prospectus for sale at the initial public offering price in a directed share program for employees, directors and other persons associated with us who have expressed an
interest in purchasing shares in the offering. The number of shares of common stock available for sale to the general public in the offering will be reduced to the extent these persons purchase the directed shares in the program. Any directed shares
not so purchased will be offered by the underwriters to the general public on the same terms as the other shares. Directed shares purchased in the program will not be subject to a lock-up restriction, with the exception of directed shares purchased
by our directors and officers, which will be subject to a 180-day lock-up restriction. The representatives in their sole discretion may release any of the shares subject to these lock-up restrictions at any time. We have agreed to indemnify the
underwriters against certain liabilities and expenses, including liabilities under the Securities Act, in connection with sales of the directed shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other
Activities and Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their respective affiliates are full service financial institutions engaged in various activities,
which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their
respective affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and
expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own accounts and for the accounts of their respective customers, and such investment and
securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with
their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our
securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their
respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend
to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Resale Restrictions </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of shares of our common stock in Canada is being made only in the provinces of Ontario, Quebec, Alberta, British Columbia, Manitoba, New Brunswick and
Nova Scotia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares of common
stock in Canada must be made under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">187 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption
granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Representations of Canadian Purchasers </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing shares of our common
stock in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation is received that: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is entitled under applicable provincial securities laws to purchase the shares of common stock without the
benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;</FONT><I>Prospectus Exemptions or
Section</I><I></I><I>&nbsp;73.3(1) of the Securities Act (Ontario), as applicable</I>, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;</FONT><I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where required by law, the purchaser is purchasing as principal and not as agent, and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Conflicts of Interest </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that certain
of the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;</FONT><I>Underwriting Conflicts</I> from having to provide certain conflict of
interest disclosure in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Statutory Rights of Action </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any
amendment thereto) such as this prospectus contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Enforcement of Legal Rights </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as well
as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the
assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of
Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Taxation and Eligibility for Investment </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers
of our shares of common stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the shares in their particular circumstances and about the eligibility of the shares for investment by the
purchaser under relevant Canadian legislation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Australia </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This
prospectus is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to
the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You confirm and warrant that you are either: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have
provided an accountant&#146;s certificate to the company which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">188 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor or professional investor under the
Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You warrant and agree that you will not offer any of the shares
issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each Member State of the
European Economic Area (each, a &#147;Relevant State&#148;), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which have
been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that
the shares may be offered to the public in that Relevant State at any time: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to any legal entity which is a &#147;qualified investor&#148; as defined under Article 2(e) of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of representatives<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of the shares shall require the Company or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to the shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or
subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129 (as amended). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This European Economic Area selling
restriction is in addition to any other selling restrictions set out below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>PRC </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been and will not be circulated or distributed in the PRC, and no securities may be offered or sold, or will be offered or sold, to any person
for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, to any resident of the PRC except pursuant to applicable laws and regulations of the PRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No securities have been offered or sold, and no
securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in
the Securities and Futures Ordinance (Cap. 571) of Hong Kong, or SFO, and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap.
32) of Hong Kong, or CO, or which do not constitute an offer to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any
person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong
Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong
Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">189 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not
acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Israel </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the
Israel Securities Authority. In the State of Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with section 15A of the
Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment
advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals&#148;, each as defined in the Addendum (as it may be amended from time to
time), collectively referred to as qualified investors (in each case purchasing for their own accounts or, where permitted under the Addendum, for the accounts of their respective clients who are investors listed in the Addendum). Qualified
investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been and will not be registered under
the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended), or FIEL, and the Initial Purchaser will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident
of Japan (which term as used herein means, unless otherwise provided herein, any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for
<FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any
other applicable laws, regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been and will not be lodged or registered with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or the invitation for subscription or purchase of the securities may not be issued, circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or
the SFA, (ii)&nbsp;to a relevant person as defined under Section&nbsp;275(2), or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions, specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise
pursuant to, and in accordance with the conditions of any other applicable provision of the SFA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the securities are subscribed or purchased under
Section&nbsp;275 of the SFA by a relevant person which is:&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation (which is not an accredited investor as defined under Section&nbsp;4A of the SFA) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and
interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares of common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">190 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the
disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock
exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus nor any other offering or marketing material relating to the offering, the Company or the securities have been or will be filed with or
approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA and the offer of securities has not been
and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No shares have been offered or will be offered
pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the Shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the
United Kingdom at any time: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a) to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the
prior consent of the representatives for any such offer; or </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(c) in any other circumstances falling within Section&nbsp;86 of the FSMA, </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a
prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any
means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU)
2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">191 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the common stock offered hereby will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts and for the underwriters by Wilmer Cutler
Pickering Hale&nbsp;&amp; Dorr LLP, New&nbsp;York, New&nbsp;York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">192 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements of Candel Therapeutics, Inc. as of December&nbsp;31, 2019 and December&nbsp;31, 2020 and for each of the years ended December&nbsp;31, 2019
and December&nbsp;31, 2020 are included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our Independent Registered Public Accounting Firm, KPMG LLP, or KPMG, informed our Audit Committee that a now-former partner at KPMG (the &#147;Individual&#148;)
previously located in the office of the lead audit engagement partner of the Company held a financial interest in the Company for an approximate five-week period during the 2019 audit and professional engagement period. SEC independence rules for
covered persons prohibit ownership of shares in the Company during any point in the professional engagement period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The duration of the violation was limited, from
June 17, 2019 through July 24, 2019, and the investment was not material to the Individual&#146;s net worth, the Company or KPMG. Additionally, the Individual did not participate in the Company&#146;s audits or have any oversight over members of the
audit engagement team conducting the audit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">After careful consideration of the facts and circumstances and the applicable independence rules, KPMG has concluded
that (i) the aforementioned matter did not and does not impair its ability to exercise objective and impartial judgment in connection with its audits of the financial statements of the Company; and (ii) a reasonable investor with knowledge of all
relevant facts and circumstances would reach the same conclusion. Management and the Audit Committee for the Company concur with KPMG&#146;s conclusions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">193 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File Number 333-257444) under the Securities Act with respect
to the common stock we are offering in this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the
registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the
registration statement for copies of the actual contract, agreement or other document. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, we will be subject to informational
requirements of the Exchange Act and will file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov.
We also maintain a website at www.candeltx.com. Upon completion of this offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any amendment to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably
practicable after such material is electronically filed with, or furnished to, the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">194 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc120909_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_2">Consolidated Balance Sheet</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_3">Consolidated Statement of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_4">Consolidated Statement of Convertible Preferred Stock and Stockholders&#146; Deficit
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_5">Consolidated Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_7">Condensed Consolidated Balance Sheets (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_8">Condensed Consolidated Statement of Operations and Comprehensive Loss
(unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_9">Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders Deficit
 (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_10">Condensed Consolidated Statement of Cash Flows (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin120909_11">Notes to Condensed Consolidated Financial Statements (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-30-42</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candel Therapeutics, Inc.: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Opinion on the Consolidated Financial Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the
accompanying consolidated balance sheets of Candel Therapeutics, Inc. and subsidiary (the Company) as of December&nbsp;31, 2019 and 2020, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and
stockholders&#146; deficit, and cash flows for each of the years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2020, and the related notes (collectively, the consolidated financial statements). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2019 and 2020, and the results of its operations and its cash flows for each of the years in the <FONT
STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2020, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Basis for
Opinion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or
fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ KPMG LLP
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2019 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">McLean, Virginia
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">March&nbsp;29, 2021, except for Note 17 which is as of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">July&nbsp;15, 2021
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_2"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;35,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fixed assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 38,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paycheck protection program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies (Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:9.5pt; font-family:ARIAL">Series B convertible preferred stock, $0.01 par value; 11,155,506 shares authorized, issued and outstanding at December&nbsp;31,
2019 and 2020, liquidation preference of $30,896 at December&nbsp;31, 2019 and 2020.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:9.5pt; font-family:ARIAL">Series C convertible preferred stock, $0.01 par value; 6,032,170 shares authorized, issued and outstanding at December&nbsp;31,
2019 and 2020, liquidation preference of $22,500 at December&nbsp;31, 2019 and 2020.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.01 par value; 75,000,000 shares authorized at December&nbsp;31,&nbsp;2019 and 2020. Shares issued and
outstanding 11,613,737 and 11,635,096 at December&nbsp;31, 2019 and 2020, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities, convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 38,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_3"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Research and development service revenue, related party</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Other income (expense):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Grant income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest, dividend and investment income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total other income (expense), net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Other comprehensive (loss):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrealized gain (loss) on available-for-sale securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss per share attributable to common stockholders, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><B>Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,533,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,615,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THRAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_4"></A>Consolidated Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B<BR>CONVERTIBLE<BR>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES C<BR>CONVERTIBLE<BR>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL</B><br><B>PAID-IN<BR>CAPITAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>OTHER<BR>COMPREHENSIVE</B><br><B>LOSS</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCKHOLDERS&#146;</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of January&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,155,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,613,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series&nbsp;C convertible preferred<BR>stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,032,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,155,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,032,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,613,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Increase in fair value of NC Ohio Trust Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Recognition of unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,155,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,032,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,635,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_5"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17,680</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Non-cash stock compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Non-cash interest (income) expense net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Write off of IPR&amp;D assets from Periphagen asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other long term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,071</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Purchase of available-for-sale securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from maturities and sales of available-for-sale securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Purchase of Periphagen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Purchase of fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(35,741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>38,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from issuance of Series C Preferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Payment to founders for settlement of related party notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from paycheck protection program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>490</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,939</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,319</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Noncash Operating and Investing Activity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Leasehold improvements paid by Lessor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Noncash Investing and Financing Activity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Assignment of promissory note upon Periphagen acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Supplemental Disclosures of Cash Flow Information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash paid for taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Capital expenditures in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_6"></A>Notes to financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Amounts in thousands, except share and per share amounts) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1.
Organization and basis of presentation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candel Therapeutics, Inc., formerly known as Advantagene, Inc. (the &#147;Company&#148;) is a late clinical stage
biotechnology company that was incorporated in Delaware in June 2003. On November&nbsp;30, 2020, the Company changed its name to Candel Therapeutics, Inc. The Company is focused on helping patients fight cancer with oncolytic viral immunotherapies.
The Company&#146;s engineered viruses are designed to induce immunogenic cell death through direct viral &#150; mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of
injection. This approach combines an in-depth knowledge of viral immunotherapy and extensive clinical experience across a wide range of indications. The Company has established two oncolytic viral immunotherapy platforms and our two product
candidates, CAN-2409 and CAN-3110, are in clinical trials for a number of tumor types. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to risks and uncertainties common to early-stage
companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the
ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior
to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#146;s product development efforts are successful, it
is uncertain when, if ever, the Company will realize revenue from product sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has funded its operations primarily with proceeds from the sale of its
capital stock and convertible notes. The Company has incurred recurring losses since its inception, including a net loss of $8,240 and $17,680 for the years ended December&nbsp;31, 2019 and 2020, respectively. In addition, as of December&nbsp;31,
2020, the Company had an accumulated deficit of $44,171. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance
its operations. The Company&#146;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be
available on terms acceptable to the Company, or at all. The Company believes that existing resources will fund planned operations for at least 12&nbsp;months from the date that these consolidated financial statements were available to be issued.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company continue as a going concern and contemplates the
realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of significant accounting policies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying consolidated financial
statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition,
results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the financial statements are to the FASB<I> Accounting Standards</I> Codification (ASC). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Principles of consolidation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The consolidated financial statements
include the accounts of Candel Therapeutics, Inc. and its wholly owned subsidiary Candel Therapeutics Securities Corporation. All intercompany transactions and balances have been eliminated. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Emerging growth company </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is an emerging growth company,
as defined in the Jumpstart Our Business Startups Act of 2012 (the &#145;Jobs Act&#148;). Under the Jobs Act emerging growth companies can delay adopting new or revised accounting standards </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
issued subsequent to the enactment of the Jobs Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with
new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that is (i)&nbsp;no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opts out of the
extended transition period provided in the Jobs Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of estimates </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of the Company&#146;s consolidated
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and related disclosure of contingent assets and liabilities at the date of the financial
statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company&#146;s management evaluates its estimates, which include but are not limited to management&#146;s judgments of accrued expenses,
fair value of common stock, valuation of share-based awards, valuations of warrants, fair value of debt and income taxes. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies
in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its
common stock and warrants. Each valuation methodology includes estimates and assumptions that require the Company&#146;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market
conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#146;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an
initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive income (loss) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Components of comprehensive income or
loss, including net income or loss, are reported in the consolidated financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other
events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other
changes in stockholders&#146; equity that result from transactions and economic events other than those with stockholders. For the period presented, the Company had no elements of other comprehensive loss other than its net loss and unrealized loss
on marketable securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash and cash equivalents </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company
considers all highly liquid investments purchased with original final maturities of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents comprise marketable securities with maturities of less than 90 days when
purchased. Cash equivalents are reported at fair value. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Marketable securities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Marketable securities at December&nbsp;31, 2019 consisted of investments in U.S. fixed income mutual funds and corporate debt securities. There were no marketable
securities at December 31, 2020. The Company determines the classification of marketable securities at the time of acquisition and evaluates the appropriateness of such classification at each balance sheet date. The marketable securities are
classified as available-for-sale pursuant to ASC 320, Investments &#150; Debt and Equity Securities. The marketable securities are recorded at fair value with unrealized gains/(loss) included as a component of accumulated other comprehensive
gain/(loss), until realized. Realized gains and losses are included in other income. Marketable securities with maturities of less than one year from the balance sheet date are classified as current assets, and marketable securities with maturities
greater than one year from the balance sheet date are classified as non-current assets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restricted cash </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has $266 of restricted cash as of December 31, 2019 and 2020 which represents cash held in a restricted bank account under the terms of the Company&#146;s
Needham, Massachusetts facility lease, see Note 15. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Restricted cash is included in other long-term assets. The Company&#146;s previously reported December 31, 2019 financial statements included $266 of restricted cash in cash and cash equivalents.
The Company has changed the presentation of the $266 of restricted cash from cash and cash equivalents to other long-term assets in the accompanying December 31, 2019 consolidated financial statements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair value measurements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain assets and liabilities of the
Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in
an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities
carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Level 2&#151;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Level 3&#151;Unobservable inputs that are supported by little or no market activity that are significant to determining
the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The carrying
values of cash and cash equivalents, accounts payable, accrued expenses and Paycheck protection plan loan approximate their fair values due to the short-term nature of these assets and liabilities. Marketable securities are classified as Level 1
measurements (see Note 4). The Company&#146;s warrant liability is carried at fair value and is classified as Level 3 measurements. The carrying value of the Company&#146;s long-term debt assumed from the Periphagen transaction is classified as
Level 3 (See Note 3). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Property and equipment </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and
equipment consist of networking and computer equipment, furniture and fixtures and leasehold improvements. Property and equipment are recorded at cost, and depreciated using the straight-line method over the estimated useful lives of the respective
assets: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>ASSET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>ESTIMATED USEFUL LIFE</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Networking and computer equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Furniture and fixtures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shorter of the useful life or remaining lease term</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for leases in accordance with ASC 840.
Rent expense for leases is recognized on a straight-line basis beginning on the date premises were delivered. Minimum lease payments comprise of only base rent. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Concentrations of credit risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that potentially
expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Periodically, the Company maintains deposits and investments in accredited financial institutions in-excess of the
federally insured limits. The Company deposits its cash in financial institutions with a high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal risk
associated with commercial banking relationships. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred offering costs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred
offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#146; deficit as a reduction of proceeds generated as a result of the offering. Should a planned equity
financing be abandoned, the deferred offering costs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
would be expensed immediately as a charge to operating expenses in the consolidated statement of operations. As of December 31, 2020, the Company has included $83 of deferred offering costs in
other long-term assets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Impairment of long-lived assets </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets
may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and
significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use
and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount.
The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. Long-lived assets consist of fixed assets and to date, the Company has not recorded
any impairment losses on such long-lived assets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue recognition </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company applies Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, (ASC 606). This standard applies to all contracts with
customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606,
the entity performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to
the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the
consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within
each contract and determines those that are performance obligations, and then assesses whether or not each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the
respective performance obligation when (or as) the performance obligation is satisfied. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development costs and accruals </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense,
depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with clinical and research institutions, contract research organizations, and other companies.
These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized
based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial
statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts
are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses and intellectual property are charged to research and development expenses as acquired in-process research and development
if the technology licensed or intellectual property acquired has not reached technological feasibility and has no alternative future use. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent costs
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All patent-related costs incurred in connection with preparing, filing, maintaining and prosecuting patent applications are expensed as incurred due to the
uncertainty about the recovery of the expenditure. Amounts incurred are classified in general and administrative expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for its stock-based compensation in accordance with ASC Topic&nbsp;718,<I> Compensation&#151;Stock Compensation</I> (ASC&nbsp;718). ASC&nbsp;718
requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In addition, in accordance with FASB Accounting
Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions, the Company treats non-employee grants the same as employee grants. The Company estimates the fair value of options
granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of
the services provided. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&nbsp;the expected stock price
volatility, (b)&nbsp;the expected term of the award, (c)&nbsp;the risk-free interest rate and (d)&nbsp;expected dividends. Due to the lack of a public market for the Company&#146;s common stock and a lack of company-specific historical and implied
volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life
science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&nbsp;107,
Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the
stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term
of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to
be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are significant judgments and estimates
inherent in the determination of the fair value of the Company&#146;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold
shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period,
which is generally the vesting period. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Government grants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company has applied for grants for the reimbursement of expenditures with the National Institutes of Health for certain qualified operating expenditures. The Company recognizes government grants when there is reasonable assurance that the Company
will comply with the conditions attached to the grant arrangement and the grant will be received. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Government grants for research and development efforts are
recorded as grant income and classified in other income in the statements of operations and comprehensive loss. The Company recognized government grants of $571 and $624 for the years ended December 31, 2019 and 2020, respectively, as a component of
other income/(expense), net in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income taxes </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740,<I> Income Taxes</I> (ASC 740) which requires the
recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#146;s tax returns. Deferred tax assets and liabilities are determined on
the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more
likely than not that all or a portion of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating
the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&nbsp;31, 2019 and 2020, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 12).
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for uncertainty in income taxes, by applying the two-step process to determine the amount of tax benefit to be recognized in the financial
statements. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax is then
assessed as the amount of benefit to be recognized in the consolidated financial statements. The amount of benefits, that may be used, are the largest amounts that have a greater than 50% likelihood of being realized upon ultimate settlement. The
provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net loss per share </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic net loss per share is computed by dividing
net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding
during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&nbsp;31, 2019 and 2020 since all potential shares of
common stock instruments are anti-dilutive as a result of the loss for such periods. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s convertible preferred stock contractually entitles the
holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated
to such participating securities. In periods where the Company reports a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have
been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recently issued accounting standards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2016, the FASB
issued ASU 2016-02, <I>Leases</I> (&#147;Topic 842&#148;), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative
disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December&nbsp;15, 2021, with early
adoption permitted. The Company is currently evaluating the impact ASU 2016-02 will have on its consolidated financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2020, the FASB issued
ASU&nbsp;2020-06, &#147;Debt &#150; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#150; Contracts in Entity&#146;s Own Equity (Subtopic 815 &#150; 40)&#148; (&#147;ASU&nbsp;2020-06&#148;).
ASU&nbsp;2020-06&nbsp;simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#146;s own equity. The ASU is part of the FASB&#146;s
simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU&#146;s amendments are effective for fiscal years beginning after December&nbsp;15, 2023, and interim periods within those fiscal years. The Company is
currently evaluating the impact ASU&nbsp;2020-06&nbsp;will have on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Periphagen, Inc. asset acquisition </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;9, 2019, the Company entered into a series of asset purchase agreements with Periphagen, Inc., a biopharmaceutical company focused on the development
of gene therapy vectors. Under the terms of the asset purchase agreements, the Company acquired exclusive rights to technology and intellectual property, a portfolio of virus vectors under development and fixed assets for $846, and the assumption of
a $1,000 promissory note. The Company also agreed to the payment of future royalties on license fees received for license of the intellectual property obtained from Periphagen and on net sales of products that incorporate such intellectual property.
The promissory note bears a contractual interest rate of 2% compounded annually, with the outstanding balance and accrued interest due upon maturity in November 2027, with no interim installments due. The estimated market rate for the Company
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
for an unsecured loan with a maturity in November 2027 was determined to be 15.83%. Although the Company does not have a public credit rating, management estimates a CCC credit rating based on
the Company&#146;s financial position and stage of development. Using the commensurate rate for a CCC rated company and based on the amount due at maturity, the present value of the future cash outflow was determined to be $417 at the transaction
date. The total acquisition price was $1,263 which was allocated to the technology platform, intellectual property and virus vectors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The asset acquisition was
accounted for as acquisition of assets that did not meet the definition of a business. The asset acquisition did not constitute a business as substantially all of the fair value of the gross assets acquired was concentrated in the technology
platform and virus vectors, which represent a group of similar identifiable assets as of the acquisition date. As of the acquisition date, the assets were deemed to share similar risk characteristics as (1)&nbsp;each of the virus vectors and
technology platform were in the early development stages and shared a similar financial, technical and regulatory risk profile, (2)&nbsp;only preliminary indications had been identified for any of the assets and (3)&nbsp;the underlying therapies of
the assets were similar in that each was intended to treat an interrelated subset of autoimmune disorders by interrupting biologic mechanisms that otherwise result in inflammation and tissue damage. The acquired assets and liabilities were recorded
at their fair values and the Company immediately expensed the fair value of the acquire technology platform, intellectual property and virus vectors in the consolidated statement of operations and comprehensive loss in the amount of $1,263 as the
acquired assets represent in-process research and development with no alternative future use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Fair value of financial assets and liabilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of
the fair value hierarchy utilized to determine such fair values: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FAIR VALUE MEASUREMENTS AS OF<BR>DECEMBER&nbsp;31, 2019 USING:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FAIR VALUE MEASUREMENTS AS OF<BR>DECEMBER&nbsp;31, 2020 USING:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Valuation of marketable securities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of mutual funds is
based on the daily closing price as reported by the funds, which represent a Level 1 measurement within the fair value hierarchy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Valuation of long-term debt </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s valuation technique used to measure the fair value of the long-term debt assumed from the Periphagen transaction was a present value calculation
based upon a credit rating estimated for the Company at the time the debt was assumed. The determined credit rating used by the company was CCC based upon the financial position and stage of the Company. The estimated rate was 15.83% for an
unsecured note due in November 2027 for a CCC rated company. The fair value of the long-term debt based on this approach plus the accrued interest represents a Level 3 measurement within the fair value hierarchy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Valuation of warrant liability </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series B
Convertible Preferred Stock issuance, the Company issued warrants to purchase shares of common stock of which certain warrants are shown as a liability on the balance sheet, see Note&nbsp;10. The fair value of the warrant liability was determined
based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. The fair value of the warrant liability uses various valuation methods, including the Monte Carlo method, the
option-pricing method, probability-weighted expected return and the hybrid method, all of which incorporate assumptions and estimates, to value the common stock warrants. The hybrid method is often used when a company is expecting a liquidity event
in the near future and is a combination of the option-pricing and probability-weighted expected return methods. Estimates and assumptions impacting the fair value measurement include the fair value per share of the underlying shares of common stock,
risk-free interest rate, expected dividend yield, expected volatility of the price of the underlying preferred stock, and the remaining contractual term of the warrants. The most significant assumption in the model impacting the fair value of the
common stock warrants is the fair value of the Company&#146;s common stock as of each remeasurement date. The Company determines the fair value per share of the underlying common stock by taking into consideration the most recent sales of preferred
stock, results obtained from third-party valuations and additional factors that are deemed relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table provides a roll forward of the aggregate
fair values of the Company&#146;s liabilities, for which fair value is determined by Level 3 inputs: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B<BR>WARRANT</B><br><B>LIABILITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PROMISSORY&nbsp;NOTE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Marketable securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Marketable securities at December&nbsp;31, 2019
consisted of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMORTIZED&nbsp;COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UNREALIZED&nbsp;GAINS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>UNREALIZED&nbsp;LOSSES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FAIR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">US fixed income mutual fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company may sell certain of its marketable securities prior to their stated maturities. The maturities of the Company&#146;s long-term marketable securities
generally range from one to two years. The Company held no marketable securities at December&nbsp;31, 2020.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Fixed assets, net </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fixed
assets, net consisted of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Networking and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Fixed assets, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization expense related to the fixed assets was $43 and $91 for the years ended December&nbsp;31, 2019 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Accrued expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued expenses consisted of the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payroll and employee related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Third-party research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Professional fees and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Notes payable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Related party notes payable </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the early years of the Company&#146;s operation, its founders, who are currently senior executives and significant shareholders of the Company, personally funded
certain Company expenses. The amounts paid by the founders were recorded as notes payable and interest was accrued and compounded at an annual rate of four percent. On November&nbsp;13, 2018, in connection with the Series B Convertible Preferred
Stock financing (see Note 9), the Company entered into an agreement for repayment of these notes payable and accrued interest. The Company paid $1,044 of the outstanding principal and interest with cash, with the remaining balance of $1,045 being
repaid through the issuance of 377,130 shares of Series B Convertible Preferred Stock. The Company paid $522 of the cash due to the founders in November 2018, and the remaining $522 was paid in November 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Borrowings under Paycheck Protection Program </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March 27, 2020,
President Trump signed the Coronavirus Aid, Relief and Economic Security (the &#147;CARES Act&#148;), which, among other things, outlines the provisions of the Paycheck Protection Program (the &#147;PPP&#148;). Section 1106 of the CARES Act contains
provisions for the forgiveness of all or a portion of a PPP loan, subject to the satisfaction of certain requirements. The amount eligible for forgiveness is, subject to certain limitations, the sum of the Company&#146;s payroll costs, rent and
utilities paid by the Company during the 24-week period beginning on the funding date of the PPP loan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On April 28, 2020, the Company, as obligor, entered into a promissory note evidencing an unsecured loan in the approximate
amount of $460 under the PPP pursuant to the CARES Act. The note matures two years after the date of the loan disbursement and bears interest at a fixed annual rate of 1.00%, with the first six months of principal and interest deferred. Under the
terms of the CARES Act, as amended by the Flexibility Act, and the PPP, the Company can apply for and be granted forgiveness for all or a portion of the loan issued under the PPP and the loan is expected to be forgiven to the extent the proceeds are
used in accordance with the PPP to cover payroll, mortgage interest, rent, and utility costs incurred by the Company over the 24-week period following the loan disbursement date. As of the date of this filing, the Company is in the process of
applying for forgiveness and believes that its use of the loan proceeds will meet the conditions for forgiveness under the PPP and expects the loan to be recorded as income when legal forgiveness is obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Capital stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible preferred stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company has authorized 17,187,676 shares of Preferred Stock (the Preferred Stock) and has designated 11,155,506 shares as Series B
Convertible Preferred Stock (Series B Preferred) and 6,032,170 shares as Series C Convertible Preferred Stock (Series C Preferred). Since the Preferred Stock is redeemable upon a liquidation event, which is not considered to be within the
Company&#146;s control, it has been classified in temporary equity on the accompanying consolidated balance sheets. The carrying value of the Preferred Stock is the proceeds received less issuance costs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Issuances of Preferred Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November&nbsp;13, 2018, the Company
entered into a Series B Preferred Stock Agreement whereby the Company was authorized to issue 11,155,506 shares of Series B Preferred, $0.01 par value, at a purchase price of $2.7696 per share. The Company issued 9,026,618 shares of Series B
Preferred for gross proceeds of $25,000. As further consideration, the purchaser of Series B Preferred received two warrants to purchase, in the aggregate, up to 7,344,982 shares of the common stock of the Company for $6.81 per share. See Note 10
for description of the warrants issued in connection with the issuance of the Series B Preferred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in November 2018, the Company issued 1,751,658
shares of Series B Preferred as payment of convertible notes and 377,130 shares of Series&nbsp;B Preferred as partial repayment of the outstanding related party notes payable, see Note 8. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;13, 2019, the Company entered into the Series C Preferred Stock Agreement whereby the Company issued 6,032,170 shares of Series C Preferred, $0.01 par
value, at a purchase price of $3.73 per share for total gross proceeds of $22,500. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Stock has the following rights, preferences, privileges and
restrictions: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of Preferred Stock are
entitled to vote together with all other holders of the Company&#146;s voting stock on an &#147;as converted&#148; basis on all matters submitted to a vote of the holders. The Series B Preferred and Series C Preferred stockholders will vote as
separate classes on certain issues that solely affect their rights and privileges. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of Preferred Stock is convertible into one share of common stock, subject to change per certain anti-dilution provisions in the Company&#146;s charter and
the reverse stock split discussed in Note&nbsp;17(a). All shares of Preferred Stock are subject to a mandatory conversion into common stock upon the closing of the sale of shares of common stock to the public of at least $25,000 in a firm commitment
underwritten public offering pursuant an effective registration statement under the Securities act of 1933 or upon a vote by or written consent of the requisite number stockholders, see Note&nbsp;17. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation preference </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon a voluntary or involuntary liquidation,
dissolution or winding up of the Company, proceeds would be distributed in the following order: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">First, to the holders of the Series C Preferred in an amount for
each such share of Series C Preferred equal to the greater of (i)&nbsp;two and one-half times&nbsp;the Series C Preferred original issuance price, plus any dividends declared but </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
unpaid thereon or (ii)&nbsp;such amount per share as would have been payable had all shares of Series C Preferred been converted into common stock immediately prior to such liquidation event. If
the Company has insufficient assets to permit payment of such amounts in full, the assets of the Company will be distributed to the holders of Series C Preferred pro rata in proportion to the amounts to which each such holder would otherwise be
entitled. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Second, to the holders of the Series B Preferred in an amount for each such share of Series B Preferred equal to the greater of (i)&nbsp;the Series B
Preferred original issuance price, plus any dividends declared but unpaid thereon or (ii)&nbsp;such amount per share as would have been payable had all shares of Series B Preferred been converted into common stock immediately prior to such
liquidation event. If the Company has insufficient assets to permit payment of such amounts in full, the assets of the Company will be distributed to the holders of Series B Preferred pro rata in proportion to the amounts to which each such holder
would otherwise be entitled. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third, upon the distribution of liquidation preference amounts in full to the holders of Preferred Stock, the remaining assets of the
Company available for distribution to stockholders shall be distributed among the common stock pro rata based on the number of shares of common stock held by such holders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redemption </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Stock is not subject to mandatory
redemption except in the case of a merger or sale of the Company that has been approved by greater than 50% of the Series C Preferred and the Series B Preferred. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has authorized 75,000,000 shares of $0.01
par value common stock at December&nbsp;31, 2020 of which 11,635,094 are issued and outstanding. Common shares are voting and dividends may be paid when, as and if declared by the board of directors, subject to the limitations and preferences of the
Preferred Stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common stock reserved </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has reserved
the following shares of common stock for future issuance as of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Preferred conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,538,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,538,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series C Preferred conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,013,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shares available for future grant under stock option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,632,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,632,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,205,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,725,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Warrants </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has the following warrants outstanding for the
purchase of common stock as of December&nbsp;31, 2019 and 2020: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>WARRANT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES OF<BR>COMMON<BR>STOCK&nbsp;SUBJECT<BR>TO WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXERCISE<BR>PRICE&nbsp;PER<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXPIRATION&nbsp;DATES</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">April-August&nbsp;2021</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,672,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">November 2023</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Conditional Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,672,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">November 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">NC Ohio Trust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">March 2029</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series A warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the issuance of Series A
Preferred Stock in 2016, the Company issued 220,805 five-year warrants to purchase shares of Series A Preferred Stock at an exercise price of $3.20 per share (the &#147;Series A Warrants&#148;). In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
2018 upon the conversion of the Series A Preferred Stock into common stock, the Series A Warrants became exercisable for common stock at an exercise price of $5.67 per share and the number of
warrants outstanding increased to 124,796. The Series A Warrants expire between April and August 2021, if not exercised. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series B warrants </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the November&nbsp;13, 2018 issuance of Series B Preferred, the Company issued warrants to purchase 3,672,491 shares of common stock for $6.81 per
share to the purchaser of the Series B preferred (the &#147;Series B Warrants&#148;) which are exercisable upon issuance. In addition, the Company issued to the same stockholder additional five-year warrants for the purchase of 3,672,491 shares of
common for $6.81 per share which are only exercisable in the event that the Company completes a future financing that meets certain financial milestones (the &#147;Conditional Series B Warrants&#148;). The Series B Warrants and the Conditional
Series B Warrants contain provisions allowing cashless exercise. The Company recorded the Series B Warrants as a component of stockholder&#146;s equity at the time of issuance at their estimated fair value of $2,124 and recorded the Conditional
Series B Warrants as a liability on the consolidated balance sheet as the number of shares used to calculate the settlement is not a fixed number of shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Conditional Series B Warrants are remeasured to their fair value at each reporting date with changes in the fair value recognized as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The
Company will continue to recognize changes in the fair value of the conditional warrant liability until each Conditional Series B Warrant is exercised, expires or qualifies for equity classification. The Conditional Series B Warrant liability fair
value was $2,226 and $6,831 as of December&nbsp;31, 2019 and 2020, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>NC Ohio trust warrants </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;20, 2019, the Company established the NC Incorporated Ohio Trust, an irrevocable trust funded by the Company. The beneficiary in the trust agreement has
provided past services to the Company for more than 15 years and is a non-employee. The warrant provides the beneficiary the right to purchase 162,740 shares of the Company&#146;s common stock, $0.01 par value at an exercise price of $1.46 per
share, subject to adjustments as specified in the warrant agreement. The arrangement is unknown to the beneficiary as the arrangement is a silent trust. The Company recognizes the warrants as compensation expense within the consolidated statement of
operations and comprehensive loss when the warrants are granted or at the service inception date if the service inception date precedes the grant date. In the period in which the grant date occurs, cumulative compensation cost shall be adjusted to
reflect the cumulative effect of measuring compensation cost based on the fair value at the grant date rather than the fair value previously used at the service inception date or subsequent reporting dates. As of December 31, 2020, a grant date was
not established as there was not a mutual understanding of key terms. The Company remeasures the fair value of the award at each reporting date, as the service date preceded the grant date. The value of the warrants as of December 31, 2020 is $695
and was recorded as stock compensation expense within research and development expense and a credit to stockholders&#146; equity in the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Stock options, restricted stock and stock&#151;based compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company&#146;s 2015 Stock Plan, as amended, (the &#147;2015 Plan&#148;) provides for the Company to sell or issue common shares or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common
stock, to employees, members of the board of directors and consultants of the Company. The 2015 Plan is administered by the board of directors and exercise prices, vesting and other restrictions are determined at its discretion. All stock option
grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be
granted at less than the fair market value of the Company&#146;s common stock on the date of grant, as determined in good faith by the board of directors at its sole discretion. Nonqualified stock options may be granted at an exercise price
established by the board of directors at its sole discretion and the vesting periods may vary. Vesting periods are generally four years and are determined by the board of directors. Stock options become exercisable as they vest. Options granted
under the 2015 Plan expire no more than ten years from the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, the total number of shares of common stock that may be issued under the 2015 Plan was
4,800,846&nbsp;shares. As of December&nbsp;31, 2020, the total number of shares remaining available for future grants was 87,042. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On May&nbsp;28, 2019, the board
of directors approved the reduction of the stock option exercise price to $1.46 per share for all outstanding stock options. The change in exercise price was accounted for as a modification pursuant to ASC 718. The Company measured the incremental
compensation cost as the excess of the fair value of the modified award over the fair value of the original award immediately before its terms were modified. The total incremental compensation cost due to the modification was $64 for the year ended
December&nbsp;31, 2019. The incremental compensation cost for unvested instruments was $131. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock option activity is summarized as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>STOCK<BR>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>EXERCISE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>REMAINING<BR>CONTRACTUAL<BR>TERM&nbsp;(IN&nbsp;YEARS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>INTRINSIC<BR>VALUE<BR>(IN&nbsp;THOUSANDS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">629,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cancelled or forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,221,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cancelled or forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,013,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">920,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,093,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of stock options granted was estimated on the grant date using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model based on
the following weighted-average assumptions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected option life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00&nbsp;-10.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.00&nbsp;-&nbsp;10.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.52%&nbsp;-&nbsp;1.83%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.45%&nbsp;-&nbsp;0.92%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">71.10%&nbsp;-&nbsp;71.42%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">74.86%&nbsp;-&nbsp;89.07%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.46&nbsp;-$1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.55&nbsp;-&nbsp;$4.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#146;s
common stock for those stock options that had exercise prices lower than the fair value of the Company&#146;s common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total fair value of stock options
vested during the years ended December&nbsp;31, 2019 and 2020 was $377 and $1,199, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has granted shares of restricted common stock. The
fair value of shares of restricted common stock is based on the value of the underlying shares of common stock on the date of grant. The grant date fair value of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
restricted stock is expensed over the vesting period of such shares. During the year ended December&nbsp;31, 2019, 109,472 shares of restricted common stock with a grant date fair value of $0.17
per share vested and all shares of restricted common stock were vested at December&nbsp;31, 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense for the years ended
December&nbsp;31, 2019 and 2020 was classified in the consolidated statements of operations and comprehensive loss as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stock based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2019 and 2020, total unrecognized compensation cost related to the unvested stock-based awards was $648 and $4,778, respectively. The unvested
stock-based awards are expected to be recognized over a weighted average period of 3.05 years as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. Income taxes </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Income tax expense for 2019 and 2020 consists of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total income tax expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reconciliation of income tax expense at the federal statutory income tax rate to the income tax expense at the Company&#146;s effective income tax rate is as follows:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income at US statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Permanent adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-1.07</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mark to market</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-2.15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-5.47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.65</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-27.87</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-23.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets as of December&nbsp;31, 2019 and 2020 consist of the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Intangibles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses&nbsp;&amp; other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets (liability)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company has gross federal and state net operating loss carryforwards of approximately $8,815 and $27,635, which begin to expire in
2027 and 2032, respectively. Additionally, the Company has $19,726 of the federal net operating loss carryforwards that can be carried forward indefinitely. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
December&nbsp;31, 2020, the Company has gross federal and state credit carryforwards of approximately $1,199 and $746, respectively, which begin to expire in 2036 and 2028, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of
net operating loss carryforwards and certain tax credits. Management has considered the Company&#146;s history of cumulative net losses incurred since inception, as well as its lack of product revenue since inception, and has determined that it is
more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, a full valuation allowance has been established at December&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;382 of the Internal Revenue Code of 1986, as amended (&#147;Section 382&#148;), contains rules that limit the ability of a company that undergoes in
ownership change to utilize its net operating losses (&#147;NOLs&#148;) and tax credits existing as of the date of such ownership change. Under the rules, such an ownership change is generally any change in ownership of more than 50% of a
company&#146;s stock within a rolling three-year period. The rules generally operate by focusing on changes in ownership of all stock considered by the rules as owning, directly or indirectly, 5% or more of the stock of a company and any change in
ownership arising from new issuances of stock by the company. The Company has not yet determined if such a limitation would be placed against its available net operating losses. The Company will make such a determination prior to the utilization of
any future net operating losses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A summary of changes in the valuation allowance for deferred tax assets during the year ended December&nbsp;31, 2019 and 2020 were
as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increases recorded as a benefit to additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company files income tax returns in the United States and various state and local jurisdictions. The federal and state
tax returns are generally subject to examination for the years ended December&nbsp;31, 2014 through December&nbsp;31, 2020. There are currently no pending tax examinations. To the extent the Company has tax attribute carryforwards, the tax year in
which the attribute was generated may still be adjusted upon examination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. Exclusive licensing agreement with a related party </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2014, the Company entered into an exclusive licensing agreement with Ventagen, LLC (&#147;Ventagen&#148;) which provides Ventagen the right to develop products
for commercial sale and distribution within Mexico, Belize, Guatemala, Honduras, El Salvador, Costa Rica, Nicaragua, Panama, Colombia, and Bolivia. Ventagen paid the Company $1,000 upon the signing of the agreement and agreed to a fixed future
payment to the Company of $2,500. The future payment will be made upon the achievement of $5,000 of sales of an approved product by Ventagen and is subject to reduction if Ventagen&#146;s costs to develop an approved product exceeds $4,000. In
addition to the upfront payment and the future payment, Ventagen agreed to purchase from the Company all manufactured product that is required for clinical or commercial purposes at a price of cost plus 25% of the wholesale price of the approved
product subject to a minimum or maximum price. In the event the Company is unable or unwilling to manufacture supply under the terms of the agreement, Ventagen has the right to manufacture its own supply and will be required to pay a fixed fee per
dose sold. The Company also agreed to provide certain services to Ventagen related to Ventagen&#146;s development plan. Stockholders of the Company own 49.5% of the voting stock of Ventagen, including 47% by the Company&#146;s founders who are
currently senior executives and significant stockholders of the Company, and trusts for the benefit of their children. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is recognizing the $1,000
upfront license fee as research and development service revenue, related party, as the Company&#146;s license agreement with Ventagen is within the scope of ASC 606. The license agreement met the contract existence criteria and contained distinct,
identifiable performance obligations for which the stand-alone selling prices were readily determinable and allocable. The terms of the agreement contained multiple, distinct performance obligations, including transfer of a license for the
territory, research and development oversight for the trials run by Ventagen, and clinical data sharing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company estimated the transaction prices, including
any variable consideration, at contract inception and determined the fair value of such obligations. The performance obligation associated with the license transfer was satisfied at a point in time, or at contract inception; however, the Company
assigned no value to the license transfer. The remaining $1,000 transaction price was allocated between the research and development oversight and clinical data sharing. The Company is recognizing revenue for these obligations over an 8-year period,
beginning in 2015, by measuring the progress towards satisfaction of the performance obligations. As clinical oversight and clinical data sharing occurs over the 8&#151;year clinical trial period, the revenue is recognized over the same period in
which the cost for these services is incurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company defers recognition of the portion of the $1,000 non-refundable upfront license fee for the portion of
the performance obligations that are not satisfied. The Company recognized revenue of $125 in the years ended December&nbsp;31, 2019 and 2020. The license agreement includes a $2,500 potential future milestone payment due to the Company upon
successful completion of certain separate, distinct events. At this time, the Company cannot estimate when the milestone-related performance obligations are expected to be achieved and will recognize revenue once satisfaction is probable. There was
no additional variable consideration, significant financing components, noncash consideration, or consideration payable to the customer in this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14.
Technology license agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;20, 2018 the Company entered into an exclusive option agreement (the &#147;Option Agreement&#148;) with The
Brigham and Women&#146;s Hospital, Inc., a not-for-profit Massachusetts corporation (&#147;BWH&#148;). Pursuant to the Option Agreement, the Company has obtained the exclusive right from BWH to negotiate an exclusive license to make, develop and
commercialize rQNestin, a genetically modified oncolytic herpes simplex virus for the treatment of certain types of cancers. Pursuant to the Option Agreement, the Company will support a clinical trial to be conducted at BWH pursuant to the terms of
a clinical trial agreement to be negotiated and the Company has committed to remitting $750 in support of such clinical trial over the course of approximately three years. Upon execution of the Option Agreement, the Company remitted a non-refundable
fee of $40 to BWH to be applied toward </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the Company&#146;s on-going obligations to reimburse patent expenses. The $40 fee paid was expensed and classified in research and development expenses in 2018. In the years ended December 31,
2019 and 2020, the Company expensed $332 and $269, respectively, for startup and patient fees for clinical trials performed by BWH. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;15, 2020, the
Company exercised the Option Agreement with BWH and entered into an exclusive worldwide patent license agreement with BWH (&#147;the BWH License&#148;). In connection with the BWH License, the Company paid a fee of $100 and agreed to reimburse
patent costs incurred by BWH, including $141 paid at the time of entering into the BWH License. Prior to the first commercial sale, the Company is required to pay BWH an annual license fee of $50 beginning following the fourth anniversary of the
effective date. The BWH License contains cumulative milestone payments equaling a maximum amount of $39,000 upon the achievement of various clinical, commercial and sales milestones of both primary and secondary products. Following the first
commercial sale, the Company is required to pay royalties to BWH, which are paid at an increasing rate as net sales increase, ranging from low single digits to high single digits. In addition, after the first commercial sale, the Company is required
to pay BWH a pre-determined fixed annual minimum royalty, which amount may be credited against earned royalties starting in the fourth year following the first commercial sale. The Company is also agreed to pay a single digit royalty rate on net
sales of any derived products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15. Commitments and contingencies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Related party leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2008, the Company entered into an
operating lease agreement with a term through December&nbsp;31, 2022 with Ellka Holdings, LLC (&#147;Ellka&#148;) for the space in which the Company operated in Auburndale, MA. This lease was terminated and a termination payment of $115 was made to
Ellka and included in operating expenses for the year ended December&nbsp;31, 2020. In May 2016, the Company entered into a second lease agreement with Ellka for living space for employees, also in Auburndale, MA which was also was terminated at the
end of 2020. Ellka is owned and operated by the company&#146;s founders, who are currently senior executives and significant stockholders of the Company, and members of their immediate family. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Facility lease </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;4, 2019, the Company signed a lease
agreement for its new corporate headquarters at 117 Kendrick Street in Needham, Massachusetts. The facility consists of a 15,197 square foot property which houses the corporate, clinical and manufacturing operations for the Company. The lease term
ends on August&nbsp;31, 2026. Prior to occupying the new space, the Company had construction performed to modify the space to meet its needs. The cost of this construction was $294 and was paid for by the landlord provided allowance in the lease
agreement. The $294 lease incentive was recorded as deferred rent and is being amortized over the life of the lease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total rent expense under these leases was $619
and $936 for the years ended December&nbsp;31, 2019 and 2020, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The future minimum lease payments at December&nbsp;31, 2020, are as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Guarantees </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has identified the guarantees described below
as disclosable, in accordance with ASC 460,<I> Guarantees</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences
while the officer or director is, or was, serving at the Company&#146;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#146; and
officers&#146; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is a party to a number
of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are
usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company leases office space under a seven &#150; year noncancelable operating lease. The Company has standard indemnification arrangements under this lease
that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were
outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legal proceedings </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is not a party to any litigation and
does not have contingency reserves established for any litigation liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16. Net loss per share </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net loss per share </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted net loss per share attributable
to common stockholders was calculated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Numerator:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average shares of common stock outstanding-basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,533,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,615,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributed to common stockholders-basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s potentially dilutive securities have been excluded from the computation of dilutive net loss per share as the effect would be to reduce the net loss
per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because
including them would have had an anti-dilutive effect. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Preferred (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,538,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,538,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series C Preferred (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding warrants for common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,632,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,632,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding stock options (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,013,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,553,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,638,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>17. Subsequent events </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:9.5pt; font-family:ARIAL">(a) Reverse stock split </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;14, 2021, the
Company&#146;s board of directors and stockholders approved a one-for 2.4579&nbsp;reverse stock split of the Company&#146;s issued and outstanding common stock and a proportional adjustment to the existing conversion ratios for the outstanding
shares of convertible preferred stock which became effective on July&nbsp;15, 2021. Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been
retroactively adjusted, where applicable, to reflect the reverse stock split. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:9.5pt; font-family:ARIAL">(b) Other </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;10, 2021, the Company&#146;s 2021 Equity Incentive Plan, or the 2021 Plan, was adopted by the board of directors and was approved by the stockholders on
July&nbsp;14, 2021, and will become effective upon the execution of the underwriting agreement related to the IPO and will serve as the successor to the 2015 Plan and reserved 2,054,000&nbsp;shares of common stock under the 2021 Plan. The 2021 Plan
authorizes the award of stock options, restricted stock awards, or RSAs, stock appreciation rights, or SARs, restricted stock units, or RSUs, cash awards, performance awards and stock bonus awards. Under the 2021 Plan, shares of common stock, plus
any reserved shares not issued or subject to outstanding grants under the 2015 Plan on the effective date of the 2021 Plan are reserved for issuance pursuant to awards granted under the 2021 Plan. The number of shares reserved for issuance under the
2021 Plan will increase automatically on January&nbsp;1 of each year from 2022 through 2030 by the number of shares equal to the lesser of 4% of the aggregate number of outstanding shares of common stock as of the immediately preceding
December&nbsp;31, or a number as may be determined by the board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;10, 2021, the Company&#146;s 2021 Employee Stock Purchase Plan, or the
ESPP, was adopted by the board of directors and was approved by the stockholders on July&nbsp;14, 2021, and will become effective upon the execution of the underwriting agreement related to the IPO. The Company has initially reserved
293,000&nbsp;shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will increase automatically on January 1st of each of the first ten calendar years after the first offering date by the
number of shares equal to the lesser of 1% of the total outstanding shares of common stock as of the immediately preceding December&nbsp;31 (rounded to the nearest whole share) or a fixed number, or a number of shares as may be determined by the
board of directors in any particular year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_7"></A>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share and per share amounts) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;35,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fixed assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 38,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paycheck protection program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies (Note&nbsp;14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:9.5pt; font-family:ARIAL">Series B convertible preferred stock, $0.01 par value; 11,155,506 shares authorized, issued and outstanding at December&nbsp;31,
2020 and March&nbsp;31, 2021, liquidation preference of $30,896 at December&nbsp;31, 2020 and March&nbsp;31, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:9.5pt; font-family:ARIAL">Series&nbsp;C convertible preferred stock, $0.01 par value; 6,032,170 shares authorized, issued and outstanding at
December&nbsp;31, 2020 and March&nbsp;31, 2021, liquidation preference of $22,500 at December&nbsp;31, 2020 and March&nbsp;31, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.01 par value; 75,000,000 shares authorized at December&nbsp;31,&nbsp;2020 and March&nbsp;31, 2021. Shares
issued and outstanding 11,635,094 and 11,673,135 at December&nbsp;31, 2020 and March&nbsp;31, 2021, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities, convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 38,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_8"></A>Condensed Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share and per share amounts) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED<BR>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Research and development service revenue, related party</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Other income (expense):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Grant income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest, dividend and investment income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total other income (expense), net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Other comprehensive (loss):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrealized (loss) on available-for-sale securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Net loss per share attributable to common stockholders, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><B>Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,614,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,647,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_9"></A>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share and per share amounts) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B<BR>CONVERTIBLE<BR>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES C CONVERTIBLE<BR>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL</B><br><B>PAID-IN<BR>CAPITAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>OTHER<BR>COMPREHENSIVE</B><br><B>LOSS</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCKHOLDERS&#146;</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of January&nbsp;1, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,155,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,032,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,613,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">) &nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of March&nbsp;31, 2020 </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,155,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,032,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,614,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,155,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,032,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,635,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Warrants exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Change in fair value of NC Ohio Trust Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of March&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,155,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,032,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,673,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_10"></A>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share and per share amounts) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED<BR>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,772</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,478</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Non-cash stock compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Non-cash interest (income) expense net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other long term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,214</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,627</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from sales and maturities of available-for-sale securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Purchase of fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(229</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from warrant exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Proceeds from option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>112</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,069</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,319</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,514</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,575</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Supplemental Disclosures of Cash Flow Information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash paid for taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Capital expenditures in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CANDEL THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin120909_11"></A>Notes to Condensed Consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Amounts in thousands, except share and per share amounts) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Organization and basis of presentation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Candel Therapeutics, Inc., formerly known as Advantagene, Inc. (the &#147;Company&#148;) is a late clinical stage biotechnology company that was incorporated in
Delaware in June 2003. On November&nbsp;30, 2020, the Company changed its name to Candel Therapeutics, Inc. The Company is focused on helping patients fight cancer with oncolytic viral immunotherapies. The Company&#146;s engineered viruses are
designed to induce immunogenic cell death through direct viral &#150; mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. This approach combines an
in-depth knowledge of viral immunotherapy and extensive clinical experience across a wide range of indications. The Company has established two oncolytic viral immunotherapy platforms and our two product candidates, CAN-2409 and CAN-3110, are in
clinical trials for a number of tumor types. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry,
including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to
fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts
require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the
Company will realize revenue from product sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has funded its operations primarily with proceeds from the sale of its capital stock and convertible
notes. The Company has incurred recurring losses since its inception, including a net loss of $8,240, $17,680 and $4,478 for the years ended December&nbsp;31, 2019 and 2020 and the three months ended March&nbsp;31, 2021, respectively. In addition,
as of March&nbsp;31, 2021, the Company had an accumulated deficit of $48,649. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise
additional capital to finance its operations. The Company&#146;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that
additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will fund planned operations for at least 12&nbsp;months from the date that these consolidated financial statements were
available to be issued. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company continue as a going
concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of significant
accounting policies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying
condensed consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to
ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the financial statements are to the FASB<I> Accounting Standards</I> Codification (ASC). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Principles of consolidation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The condensed consolidated financial
statements include the accounts of Candel Therapeutics, Inc. and its wholly owned subsidiary Candel Therapeutics Securities Corporation. All intercompany transactions and balances have been eliminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Emerging growth company </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#145;Jobs Act&#148;). Under the Jobs Act emerging growth
companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the Jobs Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for
complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that is (i)&nbsp;no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably
opts out of the extended transition period provided in the Jobs Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective
dates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unaudited Interim Financial Information </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying
condensed consolidated balance sheet as of March 31, 2021, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2020 and 2021, the condensed consolidated statements of convertible preferred
stock and stockholders&#146; deficit for the three months ended March 31, 2020 and 2021, the condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2021, and the related interim disclosures are unaudited. These
unaudited condensed consolidated financial statements include all adjustments necessary, consisting of only normal recurring adjustments, to fairly state the financial position and the results of the Company&#146;s operations and cash flows for
interim periods in accordance with U.S. GAAP. Interim period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying condensed consolidated financial statements
should be read in conjunction with the Company&#146;s audited consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of estimates
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of the Company&#146;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets, liabilities, and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an
ongoing basis, the Company&#146;s management evaluates its estimates, which include but are not limited to management&#146;s judgments of accrued expenses, fair value of common stock, valuation of share-based awards, valuations of warrants, fair
value of debt and income taxes. Actual results could differ from those estimates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company utilizes significant estimates and assumptions in determining the
fair value of its common stock. The Company has utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity
Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock and warrants. Each valuation methodology includes estimates and assumptions that require the Company&#146;s judgment. These estimates and
assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#146;s
common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at
each valuation date. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive income (loss) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Components of
comprehensive income or loss, including net income or loss, are reported in the condensed consolidated financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a
period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss
includes net loss as well as other changes in stockholders&#146; equity that result from transactions and economic events other than those with stockholders. For the period presented, the Company had no elements of other comprehensive loss other
than its net loss and unrealized loss on marketable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company considers all highly liquid investments purchased with original final maturities of 90 days or less from the date of purchase to be cash equivalents. Cash
and cash equivalents comprise marketable securities with maturities of less than 90 days when purchased. Cash equivalents are reported at fair value. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restricted cash </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has $266 and $423 of restricted cash as
of December 31, 2020 and March 31, 2021 which represents cash held in a restricted bank account under the terms of the Company&#146;s Needham, Massachusetts facility lease and as security for the Company credit card. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair value measurements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain assets and liabilities of the
Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in
an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities
carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Level 2&#151;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Level 3&#151;Unobservable inputs that are supported by little or no market activity that are significant to determining
the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The carrying
values of cash and cash equivalents, accounts payable, accrued expenses and Paycheck protection plan loan approximate their fair values due to the short-term nature of these assets and liabilities. The Company&#146;s warrant liability is carried at
fair value and is classified as Level 3 measurements. The carrying value of the Company&#146;s long-term debt assumed from the Periphagen transaction is classified as Level 3 (See Note 3). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Property and equipment </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment consist of networking
and computer equipment, furniture and fixtures and leasehold improvements. Property and equipment are recorded at cost, and depreciated using the straight-line method over the estimated useful lives of the respective assets: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>ASSET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>ESTIMATED USEFUL LIFE</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Networking and computer equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Furniture and fixtures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shorter of the useful life or remaining lease term</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for leases in accordance with ASC 840.
Rent expense for leases is recognized on a straight-line basis beginning on the date premises were delivered. Minimum lease payments comprise of only base rent. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Concentrations of credit risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that potentially
expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Periodically, the Company maintains deposits and investments in accredited financial institutions in-excess of the
federally insured limits. The Company deposits its cash in financial institutions with a high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal risk
associated with commercial banking relationships. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred offering costs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred
offering costs until such financings are consummated. After </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
consummation of the equity financing, these costs are recorded in stockholders&#146; deficit as a reduction of proceeds generated as a result of the offering. Should a planned equity financing be
abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the consolidated statement of operations. As of December 31, 2020 and March 31, 2021, the Company has included $83 and $937, respectively, of
deferred offering costs in other long-term assets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development costs and accruals </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense,
depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with clinical and research institutions, contract research organizations, and other companies.
These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized
based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial
statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts
are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses and intellectual property are charged to research and development expenses as acquired in-process research and development
if the technology licensed or intellectual property acquired has not reached technological feasibility and has no alternative future use. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net loss per share
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock
outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock.
Diluted net loss per share is the same as basic net loss per share for the three months ended March 31, 2020 and 2021 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s convertible preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually require the
holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods where the Company reports a net loss
attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss
attributable to common stockholders for the three months ended March 31, 2020 and 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Fair value of financial assets and liabilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of
the fair value hierarchy utilized to determine such fair values: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FAIR VALUE MEASUREMENTS AS OF<BR>DECEMBER&nbsp;31, 2020 USING:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FAIR VALUE MEASUREMENTS AS OF<BR>MARCH&nbsp;31, 2021 USING:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Valuation of long-term debt </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s valuation technique
used to measure the fair value of the long-term debt assumed from the Periphagen transaction was a present value calculation based upon a credit rating estimated for the Company at the time the debt was assumed. The determined credit rating used by
the company was CCC based upon the financial position and stage of the Company. The estimated rate was 15.83% for an unsecured note due in November 2027 for a CCC rated company. The fair value of the long-term debt based on this approach plus the
accrued interest represents a Level 3 measurement within the fair value hierarchy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Valuation of warrant liability </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series B Convertible Preferred Stock issuance, the Company issued warrants to purchase shares of common stock of which certain warrants are shown
as a liability on the balance sheet, see Note&nbsp;8. The fair value of the warrant liability was determined based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. The
fair value of the warrant liability uses various valuation methods, including the Monte Carlo method, the option-pricing method, probability-weighted expected return and the hybrid method, all of which incorporate assumptions and estimates, to value
the common stock warrants. The hybrid method is often used when a company is expecting a liquidity event in the near future and is a combination of the option-pricing and probability-weighted expected return methods. Estimates and assumptions
impacting the fair value measurement include the fair value per share of the underlying shares of common stock, risk-free interest rate, expected dividend yield, expected volatility of the price of the underlying preferred stock, and the remaining
contractual term of the warrants. The most significant assumption in the model impacting the fair value of the common stock warrants is the fair value of the Company&#146;s common stock as of each remeasurement date. The Company determines the fair
value per share of the underlying common stock by taking into consideration the most recent sales of preferred stock, results obtained from third-party valuations and additional factors that are deemed relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table provides a roll forward of the aggregate fair values of the Company&#146;s liabilities, for which fair
value is determined by Level 3 inputs: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B<BR>WARRANT</B><br><B>LIABILITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PROMISSORY&nbsp;NOTE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at March 31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Fixed assets, net </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fixed assets, net consisted of the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Networking and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Fixed assets, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization expense related to the fixed assets was $91, $32 and $26 for the year ended December&nbsp;31, 2020 and the three months ended March 31,
2020 and 2021, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Accrued expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued expenses
consisted of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payroll and employee related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Third-party research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Professional fees and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Borrowings under Paycheck Protection Program </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March 27, 2020,
President Trump signed the Coronavirus Aid, Relief and Economic Security (the &#147;CARES Act&#148;), which, among other things, outlines the provisions of the Paycheck Protection Program (the &#147;PPP&#148;). Section 1106 of the CARES Act contains
provisions for the forgiveness of all or a portion of a PPP loan, subject to the satisfaction of certain requirements. The amount eligible for forgiveness is, subject to certain limitations, the sum of the Company&#146;s payroll costs, rent and
utilities paid by the Company during the 24-week period beginning on the funding date of the PPP loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On April 28, 2020, the Company, as obligor, entered into a
promissory note evidencing an unsecured loan in the approximate amount of $460 under the PPP pursuant to the CARES Act. The note matures two years after the date </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of the loan disbursement and bears interest at a fixed annual rate of 1.00%, with the first six months of principal and interest deferred. Under the terms of the CARES Act, as amended by the
Flexibility Act, and the PPP, the Company can apply for and be granted forgiveness for all or a portion of the loan issued under the PPP and the loan is expected to be forgiven to the extent the proceeds are used in accordance with the PPP to cover
payroll, mortgage interest, rent, and utility costs incurred by the Company over the 24-week period following the loan disbursement date. In April 2021, the loan was forgiven. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Capital stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible preferred stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020 and March&nbsp;31, 2021, the Company has authorized 17,187,676 shares of Preferred Stock (the Preferred Stock) and has designated
11,155,506 shares as Series&nbsp;B Convertible Preferred Stock (Series&nbsp;B Preferred) and 6,032,170 shares as Series C Convertible Preferred Stock (Series&nbsp;C Preferred). Since the Preferred Stock is redeemable upon a liquidation event, which
is not considered to be within the Company&#146;s control, it has been classified in temporary equity on the accompanying consolidated balance sheets. The carrying value of the Preferred Stock is the proceeds received less issuance costs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Issuances of Preferred Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November&nbsp;13, 2018, the Company
entered into a Series&nbsp;B Preferred Stock Agreement whereby the Company was authorized to issue 11,155,506 shares of Series&nbsp;B Preferred, $0.01 par value, at a purchase price of $2.7696 per share. The Company issued 9,026,618 shares of
Series&nbsp;B Preferred for gross proceeds of $25,000. As further consideration, the purchaser of Series&nbsp;B Preferred received two warrants to purchase, in the aggregate, up to 7,344,982 shares of the common stock of the Company for $6.81 per
share. See Note&nbsp;8 for description of the warrants issued in connection with the issuance of the Series&nbsp;B Preferred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Stock has the following
rights, preferences, privileges and restrictions: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
holders of Preferred Stock are entitled to vote together with all other holders of the Company&#146;s voting stock on an &#147;as converted&#148; basis on all matters submitted to a vote of the holders. The Series&nbsp;B Preferred and Series&nbsp;C
Preferred stockholders will vote as separate classes on certain issues that solely affect their rights and privileges. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of Preferred Stock is convertible into one share of common stock, subject to change per certain anti-dilution provisions in the Company&#146;s charter and
the reverse stock split discussed in Note&nbsp;14(a). All shares of Preferred Stock are subject to a mandatory conversion into common stock upon the closing of the sale of shares of common stock to the public of at least $25,000 in a firm commitment
underwritten public offering pursuant an effective registration statement under the Securities act of 1933 or upon a vote by or written consent of the requisite number stockholders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation preference </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon a voluntary or involuntary liquidation,
dissolution or winding up of the Company, proceeds would be distributed in the following order: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">First, to the holders of the Series&nbsp;C Preferred in an amount
for each such share of Series&nbsp;C Preferred equal to the greater of (i)&nbsp;two and one-half times&nbsp;the Series&nbsp;C Preferred original issuance price, plus any dividends declared but unpaid thereon or (ii)&nbsp;such amount per share as
would have been payable had all shares of Series&nbsp;C Preferred been converted into common stock immediately prior to such liquidation event. If the Company has insufficient assets to permit payment of such amounts in full, the assets of the
Company will be distributed to the holders of Series&nbsp;C Preferred pro rata in proportion to the amounts to which each such holder would otherwise be entitled. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Second, to the holders of the Series&nbsp;B Preferred in an amount for each such share of Series&nbsp;B Preferred equal to the greater of (i)&nbsp;the Series&nbsp;B
Preferred original issuance price, plus any dividends declared but unpaid thereon or (ii)&nbsp;such amount per share as would have been payable had all shares of Series&nbsp;B Preferred been converted into common stock immediately prior to such
liquidation event. If the Company has insufficient assets to permit payment of such amounts in full, the assets of the Company will be distributed to the holders of Series&nbsp;B Preferred pro rata in proportion to the amounts to which each such
holder would otherwise be entitled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third, upon the distribution of liquidation preference amounts in full to the holders of Preferred Stock, the remaining
assets of the Company available for distribution to stockholders shall be distributed among the common stock pro rata based on the number of shares of common stock held by such holders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redemption </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Stock is not subject to mandatory
redemption except in the case of a merger or sale of the Company that has been approved by greater than 50% of the Series C Preferred and the Series B Preferred. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has authorized 75,000,000 shares of $0.01
par value common stock at December 31, 2020 and March 31, 2021 of which 11,635,094 and 11,673,135 are issued and outstanding as of December 31, 2020 and March&nbsp;31, 2021, respectively. Common shares are voting and dividends may be paid when, as
and if declared by the board of directors, subject to the limitations and preferences of the Preferred Stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common stock reserved </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has reserved the following shares of common stock for future issuance as of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Preferred conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,538,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,538,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series C Preferred conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,013,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,079,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shares available for future grant under stock option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,632,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,618,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,725,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,768,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Warrants </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has the following warrants outstanding for the
purchase of common stock as of March&nbsp;31, 2021: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>WARRANT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES OF<BR>COMMON<BR>STOCK&nbsp;SUBJECT<BR>TO WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXERCISE<BR>PRICE&nbsp;PER<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXPIRATION&nbsp;DATES</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">April-August&nbsp;2021</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,672,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">November 2023</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Conditional Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,672,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">November 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">NC Ohio Trust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">March 2029</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series A warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the issuance of Series A
Preferred Stock in 2016, the Company issued 220,805 five-year warrants to purchase shares of Series A Preferred Stock at an exercise price of $3.20 per share (the &#147;Series A Warrants&#148;). In 2018 upon the conversion of the Series A Preferred
Stock into common stock, the Series A Warrants became exercisable for common stock at an exercise price of $5.67 per share and the number of warrants outstanding increased to 124,796. The Series A Warrants expire between April and August 2021, if
not exercised. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series B warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the
November&nbsp;13, 2018 issuance of Series B Preferred, the Company issued warrants to purchase 3,672,491 shares of common stock for $6.81 per share to the purchaser of the Series B preferred (the &#147;Series B Warrants&#148;) which are exercisable
upon issuance. In addition, the Company issued to the same stockholder additional five-year warrants for the purchase of 3,672,491 shares of common for $6.81 per share which are only exercisable in the event that the Company completes a future
financing that meets certain financial milestones (the &#147;Conditional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Series B Warrants&#148;). The Series B Warrants and the Conditional Series B Warrants contain provisions allowing cashless exercise. The Company recorded the Series B Warrants as a component of
stockholder&#146;s equity at the time of issuance at their estimated fair value of $2,124 and recorded the Conditional Series B Warrants as a liability on the consolidated balance sheet as the number of shares used to calculate the settlement is not
a fixed number of shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Conditional Series B Warrants are remeasured to their fair value at each reporting date with changes in the fair value recognized as
a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company will continue to recognize changes in the fair value of the conditional warrant liability until each Conditional Series B
Warrant is exercised, expires or qualifies for equity classification. The Conditional Series B Warrant liability fair value was $6,831 as of December&nbsp;31, 2020 and March&nbsp;31, 2021. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June 24, 2021, the Company&#146;s board of directors approved an amendment to the terms of the Series B Warrant and the Series B Conditional Warrants were amended to
extend the expiration date from November 2023 to November 2025. In addition, the Company&#146;s board of directors approved an amendment to the terms of the Conditional Series B Warrants such that in the event the future financing milestones are
achieved, the warrants would only be exercisable in conjunction with the sale of the Company or in November 2025 through a cashless exercise. These amendments are intended to become effective upon the closing of the Company&#146;s proposed initial
public offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>NC Ohio trust warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;20, 2019,
the Company established the NC Incorporated Ohio Trust, an irrevocable trust funded by the Company. The beneficiary in the trust agreement has provided past services to the Company for more than 15 years and is a non-employee. The warrant provides
the beneficiary the right to purchase 162,740 shares of the Company&#146;s common stock, $0.01 par value at an exercise price of $1.46 per share, subject to adjustments as specified in the warrant agreement. The arrangement is unknown to the
beneficiary as the arrangement is a silent trust. The Company recognizes the warrants as compensation expense within the consolidated statement of operations and comprehensive loss when the warrants are granted or at the service inception date if
the service inception date precedes the grant date. In the period in which the grant date occurs, cumulative compensation cost shall be adjusted to reflect the cumulative effect of measuring compensation cost based on the fair value at the grant
date rather than the fair value previously used at the service inception date or subsequent reporting dates. As of December 31, 2020, a grant date was not established as there was not a mutual understanding of key terms. The Company remeasures the
fair value of the award at each reporting date, as the service date preceded the grant date. The value of the warrants for 162,740 shares of common stock was $695 as of December 31, 2020 and March 31, 2021 and was recorded as stock compensation
expense within research and development expense and a credit to stockholders&#146; equity in the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Stock options, restricted
stock and stock&#151;based compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s 2015 Stock Plan, as amended, (the &#147;2015 Plan&#148;) provides for the Company to sell or issue
common shares or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants of the Company. The 2015 Plan is
administered by the board of directors and exercise prices, vesting and other restrictions are determined at its discretion. All stock option grants are non-statutory stock options except option grants to employees (including officers and directors)
intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&#146;s common stock on the date of grant, as determined
in good faith by the board of directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the board of directors at its sole discretion and the vesting periods may vary. Vesting periods are
generally four years and are determined by the board of directors. Stock options become exercisable as they vest. Options granted under the 2015 Plan expire no more than ten years from the date of grant. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, the total number of shares of common stock that may be issued under the 2015 Plan was 12,000,000 shares. As of March&nbsp;31, 2021, the total
number of shares remaining available for future grants was 78,307 Stock option activity is summarized as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>STOCK<BR>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>EXERCISE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>REMAINING<BR>CONTRACTUAL<BR>TERM&nbsp;(IN&nbsp;YEARS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>INTRINSIC<BR>VALUE<BR>(IN&nbsp;THOUSANDS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,013,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cancelled or forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of March 31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,079,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">955,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,123,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of stock options granted was estimated on the grant date using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model based on
the following weighted-average assumptions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS<BR>ENDED&nbsp;MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected option life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.00&nbsp;-&nbsp;10.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.45%&nbsp;-&nbsp;0.92%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.06%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">74.86%&nbsp;-&nbsp;89.07%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88.33%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$4.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.55&nbsp;-&nbsp;$4.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$4.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#146;s
common stock for those stock options that had exercise prices lower than the fair value of the Company&#146;s common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total fair value of stock options
vested during the year ended December&nbsp;31, 2020 and three months ended March 31, 2021 was $1,199 and $207, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense for
the three months ended March 31, 2020 and 2021 was classified in the condensed consolidated statements of operations and comprehensive loss as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS<BR>ENDED&nbsp;MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stock based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March 31, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $4.9&nbsp;million. The unvested stock-based awards are
expected to be recognized over a weighted average period of 2.90 years as of March 31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Income taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the
three months ended March 31, 2020 and 2021, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (&#147;CARES Act&#148;) was enacted on March 27, 2020 to provide relief for
taxpayers. The CARES Act contain a significant number of provisions that may impact on the Company&#146;s accounting for income taxes. The Company has considered several key corporate provisions within the CARES Act, has evaluated its potential
impact and does not anticipate it to impact its income tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Exclusive licensing agreement with a related party </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2014, the Company entered into an exclusive licensing agreement with Ventagen, LLC (&#147;Ventagen&#148;) which provides Ventagen the right to develop products
for commercial sale and distribution within Mexico, Belize, Guatemala, Honduras, El Salvador, Costa Rica, Nicaragua, Panama, Colombia, and Bolivia. Ventagen paid the Company $1,000 upon the signing of the agreement and agreed to a fixed future
payment to the Company of $2,500. The future payment will be made upon the achievement of $5,000 of sales of an approved product by Ventagen and is subject to reduction if Ventagen&#146;s costs to develop an approved product exceeds $4,000. In
addition to the upfront payment and the future payment, Ventagen agreed to purchase from the Company all manufactured product that is required for clinical or commercial purposes at a price of cost plus 25% of the wholesale price of the approved
product subject to a minimum or maximum price. In the event the Company is unable or unwilling to manufacture supply under the terms of the agreement, Ventagen has the right to manufacture its own supply and will be required to pay a fixed fee per
dose sold. The Company also agreed to provide certain services to Ventagen related to Ventagen&#146;s development plan. Stockholders of the Company own 49.5% of the voting stock of Ventagen, including 47% by the Company&#146;s founders who are
currently senior executives and significant stockholders of the Company, and trusts for the benefit of their children. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is recognizing the $1,000
upfront license fee as research and development service revenue, related party, as the Company&#146;s license agreement with Ventagen is within the scope of ASC 606. The license agreement met the contract existence criteria and contained distinct,
identifiable performance obligations for which the stand-alone selling prices were readily determinable and allocable. The terms of the agreement contained multiple, distinct performance obligations, including transfer of a license for the
territory, research and development oversight for the trials run by Ventagen, and clinical data sharing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company estimated the transaction prices, including
any variable consideration, at contract inception and determined the fair value of such obligations. The performance obligation associated with the license transfer was satisfied at a point in time, or at contract inception; however, the Company
assigned no value to the license transfer. The remaining $1,000 transaction price was allocated between the research and development oversight and clinical data sharing. The Company is recognizing revenue for these obligations over an 8-year period,
beginning in 2015, by measuring the progress towards satisfaction of the performance obligations. As clinical oversight and clinical data sharing occurs over the 8&#151;year clinical trial period, the revenue is recognized over the same period in
which the cost for these services is incurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company defers recognition of the portion of the $1,000 non-refundable upfront license fee for the portion of
the performance obligations that are not satisfied. The Company recognized revenue of $125 and $31 in the year ended December&nbsp;31, 2020 and each of the three months ended March 31, 2020 and 2021, respectively. The license agreement includes a
$2,500 potential future milestone payment due to the Company upon successful completion of certain separate, distinct events. At this time, the Company cannot estimate when the milestone-related performance obligations are expected to be achieved
and will recognize revenue once satisfaction is probable. There was no additional variable consideration, significant financing components, noncash consideration, or consideration payable to the customer in this agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. Commitments and contingencies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Guarantees </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has identified the guarantees described below
as disclosable, in accordance with ASC 460,<I> Guarantees</I>. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted under Delaware law, the Company indemnifies its officers and directors for certain
events or occurrences while the officer or director is, or was, serving at the Company&#146;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has
directors&#146; and officers&#146; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is
a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification
obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification
provisions is uncertain. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company leases office space under a seven &#150; year noncancelable operating lease. The Company has standard indemnification
arrangements under this lease that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or
condition of the lease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, the Company had not experienced any losses related to these indemnification obligations, and no material claims
with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been
established. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legal proceedings </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is not a party to
any litigation and does not have contingency reserves established for any litigation liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. Net loss per share </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net loss per share </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted net loss per share attributable
to common stockholders was calculated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED<BR>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Numerator:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average shares of common stock outstanding-basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,614,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,647,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributed to common stockholders-basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s potentially dilutive securities have been excluded from the computation of dilutive net loss per share as the effect would be to reduce the net loss
per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share
attributable to common stockholders because including them would have had an anti-dilutive effect. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED<BR>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Preferred (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,538,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,538,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series C Preferred (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding warrants for common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,632,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,618,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding stock options (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">997,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,079,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,622,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,690,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. Subsequent events </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left"><B>Reverse stock split </B></P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;14, 2021, the Company&#146;s board of directors and stockholders approved a one-for 2.4579&nbsp;reverse stock split of the Company&#146;s issued and
outstanding common stock and a proportional adjustment to the existing conversion ratios for the outstanding shares of convertible preferred stock which became effective on July&nbsp;15, 2021. Accordingly, all share and per share amounts for all
periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left"><B>Other </B></P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
July&nbsp;10, 2021, the Company&#146;s 2021 Equity Incentive Plan, or the 2021 Plan, was adopted by the board of directors and was approved by the stockholders on July&nbsp;14, 2021, and will become effective upon the execution of the underwriting
agreement related to the IPO and will serve as the successor to the 2015 Plan and reserved 2,054,000&nbsp;shares of common stock under the 2021 Plan. The 2021 Plan authorizes the award of stock options, restricted stock awards, or RSAs, stock
appreciation rights, or SARs, restricted stock units, or RSUs, cash awards, performance awards and stock bonus awards. Under the 2021 Plan, shares of common stock, plus any reserved shares not issued or subject to outstanding grants under the Plan
on the effective date of the 2021 Plan are reserved for issuance pursuant to awards granted under the 2015 Plan. The number of shares reserved for issuance under the 2021 Plan will increase automatically on January&nbsp;1 of each year from 2022
through 2030 by the number of shares equal to the lesser of 4% of the aggregate number of outstanding shares of common stock as of the immediately preceding December&nbsp;31, or a number as may be determined by the board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;10, 2021, the Company&#146;s 2021 Employee Stock Purchase Plan, or the ESPP, was adopted by the board of directors and was approved by the stockholders on
July&nbsp;14, 2021, and will become effective upon the execution of the underwriting agreement related to the IPO. The Company has initially reserved 293,000&nbsp;shares of common stock for sale under the ESPP. The aggregate number of shares
reserved for sale under the ESPP will increase automatically on January 1st of each of the first ten calendar years after the first offering date by the number of shares equal to the lesser of 1% of the total outstanding shares of common stock as of
the immediately preceding December&nbsp;31 (rounded to the nearest whole share) or a fixed number, or a number of shares as may be determined by the board of directors in any particular year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>9,000,000&nbsp;Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g120909g66n88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:24%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Prospectus </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:24%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Credit Suisse </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>BMO Capital Markets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>UBS Investment Bank
</B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g120909g01e15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g01e15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %N:^6&(X0DE-!"4      !                      .$))300Z
M  #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O
M9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O
M;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R
M;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T
M3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--
M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&F4>N         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             ")0
M!,D    & &< ,  Q &4 ,0 U     0                         !
M          3)   ")0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ")0    !29VAT;&]N9P  !,D    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   B4
M    4F=H=&QO;F<   3)     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      S9     0   *    !(   !X
MAP    R] !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M6.P57B6N+.I3!IH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 0("/P,!$0 "$0$#$0'_Q  >  $  @(# 0$!
M        !@<%" $$"0,""O_$ & 0   & @$" P(%#@D'!P@+  $" P0%!@ '
M$0@2$Q0A%3$)%B)!41<8&3)787%VD966LM35(U)55EB!DY?2)'>AML'6\"4S
M-SABE+$F-$)RA+/A\4-3<W6#AI*BI+6W_\0 '0$!  $% 0$!
M  $" P0%!@<("?_$ &01  $$ 0$%! 4&!@H,"0L% 0$  @,$$04&$A,A,4%1
M8? 4(G&!L0<5D:'!T188(U64X0@D,E16DI73U?$7)3,T-3="4G:3M-(V1$5S
M=+/4XN-#8F-R=8*#A(6RPR9&4V1EHO_:  P# 0 "$0,1 #\ _OXPB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3"*$TM550]O\1113P[K-II]YC& B92,^U,G<(]I"\CP4O!0$1X ,@?:?
MB44VR43")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8106C_;W+\>)S]1E_P ?Z?=D
M#[3\?/VHIUDHF$3")A%K)>]A;A/ND=6:P::[%-EJQGL1XYNY;""CQ=S:I2NA
M%-'$(MV-"'*S04\PLS<BD8ZAA(H':3.OTW2]"&@#6=8?JN9-:DTIC-.-7#&,
MI06N-(VPW+R#(X;C9&;P &1S*XO5=6VA.T?S'HC-(Q'H<>KR/U,6\R.??GI\
M!CZSL,!$;';[HWXR[D>0.#B.KRFGJ\ ^GJ]8T;F]^.2-BI-;:IV)[7%->3ZU
M8M[]9YXS%LZB&TN@)(I5$QI&935(G'QSATDY01R9]A=0%RU'6M5':?'Z ZKJ
M-MYJ1VVZK5;<H1-CW97LG? X&9KP(JY!=+*UA8YV+!M_IWH562W4MMU&0Z@R
MYIM-C;<E-VDVG4[\KI"Z)CZ[)V$0.:>+8! BB<\/:V?(]1-$DYN(AJI'W&\I
MR474)M[,TZKR$U"UR*OB:3BJO+"Z3!)5G[39K$D#MF[=V\CXWF0DF[1H450U
MCME=2AKSV+LM#33#->K1U]0NQ5K%N?326W8ZK#ELG!D:8@]SV,EF_)0ND?R6
MU;M?I<UFO7HPZCJ8F@H69;.GT9K-:G!J@:^C);D :8^-&X3%C6ODBAS+*QC,
M$X O55KM2&&:1A[THB\MCRDUMN>LG:N+C8HMQ.H3#>L'>.F[1ZRA2UZ06E9A
MRZ9Q+,@))'>BZ,9N3)_ O518]'=/IH='1CU&V\7 ]M"I,VLZ!]P,8Y\<E@VH
MFPP,9),\[Q$>X \XGX=:0:WI+:^J%DEZ33:;'4C&_4+<+K+;#*1DD;'+'6]%
ME=/8<^.",;K3)OG<"=ZK]7P=2@KH9O;)*(FBV05R1\"/G8 ].="RM36=;O73
M(&\G".B+I.(AFH^E'1&SAS'-'K1,7 S6V)UFS>L:>'T89X/1-TRV?R=D7V"2
MD^L^-DF]#886EL\@CA87L9,^-YW4L[>:)6H5=1W+\T%GTP.$57\I5=I[^'>C
MM-EDB#)JSPX.@C=)-(&.?%')&"]2&-ZB=?S5Y6HT,2?E%F;2,>2=A:10&KD2
ME,5M&VQRDFY4<IR#5FX@7#=V,L:,&&05739.9!)[W-RXLNRNJ5].;J,YK0M?
M)-'%5DF(MS.KVW4I1$P,,3Y&V6/8(!,+#FM,C(G1^LLN':_2;.INTRN+<[F1
MPR36XX,TX&V*;+\+IGN>V9D;JLC'F?@&NQSVQOE;(2T<:WZBM>[0GD*_7@GV
MCF4A7EEJ[J;B#QK*WUV/=-&;R8@%#+*JF014?L50:R:$;(JLGC=^BR49G,L1
MJVRFJ:-5=:M>C/9#8CIW&5YQ+)1MRLDDC@LMW6@.<(I6[\3I86R1OB,@D&Z6
MC;7Z3KEIM2H+4;YJTERE)9KF&*_4BD9')/5<7%Q:TRQ.W)FPS.CD;*V,QDN&
M"ENH:+J=HN4'/LY.;,PV17-<U:(IM<D)*?=3$[KTMW3:/DU7@-W9E46[XY'S
M0K9FS0%$KX4RI.79,B#9::]3H6:TD-<2Z3;U6Y8OVHHJS(*VJG3B^,MC+V!K
MG1@QOWWR.WC'DN8PXMC:V&A=U&M:BGM&'6*>D4:^G5)9K4EBUI(U,,D#I-V0
MN:V3$D89'&W=$A #WMGD-N:HS6K)S;J*4TTK=9C;A(3["0C#M+!%*T,\HC9X
MMS&'4$/:<>YAW[;P4W!T5EDR^$N8ARGS6V- O5]:K:&XUWV[DM"*K+%,)*L[
M=3$+J<S)@!^1E9/&_><T.:"=YH(PMK7VBH6=#M:^UMF.G2AU":W%+"66H':6
M9VW8'PEQ'&A?7E9NAY:YS>3B#E1VS]1NO:F20-(I65R>.@]:V!1M%0:LD\<,
MMK6!Q6JFBR:-UC.'CY:4;'3=,T4S*HD,F*8+F.!,RZ>R>J7N%PG5&"6SJ]4/
MFL"*-LFB567+SI'N;NLC;"\%DCB&DYWMT#*P[VV&DT!*96W)#%5T>V605G2R
M/CURTZG0;'&UV])*Z9A$D;07-!&Z'DX4;+U)0LG*U-O'LY2!*K>+K3;I7K;7
MGK2T1SVI:UF-A&:M$VKY1@V77C6C"22=++/6CIBX\JGX3M4#)9?X)6(H;KY7
MPV=W3M/U#3[5&U&^E-'>U>#2P^0R1B5[6S/DA<QK8WQR-WW;T;<.PQME6FFH
M-BCFJAVIZEI^I5+]26.]"^AHUC5MQ@9(8HW.ACBF#WND8^-X8"U[LB/2/5O5
M9.H3TM68ZQU^5:TBO;$KZM^J4DSBYZH3=DB:\,U'H,GI7CMNDZDTFO895FJ*
MJ[9XD1Q'F%8V5%L/=AO5H+DU2U _4;6E6AIMZ)\U:_7J3VO1YG21%D;G,A+\
M@2-+6OC)9*,#$GV^I2Z?;GI07*MB/3:FK5#JE":."U0LW*]3TB)L4H>]@?.U
M@RZ,[SF2 /C.38!.I769[R:C@O, 8MK5H1K2,8):B%Z03.=6K>U#+@X\\54A
MF(/!8^QS2@!%%DA?B#<=6=D=8&G#4=R @T6ZF*8FS>^;G. ;<X.[N<,APDX?
M%X_!/&,/"]9;4;9Z,=3.F;UGE>=I9O&#% :FP'>I&8N#^(' Q<3A< S_ ) 2
MF3U5 [=U<P45K^SWZK:]V19(B(CO:<#.+55_&U&UL4YIG"KR$;/J>("3 BSL
MB[=5ZU:K2+0?.QB#QFFNNCLJ.PUF?4Z>F7-4TFI8GEX-FLV['->I2FO)89%-
M6 &]*6QEKVQO>V&3\G,Z.0M:[67]OJL&E7=5HZ3K%RO!%QJMI]&6'3[T0LQU
MGRQ6SO;L372!S3(QCI6?E(FOC#W,E\CU0ZWB)].ORC:TL5FRU796>0<0@DC*
M1+W%!@X@X6U./->*UD#DE([VAY!O(M8?SK<TLZ9D4 P8,6QNKSUC9A?2D:]M
MR2G$VSF;4:]!TK;%BDW<W7Q PR\+BOA?/PWB!DA:0LZ7;?1Z]IM2=EZ)[32C
MNROK;L.F6-09$^M6O.,F]'*1-%Q>&V6.OQ&<=\8.1@I3J98O+Q0ZI3*[/R$3
M8=N/M:2MTDX%ZVJ#I6%@K8ZGV]8FRN"$>2D9-0",>8[AL#%T5*6!@=V=BN=#
M)BV0ECT[4[NH6JT4]70XM7AT^&S&^\QMFS195=<KEIX<,U:RZ7#7F1A,'%$8
ME8'8\VVD4FIZ90TZG:E@MZ_)HT^HSU9&4)#7K7GVFTK >!+/#9JMBRYG"D#;
M'#,G"<6R6\[S;:\V5*5RQ-2A4HO6,#=%G[%NLYF1EY[8I*(U9E1%PFV,Q [E
MJL<>T%R&,JIWF(4$QP].V<?JFDPVZCR;TVL6=/;%(]K*_ K:4=2?(3N%XDPQ
M[1S+2,#=!RY9>I[3MTC6IJ=N,?-\&B5M2=+&QS[/I%K6&Z6Q@&^&&+,C''U=
M\')!(&Z>];.H:CU&7E(!Q'VR8FXN[U[7HQ5>@3RCU]9K13G-XB6S!$CA,5FZ
MD*U5\P[.*2+5R':N8B!5'!+=+9;4;T$-IDM*"M-IUK5>/:LB&..G3OLTZ=\K
MBT[KQ.\;C '.>W]SEQ#3>O[6Z9I]B>J^&_8LP:E4TG@5*IGEEN7=/?J5=D+0
M]N^PUV.WWG=;&\'>PP%XP2?5+K]W&UIW$P6P)R5L25M='JD-4G3ZSUYE0YL]
M<MSZQQQ%RDCF\/-IC'<$<N5Y!R)4XI%Z(CQDNV,U2.6VR>QI=:&HZBP7;%YD
M=.U)J=<6Z,=24M)E=8KGBY+&,B8"9G1C&<0;<:4^&G)!5U:U/<;>>ZC6H/EN
MU(M,LNIWY;D(<!"RO9:8<![GS/(;"V0YQ,GN\:2QT_%[N4+.+4N8C*U*L4VL
M4HYG5F]LD(V,B$RQ"2AECNE'4JT(HV2.HJ4!.!"J' "&P(]G-1DUV;9UIKMU
M"O-;AD+Y@RLUU**::<F=S=T,#(7D/< TG&2 <C92;3:;%L_#M*X67:=8AISQ
M-C@+[3F7IHH*X$#79+R^9@+ XD9.-X@ PNO]4]!G; PKBU>V'773NVR5#=OK
M-4UHJ(A;E&P[BP_%V5DC.EFZ;]U MS2R M1=-DVJK?SCAJJNFF.PM;&:G6JR
MVVVM*ML91BU*..G>;//8H2V&U?2X8@QKC$RR[@.W]QY>U_#8]K21K:FW&EVK
M<5-U/5J;Y+TVF22W:+H*];4(:[[?HD\V^YC97U6\=NX7M:QS.(YCG &-R?6+
MK[XK6R>K<-:I9U$T>R7FI-WD0>.97V&K7@IOY"#="LLNE'-#.VCYX>1:,7X0
M2BDTR8/&21SAEP[!ZH+M&M<GI01SZE4TV\^.<2R:9/;WC''99NM:9GB.2*-L
M3Y(_26BO))'(X!8<WRAZ4:5^S2K7K$D&FW-3H,DKF*/5*],ALLM9^\YS8F;[
M)9#+''**KC89%(QI6;>]55(@6=&6ME?NE?5N$%79UR9S! #2NM[)(FAV)Y-0
M[PCIPB:1)_"GB6DD=BP<,G\FFR1=H]V/'L7J-J346T;6GVFT+-JNP,L_E+3J
MD0GD$0$98QW!/JB=\(EE9)%"9',=C(EV[TRI'ICK]34:CM1JU+3]^K^3ILMS
M&O&9G%X>]O&'K&".8QQ.CEF$;9&Y_$_U359I%[7=UFK7.T.-6,+@9ZNSAR^Q
MGTS2U3,YB,,\3=+/8U-F]*<57LI',T74>U?/XD9%)L'B36V,NOFT1ENY0IMU
MJ6@(VOG/I$<&H-$E>81EC8YC)&0!'#+(Z.5\<4_"+SB+>W-&.+774J.HW7Z)
M%?,CV5QZ-+8TYW#L0F02.EA;')O%TLT,;7Q1RRP<8, =RYZK*1"1]$=6R NE
M?5N4%7)QT+F"_P CKC>R2 1#%2264=IN'+<9'@53Q#:258QZ[.0E$6*+M#OA
MFQ>HV)=292M:?:;0LVZT>Y9R^VZI%QY1"T,+6.$6<"=T+996210NE=&[$OV[
MTRM%I;[]34JC]1JU+3]^K^3ILN2\")TSC(USV<7!<:[)G1POCEF;&U[<Y]IU
M+ZV=2%_0.,^SA=:%M06FWNH@?BTS<4I<S6Q,Q70<+R2#ILY(JBQ(^C&A9LZ1
MQA#R!>P3XTFR.KLBTQP]%DL:N:7H5!D_[<D;J#0^H\,>QD3F/8YKI#%-(:X<
M!8$1R!EQ[9Z.^;56$6XZVC"]Z=J#Z_[3C?ISBRW'O,>^9KV/#FQ"2&,62T^C
MF48)P/UV^K4H2;EI%M;(9Y#&JXA7):%19SLFUNLBK$U=_'D,_-&%9R4@@NU6
M5D)-@,0L@HG-$CCBF!\G\!]9=8KPPOI6([ N VH+#GUH7Z?"V>Y%*1&)C)#$
MYKVB*&7CAP-<RC.,0;?:&*UFQ,R_6DKFE^U+%=L=F9FHRF&E+$#*81'+*US'
MNEFB,#FD6!$< WW4+.VN5=CK&TCIB)0D2KB6/GF QTHW,W<K-5"KM_$62,0R
MB!SMG35=RR>MC(O&3EPU725/S-ZF^A:EJ/E@G=$6YEK2<6%X>QLC2UV&N!#7
M /8]C)(WAT<C&O:YHZK3[K-1IPW(XK$#)@XB*U$89V%CW,(>S+FD$M)8]CWQ
MR,+9(WO8YKC)<Q%FIA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%I9
M8(3?3Q68BX"(GXR6CME[ N[:UKS<(O7Y1C+(2M6UM&1#%686=+LX.'F(BR3L
M5+Q3".2D:L[2!%\N];&<>@5;.S4;:\UF>M-#+I&F:<^DVM8;:AE@=#<U::>0
M0-8U]FQ!/4K3032RF&ZPDQMC?N><6JVU,CK$-6O:AGAUK5=39>=9K.JSQ3MF
MHZ1!7B=8>]T=:"Q!<M0SP10MEI/&[(^1N_\ 9Q"=22LT@7VI. T8&M3!"RI_
M$<LVM"+6.\/V 'CS-PKYI.0C*AKUDV=*0@BP;W90#=CEA**I4ML;)-KN/ K\
M27T*5U,G43698;4TZ*7$N\;(BBEOZI(]@L8E=IXP2R2%IE];;)UEOY>SPXC>
MB9<'S9Z2ZJ^YJ4L0,6X*G'FAT_2HV/-8&%FI$'#XIG-B55D>INQ/:[.13LP1
M<Q+,HVQSB#"#,V7=U.*I,!)/'49+'1\.KRDZTV+(H.:P1-=\DY9&;.RIH1P.
M\Z[%LA5CM5IHQQH(9):E=TE@/8R[-J%J)C)H0[-R&L_2HBRV2R-S) ]F7R\/
M7T9=M+DE2U7D(@LV(H+EEL5;<<^A!IM6:22&=S2*4]J/5Y6/I!KY ^/=?NLB
MXF<EVO5#(Q<,_8*V]K;&3^VR;^*=&ULUIX3[*GS@5R)8FCW!I:3H+^>>,FC9
M:;<$EE#L6[F1(S4<^;88\#]CHIK$4K:+Z4L5&&.9@U5]_P!&DO5_2IY!*W@P
MZG'6CD>]M=O!:)'LC+PTLDRK$>VTT-::)VHQWHI;\TL#_F>/3Q;CT^R*<$?"
M<9Y]+ELR1L8ZR_C.,;7RB,O$D72D8KJCL,%$5R6>VA!E8A,T?RD2C08R7BV$
ME9H6-ED;D\2=I.&Z4?5!L$K".J0U1DW"SEFV=J(NX_O=7(IMC:MF>W!'3=)4
MQ)'#,[4Y8)I(:EB:!U!AC+7NENBK!9CU!QB:ULCV LEPRW+#MO;JUZ=B2\V.
MWF.6>NW2H9X(YKM:&<:C('M<UL- VYZS]-8)GN?&R3=DB!?O7GFZ]03")A$P
MB81,(F$3")A$PB81,(F$3"*"T?[>Y?CQ.?J,L@?:?CY]J*=9*)A$PB814#?=
M&N[?L)/8\%L^ZZ\FC4I"AR 51O6E@?P2$V^G0 5IZ%EU&;L7;XX%<L_"43*D
MD)! P&[NGTS:..AI3M)LZ-IVJU_G!VIQ&ZZVTQ675HJQ]6M8@$D?#B&62;P)
M)SR7*:KLQ)J&K-UBKK>HZ38^;6Z7**+*;N+5;9EM8W[->=T;S)*?7CPX;K2"
M"H-/]'.N'["F-ZZ\=UQ]3(>8@4Y5[#5B\+S<?8909V:<S;:\0TXR<SKN<4=2
MY)U-!%\B\?/  3M%O*EV%7;S5HY;[[;&6X[\]>RZ&.>YIS:\M6 5J[:[M.GK
MR,K,K!E<UBYT;HXXSRD;OG66OD\T>2+3F4Y)*<NG5[%43R5Z6I/LQ6YO2;#[
M+-2KV8GV7V7/L"TUC962228)C=N"9-M (05I:62CWZTT9!RPIL=<(*"8U;V7
M<4**W28PJKE)U!*E@G"L:B6+D35U.-0=1P@W(V;B1,Y,%^T[K-)]34=,I:BY
MDM^6A9LR7.-0=J3W2V PLLCTA@F<9HA:,KF2^N7.R0=BS91M6[';TS5;VF,?
M%IT.H5JL5+@Z@W2V-BK%X?6(JN="W@S>B-A9)$=T,9@%8:<Z6:9-Z_JU'/*O
MR+TJX6:ZUF?>1=?G%&DI:YBP2LJU?0<W&/X"6BU26-XQ\H]8',":#-RFLF\;
MD7R_6VSOU]3NZB((BW4*%/3[E6.:S7#X:5>K!"^*S!+'9@F!J1R;\<@&72,+
M3&XM6/9V'TZSI5+3#8E#M-U"[J-*W)!5LNCEO6+4T\<M:S#+5L0.%M\7#DB/
M)D;P6R-#E'['T>U&P0\)&!9GT<M'T^TTF5>M:CKX4IB*M[T)*4=-X8:N6#KD
MPF\*0&DO7X]B^3:)I-U%EE$DG!,FIMW>JSV)O1(Y6RWZ>HP1OO:GFO/1C,,+
M'3^F&Q;KF,DO@M2R1F0N>&M#BPX=SY/:%NO6A%Z6%\6GW=-GE90TK=L07Y3/
M-(ROZ&*U.R),<.Q4BBE;&&L+G%K7MS"G2M6GEOI]EE;1,2C&ELH=I&0JT-4V
M[@Y(>KA5",EK4RA&UK/ /F?B.Y*NJ2RD>[?*J&, -Q\MED;:6XZ-^I!3@AEU
M"2P^:PVQ=<P&Q<-TR-I26'TA:BDPR&T(!*R,#&7#>60[86E)?T^Y/>L3Q:='
M7CAK.K4&/(KTO01&Z]%69>-66/,DU1T[HI)7$GU#N+*Z<Z::MIB8-(0<J>19
M,HE>"KK!Y5J0Q>PT8NY06['-GB*ZQL\^Z21;IL4W<O*KG49]X.RNG)O,A8U[
M:ZYM! (K,#89))VV;<L=S4)([$S6N;EE.>U)3JL<YQD,<$+0)/W!8SU%D;/;
M&T=G+!FK3F:..!U:I%)1TV.6O"Y[78?=KU(KMJ0-:(A)8G<3'G?#WG?6:=Z#
MKKN]'OAYB8+(GVA![3%F4&8M EX+7CS7+>. 10\;V>M&/5'RH]XN?/$*!%00
M[DAL,VFMLTT:8*]?@C1[.C<0\3B<&SJL>K/E_=;O%;-&(QRW.&3RWL%9,FRU
M234SJALV!*=:K:V8P(^'QZNDR:0V']SO<)T,AE=SW^(!@AN0LW&Z<KS#7%YU
MDH^DW<%?W6S'$PX.=!)^BGM&3G9*;09J)(@FF5F:>=(,%#IJ'*FDB9853@83
M8\VOVY=6TW6!'"RSI;-'978 YT3CHT-:&LZ0%V7%XK,=* 0"2X-W1C&3#L]4
MBT?4]%=+-)5U5^LNL/):V5K=;FLS661EK<#A^E/;$2"0 TNR<YJF-Z4V"8.U
MK'LJY6V1=)ZB:D?R+*M,3-(_35O/;JRP;-XF)9H BY<G\K)JKE7=+IF56(N1
M90!)NIMM93N,J:10I0M.NO,44ER3B2[04!0N2O?//([>8P;\+6;C&N ;NEHY
MZ&'86(;[KFLZA?E<W08Q+-%3BX<.SU\WZ<,;(((VACW'AS.<'2.!<\/#CREC
M_ISK,A:GUL4G)LCQ]>[-?E&Q 8^6)(VC5!]2NV9.YL*GDV\,<9)OR<5O:( "
MBAFW\%F%'M9<BI14FUJQCBTVGI@>>)OF&GK0UMDG)P D=..$[EN\+H [FL^;
M9"E-=EO.M60^75+NJ%@$6X);VAG0I(P2S>X;:Y,S,G>XW(DL]55=M#IC>N:;
M7X.@+*RLNRUG4=&>-/2;2-CXVEPUH@+.[MKLJ,<NO)3"9ZTV9DBV?EDG'GS*
M%%(J B.XT?;"-M^U8U-K8()-8O;2;M:%\TLVH3T[-..BPNE:V* BX^0S2;Q;
MP@"'%P"TFM[%ROTZI5TISK%B/1M/V9W[4T<,4.G5KU6\^_)NQ/?+.'4HXN!&
M&A_%+AC<YSB-Z5Z3$;+D-@,'H%9RUI?W:0K#NJTF2*I9Y,JAGKIM:9&O.K>P
M8*O3^U21K*903:R1069JMT1%N.MEVSU"?2(M+ECS)#2BTZ*XR[J,);3A($;'
M4XK;*,DHB' ,LD#M^'U9&/=ZRV<.P^FP:S+JL4N(I[LNI2TGT=-FS=F!,CV7
MIJDE^*$RGCB&.=H9-ZT;F#U5\$.F%!*C6?6"FT;VYUW*UIY5ZQ5'"-:,VI3%
MQ(M9)HHQ?DA22DPM$*,T6D5[:>.B-XXRS14JXJ L2MVV+G:E3U@:-IK-5@N1
MW+EUCK@?J$K(GQ/$L1L&&!LX>Z2?T=C"Z7=>TMQNFENQ+&Z7=T0ZWJ;](GIR
M4J5%S:99IT;IHYXW1RBN)[#J[HVQP>DR/#(2Z,AV]O#KK=*%:<W=.]O+*XD9
M615K#ZZA+4W7DP:W3-88L8Y*4*\EJN]>UD99K'-4I=E7%V+);PQ4:HLW!U%S
MU-VVMLTXZ;'39%!"VY%IW OZI *%>Y))*Z'AP7(X[@@?*]T$EMLDC<X>Z1@:
MT4/V$IR:DW5)+KY9Y74I=2X^G:38.H6*4<439A)/2DDI<>.)@L14W11NQO,;
M&XEQR4;TSQ\5:X&8:; MX5*K;&F-HUS7:B$ >!BK-8$+ G,"G(C%?&!6/7<V
M:6>-6*LF*+)5VN5,IRG3\*U-M=+-1LUWZ70-Z[I-?1K>JAUD6IZE5U4U\Q";
MT5LK64X(Y)6PATC6-+B"#O7H=BX8+U6Q'JNH"A1U>?6Z>D%M4U8+EIMH6,2F
M#TIT3GW)Y&1NFW8W2. SD8DNS-!U[9\I8IB3FIJ+>3^OX^A%/&^2XC4XBWIW
M:,FVH.6RP*2#691;B*+@%&:S=+PE$1$YC9B:1M-:T>&K!#7KS1UM4EU,B;B9
MF,] Z=-7>6/;B)]=SO6;B1KSD.Y869K6RM36Y[=B>S9@DM:3%I0,/#_(B#4&
MZE#99OL=O2LL,9ZKP8W,;@MR<K 0?3:Q83S>U3M]M5MLA=EU[:+V5E&L S,^
MFJY19.@M& M(>+8,VT4:*DS+ BW1*NFLW0+YA0OBBIDV=K9):SJ5;3*5&H=(
MM:-'!"^U((Z]K4H=3?*'SS22.F$T(;O/<6EKW>J#NXQ:NQT<5IEZUJMZ_<&L
MU-;EGG95C,MBGID^EQQ<.O#%&R PSEVZUN\',:-XC)-6W_IVNM;4@Y+2KB6/
M/^-M8DU.EM\%6GQXS9MN^.KB =,Y>EV>+?0B$RX<G0>M4VD[%@V;F;&>&<KB
MGN=+VJT^T+,6T#(!6W-$-:L:%FW$)M'H?-S++)(=0J31675V,#HWF2M-O/#^
M&&,!TFK[):E4=6FV<=.;9=KC;-H7ZM.4P:U?^<759([&GW(9:S+#WD2,$=F'
M=:6<0O=BXX;12)^GNBZ0LLPJ)JS!:^92$O#E(45Y&CR4'-@9J#Q(X>4=2$,1
M$PJI%5%HJ<P DL)1)H;&TCAM1J6T52!O[<LZI)'!.2=V+48;-<AY8X?E&16"
MX;I+>(T9RW(/0U]F&G9/3-FKEAV:=;2HYIZP&'3:;/6L_DQ(T_DY):X9ZS0[
MAN)Y.Z=EQT]U9W)KR+F4EE@=;G=[I<-#@S\NK,O:02B+PAN$ 4]CGC"BX$0/
MYSS1S?Y1X7! I;M3=9"V)D,#=S9^/9YD@W]]L$6HG4VV1ZV[Q^,=SIN;F/5W
MLDUNV3HOF?,^>=PDVBDVCDC/#W'6)=-&F.K'U<^CF$;^01)OD^ON\E!*CT?T
M6HQMH@&\P[=5V=IEDHD:Q&L45A+0,'9FQV;LP6R-K36SS3]HR.9DQ=S$FY'R
MICE?$>JF%;-C>V[U*]-3M/KQLMUM0J:E-(+>HR0VK-1PD8/0I;;Z=>*20<62
M.O"P<3!C,;0&K5Z?\GVF:?#=JLL/DJ6=/N:9#&:6F16*M>ZW<D/I\--ERS*R
M,F.*2Q,[#"1()"=Y8J9Z.(6P@B:9V'8Y!RM7J77YQ\ZKM)</I1*@2KB1K3A@
M[<0*KBL"@BN6/?(UY1@G)(-TEW(B\.Y7<7J^WMBJ7"OI52)C;6H6:T3+6HLB
MA.IP,AN-EC99:VYO.898W6A(8G/<UGY,,:RQ9^3RM;#?2=7N2O=4TZI:E?4T
MU\L[=+G?-3=%(^LY]+=:\0R-J.C$S6-<\F0O<Z4/.EBN2]UMURG+7-R2]IKM
M[K/ED8>I0SII&; 9JL91!].0D$PE[*E%M53)UY&PN7Y(SM34$7"R1%2XD>V=
MNOI]&A6I5X6TK6FW-]T]ZPQ\VEO;)"^.M8LRP5'3/:#:=5;$9?6 W&N<#FR;
M#5)]1OZA9OV9G7JFITMQM>C7?'#JL;HIVRV:]:*>XV%CMVHVV^40X:?6<UI$
M6F.C:$GTVH3.P['(N35NEUJ:?NZ[27#Z4;:_F'4K5UF+M> 5<5D[=-U[.?DK
MZC()1LW05=F,[\==?+@V]LU2_@:74B8+>H6Z\3+6H,CA?JD$<-QLC&66MMAS
MH^+$;(D,+W.:P;FXUF%8^3NM::STC5[DSS3TZG9EDJ::^69FE6'STG12/JN?
M2W&O,,K:KHQ,QK3(3)OO?();I+IMFM]LL]OL,S86]JA+A7UHL(NKP;A*-N@$
M*_;/K#7X6-G; C$D(4M;3G7CX(<4T52F<+()*EQH-M[].C1IT*M>HZE8H6A-
MQKEECIM/R8WQ5+5B:M5=.2?2S6CCX^7##&N(67/L%I]W4+]Z_<LVVWJVH53#
MP*59[8M1P)6RVZM:*S;;  !3;:?+Z.6L<"YS 4@NE>)@:K8JXTN2P.9XL*U+
M+I:\U0T,E%P:JBR,7)QC6EI1UC;R)U"FF#S2+E1VH@W6;BR53$YXL[9S6;M2
MT^@W<K&P\P.U36G[TUAH:9H9GWS+4?$!^0]'+0P.<UXD:<"*VPT%:C<ILU%V
M_:%9@L-TG0XRV"JXN;!/#'IS8KC)20;!L-<Z1S6.88W-R;EU-K.*U'1XVCP[
M][)-&#J6?F=O4V;83NYJ3=RSPC2/C6[2,B8U)R\53CXF-:MV,>T*DV;I 0G(
MZ'6]7FUS49=1GBCA?)'!$&1E[@&5X601F265SYIYG,C!EGF>Z260N>\Y*Z/0
M=&@T#3(=,KRR31Q/GE,DHC9F2S,^>01PPM9#7A#Y'"*O"QD4,8:Q@P,FR,U*
MW"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%!MF+V%O0+<-20>KV=>$>L
M8 (],5':$M))^SV+Y(H>X(YPZ)(*J#\E)%LHJ;Y)!S8Z0VJ[4Z/ISHVTVV(Y
M+/%(#'01'BR1G/4RM88FC_*<\-Y9RM7K3K;-)U#T!DK[KZTD540C,C9YAP8I
M&]PA>\2N=_DM8YW8M=VMYW^_ D.PK4E$>SGK^/?SDO3'[LWE4)V^.V:[!-U(
M-B3;A&H5>MQRLB@LI'R5CMS)R@HJF/E\ZI^G;,1$SR6X9^+'%+%6@U")@WW5
MM,CD9(8XGFLQUZY<F$3VB6&K1D8X ^N>1CU/:N4"O#3FKB&26&6S8TV5YW&6
M=4DC=$))6"RYNGTJ<!F:YT<UR_$]KB/4/6UCN/9UKVM&T*P*0S5W&1BSRZPD
M= BJ@P:QE-K(NGI;$G-.@9RCW8-A=1@P#ED5=A'0RZ2G*P&<N*]8T'1Z6BS:
ME5$[V2S,CT^Q+9P^1\U^YN1FH:[-^&/2ZK)?2F2.;)+8:6^J0UE&B[1:U?UV
M'2K3J\<D$+GZE6BJY;&R#3Z?$E%L69.'-)JMM\)JNC#H8H'-<=X;\G[4NG4\
M$JZD658:.XI4SY_%UIW55V#@4%3;6=Q4,^GCS  V<)Q-:U^D\>J,TP]O6U)H
M8J*!5 "D:?L?P6127)(YP(XIK<=UDK YHT5DUB*L(/7:9[>IF.,/.:U$O&\X
M@JHZEMKQWS1THY('&26"E)0?$[=<=<D@K2VC8]1S8*>EMEE,;?VU?;& UH<H
MX>\=4AF-;EU8<YCI-[F_>L(JB6 P/011I49&M)J.E64/)M7$4M,7.Q1+!F"1
M[,WK3&,;/73QSXCC+&G;&B2U + PYU"*.6;4JPX>\[49II*\L#YX7MF;7T^K
M-)(3Z(^W+*^)D;<,P3J>W!BIV'0.):W4I9(H-*M_E0UNG0PQV89XJ\S)('6-
M1MUXHP/36TXX62/D>'.^SO8G4R+-YY.MR;L35G:+N*,77$C'2BSV%-;V]"=2
M#9Z]-&LG$\G#U]V6')(%FBNIUND,&X9K*JQ<,TK9#B1\2W"S%O1F3CYVBEA;
M'8%!VIQQ/9&)9&UC8M,](,9KEE9Q%ELC6B:I^K[:F.3ATYWYI:U) ?F:6&=T
MM8Z@S3'RQRR&&)UIM>I(*_%%GB66M]&?&YQ@_0WKJ58)/HYO'R+]6&A7B(2,
MKJ^=!"048*5*/A)DCZ+5>N)&4M*,G/SK^*BX%V:NFCBL7T>"C-VDYCYMV2D,
M<SY8HVV+$;N##K%?>B$HO2V(#',(VQ0TG0UJT<TUA@MB7B1R8DC+)^=-LXA+
M"R&>5U:M(WBSZ':W)C$:$5:R)8#(^:>ZV>U:E@AK/-0P\*6+,<@?W4MB]3R[
MF4%2F-(AJRI<>\:(R=4L3U\ZEI&I0SOSYBUMO-QJDA&W*3>1,K6F$P\?(14+
M(/FL:]/Y/SEMVE;'M9#C4'SODORL>8;M6.-D,5ZQ'P@;;J\HBEH0QSPVY((X
MW3V(HWS1CB<*Z-8VV=)/G3601Q:;#(QLU"Y++)/-1KOXV*C+$+I8=0FD@GI1
M6))605YI&02$1\7:'7<C8Y:D5J3MS-Q'V1]&(N99DZ9$CG+9RJ8Y@279$55!
MNJ5(4_$(;P%>[DRS-@L8[)OQVJQ5(-1MPT9&RU(YG,@D9(96/8T %S9"UN^T
MNS@C>&.39)6@2.[?2)KEC3*4^H1NAN2P-?8B?&(7L>XDAKX@YVXX-W<@[KL_
MNHXG9B9-,UZV281,(F$3")A$PB81,(F$3")A%!:1QWW'C^?$[S^$2LQ_VY ^
MT_'W>>_JBG62B81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$7Q(W;IJJKIH(IK+]GCK$2(55;PP[4_%4*4#J=A?0G>)NT/0. RHN<6M:7
M.+6YW6DDM;GF=T$X&3UQU5(8P.<X-:'/QO.#0'.QR&\0,NP.0R3CL7VRE5*B
M7NR9]OU-UG4":4<-6F-$WG9+I<S=498L_7-@:\J[!))T#@$"QQXZU21W#<S0
MZJCDC50CA,B9TU,D1--1\_/?;9CB'/U=UT4KSRQG.6#!STSR5O?/%#.6#&Y_
MCD.:![L$J]LQE<3"+&R\O'P4:[EI1P5JQ9)>*NL8!,( )@(0A"% 3**JJ&*F
MDF4!,=0Q2@'(X15"QW[2G3L&[A"7CT3'[2O7+5$Z  /H!U2MG*ZZ9?IX24X#
MU-QZ\4[PY>)QGLS^OL^E%V=D;5/3PKJD,A'S",PDN]44.L<4SL4A1*D9LJW/
MV@9<RBG"IRJ%+X0@"9A[N)) &2?9XHI91]@PMZ:*J1_B-7S4I!?1C@2BN@!Q
M$"JIG+\EPW,8!*58@ (#P54B9C%*('/GF/:BG>2B81,(F$3")A$PB81,(F$4
M%I'V]R_'B<_499 ^T]W?X?U]_-%.LE$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$7X443134664(DDD0ZBJJARD333(43'44.80*0
MA"@)CG,(%*4!$1  $<=>B+4F54('7=0Q$Y  W21M?M$3  &YW'I<0X'GUY#U
M#CWA[LS6_P"#I/\ IL/_ %$ZLG^^&_\ ,N_^]BVV25273(LBHFLBJ0JB:J1R
MJ)J$,')3D.01*<A@$!*8HB @/("(9A=.JO+]X15'N]FZ=Z_?F; 8P,WC!XZ(
M3D1,U36%-01 />5(ZJ:Q^?0I4A./H7G*7=#A%HWEKGXG/;WYS\?O1?91PNLF
M@BJLHHDU(=-LF<YC$0(HH98Y$BB(@F4ZISJ&*7@!.<QA#DPB,D].O(8'/Z^?
M/F/ =F.Y%DH2?F*X\,_A'RL>[,B=N99$$S"9!0Q#G3,54AR&*8R9#<"4>!*
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MVE O(\CP !R/ !R/'S\  ?@  ^;"+YD013$YB(I$,HH*RAB)D*)UA(!!5.(
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ME1.H?=M-J6Z;'"5FL[1NT-!1#9E7SMXZ,8S[Y!HT1.XAUES)HI%*0HJJJ'$
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MNW/-3R(Y#J>>,@#KWG'=CF,].2_KP^"J_P"HWJ+_ .\-D_\ ^FV_/D+Y5_\
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MZ(40!<ZQ'J:@^O K(J%3Y^C^!42]/FR2QOL]GZ\^?8$5<ONG>R)"88^:AWA
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M9#R:<HRI"PJCR!G'/KVHIUU Z<ZQW^U-HV33,7=VFPWNPG]GUCNQILBK-Z'
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MM*[5;K:,6F,$C76A?FCO06*M>&NVF8I(IXXL71.^WP Q@8(IJMN-SCP23L*
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M]:3SZ_VQI^__ ,MV_J]KYOOC_B-SKDCT:;';CI'V<CR!!]V$^MYWY]Q/;/\
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M GV0307\:Y?HZ'S?^V__ #^;'XUGR6_YNTG\DP]O_P ]_5VI^+S\H7^;HO\
M*1_[.K7H75+I^_5:]W9O/&K%3ULR0D[E8;H#:N1$-&+-Y!T:0=R#QV+5%FW0
MC'2CE=95(B0 3U$3@&>G?)Y\J6S'RFQ:K+LV-1#-'?39<^<*K*IWKS;+H.$&
MSS;XQ5EW\EI;ZO(YY<%MG\G^T&P<FGQZ\*8=J;++ZWHEGT@;M0P-EXAW&;AS
M8CW>N>?3"F\?N_44KL0NI8[8E5>;*/7TK2E3$91 TZO7UFC&03DV[01 7"'L
M^3C9 Y$#*+),'[-ZJD1LY15/Z0N(7<HFW]7;/D+A$Z\OM7N4E0)I2NW-E7I9
MK).*Y,I.7S([&33;G,**@/HJ58 H'<@9_%2C$JHNXUZB@16/A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB@M(^WN7X\3GZC+('VGXE%.LE$PB^:JJ2"2BZZ
MB:***9U5EE3E32223*)U%%%#B!2)D( F.<P@4I0$PB  (X1436^J+IZMZL A
M7-NTJ36M=B>U.K))RI45+-/Q];>7%TQKQ71$!FBEJT>\GT7L:#I@ZBVYW;1T
MNGVB)%FZ[O[2]NI[B_U39-5LM-:T>$V2M88&2)+L"T6R'GDH&S$,P*NJK'2R
MU7L3=B9),ZJ[F&D&Q$A7;G3 BP+WJFZ=8^'@9U[N.B-XZT5>1NE=,I-H>=F:
MS$S\14Y&3CXH &5<%:6N?AJNHU(R%\-DD6T"1L:5.+0"+-4?J$TALN==5J@[
M1IULG&58B[FYCH68;NUB5:8C86983A#E$$5F)XJRUQ^X4144,P;3\*J_*V"5
M8^.13^:N%7KJ;%6:G8V/))3<-7& *N"&4=SEAE$(6&C4$DO$5.Y?R;A)HD4"
M=I#B<ZIDTDE3D(L@,Y"%76:FF(LKILHBBX;#(- 705<"J5!)9$5O$247,@L5
M$ARE,H**H$ PIGX(HY,;*U_ *5A.8N-=8GNDR>O50%)1J8)Z9292,@LQCC)*
M*%74091,BX<G 01;$:*@NHF8 *)%(59Z#0:^>6FHE%EP4?.*R+--KP=<&I!\
MP=8$N#N1!N4>_P"4N((ARH/;A%]7$O$M%4T'4I'-EUFRSU)%P];(JJLVX%%P
M[3345*<[9 #D%9<H"DD!BB<Y0,')%A(B]TV?DIN'A;-#2<E7#Q!)MJT?(K&8
M#/LFTA#"H<IO".629O&JS0Z*BA%0<)$ WB'*02+YL=@4J2L$]565FB5[!6)*
M/AIR,!T5-=A,2L4TG6,085>Q)>45AG\?)GCVRBSMNRD&#ARBBF]:BJ18C8^W
MM8ZA9PK_ &==Z]2&5AERP<,YL#XC)%])"W6>*(IG, @FBU9MUWC]\MX3&.:)
M'=/W+9 OB812.I6^M7J#;V2I2[6<A'+J38IOFGB%*5_"2;R%F&"Z*Z:3AJ^B
MY>/?1L@S<HHN6CUHNV72(JF8H$7\Z^_?^F_;?^<:Y?ZP2&?D)\KO^-#;W_2G
M6/\ ;)%^E'R:?XO]CO\ 1_3?]G8JCSSI=PF$3")A$PB81,(M_>EC7LUMOITZ
MP]5UX*Z6;V/1F]&C5K:#L:\S<VJN7:$+(R9&3*0=J)1I7HR"22#1115RV13
MR(&%=/[J_8;_ -Y?*!_TK9O_ *G6U\C_ +)W^^]C?^CZY_UFE+:A7I_ZB'.U
M-.[.1DM,14AI;5$E2X=,9G9E@C[)+62JUB$G6$O6G#6'@H9BPF(N1F(Z^0A"
M7B2BT(6IO4(^%5G"O_M7GX#Z^7U+Y766Z1NE2Y]/MGMTO;K15IQ@37]1U#14
MZRUEFSQ]3:7LW=NQH^T7?VD0B"5PD@W"2&D(^*,_C4%J\\FT99<UE-%PLHM[
M<(F$3")A$PB81,(F$3"+R\1ZI-KP\WOFDR3EO*62R[!L]'Z:%S1[1))&<8V]
M*DOHB0%%J1)TE4B3,%;UU'H.%%8E.0%RJ=-/M+[&[8S1)Z^S>HQ-=#4J:73U
M':YG%D+G5I:+M1BGB+I"6.O&O:H,;'N!LQAW0"03XF-M]=KV=J-.F>V:Y<U:
MYINQK^#&UHLQ:@W3I:\NZP->*+;-6^XRAY= )=]Q:,"3:VZH[:SJ=1G+6,I=
M;!/:8U'),H5-: @XV=OVQ]C35)CC'<I0A%84'+E-F$D^5=N8QJP1\1M$>:*8
M7&)JVQM&2]?K4N!IU6MM!K<4EAS;5F:MIFE:17U&4!CK!;8W&&0Q1AC)GRNP
M^?<(#,S1]MK\=*C:O<?4K5G9W0IHJP=5K0V=5U?6+&G0DO;6!K[[N&)I7/=#
M'$S+*^^,NMV]=2=RUT>JUJSZSA&>PK.%GD$8Q*\24C54Z[5PB2JRJ<_$T:0F
M#NY1U,-V#&+6JZ H+)KN7[M!H5%1?1:=LEI^JMNW*>KV)-+I^AQ.F=IL45TV
M[G'(A-:?48H R%D#Y9)FW'[[2UD;'2%P9O\ 5-LM1T<T:=[1:T>JW/3)1"W4
MYIJ(J4Q7S.+-?3)K!?.^PV*.%U)FXYKGRR-9NE\^L.]_9.@FN\&5,E7*KQC5
M7"5)EG(0,LD^LMEAZR>+=NW+-8C99@]E##XZC7P71&Y3E%%)<JI-75V;X^TS
M]G)-0@8(Y;K#J,+#9@,=2I/;$S(V/:Y[98X1Z@?O,+R#O.:6G;6]J!!LJS::
M+3YWF2*B]NG3O]&G;+<N5Z3H'R/C<&.BEG/KF,->& ^JUV\*FM/5Y)U&V2-1
MDM:>:E*8RJKC8K*(GY:6?L7=J0(_+'TI%A3%VUJ5AXE9"0?*RCRJD=F.9E'
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M-Z&_%)9U"C9KVH1 \3UM.MVF6(8JFHR32U'NKN#)'R5I8Y&-;-#AX:[FY?E
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M,Z0"2,B:3U9"QPX6/R8C#N(_B;K-ULMJVK:J[7AJ=:M"W3];MZ?5=7G,I='
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M_>JZ.HN9#M<F6*HJ4^LAU2]7U!^J0S[EY[K+W3".+FZW'+#8(C+#$!)'-(W
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M8KPP":T_T>&*9H>V* QLY;I!;ZJEP:JUZ%JMMU-58Q6RWN :U>VR2Y%7'MN
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M90ZBI^TA0[E%5%%53B914YU#&,.KMV[%^U/<MRNGLVI7S3S/QO22R.+G..
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M>N11O8/P@&K*4AN!@UJ&SY.X:NUUM'8457G](F8%ML1GJ1S&1MQ;U:4=-EU
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M367(1%4GGSU6+N/PB>O0H,U/:]@+:G:P@Z#>J-#;2I-GHT?LG5]NVI1=;O\
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MY"<=YBE[C 4O<8"\F'W%#D0Y,/ \ 'J/&$0QR$*)SF*0@!R)C& I0#Z1,(@
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MF)BT7-RAHVG*7"FQU>]LM"K,G+YZG)R/GY3NZ'E]'/L^..??[*^VCN7=FS=
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MZ]F2C*98\N8YRT>)>!)1[-S_  +A/O%'PU.](ZA#$4Q*0A0 "D*4 $3 !2@
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M;M9)FU9L4#),VC9!(BLO")A$PB81,(L! PIX8TV)W!5_:T\_F2 5,2> 1X5
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MT8,[-!6'-^>P3B2?KHJNE-/=J4H&100R F?496\>7'$AKQ1P1$/(:SU!8EL
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MIJ2^Q%-IVA&*/I.LS:-V>1M:N&N*ZD><O]ZL2+J*C5YZ*<.*A&U^(DY%W?\
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M81,(F$3")A$PB81,(F$3")A$PB81,(F$7' ?0'K[_3_CZ1_+A$[2\@/ <@'
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M]MZ!Z_A^G^O")VE^@/R!]''_ (>GX/3"(   <    >X  . ]>?=^'U_#A$
M#W  >G'H'S?1^#")P'(CP'(AP(\!R(?0(_.&$0"E#C@H!Q[N  ..??QQ[N<(
MG:7D1[2\CSR/ <CS[^?IY^?"+@"E*/)2E >..0  'CW\>@>[GUPBY   !
M 'GD  .!Y]_(?/S\_P!.$3@/H#\@?1Q_X>GX/3")P'(CP'(AP(\!R(?0(_.'
9WL(@  !P   ![@ . #^H,(N<(F$3"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g120909g02y59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g02y59.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1SL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '-"^<W8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!QVQ)P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  -Y   $U@         !                          $
M!-8   -Y                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   -Y     %)G:'1L;VYG   $U@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #>0    !29VAT
M;&]N9P  !-8    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     8X0DE-! P     $J,    !    H    ',   '@  #7H   $H<
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M6-#&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^K*X<))<OF['Q/%26A8@%R-W8<]AOMF*WJ#698YT3LR1SV+ (._%IK!G38[
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M/-9^C0:1C!EOKQ%RB^WUJ>'IK39.EM.E22_8X/U-?A((>5?*:1!(/)KU2?\
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M(3A*<8QC&.>:,S.S.[%F8EF9B69F8[EF)W)))))))).YSJ@ H"J     /
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M-.464M3!I":B91*\Q8(AZO /99LB[6U&0V)0=^36'0;_ /[._P!?K[ ?P_\
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MY( !0%4 *H   V  &P 'T '@#.G1$B1(XU5(XU5$1 %1$0!555&P554 *
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M9A%7KS.9VFE8+&I[#!.?-E(7B>;U/JK3JU6=J,\=RVB;Q)$LDD08D#G+(B\
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ML2V&1 =^"&5F*KOY(78$DD[D[Y;7J5:BLE6O#75CR988DB#-]V"* 2!X&^Y
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MSQP78X)917L!20T;-^TK<20-\V3S<R:R+V^^Q"M='Q6LM:P7Z2-_71E7X0H
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MGRSCC&.,8XQCC&.,8XQCC&89>:B;<HEF,C[Q=-?D,FH+Q-T8BOCRSC>!R1G
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MF,\(6N2L[&1 L#!5<B8EMHR$=7(<J>+*WLP)H(96,:B*0M,-XE",3*.3)O&
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M%-:Q.=;70MTU&@Q,0._8&*W:)R_GGU\I3[P(>:]@T-Z-7%65YIA@>.A$FN2
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MLZ5/>EGFCBJP:MJ]VQ/$E4*8[+O1G"Q3]R/L/8FYI.R0]G]'Z+9(B0(,.U%
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MB[1ZRJ,W=H"S!WV".I%1MUY<<E*#900[56J')Q,-;9"C%DA--6E,/*3T&*K
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M[1B( N2&==B2 -]V<DD[C,79KR.9-T=5C[?#Y&C0 \CL -E/C8^=MA[#SF\
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MOL  /ML,]YK6FN;&/<A+#0*3/"[%CPHG8(TS58*38O47&BNA1T;<630'V[.
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7CC&.,8XQCC&.,8XQCC&.,8XQCC&?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g120909g03t25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g03t25.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %>Z^5A0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&CP.6         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             "EP
M!.H    & &< ,  S '0 ,@ U     0                         !
M          3J   "EP                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "EP    !29VAT;&]N9P  !.H    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   I<
M    4F=H=&QO;F<   3J     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      OA     0   )\   !4   !X
MG8    O% !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M%YMNQ<\V6%TV4C-])C=OM>6_SGI^[P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:CVM>C2#>CQO1'(J(\;VM>QR?68]J.:J*B+I2O-(KJ^8WHEP(4IOF0S.F1%
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M-8XY&M*EQ#LS2N)O&+X4P.RX<K=G$8RX1+EPLB67"M8PQ38^X<+;.TC51#U
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M);:*"0!EN+RSB*G._P#Q$<I^2QL>6V#TS4_AQ9+AYE)4P6UU+J!P0? D1?\
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M%'U];8UW*\4):/ =FCC1F&41I76,.XR"54MG (R0%R,UWMXUEE"OG2%D=@I
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MX_\ W5UKX^O!&G'^RP\/_K[?]]3#_OX_YVY]_?\ 7KG-P?BMO&TMQP^[@B7
M:2:%XHP6V +R!4!)V&3N=JZ17EK/((H+B&:1LZ8X9%E<XYX1"S' W. <#)-%
M\?/@D5%X\6'A_P#;C_?4P_W5/^E=0?#;O'Y?KH=_=[?UBIGA3?P)_P#(F_\
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M ,E<?Y;4\6/]\?C]'RYT^G?X+O3_ &4^PWK[<[G8FG__ $]9_1/$_P# W/\
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M]QN'F<G+,+J\2!+B6! W^0Y#88FKHEQ2MSEU2=(LUW'$ZP@ZYY QBB74S-I
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M9[*VI5SV_P  F+70^U*8Y.5A3FH'CNI[->J-57<JWAW4U?UH29Y$5P[E657
MU-MK&H,,''+&_GUK\XV70S*0 5)7/0XV()Z[@^>!FOOP.A[9>JDKV :_F0%*
M^)YFKD>J]X*H%5=&<J]7IU-1OJU.A7-3;Q).>M_YB,X[X._SS6IQVV'/!.5)
MZCR]P[^ZN:T53W$_N-3/E*/^]_#X:1;:*C?RV<AX9*8Q>I43V7_&&O+0D?;V
MWVW'M$X//;RST^._7./+)(Y]&'/IL#V/ETVK@E'0J,:I5UK([7JV-*=71%-
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M55]5X1S4:O*<C54;MXDF=G;/DQW[;<MM^?+'0BL;;@#;SYJ3Y$[YVQC\:Y_
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MCJOHH6RQ.1GU6%:JJY8UQZ*7<Y$O_:?C;2KN(YVM);)G!W+VD=M"&4\M(D!
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MVR.7ZR3(#_C'H1$^LHT5JJOHO21K5<_1M]D?\)<;\CX+_(C'?GS'OH;B'?\
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MEJ*BJ*2$;G-5",ZQN:]?3<-XM8\5B:2SE+-&=,T$J-#=6[]8[BWD"RPN.SJ
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M4O#'_)[V7_JTP_\ LC3UNZ_Q$W^8_P"=/#C_ '$_E7\J?12\,2_\7K9;[_\
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M;N3DD I&V"*J)U8;C!EBGLQO8[K!?79H%1QT2(<.[C.Y6XT';./,9W SN?\
M;/.H.H8SD??\CML?KG52^$[;G%:[!;F[FUQ+_*5W@\2(IF97RBLKG^">(7=$
M".AG(-(]6DCL(8\2DC5T)YWO*L9'/>JR;PXF4Y&UO9X'7_ND//IR)WZ^^N,/
MV",8&N4YY8_6-OGJ<UM<26.)%278SX4:*"(I#>;,R/&2*C$ZCR9)7-$)41B.
M5[W(C$:JJONNHQQT!^US[<]@/KIGI77MOL1LO<>_<\B*KV#FN 7DOX569=1R
M)SA3))(]99Q)$Z;%&]C21HK6$5T\(T5ABECH9@6>KU:URKK+ DCEVY^_)QT
MW'PK"CESR,G&,;=.N,G&??G.XS4[E'28 $,"EC2)2A(@N6*M?' ]7>9>@T3H
M>5J)TL<[ZSG-;PWA5US.VY. .9.V_;XG8=_GC.">73EG/F.O/8[XZ D'E6%/
M$ASH<NF- FEJ2QRA-%> O=NN\-X2(<KFHP<?MN5%8[A.%1%3TZ=9'0C;EO\
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MO//D/ET//MC)'3K@?+[NN/OQ6(N[K.\3KK%<[!C&?X"R3Y+);"GHYT*[KHA
MM<>9)Q69/R")D-7$:O7;A@RXLL41DB1%@3NVZ,N0=P=L@$8Y#W_')Z;=<#>F
M.FXW!ZC)WP/(# Q\,=*]M2'+-OP +@08FX&V]BP%C18RRU&"[I*^<Q#H+"[V
M8]U7<X^C7-+5T-N>N)7!,D>!=O@,AP(^,9!(.<<^0[>?O.>OOH#T((/S[#F-
MN9Z?=7KQ//<=N]R;"3%+)C%O<>J:(U;<1#U5W09#CDF\L7T=K62V#/%+:5EP
M2QJB-0L.T#561X,F2(*.U2MBUXR6F&E+^TBA@E.,>-;/*[P:L[-)'()%!(U:
M'QNN]J%,_"L1DE[*ZDEEB SB&Y2*-9^>ZI)$(W./9\1-_:JV<EQJMRBO6%/:
M\9@$;*K;*,[M6-/8B15C6-;):G7'E@<OHK>6%&XD<["QRE$^9=V<-Y$4D!UH
MVN&53B6"4#V9(G&ZLI.<9TD95O9)%1+:YDM9/$3#*PTRQ-O'-&?M1R+R96'Q
M4X92& (\&$W%A:TY07/9^/45C-H+M8[>V$TZN(U!SQ"]>R&W@%A6X0<N[ I[
M J]ZL5RZ<-N)9[<K<8]9MI9+:XQ@!I(B,2 =!+&4E ." ^.E=;^".&<-!J%M
M<1)<VX;=ECE!S&Q_::&0/"S?M%"P !J8:GU"II2FE**J)ZJO"?>NE*XN>UC%
M>Y41C45RN541$:B<JJJOHB(GJJ\\<>NF#G &^<8Z_P"_E6"1@G(Q@[D[;=SV
M'6J,#NGE>8=!]K<)C7- ^2^.W,\JOA4%%)&-KW.FUE=#C6F13X3^EJQI1ZZN
MCS0D'+A&D1"C.^Y/#;:U!'$KMH9_##K:6\!GFR2,(\K,D$;8)U /(5(*L P(
M%$.*WEZ-7"K))K?Q"GKEU.(86"DAGCB17G=,@Z3I0-@%25()S6%YU:YI R^C
MFQ:RFS+&T'&*^HLGV]#+#<03GH,@J)Q8T.42#(*&7&/&F1(\N)85<^.]A0-C
MRI'*\LH[.2UF4R26EQ[:B:/PIAX;J)HI$#,NI<@JRLRNCHP(.0.UE?37L5[;
MR)'!?6PT-X4GBPGQXF:WGC<A#I8A@58*RO&P(Q@G\W\\QJJ!@VQL"PQ3&URZ
MK\5&RE5N._)DC&R"=DK[:224"WD&"^0M=9_C+9MH4TB+;Q9(9<<CQ.5H_4\0
MO&>[=HKNY]5DM9'L!:!E@AA**"8E0Z?$3:$IA3&P8-@C)HN"VL M'26TMA>1
M,8^(^M!3.TW[9D9@6\.4YD$A9ED0@AFP -Y]B8W1:;B7].*/%P2X/2&IFUD)
M:W&IEY#';-R:XQB%T":^FD )20OBX #BW<RNE3XJR1_PV51\;D1TX? P8WL*
M2K,7D\2?PV:/P([A]_UBGQ&"9)B1U1M)]E;#@2A9>)W$6F/A\K0M J1F.W,D
M:2"YFMEP!X+^P-2J%E9&D7(.3]J]W]PK\0;['\%QFRQ>9&CVL,$G,BU&2)06
M/):2TFMG4:8_%E7D-138=.^W[X '&V9*"9"#9K)PJRAUQ3WL\=PC-&2ML)8&
MFC)$J1Z)#*R0G9I2@4X;2IVK,?%>)S 3P6%M);/AD1KSPK@1/DPR/KC\$-,N
M"L7B:ERH8C.UPX=FL', V3&5]I1W-'+' O\ 'KL @6E1,-''+ A%CFDPID27
M&*P\*QKI<N!+&KNS(4@C#'5W5H]JT9+QS0S)XD$\+%HY5#%6QD*R.C##QNJN
MIQE0"I-O9WJ7BR#PY()H'$<]O, LD3D:@#@E71E]I)$)1UW!R"!,M1*FTTI3
M2E-*4TI32E-*4TI32E-*5YY,R)"&I9DJ/$$B<J2288!HGZ7E<UO^?2E1I^=X
M@U5:R_@R7(JHK8+B6"\IQZ<01R/7U]OU_<O"GU]?*N*YUCGV&LW)][<>R!S?
MU]3:M6JGZ45=9((Y_7U]<Q3.?Q^=/EYBB+P6U\K]O,Z%8P6_SNF1 M;[?QE3
M[_;3!^MQ\^5*S5?>TMJG-9;5T_[52)-CG<GZVC(YR?I1414^W6*5E=*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI4,N^+?
M(*;'^GKBPT;D5LGKTJR*51U$5_IPJ'L&OE]*^Z5JHOH[51=_\7?VMC@F*("^
MN=_9(C8K;1D;9URYD8;[1+GG5C;?\/:7-WG$C_\ !P#KF1<W#C_HB(3WRYZ5
M,]6]5U0QEI!H[R];;R10&V)H4V#+EJ@8TF..OC0WQQ2'J@E/&/&,\@%<A.@X
MR,8Y'JJ5PFBMKFY$["/Q6CDC=]D=5C5"H;<:E8$Z3@X88YU,,4D\%OX*F3PP
MZ2(F6=29'?45YA6#+AMU]D@G(KZ8[\K**+#85F.B*,\^>0;@I;J C2"KH#"H
MTA81",1T^8K&@,!OE8SC(<Q "YOF5$#"U#!Y)&!4S%""(XU8 F/4,R.1AL:4
MSG- HM S.5-RP*QQ@Y\$,I#2.0<"0#(1 21DLP!49C.2K\M,OK\'$[JHL?2#
MDV<<)RR83NN+B^+E7CH<.;+CDN[0*+SY&LB1#L6-<+U47$@>-\8@X(ASP_AQ
MAXAQKEHFD+%^'\-(Q@AW4WDZ]8XHE?*R8-C9C]'</EXDPQ=79DLN&YYQKC%[
M>@<P41A;0,1CQ)974ZH:MA$X3A/9/1->NP!R&.GP'(514TI32G.M=]PL6H\O
MW9P>A/7(48J"\R[,6".:/&OZBAEUL'%<=R*,)[(UI6&R.S?= #/89C28Z6.U
M%BRIH30?T;9CB XHL6B]$)MWF1F7Q82=069 0DWAD9B9P6C)PC*#BI0O;@6I
MLC)JMC*)5C=0WARXTEXF(+1%U]EPA < :@2%(M9+NIBM-W71GR0=]#1@L(11
ME8U5&-@@M,UKGM1R$(QJJUK.'(O"<V1![G&1N3N?P.W0>_%0QG;8<COR'88W
M//OC<8[5JCX(7[Y!V@LXGB'P7%=J=PEWHWPO(N)XQF ,RK9.'YINADV<T5D:
MRC#[(9<H.32 MA.>IT@QH4R6"!)F$KXDWB'JWCYM9&GB]7MU+M&8V62.!(V7
M2=\#0"3RR2 2 ">$ E\/#J$;7(2 =0TM(6!SG&Q)&,[@''82"[F"SZZN+&T+
M(DXE2V%K78S1LC$)!9-I)A(YLEE.5S8TJ<29#DEK1RD)&A5#(CX8TFSICWPU
M&<$\]N_3!!)[^_F,>8J0 !R_V]WQ^MA7@OJVML+/&:2)'&2X^.8[;QB1TZW5
M4&EMZZQN\A8)J_W*A/@1I-3&:CF-L;*>"M(-627JPQYXZ?$\L_ # ^/;G3&
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M*U)*#0R"=RUSQJY6]8^I$0B-<G#^A7*SEO6B(]O.GB1Z_"U /@-I.02#U7.
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MB_ER'H[J5>6^O.A(.P&W0<LD]?=]_+&-ZP?ACJ#Y].V3VS@9SOD&O0?RC'Q
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MA6W\?U@R!H269(HHU=2P,DDLB1J"0,MDX"DU/,>L:>SR6/3PYZ3)4ZO!E4-
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M>U*K.NS/)%&_(M7K.)>DL?$;&ZMGM)%N)[B,PS&4.L5HKBX:!E9?:=;D,\3
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M [<,%720WXVV#;G G\%&(F#G.,<LD=,; D<]N8) ['&*8V)\P/Q^OK:H</\
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M88522I]E96$@DJ=.FR2Q'%D2I<DI#G,1SGD*]SW*KG*NNBW$Z@!9I% &  [
M#W;BM=*]OO/YUC?H7>$K^3EL[^PE!Q_1Y/6?6KC^/+_.WYTT+V^\_G7DG^"K
MPK%@S1UWAZV8B6!8DD<&4?;ZBD C3'A>V,<\=L<+CB"96$*%"B4K&N8A&*[J
M3(NKC(S-*0"#C6V^#[Z:1TV/?)_.J/\ !1^"^\+'@==(RC;G$!WV\5VR<_+=
MX\C:TV4V\FW*:1; J(8593XG1R#R#,!24,2,$<7M DGF.'W5E7_%KWB(59Y,
M11A1'"H 1 HP!U).-M1).^:YQ6\4)8HN&?=F.['?.YK>:;ZYWCR?XN,94O\
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M%D3Y)IB0($4"//+D2 1A#*_M,23%'<7\ZQAGEE8@9<EM*;EW9B<*B*I9B<*
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MV U-10T..9*N06L-C"^7E#;BE]4M5QI#;%TVV-(MH9)/FWL>1@#M"?\ CR_
M>E)XIZ3<3X1?7LRW1M.(O<W;7)"YMY+2ZMV2-0A 'Z\ *0%T9'O]WZ-6W"_1
MKAW$;"QMS:QW%DL%ND +'Q1<VTQDD8N#DB)B64M[> 1VDVS6(Y)29S8AL01'
M8_BV,ICF,V$8PW2)]46WG64**Z+RZ5$)05TR%2]<A>)K8HY+51[BJ[R/H]P;
MB?#>+7ANE7U&SLAPSADXD#O<68O);N%9$V:,VL<JV^&!#Z PP *]/QKB=C?<
M/@-NS>MW5UZ]?Q%"J0W/JR6\K*^=+BY=&G  !0NP.2#6S3V%%%?VXW;7K0C>
M"JX[5ZO0AT5OUT7E5>WU3A>%14Y5/<C!.YSMC<;>X;C'D<"O)'."<8SDY!(/
M4[X!_'Y=.[MG<I M(7CA'2)/'*N<YO':C-]$:G''4YO/LGNJZQML<#R7^I^/
M3;Y4P=_AOL/@!OMCEYYR:^DCIVPL8-_; 54"R,3\IK>$[A7*B-:]JHKD3E5Z
ME5%Y555&3DDG<C<D9_/F/N^%9._(<CT.,]\^8/<YV^>*FA>1&/@LE,6.=#.<
M@T1[7-:1IE5Q.M"&>TST8[I5&>G"+Z*F< C<@'/3!Z#MR ^6?OP2<[9QCXY&
M>0R!G;)';ISK&V<M8X8+#22GEH8,Z*<PFC2()ZL9_#T:BM5&<N1[U1.E&JOI
MQZZX.<=<]*SVWZ]_+8;G.3S&_EN.=896X.4[CX9B7<&N-8QYO<3**YL=XEGV
MU9*;4X1!&U7)W(D_()<W(HQ6.5OF\)8CD5A%<W/V1GKM@]-]^W/'GU\J;8/?
MS.=AGD<[<\9VYY('*KDC/+T6*VD,42.U L555'QGQ6<H@4:UZHIQM7MH]K4<
MJJQ.$5K4UK0>[',D<]_+'/ET^(R=N,B.C(48E:*2%W*F!%B.03U[XD[9IJ$5
M5<C.GAZ+RB]73SQSPI\N>>_N/P \@>]<GB+-B$CF;\((0A"E&+M/D30C"SOD
M&T:IT];U:CNGJ5S6HU5]=*;#MGGU)^'4Y ._QP<UK#8,%7Y?F\=S!7%G82*V
MUH'28G?<ZOG4E?7)([:O5WXJQJ+"OG&X:Z,T49Y')W1-)V4@\ARY^7/<;9R>
MOQ^.=A\N?3F=M]ASV&?D,5.MJH3+*7DN3L,V1$DEI,2IS<H5)OR;-:2+N6R0
MQ$67$';W$NC9)X_&KCSB,>03QD?CKD;C2<L.?SY9&!CM6I.<=\C&<'F2!D<\
M=^Q(ZU>I(ZD,5R1&%YZ45\E[D151%] M1J](V^WJB<^^M =N9'D!^.XK(ZXQ
M[R.?NWY#IS\N58?.,K'AF/FN/(&M9A)M945-5'*&.6SNKNPC553!\U(5L>((
M\V6%)$LZ]J+'0IWHY!]+I%G:F[G$6L1($DEEE(+".&%&DD?2OM,0JD*@W9BJ
M\C46^NQ96[3:#*Y>.*&(,JF6:9UCB34V%4%F&ICLJ@G!QBJ;%OI<8_.DQ,^P
MM1"8\H6S< E667^3F@Y0D"UJI-/2W(T>O"1[:!!L*E_UEFR*YK6.)<C@*W*(
M]C=*2P#!+WP[;6A.SQ2+))&Q ]IHV99 -T#CE3?IV>U9EXA9-IR5#V'B795\
MXT31F..1<G82*K1GJ5KSY!O%FOPT]S#Q_'=O<7&D=R9)N/<PI-C*CGX<254X
MK1V; 36QQ.0A R\G@RFJCQOA]UCQ(M^#6ID$+3W%]<DN#!90ND4;+LJ374L8
MT!S]EDB88YD @UI<\9O1$9E@MN&V_LE9^(S(TKJP^W%:0R MHR"5>93O@KL:
M@V"Y_3Q9^25$++;6ROLPNSY==9=+QHM31.BAAU.-^<P6*"M"*5'-&JZH$M1R
MK,D2=+:6=-(64Q[I]WPV1XK>=K:!8;6(6L5G'=>+,'+23:;UV<LA#.[(,("J
MZ$7 J'PWB$"S7%NMU-/<7,IO);F2V,,)4".#-DH1 5(2,.5+^T=3.223LM!(
MP<UQRFCJ%V6(1IV(HF]J3AZLC.DJ1&],HKC"857]"O.5&M1%<UFO(28U# *G
M&""?VM\Z?^7L/*O9+R^@>0._GW_.I[K2MJANX>WN&;KX1D^W&X>/5^585F51
M+H\CQ^T&I(=E6S&=!1/Z',*$PW(P\67'(*5#E"#+B&#)"(K.D,TEO*DT+F.6
M-@R.NQ5AU'X$<B,@[5JZ+(I1U#*PP0>1%:%;18EO/X2=^=OMA1[@WN]7ACW4
MI<S7 C[B60+#='8B]PJOBVT7%B905S+'<# +NM.:#3EMA'O<<DP8\<TX\%RO
M+RXOZ2\"6[X9P^\;U/T@XQ)<BQ@@A=H.()9P^/=R.$REK)$A5\G"3%BH 85*
ML."<2EL^(W]NOC<,X4MN;R6211);F\F:*W5=1U2AW#+A02@ /*OTGUFH]-*5
MB;(@TD5 E>WNOL4<P?4G<<UD.9UO:SGJ5K.4ZW<=+>4Y5%5-,X^\?,&L'?Y@
M_(CZ^C6N%T<-)C.47V3S#4](&ZKCQ)QJDUE(G=EY(XZ]\" T\V96E...*  3
M%=+F=I@@E.91Z]-9_K9;2"U19IC;3"15F6)(P0&:02.5190N?$8D87.6 !S0
MWLJ6\5U<W4IAA$R$2>&9'8DE0FA,NZY(" !BQ(&"2!4)VUSV\QL,W#L NL6W
M#K<>5\@.-Y$&;@>X)B6,Z1.M4"BQI )A63992(VTQZD,1"N*>5T,>5)W$>&Q
M7'AWM[%<6#W)P]Q;LE[8KH15CUD/J34J@>Q*X4#"J20*I.'<0GM ]G87%KQ&
M&#48[2Y1^'WYU2,\F@LNE]+,3^LB1B,$ML35PEWR*)'5?S9Y\?,'"*2+C<.+
M4SHDM (O?*/+(-I)QD<8"HWO]^Q'/:CD0=<0JH%:A>!Y/BGB-DEF&"O=2-+&
MR:AE0UJ\:W&IADK[&@X/M@8)NFXZP/@_HN_:\(.BW18WC<@#)%TLAMPJY]HE
MPP_<)KCA&\=Q;Y5"P[-<2C8M;W(;(E,ZLNCWD1TJI%YJ;3V;Y-/2F@VB0.NP
MC(,,J')C1I:>9#("@"+[@T4%JUY9W9NH86B64O$L+!9CI22("64O&SC0Q.EE
M)&Q4AJ6/&9Y;N.RO[-;2:=)6@,4QN$9X0&EAD;PT\.18R'&-2N V&R,&_-45
M>@II2FE*:4KX[V7]2_Z-*5IW2(&50UK'-#(CFK8X",>C""*WL-$4;V.Y81BK
MUC(-R.1>%8YJ>J)TZGD0>6<8V^(R!GEOR '+(5J GX.GP:L7)FLV7KQ0LJJK
MNCF5 ,FS<%#45&32!R<EKL-H19*RHP.+D3Q("\%AL*C;9P32JR5UUTN7%,P.
M>"1Y \^P[=!OG<X&,'"IAD?@E\*F33?/S-C\)J9#Z!F,26XA"/@T:QHQ9)CV
M8 @6T+#)-##N&Q<DQ:AM81;0,N3#/!Z(QA!D21&U(WY8)_T) 'GL<'J.]*L^
MFV.VGQ[='--Z*7"*>MW,W$IJ.@S?*HS)#9&25N-.(M*VSA*=U8:9!:3LMLVP
MVV1HPX\:1+*".!@V<'.P/(D 8QVP <X/(YZ[TJ X+X/_  [;<;GDWBQ';P<#
M<!39%(K[>9D66WD+&Y&7F(?*C8AC]Y>V6/8@7(B%+\5)C555OE",:.Y?+F()
MV1C(.,9\LC.<[=B1R[#WY&<G&.E9VF\,>Q=!4;9T%9@,$%/L[DN89=MU7DL;
MN7'Q[(=P&92S,)J-EV9_B3;MN:90R1$M_B$(3+0K8T<*"C(%L,Y VQY[D;C.
M3C?.=C[\XK%>'9GPH^'_ ,/EQD%_M%MS78E<Y)#!4S9[;&^N#0Z"+,D647%\
M?^/VMHF+XI&L94B;'QC'65=$.4_O,@(\8E$P "  "<8.#TWP,G(Z@;;_ (*W
MIVH>PF+G<-[7M^/WS>IJ]2=3+ C'IRGVM>US7?<Y%1?76&YGX?@/C\]^]*LO
M6M*:4II2FE*P5S01;E\20Z3/KYT#OMB6-7)2+,"*4@VRH_4\9@ECR$$%2A.
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MIX!([U5)\6!!-8VH2*J,B7%(4:])UUL0!]K)SG!&-QY_CYYWK(^/Q_V!^?P
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M 3'/>7!4221.0/%"0 JSKE0TNE3D'&W6O)UZRFE*:4II2OCO9?U+_HTI6O\
M$QW$8V"8O>VEY%Q I:"H4\Z1*B1J^4=T$/#I$68\82'=Z=18SP22>B/*_A$3
MK%'-,Y2*)Y6.3I16;&_/ Y8[] #VKC-<P6Z:YYHX4SIU2.J@GL,G<^7/X8J/
M4L$63">?$,AQ;+!,1KB#A6)(%@%KPQY(_,ULH1RQG/CRX9T;(,'D,N*7A1R
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M\1XH!G5)/,3JAAD?4=B9)$( \-<"LYD>-P]H\DQ)< BQAUF:WL;'4V\CLX!
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M5?S!C$QK!L8-C4X:QC6L8U/N:UJ(B)^I$U0$DDDDDDY))R>6-SO^/.O0A0H
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M=,]Q5JX,@K&)8V$LLN[N%$+XA/?&CPX44>9Q@C<D8QL#L<^[<8^_)SC/+IR
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MJL#6-S.CF7-;%D5#PBR"@L8][CY9+G,C+811F 2%+>-KR#A6M?)FU4LK&$>
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M2/&;W)DPX(@#E'S=T1#)*RJH(742%!+$*H.<8)8@#J<\N591'D?1&K,VEF(
MU;*-3$==@"6/O/.O?M=CEKC&'18-ZL5MW86N2Y-;QH+^Y!K[++LCM<GF5<(O
M2SO1JP]L^".3VQ^;\NLKMC4W0@D$DCE]"E6%K%*:4II2FE*:4IQ]OW:4KJ.
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M,XZ#.=N^^U6?(8]',3ROF6D43G&ZU&A'L9Z.,QK%1K4X5>')T_?RJ(FN8/\
MS8YX&,\^W;ZWK!Y[#;(R<\\;8.=\#KSS\20.A"(=S9"MBN1!O51K^+15:BH!
MS6_C&NXZ57V3E5]>-!@8R-QYC!]_;';YUDYR>W+<$_=U!SCITY]>OI*"8]H8
M[>T8*(Y1$Z&M1CN.\KG-Z6$:B^W'VHOJO*KG((W.X.1D9^'7K[]ARK!R#@#I
MC&?/GW^)QOG?O5.7X#;R[QN7X;.KAV[ZZ/4RJZ](9M9? A2)LF&X5C&%)DU$
MX3["> I_AUB&1',Q$"(H6'7.H@[_ !&,:1^';G[MJR,8QN!R&^YWW.WGY?=R
MK1V';J2(YX4S&\>:<T;NS+ ^8/+"=,"1J ,/RV.OFDE1N6!.110W31(]CB#<
MY'MR&R#@<SC?[CR(Z9/08K!V).H[9VP-ASQSWSD8W'3MM<F!X*?$85E,NK -
MA>7)(\JUDP(SH46**!'2/6P*6*I9)X]= &\R(R5*DGD2Y<Z=(-URNV/4D$C'
MW_@<GX^_SY9)YYV ['?'0_/I]^.<WA%5'G",R-<_J4 3HWJ>Y[6N85YFHO+N
M/K='"N3\G[-98<B1VR1TYC !Y>1Y?.L#'3&/=G<XQD]QRQG/G5(X1/!CFX6Y
M&,7Y6P<OR;.293BJ32$C1\FQ^3A&'4ZRZXYD&"S^$GI3UT^MC$+8PR0A23Q0
MPYD20?4X(!&P&V_?<^_?/P[\ZV.<;<^GOY9Y=.>W/W<[DCLED\R.4(DI(DHH
M&&"B@,Y'(CU5C$3I4*]?'"<]+5]%5-%VZX)WW&QQRWZ=?ETK4]\GGC /+.Q\
MSW'7R[8?*<ZQW#!1(UE+>"TL&I'JJ:!'E6]U9E:JO(*FI*X,FRLCA&3N2RQH
MKP11\EEF$)O5K.,G).1N>Q./+.PSL/P'1OC &#MTV/Q'W^><=ZC(]P,M.Q0T
M&S6>G545P)603L0QR"=Y..2S/,9#-M0,Y7J5/A)9#&^GEU<G3K!WYGOL!R Y
M8Z??Y]ZV P.6<\\=^IW(J)5\3(:K<.MRC>9M8=+!HH>!&JI1Y&(;>VTMCXQJ
M<K9@(CI&1W;2**+FDF+%\XPA<?A1:EI4';^>N^,R<.XG%;7\21<+O/"CL^)*
MY"1WIR#:7H.T7CG_ +M*6\-R#&VERH-K!P]+RR>:TD=[ZV\22YLF&6>UV/K%
ML1O((<?\1%@NBD2KJ0-HV5147V7]/^O_ +/?5]D=QV^//:JNOO*+[:S2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4K$7E2.ZKBPW$< R*R1"EL1.["GQWH6',%S_ ,( S&NXYZ2,ZQ/1
MPR/:L2]MENX&B+%'!$D,H^U#-&=4<@/32PW[C(ZU(MIVMIED #+ADDC/V9(G
M&F2-O)E)'D<$8(!KHQ^V):1'LFB;&MZ\JPK:&BKP&6-J+W1<^KHDL;F2HA/9
MX"M1>"->UO.PNVN8BLR^'<P.T-Q'^[(G[2\_U<BX>-LG*G&20:VNH!"X,;:X
M)5\2"3]Y#^R>7MQG*./WAD;$$Y[4^HM-*45$5%1?5%3A4^]%T(!!!&0=B#R(
M[&E4W;8GD^'NDV6VMH&-6FE/F66&V]>6YI6=]ZOFS,;#'G5L^H.\CW23UD:8
M2KD$4Q(M>&88CI'C+S@_%.$%[GT9NTAMWE:6YX1>0O=62AR6EEL%22*:U<L2
M[01R> QR5C#'?T5O?V'$ (.-6[R3+&L<'$K:<6]R=  CCO"\<L5P@4!%F:-9
ME&D/*R#V8AFC=Q\CJL<KDSNJJH68Y%5T/7A%3,@6!*\K95G><WEI96$FO,RC
MJK484@0H4\,]0\RQ=MXW4G'8O2/B-KPVU;CMM:V_%^)6MBPX+:R03R6Q$D]X
MKW=S-/)#_P +!,@\%4D5V U@@@V'"I.#65Q=S_HJ:ZEX=97%T%XI<++ )P%@
MM3ZO;11),HN9X'_7/)$Z YC93FM@:FIKJ2NA555#!7U]> <:'#BC:($< DZ6
M#8QJ)Z<<JY5Y5[E<]RN<Y7+]%M+6WLK:&UM8D@MX$6.**-0JJJ\MAU.,DDY9
MB6;VC7DIYYKF:2XGD:6:5R\DCG+,QYDD_(#D  !@ 5DM2:Y5HUX3\IE5FT]A
M14E0_(,CL?$!XOYH8"RQU\*%71O%5NV UG;6)6&\I#22<,8+(\:;.E&<Y(L,
MH@2S1^?&;QX;N*UMH/6+N6TMY%B+B...);>%3-,^Y2/60HTJS,QPHR#B186B
MRPRW$\XMK6*8QM)H,KR2N798HH@5UN45F)9D1 !J<%E#7!GF*99EH8,RYPR!
M'N*9[S4648!E[/EGCYB(BD\B/(\>J:BWKY"C&EC06\H]-;,8P<V!(5@E96BZ
MXQ$0TG#[:5/VEMKS5*.Y5)XH5?2,G D5CR'G*%OPN3*I?3Q./LFYM=,1][P3
M3.F>6?#;&3D]#@L.;NK:',ZML-NIQZLYH<ZRMA9;66L"<J]UK;;;U1=5=*09
MG'[(,P\C/0WG(9O*/C],^UOK>\1C$7#(?#FC=6CFAD49*21N 5.#D;893J4L
M#FHMS:2VK()@"DB^)%*C*\4R9(5XY%.E@&P" =2L-+@-D5);LVZV 54S*[N]
MQK-L<K5^(9714N'6>/W$>B9]:VM:&83+,B6;(IHG=LGT\B&\]K&BFC0I09SP
M,-)+9(.,8QCR \MM_N\NM1@H'QY^?O\ GGO\-JM^'*2:$<ZMD,E0)]>"14G"
M1I(A %$T@2,>BJU_6-4>)[.MKQN1W4K?5&V!D;Y);;?Z/+W_ 'XWR<9\@3L<
M<\?=CSWW%07<;([?$L;CS*&I'>V4N\IZ]*R3.<$DLLTST.%3,:1@BF&+L0U(
MHXZ3#!=*(P R<^<]*.,7W!K""ZX=9)?W,U_:VB6[ET5HY2QD*LH;$FA&6+5A
M?$90QP35OP2PM>(WDD%Y</:0);3SM+&%=E=%&C*D@% 3J<+F1D4Z 7(!X[?Y
ML//:%F2B[-?'?8W=5'8C9#B.A5MK*AQIK1%C1WQS2 !8XX',_@AE)'<\CQJ]
M>OHUQO\ [0\,/$1;M C7=W#&K:PS1V\S11NX=496=0&9<>RV5!(&:UXWPP\'
MOO4FD\1U@MI&.%]EIH4D= 4+JVDL55L^TH#  '>P'KV"@BB($45X%(U3,0C2
MO5W\9RJB]7"M>U45$5?3A?9+_GDX.K/3; Q[C[OK>JP/+',$[YSS)_W_ *8Y
M#,=%>Q&D(T#^VI$:PD@JJY'OZFN<B,"1%5&(WE4^JJ+]7A<$+[L[XWP <CG@
MG(//Y5@9[?9.//&WSSR&XSD' QM7^4YWB^,R$J 29%WE\LC9=5A>.QVVN2G+
MT_4:6($B!J82O<C26MY)K*>*BHZ5/&WEVLAL\Q^R03U/NR>?*LXQG!///+X$
M8YD8Y?#'>JNS:ADYM!'!WLRC%\)HK$PY;,%QQ(EGE!WBZ>TTN96<4\^+)$UO
M*&P>CIK&!(5RP<F*C6G="N.(65HP2>XBC9B0B%LNV>T:9<GI]G!Y8VJ5!9W=
MR&,$$LJKDNZK["8Q]IR0B^XL??U.;H<2H[)ZUNWF]^XU0V$UI249+RIRZ3&#
M^0TS/G-Q_*,ECBXX8Q_GUB-=PUHU]M8M^(6ER[1P3QR.@!9/LR!2/9;0ZABN
M=LX\LUM/8W=LH>>!XXV)59, H7YE0Z$KJP0<9SOGE5J8EMWCN('EV49)]SDE
MDU&VN79)-)<Y-9,1RO;')92$1(5:,CGDC4E0&NHX3R$="K8ZD?U3,_T^[Z^\
MU%J=:Q2L;<4];?U<ZFMX89];91BQ)D20Q'B, K5:YJHOJCD]',>U4>-[6O8Y
MKVM5(E]96W$;2XLKN)9K>YB:*6-P"&5ACJ"593[2,,,C ,I# $=[:XFM)XKF
MWD:*>!UDCD4X964Y!\QT(.Q!((()J@=NZS<.JQJ;$!N''GAQ>YR''9;,]J2W
MIAQJ&RDQH$UMY M:.P=YZG; L)#+1UD09I1!CDM",8V?/O1NS](K/ADT,/I$
MMPO"[V^X;(..6QO"JV5S)'#)ZW%-;W+"2W\%V$S2L"<*X&P]7QFYX/=7R2OP
M<P-?6]K>)^B9Q:IJN84>6/U26&XB!CG,J Q>$&"@E3G)S<.GW8RE36+]R1XU
M7<L95BQ[#*T*3P<+W)TD62ER*6,1'(WR2(>,]XNLQ0(A1(VQAL/2[B9DN)?2
M1.'P946T=CPJ!5E3&7E<7CW,NECI$0+J<!BR[BHDEQP"R"0?H5KV<:C</=<1
ME81L2-,49M$M4)49\4E6&K"@^RV;UU[NO,4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TS^7>E-*5$+V'+@3!
MY-4@=(DQQ)'MZ\2?7M:EKE>Y!L3^^6->JOD0/XQ6ND0N4\RUS*J]AD@E7B-L
MI>2-=%U"O.YM@=1"CK+#NT1W)&J/!U8J?;2)+&;*=@J.VJWE8X6"<X&6.#^J
ME'LR=%.F3]C>2PIL6QB1Y\(S)$26)AXYQKRP@B)RUR?:GIZ*UR(YKD5KD1R*
MB6$,L<\230N)(Y5#HXY,"!@]/<1@8(((!!%0Y(WBD>*12CHQ5E88((/X'F#R
M(((V->K76M*:4I_K_K[Z??2J?W#QBRBL@9;BP2R)F-Y!!RF=CPFM<R[%%%)@
M7"UXN6M#>'H;&T%$1O ["6L84E$?T&9X[TDX9<QK:<6X8&:3A?$(.)3V"*"+
MR.)9(;GP!^Q=-;3RE2HQ,RJK N0P]!P>]MW,W#[\A8[VSELH;LG>VD=HY;?Q
MC@Z[9;F*(OG#1)J9-@5-ETMU5Y#5PKBFF@L*ZP T\64!W4PC'>BHY%X<,HWH
MX9@%:PP2M>(PV$8YJ>FL;ZTXE:PWEE,D]O.H>.1#\U8'#(Z'*NC ,C JP!!%
M4US;3V<\EM<Q-#-$Q5T8;@]"#R96&&5U)5E(9200:RNI=<*T(\*D&TJ]MYF;
MTM>2X?$WV\7]%?T\=PVSI=(?Q7[NSQ3JI"N8,]E32Q$(R \@DL(<V:,3UFCA
MB)%XU%-#Q&'B5O&TQ2QM[:Z@3'B26YAAD62+/VI87!/AY'B([*/:"U-X?)#+
M:2V$\@A#W#7%M,V3&EP T;1RXR5BF0@&0 ^&\:$C1K(W.I,UQ7(4<VJNX)I0
MT_A5:<BPKB _CEP;&GFMCV=<=O\ &#-B *GOT\*BKSM^)65R/U5S%KY-%(WA
M3(PYJ\,FB5&'4,H-:SV%Y;D>+;R!3NDJ*9(9%Z-%,FJ*13^\CD>[E40//K9^
MZ-$_&),6;/BU-Q#SDE>49X\>F<(1J,%L6.KA-MF7*-=31I#_ #0Z\]^48V@>
M5SH#20R\9M7LF61UAN$X@\1#1B#2I@69URIF$X'A)G6J&4D!3FI@CFCX5<"[
M1HXVF@>P612KM-EEN&B#8;PC#_?, (S(L +%P!5KN:U[7,>UKV.:K7-<B.:Y
MKDX<US5Y16JBJBHJ*BHO"^FKVJBM?*63DFTXI6(3,<R>^PRLD'7![S%ZA<B=
M!QJ60IHV,6U37E==Q9F**5U1528]?+@3L?CU3GR66(IPM; CJ,GN#VY _AG^
MN]:D$$D'X'E[_K'OKLC[TXT>;(CUN*[G3I%,1D&T"W:W/6F!+/#CSF!EM)C[
M1C.Z-*CRF(KG*X,@3^>ES53C'<VURUQ"DT<LEK*L<Z#VC!*T:S*K#HQC=&'8
M-71H)HEAD92BS(SQ,1I$B+(\988/V=:,N=_:4C&Q%>ULG/<S>^#B]-9;98U)
M:YUCEV21*_Y72D(Y7/C8MBCW2Q53W]3^Y<Y6$1H[^>QCDMSVR@] JJH5550-
MPJ@* 3N20!S/,^9W.=JU)+')9F/=B2<#D-\[#ICICI60^8[#4&US;+/66B-^
MM?LW%S5MR4B^Y3'2[\N3EWUNPZ+Y1J<,9':-$8F<D?7Q^OAV%,#M77\SQY">
M4MMT=SK:D7MM+3ON*BJ=*&+T8"9>X_15&2GCHGU7C2X&XS41IWE;RBL[>[._
MOY^7QQFF!SQOWKUV=/4X+!I\6V\IJC'+7,+9U6&?%@AZHHP09=E;7DXCVN+:
MSXE?#D+$^(&.LFR+$;*<\#C:K.)7$R>K6T#!;B]E,$<A!/@HD;2RR@<BT<:'
M0IV+E<[ BI]C#&YFN)U+P6<0FDC&1XK,ZQQ1$C=5DD90[#<(&T^UBIGCV(4F
M."<L&+W+ _#K"ZGN\[=6IDY5TBQLC(LB01SE56LZV@"U>U'$(*-8WI:\/MK0
M'0@:1L&2>4>)/,XR0\DK LQW)P" I)  &!7*YO)[HCQ&Q&NT<,8T01+T6.)<
M*HP ,X+-S8DY-1C,%AS<NP.LKPM-DL.Y6]/( U$/3XQ'A3HMF>:5.%9"MC&C
MTX(A'?PR69)(1/\ A4@L:%?>')Q#AL42@W<=P;B1U +PV:I(LAD; TI,S")%
M8^T264-H)$NR\2.RXA*Y(M9(/5U5OLS7321O$(P<@O"%,KR*,H@TDCQ0#:&K
MNJJFE*\%I:0*6NFVUI+!!KZZ,:9,ER7H,$>-'&XIBD>Y41&L&USE^U>$1$55
M1%BWEW;V-M/=W,J16]O$\LLC-@*J*6.#R)." .98@#)(!ZP0RW,T<$$;2S2N
ML<<:#+,[$!0 .Y//D.9VJH=N<>N;>I-<Y7&?71K[(KO+ 8V7E)*CM[(TJE6_
M;[))@T_PX!*M$4090BDEJ4K6"C^3]&>'WMQ9/=\4C-NM]Q&]XK'8G.L"\N'E
MM_6\;9CMS$!#L%8'7[0 6^XU=6T%RMM8R"9K6SM+!KQ?LEK:!8[D6VV"DEP9
MB)N;IIT8&2UV(B)Z(B)QQZ)Z<)[)Z?S<)^K7M@,;#E7FR1U/S_UK[I6::4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2L79*][H,-I'B9-EJ(Q!/<,B!%&D2GC&1JHYCC*!!*]JM>T;WN&YI$:Y.$Q)
M,<>2OB/I+#(( 5F(!&X+8QD<@376,#$C[$QJ& .""6=5!P000,YQBOCJ6 B(
ML<;X94_)/$*\)D7[WJBJTWWJT[2M=_&:NGJ\8'L90@Y#(2#GN=\,3O\ :!&Y
M.,T\:0[,0X(QAU##'ED97WJ0?.OL:2<1T@SE:XKFN?%E,;T#EL9QUM<WE4%*
M$BHKQHO25G)0_5:482.ROX4G,@F-@,*R@@8\G&02.H.1R.#*I7Q(\A00K(=V
M1CG!!_:0X.&Y@[-S4ME-=ZY5!Y*/Q&8>Q"QSL:GG4]K'8U5^"S#.Y+:QQM1%
M2!)<JEM1,1>P=SI[4X?+ZJ5U/"IFGC&;"=]5S$H)]5D;[5RBC/ZEV.9U&2K$
MR+L6%6*$7T:0N0+N)2L+G/\ Q$:[K Y.?UJ#V86. R_JSOHQ-1D85C"C<UXR
M-1['L<CFO8Y.6N:YJJUS7(J*BHJHJ+SJY4AE#*0P8 AAN"",@@[[$;CRJO((
M)##!!((/,$'!!\^XZ&N>LUBHLMO<3Y,P=' @$BP))(19MG+.!DF6#ALD40,:
M-(>HHQ>8Y)!7,19 S#8)[1J]T+Q[B5Y!;Q1E(G,;/*[*'=3AU0*I("G8L>N0
M!MO*\*"-8S/)('D4.$B16*HP)1F9F498#4% )TX)()Q7;&O"-E@K[N"ZIF'<
MYL1_>2773B-17=N).:P?$CH17MC2@1I#VM<H6%:Q[F[)<D.L5Q'X,C_8(8-$
MY&^E9!CVCS",%)'(&M7MP5:2&02HH]K;1+&"0,M&2?9S@:U+ 'F5VJ+6N$SZ
MNQEY-M_+CTUQ,?W[>BF(]<6R8WIU'G1@?C:RW(U.VR\KD0SUZ$LHMD(8QLHK
MO@EQ:W$O$_1^5+.]E.JZL9<_HSB1&3JFC09M[E@,+=P -R\9)1RL8.)PS0I9
M<6C:XMXP!!=1X%]9KT$<C[30+L3;2G2O_A-$22<AC^?5]K.6AMXDG%\K&/N$
MQ^W5C"2F-1$?)I)XU6%>04=SR> 1Y1-5GG(T0CNWJ1P_T@M[J?U"\ADX7Q55
M)>PNR 9 -B]G./U-W$3G#1-K _O(T.U<KOA4L$0N[>1+ZP8X6[M\D1DY(2ZA
M/ZRUEP#E90%)!T.XWJB/!7_O,7R?_G$>+C_^Z;>'7K+[^_7_ /I[3_\ YHJI
MH?L'_K?_ /<:V9M<9QR\5CKJAIK=PTX&ZRK8<YPT^YBR0E5B>B<HU41=54UG
M:7&\]M!,>\L2.?FRDGXDU,ANKFWR(+B>$'F(I7C!]X5@*]E?5UU3';#JX,.N
MALY5D2#&!$C,5R\N5H(XQC15^U>GU7U7U]==(H88%T0QQQ)^Y&BHN=R3I4 9
M.=]JYR223,7E=Y7/-I&+M\V)->_76M*:4JKMM7+)F;E6?/+;#<FY&)5_Y.CJ
MJ+&51%]U:TU*9OZT]->6]&<R/Z0W1;5ZQZ17RH?_ "[6*VLP-P#LUNXW)ZX.
M*N^,X2/@\ &/!X/;$C_FN9KF\)^/K SC;ITJT=>IJDII2FE*C&3XT+(@0'#G
M2:FUII[+2DMX;0D/7SF@/$>K@2&$CRHLN)*DPYL0S.D\8Y$8\)VA.*%>6:W2
MQ$2O#-!)XL$\>"\;X*M[)!5T="R/&1AE) *D B5:W1MFDS&DT,\9AGAD)"R1
MZE< %2"CJZ*Z.-U90<$9!PBTFXDI/+S,WIX<94Z7R:'$EC6SF^B=0SV]Y=UP
M"\)^6M6=J+ZM8U$Z=1VMN*2 *W$(HT_::"TT3,.F&DFE1#CF1&WD!7<3\-0E
MTL9G<_92XN]4*G?8B*&&1ARV\1>6Y.:S^.XM4XP&0RO;(-+G%23:6UA(?.MK
M:4C>A#V$XW)3*QOU !9VXL07 (@  :T:2K6SALU81:F=R&FFD8R33, 1KED.
M['?8;*HP% &U1[F[FNF4R$!(P5BAC&B"%2<Z8HQLN3N6W=SN[,V]2/4NHU0S
M)<YIL:,"N?YBUR":G56XU3B2;=3F\]/=;&:]K8D-CN$-93RQ*\'_  LEJ\(M
M+Q/CEEPYTM3XEWQ"<?\ #\.M%\:[E)V#,@($,.=FGF:.)?WL[586?#;B\5I0
M4M[2(_K;RX;P[>/NNH@M))VBA625OV5.^(W$Q.\RN9$N=Q'@9$AR!S:G!:\R
MR*:'( ]"Q)M]+>-C\@M(KT:4(U8*G@R&L("+)DA%.U70<(ON*S17WI"Z".)U
MFM."0,6LX'4Y26\<X]=N$V*Y58(FW5&8!ZER7]K8));\(#:Y%,<W%)5T7,JN
M,/':H"1:PR#*OAFGE4D,Z(=%36TLY3)(*BG8(MM*$LAQ)'4Z+6P6O[;ITIC'
M,>3DB]F)%:0;Y9FD1'C""08?H)YI ZV]N%,SKJ);)2&,'!D< @MD^RBY!9@<
MD ;U<,2%&GFU")&"@+L\KG)\-"0<87)9L,$!V!)4'SMQ.$;DEG.N+.4[U><E
MK.A,:O'*L!$K#PX@!HOY+6!ZU3A2$(_EZZ"QB?VII)9W/-VD9,=PJH555!SA
M<;<B373UR1=H4BA7]U8D?..19I%=BV.9R >>!4JU.J)32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5X+$!3 :2.B+
M*B&9*C-<J-:\@T<UX7.7T:V0!YHZO_B(7KX7IX7C,K,H*;NC!U!QAL;%3Y,I
M(KI$RJV'^PZE&(Y@,-F ZE6 ;'7&.M=T24&8!APN56N3AS7)TD$1OH\16*JJ
MPHW<L(QWJUR*B\^^MXW61=2DD9P<[$$<P1T(ZBM74HQ5N8ZC<$'D0>H(W!KR
M7+.:\YFKTFAIYZ.Y/16FBHI6HJ^_01K7B*B?E"(1GLY47G<#]4S#8Q_K%.PP
MR^T"?(XP>X)S6\)_6*O20^&P[A_9/Q&Q!Y@@8(K)-7J:UWWM1?Z4YUV!R >X
M!KF1@D=CBCFM>US'HCFN16N:Y$5%:J<*BHO**BIZ*BHJ+]NA 8%6 *D$$$9!
M!Y@CJ#6-QN"01R(Y@]QYBH1TFPLCG,:61B17J]XV-4A\:(]Z*YXVIR\U$Y7.
M<\;44E5ZO8CX"JV'38?A+Y]J3AC,=@"SV);<D8RSVI//FT1Z%,8L?9OP 2$O
MEV!.R7:@' /1;@;8QA9>I#_:FPBC.,9@D8416-((HW(\9&/1'->Q[55KFN:J
M*UR*J*B\HNK=71U5T971P&5@0596&05(V8$=CRJO92I*L"K*2"",$$;$$'<$
M&HE%,S';:77RU[5;=3B3ZF6[E !G2^'V%4<B\M&4TI"6$)[W-22LJ3'8B$C,
M0\.,^JSRQR;17$C31.<:5D?!EB8C8$L-:$@:M3#)(WEN/68D=-Y8(Q'*@W)C
M3:.51S("D(X_9TAN3;2&SKXUK"/ ELZX\AG2[A58]CFJCQF"5O#PG 1K# ,-
MS2"*QA&.1S45)4T23QM$XRKC&0<$'F&4]&4C4I'(BHT<CPNLD9PRG(SN#W#
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M?9:[]3L8_>QENFD _P#MDXZ;$4/"K:/_ +QQGAJ=U@-U=O\ _P"*W\//;]:
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M\\9<;K7>KH%>9A[@[5]49*LVHH(2*GH\5:AC-7\BP;ZIK@(K^\.;AS8VY_\
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M<$"M(YY+(YA=EG8 NRL0(QT72,!GQ]HMD#8#<9K.U]76U04CUL&) "G'XN(
M0&*J(B=3D&UJ.=PGY3N7?IU,@M;>U71;P10KVC0+D\M\#)VZDDU&EFEG8O-(
M\K$YR[%C\,DX^%>_7>N=>6;*2'&(=6J1S>EHQHO"E,5[1A$BKZ(I"O8Q%7T3
MJY7T36DCZ$+8R1@ =V8@*/BQ \N=;(NM@N<9SD\\  ECCK@ G YXKQAJ8[V]
MVP&*=,+PXQ3C:1K%^P,=C^I QQ<JUC&\*[U(17%>]R\E@4C5,%E<[DL 0/\
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2D#8;#E66U*KA32E-*4TI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g120909g04w14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g04w14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &**^8P8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&CU1Z         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             "-0
M!.L    & &< ,  T '< ,0 T     0                         !
M          3K   "-0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "-0    !29VAT;&]N9P  !.L    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   C4
M    4F=H=&QO;F<   3K     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      Z5     0   *    !(   !X
MAP    YY !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MJ[G->37N;,<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( 1 "70,!$0 "$0$#$0'_Q  ?  $  0,% 0$
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MAXFXI)V=\/S7D\E2(UR>M<P2592[M#LB VCRI H(5E&B2"DGME K25$+$PU
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M,,Z$?H)8YG'OPPA%.O#F817Y*FJ[%84@)I@!>JGM!>FBC00 1#6H=! !#LB
MW$*TIKB<M@W\<<]"E4P&>T[N..:F:C3:Q&JHTP:AW&JNL1'6]KC4.MM0 !UO
M;3?%R@&0 ZHM1I[9E[]NH0L-O=5=+CS$;<AU#6VNFDT!S$(GMUCH-=5[ (ZB
M W'2P7&VPVU#H%^B@W"%3OXS\^,:?&5V$.U6.PZU#>PV[^=]M;7O>X8B@W#R
M;-OEA#MF7OVZQ#:P5C?0.MPOZ._?G-!N$(GMF:WKKTO;W0AMYO,.N@B&VXV>
M?&F_JA#QE?Z.O77ZL=.86UO80WTTWT ,(0&LRP?3*];[5".@:ZC<-0UVWVV
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MY7Y7PA$80AA")$! ;" @/00L/7XL(1/8K !J&FKL@( (]D; (A< $;6 1#4
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MPT[0".@Z6M8;A<>6HZCIYAQ]1<<<;/+P* 7'00MK:]@UYB CUTTN%[^_A")
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M6*'J2[BG5/+WZ<TWTOL2S9"T;-185@,:4R"#*&P+.:E'Y60L.T[1D^Y:J"R
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MV@VL/I0B!#:VPZ 'G"P\]^O(>8\L(0$;!;;D(6\]NX+[Z>>XZX0@&X"%QZ
M6T$1N&P!UM;H-K"  *$!T#32]]PU$!MSVV'NMMUNA 0 0'ISY6&UM@UW'2P=
M;\APA#38;A8>[;J&FM^=A'776VB$0(^BX7M;0.\-["(6#KJ.H6PA$AIN(!IJ
M "%[A3;3OOL-[C?8-<..G/Z<,80$.5]]0UUT$1&^EKCJ'.VH=X(0 =;:C>VN
MNX#8!W#3XM.880A;01UL&FNPAH&EM[:Z7TTL.F$(FU@N.NOGOS !$0"]^NH!
MO:^H(1&FHAK:VVF@6UYW$!U$1N _$A#;2UQ$0M;2VX:V"V@W"_/33#CC="*I
MCOU*NX6&Y CWW W7W[^]IIBVO,='''!N-[>KTQT >&E_-2R5_8 _]W_&*CGM
MC2=)_&);XE?[>[./E[E^^_5@G_JM_&E?^5G"F>/-NCI:W\^GK\6F-9R[3' L
M-E*#/9EY\:XY8&'KZWPXXI$UZ<Z;Z'U#(TPKUQ-]NH!Z=QL/R!YL13/GX]O7
M #,9^WUD$^6 C?UW\_?@!3C+HYH@4S[,<-A %*TPRYL!$8F)&&\TH,:UZ37I
MJ=W8&$.CMW##=U\^^D/7U^'"'-2M=XV C/?G4<&'\>WRX?1GZ(89<WDI39E4
M5$3<?7IKIYAOKB*#C?ACTBF$00*UR(Z/+T[JX#=$>;O[L3T\W/$].SS^3&GD
M\F#U];>OIPAT\_6,\MM,O1C$[>N_OA\?O8C/C+R'S>6(&(PJ.RG-L-.C#,5B
MJ(T-O+=OSMN #_7^N+K>WJ],9+ K?_W<B1^-NB]$B_+ ^]SPYA__ !I_7[@>
M;'ZFRWBTM\0S\VGZ.B,F;\;F?SA[YQ7T1PX>:_KZ[:XO_1%@=%=F5>.K&,F<
MLLMF&:Y=5*5\66*WRF7+6YB<6N=-L;<7ZI;3#VFEHJ:7*(R-.H2,3N^-)PKC
MG!C$RJ25)BJU8D&5(]2MBUIBS[4"&YQ#<L9%MV9:>LUZ<:EM69]\OA]F>E%H
M7,L2[Z0TEJ9H),+4&[PUFXV-8\M:-DWW))QR8[O<:EG6;2:E'9E3HL]CN<LN
MR$VA3<L_,,*UI=EKQG"@%PH):QE_C#T_=QMQW<YX[-T:;Q[>N/J5^*E= ,HY
M]:@^7EO\>(BI.8ZJ8[R.*8^D>S./?D Q_K.V?N(C'P-->,S'Q[WSBH_0Z4\4
ME?S=GYM,6$4\5.5S5Q,$<*,H%_AV9S]"4\\RY52=KI;XAFTTE&*RI*WY<26E
M2>D>Y+":DY)DIC*FEO>TB)<E=$2)>U@H6D7!)/*E#.HNN,I<+;H0:K85A<+J
M* I0Y7P%BJ204DA6$5EY =#*JI6I-Y!(\%8&82=JD[4YTQRC=\7O\Z=Q._WO
M><_^CF28B1\=D_SJ7^>1$O?<G?BU_LF/R%\=NC4X80AA",XU?!X%;U#V<)2L
MBZ-'PR0CB#S@DT@8GI]1QT<P7-J.C;+$(_$V58_R$]8Q9AY2)/(""EAR=Y?W
M9Q<7!N8D9AB+SQ/42M10%$S;DJPE*D@KU0(6I:EJ"$T6T]B2,$I2 5'&X6S4
M"M#JPX:UR52E  2:A2=F9W1=E=X+'.1K0O;TZ9AY6(8Y&C9X>^2 ]T>"6]+'
M\J<ULR,I<T907Y0T)S:VB$/T)B]3A2IH1KUJK-W+=A;D:E^7NS>TV1;$N2E(
M;>*E:H)31-2M]EIYE'OO?.)<72E0 PZHD)"2JLL+ ))307B34D42I2%' ' %
M(Y_"2*5) KK+3P>,?FN3C7*<QINL09N39V>6:/',F:N7$N9$3XZS9JRGR-9E
ML.CS=+I9,&O-;,Q'+8BKS%898@A\%H:"#W"IR6$BT+;;MJ*;?*&FPIAL)4J\
MRZV5(#:GIA27%%#:%,M7%AI2"MRII1-5)J2P"D%1HI1(%%)(!J$H\$5*@I04
M"H&@H,SA&V8_!AG2L93)(KF>Q.4%,RRF>9,-=T:]<J1LH,,OR\0E1V42$Z)-
M9THDD8A\Z4/DKB41B*+,)U<8\8EBL)4HI!%U;Q4JU@BXE;2PO6MM+!2 HWD.
M&\E 6JXE:VPE"UK+0"B5.50L"$L%52%)NE!4"":8$8$E(K=!J0!>-*)2:@QU
M3/9HGO+J<+N>_P#C'!94#XJ!52I>*?*#.PYGTKJJUE!BZFRFNA774HH$P:3A
M$P*L>NG!(PNX#P12B<,L,,,L,-T8_;&R*5*2"U))"@\DI:32G6%%'&%EJT]"
M@E700IHHJII/)H5)DZFDHT*Z*5"<DX*0,*+JIF@PPRQ',:$5'42.@F$?#"$>
MZ#A__H52<_W%>(#_ $]S/'/9G^.37QTO_=4Q[3?WK5_1<^<,>%_'0H\6&$(R
M"S,R'3P/*S+3-QCS+BF8,:S%>Y3%!+9&>;,"YCE<,8X4^R)N B:QJ.#(6M 5
M.FMKKD<>!>U>SB%V05UET%MZIRQFIC6//,*:6VII*%U46U!2'%.)2:MK7=)U
M95<715TI-/?!-:D42E04E05485J% ))!J!E>&(P/DKC[C)BB.QGP1'^^;\$'
M]\'!_@5F8\NV_O3:'YJ[^S&1*>,L?&)\\?JEN*NM WKUQ:)8Y&(D2I66W-])
M-:]?6F(,.H1(:%!R<BM8JJH A-2>H()J.,H PXJ@:JZ>. 5(!(2"0"3D*G,T
MJ:#,T!C9S@":5H,M_-%@^&?B?RMXK,OJY]EFK=4AS0\.$4GD#EK=5'\Q<KIT
MS&BG?8+F'%3C354>DK0HI&@Y/68>C6D"4X-2U>W*$ZLW)FY-Z2=U3P'A)"VW
M$&\T\VK%+C2\E(4,C@1DH @B*&G4.IO).1HI)P4A0S2H;"#AYHN4YC_)ZJPC
M<#1MMTI$=>6PWTY\PQ;3[T=?GBA7OCTQL ]%A'<0V"P@ VM;E;4=-[=:HB :
M:7 1U'3T<QN&U[B&FU[X0BRN75PS.S]ZA+(9KS_,ZCV@7OOL&X];[XY;H7_'
M[E>_KS17_P"SK*C?]*?XH\FW]36__P#=5J^3@[8O58=1JVT'S:VMISZVZ=;6
MZE&@1/G$;!?SC8=]1 +ZVVUU[L(18Z3V_#_RI'_S"S2O<1_3L%WV$0VV'S7M
MCE-O?^V#D[_[*:?_ #^BT="LFGU-=,]_NCT.I^KZ1UB^ :CO>^@C?WMPTUL%
M]=?1?JT<]@-AL%O,&W2_/N#F%^U?3FA#>U[::V"^@:]0$-[!;8-PTW0B0_\
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M8D>&JI55?@^$:DFIJ:DG,Q5?7AX2L!0>$<!N&. Z(H\V;S,Y >U'2Z3FMBI
ML:U+<8_NM:!2V.#^3*E[<>CJ5BG.0KI0G3R18D,+J3J7X@EX.+K<"BU%->K;
M!J$(!!"@;J:W@DH"JTK4()0#F$DI&&$14[SY>>OGQZ<8UMLZF[-Y*#/,94U
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MYVUUVPA"PZCL.PZ7UOOW7'F%]=NY"'N=1N(C;7GKIJ%Q#;<>5K]^!X]D(#J
MB/33301MO>V^^@ZAL&N$(6YZWU$1M;?;37SW"P6VUPA"U@VL-N\;6$!OW:"
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M6=!2M \HBB@+:FFUD*4A)4,0J@O W5(J#G4)4I(.P*-,XFI&%<,J;*5!I3I
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MNEPOOUVTL.G0=A0B=/2 <K!S  &XAZ;CMW80@(\Q^J -AJM< MZ0T'NN.MA
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MYT_*<=Y_Z_B>_=D_E"5_2IB.YICX%SY! ZS3#KB?G0GA-_L),_/VG&^;^O\
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M+C8  1"^@CM8-/A#>F_FWTJBF-@Y@/L:X!U0JQY<DYOGTL-MAN/=BS,>+O\
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M-<D7)\\L-MZ&V$5J-$A2 W>)("0DNOH25*) "0;Q-: TBE7+MRM(!4KE!TE
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M8=0M\75")O>P@ VV]SKU'00'8.X0UU$+  80C3O]2&N_FY:#[WFWN&N$(GN
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MY8@*3)ER-&V."QO-*<D"TT24KO16BKH<$J0]K4UB-!A2=:96'E! *$"O7F7
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MM)F)9HJ=60RN7Y8SBQBIR]$O4PM^7TH7F&*U#8X.;&>W2:F,/F7[L9)I+9F
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MOG[/;#VNU_IFC_%CTM?ZKT]PX:SF[?9#5\_9[8>UTS2ZJFX<_%U7M<?[+O\
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MO,/6_O\ KRQ/''!@#LRW;<@/7GCCMR$1Z^OKSPB2<1S[Z@?3S9X;-L^M_/\
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M0PA#"$,(0PA#"$,(0PA&S6K24)7C#1$:AN%!=-NV8(;@%]  -ZJAT .\0 9
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M&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(H%R"Z]7K_ %4=!VU
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MX''LBXWMZO3'0#X:;\U+)7]@#_\ YQ4XTG2;QB6^)5^V8^7N7[[]6!_5C_\
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M^5PWO<1"]@T'8?,([ZZ QXX^GFA#6WG&PCJ(WV$ #7K4-PWUVVPA$].NW0
M=!TT'74>6^^F$(:^^-PU$ U'GMON !WCA"([NFMA  M:^_,= Y!K?6V$(6T#
M3?K?G?70>8 %^>FV$(#OVMN8VM<!Z;7 ;@&X6WUUU0A<>07N(W$//UY6W\UN
M^Z$1IH%]+ZW#;KI;G;;7;O'"$380WOL&X[;ARO;NW#74.B$60S,US&R"O?\
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M%2%2)H1EP-,/4(R530NYSI6906I680VJ[9C!6R[/)EW9X.S$]+(;LN65*/\
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MA#4!#EOJ._+?<; (;<[#A" <@Z7'EN <M][!O>W4>:$34 >81TMUVOMZ! +
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M=MYED 8W-4T^^TV4E*D-OO-@A+JTJAUS/G[XU*61XE+FY-:NE)2>C5UE'45
MC2MB(BJBNLD32JJTK,TDJC"3"ZUU+:A%;4H%*2-$*F'EI*%.J4@TJDT(-T)
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M$.M_==-+Z7L([AIW7WUTWPA"KIWZ6OT"_>%[@'9ZWN(\D(7&^V_(=M-]K6T
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MA] :C:G0-.Z_+4>6GI0A?:]K:?  7YCRZ;^<+80BJ8X(C2K$=^T1\1OQ^]T
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MI.1F)Q#-33FJ]N*R->SA;I&C@/B,4(3-P18TM4]OI5-$C*S+#5H4:+2G4)U
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MLC;$,NH4JI@Q R,;BH%*F5T3-HL,.-M-H;?*PI5U+@"KX6&PVVA+;E]]1*_
M)12XJ^I(J1*&2I)4:H H!5.%"":FI%$@4Q .8 %: [9L\'9Q).<DAD0:ESNJ
M19B(I$*!L;ZQ=9(KE^6N5;Q-)C%O:DPOKHC5.<>?HF\0-N(/>R'X!)8GIV8(
MZ@?6Q-5)M25"''3=!:*05&J4A#KP;;7?4A)"5A:7%&Z4^^2E2RDF)$NX2D &
MJJT%*DE*:J  KD<,Z[2 #& \X22:./SW#)#(R7U2R/:OV2J:I/1*8^8_6"AR
M5(W5&J5-+JII.$Q*I=T!RHA8:294G6JTPEGF>@V4K2EQ*2D*2*7D7%7=@*2
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MM^.,3\^)\'A]A[Q'_;JBGO?D%?KS^^^M$T!^'M+]?>_<A]>3RN?"6!N^\S6
MJ3\+ZMN-(CY\3X/'[#WB/^W3%/X"P^M$T!^'M+]?>_<A]>1RN?CV!G^1VLMI
M^ZY\5C53X8GP=W;I[?![Q(!1>GM6SIB@Z7]UI[!TB.G+MTB.W:IWP^M$T!^'
MM+]??_<A]>3RNT(#E@I.-"+'9-.?%WSX&@KE'L-X-,\^'GB&X>(!F-PQN;:J
MRJ5-E"! SHJ"TKI$G9+116[Q:6-@&'*6R4MBH\*G8E88:8M,/+=R%+@A<4C@
MJWV5T>EM%I9BPI*1:L^3D&PU+2[*2&M54G6(4<72ZHJ6MU14XXXI:G5%PKC@
MUKV_:6E%ISMO6Q/OVE:=I/JF)R<F%7G7'54%T@42VAM(2VTRV$M,M)0VTE+:
M4 9EQSZE6/6HGEW&A\G+GBMS9UQA-[>KTQT ^&F_-2R5_8 __P"<5&-)TF\8
MEOB5?MF/E_E]^_5@_P!5O_WM4=+7FZCZ\O77GC68X".@UVBO3U&I&!.>_*'K
M?UT^7#BG&/HB?-Y*4.&SRX@4QRAA$<^ V[=O3=QP&>66$2/GO_&/KKKB!T4^
M@<881-!NZ?(!3<13JB,3#LW]F/5ECZ,9&X<]>ZX?<'U#T1@=F'/0^L<'K@4/
MDVT)J,*[0!NWFIZ8]?7U^/$\<<>:%:Y'#.M-F&_#*O ,/77")S YZ9>7FX\D
M,(5Z\CLP&^N%1@3Z(F^WKW!;7?8;\QY8BF?'/0\V-*;!MQPBG12O34'837&M
M<,_+DMU]%O1SV] >FVPJU]N?DS\O578QQI3M!Q[0:U-:>DB+6^/W_N[XF'1T
M=)]FW'812*HC?Y]_P;_7XN-[>KTQDL5\.@_%S-/QN8\9Q>F1?E@??UY=/W:?
MU_CQ^ILKXM+_ !#7S:8R9OQN:_.'_G%1PX@-QT[]N7F#;Y,9!S[>K/9EAY(L
M$&IPY\MG0,O1&?G#_":565[S0Z0E%)3*!5STM,WJ\GGLY^94'M:6DHW\^03)
M!)X6W-Q3*\HW"LEK5 ":3GK#$/LFVH2SN9Z36@46Q+EFT7)-)N6:I;C=O2XE
MIAWNQM3DLF5L]R3GW73,2[C84^CPY-+8=#+SA3U#1:SK]BOA^S6YPIUEJ)0R
MNP9E<S+-=R.AN95-6@U.6>RTF6F&W2EESP9U2U-:UEI*L M>8W]?OXZ8<R=Y
M.VO'3'+S7;T8YX;QL)S//6-98!48734 "%5= " A<! :@ 0&_(0T$-L1!)Q'
M2.S*/3>S>#NX!5;.TJE7!/PH*5*EM0J%*@_A\RI-///.2E&'''&UQ6JLPTTR
MJJLPRNH:JZZAJJ$1$1Q\*S-J6D)F8 M"= #[H $R\  '%4 %_ "/T)E)>7,K
M+$L,U[G9_P!$CX-/^K'7;Q5\!N2^>&:!/!SPW\#60&3$;5QYLDG$-QA_,RY7
M-M, A3V<J+1Y>Y!*U\.*(DN<TM3(E1:B4-XJFG*UK-!T/-,DIJ!*CSY*TIB6
M9[OF[1F9A844RLB)MXEUQ-*NS("R4,()!"#X3RO!P14FEYA"UZEJ7:0* N/:
MI'@I/X+?@XK._P#!K7.M.PW,?(S*_AL\'KG-DADU%D4-RXR^X8\XF:.L:$!J
M&@O\+V3J5K@O5&7/<GEX<#U3J].JNLQ8Z.JQ6N5&5GGUU#Y;4P]-VI+S#ZRX
MZ[.,*6H_&H  &02D4"4C   #*,DMI:EUMH%$I:6!\DDD\Y-2>>/R<L=GC5H8
M0C6694490;0(!677290-5--=(545!52(T5A516%P"]-=-5-0:5 ("(80C("/
M\4>=[!(Y')*9R[KSYQF"JS,GZ8U4>V!-94Z%O"1[6NSI'C6:0(*WAKD<D:#U
M,<>&1<A;Y ZT,RML/4 ?1C*DY=24HU:0&VPTV0 =6A)24A(4%)-U24J 4E0)
M2F\#2D5ZQ=2;Q\)5Y6.9-:DTQQ!(J*&A-"*Q='-[CQSQS0E<?D;.J:,K443.
MBKC'H] T5*="EDT0>\S9,US-6I=/9!:OEU4ASBS$=E+M6:52<J?"C*DWCFMM
M.366;.EF4*24ETK"PI3AJ2A:6DEL 4 ;NL- )Q]Z<?"565.K40:@4I0)%,05
M&]M-ZJCC7=L I81@SUS<C$;HB#'.GA%&*$V8",6,?)%3<>ES1CK%$YV2L3K4
MJBA=0^L,8CJ*KRSQXMQC(UKFD4#@B(549*I=E:[ZFTE?V(WJ8_85*6W0[+JE
MK-!@;R@:@D12%* N@D#PC0':H $])"0*[*"F47+,XU>*&H'&M-FX]-2YY?I#
M*'EZC[5&8Y)'J12A8[K7=X>)0PL;=(G5>)D@?4[8>X.:BIA;7IV:&+V-:G%6
MC.M"1E,/L*2 A#:4J4M24H0$A*4H4HI2/!23= O%(*JD Q.M<J3>()))( !)
M-:FH .-X[:"II2IC'21R!VED@?)0_*:%CY(W9Q?7E86D1H*%;HZJSER]32B;
MDZ1 E ]4>:;Y.C2ITQ7;[!))984T!E)2$)2A(HE*0E(J30)% *FI- ,R2=\4
M$DDDYDU/28X;$PAA"/=!P_\ ]"J3G^XKQ ?Z>YGCGLS_ !R:^.E_[JF/:;^]
M:OZ+GSACPTH4E2]<C0T')T]:U4G24'K#J4Z0BI2=032<J45^X(3EC6%9YU7N
M2BJ:JZM*1QT$F@)H30$T J338!M.X1XL=EDG\'16T/\ FNS-^9SXG3Y#@X'Y
MK/&8.52O+I"4Q(*LPF$J>P#R^7NADWRY>LQ86QP!BDU=+">K=<QH<8I:4=:A
M:E2^6BU 4,J4TDF9IJ4M/!TWCJU:IVB!JW4M+4XI'A ):<HHT%;Y9H5@*P;]
M\2FF'A"\G$U05 )"C0U4*@1<AG\&;'G(_-&&>WV?II;EOF+#8\KD4@RT2P]O
M?F5+EUQ>RK,*K*N./\V((S0;W=SX?HX.7LN4RV$(E;2L?%+PU-_D]?DUI5JJ
M 8<#;1;>;=-U+I64*ULDAK7*2V2T4B96'6PAQ5X)ND@U,ABM\5-4*2*E(%X4
M=K=!5X52@4)*1G6D8V9[\%=>3.4CAFDWY@*ITF:,T%N7CP".&T1UC:Z*G69-
MK&><XOLI)D+@\N=$-6J%B2.Q!]B3.HJ5,JB=&O;6K0#E2\^'W@R6PV5,AU-5
MWE'!LJ "4% 2-8 "IQ*U4O:NZ08H6T4)O5J JZ<*4.-*U-:X'($?ZU<(WG@M
MX?$\P/"(<'D*G<98)G#I-GE#VF1Q64M"!_CK\U*E)E*EM>65T3JFYR0GT@ '
M)%B<X@T  *Z!#$6NXMJS)YQI:FW$2SBD+0HI6E0&!2I)!!&P@@Q5+!*IAE*@
M"DN)!"@"""<B#@:[H_2@<O![>#W:FY>Z*N![A4,3-J)4O44(N&[+!P65D(R#
M%!M"1 BAQZQ:IJ++J A(D(.4J31H)(*,-KHH'E";3M-2@D6A.U40!6;> J2
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M/$*\<_.T99H^J>(27E=$9D$GD;*_''.D^I8WHB.#&DZ/RTRTB;G7,42P4!K
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M?+[(V;CQ20EQ0+D Y;<3I7EJ12D$P.%G/NOQ0*2:R1,M[0J1'L!7?L]JD*A
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MV&I$/7^/#CCCTQ!P->H[<-F.&>\U /7#7UZ7]?/OB/7QQU0RSJ#6N%3G4@5
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MF-P9%:)Z25F-J@U#0I\O2U2SH9>2X30 +25 $J3?0I%Y%%H*5I)JE84"@B\
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M3E^6:5-VMVII44-*X5%30TS%33><XR!ECGMXH/,.B.3Y[7&VHZB.UM0Z\MP
M+ZWM?$0@&VV@AIIIH-]@MJ(B(;[VM?410AWV$!'OU"UN8[6"U^HC;S(1 ZA?
MEKUJZ  #H( ([Z6MH'G0AV;@ ]^H (;:7$.06O8>6E\(0MKR"UK7$ Z\P'<!
M#??8=,.OC#CKZ(1 WVL.]^0B.E]1#7K;J&UM\(1(Z;VV"VVFHWU +!>UK6&V
MNMKX0@.P '4;B&E][ %M;B W#D&U\(0TTYAH(  ZZ\O1W!?;T(1/>%AL/0+
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MI(!"1U6V>0Q^9M*;F;*MF58DYAYUYN6FI=XN2X=6I>I#C2E!U#=ZZA:DH5=
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MU^_(Z26G(M)82MMYI HA+Z2LH2,DI6%)5=&0!) & H (PGI!AU960I"CG<(
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MZ29DB6;4)?W>'1U1+),W-SP2<K:8XB)1GNCL>3[FLQ,R XMQ$A\G XR/+G!
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MMI:RE&J7$&)XZ[OBMP6DJU#FW<WJ(],(Y: >#AX<<M9HLF\70/B=R.S"#,Q
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8L([P\(0PA#"$,(0PA#"$,(0PA#"$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g120909g05n11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g05n11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1YF4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'DJ^=U0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&Q30Z         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             #A
M!!,    & &< ,  U &X ,0 Q     0                         !
M          03   #A                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   #A     !29VAT;&]N9P  !!,    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   X0
M    4F=H=&QO;F<   03     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !0]     0   *    "*   !X  !
M L   !0A !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MFMVV9HW.?^LG5T$Z
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         /_A0$IH='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC,# V(#<Y+C$V
M-#<U,RP@,C R,2\P,B\Q-2TQ,3HU,CHQ,R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.G!H
M;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @
M(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM<#I#<F5A
M=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @,C(N,R H5VEN9&]W<RD\+WAM<#I#
M<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#8M
M,C54,#8Z,C8Z,S0K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \
M>&UP.DUO9&EF>41A=&4^,C R,2TP-BTR-50P-CHU-3HR-2LP-3HS,#PO>&UP
M.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M
M,#8M,C54,#8Z-34Z,C4K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @
M(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @
M(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E
M/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^<U)'0B!)14,V,3DV
M-BTR+C$\+W!H;W1O<VAO<#I)0T-0<F]F:6QE/@H@(" @(" @(" \>&UP34TZ
M26YS=&%N8V5)1#YX;7 N:6ED.C S-3!E-3,Y+3%C-C4M,64T-RTY-3)E+6(P
M,#$V9C4Q9#$S-SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C8W9F)A9C$S+3@X
M8V$M.3(T82UA868P+3)C83$P-6,P-CDV,SPO>&UP34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C4S
M.34Q,&,V+64U.#$M.6$T9BUA9C,Y+65A83 Q861E86$W8CPO>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F-R96%T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU,SDU,3!C-BUE-3@Q
M+3EA-&8M868S.2UE86$P,6%D96%A-V(\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#8M,C54,#8Z,C8Z
M,S0K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXS("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E
M<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYF<F]M(&EM86=E+W!N9R!T;R!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS.#4W.31B-BTS,V$V+3<R-# M
M861B82TW-F$W835A-60X8SD\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#8M,C54,#8Z-34Z,3@K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXS("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z.3$Y9&8U-S M.&4V.2TX-S0V+6$R9F,M865B-S!E
M.&,P-F)E/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(Q+3 V+3(U5# V.C4U.C(U*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @,C(N,R H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,#,U,&4U,SDM
M,6,V-2TQ930W+3DU,F4M8C P,39F-3%D,3,W/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 V+3(U5# V
M.C4U.C(U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N,R H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F
M.FEN<W1A;F-E240^>&UP+FEI9#HY,3ED9C4W,"TX938Y+3@W-#8M83)F8RUA
M96(W,&4X8S V8F4\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS
M=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-3,Y-3$P8S8M934X,2TY831F+6%F
M,SDM96%A,#%A9&5A83=B/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-3,Y-3$P8S8M
M934X,2TY831F+6%F,SDM96%A,#%A9&5A83=B/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@
M96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_\  $0@!?0&Z P$1  (1 0,1 ?_$ !\  0 " @(# 0$
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M(:UN"@,F-1A)$M%@C!*)/"+?$82XD%P;;[^W>1':GB@L5HY%;#:6)9V(C?\
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MHU%Y-8F^:HQJ-:BKS5$VISH(6UX8X6?TQM1J+XJOBY?BY555^*F9<XA]1@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M&JK;[#$1U9Z2FYW:TQEAB7N:2MGK[]3Y\+8SC0D/0[;Q/#PU_'3HG+F"ZNZ
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MI+/*08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M_NC[H_Y9PW_3SR5F+?'EKWE_]*OA\ORI+/,B# & , 8 P!@# & , 8 P!@#
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MTCK<ZRAZPRK\B6G4@5#1+JE0M9;-W]],4*@XM&Y62E'R")I/\:!8GE P!@#
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ML%,ALR$5+Q4B(XZ*='R()#!890[BV7V'6W&U*2K6\H.=P!@# & , 8 P!@#
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M]T?\LX;_ *>>2LB>/S7Z=/@GS^O4>7Q_E4_!+/*!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# /S>]:UO>]ZUK6M[WO>_IK6M?QWO>]_P -
M:UK_ %W@&J[T@DSYW_D0;XG!DE'?%Y\?MV8E>QS BU.5CT[Z+B7R6!*9'R8C
MGY:6JD0TI\-3HK[S>JUJPRR'4+NE3+%G-5\D3]=I^/7/H-IH((.-#$CH\4<$
M  9@($(1EL<0,,5I# PHH[24-,#CLMH999:0EMIM"4(2E*=:U0?3@# ,9=D[
M)S+S[S"Y]D[%<(>A\VY_"%V"TVB<)2,%'@"(^NFVT_Q>-D3GU- Q46$V_(RL
MD0+'1XQ)A+#*P-!KK7QB>P_GT])=C^1OAM4J'GWSYUV[5NK\W>[[9;+'6BX4
MKGE.@N??O&A8."JD]IR)/;JS1#@;13 +<P4;$Q$C+M19<IO%4WOSY??7Q1//
MHNM^.MJ#>H\B^>X_R?YBX3YMB[$=;@^*\RJW/DVB18T(5/OP$:T,9+*"T^2F
M/9.-T00)')))3'"+8"22_IC3J\@2*P!@# & , 8 P!@# & , 8 P!@$%.M<W
MBNO]YF(NN3UXY]<N<TGG]RFK15R( H6QO-SMM?I45NKSXSS!<O!+'FR8VRI>
M89$5)KBS=/M_:2UZ/@\M/@NS5>:W5QV5Q^5R.4Q]>E<9:8^HU:U%N1F]LJO:
MZ."RCZS):BHYTB0I/&K51=^89_#P]H.U%B"G:R6)R.(QN*R%F]2?5>RVYMF\
M_'0>Q6F*U]BLK;+X+J.:V-9E@E1R</#(7SP[2WN'\P=YXW*M4U51B_T1N=4A
M<VAG3>TDZF7&E*9<EOSVBMR+HZE#.&;>6-O;"F\U?M2W(-[19AN46!U]+TWM
M*UD5*RNVBL]G141R0=WP=TUR<;8^%'^\BFV]DG8YW9K"NQ+9VX]:$/LS;*HM
ME&HBH_VA6[:L_>\??.8JL=)Q+&JL5IF;.@-B& , 8!$SS9_NC[H_Y9PW_3SR
M5D3QZ]>>_DGZ%Y\OER^6U_.R6>4@P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@%!7S->R^J)-YM\8'BHM1_M+V>AR!D)>+(^B^%\,,_,,73
MHDZ4REQR#?E((2?8C9#7VSHJ#C;%8(_;4L-7]E15\$UM>F_6_J"SKPQXTY5X
M)\S\Y\V<E#1^D4^-019K*Z,@>7O]\D&6%VR^3WX5NJ5)6"1:VZV/MYYJ)BV8
MV$#7H",%0B@EW@# .E='Z/1>0T.V=.Z;:8:DT"C09]CMEJL!C0$1"0T:PI\L
MPLEW>M:TE"?P,LMZ<(*(6T**T\0\TTL#5XJ%3ZK^T0=Z"ZMTZ/M?,OA]X/=7
MGN4\T+V=7K%[&OE=*<">MMGTPL8QJEBNH+%><;>TF$#?>J\"YNTF6R<A,?ZO
M/7VWU1=^/TY?'X#:E@("#JD'#UBL0\97ZY7HP&%@8*&"'C8B&B(P9L..C(R/
M$;9%! !$9:&$%':;988;0VVA*$ZUK('+X P!@# & , 8 P!@# & , 8 P!@&
M!.I\>Y-TFTUY=K*E86]%0TM&0TC5;=-TZS3-8 >'+FX1TB#."=EX09Z18()#
M)2^D-9JGAU#J(=6O9L+GLWB*5M*3(+&-98@FL17:->_3KW)6N97L-99CD;!8
M>V%S&2,5JR)&C7H]&HB:MG.SV!S-VI[>^>MDY*\\->6C?L8^Y9I1.8^S6<^M
M)&Z>LUTS7/C>CN!9%<Q6*YRKEZL5F"IE=A:G6(YB(KU>C1(B'C!]N*9"CPFD
MLCL)6\MQYW:4)UM;S[CC[SFU.O...K6M717+=F_:L7;DKI[5J5\\\S]<4DLC
ME<YRHB(U-JO)K41K4TUJ(B(B=_2I5<=4K4:4+8*E2%D%>%FU;'%&U&M:BN57
M.5$3FYRJYR[<Y5554YW.,<H8 P!@$3/-G^Z/NC_EG#?]//)61/'Y_A/BOA_X
M5?#Y?E26>4@P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"&?O
MOVSR[X_/,'0_2?4GFR1:R'J,I=0:+9%E^B]#EFGVZI1X3[GXEJ*E2V7"9 EI
MDC</7P9F=>8<%BWTX!75\,GBGJ%8#Z-\C7M!AR7]R^TW$6F9:EQ%,$\6X^7^
M7?IG+(0$A/WH!UZ)%AR9R-3M#L='1U8K)"=%P,B^=$^/7Q_CY)]07PY0, Z[
M;[=5J!5K%>+O8(>ITZHPLC8K/9K!(#14) 040*Z=)RTK)&.-"A  B,ND$DON
M(;::;4I2M:U@&K$\YU;]HH[\X,*[<.6_#;P&\(06[]#ZS:/;'0JT6E3C3*VO
MPOLT2-/&VE.]/HW 1KR"5H1?))IJDX\U5.:<//?QZI\4UZZCUZ]?MSVF*52J
MCSBHUN@T*N0]0I5.A8^NU:KU\!B,A(&#BAFQ(Z+C !4-L"B"#-(:::;3K6M)
M^JMJ5M2MY [/@# & , 8 P!@# & , 8 P!@# & , JTN_0_/=F["ST"([M<^
M4ZJ+ES!L,Z[+648*=DCGX>OL%\VB;3$62IR\2-*0AL?;$0<:,VXIL0E]EUE&
MRT^R8[%]J:F"=BY^S=#-^W)CY:M9L--\E:*-L]E8\M/3GJ7H)GPV(Y:7M$SU
M1%D8UR*O OA^2RW92[V@;E:_:;(X)*"Y&.W:6>XQEJ>5\%5LF'@NU[E*Q V:
MM+%?2M%&BHUCW-<Q.-+.XF1 F(N-EHJ0'EHR3!$/CY01UI\61"+80^,:.\Q_
MX762F5H>;<:_\:T+TI'T3O6>03Q2P32P31.@FAD?%+"]'-?%(QRM?&]KO>1S
M'(K51W-%3GS/:J\T5B"&>"5D\$T4<L,['(YDT4C$>R5CF^ZYKVJCD5.2HNTY
M'(9\C[# & , B9YL_P!T?='_ "SAO^GGDK(GC\%_">7QV7R^7Y7UX?E99Y2#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'Q24C'P\>?+RQHL;%
MQ894C)2)Q#0H(  3"R3#3"GU(9&%%':<?(?>6AIEIM;CBDH3O>@-6WB$>=\Z
MGR&O^I[8&65\9_@NX2%5\YU.30O4!Z([]$OCDR'3I6(+;^W)5V+2X!+--E,I
M0F,8I\"ZSMR2NXBL>O/?)%VGS^J=-?5%WSY VG_]/],R P#C)J:B*W#RMAL$
MH!"0,%'&R\U,RI; $9%14:,X9(2,B<2ML8,((1ETDHE]Q#+##:W7%I0G>] :
MJU^N/6/VAGOTIQ3D$S:.8_$3P6ZCC=FZS&*+@Y_U]=X$IDG_  53W74-$HI[
M:=I($T\.X)%B*8MUA8=GS*? QV/7S1/LN]ZU\-?Q\1Z0V@N8\RH'&>?U'E?+
M:G"T;GM$@PJY4ZI7@F@(F%B &_ML###M:U]5KW^-\HEW;A1ICSYICSY1#SR\
M@=ZP!@# & , 8 P!@# & , 8 P!@# & , I?LHM5Y+?86+JG=>;7:0Y--W:L
M4F@=%JDA&4NLQO3W9-RRP5GZ7$@RD:Y9XZ1. 3'?GG@FVP R@#DLNEK_  ^_
MTWW<WC+$MWLWEL=%FZ^.NY')XJ[%-D;DN(2)M.S3Q,\D,K:<T4<JS=VUZNE>
MR6+C:Q#\YW64<#E:U>AVGQ&1EP5K)4L;BLO0FAQU*',K.MVK=S$$4T#KD4TL
M?=]XZ)K8XWQ2(Q7JB6D<)H!G+..\YY[(2+$L?4ZK&11T@*IQ89!C;6W2=@J=
M2AQ0#3SJV05.(;7L1MG:FV]_5"?&^TF3CS.=RN4BB=!%=N2S1Q/TDC(U73.\
M1JJG>*UJ.DTJIQJ[2KU7V_LQBI,)V?Q&)FF;/+1I0PRRL55C?(B<3^Z5R(JQ
M-<Y6Q*J(JQM;M$7DG=K?,GURIVBPQ4$=:92"KLU,QM9C%(1)6(^+C23@X*/6
M[K;:3I<AAN/$4YK:$D$-[7K:=;SI#O2C?S;\M%_O-@ D>G?^G6ZT?7G3K'H'
MM%=\['=#/Z=XQ7RR"'GR.>>A@KEK8!%BE"$3E&81H*B3F[S6Y-D6JF0K9$B'
M-_#]N7S_ ,;!)?B?KWU2J_>44>E^:\;K7./<4+8".2M<QEK@9=.070+FDEVN
ML\XZN59-[A+B=8N7P%J>+LM0$KX,-;JN9#HBI.,D 9=-Z@M2WO6M?7>]:UK_
M %WO?TUK_P#G> 1,\U[UOJ'N?>MZWK_U9P_\=;^NO_V>>2O_ ,ZR)X_/^/W7
M:_4>7KQ7_P ^:$M,H& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M -;OY</0?4/8G<Z?\+?C.?="OO5AA+%[9ZK$[=>#X9YY^@!LK79 L924,S5Q
MBCAG).,<>8=.CY"O5)6_I>GW 8OEY[])]T!>QYR\^<O\K<1YQY^XU -5SG7,
M*T%6Z^#K[:S"M#IVX?-S)3;;7ZC8+!).ES4])K;0Y(2QQ92DH^[I":#-F ?'
M(2 $2 =*RIHD;&1@A,A(R)Y#(8( (;*R"S32R%ML"B"CMN/D$/N(:990MQQ:
M4)WO0&K#W+K/8/GQ[O.>1/*MDG^=_%]R.S,1WJ_TY#-NA%>B)V,?8/WRCE9A
M#&FSX'3P[.MO-[<"(9);MU@8)AD5>#LL7:_!/LJ\_#R_/AKJ#98XGQ7E_G7E
M=)XIQBGQ5#YGSR$&@*K6(=M2!@06-J6X\^\ZIPJ0DY IQ^0EY8]XB1EI,HN1
MD"2#"7GEWH#*6 , 8 P!@# & , 8 P!@# & , 8 P!@# *RJ*1T*@<SNG'+%
MY]![%4Q9V]Q-NLW+KK4K*<3)V>1-L1;-DJLQ^CRK,\$!8 /NI^\^6TA KB/M
MJ2WI/K^2;B\GF,?GZG:B3 WGU\;/1J9C'WJ<4<-.*.JQU2[7]HA6M))5EX5X
M&1N57HN]KOQ?&ORV*PV1[/6^RD?:"A':R<%^[A<C1N2OFN2R6WLMTI^XL):B
MBM1<2JYTC4:S7"J)J8?F9BRB^?\ D(5Q%D@K-'T2!CI@27:?8DQRHX1(.F3F
MB=:?20AH=M+GW=?C5O7XM_7Z_7>A]KW4W]J,[)0?#)3ER=J6!\"M="]DLBR<
M4:M]U6*YRJFN7D>A=C6W&=E<!'D&31W(L96AL1V&O9,Q\+$BX9&R:>CVM8B+
MQ<^7,R)T"I(OU#NU$=F)BNMW6HV2I.6"O$_DI^#18X8V'7,0AGT5^4EXQ)FS
M8TG\*OL&,,N_3?X?IFN&S%1/&_BSNT7,<KA^Z7_A4ORWB/ ^G^=J]#\#X=(<
M=N?8:7U.E,<^G'N]64R]6L69;:A65V+5>KD;'1A/12E7%U]#PK 6YS\?TY>?
M7KRZ?4?Y]=$Z&9>&^(^]5R_^;I#T%Z IW5N<^+J_8(7SO"5/FLK2[?8YB7HI
M')HCH/<IV2NEFB)ZW5?EA\Y6PFJ9!U>+D9:S3MC-;;4Z+%CWU\06+W2DU#HU
M8E:7?*U"V^I3K3+,S7+#'C2L-)LC%,'#MG %MNCD(9,%');2XA6D/L-.:^BD
M:WH")/C6B4SFEH]ITCGU7@Z94(/UD$F'K5;CAHF%C$G^2_*DH;H*/#;:&'T5
M)'&'/Z;;3]PHEYY7U6XK>XG]WS_"%\OE^5)O92# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P"M#Y5/D)@/CP\R270  &K?W7HTBGFGFWES0Y,C(7
MSK$ZU]B)_'% [T>77ZXIYJ8GM#J968E -?$):EY^+2Y%72<NOA\P8Q^'WX^I
M_P 9\4L/3.]GN73VSZCF-]4]/=#E2&I271/RY!4G%\]$E-:5]8JGM2+K<@D5
MU01MF(EBA%;BVX=@0B<OBO-?7\<O)$!;[E!ZWGFAVG7WW6V&&&UO///+2VTR
MTVG:W'77%[2AMMM"=K6M:M)0G6U*WK6M[P#5F]-=[['\W_H&R^ _$MME:/X+
MY=-,QWMGUS7]O,)Z*^(4M)G&>4R/U_*S,=)H:6PMQM#P5C4AR9/4JE C,W#'
MKM.>M====^7\\]_N-C3SSY[Y%Y8X]2>$\-IT;1N;4&)9BH.%CFDZ<>7K7XSI
MB8,_#I^7L$T8IV2G)DU3ALG(D/E$.*6OZ:R!FG & , 8 P!@# & , 8 P!@#
M & , 8 P!@# *TJ#T^B\ YM<N&]AJ]SC;PJ5Z!HQR%J%BE-=D1;925+ L->L
M<$$0R;*3,9(AQK_YPT4V**&T,M3+(J/M^N9/#9'M/EJ':/ W,?-CNXQBL;8O
M5(?]A6C#"R6K:J6I&+'!6EB?*WNXWQS,=QHCG/7B\;Q>:QG97#Y'LSV@I9&'
M)+/E4D=6H6YU[0I?FG?%;JW*T3FR36898X7+))')"]G O V-.&8OG2*N$'PK
ME$/?_P UJX1U(@A9MHY>W#QB&Q$:9#/<5]5+."$_+B&J7O:]DL._C4I7UWO0
M^U4U"QVDS<^,X%HRY&R^NZ)$;$]JR+Q21(FD2*23CDCTB)P.;I$3D>@]D8,A
M5[,8*OE>-+\.-K,LME572L<C$X(Y5=[RRQ1\$<G%M>-KMJJ[4S1FOFQC & ,
M B9YL_W1]T?\LX;_ *>>2LQ3^[_M\?)//_SRY%7P^7Y7UX$L\R(, 8 P!@#
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M1>[24VVF8N=RE6&!U2U@EG&D:6\M"!P0F0XF-8$C  Q62)KD"5F4# & , 8
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M97SI#OA@# & 1,\V?[H^Z/\ EG#?]//)68I_=_V7\%7P^7Y4EGF1!@# & ,
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M88F+G:C-*=6LHU;.D1\8V\L"#CDL1L>G332W';T!-/ & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8!#V3]7@UOI-UH_1>5]$K,#5Q8HR/MK%7D;A&2+1
MTA/")E"TU4:9U%1!;,4P3$%$[T6XIPX<T,)P-.R-[A[%27,3CLCBLUBKEFZ^
M>.6BZY%0FA6.*L]86>VNKK-/&Z9S)V,]QJ)&^.21LB\'GLW;N*GF,EC<O@\M
M2JT60217FTIK\4S9)K,:3O\ 8F3I#7D; U]=[O?55D;)'&Z-.*1W.[H/T6CU
MB\"1,O!"VB*8EAHF>&2)+AL$_BVT@T=*W$MN+;TEY&DK5I33C:];_P WTUJF
M5Q[\5D;F.?/!9?3G? ^>L]7P2.9KB6-RHBJB+MJ[1-.14\#<,1DF9?&4LG'!
M/59=@;.R"TQ&3QM?OA21J*J(JHB.32JBM5%\3N+CC;3:W75H:::0IQQQQ24-
MMMH3M2UK6K>DH0A.MJ4I6])2G6][WK6LZ\[(B1Q[W3YD[U<GZ3RR^2EB._3+
M)-PU@>Y_T2"Y]<H:G'C1EIE^?],L%5BZ!?8R#-+%;-.J-CF!M-/MELNO";^_
MH#QXK[N\M>A+PCG?*>E.3UF/A9NRU1,C3KU5(7H]8K4B/$V&S\IL]LK<)7.H
MUV$D# V9*9H4I8 !FS0RUO\ Y(H<EP"7F 1,\V?[H^Z/^6<-_P!//)61/'YK
M^FD_!5\/ES^ZDL\I!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# ,)>C_0?
M,?*O#^E>@NQSS%=YYRZLG66>-<6WHDS8Z=-1L%$,.+;_ #\_8I1T.#@(UM7W
M9"7D Q&_HIWZZ= 46_$7Y]Z9Z[[A>OFD]B5]X/H'9ABJ[XNY;-M;?%X9YS1L
MD6#L$4.6G>Q9NXQ1!#<?*,,B.'Q4C8;4C2T7Y*!)KGM?CI.7+_W7F#8_R@U\
M/DN^0OM/0NQB_%G\9;K=E]A= $^SVCL4>0XNJ>3.<EI;9G9Z9G@=/HB;RP$:
M,\EW27BZRV8$R$*7<I:" 9B[Z)U7Q\OC_ +%OCN^/3C/QT\+#Y5S5MRR72>>
M18>Q]BG1FE7CKEZ(VZ\?/V&0WMXO4<*^44Q7(199#$, XK6W2Y,N4DS[Z^X)
M\X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 5[=[DYZ([E)'6:Z>B
M:)0F^?U;_"-JY37Y*:I,58M2UCW9Q[6 !#6 61(>%_0RFWY./_ R.EP;\2$:
M94[ZCV9AK3]G(HZF/[*Y+)+E+OMU+-6HJ^0GJK!32FZE++/5?$UK_:6*V&7B
M<Y>/2JJHWR;M3-:@[332W<EVMQ>+3%4?8+V#J36,;!;]HM>V,OQ106HYG.9[
M,]KIH=-8CF+I$15FAS.0:EJ!4Y%BVOWQDR&%>;N!48S#$V%"M;TF2(BAQ@F0
M'WM:^CP[8@R4.)5_X6][VG7G^7B=!D[L+J+<:Z.P]JT&3.L,JJG6%DSGR.D:
MW^URR/545/>7J>BX29+&)H3)?=E$DKL<F0?"VN^VB[U,^!K(VQ/=T<Q(V(CD
M7W4. [U39_HO#>S\^JA^HNTWKE'1*=6Y-3RATQT_9JA,0L.<I]&]+82)(&CO
M[>1O2FM-[6G>MIUG7':&N5P6F>E[+0>-^6^.V;V7%6 _QMV/A?KFF>A.8R-$
MX+PRQ ^>SJ)R]CD5A(HE9JPTM#=@1"0U5_<_8[8!:N;-REHL9II XDJ_%3P_
M]^G7_'@"6?#9Z=[MT3XN:#5>!=CY/->(J_9Y3T4?T'DUOYW6>:*C/,EC\_M\
M:K%ML4+&5OHNKE>K/%V"+?YU*6*")J_/!;&42.T]%:63PZ[3KU\O--(OKEY"
MZZ\QUQEJK+QW/[1$TNWDM,)A;/.U9RZ144\@L=TATRL-3]67*H?"02(VTF>C
M_L//ME;6[IC8[U!$CQ?&7:'LGM&-Z+;(>\7(;UD'J9M$!4W*/$RBG?)GE5X'
M8E6=L5L<B]"1K@8#VE3\A^;(%>/UL9)6@QXGC\%^_)"ZZ?%-_JJ?@G'E(, 8
M P!@# & , 8 P!@# & , 8 P!@# & , ;WK6M[WOZ:U_'>]_Z:U_\[P#5@[3
M(2'SJ?(</YCJ!Y97QF^!;H#8_1UHBR=JKGH_O,>\^B*YO&2(JT-RM=AW!I&)
M=?"(<8;B4VN?0[]V9HYFL>J_!/U5/X^OCO2HB@VD8R,CH6-CX>'!$BXF)"%C
M8N,CQVA (Z.!8;%"!"$80VP*((,TT.,.RA#3++:&VT)0G6M9 HE^4+Y(>IQ'
M1H'XW/CJ!9Z-[Y[,-H.=GXUQ@RN>6:'(L-[DNA7L]+9@<18QXHG4G%"236TP
M(#@UAD!B"C*Q#6";]>OF@)C_ !I?&]S#XZN-$5>'/=Z)W'HAFK9Z"[W8$.E7
M'JE\.4LN1(?D3W2I,:LQYI!6H&&=,=VG;Q,M).%SLG)G$$1$Z>O7\^8+(<H&
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$(_0X,./==S9,;ZAK,@
MFMAM,](XD]+3-91]EV04R!,U**-D]D%@.+^\0Z15=ME#D,-;/6EO:6?0^RLD
M[\?[,R7L=<B6V]S\3VA;!7N+M(MRP7IXX>&.5$X6M9=VQS7+W2*[;O->UT5=
MF2]I?#VUI3>QQ-;F.S;IYZ2<+IE;%8HP23<3X57B<KZ6GM>U.]5&^[GSS^?<
M)3BG,Y'H#<LU<S*C%OV-,Z(R!,*DEM;V\]( L#BH"((U^!]0FQV71].:9?1I
M]#F:UVGBH0]H<O%C%@6A'>F;56M(Z6!(D7W6Q2N<]9&M7;>-'N:]45S%X50V
MGLG+D)^S>&FRR6$R,E"%UOVJ-L5A9E1=NEB:QB1O>FG*Q6-<U%1'IQHXS!G0
MFPC & , B9YL_P!T?='_ "SAO^GGDK(G]WS7]D]?#IX%\OER^ZDL\I!@# &
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M,EI4H+38D\E]80SZTES)RGIV7U^;?'%CVOOK75?RJ^0+2<H& , 8 P!@# &
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M@B!1K3+$<&,(PP* R.WIIAD(=IM#(K3+24MLML(;0VWK2$:2G6M90?;@# &
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MH&_,G,UN$G)-$U.5^AQ,O)R$-SNNS4NTQ)2\!18^O0\D8,(\:$\H0;[0$I\
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MU(EC:-ZH8;NE+6USVOTY)R_.P7\0%?@:I#1M<J\)$5NO0PC,?$04#&AQ$/%
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MDPDW;0;L543JH*+>I5_W3\FE2D.R?(_V 7XFOC 8WHU/#4VX.G]GZ]7TJ_-
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M5'<# & , B9YL_W1]T?\LX;_ *>>2LQ;_=_V7\>OF7R^"?E5_)+/,B# & ,
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MT'6K7X=MIYI]_I^_($=__7C\WWM+;X?C#X]:WX^Y[)Z^U&]K]OS,@'94 O\
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M#Y%_515^KU<7^JR%=_Q<)P3@D*0MM"S&Y&?F)A-GEOO:94VN1$G*2^8RE*7
M=?ATG37BJKR7?5?-53EX^'V0$J8SY=?AH\.-IXI\?7&2.[]%+_!%A<[\2\3>
MFY*RF,[TAG<UT4L&,U;M*7_F>E )6[R"M[V]]@A2];5>71-?+[_POZ@Y=7H'
M]H0]JOZ8X5Y@XO\ &WRR41]&>A>D)E'0>OL".?ZDAT_48;L"0VRO2FH^=Y4*
MTA]/X-S;6M;=2Y[Z<O/?X_SX_0'*5[]GS"[3(BVWY+_<GI_W%84DH/71W;C+
M<RXR"1O>G'10*I%R<I*C#(<^J&G*],5%'VDI2D%G6OP::\5Y_M]O+R1=]5\0
M7(>=_#OD/R;'L >=/.O*.4.,CI&<FZS48Q%M.:2C\'_U6YFLEVN76M/_ -QR
M3F2W%[WO:E;WO>4$J< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P")GFS_='W1_RSAO^GGDK(G]WS_"+YKZ\$!+/*!@# &
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MM[0KZ;W^%6M;UO:=_3>M;U]=?QP#RP!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & >*5H7K>T*2O6E*1O:5:5K2T*VE:=[UO?T4A6MI4G?\ %*M;UO6M
MZWK /+ & , 8 P!@&&O1G/)OKGGWN?*:U*(A+%TSC_2J! S+CCC3<5,W&FS5
M>BY%UUG_ ,S;09LBP0XXU_Y$(;4I&MJUK *H>+N]$[??_C#I0OG#L?%SO$,'
M8YOT--]&YU+T:HT^6C/-%F\] <BYS;I(<>O]9C[C:K>W:P9?FIUAK#53H<9*
MRQL>:;%@ZGEX?#\ N7O %TDZK+@<\LL!3[D0TPF$LEHJ9EY@8MY!@[A+DA5
M+72"Y=#P*"A66F;3$['(?9,4Z^@=0A%!"BE><_9-#GNJ6&&]7<*>-Z]T$;I-
MG;D/(-L>&&GA><<]Y@VQ#H8]9C."QBJ_S6!(6P4Z<1N5(DR-%I&?'#$B)K?Q
M78,@_N\]S_S3^=_Z.KG_ '>Y0/W>>Y_YI_._]'5S_N]P!^[SW/\ S3^=_P"C
MJZ?W>X _=Y[G_FG\[_T=73^[W '[O/<_\T_G?^CJY_W>X _=Y[G_ )I_._\
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M]S_S3^=_Z.KG_=[@#]WGN?\ FG\[_P!'5T_N]_\ \P!^[SW/_-/YW_HZN?\
M=[@&5?/W*)GC?/B*O9+@)>[/-7SIW1[/9XZM+IT2=8>I="LG0IAF&K#U@M9$
M-$1YMC=CXT,JR392116UOR#SBU?A S;@# & , 8 P!@# & , 8 P!@# & ,
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MR6,Z?,RLEZ\O76;5>^D6R\0/ F(\J(M5CC;#"-\?/D@6*A6WF)T(8H,_3YY
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M*)!CBH_<7GI/BGATUSWM>7\\T^1//ET5.O/FFNG7S557Z&R)F1!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M9LEALMIB*^69C>)=:<KM-S7'=BZE=[E:1.8\ZK$Q0Z!>T\]L\W9;D3!3\I-
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?Y55?KS ^@P!@# & , 8 P!@# & , 8 P!@# & ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g120909g09b98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g09b98.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1BB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &(:^8G@X0DE-! 0      !<< @   @  ' )0  M0971E($AA;FQO;@ X
M0DE-!"4      !#]I6B(9L\8>(^>]R?; 1Z).$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0&CT[@         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      -!    !@             ![0  !'X    & $0
M4P!0 #  .  S     0                         !              1^
M   ![0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ![0    !29VAT;&]N9P  !'X    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   >T     4F=H=&QO
M;F<   1^     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    #.$))300,      X]     0   *    !%   !X   @6    XA !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !% * # 2(
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M:SN_E(BIVY7466/%>#ZK _:QPM:"6[=WJ;7_ $?TGZ/9_;3K\ MK
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6[?O;&;VC87+5V<*$$MN>6Q($7GA \K,P4<DA00 23QR3BCKJ&LA-?74JE"
MNTAAIUXJT1D;CN<I"B*7( !8@G@ <\  9'S$S,QQC'&,<8QQC'&,<8R&F_/
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MLY[S#'SSQV^F:+U=H5Z7ZEW/3ZVC=74W9*@M-"*YG"!3YAA$LPCY[N.T2O\
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M33U>Q8R@AXXL7.CBFI<F,ZREC/=NS]6Z1_;SJG\W[?\ U_W?'E/H^W\WH?\
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M;165YPE%B!*RK.,8PDN/5G.<Y\,8QC$C.<YSGW8QCXY]W+B[W1L0%W.J8G@
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MI6-1Z-S55%-BHL\]Z-+GRHDE3S*T<K(BR21)!*)EQ8NB[+0-/-?J+^"J30I
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M[2K9,:8SXZ>U1G[.M:+G^&KBN9_AS_D]Z$_D;TO\/A^TE'X9A];>G6?5H_\
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M+2I&<H7GS5I4A7@I.<8[-K+U+9Z^I?UUNM>I68$DKVZDT=BO,G''=%-$S1N
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MVIUEB]D-W-51)=G+K6KXE"5$,EGK!<"UBK:5DA$Y]_O]_P!>,[6=JC>PP&N
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M^@K///)GZ1UQ)Y^M/+]?LS 6:41U/V'TH!$[(VC9 EO'[$=,BKG<9M@@K4#
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MS.2 D4,<J%Y9')"HBCCEF( Y YY(S"V+*M*R"?62&6-%]2SNR,%15')9B?@
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M8\O'ND,LNI;>_P"L2KCZ/M_N/W^;&6/Y7&.,9@FQ:A+NE<2-&%& IH:;K]G
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MX!4+&>&)!+?." ,2[0FKK8/)A=OR>P69[%G7H_M;$>;)"LA9>! Q_8XRL+5
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M */%3\W27_X\P>_;([7ZL$C+-<(G7R:!DVBMUZ8S6T;&?+XQ8"L<<EV,@H_
MA_\ )>E4M2G7\^;X8SAIWWHSK/5767COT-1H[GJ&KX36-7/N]/J)TTQZPFV
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M]H7F/JH8PQDLRH>QBD;P1K(&1+CD2K[0W8KBHIC8%^Y9T;@#@M86Y(W';$A
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MA9YTV;#C2V7!%5KNRJC-N,X=(EPXY"T1(+2IQ%V4PS[;5W4/8LD+ N43ML*
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MH,B^=G/.+C$^=O(&I/G3XJ?.QCK?U]3G*?%W'CC"TJ1G./=YR58^.,XPP/\
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M/.8;PMU>?>I:E*S\>,9]O&,YF;/Z"%;-LG=E\HEKHE9B[X'[&J=G"DZ3*DM
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MGK1#"@+*4(9JKT1-F"C88YETC8! J'[8KR7E'AS&46U'T4NFN;]ILNW$UH.
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M*Z=)4>!>1,RW72TE=C7V4LYA!^R26H\6(+!"  @4_NQG2/C&4LWSUROV\MJ
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MG.,9Y8GL2V7[Y?++^O)2**+N)/+,_E(@=B?4LW)/TY[CC2(<)W<?0SLW 'P
M[B> /F S:W+&7,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g120909g11i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g11i11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1GJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &<Z^9@8X0DE-! 0      &4< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(Q.34V-S8< @4 /$UI8W)O<V]F="!7;W)D("T@,3(P.3 Y7W=O<F1?
M,C0@,C)*=6YE,C R,2!#86YD96P@961I=',N9&]C>  X0DE-!"4      !#]
M&94FWJ7M)'G+P:K]*5CY.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              V@
M  1R          $                          0             $<@
M V@                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M V@     4F=H=&QO;F<   1R    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M:E22222G_]'TRKJ&/=E68M>]SZ3ML>$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $7 6P# 1$  A$! Q$!_\0 '@ !  $%  ,!
M  H%!@<("0$#! +_Q !5$  ! P0!  0%#P4+# (#   % P0&  $"!P@)$3AW
M$A,4%;86%Q@A,34W6')TF+.UM]894557ES9!86)V@9&FU=?P(B0E5G%XE)6Q
MP='3-*$C0D;_Q  = 0$  @(# 0$             !P@#!@($!0$)_\0 4Q$
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4!XOU]5^KW: U">\/XQ(,UGDOG$X-E\-F9[+$DQI56'W%.7<PA<S*@[L(N
MH.&DQY(A! J'E9-JZ*CV]E\ACYJOG96P&3M*Z0&Z88/&323'92HH'B43&NSJ
M0E!83"H"-<BH;&TL0X\<B[L):OB"C@L\35)$W3U55TM9--N@@!^& EB4Y#S$
M@_34<NHUK'5RP')1RZNB+6-']Q-2RS1K9:S1-<BW9LT7:WB+JKIM&N*F>5FZ
M-L ,YT H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0&'0/P];-[K=->DVZZ S%0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MBN2>&2F65\;7L!T!H!0"@% * 4 H!0"@-$NCT^!K9'^]7RP^_F;T!O;0"@%
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M!B[G?V->2W<]-?L=Q6W< ^>G#/?&'^]1XW$7D/5?U*_YC(/57J*\"@% * 4
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MRR1'*]C;R7^+)R8^CONC\#59;VP."_?+I/RNK^9%7VMZ[[EY?Q?]1[&WDO\
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MZ&;=):RZBRV&"5T5';5-6RF6/B\W+?#/JR63MD!2B<ZA88B.$%I9'!Q4L5:
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MVKDE"+@FVF]]LM,KN9NR3<>J4VN5)PDY-J*Y>UM13W]+?^!HX$VSS=4Y6>S
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.."@% * 4 H!0"@% ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g120909g15d66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g15d66.jpg
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M,E%5DI.6TR0S.%)XMS="87>X-'$F-4-T=;.1M+;_Q  > 0$  04! 0$!
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M<+?F#2_W\M<00A]E&<<U6IMDAXUQHLSKCI/,E9Q)%TFM8?GK_;96MR-YA+!
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MIGP=@#G6Z%6^#UV/SZM5DDLS*JM(.4V1W3-T+/7&$H4;3\:WCX/_ ")NASU
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MV%V^)W*$79C"6<V-87'('=6)O(]"N Y3,CV,P:6PNL3CV3V>:PLKJRLKJY&
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M&DD<@7A)"(K,<@3D. )JN+9?9Z:6.&+9C9UY99$BC08#A&;R2,$11G9@9LQ
M&9 X\355,_".[[J],2L!,Y;183$')/H>58JXMPL95E)1CI5D^:*F2Q^HF91L
MZ051.*9SD$Q!$AS%X"-C#L8;%L/L<5P[',8NL/Q*SML0L;F/&L9"7-G>0)<V
MLZ![M7"302)(H=58!@&4',"[>;(8'87=U8WFRNST%W97$]I=0/@.#EH;BVE:
M&>)BMHREHY49"58J2#D2,C5M^,UWN>F9KW5X9]WFLSG%]\:XU]-XO]]K'][>
MS7@ULY] 81]SI\9KO<],S7NKPS[O-.<7WQKC7TWB_P!]I[V]FO!K9SZ PC[G
M3XS7>YZ9FO=7AGW>:<XOOC7&OIO%_OM/>WLUX-;.?0&$?<Z?&:[W/3,U[J\,
M^[S3G%]\:XU]-XO]]I[V]FO!K9SZ PC[G6V.*\G_  Q>::VC<,=!+2U8=I=/
M'S4KCS;K46,LA_Y7,*I<:M #,M3B D([BRNVICE.0%N8AP+X9MM^$[R-\GF,
M28!M9RK36.,P2;J[PZQQ#:['KFPEX:H<17 (\4&'SJ"&>"]:"=5*L8\F&?J.
MS'X.6UFV&')BVS_)9A5UALJ;RWO+G"-E\*ANH^.4EFV+<Q-Y$Q!"RVPEC+ @
M/F"*@[)>]_X2/#EF7I^4+G*4BQH)%<>#9[#V'&IG+0YCD3?1SD,>'9RD>HHF
MHFE(1KETR5434(FN8Z9P+Z3L?R@;/<H&#QX_L7MM-M)A,CF(W>&;28I,(9U5
M6:VNX3>K<65TJLKO:WD,%PB.CM$%=2>,VBY-(]DL1?"=I=@\*P;$$42<WOMF
ML*B,L1)59[>3F9ANK=F5E6XMI)869659"58"/_C-=[GIF:]U>&?=YKJN<7WQ
MKC7TWB_WVM#[V]FO!K9SZ PC[G3XS7>YZ9FO=7AGW>:<XOOC7&OIO%_OM/>W
MLUX-;.?0&$?<Z?&:[W/3,U[J\,^[S3G%]\:XU]-XO]]I[V]FO!K9SZ PC[G3
MXS7>YZ9FO=7AGW>:<XOOC7&OIO%_OM/>WLUX-;.?0&$?<ZA+-NYC/6XJ/K9\
MQW%.VL*J\EB5XZ=4I%:*Q>2Z$<,H435&NP*KP5T8^/'E?BY31!+BV!(RJ_24
MM)/)EOKN^N0,]//+Z\O F>6K=BZGF$9;AJ*:2V2ZL]*Y9=IAN%X>TGN?AF&X
M>TH7>^Y^'V=B90I;1O3:PPF4(6?1KU:"S:<M1SUZU36=32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*5L1M"_XLMK_ /U$84_[E5G6'B/_  ^^_P"CNO\
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M'X-7E<VY D RO@Z/!S*,S]3E<E1K*00Y8>-3Y7+4[8QD3FY.<H"8>9,Q#@/
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M6LZL6KY6'S>,LM>DGAQ3:1\Y$OG2A2&4,1NT?MUUSE(0!.<2I)F,!" )C"'
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MB"E$4HV<55602AGZBC4I&<LHNW<(IQS@R;PZJ"R941.D<I=Z)8B0!)&2REE
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M\5509J/ R+7!;$=K((N%D6QUN0JZJ+==5-(3G315. $-BW^7,;W5F%YI<ZB
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M"G7.1!N;D-R_L@;<S@O2 )O,H*O1"4OG*!A\VG^O]?ZX?+4]MQZ/DZ>CY:^
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M*(@7B8.(\'^O]?Z^3X<Q';</R?EZ?W?NKD<L7S..C5?B4$@%J)T&X&.MP-S
MX KDP)I ;EX&3%4P@)A$H"  *I[;AT?+T]'R4 L7SEXJO^CZOQ.(-VXG!UQ#
M@0I>L@46_#C^T$P*<> =%^\'^O\ 7^C4=O\ V?W]''_V_?7PA8S_ &;I%7P
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MGMN/1\G3T?+7PI8[E2YE'H'%8P+@5! 2E;\3<IDA%P G6X<G,0Y2$XB8 4$
M 3*=M\GP9=/3\/\ [4$L=RJ\JCT3@X $0%% "F:\2\3*B"XB1QPYN"92G3X@
M4!4X"(@J.V_L]'R]/']W1^^OIRQO^T]&J^'@"?4^=!N'.;E_:]9Y7!NB #>9
M,4NE$Q?.8"CYM*=MP_)^7I_=_K_W^B6+YS\JLAT?5^*8BW;@<77$?D' '(E!
MOPY?VA3&4X\?V7F#BIVW]GI^7H]-"%B^9#I%7X%%(1="1NW$Q5N!>!4 ,Y*"
MB7-S<3J"F<  H@01$0!3MN/Y/3PZ>CCT_+T?OKB0L=RM^D4>@<3GZT!$4#%(
MGQ-T8MQ,X**AQ#DYP4!(I1$W QN <5.V_L_)TTY8[E']H]Y^L\ #H4.7J?-_
M3$>L<>L\G$>B .BYO-TW#SZ?Z_U_HT[;X=/1\O3E_=G\G10Y8[E<]&H]$P&)
MU3G00*4Y?D](+D2N#"F8/E<@) J!N!>82\1X*=MP_)^7I_=^ZN1RQ?,MR*OQ
M("/%N)V[<#&<<#<2K #D0(CQY?ED$YQ 3?(#@'%_KH_]^&?[<OEIVW]GY>GH
M_P!9T*6+YT^95^!!0XK"5NW$X.?-\E,HN0 R']+Y9C$4\P?L_./!3MO[/3\O
M1Z>BOA"QO!MTBCX!'GZYR((& G H]'U;F<%Z3B;@!^EZ+E+Q$O,(  JGMN/1
M\G3^^O@%CN4G%1[S]9X* "*'*#3B;Y9!%QQ,YY>7]D8"I<1,'2\  15';?V?
MW]/P_P"=#%CN5?D4>B<%2@V R" %,AQ+SF7$' B14 Y^4J8*$$0* G !$2J=
MM_9Z#W>GCE^SHS_;7(Y8SBXZ-5^)0(3JG.@W 3J<!YP< 5R8$R ;E ADA5,(
M"(B4H@ "J>VX='R]/1\E?>6+Y_\ >R'1]7XB/5VW/UOC_0Y>L\O5^7S])S=+
MQ\W1<//I4=ME_5S_ &Y95Q(6,XMND5?  D/UOD0;B)%. =&#;F<@"A!-S <5
M>B,4  2E,(B *GMODZ>'3T>FOA2QW*CSJ/0.*Q@< 5! 2E;\3<ID1%P G6$.
M3F(<J9 $3 !Q  $RG;?)T?+T_#^SIH)8[E4X*/><''!(!10Y1:<2\3J"#@1*
MXX<_[,H&2X@4.EX"(@_U_K_7]_".V_L]'R]/']W1^^NEP#8%#]5,N=+B7D%P
MFFFH(<@<W.5-10H#S\P% #" DX"(@(B /]?Z_P!<>GAT"1G\.7["?[LO\ZZ-
M*FFE*:4II2FE*:4II2MDJ]NCR73L%Q&":;(JU>$;7G,%NGYN)4;(S5EC<R4C
M%%"L-16D.H>%HJ"5@,8KQ\LWBY9%O9XJV2T--M%XY,476$]A!)=M=RJ)',5O
M&BL"5C:WDGE20#5I9]<P92RYHT:LI!XB\L\BQ;E3I4O(Y(RS(E2.-ESRS TQ
MY$ C4&((RZ=NS?"@6]];+%>IJCS,C:;1*WEK)+'R2#^"1IEXSK8\_+"UJ]LH
MULAGN58:Q6(]*89"M*%GJ3[%#%"@6#$\Q&N9!9WKO<*,(D2RHL:+$5 @TOO8
MK5+3C)'+&P@=$WC0H4D$Y,J7"D #)Y\Q8N5)8EP3KS&EYFF_)96!D#-I#L&7
M=C08R"<[S"?"A$C)]K..L)OG?@V4,K'LB929K,O 1K19+0ZB7499,76BO-)&
M=D+=,O)ZQU*"J+^/D&=>0QLCC>IMK'4+72V!:D*"Z U+VQ,!U:MVD>H,D\;$
M*L:A4D:0$%S-OI"DD87V39F(G(G(;S,:2S,1DR,,SJ.;*%(R4)H34CQ;DSX0
MFRY'P59<**T@8M.SU^JUR1G#S-4FBO6L*RP:>8?27A/&1[FM*R,[@R#=PJT9
MD*&8PD$Y90$K'6IU7HV>/?@P=(+I+H2ZBCR.JZ'3+4;K2JZ9MV%"W+!@T3EF
M!96C#LE4/>%X6BT9:@H+%E8G2(LR<X]1),0(R<!0=)#:0:Q>M[OJ+$V2CY)F
M,$*3^7*U1<:8SE+@.35V$(2L8EQU#8MI\Y0J?XDO4*MD/Q4J=00GI>YR^4J#
M/K1TVW?8P-"6F2AB7'PZ9DEA6[T6[S3SK%N S:[B9IY%EEWH+Q"220H(U@E3
M4I$^J-6JE;A R.8<Y%2-"V\(&4:!%95TG)]*KJ+F1&R.:9,14R.OA1;B%N:3
MT5CHK*!:Q=18^*J]W.1F,A6K-M=L;BS-B5NIU:!B+*^/MCB4HZ1@ZQ&%K;BQ
MD>Q2 >+,:V<XHP&+=LC39NS.=X(AF%>.]C$9+R.[1CGA)5Y&UZ,F/;L1=-^^
MH$(  %&1;@2K0,6R554,=QD"JC3JX?DBE3^$]L=$AJM!U?'\T9G2+YC*T0#B
MUY$B;E/R4-C6X8&NS%A<;G,XP->Y&S+RN :LQCIZI6FBU6MUTT?7HG'9(NJ5
MEO'GP*.5I&>9<Y8ID;=PF)%::.ZC)CB6;<B/3=.622.61WS=IM4CEBW[(JJJ
M$Z'1@6<,Q"-"PUL8]9;.$9,K(JKI41Y(M>7+Y\]E'KR2DGCJ1D9%TX?2$@^<
M+.WKYZ[6.X=/'CIP=1=RZ<KJ*+.'"ZAUEECG44.8YC&'? !0%4 *       ,
M@ !P  X #@!6 2222223F2>))/22?A)J?MH7_%EM?_ZB,*?]RJSK$Q'_ (??
M?]'=?X#U?M?]YM_^?#_B+4%G9O)&:/'Q[5R_?OY0S-BQ9H*NGCQXZ=B@V:M6
MR!#K.'+A8Y$4$$2'565.5-,ACF !RLPJZF("A<R20  !F22>  '$D\ *L $G
M(#,G@ .DGN5>9>@WB O<EB^:J%EC,DP]L=T.4H3R$D4;@PNS"74@'E1<UPS?
MPLG9&TZDI#JPHM/")9,AF(M^LAT>J5FB>)9UD1H6C$JRAANS$5U"0/GIT%>V
M#9Z=/'/+C511PYC*L'#%"A4Z@X.DKIRSU9\,LL\^%6&2BI*'72:RC)S'N5V,
M;)I(.TCHJJ1\PP;2L4\*F< -U>0C7C5^T4X<J[1R@NF)DU2&&I65P2I# %E)
M!S&I258?K# @]P@BJ2".GN _L(!!_4001\AK)Z%C:^Y2FE:]CRI3EPF&[$\H
M\9PC%5WX/C$W31@>3DUR@#6,C0D)"/C^OR"S9H,A(1[$JPNWS5%6B:>&W77-
M(D:DZ06.6;9$Z5'2S9 G)03D"<L@35:1O(=**6.6>0&>0X#,]P9D#,\,R!\-
M8].P4U5YN8K5DB)* L5=E9""GX&98N8R8A)J)=K1\K$2T:\31>1\E&OFZ[-\
MQ=HI.6CI%5!=--5,Y0K5E=5=&5T=0R.I#*RL 596&8*L"""#D0<Q5)!4E6!#
M D$$$$$'(@@\00>!!X@U:M55%9U.8PR+68%O:;#2+1"UMV:&*UGI.%?LXEP:
MPFM*<$5%^LB1LH,LK1KFC'@10>M+U.QH)<RL-($;VDGAD<HDJ,XU$HK MDF[
MU'+I[7>QY]S>)G^4,ZS&ZJ&*,%.63$$ ZM6GCT<=#9=W2W<-8+J[5%-*4TI3
M2E-*4TI6R>$O_"7>)_[#4O\ ^5&W/6%<_P"\X=_U,W_HKJK\7]%<_P#*3_'A
MK6S6;5BFE*R5&I3+BG25Z311&O1-EA*D\7%PF#@DS8(NP3$:B1J(]*HBHQK,
ML=5P4.C1.FDF<>9<FM-)CV'1;06FS#O(,6OL&Q''K>,1,86P["[W"\/O':?\
MA9%N<8L52(]LZO(Z\(VK8IA5Y)A%QC:HAP^UQ&RPJ9S(HD%Y?VU_=VR"+\ID
M:'#;HM(.U1D56R+KGC6MS6NII2LFD*E-1E6K=Q=HHE@[9(6.,AEB.$SKJNZM
MX'\+E6;E'I&Y$O#L?T)U  %^=3DX]$;6FM,>PZ]QO&-GH))&Q+ K7"+S$8VB
M=8D@QSW0]SS',>TE9_<R[WBKQBTIJ_+6MC<85>6V&8=B\J(++%)\0MK1Q(K.
MTN&<TYV'C';(%Y[;Z&;@^IM/Y)K&=;FM=32E9-8ZC-55*M+3"**)+9665NAA
M1<)KBM"R#R18-EE@3$1;K&<1;LIFZG!0A2D.8.!RZTV#X]AV./C$>'R2.V!8
MS<X#B(DB>()B-I;VEU-'&6_I8Q%>P%95[1BS*.*FMEB.%7F%KASW:(JXKAL.
M*V>B17UV<\UQ!&[A?Z-S):R@QMVP !/!A6,ZW-:VFE*FO<9#1->S7?H:"C64
M1$L)-FFRC8YLDT9-4SP\:L<C=LB4B213*J**&*0H )SF,/G$1UYQR1XA?8KR
M<;+8AB=Y<W]]=65P]Q>7<TEQ<SNN(7<:M+-*S.[!$5 68D*H X 5V.W]I:V&
MV&.VEE;PVEK!<Q+#;V\:Q0Q*;6W8K'&@"J"S,Q  XDGI-0IKT>N.JZ0<,^L4
MW#U^+(163G96/AHY-50J*:CZ3=HLFA%%CB!$B'<+IE.H<0*0HB8P@ #K!Q/$
M+;",-Q#%;UF2SPRQN\0NV1#(ZVUE!)<SLD:]L["*)RJ#BQ 4<36596<^(7MI
M86P5KF^NK>SMU9@BM/<RI#$&<\%4R.H+'@HS)X"N$Q%O(.6E(20(1-_#R+V+
M?$34*JF1Y'N56CDA%2<2J$*LB<"J%$2G* &+YA#5>'WUOB=A98E:,S6N(6EM
M?6S.I1VM[N%)X69&[9&,<BEE/%22#Q%4W=M+975S9S@+/:7$UM,JL&42P2-%
M(%8<& =& 8<".(X&K=K+K'K)J?49J\S[6M5Y%%>5=M)=Z@DX<)M4C(0D._G9
M QEE1 A3$CHUTHF41XJJ%(D7Y9RAK3;08]AVS.%38SBKR1V-O/86\CPQ--()
M<2Q"UPRU C3MB&N[R!7(X(A9V[536QPG"KS&KZ/#K!$>ZEBNYD6218E*65I/
M>SDNW:@BWMY64'\I@%'$BL9UN:UU-*5DU=J4U:&UI=Q"**J-.K*]MG!6<)H&
M1A6\M#PJJR!5! 7"P/YV/(#=/BH9,ZBH!RI&UIL7Q[#L$FP2"_DD23:#&8L!
MPT1Q/*),1FL<0Q%(Y2O"&,VN&7;&5^T#*B?E.M;+#\*O,3CQ.6T1&3",-?%;
MTO(J%+..[M+)G0-_2.)[ZW41KVQ5F;H4UC.MS6MII2IKKL-$N-O.6; O&LEI
MR*RU@B*C)91ND>081DY5<_NIE@T=&**R#24<P,*N^03.5-RK%,#JE,9JB)?.
M,7Q&_AY6-@\*BO+B/#;[87E.OKVP25UM;J\PS&N2V'#[J> '=R3V46)XC';2
M,I>%+ZZ5"!-(&[&PM+638+:B^>WA>]MMJMB;6WNFC4SP6U[A>W<MW!%*1K2*
MYDL;-YT4A9&M8"P)C7*%->CUQU-*5DSFI332FPU[621"NS]FLU2CERN$S.%)
MJHQ52F9I)1J ]*DBBQNT =%P< 3<*+N$TQ$S97AIH<>PZ?:#$=F(WD.+87@V
M#8]=QF)A"N'8]>X[A^'.DY[1Y)+G9S%%DB7MHECB=^$R9[&3"KR+";/&W5!8
M7V(XCA5NXD4R->85;87=WBM%^4J)#C%B4D/:R,[JO&-LL9UN:UU>X_P6NPG'
MN8*N_P _YKAD[57TYYY 4&DOC*E@Y%:'!$)>S3Z*)R#*M4WZIXB,B5U 8F78
M2BTFT>IG8E3_ #9_#5_">VKV"QJVY+>3K$7P/%&PRWQ3:C:.V"'$K5,0UM88
M/A<LBMS&9[55OKV^B3G0CN;*.SGMV6Y+_:/X-'(?@&UF&S;=[8V:XI8+?36.
M!8-.7%E</:!!=8E?(A7G<2SL;6VM)&YN9(+E[F&93 %]DLD;'=J>3JLZJLQ@
M_'D"DJU.W8S=&JL'2K+"J<@E;N8J9KT>Q<$,U4$JR;-X#R*<'(5-_'NVXG1/
M^?NR/X2'+=L;C<.-X?RD;5XE(DRRW.';1XWB6T6$8B@8-+#?8?BUU<PN)ESC
M:X@W%[$K%K:Z@E"R+];[0\C')AM)ADN&7>QF 62M$T<%[@N&66#XC9L1DDEM
M>6$$,@,39.L4V^MG89302H61OR+[DL)2VW7-V0,.R[P))2GRZ:4=+ ET'AB
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M$!$! ?G#2H/0?U&JN;231FI=%$A4DDI1^DDF0H%(FFF[5(0A"AP I2% "E*
M     'F#4GI/ZS_?4+Q5<_S1_=5KU%555,6:\@[;L6P%,X=*E11*8P$*)SCP
M* F'S%#_ -1\P:=-02%!)Z!5+I4TTI54T9KO3+E0 IA;M7#Q7F,!>"#5,55A
M#C\Y@( B!0\YA\P:?Z^:H) RS^$@?M/15+I4TTI54BS77;/':8%%%B"!G B8
M ,4'"H(I<I1\YN)QX#P^8/..G^502 0/A.>7[!G_ )52Z5--*5?3((^+*3GH
MD^L#.N$!6Y"]**)8]JH5(3\.84P.8QP)QY0,81 .(CJ?@'ZS_EZ:HS.LCX-
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M(RC-MYF0<LC$&Z?=[#9]HV/Z+5: K1HROJ1%BLZ*TNJ_C7=U:TV,KDS(U:"
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MV3-N_"2^\6V^PJ;JYN2SBOMURY-*Y&FSRD=EW L<R>"G&]*W92]3W!N))N0
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MMLQ/7K(I8C'&3[S4+(6SQ570B28>@)Z*2E\RP+IG,6*7A"JL0F<R+'HE5DE
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MYM*G+Y3T9=/[_P!?RU\,\YBKEZJR+TRI5>8J' R/*)1Z- ><>C2-R\#$X#Q
MQ@X^?2F71Q/#]_Z^[7([[G%P/4V!.L)D)P(WY00Y $.=N'./1*&X\3F^5Q$
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MT4<C2K(((-1<K$%%S<.T\QR9CJTW,-LJR2%%6.XE)DB1&D7,22VE9ET%"\A
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M;&:-"\I"]$W.[=/3)\2E*8_%T\<J\R@G.'2<@&Z,A"EG,G+Y!D/U9D_WDU
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M6KNWN(+/UL?OF;*:N49$%Q_"R#ZF(8KA6DEFQ6DCW+RW-K"S\X,RW3NKND2
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M-(XV1'#*I-63<(9S,%8,%D 9LI"S[O1 Y!':NI"O(VIRSYL-).59]CS?O%X
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M?+G">KU@#[AR![R===V-,2_2ORI_2>RG\'5SWOSLO /8;S+'OXBIY<X3U>L
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M^S2'M+49CN#]_IJK0?SW^<>K5SA;0R:2K!TX@8-!!!RFHJLW:OA73(4>(G2
MT@<HG#]P"4P?^FI! (.D<"#\/IJED)4@,Q.702,OV\*MGA]#ZN5W[-(>TM1F
M.X/W^FJM!_/?YQZM/#Z'U<KOV:0]I:9CN#]_IIH/Y[_./5JYQ=G9-CO16@81
M$%HQ^W3%!L_$5%ET#$225XR)OV"AA JHAP$"B/ Q1\^I# 9]J.((^'X1^O\
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M(YDW<*.';Y^\71:M&J"9UEW"J:21#'.4HY)C@2,NZ1*B)J9BB!551F221D
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M0P2.54^72MSO*"JB*UKMB*R*ATE4E9V835253,)%$U$SN@.10AP$IR& #%,
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M1^(OHIK?\YO&/IIX\73ZWVC[_EOS>FYBZJ/Q%]%-;_G-XQ]-/'BZ?6^T??\
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M2B:W692I8PJTXE7ZG%Y$KKI%K9Y2V*L)O&-7D\8KXF*\F6KR$P$*%'.5;3'
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MTW#5MN^(FG.]4*,9"+"B6)>*@)W,+'N%%^?IAX"[45,Z,3_](5A2X!R< J8
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M](-ICE9YN[VSO' D,N[W'X:<KF3220(99?)M;54$B"!$D$2"<YA*DBFFDF'
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MKHM]%UL?CKZ:YG=R=6_BMZ*=0??0G?V9;\&F^BZV/QU]--W)U;^*WHIU!_\
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M;['JNF*JE@,=HY48/GK%1= R:IV;QTV,847"I#X=S8V0N,/ L[4!KF4,!;Q
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M.OF\J_K4[6&Z;UE<_P#?)D7]1Z<PL>\K3S:'U*<XN.OF\J_K4[6&Z;UE<_\
M?)D7]1Z<PL>\K3S:'U*<XN.OF\J_K4[6&Z;UE<_]\F1?U'IS"Q[RM/-H?4IS
MBXZ^;RK^M3M8;IO65S_WR9%_4>G,+'O*T\VA]2G.+CKYO*OZU.UANF]97/\
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MB_2?FM)C0#RB2(:8Y%0E& "+O5B9RSN#)F)(YD"1@&%BQ;-:N-9')2K<65F
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M<D/*%B%GR;[*VR<F?*3?+%97"B[L</V9>UFSQ"\;5"\^U=O*5!;0=<,9U*P
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MDDFOUVMK:WL[>"TM((K:UM88K>VMX(UBA@@A18X888T 2.**-51$4!550H
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M_P"/)>R],AW1^_T4UG\Q_F'K5<VE89*QTJN>?A#JM2LA153<2((HBLY!-07
M#&@804(/(ERE/P/YQY0\^I"C(G4. Z./PD?V?@_SJDN<U&EN.>8R&9X?!Q^#
M^[.K9X ;_62N_P"/)>R]1D.Z/W^BJM9_,?YAZU/ #?ZR5W_'DO9>F0[H_?Z*
M:S^8_P P]:JZ19$959J0C]C( >?=&%1@=P=-,0CFH<AQ<-FQ@./#F "E,7@(
M?*X^;4GH'$'B>C/N+W0*A3G(3D1V@X'+/I/<)K#]4U<II2FE*:4II2FE*:4K
MTKVR;R,689PK$XWO=-G;J+&[92E9RJ)5>!<P5OK.2XO#K%-DYNDA<VSN%)!O
ML9*R4O5U\=6B(O4>L2KR$M!L)60?--)?8;<7-TT\4B19Q0JDF\</&\)N#GNU
MB(;4)@JOOD:(YR!6*A3FP7,<<0C="^32%E*@AED$8_++C++1F5T,'!TD@$UF
M%1WI[7XFOT0]HVZU^SVN"NE:L=C F&,-PT=)Q!+=*V.]5MXZBEFD'9J]/)A
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MD4"L.5U=@5144)&H50 ,U158G+I+,&8LQ+'/B<ZB/615NFE*V(VA?\66U_\
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M-')&X*NC%6!!(JY#-+;S17%O+)#/!(DT,T3M'+%+$P>.6-U(9)(W571U(96
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M_;IR_N-6C45732E=HKK"B1L*J@MTU5%TT1.84B++$2365(F(\I5%2(($4.
M8Y44@,(@0O!_[_JXY9\/V"HR&>?PY99_)75I4TTI7:HLLJ5$BJJBA&R0HMR'
M.8Q4$3+*N!22 PB":8KKKK"0H 455E#\.8YA%_ET5&0&>0 S.9^4]T]T\!75
MI4TTI7:LNLX."BZJBR@)HI =4YCF!)ND1!!,#&$1 B*"::*1?Z)$R$(4 *4
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M_P Z@$'/+X#D?U_Z-4NE332E7ZSH(MIZ10;I)H(IJ)@1)(A4TR +=(P@4A0
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M^XR9A6I'->B596TXTG8Y\$$W!R[9WFQV\5Y",.#1*TP1A-+O'W<M]"G:\V*
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M=HMUB*J-A6*F"Q"CQ%,3]&?E W]?*;A_5J0S @YG@<^D_!\_]U08E((  .7
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3*:4II2FE*:4II2FE*:4II2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g120909g17h55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g17h55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      (H   &M0         !                          $
M    !K4   (H                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   (H     %)G:'1L;VYG   &M0    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "*     !2
M9VAT;&]N9P  !K4    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     @X0DE-! P     #?@    !    H    #,   '@  !?H
M#=P &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #,
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MMM9M=E=1;4!N+S==M 'YV[U$(=9ZZ1_RGF8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+?!BO?B-.6.VR7'>Q.\!5[YMV)[B"W2/G2W:T?3?"WP8KWXC3ECMLEQWL3O
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MH^H"Z&T,"K=-85D]Q23-W?(F)@!0"B G'OBFW !$W*4AS;?I VVVT!XC#J%
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M X"(,9,!.!-C[@4PE*',(<FQ2F,<QM]A ?UAZ& ?]+0%"D&WA7'=].J8'$
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M2!>5?W"+;#^KL*VP[^?Z=01WZ[#T$ #^P!W]L!<27*7D.H&^XEV( [";80W
M! 1'KN.^P>W?SV'0$C^'3![K-EM4:NW)8:EUY \K;YU412;,X] #K&1\1T(D
M=4B9A.?<QDD2'.7=8R!3@JZ96]"&PPN5@AHU.AX>B4JK4&!O!)/V+?T0_EVH
M[@$G*R)"N)&.*[3_ $R<7''"36*!5G[Q%182D M]"'3<NDI&=;)SZB;I-SW+
MU19K&K'(!_5=-D5CR,LDL!@*H,S)NA6V,0R)?6$0*E9*] 6)P9\A&)Q:'@&"
MB#&*>R*23-ZNS1</!; 1X46(INE3$13;]T9(I (H!A+RE H;66MU8=LAB9([
M-T@)E47:@.8]\HD@3<$SR\(!79E#&(4A!=-'A3&/NY.9,QCE R%8X6I\3U9&
MJW5JC&WQ$#IU6Y((-VZRTL4FXQ,LFF5!L1\OR_H5T>[8SH&!$"-Y'PYA T[W
MBJ3>/[/,5"QM!:RL*[4:N2B"FRJ8"(HNFYC@43-W*(D62,(!N00*(%.!@ "T
ME!$   $HB(;@/D!@Z^SKN(#MO[>OGY: QQ9!$9$-P /YNGT#R_74W]H^W?\
MMZZ \83?^<[>SN1^P5//_P#SK[- 7 4 -ZHCU$=Q.(CL4/\ 2Z<N_4.GNWV
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M^RR>?UE\N?X51M=%]]5A'L%-]4B1S7'UN,>\*'Z3##JP_E0O[7G+?]%F#O\
MA_&:RTWHW7^AKYEX-5#Z1[]H9^4=3KU:\#09JX=L,R_$%FK'N(X=8S(;?/(M
MY>7!/O$J]6&*:LG:;$Y =B W@Z^SD9(_>F(10S<B/.!U2@(&SKBXCS9%NU?X
M1L0+HQ%(QW(J*V"!AS$690K*H1[>O^.=AXQ)DXG&;X[ZH,8]Z^3<RUE:O9@R
M[8UP>/%@QC%AD"K81C[5&GH)Z@G4H.F0;8M;D&3QB:1@+.W4*4KQ$&I5F[Y]
M+ID!].3#YTJZD':JS9TW38D3;I@2)4X28AWA60R09-R9_'SS6.?QK)BJ*":
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M)]%/&YR;"BZCG:S!VCL8-S"BY;J)@H %$_+WG*7F   QA+ 4'90+T#N"#ML
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M*FX,V146 @F'<NRICB)-@Y ]4 #KK">I[2LEO'.'*I"*)F;@1(PB &(EUW2
MH^L(BH(B<V^X@(!_H@  6M.HFA&R<XQ*HDW9JD6EFI!4$Z\>HHD+A1 Y>91)
MVTY2NFZB0@8JB("40,!1 #&_&?2V]UHE?R_&)HN9RMNB5:Y/VB10])L5T6[V
M'GUB)#R@F_;R#!^!BE A59-\3F$J', &L<  Y-A';VA[1 0]OF >M_#S#VZ
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M,/,;8X'V >A>80QC'Q/1+/6[8G="Y017<MTU !83F%46XF,42$352/WQ$1V
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MD9EXN_=1M%KE<!<S=(ID&,$XE8R/9<J)"%,+1),$U#F RRBQU#K&464,<P%
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MA3%WV$!V #$<<5P=BI+LBB!0A'J:J@]/7,HNF!P'?H!4'A0 0,;KZW,8W*4
M*]B!R=K/23+O1%)S&"<I3J") 5271'G*!M]Q.1ZH ]!+L0HAN&VP&>'K!=RL
M42NBMD2J<IU$4R'<"4X"F/<**<R:0@01W4,BH<.FRA=] 8CRE'0Q*/8$RHF"
M519NWD:_(D)GJ,G%",XS>"^,(&*=-ZP;K@910HF.B ="E*&@,H9U!KEKLB,<
M3C,2O7."LC6.@M#IAWAF]?@;$U1CE@,3<"$/%R(N#  B!TW0N#*&%10! Z\4
MC_TGS ?T1.H#N ]3]=PZ;C[=O=U$1WT!([&^+)&SXHM60FTO%M6=+5.FYBG
MN!D7X&4(JJ=D"*:A.5$CE,R@J"4I?6$YDR>MKD/48HG6)N<+:H:9ND?&$;9I
MF43^*C95MMA..JJEO&86Q+99$62H>B4:JPK<TDBRDN5>C3U&XSAGIR>,>$V0
MMRS0J4G8VYW2[@H<C@J,DT/+."\W+SE!.,:,4#;"(D)WP] $P&ZYYX_!C6I1
M28P[9=$R3E(Y>1%)LL9),R!3&.DJ44QY#'5(<AC@($];?<VX=0Z3(K1$PMEA
M(@9LDW*0@IF$HB<QC;>H ',)M@W,8WD/D;ST'V(WS;@AIV45]<ZA)=P8!
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M5-L*IUFI/$KN!V(0@ !""?O)IPN=%TYBUHNM-4#76P,4$&K6PV=TZ8L4FQ2
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MJB:;.95EIM_!A[*3(KV(1;LE"MI"/DFLP@Y H&(FK'D6<H[B40,"BBB92E(
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MX"Q7.1%PN4P&AMX\=2#MV_>K'<O7SEP\>.%!YE'#ITJ==PNH.P;G554.H<0
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MB*IG# #E511$H 82(]V0OJB)P]H<P$%,FM1*^;M'&Q!%TW26$H" E,44EN<
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M?C]\Y\^-ZJIE++4)"(]Z>-JSI*R3[]),AO!-(Q;OH]NKWA#IF7EK FP2;IG
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M8 $  !$2E$# (>1=^;<0Z;" [B.@+>?.!:MY%98QTFY3 =!0HAWB;9) B95
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M(0B+=%*4<)<BC=J901$EI7IRG7\E0$'?K=1[HF_NWYU-P#SWV'<HCT$1 =P
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M\XB>.3",8[@P6>-9@LS98UT_!8&AXDBU)GJ6#IX47B3TAU2,H55@S7*//)*
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MV,.P[!O^E2 ?,0#H _V^7MV$"\@ 2E*L0Q1'<FW*4NY.4! WJE#E*(CS<P@
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MW"JJ[E=PH=5910ZJAS'$PZ Q_8P$) F^^XM$AZAMYJKB&VW3H&P;AOU ?;N
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M  P /7?WB.X$ML%<7V2L/OXUFN^4FZBV430/&NE%?&1[ O*021KL1,IW;<H
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MKY^5-?M:[O\ T(X4_P "D-5^]5@WNVE^L14^(=ZW'?>M#]#@QUS]<TZHT T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M=O\ [S2IWO70OOR"W@*]<=1&?#G"&ZQ\C;VJGU!>)CX=O_O-*G>]="^_(+>
MKUQU$9\.<(;K'R-O:J?4%XF/AV_^\TJ=[UT+[\@MX"O7'41GPYPANL?(V]JI
M]07B8^';_P"\TJ=[UT+[\@MX"O7'41GPYPANL?(V]JI]07B8^';_ .\TJ=[U
MT+[\@MX"O7'41GPYPANL?(V]JI]07B8^';_[S2IWO70OOR"W@*]<=1&?#G"&
MZQ\C;VJGU!>)CX=O_O-*G>]="^_(+> KUQU$9\.<(;K'R-O:J?4%XF/AV_\
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M8A"/9MX][7+)$3E;F&FR4G#.^5$R0$++3V5/"1'TN$AE\G9TQO+//Y2J7?\
M+4+G)S5\FY_9\3=[:3^2*5F.WO6:B%Q#*5_69'8-(J/@IJ+EG)(K'KJO$?JL
MG &SZIUZMTBKUNE51BTAJQ4:_$5FMP[03 UBJ_7H]M$Q,<U YSJ>&CX]JV:)
M"<YS FD4#G,;<1 ^YK/P;V4DH1E,Q;N:AFT:]EXAK(-5Y2*9S/C/1#N2CTE3
MNV+:5]'R'HU=RBDD^\"\%J=7PJ_(!4/$([<W>DY>7GYN8-N3_6W\N7H/K>70
M>O0= >8*)F-R@<HFV W* ]>41$ -MY["(" #Y"(" =0T!C[)^7L583K1+EF+
M)-%Q94E)-G"IV;(5JA*? J3$@1=1A%$EI]ZP8FD7I&KD[5F5<7"Y&ZYDDS%2
M.)0*PTOM&?U:'O+&Y55Y2;$V@7L!<&M@BG%7G&=J79-:PZB)])V>)DFUC=24
M<V@5V;M9.7</V2,>9PHZ0*H!4*_9J[;(=E8:O.Q-B@9)-16.FH20:RD6^317
M5:JJ-'[)59LX(DY06;J&25.!%DE$C"!R&  -:%9[.'A=HE[=S5IS/F6]5Z@W
M[)'$_"8-R/F"(+B#$]PRY:LB6N=RLUHM9@JB\,FTL5CR$[ID]?92RL:O(I24
ME7UVTW"ED&0$9;/V,N(R\-N0,:<+F1W1R9\QWPWXJ1R1?I2NN$,=88P1;I[(
M>+[IB%UARBT9[9,IU%U92R-0NEPGY*3L2C>)?V>WO_!"9^!LPR=PX</F0.'0
M. N5>)T_'%IP\%!KM'J<W%PEM0Q=C@*? N5JFW>M9%06%5](TZ*DY,L4]:1Z
MTY$(O>[7E68*@6=D+@HX?,S2G$PC-6*SN)3/<QPXJ9?8P%HABNH"3X<7\-<\
M7,X]J,0]7KJLB1*+?SC:5(\7F8IXDNP]'I.4' @3C Y Z"8-P'KT$.H[C_#R
MW'I[ T!ZUG39NBJX<+I((()G5766.5-)%),@J***J'$")D33 5#G,(%*0!,(
M@4-] 4VO6*!ML%"VBK3478ZU9(B.GZ]8(-\VE(6<@YAFC(1,Q$R;)19G(1DF
MP<MWK!\T65;.VJR3A!11(Y3"!6= - - :X*+V6?#'2K<TLSR2S3D&(@[WDW)
M])QAD?,-NL>'L>Y"R[+6^9NMRIN-$',;66-C7=7VW>A9B19RLA6?3K]Q7G,:
M_5%X 9"-62>Q9Q,/#YD? N$+E8*\AF.M\.>(;;;\I2DI=)K'^$.&VU3UJQRQ
MP\%94I*T-D2DKS:C:FVZ?D)9<ATV\C:5+&\;*"]#S-F.4.&'$.6>'.1X59^!
M7A\,/Z;6J E6ZD[& /$5.H*0QZ]#PCI!-48YK&I0,8T;D33,!&B'<   .X!C
M$R-%B[++A1M^1K;>[6QR78:_<I_+%U?X4D<HVT<$1N1LZ4BQ8[RWDJOXX;/6
M[.'NUWJEPMS22D&SWP+22M-@L<-&1EDE'4L<#*/#!P.XEX5)ZV6^H6?,&0KK
M;Z?0\</+GFO)LYDNQQ>-,8'L"U!QY .I,&[6*JU:<VFP.VR23(\K(/)1P[FY
M647*@HD!,G0#0#0#0#0$>N*;ARJ_%AA&S8-N%FN%,AK'-4"QIVJ@N(%K;H&=
MQID.JY-JTE#JV> M-?%5M9Z?$'<(RM?DVCEF#AN=ONJ"A&,8R@AC:NR5PG?8
MJ7>Y$RSG#)V6[!DG'.29[.63W&);_;9A;%,%<ZY1:.^H-CQ,\P(IC*O1V1;P
M\C:0&(2QC6TV%Q=DQ"W-(^9:L8Q]P61BGLJ*MBWB:X2KQ$K,C89X*,$SM"QP
MI)6%R_R1E2_S,I8QJ4UE*NPU0J>.FD1A&&OV63XY<PZ3U^,WE.3=-F-90AB$
ME@QH)!9\[/F'SYQ+XSXGY+B1XB:59\/L$FF.J%5W&&YG%=4?*J+!.VF$J62<
M/7TT3>K1'.%H"8O<9(L[<C755X.$F8B-<N6RP&&4^QJX8GMKM\E;[?F*^4"Q
M)<37H3#MCFJ0WI='><7A9<N<9"%L5;H,#E>P.9H9V25KQ,@Y&N3:I.E&C^$0
M0D8J(>,%H)8\,G![6N&R<R%>'&4\NYURGDV,H=9L^5<VR]4E;D>BXM8R[#'=
M%8EI-/HM<9P-9_.&R29ER0!IR?G['-SMDEY:0>%41 E[H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H#UK)]ZBJD \O>)G3WVWVYRB7?;IOMOOMN&^@.O%CSL1<E
M4>JQ,('%[%FLE5I5=HM6G$L:7FR>CX:K<.?%M@:'=J-LJ9VR0XB$57'%$YL!
MJ31'-)Q1$(U)TSK%"AY6SOIQF!DPG9!WXV.IG'3_ (AJ/-LI_"67\.,9NPXB
MM$Q8,0M,B63B$FHE7 ZPYA9P5+B645FVNU6U0\Q7;*A98/%%8:M_0Z)HI&L@
M2&N?9KHY"X>\'8#N^3V5P1PODW+N05[K:*DZE['DIW?L-\1&+*S9+ZJK:"&?
MY/A97-L-D*V79NN@TM-MISIY#UZH(3C%K7 QC28P+V5U]>76Q6*2XHW'^4[#
M7;",]$4RPMLF3KZ+S5B;,;%QD"UR>3IF)L4AB]KC5[0L /F%5@5,=5&XRB#T
MEB.#D),"[<6]FWD/'7!MDSAL;<3[Q+)MFO\ 4<C4C-==ISV*0QU<J$7'#R!F
MVM#<760:.'4],4$T[?F3.9AVEO6M<\:8(^EI2:L,Z&;[9C$<=V."\:V@$S<0
MZN0VU0R# 6^E,\NU&8OT=$UO'^6N'&PXEJ+@R^0&KR1_,G"_#^.*UK&+Q*5L
M$O>K+>'1D%)*5A9,3RRY,?KI/;4>QQ_,J@T#&D/GAM'U.O57$D%:H".I$I&0
MU[FJ+&80C[U87L8A?>Y0>9.;8?=A,%,+U9%"RF2>.90D>H+X7&,<YF?+79EF
MR/@; ^&H[)\%"26"+CQ"257N,C0GLVO#4O.6/,]XXBJU3F:5TBW=7?8PB,NU
M1U47Z4N[CDE\8P:*<.T:*-$HP,8Q:8U7[*&R7JX+WK.V<:ED"=E+E'V=Q#Q^
M-K'$U-@W/>X6RVJM0$5.Y3M#MO&6NEQ+['\P5T_> _A)65*\;*Q3Y["*@4&(
M[(6\E!M'VOB@_.R,&L8C@+),.Z5;2W_($?04^&]M.T:]V=QEE\PF<4ND\%62
M4IM30K[*2K$_E:=D7D_-BC/%N8G7C'Q-X#-HVCVC5@R;HM6;)L@T:-6Y"I(-
MFS9(J*#=!,@ 5-%%(A$TR% "D(4I0    T*:[N,[L_6G%]D*BWUYE2>I"=%Q
MY/T4U18!9C52^M+#EW">2I:#RC%UV[5 EZQQ/0V)9"EV.@2PG:/T[6E8&DE'
MR==9D= 0I?=BM95Z_D2%5XFXBW#=\B2]N4;92Q!-W:KS[*8J&<JFG.91J3/,
M=:B[]F2OFS,SL=>RT48*12L>.:D[DXJ1:1]?8U43]=2<V/UD!WV4.17'C8YW
MQ)T^PT^)=3SZF4*Y82G)^I306W,&/,PV:LYOB S2Q9Y0H:\G2G<'$5>);T3T
M='NXES(/IPT4[9RP2RKBS)\;<OV/G5[)-PC)WR5@LPXFAF-UL<I9G%'98%>(
MXOM-AF9?A FK%6\GT]OF)(]\H$E*<*\]&K5(TU&2(062W4;)STLK 2"UH#[?
MO\XS9DX;>S-;\/V3<;Y7<9?/=[E1W39M(3CJG+1DQ/4A+ASA\+&QHA*KV^;?
MQF/V5PAVF2X"N.'$PRB31\'"KA)RL0G;5Q3WXK[-1OCC/--S\YRR2PVRH94L
MUW(\5IBC2:=TFT5[B;C)#%I9\]L>N6M<<3>?*Q97J8(+1TA(XG@#N(<7*L6\
MKH6]7^X[3&&2^RNL%W'(!29AQ" 7'-=QRJ@]N?#_ #5KG+DG>FN;&[>!SO*(
MYQKY<N/\/#F!HOP[RS1E2R8R6QG23^BYH6#48T"GONR&K2\FE,I9<K=FN2%X
M:WR5G<E8Q0NTG<IBN<1.'LVT]YD,Z=VAGMFDJM5Z1:\<M)(7,>LV:Y9L,M&E
MBF;V0@)L/CCI+ D.Q:7=&P^-:XA:[%0N.>&];!THFUQ5/1KV_NI[%^9*5=K#
M-62A9CI$\Y@\A6O*L9E&R0SJ5D9E>S4V.\/;2I.4U6($AL,]FS-87I6?(1CF
M+'Z-FSEPPUO!$CD6 P#5JE-5N=J)LJ,8&UI1S"QFK,O5(:K7ZOUYK3)&(3>N
M2T=I(R-L<JR!T&@8Q8F,R& H[L5EVV+;325^(&*//O:O4ZK1Y%'%#EQ4Z17H
M#B?REQ%35%3JL[D:;<2F-;E&Y AL:6*J!.QX2$13F,G(/'Z#H8%N!(+AG[-:
MS\/G$A2\\/,_A=V51PG&X:&N*4.3B9N4B&-"QU5D(U[;W>1+ YD*C#6:D2]W
MK,-8(^?G(ES<EX-:TO8VN01T@)=\5?#.WXH8#%5:>7FST%CCO-=3RT^E*5+S
M]:MLBVK,%;(<T)7[=5YR G:C(/3V4BP3\<\651;M5V9F:R;XYDP-9=T[%]*2
MNEO=4G+M5@L3GJN,*KC+$UGQI+VZ-KD3B*V\,5NI,#=YI3(4=*9%BXI]@*W$
M"5F%4[8X_EIM+A6<!PR64FP#WL=\B2%AG9-_Q>S[Z.G,72]"*@XJ4XE*Q*DM
M6IBKN(AA,L<ALWJV-'!I0+LXH<BJ\8ER,5U;$%4Y8\4]A S:%[9$C\2]FRRQ
M#D#-MK@+I4AALN8+RG@Z*C$L>.&DQCNO6[/^<\PT:*K4P2W*-0IM,K>:D:&Z
MJ@1+5%^ECZIOHA[7V*9X5(",=?['K*T''8<CF/%)5ZPRQ5E"K9"0@\>X=G:O
M7F*U4C^'&&4E:4A)Y:LTU5+A=XK!]Q-?Y!&<<0,_+9HLLJXKZKB-7&Q 7]5N
MREO4"[X?I%UGVHJ/L!2UD<200V*;)'->)-K8;#PXRK^7XG1ELMV*0OMUGBX+
M>V*SSD+(UF.F,DRM1MLC"R4;3Y&M6T"O<1O9;6#,>5\V9)I.6J'0D<TV&)LL
MG'2N*[)//HZP(801PN6Z>E*YE>C>D+_C@\9'9"P=9'#8I:';I6WJNV,RK*1$
MC AC'F7SQ<]F_;.);),??JSQ1Y%Q"V3QA6Z%-0,$W?/$9R=A9BPU^1OSI9E9
M(%'T_.X'RGG+%#DAV2B*$G<J??$Q-*XW@V2P&.J_V44LVR9^=EJSA&V*F-<K
MK9#4I2-$L#)3(*:1N(5] 268W[[)4O$W3(54>9HJD- VF,KM:BF]1Q/ PIZT
M9NO#(5("6G )PA3?!3A-+#DWE-?,ZK)S *M+_-0*T-;WS.*H=0J@0\^KZ<EF
M+R+K[FNN8W'[.+:PK.JXZ3J]-49R<A /K38 )Q: : : : : : : : : : :
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7 T T T T T T T T T T T T T!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g120909g22i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g22i22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[35D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    -4B^$V0#A"24T$!       71P!6@ #&R5'' (   *N !P"4  (<G(Q.3
M4V-S8< @4 /$UI8W)O<V]F="!7;W)D("T@,3(P.3 Y7W=O<F1?,C0@,C)*=6
MYE,C R,2!#86YD96P@961I=',N9&]C>  X0DE-!"4      !!#!GV[SLD92
MTR\_D'X-V".$))300Z      #E    $     $       MP<FEN=$]U='!U=
M    4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
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M]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
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M9T56YT1B-2;'0               !4;W @56YT1B-2;'0
M!38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M     .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;V
MYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W
M!L;VYG       X0DE- ^T      ! !+     $  @$L     0 ".$))300F
M     .             #^    X0DE-! T       0   !X.$))3009
M $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M     ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@
M &       ! #(    ! %H    &       ! #4    ! "T    &       !.$
M))30/X      !P  #_____________________________ ^@     ______
M_______________________P/H     /____________________________
M\#Z     #_____________________________ ^@  #A"24T$"       $
M    $   )    "0      X0DE-!!X       0     .$))300:      ,U
M  !@             $>@  !.0          0
M !              3D   $>@                     !
M           !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M$       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M       $)T;VUL;VYG   $>@    !29VAT;&]N9P  !.0    &<VQI8V5S5F
MQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6
M-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6
M-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M  !'H     4F=H=&QO;F<   3D     W5R;%1%6%0    !        ;G5L;%
M1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M$       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
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M5T;&]N9P      .$))300H       ,     C_P        .$))3001
M ! 0 X0DE-!!0       0    '.$))300,     "K,     0   *    "2
M !X  !$<   "JP !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$
M  ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T
M(               $  /;6  $     TRU(4" @
M                                         18W!R=    5     S9&
M5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
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MXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                               %A96B
M#S40 !     1;,6%E:(                     !865H@        ;Z(  #
MCU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML
M]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !
M9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                              9&5S8P         N245#(#8Q.38V+3
M(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D
M="                             &1E<V,         +%)E9F5R96YC92
M!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "
MQ2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                !V:65W       3I/X %%\N !#/%
M #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M   0                        */     G-I9R      0U)4(&-U<G8
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M9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X"
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M .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,#
MP,# P,# P,# P,# S_P  1" "2 * # 2(  A$! Q$!_]T !  *_\0!/P   0
M4! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !
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M_0)_JH;.GX5;FN92QKF_1,<0=R=Z.H*WU]PNS-Q'
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(S%1=K<7)"55D973,F$80;'P,S1QLS5"4F*!P?'_Q  < 0$  @,! 0$
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M98.64!! $4)E*8LXC&.,ISE&,<YQB 20H!)8@  623V  Y)/H!R=>D@ DD
M62>  .Y)] -8_7]AH-LI:S9-6NZC9-=NE!/T]]0625Q36J)L?D+M;:5QV47E
M#8Q^1,JG*$F/\83SCSUT>-VCD1XY$.UXY%*.C#NK*P#*P]00"->*RNH9&5E(
ML,I#*1[@BP1]M9C\X_XX\QUEIXTUK]GMFKTUUK^N6^QT-7L.VSL1:K16-Q7(
MW.REIU,/VXM?JVF1/7)*M'.';&%<!F2*F<,M8$'.)^9K'(R/(L<C1Q;?%D5&
M9(]YVIXC@%4WMY5W$;FX6S>L2Z!E4LH9[V*6 9MHMMH)MMHY- T.3QK8/SC_
M (X_Q_W?_?S#66GC33QIKZRE&$93EG$8PQF4I9SC&(QCC\YSG.?QC&,8_P <
MYSG&,8_QS_AX[]N?:N;^U=_RTU@]9VK6=UHT-FT[8:/:];M(%)6;!K5O7WM)
M8P78,H>:-K5,MH-Q VN=4LEV"8&P P99P04XQSDCDA=HY8WBD4TT<BLCK8!&
MY6 86""+ X(/KK%71U#HRNINF5@RFC1H@D&B"#1[BM9[S#66GC33QIIXTT\:
M:>--/&FGC33QIIXTT\::>--/&FGC33QIIXTUQK_K39VWH7%> >J7.R4,MY]K
M_:7EV@J*;/FP_MTNN::2PZ?L#>PPJ,2MYZVDSJ='F_\ XW&'/XPQX+RB6<)8
MZSX1$4.9G]3R%<P=+Z;D3N8]OB!YMN-&L9<%/$82N$W K8Y]+I.N%Y(,;$B*
MB3,S(8AOO;M0F5BVWS; 43=M-T:'?55_<7CGMIR?1NO>_OLMU/C0^S<D]=-W
MX'ZU:AZQ:MN&J5M1NWL#:U?/D]QM]IV^V9VFVV)%_85(:]4)C%7UAA_RJ<QN
MC+^Q9=)R^F94V+T/I^+F'$RL^#-ZC-U&2*5WAP%;(,21PHL:1L$.]B2S#RGA
MC43-@S(8Y^HY4N/X\.*^/BIB(\863(98Q(SR,79K8;5%*M7[ZC/VPH.P>IVU
M^J/K!+OG5K_1.Q:GL_0>X=-[K[C7_"S]2Z'H-!K6MU?**;V ;H-@ES#7UA,,
M[672]7'1V&X0SB)[XK@F#.2.F28G5(^I]3&#BQSXDT6/A8V#TE,T8V//)*[Y
M3X"NGS,I-0B60LD1-", @#5F+-AOAXAR)GCG1Y,B:?/;',TT2HJPKDLK^$II
MI"D84O1-UP;E^G&[^_.F^N<G^?:3RSVZUG8>P;^?E%I9^YZ^Y1TSC:*M)75F
MMM=R/S%YOJ[U3T!7>Z==YRL'85U2@JLY:OX&M$=1U>'HDO4-LTV3TN2/$@&4
MJ](\+Q<HERTBX0R5^6#0&%B@8JS$T%-W.P9.HIC7''%F*\\AB8YPD\. @%5,
MYB)F99-ZBQ>T"VO5(>E[=IVF>W_]6CVUL>L[E7=A]4^ ZWJW+^<P[-<%_.R[
M;RK#6S"#IV7$F;+E5#U'H6BU^M5^*L&M)[G]%_%;^X68SS<X\4T_2OA;I0Q8
M&Q>IYSRY,YQ$%1Q91$>Z4*X&3)C8\QD=CO:$>'>Q>8$KI'F]:S3+()L3%6.*
M/QC6YX;8;+%Q":5-HVE0],/,>?GV,UOO7J'H?I%QY_O_ &2ZA[.J1L/9WJG;
M/;"_Y*G8;-SOGZ=I3<4U?N-K0[,#A]/LUML=Z=B5*BELVZ*ZLM6&V7^1*T_-
MT^3"ZK/UC+7!PT/3B%Z=BX?2ERV$<\Q1LR7#1XSF-&L48\[&*(R%O#(H:929
M&#'@0G)F895G*FR,UH06BC!6!)V##'#L[$[%#.%VV/7R.]C]BN6^KU%1WWLG
M6Z1ZU>P?O/H/'J#V TGV6'[([#Z^\,>U^YAUS7__ ,)6SUVED ^=ZU1BEUC:
MKT3CFGH7KZQ;8F$T7//5Q>GY/4G>/IYFZAT_HF1ER8,W3CTZ//SE=3B/_IWB
M."#!('DB38LNP$(M$Z\,^3!B*KY03%R>H1PKDQY7S+XN,5;QU^:**01(AC61
MK:,L;)(!UJ.[[7K-%0_U4-BX-[8^PG5O6;UR]0],T71K;'LAM_0JD/L!T^_G
ML;;.H;^&S98?0K':+6J6Y8E:V;"J]_MU$G9I4S^45]L,,CO\,QYW2L#%ZCU'
MJDT\R_Z=% WR&.@C4RP4 "P>61*101'$[(SJ"<))$5.L/C9F3-B8N%'&A^:>
M0#)E)<E)-U^3;&"VXUN=0=O&I7YOR+3:V]]/_4?G7LUV=#UTY'Z2=0]ON][=
MR3OVPK+;:6ZEK/-T-<IMTUVS**GY\G?:]OMG44- RNG4Q#8DJRJNL-.YBY&5
M*Z]6ZI/T[".?E=9QNE8,.5@QGP@OBSEWAD4;LCPY(%>206Q(WAJ &Z*!%;"P
MHLN=<6# ES,AX<AAO#;8E42*1MB#+(R@50!H^HU7U.3[FM8?T@=Q=]BO93<.
MN^P;?8.A[AK&Y=8O;S2H>K>BZ?LVP4&J66F,8#4VCEJK:\_'G=-A%9;$:[M&
M"8ML 6I%:O;U-L(K\50KT_IT6)@C$QX98<5%F_U.>6)))A,/.JKLR/T,>R,!
M0 O+[L,/Y@-T5SE93S9)R))$DF+)\G&DC*C(>&8[H0)&MRW=J  AWA7:?;CV
M+VC2.H5O<=0USVQV_P!A6E$=0V?WS-J(-7H]7WE^&Q>OS_HCGGV4,U@- H[5
M(TK-YO:[*PD/<([3B; 4,2L[#Z7T^*?&.'++TN+ W&6/HGBF1Y(!X><.M>,"
M#X[QFE41*I,>PUN.G'GS<EDE&0JYC9)&QNH[%15D.[&/3]A!J,,"6.XFG#CA
M=3![*VW0NI<A_J1^XB?L+[(:U8ZQ[:T_KOZ>Z-SGLNV:;H*>U:+:<TX\CL2>
MLT;0E;TE_OEQLI+*M/(E4Y%*Q8DE*T+^^*+TY8,;+Z!THX&!().F/G]6FR,2
M*:=HIER,LQEW 9 F.D04_B!8>;;P=V4TLT'5,Y<K*0IF+C8,<4[I$LD9B@5_
M#6PY:5F8J;4T3M%V+6<MYUIW3/ZU'6[3<>R[N;H7K1Z[\*KZC3B=7L:C&U;S
MN&O+[!O[M)HB[RN&>7KT">D/[7K56AG6#;K:K7=U$EDX&,JO)GF@^$,6.+$A
M&/U#/S3)+\LKF*")RF.'G()&09#*L<DC>((U*)2CF7#''-UV9WFD,F)BXZJA
ME*[Y)%)E81BOT>W9N3\ DIN6.N_>/\,8Q_PQCSBM=%KY\::>--/&FL>G:HOM
M6J2A\&9I'15]F/$9QRJX>MK[<0)2E&,9RE7VB+/R%F<,1/&.98)&<(['ADC2
M%W0JF1&986)!WQK-+ S  DBI89$I@#:V 003JCGBE>>.-PSXLJPSJ P\.5H(
M<E4)( ),,\,EJ2*< G<& R'FO6W3QIIXTU_.W<*^V/;_ .J1[D=2]9-,]9MX
MK.!<VY/ZF29]D[;> 4U6U;H1[!M4M50TG7[V+]@GL5D-2_P^>OF!<:*H,SFV
MU(/=HW2\/X;Z1C=0EZC"^;D975?_ ..6 NX5VQ(A(\SH55HU)7;8LDL"% US
M1&9D=7SIL:/%=,:*##/S1EV@L#/(8PB,"ULH8$C@*!^(G43Z3Q[:?6?K_,_Z
M?76/<=SULYM?<IZ][J=9Z9R?8*+A0^J=BWGJDJ9CD_,-LV<)O[+Y[S2A7_GC
M4E').WMU\3>?432F,%?)FRH^HXF1U[&Z0.HY$>5A=(Q<?*C;-^5Q(<4L,K*B
MB"B;)R'I [VB40MT6UK2%L6:'IT^<<:-HI\Z:6%UQ_'GDEIH8F;<4AA4[BHI
MFM2>Y UE/V%]G.H>JVCZWJOM3_<>*GV@[PUI!;[N>I^MOL9[B>EW*FL4%!LV
MD=9MZ>5:O:([592&[=P0I_[SJ:.$Y6PXALRL;#@].Q>ISRR=+$>[IN"L^S#E
MZAT_I'6,I=[Q38JN&*M"HJ,L_A.X.P A1@,G+FPXT7+#D9>24+Y"8F3G8$+%
M%>.<H5#*YO?2;POXA7/AWQW6?<'6_P"C_HF/:7VCKM3[5UKM71Y774]\Y_KF
M_(5/&&+!G6L.W=3KT:3;>BZUT'&LZCRK=9SMV+BO;>LPJ/65R&264*R])D^*
MY3TSIC2X>+AXX7&@R'@=LS;XA$;R;HL>3'\23)@ 0 @+:JAOQ]F<O1$^:S#'
M-/D2[II(UDVP!MNY@FV1TE9(XW\Q8<\D[A=7^H=W3V/'Z%>W=?T7BN_>L%-K
M6F46K<UZC7]^Y_M6Q]-O-EWVBT&CI[576T&[&CIMB5M@V&[?OO*L-TK-A4C>
MA,[+0:CH&%@'K72F@R\?J322R2Y.*V#D1IC1QP//(ZF4A6>,J5AH,$<*Y4JH
M&IW4LG)'3LT2028H6,)%*,B-FE=Y%C52%6U#!B7[$KP*)($<\XX;M=MWO@?H
M?QWW"]AM>X)Z[^D\.I=#W+EW2:(M_NM]U'>%->YWIBVVJT3U17:M3:]K5VYI
MF:6NB_7:X,2U=9?8VS:3WY&="F#G];RNDX$N=G]9&-CQ9.._APIBPM)/,T)<
M,\DDDL8F$C%6?DJ10UJBQW.3C=.@S<E,?%Z>)96BD0M(99%2)/$V$! J.5VJ
M#MJCR;I[S3V,][?8AR'8]'Z-L]+VNS]A+#4>?<WLO;SAND<@UVFU/?&:9CAN
MX^KNP)0WO9=CLM0I[25O<6[O]]V5DP#8Z0RR$ 0-;9/3^B=/'RDV-&^$N")<
MC(7I>;-ERO+CAQF1=22H%C69E"HM0JH:-@6%F'#D]0R")UD89#9+)'$<S'C@
M1(Y2OR[XI'B,QC#6U>*S'>K4!<G>PGM'LVUT_P#4>[[NOO'TOUYZ)ZJ]-WOC
M7K)ZR<[Z#INDA>L=/UZL#J5]M^A7E187'5#]9VU]DPYL+G6KZ)5[%,<&4L$K
MHN!TV.-_A_!@Z+C]0@ZECP9?4NHY$$T]++*_C)%,KJN,N-$JB@P+O^*]U:V9
M.6[+U7(DSY<:3#EDQ\7%AE1 611X;21L"96G=JY!"J/+SVVQ#3OC_4)X:YW7
MV;Z\2\])_P"GAI?<]R!:=+K4V+CK;P!&WZE00L*LEM9T6WZ+HVPW75%E#,6=
MJ@109K2KK X4\UM*/]"S5P^G8@3K'7YL* KCL0N(O$+,RN%5X9YXEQK"JK7Y
M6L;=BQ__ ,E 9\J<M@],3(DN0>:5^)*&VZ=(V:4 DM8Y505.C\6J_;/H]]_3
M8A;^['M71]$]U=8[WV+L=(AN.O%U?G_KXG4_W315FG:[;:G9+T5^P7:M4HZ+
M<['-I:T9'F,4LTH(5($]^8W2\=/B+9T?I;X_1Y<+$PW:*02SYQD$4C32)*K/
M'4<[M"I5'VKOW L-:X!F2OTJ\_+67.3(GG0.@2/' #!8U,9I@615=K86:L@'
M6JQ]K_:ZA]6/7K2M=['TS8=,]D_=KV8T;5.W;;U#2-+ZK_\ @^<JMK.MTGGH
M>\= JIZMK^Z]'M*6\-4;A:J$N,5R!ZG6\?L%2"OM'3>EOU//EDP\9)NG]&Z?
M-)AQ8T\^'\]DH#-D'!@;Q9(<=&0-"C!"Q#O5&]?S>8N'BQK/*R96?EQK.\J)
M/\M$[^''\Q(H4/(5-2,"=MJ"6VZE@_5O<K4O5_JW/4^L[57X[Y[9>MWK;ZF;
M\S["<^]B.P<YN>@;$N+ME/<=5Y[  [26J(4-C95 ;V'\[4I7+*#C)0J"G&(,
M;I$O4L:<XL3?)=+ZAU#JD(P)^GX<Z0I>&Z8LW*"5I51S&2C,@=11(&XS9R8<
ML8G8?,YF-BX4GS$65/&96 G5IHAM/AJK, PW!2022.?OV/9.L\'G_5PU-#VS
M]F]WYKP#U+Y3:9V3>-ZJ+7=*GV8Z0.UV.E#I5ZCJU>IJ6O6U0'7:G8M;I*]0
M/ZFR,C1RE.->PFQ(\7-/PK(>E=-BR<[JN2HCA@=87Z;CE$<3(96,T@?Q'C=G
MW$Q^8L#MTG>;'_UE!FY<D6-A0G<\BM(N5);+X;",>&K*%5E"T0Y841>NQ']-
MWA6O^N_IQQ7GFL]#NNE5<-1IKHEU9[36;;4U]Q:U-?/8]?TQZF &L4TZJV$-
MI"IK5Y-S6,9V3;SCAF#2Y7X@S9.H=7S<F2!,=C,Z;$C:-F5'81R2AB6:5XRN
M]N P"D*HXU=],QUQ<''A21I5$:$,SAP+5;6,@ >&#>T<]R23>KT>4VI^GC33
MQIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTUA+'6M=M[*EN;6AIK
M.XUL[+6O6MA6).6-"RZME-QBF=9 1FK,VI*2K142@FPOG(2RF/.8^9K(Z*Z*
M[JD@ D5695D"FU#J" X4\@," :(Y&L2JDJQ525)*D@$J2*)4GD$C@U5CC7WO
M-=H-G2C6;)25&P5T6TWXH7=<G:)1>KF1N5[D57@G!AM%P(6DV,#^Y5D0S@G
ML(RP21XVW1N\;4R[D8JVU@59;4@TRDAAV()!X.C*KC:ZJPL&F 86#8-$$6"
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M-!VJ]3^@=>P_B/IQZI@)D+B'+S\2-IT1&F;I^7-A2S1".20-!)-!)X+$JSJ
M612:U$NL>V&N7F_:KH5[S+L?.3;^S;I<_P!@Z%IPJ"BVYZD2/9N()_&U<MZM
MTE:JP^FO?U-41I<6<QQ$DACG=YGP7EXW3,WJ6+U?H/5EZ8D$G4\7I>>^3DX,
M<\J0)+)<$<$T0FD2)WQ9IPKMZJ"1S^#\>X>5U; Z3E=#^).C-U9\B+I.9UCI
MJ8F)U&7&B>>2&*LB3)AE,$;RQIE8\!=%)%&@<P;VHY?_ -N\/7RO);7&XKT5
MS?;#;UP$IZCJ0:) 5E8(;#=F?!E>U74:KBLIJ*.91C;5G\A-236,1CK\'=8_
M]-GXHD6&# ?)@QL2&5I!G9[9$K0QRXF.L3[X&D29%ED>,2-!,(P^SF0WQWT+
M_P!5CX/B;(R>I)BY.7F9,"1-T[IRXD(GFAS,IYT*9"1O"SQ113&(9$'C&/Q!
M6K:;[F\UW3;=9H%-;Z)3:WOK=Y7\YZAL6M#JN=;^]KRC=A8 UVW)83L,0*A7
MV#E6U:U-:K;+I,$2,3&(?.9G_ G5NGX67DOE]*R,OIJ8\O5>CXF;X_5>F194
MD<43Y< B6*UDEBCGCAGFD@>1%D06:A=-_P"(_1>I]0P<2/#ZQC875I,J'HW7
M<S"$'1NKRX<<DLRX609FE*M%#+)!)/!#'D)&[1,WE#?&F>YG/-VVO4:1/4.F
MU.J]%N[#7.;]3OM7%7\\WN\KPOL?HT5C_)%M88L0U=@2D9M*>O7M\*%_4)+.
M(_+W/^ ^J=/PL[(DSNCSYO2L>/*ZOT7&S3-U7IF/*T2>+DPB(0'PGFB7(6#(
ME: N/$ %D8],_P")'1NJ9W3L>+I_7(,#K.3+A]%Z]EX"P]&ZME1+*_A8D_CM
M./&6"9L5Y\:%,@1L8R?+=O/.(U]"T\::>--/&FGC33QIJ.M,_P!5=;_YYJ?^
MF'.O+3/_ %/HG[MG_O'5=4_3?U[XA_>V/_8>BZCGV7S/&EU/UXS*6=A##\1$
M0T_Q.NL8YE" XRE\H?GYXSG'PQ\?R3(X_DD(N&0,A;4/Y6.T]N%[GZ#B]=)@
MFLA2?]K?TUSZFJ6I:DLM?-,0C,-DZK>0;ML+I$@V"),$-<JC&(K$<?9!F<U1
M3Q A5Q8C F;IE69?/"B\>4QD<#O;#D$ >U \^VNB6B!V/:_8_P#T>X[:RB%\
MP"RL$?XD*4@0GE-RSN<J(/M2,2#"^*P3S61)"!.1)XEB$)'CF(PEG@A(X2Q1
M[%(E,@6^$'"<=MP[GFN; [\UK%]O %7?Y?7@?E?%_P -;[6XVBK*TZ@!U* G
M!FG_  A<&_<BS$!'(U[C"(G E^W)!")7,&$+ QPSD>,96#"8PD[3N)(!&XD\
M^A*WM(][&VK_ #U%8C^)X03^'Q5:[OZ\?]O3MK/*M+[&#%K:I]5B*)&"KY_[
M2>L)_<<@Q#FO-:HV1$ /\5_QE*85\0S]LH#A]IOSJ=I8I!%>* :&[P(K N^6
MH\_ROVOF.\)#;=^)8/<0P]AV^E^_KZ\#DZ"QLV'6;:I4TK9E109GD4K*TW.\
M^LC@Y(DL&5K7>L+DPUF/Q4,6,C+X+@L8QB$Q,2!'7F^:A+=[152O<<+?!YY-
M"Z';4N..,"WG0,*'Z..) !V'X8F(/U##L+&MKK,%&FMG&L5B8XA*2"#CTIM5
M4A! ; YY%EV&(#_,3,9+C%O DPRS-GYPR/2V]G'Z5I0">>=HI3QWH$GM8Y[_
M &UE8[-3,W8T5H'G_<2#?'M]KK6R%E4V+.,+/+YF.O8*(>8$(#,S3@&),#8S
M\28AF<8QCF$AX_,)DP+\1EY$"NID(LJ#R02/J.W/;^NL@;'<'GT_/_#^6L!/
MG6J7B)%[2MA!JQR$Q; F6(GL&%" -C#K-<7&9+P*(.1J&*F/! Q@O&!!PF.1
M'D3*5*3, E&B/;F@;Y^MW[\ZUL5.Y2/$!!6C:T38[COQ7TNQ7',(*<]=UN;^
M=3LU24<W/KNJ[!5J\:^'52 RU%HS4U M?Q<B8;E.+?V+D1'-0GU8L?+=\V/)
M,:RBV H&CP:Y/!\P_IWKG6*Q*H\D80GOR3?>Z]OS'MSP-:/L^P6XPIYR$=)3
MJV)ZAA#9*$@UB5X@.&Q:C:5,PO!V7P4QB(G054T3_+"[*Z\6#2HL=.%2:.61
MKYCD!OMP10.X<BR+]/:LUXH;&^I L GW(/;O]A=Z_6JV6B5%B\3G2F/),@I-
M4$Z<0EZ. W&(F*1NQG#,\*X8 8%6Q-ID$89FNJ9,@Y:WA-LCBK]SR2 0"?H/
M<WR>/?61%BA5GZ<G\^_V[_34\J; @S7TM@*T')QJK@ =/9E!5EV*9@%(H)40
MH G*R4<3DM+)($E60"P0@4/RQB=88:D:)?.MFV2S3=B"0 + K^(UJ*UW^G-<
M7_\ 7\?IK"U%X]5DV4]HQ46=] ?[5=42-\&@RE,*P,JY+D["Z);/!6(29RX2
M,G\!.488C2AN:,ED1%8Q#AR1P"H-GMM[\'Z^_.FPT#_@!_P7_P#6M'ND:H;$
M&9MP18A86$8V&R36054$PJ@]84(A 66@U%R)$U8A&9AB>96)L*$_VZS=E'84
MQ[6*@<% 220*%@"P.2:^@ /MBS #D'V! ''K1/I=?F1W[WZ 8LB6R20PUB85
MQR:!"5E M\\)E9&#MDL*RB9L-:$Y),-#0RRN%59<#DC$F9<N89!O:0,Q8<4"
MJQGTLW0[<V*'/Y:9S6TB^_8BOR('\ZU^>S78D47" 7P? T0G5BR1,JJQ1&^L
M]FVS&;+-K6J&$)Q12LA#^2+ D[)^KP:&8YX\3/+$V_PUW&GYMZ',:F@!O'XB
M>U4!SK2\A<41Q?TKU':@/742/NV),!>UEAAH)ZRT%8N%IHPJK! ,(L6#02';
M:%6+5=Q!;.=;-ADC.<SF5>>"RQ*>5@=BLZ1* =ZA'L@AJ1;46>.7-42"*XL:
MK[@<#FJ%@?8"^Q/8_7ZZZ&>B*,D-8W2$QU(YF?UTTXTY!D6^<Z:>)?9]4R0B
M;'XQB48SA&.,1C!5$<8)@Y7KSA\Q*$@58@J^)5E0[D$5Z<D#[:BS"F'FW6H-
M[0ON*XX/:[^NKZ^4FM6GC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC3
M3QIIXTUH'5M.:Z'S#HFA)64J9S=-)VC5E+:.)RS7,WU*[6!<S$><$E!<C,23
MB/.)RA&6(9Q+./+/HN>G2NL=+ZG)",A.G]0P\UX#7Z5,;(CF:,$\ N$*@G@$
M@GC53U[IS]8Z)UCI,4WRTG4NF9V!'D42(7R\:6!92!R0C.&(') (&JE<KWKV
M+T72-%Y@YZIVF&N<ZFIKU_L%=T#1P:C<I:G021KCZ%##AK:RLMB;11PM5W==
MKZU?EP_\E:@@ODTNTZWTWX5ZEU'J76(_C2(IU;.DR\;%EZ7U%\^"3-RA)*O4
MR42"&+%224O-C393R"-3%"Q?:. Z!U7XRZ5TOI?0Y?@&<2=&Z?%AY>9#UCI2
M=.R8\##\*%NDJ)6R)ILR2.,)CY<.%'#XC>-D@(6-:;+UA]N,50.L6[O/MFZ%
ML';N6]VVK2JV@9'NU:YK-M7*)Z35;X_N(=<S0:/JK-D@!$=/]38_Y*(&V6G(
MMFZZ+XO^!_'?HD$75<3I6+\/=:^&\+J,V4IZ?-'F02N_49^F18#9?S74<U(9
M&D,X,9\$LJ+$47BI_@;_ (@_+#X@R)NCYO6,SXHZ#\59_2H<1QU."3!G@BBZ
M9!U>;J2X/RO2\!YX5C7%*R*)PDDLDJRM(FP^NW9+&A[;VG7J3%1[#@]BKWI_
M)$G'JR4[?2*'7:[G-5JM@V"PPH%#;])7M2848>5R!QFLFW-0H)Y'5XOQ1T&+
M(^'?A_+R#/\ "K?"N-T?KCQQS+X'4,G+EZM/F1HT?B/+@=1:$"18W#1+,J"0
M-YKC,^#OB*7%^)_B;#Q1C_&*?&65UWX>CDE@)R.F8>)#T;'Z?-(DQC6'J/2T
MG/AO*FV62 R>$4)$J\SY)VK@G&-!-K>R;'MK6@\SJUV/7FMKN?5M9M6].UA"
MWF3[]9UQ;M'[-JMG+IMD-OA;$$\B )@9)!9I.K];Z!\2]?ZFN7B8N G4^L3N
MOQ3++U2:;#Z;'*!C;>EPS#&>L*&/'1&@WVX)92 RWW0_A[XE^$_ASI#86=F=
M1?I'0X$D^#X8>CPP9_59("V7NZOD0'*BW=0R)<EY!D;*CI5=3L>+.9<_]DNN
M[EL^^=RU;:.9=53T[:*SC^RDSHUWRSC![S(:DA=0U2JVZSO=EW9ZM9*RYM6S
MY5']*Q:Y<2BV A/;]8ZC\)]#P<3IGPYF876.BR=0PYNNXH7J6-UKX@7'!F5<
M[-FP8<;#Z?%*@2/"PB[;G65W=PS+1]#Z3\:?$74<_JWQ3@YW0^OQ=-SH/AS-
M+=+RN@_#3Y6R!CT_ Q^I3Y6=U*6%VDDS\_8 L;0(L<>Q6C_4/2;O5)M/4J(F
M\4A=<5]=]KY3IVV?V@M2,;M?]1#=W.Q6[S ]KV&\7ND]IQ3/;1MEK UC?8GB
MO4 %).))6N?_ ,0OAO(PNBY(Z;D#+?XJP>MY^$<^3(7I^+T5L>#%@C3Y'$QG
MQI,(Y$>'@0%(L4@RL3)*:J.F_P##+XJQ<_KV*_5,1L*/X-ZAT#IG4!TZ+%?J
M>9UX963F9$SC/S,I<F+.7%FS>H9 DFR]WAHJQQZD_4.==LZ)+@M3MO%(\UT[
MUDU-QO%!=;7K[<NF],2T-O1:"IU\^O,6T*G20KN6#[-]:P"Z8S@ 1JYQ"8LJ
M?.ZK\/\ 2A\33X/Q W5\_P",,Z-/F<?"RD'1^D/U./J63-E+EI 9^H,\<4<>
M-#NC58W8SKN11>=.Z/\ $_6#\)X_4?AA>B=-^","27Y3)ZAAR'KG6X^E2=*Q
M(,1\)\@8_3$CDFF?*R DK-*BC'.QF.D<2]9NC6/2N/&M-4ZSRSCW#+=[<$-'
MZ5U'7=YK8;?))U&EUWG-9J^22'J=$:S=L(;)MCC-N5:(*FN6378>R6Q^(/B[
MI472>NB'-Z)UKKWQ'!'@2]2Z1T;,Z=+\B)8I,C*ZK-FE0V=DK!'%\I@Q+CJS
M&>621TCJK^&?@CK,W6OAQI^G]?Z#\.?"V1-U*+I?6NO8/581U+PYH\7"Z+!@
M;R.GXKY$DPSNH2MD-&%QX$C5IMW6SSXIK[_IXTT\::>--/&FGC34=:9_JKK?
M_/-3_P!,.=>6F?\ J?1/W;/_ 'CJNJ?IOZ]\0_O;'_L/1=1I[._/^QZO, %9
MS#81$^H)(")^!UED3YQ).6,0R+,<%C+$22C*$<X$3\9CF/@@'(4$TI1PQHDT
M5YH#Z7]0:.NAQ #.H/LU<US7O_GW'?7.^,KY49*I8RV+$Y(G9KF:@59B K0L
MOO?#9+08@T9>:K <FC$QFBC!+&:R><%-?J8*!4MX?X >20PXL_2ZX^@]+JX'
M'J2. >?O7?\ CV'.O-;;6  TH.3=_39EF+D)*$KFL_5D?[RZK+]6(%DS*+HC
MD46RD7%9AEFN+EP;D,9K""'C50&4 @JOE8,>-P_9/>Z[GN/762V+ OF^2/O7
M'/L>.?MQK(-_K-3/BODZY!H 86M3^I<)-,I+RP6KRF K8*Y9N.0P7R_@:LS&
M3+G) EA+(XFQHWC+J-T>[:5*[#9YL,NXD=J%#[@Z [B-RAO:UL"Z^HKW[_RU
M]J2AN:&RL6JW:;R<VUEZU&2$+-3*DS*,E5S,8'XH6\%C2:87?>B'\XR"O=:,
M;$#Y/-'+MW0*5W6Q">8@6" :H7? Y[:\DBC;ED#<W7MZ<401Z"^3^5ZVN\VN
MV)EI*UL=E$^BL!X2P&:S]JS (Y9&3K#O7;C(L&.A&R976Q#\C@HJ61<C8'YK
M3'1C(8XT"%B%WCS &N]@$@ 5V(/-'6"QJMB-0!W.VZNOK9_[?UT%MR]8N,M8
MI=2?%<R7E5[,'\N _)@3F_\ *Y9= W6@PY++[R1&@*1,&(F1S!*.,1"=WA,R
M+N_#X8%4!Z@<CV!(_KKT\@@USW/_ .>GV[_4:RL-\K+0M25RZK$DGRX A,+>
M/Y.!_P!8ST&((1A+&).H_*9(,A$L +55D,RQ, DL'QGC#.BEJLD;K5^:OT '
M84+HW9'.O$N,%0UO8)4BP1P>#P!^("A]>_%[?2W>)"A65=@._@+&/WKBR;4/
M9?DS&1@">K&5686G<P).#X!BAD,(BDF4LL_7%>(MYW3PI  =J@D6*)'KQ7O8
MLD?;(7:EA1X/L!_#CCUK\]>B>$HBP9ABK/%<Q(/A*^#*:\Q?/,FIYG)87W_<
M(6!"85P,.,%"#Y'F*<]2[SR^Y6]*!4BQV%WSV[^G?B[W_P"'6I'A&Y(PUL2B
M,]:)-D3RUVNBY!*Z4D/$RJ$8QB&1C%#$1XK03^3G^TP=B'XS':A". FY)>Z^
M':U[D@#OQW[DZ D"K/L>X_E_/^>LL+7J +))94 0"XUK1"4J[$TAG4E@,C8L
M(0&S%H$OM)-?$"9%AMF68YC+$8X&:<L&,CDT;W=R#Z5QQ][(KO6O?\[??Z_3
M^OMKQ[-2F=JE8&JE%LM 63)A9%&W>3"$F,&!G)XJ_L$8288!,XI!.FKEP\8L
MS'\_-N/(%<LQ<%FMBK$"SV-=O3FSR:O6) /?_/YC6BV2XV%U%EUDTZNGP$P9
ME@^Q7*OHC_45I&:O.(+Q7:!B4CE32--I4^68U Y8DVQ-MKY8DL25V77)OS4;
MLW[BCQR#>L19.T@57]/8\WZ>Q'Y<Z&VEK+)V+*VKIO.:V>3KUB-"O:9$;_N[
M3C3>4U%11IUK&R-$D6L%N)@C,JX5Y+S$"9#O7:L;E#+^T>1N[51NA5\\"N/>
M_&%578^]&JOM9^MD'@\5SVS=*%!I-:X0O@5]776;3<)V"@+4Z?[K!L1)7YSE
M..5S'R=5*:(('FH>4F1_8&$\R6DD208\L/B/*HVL"%4<79)[\4:-CV/;6J90
MZDM['S#TX]0+Y%_<U7-7K"@Q_*EM6+\YH%=:BY]HB)YE;B&RS68"PP=![Z@#
M-&&#)J0>6&-@"YR2A (X9L&B,=,#M-B(@G:2!9'/Y>E]N."(:A0:*L5(\KBU
M#$WQ1Y!OZD\V:.HW9FI2V8VV ;'8/LL9HSOU[(UI 20?2?AB^4+)1HQ[1,U;
M4*W#(@I&_:Q#,ALAB6$V,+.U1HJ#P6<!U'G?G@']FJ/N3W%5SX4*G:39_P"Q
M[?GZ'^IUT6]'[.-M0;XY$(0XE>HQQ!8>1K1Q@+V8P!C!"B^ H9B&68$F211D
MFW(CDSE)RO7 5R8@6W$0"^;-[W[D<>OI[?PASUN YL+37579/%?0\_6]7J\I
M=:=/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--
M/&FGC33QIIXTT\::?C&/]V/QXTT\::>--/&FGC33QIIXTU'6F?ZJZW_SS4_]
M,.=>6F?^I]$_=L_]XZKJGZ;^O?$/[VQ_[#T74->W;)5.;5IQ$3A^=IK@$B]%
M[Z#B;6=4(I$]>([*AF\&_6"U$!L#F7$<P_SXE'5TU@N7&2"1MD'E[\HU>HXN
MKYX[]QKHL/\ YZ_4-]?3V]=43L*55NQ@!VXFXFAKXB5R6/HE$K$\?09=Q^T&
M!!5 2[#*L .SP)H8B#9 !B(FS7C.RQ'9'&@\4AI&W V3Z *:-5Z&^/MJW#>E
M'DCGTO@\CDD?E5D^]#QVNH"?UJV"E7,CJ\AQ&=:"S;_DK=5,\5AB8##+RA!R
M?">*B_WR6.KC&,EF/(,8T+,GS"^-*-R@W.AM%4B@ 31W5P:'WHZ$MZ$?PX/%
M=A^7!''WUJI27&JIV*J""J![']'84LKXJ#-WK3"A<Y1,-22>?U7K=;]BR*0-
MP*T29+@!)&+%H,HK',%82&4H'\TG:N2-HYY X%@5W%^FU;*\D7S_ %/%CD\^
MO] .,3<2-7O08FH[*LJZLSXAU=M4+ZY6B.>(UC$J0MU1'/W6@M216LPV '#P
MB;!_N2!@FJ$JJ .Q5KNG1@3?%V17TX-\<GG6.TCA3R?3Z'M]?\-?7:=?L&HV
M5UK#FI- "%-MV@&M.50MB"5<SE@R]<1^+2>!LS(&/VK06.\W. A+34D(>;A
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MQ@D&(1+)B\TBD2(NTDTW[9J@HOCN;OM^8YPEC) %B[YOGMQQWO@UQZ<Z\\)
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MAMUX"58))2;=R5T+@L*)A*3"ZI25MDK\V*ZC<Q,SZXUG,%&$0H^1QR1TJO\
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M#13Y"Q.>)8G(H)9)D'V2H.ML3E(";VQ!;-?[W/.T 7SS_4ZJLQ=LB_5.>/\
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M1FDT,6JB<#L*J98(W^H;!6A=P0/)M'X2-IY/(Y')[>O ].^O-RUW'I_WK_\
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MCNZ)65'N64:]71NGU=[ILMDV'3D=EV67]A*53^JVB8JK\--:=M?I5M>SZU[
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MM>"6(QO#E#@KAF)_']>/LJA!80(D(5EVR;B=P&[S DEB"U D"Z%<'7I0%@S
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M:P.:-DFN./X\>VOLIM+)5V*%BK94,YEIRWFP<9V"/95P,5:M6.3>@,EKG,$
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M.KE@R:U4,-U)PP66/[<J9"_9#%*1%""GEP "*%AC.<N*V.4D*QM+N*1@\*5
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M/<:!('+4?4UV]CKP9,5V=X[&J!'I8Y)]J]>Y^^OO:<?W^TBVJ]HK3R<*ZO<
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MCZ:\&4@/X>.U '^/?T''K[CV&F8XOWJYM77K3GS=&+(6ZPY*UI[+UV"=LR^
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M/:-<VK5[6JU2NV,-I2-3J(*1M[%BGHJ(*S7T7SSESD^"4Q\*X&J]B/F0H3&
M[F)52DB45:SS0%V1^&B!9Y]-=QU3X%S.BY.)@=03;D]1P\7.P)\>7Q\?(QLI
M2R.E(&+6KH% /*$D]M:WM?M1O MQT$VH]%UVRX_M@76++HR\J.WK:TB&:N:E
M.K9)(3KFK_:CVBM7K]=\_DU@KC8LY,H!9J0,64"9'BE2=-ICA:-T:1.=[C>J
MVJ#S$B^!?(O4KI_PETN7IO49,P=07JV*ZC&P05B;(B=_#:8!HW8K!R\G84*+
M#N/VMO:CI%;=N-I9OMGUMX4J76$=;'I#CC6T*6 5[#]^[>_C*T$\Y+^FE6+3
M;&7 Y-,V*I($4QH*\%=Z(ZG<Q;<:7@;=H'>S=W^1[:WXOP)@Y&-$'SCBYD=3
M98RGVJ,5TN,QXZ1&:_*7+%N1(H"ZD;3.^;AOL>A:_36^R56]:UK(;NII-BI*
M=9LV"END,NXK%JZ9;6O+84YL5I%6UP7$))?J.P#9!8'F\7A^&3+&ZR%:D2]H
MNN#8X-<^M?EJBZI\-X_33@Y+,),#)RWQY)$R10V,/*)'A4)N4BW92%NR#M(U
MN7/NKWVYZK5W*NY;,Y*PK_V\V;FL4>L8@P&> L5C.M/"<N*NU@S(JK2%B01:
MYE%A9K&#2AB>$H\.1T(K:17-A@1W5A^(7?('':N-5V;T9<;)\(QM"JF,,DF5
M'-(/&O:WB11K"544]J6#*0?+V$ [YNGNLQ=U<^>[MK]+JE[T$*#;6W<Y1/>:
M5IX*#.6<MJ?S2"]Y-V^48*"X');*ZKRBT*QK"S#.9<!PQY<B&1V\(A&3(5$>
M9GM6?]$3&JIY=@#$M1W 7KH<+I'P>N/*_49NIOE0=/,J18F1!X.9F&0;8T=H
M&>)1$P8J0YM6 ;D'4HZ]M_9Y[5=KL=G#?46IKMO; LSS^LUZ7PNJ]4VLJUFQ
M""Q7NPJ,)7+=VZHJY*9&DT3KU\UI?L:'* !1!4CD*BI,9"K;N0ZE$(+"@JV.
M>;(XU49&!TD8T3K@9^/)E/&<9SE).AC5]DZ&,0K(7:P(SQY@?3@^W7.P[IFL
MK+C:MW(JK?\ [&*F$*NGK8%(N<D!03)9HKOVT+-;Z6ZN8JA:9ELY9EB0#!GY
MJ=7#NJ1LQC \1!1*'C=NVV5HFC?%^O;6,W0\=GGAQ5D,T#QHR^,)C3A2TCJD
M*^&L8-2!G)5C7IJO';/=V_YSTODFDH;29+7>K(*3UW=F*ZINDK+<G;$J51HC
M:*].H*I5OXPD'^YOY4IZJURDCFG<BY(@;'&P1D8F3,) LT"B0Q,0MPJ"9&0F
M@\JBBL0MB+:J&K7IOP:)<#J74<QF\'ITPQ\F(2KCS8X<@IECQ%99TK@PIR2Z
MN' 4@^'7_87W)WBTI:?4ZHU#-2OB/9+7I&K4M(C;WX]F=G:K:\"I?LK&NKJS
M7%0U"=K<)87M;MH5A$ U<P6(\/IZ1>*SRREF*^'$P!B!B4H9"Z<NTA/D4?A]
M>#4O/^%?A[IWB2974"8Y)(CBQXF;!DRB&6--OC@1+MD\3<S*.1&0-I()UM'=
M>^^SVBZ[I#&@!LMKVFZ?Q2[)44.J5FSU]-8233>E:FL&!ZUD.N+D5LJL[;(U
M6)3L%'1AF9+%4[AA08V1).LTORZJNZ)G(MC?X0 #;'T' ]SZB+T_X:Z/EIU!
MLG);"CQH_'QYI<N.YXKD4+'%X(,F03X1\($#;N)8#MK/KI[>=BZ]MC^@7VPA
M1V?4QVMCM):K7/A6Y16<!65-;-?8*/7[FJM+[$S[%6&G6&P.I&-%U$3N&3CW
M=0Z>F+&F1 [/#.JB%)=JN9!S* RE@52B"2!1]_3SK'PQT_I^+'FQKDF#)^7&
M('RHM\IEC,CD;87&R( K(2WE8"SW&M;W7VZ['J.G],)<=<3USHO/K38*P6G6
MO/=9':['7L7(E=0VO7T7KNK':TQX%Q7@=D\A7W+,6XS8K&TY!GCCX?S,F.(H
MEDBE%O()G(C*JQ='*Q'80VVVI@H(X-ZNL+X0Z+DY^% ,//EP<R!)SG1=079"
M$@9LA9*Q&4%9=H/?;V];-XN3[CUO;:*@L-TMF:"V+7&+<U2 Z%T>6R,YBA@+
M?\/(8)X3Q [X<38@ YL@@T6 L%)6G;N8*; )%"R!7!%D D W1(%CFM<3UKIO
M3,')R(\"7(R<<2K'!)(45U%TYD511]:JNP//(UF7M\<K:VI#GISI[*ZV0FOU
MKC"6M*0LFP+OW#:U<C&JSAF8::N<-F<29SA58SF8YS#&)^@;P60$A5W-7)X(
M!/\ /MP>_&H*]/(:0S02(L40:14E5R"Y C9V*+X:,S  4QOB[U&&^=EWF6I[
MOCGNZEQN.O4=PVK&WIZQR"IJLY4S63=-FMK77:H;(\_""))Y=A&44F6"3%&2
M$*TL7B!C"Y M?4\VNY0P5J'9@/>J(.K;'Z)AI+B'-:9H9SM8X[ [7>/Q(TW*
MLHW;:W4..0:[ZU72/8;J3';.;<9VBT$Q>.ZLKO&[/(I A4%5LMEV'6D->1$U
MKZ<U?MS4_P F)R-N:V,!8D2U"BTIN>3WPT.$^=&S"/Y@PI&Y!8A0A9@P%-6]
M;[4&'<\#5G=%Q,; RL^.3( 29,;'CE4 F0-#XC,P%, IDXI:.T@FJUTE\KM<
MOJ.M,_U5UO\ YYJ?^F'.O+3/_4^B?NV?^\=5U3]-_7OB'][8_P#8>BZ@GW4V
M/JNL<@%8\<VM+3]S_N>J@&TL5EFDBU\1-F?0,-H911RX(6!"+\?D(OP)C.,Q
M\=&BPINH0Q]0CDDQ663>L;.CA@A,;6A!I6%D71'?Z='A1139"QS-M0J_/(Y"
MFA8YY/MS?MW',SDOM_[8%O\ ^"ZS0[&!)Z+,Q7Z 3A D"&9279 9=42C?V#C
M\XP,+'^;[,?B6,8\Z;J/P]TM0LF#.5C-TC2,SWP0KAF;:0#Z<<]N !<-TB(K
MO5@5%DTS<CV/<K7'L3S>N@(=AZ'L-/)S3NGD*Z7ZI*KW)RSS/)(1C#$X) 7^
M LDG&<BSS\HXA(>,9S*,L<P8<:&1DGCD*C@.A8T?KQ7VL<\\5VKVBQ(VVRHR
M@6+#$EK[<7Z&[/L*->FA]7Z!U?C&KW'1-XZ>O7Z)J8_VMOMG'54!5*9(PADZ
M^6,1B:"Y2"^@9VAE;// ,?G)8CC,P</"SYX\:"*5YYC4:LS %O06A%78->W'
MT/BCIHLL7(52Q#$@51]00;XNN_&N<_0?ZIW)G:^PMM-]W+331H5TC_J'U_3-
MD_>*(T(3(@%FM_:-+,\R%]$FH8S"!2#^SZ_E+K\7X)S$E:/)^'9\E% )>/(S
M(R W8TLA!/U/'T'.H)ZET%@P$Z(RL%(\8'DT*-MP18X/'\]6S]<_8;>-Q06W
M!CV%:[-J5K#(T$242.AV8U\$% =R-JJ6!!Q3)I9!/Y+K + F/HS$HLSE1==Z
M5AX1\&/IF1@3I18MD33H>>0PF-J*]0.:X/)U8G#QVC$D+F16%J0>#[>_%7S=
M&N-3UO/3^C&-"6BN;^L3"N"-JSPM:4X?G&,XMA>..-@?$,2C)H _V9#C\LQQ
M"/QG&FQ<3'+ 3K8+4/.R#GM9##Z4;'!Y'&MV%AXV06653$5/!9F&X<=A9^O)
M/IV]H5K^Z=9F9<%_TC;Z6,K'(RN#I4(JR%'.8R4#ENH)C\PEB7Y)(\RYQF$?
M\,XE+-B_3\%#0Q%<]@?F)^&/8\25P2/:O>N!+?IN!&0"#)SR5D<#OV!5A8KO
M^T#]=9"V[YT9)><T.A[.X@<,I_R7Z*67E89GB$30R%"5=$GRQ+$5F4F,S_\
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MDT9S^-28L:-"[Q.]^45(PVT++'D W1%$'OZ4#J;\MC+^)";[6[ "O?GM]_\
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MQBB7'E8LXCOR@B3S+1_ =O(J_%M7'>0]J<J]@WOE6N[0TM3UZR5OM-".=DM
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MLQH)'?>J@/$K. 6\K!00/2F9@;"U3'@D=]=DT$L^5C=05,/(W8RHO3P2SL8
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M]A-9M652X']/(*X8*P+F%H2'AM %G+(UV\9)",,REG'%_&/7?@CJ^-+D]/\
MG'ZGD*/+*'54:Q9<;RG 6B5YN^0-7?P[B_$F)*V+FS028\*T-K6ZJ+Y%V21W
MY) [$WKN92[#3$JRK4FV4-A?,52-&K>&-$*L6#S*O]OT!QF2XASA\Y1E&$Y9
MS&7XE@?Y\^.-$]EW4F(@G:";*^PY!YY[,#W[=M=B\<\A!D+$+R M+7?U7:?Y
M^_OQ<%/6]3_MA!/8!4S!\U]>!IV,E\".^ ?V?8O'\X%\YFF649#_  6</\)Y
MSF.?C4F6:.5R@D5025!+=NU>;N:/%^U$\7J ,J:.3RLP ORDDCV]1=^O'(//
MKKB/_4\]V^*?T\N25>^;0G'>G=E[%KF@:]J]$ZJ6Q+KN9CMN@6JR4C*+'<UK
M58M2K<G9']=_852CS4ESD^J6_4# ,>3SAG4EC9.[N15GCMR!QP#QZVT&5.B"
M7>0IXNE[D T>/4V>2/4]^-:M_3YV%7V(YQ==AV;8K[%CU6Q#M>L:OC7;,>B<
MXU)D0ZW7-5HIVZ-9>7K(UD\O[?M6<'3O+YIXE+@-*K68G-AR\EH5S)E+0RDA
M8BNUE(X!L $_8D<=QVU(FRYW )*]J'D3@$=[V]K[41?K];:6--3TUU%'=!R#
MJU?@Z#"VNL,P9L7FY*Y7<A,V(067P2<"&67)(\)D'DL/SB,<3(@N1$QQY 9#
M9&\< >JGGAB+'^7K;%FQH!X:"62K8$"MWJ?XW7'H?759/8^RY)1T\[WI6RVM
M<CK\58ZK*Q3MJFY 5IK"(5<P5PO66AHF;S I,FQ]<9P)B4,Y-*5UT6+.GE?$
MQH!N=2TI!#!^#9%V:J^1_0UK"7)6."3(91&[S=@2 NZQ0^EC^'WO4Q\PM^NN
M::+;]+S&YH'T8AP:R3G7)15G"+2>:Q>2-@9THYX+C!!QP:?YC&99X_$L5^;C
MXZ9A@D01S*U/YB.2!QR?:N10-WZZW"2"8@J_F;_K( )Y[V3Z?2_0:]5GIU_[
M+\DVC3J[J!N9;?L$K&26]\T(S6[ I9U))Y,F_7NJ@-E,00X6>%B<<-BQ/(?A
M&6,>(<C#Z'GQY.3B)G8Y,1,+V>*\],NXW=<_D0#VK^H*71L8938[%+24$$^8
M7V/<CGWY%<^O-/C']*#N]3NU9LO2?<SI-N[K^V5K5;3H2L1U5[3KVD#L0M,V
MSS$AJM8B0;",4<AEF123CB'Q_/T'K'Q[\,2=/2'"^%HHEDB;?,&<NDAH<*01
MQP>6X(]>:Y+"Z'U3%REDE^)IYX]_B"$1QHO>Z-#D\ $5S7WN[O5.^5_K(TRQ
MNNG;';6 7S !5ZI;6E?_ #B#[IUQLX:FF-&*89?]YRN-@!1K8#*.2?#.<\7A
M="/723B9"PI(P8B3:1$0. 0:Y]2"" >.;!UV>?D3)CK(F*,]54"9R"2&%#L*
MNP >>PY[C6IZ/[D;'M5A0BIM,J:6OV.R:J5ZBIM7=@>+^C QC?R,DP,LA/*<
M0RD0Y 2R6?XDP-<<1^2<SX1AQ!(TN<L\T87>;55[$@+Z>OIZ\GO>M$),T2R+
M"L())9%4 @UV8T#QZ7]=6Y#LPK6L3,YKKM%N-*//ZHF'XK8-'Y8*-G$!G$3,
M2*3),T3B^9\2Q*(Y2^.?.:DQ7A+$M<+$JI #"Q8X/:Q7!!]>:/:3%"K/ME&X
M$#9Z>84>.>>. *] :U<'U7O'+T^\F?.!EM6=,H4BOU95QF$7Y1$&0QCS/(8S
MP,\B9G++$2RQ+XYCY39B(DBA&+ I9L40=[@CN>.!_P#FJSJL+031HP()BW5]
M"S 5]./<\?SN!Y#U5Z>--/&FGC33QIIXTT\::>--/&FGC33QIIXTU5+VFO-:
MI*?7\[)?RUH=F+8ZNLM0,Y4>7LCUX#_96G_P@-U9!5YV)#9B$05C&).$!YG'
MT*S6%0N:)H=_OW'K7OW[:O\ X;Q<G,ZCX.+ V0_A$O$%+ Q^+$K;P 3MW,H)
MKUYUQ.[9T&GZK8\FWG0TKSLTN8[0>V>H-'K=A1K-X:N$;:D_<1_70O:[9H:^
MVO:7N?X0SI%)(C5+*%<V8TK7I4GAKFP9;PXT>1$4WS%1)"T;QLM-?E$NXH"*
M+<CTO7WG$Z)U+X:3.BS%3HSYT$"K)D9"R28T1HR(T,9\6)G##8".;'K5?'/?
M7_K6.WUG9.VNI$!JVG5W2-0YGI:*BKDMW6T[8=>?K+%>V3FX)C3J3=V*^M.'
M8*=78;UP[MPL5:N4PMOFS<&/#R,7 20'*G,<F1,6I(4*A"K$D42 6X_"1W/!
MB?$75^D]2Z-TSIW2TG$F#F9$.1FY&1)_[@S3*^]O";84D8;XHWLPQTM&[UHO
M ML=Z+_/_P#X4-W*J%RKK2=#IO(405=*GH5=3TC+NBUT-=I0B7<Q=5EH)5T(
M[[9ZRR'4IG"K+&/KA)ZI#'B'%CZ>08YX%EDRB#OG=O+*2U[B$8=R#Q?'-:LN
MI8AZ;' ?A;'5)>J],\7,SY!-*TCF3].P=Q49@$;JKL+19&_9JO'UCJW/=?ON
M?2U-!7;+OE'5:VT?TZJE'5<HZ6'1K-6&K;M>;M7OT-@YN6RBNT35:&5FV$ZO
M]--4YI?Y<^G8;&&<SLQAR<=D9Y0TC-D1.#\Q&JL)"L:5Y^* YXW#4?!Z?U_*
MAZB,IEQAG=+$T,[2I(\>1+D1(\\ CMS\O$MDH05M2>"=60]/MQ[#8;!?:&T_
M<LU&TZYL-Q6;:VOJ[?\ 8-5K6R65>&B+65;CG\KMF;.V2%=EVU6ON2"49_V[
M+*Q<+QNK08D<0GB"(\8AA**SDR[D!&1M>S3&QWVV*YOGEOB/IG3,7$CS6Y.)
M/%%X99V;-GE0EY/&D&Y4,(\2@2-W%T-=">?0Z9L>N;LYTE^I#A%NY(/2]853
MN,P-*XL[!-".TM'D=TDZ,U6J9'^+JB(R4.(<Y#8GG%/(T(""-&4E0)&8V;(
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M'4QN$+MN.T  #M=GS>WI?-_EKJ#_ $UEC*Z?T"#%Z>^/_-H9,5E<BS*AO@Y
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M>T/L;07+$HA&8179(9:ID]',@K171!//Z\88R=VF<RR;594"*J>56 *B]M
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M+\8CGKIOA;XCQ4$T"KF1 GRPD.U>MA:JQ570[^VIL76H\"788&QRW!,R^64
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MK2AE:1::G!:C9'81E=PY*GANU\:NMT/H.E[%RS1]I_N6V'J]B]FZT3?T<L2
M!K$QPB$P5@CB2NFOEJ#B38L&"//R6Q^<XS'DL:*;IF?D8\X"S!?"E3@=P;//
M%CNI(*GF]=KA=/EZO&\N)W6/Q0#7F7GL/S]N_:JYI#=;98D]A- [42]WV-+H
ML'Z^OUW2A6NQ:IL-*54[C5H!NA+^MAEXI7)$K;JJ'%=A-  R_&.,9[+&CQVZ
M+DX38^/)).0Z9$E_,(Q\HJQ5+P17/)%"KU4]1Z1,C)1ECF5P6 X2@18J@?7U
M[<\G5MM W0>+7I76":W9K\_W5F@V*LJ;6J82.+%94R0V)]\!91A3&8(!$A6\
M9F%AD9"0R/,\Y)S.9BNV/'BI*C9$?%D]SW [<WR.]]JL$ZGX6/,)2Q<H_?:"
M0OU%4?6[H<>G8ZB?9/<?UG40<O-*W_6]@7JK(N;59:\?>Q0Q: 8V/Y)6B,:X
MQ6S?S%1EU:)(5V2X.2'U?;B6>-\.=8D $W3I800*)2K['<+%$UR!1_/6V3J^
M!.,A6DA=X :6+N2. #WL@D>HLB]2%K7MU3[.Y8ZVPCK*#E8O6EH[ V^0?K;<
MME(/Z?ZKCN(")6G-+ZV2@F.0 $"4PHRE'&=61\.9$*"2$,\A<ATCC8E0#R.P
M((![>PYJP1'CR8@J.7CA! 8E^+'! ]>:-]Q]O;9Z[NG/=]V6WTINCU1O9P1%
M;EF5@>X:^R5I7,TEZX-? L0-D4*:44RG!@F(D^N1<BG/S6.E]5PL8Y,,DT.X
M[U(W0NJ\7N.X6+')_.Z-F3%)#."BY6/D!_Q1^5@;].>>UU?V'J-09RCWC]7-
M:W\'K!UOF6L<+[WL.[[#4(\^UBK:S0;G5JUMCLFN=!HFBAK;!M;8J(,:C%>9
M#%G6[<M:43\LY2 PU03]7ZKE9,4>1F23S14M2R>(!86J)\Q%#M?V-W41\4XL
MY$&/#&CL* !6O=@/0DW]_P 7&K/[WM>GOZDJ8&I(-Q68=78K:JX,"S=2P2!?
M^X?<.'_? C',Y4#2#C\?$<2DR/\ !+O#^:CG99)B"RJVP5M!()_#P.?H?L.:
MUO='C)%*0:/N;(!/ /8<5ZZKSN71>2TE2;4]CV>I'KMSKS5<@S;[&*DO)(6P
MAI.ULJR1\D9M:\+I3UYAYC^QD?PF..9Q/Y;B#/66+)CNHW$E*I?=1_:-!J(K
MUXXYNZSAD#>4HNWU8DH;/IV/'?O?H>.^HIT7>DN+ZPQJQ;NSV_0K;[:W4-FU
M78!&M:$5J)=N>&JU52-L-J,TII_M!&5DDK'(LLX5QF8['+QH^J3#(,0ADV5.
M2KK;>:@HNJYNR2;'860-)$ZN?"$;(>^UA8-&K(NN.0IY'?GMJ%O83O/;],J=
MF]IP<3JIZ9ITK ^K!<2O!V=A)E0VN!-NM5 4,-K&R<+$WRQF.(Y9!^Q+./MS
M<="Z1T[+,71FZC(N5DM7Z607"P)("$@E+OE19H ^@&JGJ&9F8V'EY;8[R'&5
M3"@!/B$@V-O<D<4>!7-#N,#Z/>]O*_:"'9M.HN(L\P[KGB&XWM55 V^TO.8[
M"^GD6#!KJ @06E5(Y7XL8159^$0_LKBG^<R-B5\2?!/5?AIL"3*R8)^DOFQ+
M+(H RT5PQ'F/D(' O9Y2; [#7-=$^,VZO*,-<=\7-4N "&V&O+?-D43?-<'B
MQ9/;;^D^/<V^2[!LNZW-18V.QYU^8D*!=).HHL4H+&E>KE4TT4,K3+9J-NLP
M<$5_#!R1:8-./R\^;?'PQ(NJX^-B(ZICXBJSR&VE:21Y0Q(X-(RJ-H516T*M
M5JZ3YCQ)SDNSR&3UK:H"@4G%T2":-\F[-ZZO^<+K;IXTT\::>--/&FGC33QI
MIXTT\::>--/&FGC35"O?NH"YS:OOR;->:HQH2VU;RA9:O6U5ILT6Z"DR8F:
M5R,Z ;-:O(^Z!@JK<HX6D,:Q2$C'S?C,/&C1HA,)76,HU;?,P%M??OP+[D&C
M7'7?!F:</J4X&/'DKEX@PY%FW>"L4V9B>(9 GG82*#$ I4[G4AA1#?R=OO;3
MTO3?[^W[;?8?1J3;,*]0V\NNUFVDUYB6XA8/JNW:]35=9ER(#A:N';NLJ+3
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MS+QGD,J-,L:JQKSF*,\ RA>$W;=RW1VD??4W-^'>K=-:.3+DG9, V8&D'B1
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M5>DH;=-IR%N:#WY+&ZUTO'(;+PWB,8C:1V'E65B"^U%[(RIR!?G H+VKE/\
MB!\/8$TTV=TQL:)8\(!TB92D[^+<S(J%A%MC)V[B X-J!S7=8:P[AY&YRP[5
MDE%QERMA')5W\$K&E<)2@N> 92%(HCX'/#$<,"A,4X2GB..36P&# !25#@\$
M\V*L78/J/;GT&OCC%XQX2I31,S"2B621>!3=QQN!!JAZW>N/?6.*7S_L-NFL
M=)/L%?1=HUZO<TS:M1V"[#4:WMNH1WE"E(.LD+"ZNV*:_8ZV*5?E2>KV*QFI
M6:S=B?&(])B=2"]/C7&:+Q<*:0RPS0JQEAE*N4:5@P"EAV_%?;VU]1P.MX\7
M2L;.P%CD?ILJX\T4T*O/+#)LD=FW EE64>1QS2JIL"C?WC'*-8/I!>?MUM/9
MZ7JMR]2UD-00VC3U:Q*L3KIUH"L%-6MMWN&W;*S;N]8R"E%:%BU7_K/JR+"E
MRIG$ZSKXD;2H)) \BR*);:V7T1=I "U?%\BCK@.J]2EGEDF=I!,]3D9, 8O-
M*^YV  ''L1Q8  L:S/5:QVUY;L&BU%;M.M1)!G4:>^U)FRV%BKQ]*(=;N3$J
MWL;$%,#1PY:6L%65%!5K<+PN*$LBLL9E3(CG=@X(\217I WFM@2>&+5QM()N
MEHZQZ>Z09<62SPO$X$DJR* 3MK?4<HH#@@;00P]1?'[>O_+C:BOJ=T[7;9J-
MZ_'G/]ST%GO#.U(V%Q4UU3K4"G"8[2"K8DT %<'0?16&:@!R;%BZ1H^,\W*,
MS&(%7C5V:-]J@@,=VT-0<U^$[K%#BN-0.J94<FY%7&DW%MDL,(B94:5I%5Z
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MAEM$(A"0S(/%WLE%7=> H()"HQL=JNM>/\3+T]H_DVBFF13>>(R)?$GC(DA
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M<BR*4T,DSB(Y8L'GD)6:BH:HI+&T\ @6+N^WY]M3C')DL6BEB-*6K<?V:[$
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MBC^YM9:-I\2"3"P-@T<"_P"[0A/,1RSB.9>5'_$O%P,;JG3CT]2L<W31))8
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M1)8(L-6W6W3>9Z?;MZ8?>%]=V/H@&8ZII5 C_*K"JOT["UAL@Z%&LDV:ZO\
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MI&-K<7J*MFP,RQ%G9JY1JH135,<"\B"3="N-! T5[VEEBIII]HW!-TEJBIW
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M.6,!'&*T\_<,\%XR/.,91GC;'+&9#?D)YV'@KQSZD?\ B^;K6:31L:4FZO\
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MQ_;JMK:ZN=*A1-_'V6ZVCP-C<6,HY4E#$:IF","KT6Q0K1N_S)BI">"YC4J
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MW\*F%EQ:*"/,J$AA0"FR-=+)U#H.5D8J]"?-Q58-+,G5'WX\ @0R Q*6<)3
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MFV;UVBP+HVY;0TM77]155P-:VK%<+8=+N/TZ7.IZ_P#NL#!K>5A+RO+M2V<
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M2M0 ?]UR(IM_QT@?[8IYP^,,9G\/-?PPD$'Q%TO'ZAD[<+YD L6VHREBM/1
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MD>4Q0E*'UQ'&.2#C+S+&E@"B10!*QL,:X*T+)[B_Z_8ZB-+')%+(P_2;D$1
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M:Q)*^A)]3_/^)]]:_M?%*W=Z2RUW9]?UVTJ[6JNJ5J!+6\$W"NV',<VXD[$
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M6#"MC<'I LY&BZ(0_P!H"S4B?@QH3(M,7UF#$F)Y_&/QF!!D28LGBQ,%?:R
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MB,!++"A&.,8QC$<8QC'C36?\::>--/&FGC34=:9_JKK?_/-3_P!,.=>6F?\
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M3;PM%@09% ->PK4_)SFD$>*(98Q(J;FW?HY. 2I*U9KL 0""/H=4CL>H1/[
M5G <\_LTE*W8(V;^S554P'6S46S4]:6PD4]_8V3,58+3B)NS P=9QEHT4OUH
M1(#R\?I\TW1)>H2=0Q($WGY>"-T7(E"]]I*Q^8D#@"P#P?>;B3]-29(5CE\2
M,E#M1Y40D T6D)5$-W88 DD>Y%CE-?V?LUR;F5!=4^I:W0,6&*8%#6,+*WA
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M,2=C(DZB=6)E>+B-R?,"I5N:[ CO? %:\Z'F9BQOBR(GAGSN"V]4+FBJV3M
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ML=_17=7K"DV+.F9<'FL::D7U]]-^A<ZZ1H?2>G;UJ&V7-!6^U.P[3+5JBYJ
M7/7/9GL5!N1]GJ5;1E\U;3ZCS?6T.?5"SEE8685RE%^V90>)F::ACU__ *<F
MU\;CKFK69.:;/2\CC?W'(.B76_\ LELENUN\261= V?<>$/]!K>1U3>NSM6"
M[1+7;9P&ULX9:ID-*)93PDTU8+TY]8.D\!VGI5UL+?/]'T7;:K6$->X+QS8^
MB;#R76]EJ7M@=V?HVLU_1(*1YR?=!VU97'YOHE2CJ%0"@"^1Z[M; [0&FK]>
M--/&FGC33QIIXTT\::>--1UIG^JNM_\ /-3_ -,.=>6F?^I]$_=L_P#>.JZI
M^F_KWQ#^]L?^P]%UK?<(+$UZC@U$<QRV06,1+^,QD3^'N,CQB.<_YI_/$?AB
M/YEF7X_'^/E+.2L3%2 15$B^Y - $<U]=7*]Q9 'U_\ OB_OKB%[6Z+6=N;M
M^81:(GK+&9&M61TE1L-<Q^F"88JL?SBSB!/HN _M27 3'VC#@!23&5D$.G^'
M\J3I4/S8\$R'OCS;_$9/954%BC#C<#P38/8ZY[J>,L^3"1 LJP,KL%;S,P-K
MQ8JC_M/\>VH*UC@NG<YJM(L^B+4?2MGT8=FS4=7W*DU:OO=:IJL3%N%MRV/$
M:.OT>KH(F**R,T25<4DRA(N/(!!D9/6\IYW7"\;'Q^H,0V'B%WB+. K':QY9
MJH@!>*(]=2SC#);?.T>-L4R/.8R6I /+1-JRCLQ()K@GMJDEEV/KOL-TFMUG
MURV#.N[2OK#6^Y2M*[6<ZK;ZHB\^LVO#=TK-X[1$PE(Q!AL-:E/8UW:F H-I
MR7+<A^D]+Z>Z=7P&G\1R(9(9)8\J"[90N+*L0+>C4S+2V":K4F/$9]LF#E&;
MPDC,@,7Z"2[O=(.X() %ANZD'G5B0>T.]^N>ST_'^SZK==KZC7+I;1O2?/ZR
MA_B$*6]3%::S5ZF%:T'>;<THJ<:]]DR53%8LLO R5%?+!X&/T).N8<^9TKJ*
M8<2RA(X<X209KL?PF4K&<<PN"PB:.1FWH1)0 O9//#CRQ">C(5N5X"3%&*M8
MS$XWAE_8H$'<;(XNB?L/U_V*[5R1&X['O;MNL[T6CV30M U"AJN?CY92$:O0
M ?VZQI8MRE)]0==0:^#8HOS%8YQ=(7.#S_6=O^A]#PH.K#'&,D<T6%)\Q-)(
M)O\ 4&5"SR012Q+$IC(.YDDD4C@JIY$;.SBL2S8,ID#LJ!TC"O";\S3*9 J6
MIY+$CUHGC7QZ\[9S_C)=QVGI_+[W1-$N$VM''M)[9_;[;<=P<LE\65;K2YI*
M,"UBT5F6WV+;,VKE+76F:JIR0A;)90?G4DZQU&3&P<7)CS461VQE"B 01J:,
M331IX2RV" C"-B#=D7?K9&!3R;GQ\A JRICLA.4Q*@RB-V90;8$;:)OGUUDM
M1]L=IUSJAL:NMIL:3IM+IMRTRG7BJ[:LU*NK;!YP%I\#MJ99U"MQL;%RBO63
MG]*P'ZIA\3.(FW_Z"^9@21Y$DD<N%XB&-&=Y_'*@JT0 ?QP&7SN=@(( 5B #
M$F;",ZS!8"9U0&>2E=3&_P"*4$4@'%E0W )J@+WVGT3T%VKHFQ;CIFO+[46B
MC?[0.VW0HM3URU 596WV'>V,L"IC7#FCS?=D;7(BJ /.8$5BENY58S&CQ87Q
M0F#!ND2.5@B))"CMDSJ>$QFA5;8NOXBXKT('.M74.K01Y+10PID1+MDFQXGN
M$BJ,L;R50- F@!Z@]]8O=N<:,AM=IMVV[ U8^N'?259%M^U!VXL-D?$E=J7B
M=9MC19E*KKJNV17);"M*V\!+*2"<1KFJ2"1ND6>7#@,6.J=:Z0C&3!R\1(H"
MBQG>\8*%3)M!((5#MNF)-:B)U/'A(";4ARI70-#-,<I5 NB@.P;=NTE7/'![
MUJU_M7Q#6^9:EI>WYV;&O;=SO1J"HY#U.RF"XO=>4I;\K=7KQJ1S]A?< FO8
M/+&FNHY;LI73LXX!]?VXYSX=ZKNS,J/Y63*@FG=L_ B >,[@H9CR$1E'*T?N
MP-5OFP6R!#%DNH@$3?+3RAFD4V6\VVS8WD[JO@ UWU:2@TC4]\YEL>O=!HJ?
M9R=*HZ>>QLNJMH,+[55@79J;:D@Y8.EUX2=C)@<%4K0)ZZ;O[('!&@8Y(/4)
MLG'S$R<-LA(L64K%!&L2L(I" 4E,=AMH'/G8D6#S6HV#!B2"7 :6$^*3MF3>
M-QC)%G<I-CN" #Z[@16M4L.<A#OVM]?O]PW>8M:D9'7=(_F,5//D7K0<J_\
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M/@QOGA%*V,P0!R#)'Y@"&9U3RV#>TGO0X.XF]R>I=(DG\*+,B>=B ,<!D=6
MJCM_\\=OKJZR>RLZ_:+ULZQI6D,$S"EK6&-;41A_&(X2&Y$>%Q_.'U3E]Q<E
MP3XQ&/.)XGY2?+AXV9'4L#17\+[O;;S8OL>>.>.;\,OAOM,9HD["K%P!]?7^
M-U[FM;7K'2=<VYAW%0\H1&LC@;CLY_"&&XCD0@!_+\0Q,$<?(_S^OZXR_/QG
MC.<XTSX<^.%9U-LJLJJNX[3=$D$;;H@BA0-T=919"2$K%(K<\E3VYY![>MV
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M!+:YD_"&RZWLQX6F+1:<;>@(@ZC(-G"+2#M(RL2K:#/$ E$Q8@9C9F5EX>3
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MQIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTU'6F?ZJZW_P \U/\
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M25[7*7:02S:J7'J6QKK916P$NP>M>3=$.2S 23::SF/A_NQC'^&/S^/Q^/\
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M:]/W>^U2OT?1M4YYSP>@L6UY8786DDZ :VO*OW44E"--0AUY?J:.S^PVDJ]
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M[Y'!H+YA5V18U4=6R(HXA'+"95<BF5=VPW^)UKR 'D$'FN>+U,_JUI-1HD0
M@H^NY=Z8@(XK>:Q62.K_ *5E: S$<F!PP4CI,L!$R469+SQG[AQA(4;XCS'R
MVVN4D>.0DTSG:I%@@TH!! Y!/;N?33TV.*-BZTPD[.&#;O2M@%+7<USQS]8*
MMZT3W3+QW6-[MJBMJ]M'!FL4"$583.J6WU6AQD+*,OP^@%FG:GG&%9PB QH&
M^J!,VF%(D72UCGP8<AY8RJ2[BS[GO:_EXL&B#Z]JU2YTDDF:T"Y,J+CRVZ@
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MH\./5AV)OW[UK7ZJM%49)7O22O2S+/#;"^;(0SQ/.09DC9V-8K7MSFQ&7R5
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M9D)6<I-".N-M<J\TEV%IKL36_#)##@P.6%3%(R#(B9@3'1=&Z[U+ C=<6;P
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MX99FV)>W7G.'Y*PN]*7^T/F'TXD.$10(,T84<V))B84LJ&2/YP^&TC-?XAN
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IQC/^.,?GQKW7N\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTU__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g120909g29h20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g29h20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )=J^EI X0DE-! 0      %T< 5H  QLE1QP"   "'W@< E  "')R,3DU
M-C<V' (% #Q-:6-R;W-O9G0@5V]R9" M(#$R,#DP.5]W;W)D7S(T(#(R2G5N
M93(P,C$@0V%N9&5L(&5D:71S+F1O8W@ .$))300E       0\]^8W/R;$)MG
MPB5Y5N.2TSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D
M("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U
M8D!OX            $)R9%15;G1&(U)L=                $)L9"!5;G1&
M(U)L=                %)S;'15;G1&(U!X;$!RP           "G9E8W1O
M<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F
M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              UT   </          $
M 0             '#P   UT                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   UT     4F=H=&QO;F<   </    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      ;70    $   "@    3
M >   (Z    ;00 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!% )" P$1  (1 0,1 ?_$ !\  0  !@,! 0
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M!^0LTP4Q_P /3M_3_P '6IFDW3&\'(U#8A/[2[9LHBLKT<CR2=DH#HO;T\M
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MQ5'R$=//Y?)YL?A\M61;$Z+;GOK'CM!]%\?&I[.:;<Z.S7_#KDM)(O+-'/\
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MRG?UY]E7'OS_ #J?RN]T_P"[OB?X6NOGU4K6_2;\W=:F&I1GO22RYHBMBJZ
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MYX)7]FX57D?N[^G2W_(-C\;U&O<?T.7I"N_SCO\ XEIE86>?_EE[\_6QE]F
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MO[-PJO(_=W].EO\ D&Q^-ZC7N/Z'+TA7?YQW_P 2TRL+//\ \LO?GZV,OLP
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ME&!0JX59WD#K Z_:%A 4Z FVVS(RK#$R<^UD?$P5U22#=(L;R2*"%D;EX)R
MQ#8?#"[CTW@*?3+FQM>'M GLIN*.Y[JU]##Q$EIJ-CINM<,1W&J6FGWVJ:U
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MKF)=/-S+S_"UDD;65O=PH[RI<S0M;S;/QTKJ->Q#81%CL<O%MQZS+%A,4C,
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MLS2<"7>#?O=PX43NG9V!"N[VRQO?-T*8.<[Y+M45,#2RN-KR.P   9B<!0H
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M;4+>'5;6*+B SW-U#<,D<&F7DA;>DT5K$WO$77YD7#48S-R$9>R40(DS0AL
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MMR<T[/FO>WFZNJW5_;;JMXK^]>_OV]WW+4ID].IZ=G7LSVX\V:YZK?3;JO\
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MCDR,B)-@%-ZJ=^GI$S>/$2B<Z4G=(HVEV8G9D!&C( "-V4'5^N!S2WD)!("
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M<6CF :C<7&FW272\J>*3=;3Z5:/!%O$)4SQ7*7,,SQGT,>6^UFJ@QTO:.N3
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M4I2E*4I2E*5LS=#UY+9_YX)7]FX57D?N[^G2W_(-C\;U&O<?T.7I"N_SCO\
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MDED8O)*[22.>UW<EG8_?9B2:^AD4<<,<<,2A(HD2.-%&%2.-0J*H\@50 !Y
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MHK-WZ>NXR[S1<OD'+U#)5JO*3:B#=,EDR56;BQ[>PYN[7R>DJVS2=-:U!GG
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M3;YKHX.%L%%4D,E,,5E4T;IXK*)I7RMGG@EDLCBIGCC?%.ZJ=LKVOGCUOO\
MD&,GR#.2,GR9P<9\QID=F>OF]KY1[8K]>NU_<OUTI2E*XZ[=?5UVZ_-UVZ_H
MI2N:4KCM8WOU6O:]_-UVZ_HI2N:4KCKM;W;VM_C2E+7M>W7:_7:E*YI2E*4I
M2E*5Q>]K>[>UOTWZJ4KFE*4I2E*XZ[7]R]K_ .-*5SUVZ^KKMU^;W_HI2N.N
MW7U==NOS==NNE*YI2E*4I2G7:WNWZJ4I3(\]*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*L-YS\73W(.+1XEKY04VV0&+
M0**HKG!B),"KKLOR(T'L#9EI(PP/Q$F?!,XMJQZL]A["5@[RMHL\"W<]\NV=
M\,EIMXMJ[B7<86$DF%8JXF2VN(X=AV2!&+R@"0QMRSXW9FK6YA:4 H?'&%Z]
MFTRQ.Q/4$X$?U(8;@2,]A%M^7'OF_I*/-89K;;>S9WKN-FP;?(5 <M*1>5/(
MS(F.X99*L=5H;EPE+>,(1/:!K4D6#1^=[ +L1&C(X6!1M<A(;8.G]UWUI]P_
M,EAACE<.2TW?+IN0PI'SC;[3(TD2S%FCA7,[*[X7.VGRKB,%4D=D&WZGE!^N
M\N4YF=N&*##.0$!"C."8(@&Z5]20F5I23*Y \X3 V4F9:W?Z$0N^-B3V@+S4
MAHHM+\D%1TDDT=SY W3:;/C8*/B'>(ADU//G"D<.#9RVBB-!&JB02RLK3"Z8
M;66ZY:W2H#F-6[T ,#LY\8LH =7AB]W')RNU<A>6,D<O<(R3D,1S/JP%!QXQ
M&,?FQU9TA,3G^Q=D1"\YESU@H8F\'!;HFVD'JDM;$HMPJ36TUX6B+&S2"9GE
M=?\ (<0<> !@:&#I=G&I<P5*-WEW3LTVEO%%$XB3(6.1K:*Y CVOJ'_48E.9
M2!+:LF\M)R^8C $;:@$N@[,N[RLO,=#NR+?Z62H.W)64,57;G:<>,35>..T0
MY^QW>QEKR V0XF^K!T+;LF1,=&M9,(C*R/J*UVCB_9K"#PO8<7FJ6PDMD$'S
M9U"G\37CC]JU2,Y9(@&XRVNI-+>V'>T7+F:0DAFFYB O)D%2C0M$8N4%^F[P
MX)()+9JQ+<B4\UMR!0.@3:QVK@@ A@P??G*XP1XQZ;;0=3Z<Y_Z#$S!MJW6D
ML5$/R;M#%25S#23W<\N,D=/[Y%#Y!,I#GLHGKB<!8EMDGI8]GL]49K?;<V8^
M'4IG SK./L$'M]+/IER8^?,@8(N"L=SR(PMQ;.ZA1#S8VDMTN4$"\V"-F39*
MK,2**I<QA^6F,DCJ4#$F-P"<-M(64HQ<!78;L@XQ5T*<'Z1M!>,+LMEV=*3G
M8NQAL^1DN6L+B]00$%L5G+-62*&-P$5;D#Z,PU[&2VKY.*)/S\A'D]G"I;@N
MQQA[ENE9F72CN!@($<,1B*&8-/,T)CG64LY5.7,RSQLJJA6)HR#S.M4)= @[
M\[F8,#LPBAP5* +DED!0@GIN!!!7K;X/TGTD,\BL#OMPH1.244>#.9%F4OI^
M+%A2[#:O$R5R-.-R+7TJ(W+P(RSA&X2 =HY;Q@QFTP\#'(_BU=14<TNC<:1$
M\O)4JC* H7GNK PWT8WI,@ E7FPAR-Z9\:-^C&J(BO&5>822"<_4*?JH3D%6
M;Q3M<CZEAT!7K@1_5VM>DW'OXS!S4IED)UV/ANEH84>CS&CCKD$WBAS0@R5F
M87(B:$C/DS)N!I;NSDMY3$>MB9Q'H@BDH=6"'LX3S:.5>5$26=I;J8!EN5#&
M1;IHTDC7EHB"7O?8(Y/J6;>J %:F1+L,$+,J!(UR#%TVF(,5)#$G;S"=RX)Q
MV^2+H@.E'2@DE:%#DW=;3QA^HFT;, 7_ !MOKI4&P:ZF0W&V>"B*(>3*<B2Y
M%IN-]'"R;D7IVPXG%T<"85TG= =)OT?FH52/D<R8LKB[$VXF;O?JI:/O0 P<
MQ<-/O#=&3.Z8K>;6 +;]J!6!BV8&S>,,-QE)#X8@( 0,^45MEHCG<VUQQ5O&
M3LFD&P!4@[>]&B@O3$32.AG)L38=?8)7*721B!4CT8S)V->M2+V"C+2R#M-L
M/CN;X*5#6Z-IO/OMZHL++_TQ+7+[2%8'E 1J6+,5*\XP[!@[GVL&G(N=D&"Y
M?/TW B&1Y!(2S8P.TQ[RQ'8,]*+W!])OZCX FT);4QGJ30ZG.')<]Q5SBRNY
M,E=6^"I#BF.%6(J<1^]D-L8X1Q@@CO?%=X&LH)2OD/<"*^[21(Y(@,7B[ %O
M@_(Q-N7&2._L\GQR1:_58)!.:>+O ^K#9.[)AV[\)@CM/)^KPG5]V,D#LC0V
M&]):.V)KU<YL69%8&YC;@K,D (WCV1=,I*M+MD9R6*D,RCR$9L&:VO;:O'ZF
M-@V$TL)EB9<G.\7+;$C8Q R:0T4VR)%D#!8MYN@2FR()(N.8I(EYS3JYCW1X
M$.,IB(2[#KF1BA!+8"'#;FR#DK@;-FPC=A@Q8'))J/R$TYLJ8[0@DOD&G)IR
M)UXEI-E$@D%9[:CNM#VJ]UVD?A4GM"1.T)5#@BK\Z"5$AKS[7ZYN6Z\=Q0CC
M!XXY831_GA0M9XDAE1;F.UDY[.9#;M*)K?:%6) R.V%;<W*EPD@8;VR,54DC
M8R(Q1I%" !0X79)GZL]5\F!N7)&#XISTHV7A72B&Y >&#YU,(D 6/S',J;1*
M<>G"2N;<5OUSK[UF,%XN:+"]>+VRT*&E;?:+)2=*&L'CEADBV;RF1E;A9-'5
M4+1QNVQ JA;K(!:W$O? #JK3+_U#QF%A%MVJ<^*E4BMX=X!(&6PVZ/.1O*\O
M(.$(V*1)E@22,=34ONT>DR"[3":\:2O9TFO;#"6 )2JWT"E!;LLY7HGPW;<Q
M2T4#N'<=9-".\0PF*ZV;M9VHP2".F[%1)L,D@^?.D/ TNR&/M1X_^I,I(2XV
M"W7>Q#DBV)DF/+.7#-N)6H8O P7+$@9#?2MIZQ[N8=H) RX"H%;L\G;[@P3I
M5&^</=%"<W(W8RC7"DW!.R'&E)K)I'A8XCN!Z"E(I1HZAO'=;!:,/]:LG41G
M&VU%6,E&2>*#<7P8HS@6T8\P!85S'*(V O247"F %&&'NL[A*W,B@ V,K;@Z
MF.+O"XW_ %:E@3#UZG?U_JQ'(*@!I.A'8013:,Z8Z4F #&@F+2F:!\"J^NGQ
MS,8OH&7!8T_8: UO$D1T/BDBDL-8#82"VE'-@$]EQX>_'YG$3$')PY0OD[F]
MD*S3Z-*2TB1G E5 PND9AWU(Y+O&DGCO \8@8@[6$@D" (:I\N]0 (2,E-W5
M' Q$B#:&9?%$BL7&<E"" 3D"\#D?K7F@>VY+36AY8^@\6)ZIC;9 ]&<M6MS1
M>>1&!\GWHL*^]7<?DCS$"XV6?TE9UCDDDE9@X)IM7[-CE)%%+"UFL%MXUN4$
MLBSR'#"8JL4DMF&8"-T&\0I<[<$Y<(6!\4"M,ER9"T3;5**"5*@EE2X(!W9\
M4NT748.,]0 "+9YMKGI.GVQS,X $)ZV?L+;%C9)TU.\?W0!WK^0[LAQV',=!
M1I<I'G#20-=5Q\.TF3_<[X<[P+,9HA$C2;DP-?D[N.71Q"L;K"06BD7Q+O>)
M$MY$8W3[6!7G2$H+8$%=A="1A:;I=ERREP0K*3F(@J9,KRAN7QMN"QD*]A .
M"!5U.A0O/QC/I7EN62(&80IIP>R@3LFVUN*S3W>WA^OD9:?FL<A*I5XRAQN4
M)F5X"$C\N/J 7+?9^4D>O T@U4TCEE<MIC1QBW4HXN,R[3*W_3&27:D3R  R
M+&5YC/&N[,00!EF+7$8N-S;R"IC\0G:#S,+DNJ@X!.0H5CC#9 RHJC X)TE-
MF6JL6Q#;B11&PC":*34_Q2=#L=A8236&<Y+RZT1$IN'_ ![(1!'9J&O \)31
MVNSD+M10\-%L%X?G%K@MI),N1!M.=G+2^W<G9-RPG,; NED,7/,F(2@ 0E@^
MZD!=>+_.=",[F@QN! 8MM'6(C.T*2^0,]#5-IC'^E*UIJ4A/'&TMD2R5,X.W
M7D$98,=!'5V!\IHHNJ>4APD)KI%P_*!=[,HH.C"3Q8T,P#O2SD@T*"7#\AA7
MC?19IQ%R(40R>)(3=("@N5"<QI)=H5K8R-)A4;?M *D!*IN+U$9N8Y.,E<1-
M@F(DA J G$H4#)QC/G-5 :ZWZ1>1M)>[/RB9(AQA'63S3<8EV?'0[+VC9ER#
MV(>D\AV+D"'(18ILJ+ZL'ZVQCZ8:4L(>X9O<&;I8G+VYDVTH\_2DV;40LZSB
MXDC%VD?6U18UA!8N(9)VDW[HVD&W*X4JM3[;L[LDX4(8PQB+$\R0L7( 4N%"
M= 0G4 >4U+D=U=TF!QR&>F)-)X(^=Q,;')/-VY'C_GL4TE%A'- H%S)M<0TW
M 1] G-9+QNS4CHTK-,0XMP032F+I:TN<IS2S:0H8(B2@2-(D>VZY*[SIZL%R
MR.^V-+LAG$>Y@#RP.6#*J7F222N5 W$Q%SM[X.&P&49)A QNP,@OG-5,XI[*
MY9'.6,D@&Z7NR7P>/0;;1"<]WC,/8Z2'G?59I1+2S#7Y<9$!,MP/)P]]LA&5
M(')"6%R,VT-'8NH1CJ MRSHWL-DMDDMOR@6EA$?CN;ED,=P9VE5G9=G,$/+*
MJK("(Y%# YJ0O,;AD<OA48L, 1AMT?+V':#G:6W98@GJN*RQ5AJO:4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*QT<T-V\B-,;.
MU*^TT$)RL 1UOMA8S"$]2;!V,)GL]93C1;2!PNTE@%V]M62<Z$*[ 2 3B8N'
MD+%-4C3\X!*),<%AV4L+>UN(;@7#"-EE@VR<Z*(QQ&*Y,LFR4CG(K+%NBCQ*
M3MVLHR&M;B26-X^7U!5P5,;ON?*;!N7 0GQAN8[0,DCLJV'#FASABS?P6RX]
M'9>2'A9)FA&3&J=ONY(4#--?3*:(;D<['%XMH:H'$3D2)U)EHIL!MM*3N'2$
M@ FL$RP4:YNSI^GN2W?2HI9<NL]N$5C*D9MQ$0TFXQL9N^"1 F-K@X8U1%Q<
M 8Y66P2%*/N("DERV=OBL-NS =NU>F*F0QR9YQ1DN;G4)A[?D%"G,;9L!<29
M\?=OZA>2&3L=2\E)H@?AJ$QDK\]#!!&8:UUQ"38:7L9;F9?S06ZCQ\+@6 M2
MDJV>G.$CDD-K(&8L_?4$X53/:1[9"B!'(CEF=&C90HC.\, Y$>?< EE42(<
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GLX^:WT6I2G9Q\UOHM2E.JWFM]%J4I:UK>Y:UOT6ZJ4KFE*4I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g120909g29w29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g29w29.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2:Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )IZ^F(8X0DE-! 0      %T< 5H  QLE1QP"   "'W@< E  "')R,3DU
M-C<V' (% #Q-:6-R;W-O9G0@5V]R9" M(#$R,#DP.5]W;W)D7S(T(#(R2G5N
M93(P,C$@0V%N9&5L(&5D:71S+F1O8W@ .$))300E       0\]^8W/R;$)MG
MPB5Y5N.2TSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              P4   81          $
M 0             &$0   P4                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   P4     4F=H=&QO;F<   81    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      <(0    $   "@    4
M >   )8    <!0 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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MNH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(:8C.B3.)F8G^BF2*RHLPBY:+_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ML<$F)S0V@I6AT3A$5G)T=WB%HK*TM]7A\?_$ !P! 0 !!0$!
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M\4'TET.0V&\LM!O!\IQ\8M%MK>3C#;PP9O;"NC?=\<'H13PN?R'F0'27%_E
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ML&M'<563N;XX7(\&WX8U^F<DS&G()S](+8,D*AB:QFU#ZF?X:D>COZ2+T75
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M874; @WB6+A1X#)*J*" H$F//"2U4[]$,AE8&) 0@8EP6"7->2@U\JOZ^_\
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M_NZ?&3_3L#]*E0?GK_(>V>=B/_O/_C3?_P!>8W^G+CWNYXMUS+72N1422O\
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M5E,QSD8D3X5V!-=H[*K](6/=&OIV'"3'7U,:.H'DL-'5_N@:$BM&3_G#:?\
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MC\R"RI811HI2)8XW5HCR,$C5G=CH*H))_@/H!Y)]@ 22 "<I9E0%F(4#W)(
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MEK,586;,Z2R24X8JM4=*QPG_ )/&RB,/$G[5=,)'+OU,7V(HBD3H0*248%)
M5Z==6RS;(*^">M1[CY1U?7I?PB$^?$5%@=/,5,&^\HJELBN2("AI]%8UU:+
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MCC9V:1V=D15+EI7EE8L06)DDD<[^9V;;'GLC!Y)'50JO)(ZJ BA0[E@H"*B
M*#K2(B#7RJHT _ZC2TEVY\5>=&\J%$<17$LE!MA$7Z3YE2=&/9!JJ_A"18O)
M%16]T5%ZNY1B[W1?PJ+TQATQATQATQD0\N[J#.5(F7JZF35[K?*;18W'"D?%
MELIOC?\ 2EU;6"0%-S^0S D[+'2:4@>6(&-X597#6FGN<]0V]Z&'NEF9NW%&
M TLA&PH.^E%&QURR$$1H#Y(+,5C5V6V[].E ZG;PJCW_ #8D>RKORWZ >2 =
M;B[CYV,(M+?7'1Z?E#41AOU6\E&>*EW&# WXU+G )2C?Y5Q]%)(7^AXT4R:,
M1""[FQ+O-+;W^ALTTW<TJ*8X4+=J+>^D,?+.P"]R1M#JD*@D * JA5!$Z=LQ
M#.VNI]$;U[  D]*CR0H.@2226+,9GZLY<QI:S3LSM803 R @UKQ8(HR)O8#@
ME-(A'C(L"4:]1PQFR/+)5K7SJ(.1)%&Y(W/8QD),W&,EN,V!R&\@_2;>U-%H
M:8P,TZAKG"V;*X8= /%U6*]A\L=:XXD:>QF-21\Q$ S>T&O<IZHXCA^4XKAK
MTTL=[FG*442"62,GK2)#+*B%(A)-+'"A?QUL2VD5G$>6U##+##(Q#SG2  D$
M]07R1X&V8 #\]G0\Y6_T-G<X6-QSXW?X/:8# P^H?U*LH*KD#/5^9=>#V7-%
M]>9S48X7S(M3\=?9ZWE(@O#GK66TBM?4K(,ULKK$4/J^/U?;DY&U3L^FI>$I
M-4^&>NR07E6M#'!"H1;B.D,5A[HL,T1DEK]AB>ZL<6F+HL6.\"M?KF* A .I
MI0R= T)/W2_<9]JS=/1X!R\.?!!ECBRMW7"&6&;KV-I[&>" J2>B);-7"EP3
MR,=,$>D(CP;.)'1O?-$A#%>.2Q(]HS)8_*Z5\P0[Y/\ K4C;',G]IHD]N9O_
M -&5CVK^?M/STQFZOU__ +^NF,3(4E*B;.\J2-7HJI#"D34B_HL3EDCDD65B
M]V2*Y417(O:-J?MZ8R)<H35YF2U$AH;4="-*0(06E0X$("&6\FI,[ V8IP39
MA2&O@F@=2P&B0/.E()CB64HJ43_7]>^,BC0;?B[U!8?E>M&;L[ +AZ[-;?@@
M I56I]MFAK1%&JG%1'0%CEO%/&BA,$C,'G]JP401_P"FEOYSZI/ ^K?3G/0V
M8^4L5_3\L]NQ!07L6Y['&P6)!#7$D<R2]X"1$62/J20QSJJ2)#(-8K\UQ7J&
M'EHJWQ3_ -CVI:]I.UVF::'NJ1'U!PRLT<JA75)!I9.A T3LX<:=A_4'EJ/0
M:KCVNG=C=6J445M.E\*&?5ABE1W53<3"A.*A8Z<=ADDHRM6R!EBECGE$BEZE
M>DN8H^N>(AY&UPZP'C>0:"ND\OQT?=K1P2)9JVVCA-A-2(CNT2]-F&6-NMHN
MO)OPO'\Y%6FOT(+!HV1+5,RB98YD".LT+E5ZAY4,"O29(]$-T*<F#)N-<^]O
MHA&255W:1$U_LM6$LD 2L! ;:NC<QC"_GD#SSBRJD$Y%6T"5$E5S&)OF9K'[
M#/"1&DL+VO8O=.Z?2HJ=T<US5[.8]BHK7L>C7L<BM<U%14Z8S4+)D5_PP^SB
MWM1SI%3SB$B55;[\R)_F=W1?8@14?.]J]E;$R61C&5VO<U;\&6)W(/'X-G>8
M&Q(GL^5>-JT>4\^"<B12+3E+CVK$ADFFT<?:4W;8JJ'1V[B4F^HA)-_'.#MY
M:,MA5BE*K*JA8)V.M@>%@F8_W/812$_LCI&U$>J.RP,9+J"4.S)&!OR229%'
MOU;)ZU&^L>0.H::PU)=5&DJ*S04%D#<T=T"+:5%O6%0FUUG6G0L)"/!,&?)
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M8QGZY*-!'!H;0MC(H"'3G0&3QM8\-@9:/*6D(B]72BKU'J;I4#J;0!9M>[$
M>3Y\#[#*$C1.KH55+L7<JH4NY !=] =3$  L=L0 -XNBYNXN1W0W%T"E+-'(
M.X*AIIJ:2S">]4=&403;VSH0SF(]9HZ]H9,\+X^YD;5DB<1%C4*BJBCV50%
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MVX^A&24"O2%T=/83OL2E9C:%>:*5F9#&G2P8$C3,2" %!\Z\_/['VSEWX?\
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M'.2MPT..O7K,QK5Z5.U;GLK&9F@AKP/++,L2J[2F)$9Q&$<N5Z0K$Z/,'CS
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M-W9I'@=)HI(NZS2(3)&SR!%D>_[FQ-18R7Q.<8]8D8]$1DKO:7O%&QZJK_\
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M.*I=)N!J,O061-Z)4Y>@K*J*]DJ\^%=7[JI+3]-E?:GV-O*)7>^5=**P-H8
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MX],?#NK>"VYIY$6OO=]H!@K.6L?9%(3#396HL9H)!J/&9UL95!A*,LD24N.
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MK36>.L57GXYNZG'TTBFAA:2M8ALQO;%&4#C8A2G$4E:XTT(2H)(CT,#$8.-
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MQR/<Z%K9YU:-\J9%C%C>KIN\43NLAQ7'2<MR5'C(9$BDNV8JZRR;*1]Q@"[
M:+!%VW2OS.1TKY(S%\WRL/!\1R7,6(WEAXZI-;>*/7<E[2%A&I/A2[:7K;Y4
M!ZF^4'*[< >IZRY<V1V+T62KJ,U],?H:@RHLR[ 51ZTD 0NK.B+$%E26)+0:
M80Z!8X3/ ED@-?*R!"=T]6^AHO3W'P\C5OR6XS9CJ6(YX4AD5Y8YI(Y8NW)(
MI0]AU>)CU1DH5DE!?HY[Z%_$B;U9RECBKG%Q49EJRW:TM:R]B)HH988I891)
M#$ZR+\1&R2J.B0=8:.)@H?)SWQ)S1NN0L5;8?9LI,B$&&%:!/TMQ5P5A45L2
M3;6TU*$.\/6QVE1,/7OKK)Z0R?#6OE=$#9F$1V/3/.>FN-X7E:?+\9\7>L-*
MT$HJUYS-$]<1PUULRL):)AG5I3-"I.I1( \D"(97K#TWZOY;U!PE_@N:^ XZ
MH(1:A^,M0"&6.TTL]EJD*&#D%GK&. 06&Z=Q=I^F*=W6S %@?FIA:B[=*94R
MRQ U6B?]S1RO5(@ZZ_:G=&SR]F0"7+?&"Q(<P<N$0Z4=UCH7]'^OZ_Q\=+_K
M_P _Z^OM]<>[)&2M\XWM>Q>_9S51S5[?GLJ*J+V7Z7_5%Z9[D%\HZW3MTU%Q
MGQM,&/O]G5&&F7YHT=A7\<XNJ*A'LMW85DCXXK0]3+&*CQ]#/(R*ZT!3BRVR
MT&>T:P2(8TZ6FEV8HR%"@Z,LI!*Q _W5T"TC^ZH#K;L@-MV;81".MMG9\]"C
M6W(^I\@(#X9ON%;3PX_XKR''$)<E(%.9H+=6RZ;:WY+KK;:TQJN=\S2:4MJG
MV"L<YS00&/@IJ47VZRAK*NJ&%!@HEGDFUU$!%&DB0=,48]M1H/E7?]YM=3GY
MG9F).>I&J#P-DC3,WEV_TF/D_I[#V  \9(_5K*\B'?\ #]-KC6ZS/&28/E*N
M@1E%R/0#1):,2))'05&J"1XXVYQLTDCOU#):!\P3D>IU//1Z :LO:Z_%.T8*
M,.["W[\+D]/^DA\]J0?1T&]^&#*2IMO&&^93T2#]UQ[_ *,/9E^ZML?4:.CF
M]Q9O3MI56X&DK!Z#?8FX?EM]GA)YB@0;R$,6P&LJ,TB ::QRVFISJ[1YJPD@
MB(=5V48%I %?5UO7!>3Q"-E*,7BD7KB<C1*[*E6 \!T961P/'4I(VI4GV-RP
M(8:=3TN/H#H'8/U5@0P_(Z/D$#GSZKK)+'FVTA;(CF4>2RM*K$\O\,A\MW?3
M=^_[4?)!>AN=XHW]C8_+NJ(B;/P:=-7J^LDSM_X554&_X@Z_4_?.#?BM8[G,
MTJ_C5?CT?W]GGGE+>/H>F-/;W'\<Y]\N\DZ?(6M319Z"L%<?73VDMK;!$V#9
M4@)05P( T!M>QLHWG#.:1-,0D<98D;!D69TS-@ABCE5G;J.BJA5('A@3U$E6
M'W  ]R#Y&AOYM]8^I^5X6U3H<9'3B:S6DM/:NP360XCE$+05X8YZJAXNJ*2:
M2220*LT*"$]9=691\[6350+=T=9;U,Z.C,L*$(F*8:%W9/(K.F$VJ6@[?MY"
M@'L+\$1HM09*J1]5M64@F)RC#V1R&ZO?PLBJA4DG0!&CLCJ\C,+QWX@V@>QZ
M@H5;=20=$UKCH)4:-#H$R\7/-=%J,:W)V+ FZ5 BISL=9T$XJ]0^WP05>ZIL
MTY P) \!@F?M+-2I(1)HV2"$9+23NGE''C8Z.8>DL92J.9L4(@,N=A=(8F"N
M\77LEFZ?AIP2#(J:#-X\31+I3]=NG3)]6$FM9]!^E?7O+\'%6:K9'/<#-%'-
M'0GM"1DK2A6CDX;DW:1HU[9ZHZ=EIJ# 1PP/QJ,\PZ2<3<BXKD3,!%Y.Q^2X
M 886ZJB6H/?4UD]KI"8;^O>]"8"IY/<(89WF$LD5;&M+,"EB*FU2S5GJ2=$R
M$;V4<>8Y!O\ >1O8C[CP5/A@&! ^B. ]2<1ZEJ&UQ5KN]LA+-69>S>I2D;[5
MRJQZX7(&T?YH)TU-6EF@9)&S<HRF9[C'E338^M@CV(O'^SM:><(:-33+ZLSM
MF94MEEBA]XE764(Z1-D>])']FIW7NB^TDBDNU(YB!#):KI*2= 1M,BOL['CI
M)WY'C-LXN*";D^.ALD"M+?IQV"3I1!)8C64D_0",MO[><_'-;5MC8W\@(4!!
M*.B!&JIY&32#)5H% L)DA;FN:X9SWSEE3ND5\I,D[%60AWMKW6*5(X%D=@O[
M[2@$!N[U$E @((8:"J /"Z \9]:AE56+$!^INI/8AMZT% TJ@  */  T-^!D
M]#0-&''&8JO:/!$.U7?:O9#&V)%=]KW5S6]W?:HO=>L&S=3,WL68MX^A)WX_
M0^V0_P##],_1WZ&S;2R]*O#TMHZ628&CMZ:KFF<]TDF7H-/>T>25LCW*LC79
MBNJ4'(=Y>X*D<_DY)$7KFWJ%$3F;P0 =3Q22 > )Y8(I; UXT1.\FQH:.Q],
M^<?6T<,7JGEUA"JK3QRR*H"JMB>M#-94 > 18DEZAH:;8UXR:N5K6SJ,)9GT
MT0SK5A>:B!0F)\\$!-CI:6O0B<:.0=TXXJ$/*F&4B%YD<+XDGA23W6Q>+KQ6
MK]>"<L(6+O,$(#M'%&\KHK$$*9%C*!R#TENK1UK-#YBS/3XVS/6"&PHCCA,@
MZHUEFFCA21E#+W%C:02&,,O<"]'6O5U#0#Q(TMZ';7FFOM(>,1\D,>[=2C B
MS1 3@3V@(F9I:062Q]@DRN@.L5))@ ?/&-(Q'JY9372D,R5*5:G'-&L<SUA9
M>215E$J0RM<LV2(]B.1TA"!W6/KV% $)./#SP2V[]N_) [RUTM_"1QPN8VA>
M:%>/JU$:3I:2*.2P9&2-Y.WKK<EY?O;$,X1CX!63#L&=+/-YSMD(8B.DC8D;
M613JV8ASR%(>[NQOBWW&IU#T"S]PAGZ6+Z1=)I"= [.RAZ$ 3I &_/@G)^ST
MQF(%4ZD$9:1NI@SZ!90 .E_F<ERS'0&MG6,[3BY"WL@:6Z. +L1&.^!#^OBU
M^B'E;&^*5:N$0B*U;(<L#6DK!(U2TG9!,QS(E:V=3>[!%+8KQS)$Y_:'X5Y:
MCJ6#*)FD1H"(^K:=8/1T]2G;><=>CXZS-%5LRP2S(#V5^,2&ZC=+!C76)TL!
MI"@#]# OU!&! UF/*?IN)W-CDV&D TV@I*JRSE;96AAPKK\8ZY%TPE(59DSO
M1THOZ(9+4PR,<KVFV,8:/DL)W56^[?XV*[VDDGJV9X;4D%>*)A5DC@DJ268Z
M\:+H2?$H)W4C12(R$"%!32[7&\K-QYFECKVZM:>E%9L33(;<4MJ*[%5ELR2-
MLQ"F_P .K G4DRQ@F9BZKBNI9M#*1I*VN*BE%"@IBK$,<D6-\$I,LXS)R(W,
M&L)IYT<R-SXU)A9"HSY7CD1Q:Q8I4[?0;56M9,9ZHS/!%,4;WZD,B-TG9WL?
M7SFPLB,0616(]BRAM>=^-@_7':UC/!D;($BB8C6L8B=O%R?A>[>S71,8G[E[
M]G)^SMW1$ZD@!0 !H   #P  - :'CVRK^ORQ!B)%DT!939H?BU]-./;%><:#
ML?\ *C(%B(G54BCD%@982RPJ_P AH26/E:Q)HW.]QE /5!ZR'^GR(#CSC,2C
MU&UN:I]N.1<J41GL#2N/L*J&>Q !E#)O"+8ZM+=29V*SJ5"B&L9[ \4$>IKK
M+8N$X,<@C6K+O'41^VJ1E1-8E 5G1&966..-64O*5?;,L:*=N\6^>C_1W_I
M)+]Z62OQ<,AA AZ5L7)T"M)%"\BND,42NIEG,<IZF2*.-BSO#S 7^)9ZEL[J
MY%-W8U["'/"IM9<8#&2Y=%EB@(? HF>!SFL49H\K&I,-HE+C<J=T+\'K)N:^
MDN+GKAEJB,N&Z3'9LB?QM=]4IF@+$C6FA"D>?EWH=/?\/O3$T!1*$T!UI9X+
MUKXG?OU V)+%8D'1T:W2?8=.PPZ^<#<F<6>LG"";[7XW)6NGX_LAX;/)WU)3
MZ8#''$J$?#?YRRN RB#Z^\J8/.ITD$=;(Z.*RJYPQ3JX^&+1N1J7>!LO%#:L
M)#9C^2:%Y*YFC5M/#.D;^)(G\21,SKHI(A*2*3R'GN)Y7T??>M7OVDK78BT%
MJK++4^+KJ^GALI%)XE@D 66%F=02DJ?)*C&]<;Q1X(FQNAB'8QK8FM=''$V-
MJ=F)&C51B1HU$1B,^D;V1J=NL'[DD^2?)/U)^Y/US4B222223Y))V23[DD^2
M3]2??(%]1UF +QLRY::$DN4W_$NP5SBHF.C"RO*>.O+MS51_DGE0@VL,O=.R
MP2RH[]JKWDU/\MT^?VD4\?C[R02*OO\ 3J*G^&\M3#Y-^/E>-O/T"R*2?_=W
MK]?MDH[;!9CD6GAHM:#/85D)X=D@X]E95;GD!2)+$R:>K+#GG$D7]I04LCQ"
MHU\"(9&HWM&!_AEW&+!PP"')8PAVL4=>=(-*--+15<NBH7"0^Q N?NE8R"OD
M'B;# )/)5%2AC"B0P>/LI(K&A]L?>1Q%1BV6<=2XIZ6M@19$J7)'+(I)911Q
M,CY60Q2DSSFG&$3F&.).G69K)R9(X(&QL:_Q\YNZY5CSMD4G^:OCAMF?G[?4
M$P6;?Q]_D1/O[[?GLO;MTQGO412+42ECQK*54S#W(T;$[R3/K)4*F&B7LJH\
MX1A **U.ZM)<W[1RITQF#5R1DX^](A>DK%HCS!Y(U[M>L0<I,#V*BKY(JL8]
MJHOVG9?QTQCG1>Z(J?A41?\ O3O_ *_^U>F,^],9A(8LD$T:*]OG&]GE$]8I
M$\FJG>.1OW'(G?NQZ=E8[L[NG;OTQE5 JGU"9 >C8%;1:4H\#.TIP=_-/>#"
MWY4E41H-$1:1LB-#J:QEEID2!\L<)@V6IP!&-L[Z!48\_P"_]<WI1?4^CFS2
MV&6)A^8,2\42 . N *2JA0P4!TA P9E@%9DV#1$M9V5AR!53BG"QR&/<Q_7]
M?T,38ZOU0"T)3I+7.&GE#!/+#F8"1/$\MC8]"E83),*'$0$Q$ESD,GLUB2)-
M'9L(;+')&QF+81<[SYP0R@FRTE!)QOBE.;,^81BZ"O)AL=.5^G^Y/+#G[*H(
MF"<"P\LV9@40ZE00.DF+8S8OBO4Q7!WTZ+G)Z\" ]XD\<=/"XRKBEK2!""2'
MD>Z#9L";?#7TH]46'X)42459(3*8^!GAW]-;_K\O?^O.)98G(9CO3=C^27UB
MGG\N/N[VOJ!H8:]*?CWC/5Z6E"[Q&G,+'#Y&J\U>U1<BP&,"!JX#H?U,8@J>
M37^6.W)]4@Z%/CP9)HHV._?_ "9D0_<,0?'O:E\O OT,I8^_GHC=@/\ W@K>
M?MECM1QUD]>LLMS7.D+D&@%^8.64),L8A#RPDF;!*T<Q RI)9AHSQRX(UG(C
M]I822(Y=1YOTGP'J$N_)52\[0Q0_$PV)J\O17F:Q6ZQ%(L-@5IW>2!+<5B)3
M)(IC9)94?8>+]1<MPX5*-D)$LLDHADBBFCZIHA#/T&1&DA[\2K'*T$D3L$C;
MJ#QQLL'U&>D+L;>GTVELKRDR%G9Q))?D^\($ "R,Z$LF+QCA+*&A21[CS7D$
M!2-C6L6NKY_@P:CZ:].O>N<A5YCD;_/TN!Y.:CQ];DY!/!M>S/6>6 ((K5F$
M.=3VS/-$Y!IFG6?X5-CYSF5JU:ECC:53B+7+T(K5N>BO;F*MW8IQ#+U&6O#(
M5"]FMVHY%#?$_$6$-AX'X?\ 4[C/47O6\:T?#?)=)4WO&XO-&0V]_%B#:&YQ
M-F<-'D+[85%'?6>@XVL^0H)7:#CBIVU57WM_3 6%L355\]86!'UOFO2''MQL
MB7DXVU$;1AGJ=E_DNIN222%I(4AL2U9%436*[-V9RG2[=08Z!QW/W8[BS57N
M02B'JCL=P#JKL @C?HD9XTF5F"QN!UQ!CH+H98//X5NTOK '3Z;0WE!EX:1]
M=1RV148R'32&3/D).;)^J&M%F A40DLR:V:CIX)[4@$AX2<:J^D$YGG.0H<W
MS7+<KQ7 )QC4>,DNSI$+$_?L==FTK+>LM 8(A')/8EN@F:-K\M28U5Z-8]1'
MC>)I7.*XKCN/Y#EVOBU?6M$\ABB[<)$$#*:L F$TA>.*&.H1VW2G'.G>RPM;
M05%36+3@!1Q5SU*=*/(Z0KY,ASY)3)3)2GS3F3%R2R2$S%2RRD.>Y97O55[]
M0X_CZ?%UEJ4(17@5Y)>D,[NTLTC2S32S2,\TT\TKM)+/-))+([%G=F.\T.Y<
MLWYFL6Y3-,R1Q[*HBK'$BQQ11QQJL<44<:JD<<:*B* %4#*?\+<W<-X?B&JR
MNMYBP5-=<5.VG%]@#<;S,5^A>!Q#KM)@:V2S L+1AS+$VJS IKG2QL)FD*=*
MUW:9JKG;56P]AY$KS.LPCG!2*1E)GC69NDJI'2&<@:/@ #WS&0S1K&$:5 T9
M:,AG4-^S8IL@G?D+OV'OF*Q]:/I3XGEXSR.\]07%%#;\H6MA5TMA)M<^7G2-
MH3&Z\.H+"^#/GK:0NRD,);G6WQ($-K(!.#7DRGLA$FHCXV_*DKI4G/94-(.T
MX8*3KJ", SJ#K?0"0""0!YRLV:ZLJF:/YMZ(=2-^/<@G7N/)T#[;V1BMS-M-
M=QI$9>S#T=FS2$6 U595K3H9*(2OA4@ ^T!7Y;[<@4605AS:\F"$^6%BLCKX
M8Y97\9]<>O.:] T);7(<?Q_*?'7KXXJQ3:U!'1H0IW8_[6IMWI[4E>(CN2<?
M.GQ;EAV:,:F8]+]*>D.,]8W$KT[MSC_A*E5N0ALK7E>W;D/;<<=9':BKK-*&
M,:7(F^'4 ]VT["(('!W,UW=0Q<:UN?KOU("K,BIKJ6(NLJA%%B80P>UJIF36
M)<D$),4T+J^?Q-;XCE/KY7*:[3?PX_$OF.:=O2D'%T6Y%(;LE3E'2QQ_'P2?
M\[,=Z@PDL3F,61*AI2(E@%8)6IN39;9O6_H7C>*4>H9.0LBD\U9+/'J\%RY,
MK?L0]6Y&4@C$G9*/\3&3$=RQ+90"$29>\T\;9S19NKU>_P L'JJI;*LU+(WD
M"1CF$5#)C8AX'H22*R6P$'(&BFGFDAAB\'S.5KG+UX^L. XX)1YGG^*CY:K%
M#%R21]R"/XQ8D^(,,,C3/%$TA9XHWEE=(RJ-([ L=$C]%>I>27X[B/3W*S<7
M:>27CY&1)7:H9'$'7*G;220( KND:*[@E452 /N.YOR',V@/I.).0:G]0X\M
MRAMG26% 19/LP4&]NM(KR4, C6O(66 X<RO)G>U[F#G0CD0DA.Q%'U=5]7\D
M]7TAZCI13<#=GCYVC;XQ[@NP&(I6,$JV:W;@9W2=+%>9W.TCG2)E>!\GRWHK
ME?1W&UKOJWT];-?GZ4,O"7:_(QUA5F#]5B.Q"8+#?$HJ/#)7L11J-&6!Y8WB
MG%1N:N0-E;;2Q$T\80H68N+0"G8-9&05U<^MEG'BL_!0GDMN;0=CRH2WRHL4
M$S:\0N%TB1E?-/XB>KO4MOU+<BY;L5(.%OWZE 5KMJ"I4:G)+"+FEK-.+]^%
M3.D[R K#*M6"=.LK8[-Z*].<%7X.K)QW=GFY2G5L6S/4@FLV?B521JY)E$1I
MU)&$3PJ--)'\1-$P7JBF3TR6 !DUW'LBX;'1 P5UM6&Z$YU@13@E_-=9!5)=
MK/.0..$6)!//,R92)GR-\Y(QHAAQNH?@[SC\G_:$/JOD/[0Y+CX:5[CI>8L_
M$OQ\$JV4M5Z4MR1Y%^&DA0R66=[3A_GF$$<$4.@?B9Q$?'FG-Z?I"E1NRVZ=
MR/C:X@6Y-"8&KRVDJHBDSI*P2LJK!&5/1&96EDE1?6)R]JLV1EL+C+<W/C:"
MG-T-S?4IKA[,P%AD00-966HRH2#"0_Y!EB77$0G.8RO@B+C&G+C(^W/PUX#C
M.5CM\Q<C@OI7D@AI0R!9JI:6,SM:>/J,=@&/MI LBO 0\KD.RH5^+?Q>]4\O
MPK<?P?&S3\<]R*Q9O6H2T-L)!*D"5(I0.Y7ZG,CV'C,<_P D<:NBM)U5\]//
M,F]SG)65HC=1H-#F-;=AY^VJ=%<6E^L$MJ]PM?:515H2:=7$!V,HTAC!IVAD
M5KCW3BO+8(4-N'K/TSQ-GA;MR"E4HW./@:U#-3KPU5D2'32P6$@2..5'BZ^T
MS*94F$05Q&'1] _#WUESU3U%QW'6N0N\EQW*V4I307[5BZ\,DVQ#9K36'EFB
M=)0@E02=F2!IBZ&41R)??EKFKCOA6RJ-%RCJJW,UD-%;ACJ5*QQEC86%AG&A
MA58:(XNQ/+<(2BI"Q6#CCSDDS0#Q33LXMPGI_F/45LT^'HSW9D0RR]I?V=>$
M;ZIIY3I(HQHZ+$%VTD8>0JI^BO4/J?@_2M'^T.>Y""A79^U#W6W+9F/[L-:%
M=R32'8)"*51?GE9$!8>C.=O3?HAB:6TY=XBMP[@5],14D[3(D#64%BV6&<(@
M-;.3WX"XR%%= SW4(;(K)D>CU3J9'Z9]75)4LP\#Z@KRUI%FCG3C+\;PO$P=
M95D[(*%"H<-L%=;\$9"E]6^B;L4E.;U)Z:LQ6T>M+6DY;C94G28&)X'B,["0
M2!BA0@A]].CO(IW _&'I&SA&IX\Q"3[+8GLR]7)<7U]:)![@I-N2V4NX-L+
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MM5+(>5V"AI&9B %#,223X 4'ZD@  ?8:]AE]D@0%F2)54$EF5%"@#9))
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M/+!"!Y(S@:%_$\]4NHW7S*NUR=91++.:)EX\A4GYD8")RO&AL7%#,V1$4Z>
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M/2ZAQTMT2:?M]MU7AGCM_%7'%%BC;=UZ56):(0?["C PNL; NS;7AU\LY4L
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MW5^9 2H(,HWN'X34J$U>Y=F2&:_5CH)7$J+(U>&5)6DL1*X(61I(XXA,!UQ
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MO^5T<#(T>W^DRRKW7RZB9>S?5>R*O]D5?^[_ +__ &=,97'B4]-CRKS5R!-
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M?8E._>99G2FDFV)LJNF,.*)*F<^69SW6Y9&ED>5]=4C,Q \ ;.^D#Z!1X \
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MJO<SQ[],8E8JHL(9&D3/M0P!HRH8PCE?$\N>>=>\I(ST19'01L:^4XEKR3+
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MJ*:\KUY[$(GKF2PDSB* I(MJRT1D7MRPR,[R1]H%1ZOD#P0-L?&P- GI/@^
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MA!V1P#""#11P##PQLBAAC9'&UK&HB1B2Q+,2S,269CMF).R23Y))\DGW.7
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MKD&)$5O=?_)2#1.1%7[\41>A_K^A_7Z8QVI^$_X)_P"/KIC&W7JA>CO#?M6
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MF6EU>VYBM?8W^CO;*<NWT.@M)F^_975N898FR]G3D.1K&ML22O*W5(VSH*H
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M9=8O?*:5>WYS]Q]?_NXC_P!GYZ8S#KT1<C?HOX_1C%_[4'<J?_:B=,8O&%P
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M5], Q9/%:Z-YEC.- XDH>2!(HFO62>=711,=(BL2N..25@D2/(Q]E12Q/W\
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BPZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8PZ8S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g120909g33i33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g33i33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[20*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (^Z^D9@X0DE-! 0      %T< 5H  QLE1QP"   "K@ < E  "')R,3DU
M-C<V' (% #Q-:6-R;W-O9G0@5V]R9" M(#$R,#DP.5]W;W)D7S(T(#(R2G5N
M93(P,C$@0V%N9&5L(&5D:71S+F1O8W@ .$))300E       00P9]N\[)&4@-
M,O/Y!^#=@CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              K,   ?3          $
M 0             'TP   K,                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   K,     4F=H=&QO;F<   ?3    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !SA"24T$#      9<@    $   "@    -P
M >   &<@   95@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M3P!/24^33]U0)U!Q4+L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ T0)= P$1  (1 0,1 ?_$ !\  0 !! (# 0
M           *!@<("00% 0,+ O_$ %L0  $#! $! 0<,#P8#!@,)  4#! 8
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M<N<D\%%.]V334SQ];1M#U;B"ZNGZ/1FO6F',4B"A8T! ,LTKE(H(@2 9)71
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M;?BWBW]VZ?\ S;'M[?$C\1-\^2\*](-/#M/[RQ[B/YW'UVG<V_%O%O[MT_\
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M'("C';KZM^ICU'J4L=AN1MUYLW@KNT=S[CR=:6BZST.J."4TK5(6T^])MZD
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M8JJ]H]D?#C/JA>IY/M/O#_\ RW;?\]]GUI;BG[?:A_:K_%(,S#2OZA!_Q?\
MK29C%ZH$^SXL_FV__3JM=<0=M3V)_ABR&OFQ?0< _P!KB/X-%R.%6.9"'%,8
MIC%,8IC%,8IC%,8IC%,8IC%,8IC%,8IC%,9(&Z ?PE\C_P!AX%_'CM9!P_\
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M!YHE\1B3S!DV3.M+ 4L[1@RGT#@A>4[[EMMFYF)VV)V*@=1!V(NE?J<K2C6
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M$30QQR]*TD1C$D8)$T[3ARWHUC#*1&H!;94*.C.W(JGHV*LY7E4,&V/8B<A
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M+D<*L<R$.*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8R0-T _A+Y'_L/
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MZSZ8'$'ME+Y-IY]#^XOZ6G#/M6H?*M[(RW)SXQ^_/GEV9]<C-2YX1^Y/A?\
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M+"8H.:$VK<\J)$NQ>LK10,G9YQZ9<>^_6>O;Y)B66T&VT$Y';"]L;9D\B#;
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M<$=M:(E" Z*;OGIW=S<A*),?0V8RBAP3(-:1*R(4J%A 5L7Q&NEG$D(@UP)
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M]KTWY7H9$IJ;.?//%,8IC%,9^<^VV-^R_9?[MOSUR7;<;[;?E]C&9Q20YHA
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MSI5:E;31ZR5*D#7B^JS3,VNR"M+8JA*1U!I'%6E-=*UFE:)Q=H-/]?,M;&&
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M.(/;*7R;3SZ']Q?TM.&?:M0^5;V1EN3GQC]^?/+LSZY&:ESPC]R?"_Z/:/\
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MK2K4G:O)+#'92M:,-AZLDJ1V4B:!^99.1JP9S6,1W;T3GHJ.-C "+2."R%^
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M:_8U?7--T^[:TNW:LT9ZPTJLVLL56Q!7-74W[^A$DR+:@18Y)(%]I#D7QL:
M3R$2UT4$&2!;;BP9VAKZ"AR(<3L.+\@(T@)4D88RB0>A/6T_U@G@"<-G"()M
M%RB+5Z1P9!4W%6L5E#]'$P.\W+]CC!"R)93EYP=RA$D6RD>*$.Q)  [9N.^
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M2Z.KD]'&Q++,CB02,><%8E:-8P I)YBP.8[P9QGPKP]4T22[I9EU#3-3JW+
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M:$SXC5:YJ_%,8IC%,8IC%,8IC%,9(&Z ?PE\C_V'@7\>.UD'#_\ 2VO:XO\
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M'_L/ OX\=K(.'_Z6U[7%_BDR97F/?MOQO^;])^,6<D]5E&3NS!7J5?$KW/\
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M^>%E<<,LKIWSQMG;&^5NU_>-_)OUCV1ZF_J;]NV/\]GP>7^[/1V?]?\ \?\
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M8HYAR9%RX($1F>&3%Z]76=.4%5U5%,J]%$=B8HR>8/N57?F4 *W9Z)0-E;M
MZO4RG,_7L[#JV[?4ZR1[!)W(\N_ESKRLOEAUN%:&Y1(C#2-ML&<>:E39(@W
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M,8IC%,8IC%,8IC%,8IC%,8IC%,8IC%,8IC%,8IC%,8IC%,9YM;MOV?\ 5O\
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MU3+3%,8IC%,8IC%,8IC%,8IC%,8IC%,8IC%,9V @06/E1P(",(&C9=XW'"A
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B8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g120909g35d25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g35d25.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1AH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &$R^8B X0DE-! 0      &4< 5H  QLE1QP!6@ #&R5'' (   (&IAP"
M4  (<G(Q.34V-S8< @4 /$UI8W)O<V]F="!7;W)D("T@,3(P.3 Y7W=O<F1?
M,C0@,C)*=6YE,C R,2!#86YD96P@961I=',N9&]C>  X0DE-!"4      !!\
M8_S=S5KY5?>"8MILFE;2.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              W8
M  =C          $                          0             '8P
M W8                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M W8     4F=H=&QO;F<   =C    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M]0UR)IY)3X0D*ZJ/@@'4,4_G'D#Z#QR=O[G[Q4,C,8ZAPJM=0_0"PU.='?\
MFRT;FJW/P69EUY%#F@9.;8'S_,LI<&P1[7;J=WNW)PX>Q^U&O<?8VJO7MQ+!
M7D3:_>*[W5QL)+@S] =F_P!'_P $4:<?J++VONRVVT[8=5Z0;+H^FVP/.WW?
MF*6"XNQP7FTF3_2 UMG)Y%;6-V_N(/32\OO]3[5]*1]K# .7?S'I?F_U_P#@
MT.Z4V53G6EAQL@8X >'@UBS<7"*G:N9L])WN_P"$0759;*ZZ\K(]<V7B',::
MB&$&*CZ;_=M</I(V;/V.S;ZFZ!'V;;ZO/^"]3V*%AFK$)W2;&3ZD!_T7?S@;
M[?4_>0.R#L@MZ0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( 1P"70,!$0 "$0$#$0'_Q  >  $  00# 0$
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MJ6,6UZ'5T>YF6\BE5U:6UDDAA=+?,].^%R&+'5-CP\%;!-G;!V'%G3%4C+3
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M\.Q]I;^\Q^3BE0]O?9[&E-:2^POJ9=LOJV1K,7B/;)]5QXJK/9X>LIG;)-X
ME,UZGUS,OZ]M]B]5R7J.N1\E)^ ,R-AA<]M#Z1,L6\)N#MG&YB$1GVHN5WR.
M5"1IN&YV5<C-1R/RT+8SC'0G:.I RS8.U1G+'!P 3@]JU/U%Y06C[3O= I96
MN;!0&-FQX!M-L%XD8B"BYU20$,3XT.[()$'L!4?=B0Z!#@UHR:E9V=R>0[&P
MP *72KL^E2PQ2RB59>22)%C5F9<MY"V,[ T0,I+A0J;?,S,,5X[Q7=4V%=X!
M5F888#:&P>QP[;  220<A0,GT0PPQG&,^A;]N,9_P$_7YRZN5SX=C[2W]YC\
MG%*T4Z-6FU7WK<PI"%8QU=6_MC*<=L=J%KC&,8QV]F.V.4;+X5]^[I?HH*^8
M>''Z8>)W[Y.J_F3A^MZ_#L?:6_O,?DY>KZ?7RMAA*5*]$W[,=_\  3GW/\W%
M*\SB_*.5Z+K@-TF-)7,2G2-=UMLMB?$D(V6'%TWN"2G(;7-PG5A!^!K-BF#Z
MY,.R%3L4C&1,5'@N(^K4RPEP]<E.L-)=I&B6XBYBO-"492I-Q;[3-&N6W.BA
MT D16)+9,816843>@*',3;2L<F0<XBE;:C' Z,3G*D@  DMG /HA4)V'N56K
M]JB7X:1C;!$1\L(;"284[$/M'#-$>='30&<A2HB5+4AD\7LP4A.'6\)2K&,<
MR1&C=T8,&1BI#*58$'!!4]5/M!ZCL:NJP90P((8 @@Y!!&>A'<?'61^'8^TM
M_>8_)S2LU0GL,X2+V:;QW.%QGLG'MQESVX]SW,_7XI5=X=C[2W]YC\G%*>'8
M^TM_>8_)Q2M-=Q]5Z-4WN5IT?J&S7\>$&@ )"1K4A%XE7+Q=ZU?K+1*A"U5U
MIR5G$SC5!?BSY8%:G8R4LE<:"B)MC-@?K]^"QY\2R&>.+<7(#AMHBB>%)9'<
M'"!#,K -T*JY++Y=U>2<HQ41L^,#H1DNRLR*!W.=N"?42, ]<9STU=1=0ZE:
MM+V* C&(,VORWJ*<K9DO&'3T7(#L)9.7)10V6Y6&#S.#3D3$9L$;#24NS"$2
MF(H,=]IK$=Y9R6<@1R6#+O1PC*K*3E<$C:QVE2P0NJEMNYB":S!.LZL0-I5B
MI4D$@@=20.JC.0-P4G&<#(K9'P['VEO[S'Y.5*GJ#NIP=G'3=U 9PTC&<:5V
MEG&<)QC/^1$Y]?M[/\WMY!=?:UQ^ F^C:O+\<?<7Q=^+.N_FNZJJZ:/UN6@O
MX%M7?B1!\6OVM;_@(?HUK/!/W&<(_BQH'YJM*FWD]>GIQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*IGWW&<IPV(03YV,YSEE0Z<([=NV%>G?9]N?;G'F]_<]OMSCBE='
MC2/N4=\9'?3N*4\:1]RCOC([Z=Q2GC2/N4=\9'?3N*4\:1]RCOC([Z=Q2GC2
M/N4=\9'?3N*4\:1]RCOC([Z=Q2GC2/N4=\9'?3N*4\:1]RCOC([Z=Q2GC2/N
M4=\9'?3N*4\:1]RCOC([Z=Q2HXV9J^@[BBXB&V10W+.!7YUJS027SLQY4-8&
M8N6@T2T7(Q$W'R()N8:>FHIQT8MK+T?*'!NX6P2ZA4L,\MNQ>%RC,NUB "&7
M<K;2&!!&Y5;MW4'U5H\:2 !QN (8=2,$9 /0@]B?GJ.ISI4Z=[+'S$3/:/AI
M.*G[&;;)2,)<5F/?GI0*PQTR6T&F>2.$S/!VVU,V&.!;&C+!FS6!V:#.>F9%
MPF5;Z[0J5N) 501J<C.P%64$XR=ICC*L<LNQ,$;16AMX2""@P6W$9;&[!!(&
M>F=S9 P&+$D$DUWR?2WT[RZLKD-"U-_*Y=,Z0E,7%CMGRF7Y)\E^59&D66I9
MJ45+&M3@<F@L&?$4,#-C'A  #C!>W:]KF4>7:/-U"^7 4GJ-NU=N/@$97!)R
M-O">\:]3D], ]23D#H<ECNS\+/7-8[5NCGIUJD + BZB1(9%G&+'Z\E3_$V9
MV7'Q-H:=S/,S QXX'H++8A7H,%P2!*&L$^T7&/XG)?)NTFH7<CEC,PRI38H
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MC':#C)D*.&P6Z$9'7-3<NC_JOL4M>!H3J.L-5K,A)7\FN. [KW<N:E$R-9W
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MC#31.I,>0[ 8%M<#=B7)<JS$R2J=^U06&-W1&!V1YV,K -C8,X^#TK]==FJ
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M*;4XKB&XAECE(<R- PV!E)RR;V4JV9)CSYR>8I*B,(<"054M'CDCD5E#* )
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MNQ@V5)=-K!ZDML99=QV%& #9R)  LBE%('P7W@L=P(P>AR",_P"CK0.Q^G:
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M_.?KJB.C(].!?-#&QYQHJ<]F&L=TJ<[9QGLC'?&<>[C/?&?KXXIC'M_*2?\
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M$-709-XI;;ED@ LF9#S)S,=&X+*:LVD*SS!&#MY)7$<1 DF:.-W6)"5?#.5
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MMG"%J1C/FJSC..GM]1'?U>L'^3/\M,=OB[?Z*J>\OC_S8_[XCF:4[R_V,?\
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M ^42D0]Z- ELQQC9/H'A),8&4 </CB&VCHUXC D@.,8V\PWI+#+ VR5"C8R
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M; #22G1OJN5L<M-N3.QA(J:VO!;P/HT?="QJ.YM.!FXBP-6SU/@=9&79"4A
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M#6FHW>K6B/9C)1^#M%)L,?9(4MZ)E$.QTM'O$Q_@)6-*2WXN,,+;%+CSLBR
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M>7B:Q777,5FOO!$0$&E:HS.41D&_&QSL,*C*6HM8 :@<,9%8\S9;JY486XF
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M1ZR;767&]04%I=+1 M5!35>@&LU=FK(6W66(#T<8G$2/74K5F#'!] S%+[.
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MGU"S (%K>RP1O<VX!>0@13%T ,CD!<%V(W&2><^NI3BE.*4XI3BE.*5;XO\
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MW5A8RDX]SW$)0GW?9[G:C9#S7W[NEZ^O^U0G^3-?,/#C],/$[]\G5/S)P_\
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M4V%YJL8I$Y[,^:*E7;/_ -%6,^]G'(+K[6N/P$WT;5Y;C@9X+XN'MX8UX?\
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M_P"W73G_ "FTK^F^4_1+O];7'^)D_P!FK'.B_NL?^&OUT_3&=/G_ +==.?\
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MA/=;RD7.%HSV/$SG]6C/L])[OL5[/\_%*KO3-?9H^_;_ #N*4],U]FC[]O\
M.XI6B^YND%&X=O/7"9GJD7KZ=34"[;69:OR#]O**H]2VS40("O7,"Q1ZZ_4[
M&)M0EVQ,C 9E&&1)\.,+2JZE&PO1M[\6\&Q5D$R[Q&ZNO+ DD@D+M&5.Z1#
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M!UK/I,&W<) 1T[!B22$8 *!N+$2QX4 L2X !)Q6A?E4\:NW;TQ=*1(@E8O\
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MQ^9SD5;K"=DVF UE0+EL*4K<M.QU+K<O938:I0+4W990:'">.=!A8S"AFRI
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M*=I4[00R.2$<8;.&(/E(#@*S%0JDUOC /Q%@@XB=$ "2+,Q@$H.G'JDW"&9
M1HMM'C(E\^++\U#V$Y)CCS@'LX]((62.IMY?.92K,I[JQ4]".H)!Z, 1V[$
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M&$(.TE3CY)+S3+2$Y6XM*<9SS*JS$*H+,3@*H)))[  =2?B%8) !)( '4DG
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M(>(2.WA'=GO+CW-TUI9YI$>:\6=#,_OT2O#[W)YLE=I91GH,DBJ*1)S[A55
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M9+KC"B(V7BR"H\YA+S3K.712'6\.M.-Y5A:%8QY]T>-BCJR.IPRNI5E/L*L
M1^4=NM7P01D$$'L0<CYQ5T?26I2/#.L-8QC/G^F8<>[Y[X[9QYA#';';O[,X
M7WSV_P 'V]]:S73Z.3^%A?(7OZ0XI3T<G\+"^0O?TAQ2GHY/X6%\A>_I#BE/
M1R?PL+Y"]_2'%*>CD_A87R%[^D.*4]')_"POD+W](<4IZ.3^%A?(7OZ0XI3T
M<G\+"^0O?TAQ2GHY/X6%\A>_I#BE/1R?PL+Y"]_2'%*>CD_A87R%[^D.*4]'
M)_"POD+W](<4KC*)+&/:6%C'N>T![Z?[W!.*5QAN0S[,% Y__=[W[WP_F.A_
MK\A^JE<^AD?A(/R![Z?_ -\^WF<#V4KRV\K V=C5/2KAU\9S&?*+]#&$8:%=
M:SA>=Y06$YSE1;G?&,]O9C&,Y]N/.3[O.OH_]NO/^R[_ .B']<?E]55KKX$?
MX>+_ .:O4KT<G\+"^0O?TASD59IZ.3^%A?(7OZ0XI77YI_?MXL'O_P#9[_O=
M_A_O?7Y@X]?^OVC_ %@=.]*YPD_.<8P6!W^M_<#W?ZW^[_WN.G]1\O\ ]?ZF
ME??HY/X6%\A>_I#F:4]')_"POD+W](<4K\\/2&_Y1!G:GE'4]*D5T=GZ[_LC
M>_\ ,H_OR;W+&7#ZK?4&N,2*01M?PLG"_4_B.Q$9"6^3B1R:J12\WAA ZU^B
MO1IIBTSTQKT3>YEOM%N(2FS?+MZR,&#?"STQ@#UG Y\7/WS\HQ;#.QR^[</*
MO3H.V,8Z=#GU"MWO&>6J_8[Y,S^5G4]_57E#;HGWVJ_-:_[RI\7?M@_S_JKC
M)WEJ<>[7?)F>WO\ _*SJ>_S]_P"]7_GXQHGWVJ_-:_[RF+OVP?Y_U5\8.\M-
MG/;%<\F5W]O_ ,JNI[_/[?J4]_\ CS[/=YG&B_?:I_@VG^W3%W[8/\_ZJ[/&
M>6J_8[Y,S^5G4]_57F-NB??:K\UK_O*8N_;!_G_53QGEJOV.^3,_E9U/?U5X
MVZ)]]JOS6O\ O*8N_;!_G_56H?2Z7Y6Q-PZL,TJ!\GJY(JZEK.J\XLEFZBVA
M6K=]1M%P8W6,QU:<<>KN <1RAGI-+,DHQ1V'6DL8'SFK:KH&Z\Y;ZQ]MOOWK
M9@<SEQ;MFU\[ NWJ<'=GH1@CY_P,+?TSC_W-:<R'CO4#JGIJQJBZE[DZ*)DL
M.069[$0"V,;7&V?G&<,NP1D[>>,\M5^QWR9G\K.I[^JO+6W1/OM5^:U_WE?0
M,7?M@_S_ *J9-\M3VSWKODS.WU_[[.I[^JO&-$^^U7YK7_;IB[]L'^?]5=>3
M_+2_7KODROY5=3V?<]O;_)3^+'O^YQC1/OM4[_>VH[9_Z_7N?BQ3%W]]!_G_
M %5]X-\M3G'ZFN^3+[?N6SJ>_JKQMT3[[5?R+:C_ $/3%W[8/\_ZJY\9Y:K]
MCODS/Y6=3W]5>-NB??:K\UK_ +RF+OVP?Y_U52E&^6E[,>EKODS?\:']'VMG
M4_\ [;Y^/,[]JK[G?W>_L[<R%T3[[5?\&U/R_P#2?-_JIB\]1MS\O,'^A:JO
M&>6J_8[Y,S^5G4]_57F-NB??:K\UK_O*8N_;!_G_ %4\9Y:K]CODS/Y6=3W]
M5>-NB??:K\UK_O*8N_;!_G_577D[RTV,]LUWR97?VYS_ 'U]3W^?/^2G[G?_
M #=_K<8T0?JM4[?>VIZ#_O\ 7O\ +UIB[]L'^?\ 57*3?+3]_P!37/)E]\^]
M:^I['[O[%.,:(0/-JN/_ ,-J/_\ ?-,7?M@_S_JK[\9Y:K]CODS/Y6=3W]5>
M-NB??:K\UK_O*8N_;!_G_542;],\L;G1>Y\6BO\ DX$5K.JMA8L*X.T]2CDT
MF$^I.6]:JB&SJPV$N32#Z?("#'&Q5%8:P^M#65*Q%.NA<B?>^K!>3)NPMJ3M
MV-NQF3&<9QD8)[]*\]Q:&_0KQ+Z:?["]P-8]+-K@W0MO<^XYYMA+MB:<1;S$
M)66,R;0YVDUWZ',\L9C1^F\5FN^3A76\:JU[B 7-6OJ3;F5PN*E$8BU2S855
M<#;DU!>@R<@1QP9)674L+6UA"LY@&A\B'8VK%.5'M+)9AMNQ<9"O@''<#I6W
M">?T+<-"Q(-D- T<69N@1=&U&G6_HYN1$3$)S#L,PC)C$A8(2N#4K>-\M/\
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M\Z(0^04-+2Z2SQRR""F7VR2'G5Z"ZNE,9%Q.#""L1$K@QJ<95""-JD  @8!
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MK:,CNZ+Z?],1VXIC$AZUVB#K*FBW^0<EAG I9\RVL0Z)P@J5">="DRG#5$R
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M$W R8KD3.O$-Q$LIF.-*?:M64ZVUPLS*S!(YP IPV][>6.,A@05(D=3O4[D
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MI@A<)S;-GG,,;#8"TF2RH.@+-M&TLI7(Y F>15Q-D@MU(;H&P"3T!(SGK@C
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M?.]WO[>_?C^O\F/]'3Y*5PEEE#BWD--)=<PG#CJ6TI<7A/\ @X6O&,*5A/\
MYN%9SC'UN*5PXPRZIM;K+3BVE>>TIQM"U-+[=O/;4K&<H5VSG'G)SC/;V=^W
M&3[:Q@'&0#CM\7R5K_2NF76M(WILCJ.8(N=DVSLN#CZB7.W2XS5F#I]$C3U3
M+- UO"'OYB:/3R)YQ=@D8J%$:7*3.6S)$DG(PB![#W,CP1VV$2*-BX6-%0O(
M5V\R5AUD?;T!8] 3@5HL:J[298LPQEF)PN<[5'J7/7'_ -:V#PA&.W9"<>;G
M*D]DXQYJL]^^<>SV9SWSWSCVY[Y[^[RO4E1+-Z0U]8=QTC>TI&EO;!U]1;[K
MFMEID"6XIFK[)E:9-6H4R&2KP)Q)1]"KK@QA#:G@TL$MLYPDMWO,L\BP26X(
MY<DD<K#'7?$'"$-W  =LCU_)WT,:EU<CJH*CMC#$$],?%4L*9:5EO*FFU9:5
MA365(3G+2L)RC"F\YQGS%83G*<93VSA.<X[]LYQR')]O?O6^![*)990MQQ#3
M:5N]O2K2A*5N^;CMCTBL8QE?;'LQYV<]L>S'LX]@]0[#V?)[*5]80C';LA./
M-3YJ>R<8\U/L_4X]GL3[,>S'L]F/>X_^_P"7VTKKR..I32U,,Y6SW]"O+2,J
M:[X[9]$K*>[??'LSYF<=\>S/LYG)Z]3U[]>_R^WN:Q@>P=.W3M7=S%9IQ2G%
M*<4IQ2G%*<4IQ2G%*IB"V!LIP[ES&5XSE/F,O.^S'N]\M-KPG_\ :SC.?K=^
M*53^M0_LG_DA7S/%*>M0_LG_ )(5\SQ2GK4/[)_Y(5\SQ2GK4/[)_P"2%?,\
M4IZU#^R?^2%?,\4K$+]7*ILFG6"C6AD\B!LL>Y'R"!/64>8VC*T/,% GBMH(
M"."*:8-"+95AP<L=EY.,Y1VS=TW4+K2KZUU&S9%N;2598C)&LL;$9#))&X*R
M1R(6CD1AAD9AZZYVK:7::UIMYI5^KO:7L+0S"*1X95!(9)(9HR'AFBD5)894
M(:.5$=>JBM8<]&FI,ARX^;-L=!=I7;V;S*BF1<<5=X6]MU=JUUR;#C*B'"@Q
M<SBG03A1%9BH":44V>=ZV\=+RA!?K_LA:SO@;T32S'9"P;3H7@NI4TZYTPWA
ML;NWDEO)+B2:#T^Y"+=S7-N$,4?(Y=O B>'^Q?H/+N5]-U@2:@=2359X[BTA
M?5+75ET]-0L[F*&QCMHH+H:9:-(UE!:7!D$TIG,ES</+D-SZ5-27ID-J8/M[
M*TM2HLZ^ Z.AVV 2]O-O1(DWXR -;&>&LDD>9$S%>;@[#"M%DBQ,N&P\M'*F
MG\<:SIK.T$=DWFA>V62*8BRE@L8M-22W*3QEU>TABCN+>Z](M+@HCS6[LH-7
MM3\/="U98UN9+]<+<1W3130AK^&ZU&75'CN>9;2A&CO9I9+>YM!;7EN)'CAN
M$1B#5V;IAU;:*75Z&9*7(6"JZ;N.S@)T3!<G&;$D7)"V14B097#/1CG^F>$8
M+BD1DM'CN><#(L$I21S2TXUU>SO[S4HXK%[F\]SF;F13\N*;2HEBL9HDCN8\
MO$%#NDS30S./?8G0E:VOO#_1;_3+'2I9M0CM; :JB<J:W$DT&M3-+J$$S26L
MN$EWM'&\ @G@0YAF1P'%)6NF>A@T38]&LY+LR%L_9#E_GVX^,." &$$M<?9X
M"GQH<JJ=RS6HU48T.1'*=4*2J1FUBC1S4@A@>2[XSU!]2TG4K-?1Y='TE=,M
MFE99)7D>QEL[J_EDA2VW7DW.9TE YB"*W#/(T6]M;+@/38M*UK2[UA<Q:[K3
M:O=K"ABA2.._BOK/388YWN]MC T"J\!8Q.T]VT<<*3"-+K'],NG0*U&T_(TZ
M;68O6VP]3#1!+K[3"J5LN=BIZ=">( C0S7#AGX8$:-E_$XDTLI=)/*D)-YR0
M5#)QIK<EW-?<R!+R?5]*UQ[A8BS#4='MI[:VE59'>-8W%Q(\T&PPEB%B2*$"
M(30\ \/Q64&G&.XELK?1-9X>CMWF4*=+UR[M[N[B=XHXY'EC:VBCAN2_/VAG
MFDFG8S'&IKI)UG8VSB[!<-F3=LDT> DKU*EQ)]A/K?JIN&^I L$JH/5(BN8$
M9:(2,[65%IFFTV'!N)O&#N6K?CO5+0QQVECI-M8PGFP:=!#=Q6T5WSVN#?QR
M1WBWR7>]W3>MX(_1R;7EBV/+JG<^'&D7JS27FH:S<ZA<#DSZK/<6<UY-9>CK
M;>YTD4MB^GM9\M%DV&RYHN@+SG>E>^UDEMZ;=96T6/!<DK?$ B:H=TL4+&.L
M$XEJ%F*D8L,$XF>@)HYJ0C4RAA8\O%%1L@64XG$L_(BM-C)J6/&.K6+RRK%9
M3ROK:\0(\T4R<C4^?%/)+&EM/;QM%,88T:"9)HXT7,*QR,7JYJ' >C:@D<;3
M:A;QIP^W#$J030N+G2.1/!%%,]W;W4JS0BXED6X@>&620CTAIHP$&/VKI'T_
M:I.3EGC[A%ER9I$BM,4H!L<8Y4[7K$"Z,,96364LQ<A7!DA@O(> 6,8<R:,9
MC(JAK5EQYK5E#! L=E,D")$.?'<,SQBUNK219'CN8W9IHKM^9*"L@=(VB:/S
MAZM]X<:!?3SW#27]O)/(TS>CR6RHDOI=G>PM&DEI(H2WFLDY<+!H6225)8Y,
MH8^2.D?3;D7ZJ!*MT*T@L<MIZ&4$"XWX2-UE%,"9'16\Q[L6@/5%;9]4OANQ
MJVB9D=0N13FQQB<>ZX)A-(MG<$QO&RW$<\@.^;6)V<.;@3"8R:W>-SUE68,E
MNXD$D6]M7\->'6A$,37ULJR)(K6LMO"1RX=!MTB*K:\IK<1\/62FV:,P,LES
M&T9CE5$DQZ7UIT[:CJ<!(3,C&4RE TZE0YTF#*RT@ZQ'9!C(EDG$5$K?*.(9
M$2E2V 4(=?[YPVWYV,<^:<><>:/H$=]Q=Q??1:9:ZAJ@](GBM+RX3T_4YG:*
M"&ULX;NZ;F2EDC54DP  S9P3]+X)X*U"^CTWA/A>TEOY--TM(;:*:YM89!8Z
M9;HC33W%S):V^8X4#2L63/4J@["Q_IO^G[]F,I_(+87]5>?,OL^>%G[(+W^+
M'%7\RU]#^P]XA?WEMO\ +W#W\ZT_3?\ 3]^S*4_D%L+^JO'V?/"S]D%[_%CB
MK^9:?8>\0O[RVW^7N'OYUI^F_P"G[]F4I_(+87]5>/L^>%G[(+W^+'%7\RT^
MP]XA?WEMO\O</?SK3]-_T_?LRE/Y!;"_JKQ]GSPL_9!>_P 6.*OYEI]A[Q"_
MO+;?Y>X>_G6GZ;_I^_9E*?R"V%_57C[/GA9^R"]_BQQ5_,M/L/>(7]Y;;_+W
M#W\ZT_3?]/W[,I3^06POZJ\?9\\+/V07O\6.*OYEI]A[Q"_O+;?Y>X>_G6J*
M/ZN] M#80NXRF%8=(SVQ0]A9QV4^XI/MQ5NW^#G'?WL]\9]N./L^^%?[(+W^
M*_%8_P!.B T^P]XA?WEMO\O</?)ZM5-5OZ;_ *?OV92G\@MA?U5X^SYX6?L@
MO?XL<5?S+3[#WB%_>6V_R]P]_.M/TW_3]^S*4_D%L+^JO'V?/"S]D%[_ !8X
MJ_F6GV'O$+^\MM_E[A[^=:?IO^G[]F4I_(+87]5>/L^>%G[(+W^+'%7\RT^P
M]XA?WEMO\O</?SK3]-_T_?LRE/Y!;"_JKQ]GSPL_9!>_Q8XJ_F6GV'O$+^\M
MM_E[A[^=:X5U@]/J<94JY2>$IQG.<YH>P<8QC'NYSG-6QC&,8]N<YSS!\?O"
MM02>(;T  DD\,<58 '<D^XG0 =23@5D>#OB$3@:+;$G_ /GW#W\ZU G0I<*[
M:9WK#M4 >J2@;%U56B4ASV0SD)+ *U_KAQA_T+PS9#.%HSC.$$--.8^NC'/H
M/"^M:;Q'I::[HUR+S2M5D]-T^[$4T(N+6:"!HI1%<1Q3(&'7;)&C#UJ#TK\X
M\&Z7?:)Q%XMZ1J<!M=1T[Q1UFTO;8O'(8+B+1N'UDC,D+R1.58$;HW=#ZF->
M@?K4/[)_Y(5\SST=?0*>M0_LG_DA7S/%*>M0_LG_ )(5\SQ2GK4/[)_Y(5\S
MQ2GK4/[)_P"2%?,\4JB.DQ%)&[9?_4FBJSW$*Q[,.>WM_:?;GWL8]N?K<4JM
M]:A_9/\ R0KYGBE/6H?V3_R0KYGBE/6H?V3_ ,D*^9XI3UJ']D_\D*^9XI3U
MJ']D_P#)"OF>*5"'4U)B+Z<-_I3E[SE:5VEC'<4E..^:1.>ZI36$XQ^[G.,8
M^OGD%U]K7'X";Z-J\OQQ]Q?%WXLZ]^:[JKGTT?K<M!?P+:N_$B#XM?M:W_ 0
M_1K6>"?N,X1_%C0/S5:5-O)Z]/3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5QVQGW<8S
M_FXI3MCWL?Q8XI3MCWL?Q8XI3MCWL?Q8XI3MCWL?Q8XI3MCWL?Q8XI3MCWL?
MQ8XI3MCWL?Q8XI6D743UH57I]W/J'5TN%&%Q]R2U);$FGY1\:1HE>LDZ-0]=
M'QL*-&FJL)5KV(;B.?%<+C4QM=A+-.8>)7&MAO\ 0M=/DNH)YE+ QG;"H (E
M=4,LJDDY4)$,Y R7=%Z;LU6FN5ADC0X.[JW7!52=JD#'7+=\D84,W7%8U)^4
M*UU'4=RUO4&XCRLA2*Y>:?5R)[5IAEKC;K-Q,#4&!I*MWZQQ8!<@3.Q9<J(8
M0DZ"BW7CB0W6TB>-D&E2F38)8R%E>*5PLP$31HSN2KQ(Q4!6"MC#,  >^-#>
M*%W<M\E ZKNC);<<*/*S8)[D'J!W J^:QZZ*;M C8$7#:SVDS+:WUO)7R;4F
M#CY.$D9.!K=6L$[1Z].Q4D6-)V0==OBXZ'2XR(+9G&9 ^$=*BQVC"=)M-D@$
M+--#B>98ERQ5U#O(B2.C %4][)<@G9E0V"2!M'=K(74)(#''O)P"IPJDJI!P
M2-P ]O7':H/@O*8U^&8P-L2K9MEED1*C8XN!T!$W*Z-,U:U5.?MBSQINUU^I
M0M^CHX2N2 D/8-?G2KER,;?P/5X% ;F7;#:0[=8Y B#F!GNBD6&218\%8VD:
M,DN&*RJA1,$DD@5&+T#HREV)4!8@S':06)\P4-@ @;<EB#@#U9I.>41@QS00
MX#45W*),F:T($!.RE#AE3U=L^X1]-BVV)DA[;*@1X8TV)9S\Q=ES#RA <0%A
M]B-Q*^F%T72GQEIHP-KDE!(VQTMS<F-E**6;84&4W#)(R2.NQO%]4;GS*.I4
M=&DY0;()QA@PP<=AU&:O<;Y1_29H,K(F5J]1 HE(*V3$K-^H=[-BIF5*1"F!
M(C[H8N,GK H<_ M*L:8:X17@E8L<+#*+!25HVDW(*@-$Q,@B?!D'+?\ 5!B8
M\%$Z9D4M&<Y1FP:R+R,Y\KCREQG;YE R,88X+=<*<.,=5%4@WE#Z8[B.D7-6
M;*5#S5/AMA"H:Q0,2<+03I%H$JWV!MR_8%6'@>0B)4.&@7Y>RK",4R1#LR3+
MP+.?<J7J.=$&61H3GF;6F"Y$2$19SD,I9@(\C(<KUIZ6N VQ\%5D[ITC)^&?
M-[""%&6/L!Z5U5SRE>G[0/)R,;0-IY@J^JR3%HL+P%.9AZ[K>K@ZBF)+;)+S
MMR01*41%?W15+$DVNC3)SL$'/3 P)$8&"9)Y?29TP&DA#,$5$S)EIG-PJP=(
MR!(7MI$&X@;RBD@DA<+>QMDA'PI))PO1 (R9,;LE0)58[<G;D@&I&VI?HS:>
MF=%[%@XZ7BX*Y[FT988$>>%9!E"(&3O #T)*$!,D%>$:FHE8LP&,^XDU@(\=
MN0&"/20&Q\)\<8C#I?!T+;2T?BMX>(Q7S+N&OP;U!QUVME21T)!VEEZGZKX5
M.)-2XD< @-X?<;,N>^TZ'<$'UXR,''<9Z]:W/]&W]K1]ZG\G/L&T>P?-7S;K
M[6_PF^NGHV_M:/O4_DXP/8/F%.OWS?X3?77G1U/=8U_T);[U!UN@ZZO@5>TQ
MLW940.3<Y> -;E]84Z.O,M"VF38K$V#&29E??DY4&J" D2CU?  L&)9+4SX"
M-ZEGIT-TD3-(\1:YAA;WI&7;,YC5E\ZL0'P&?& Q*[3M.:LUR\+.  RK$[_#
M<$%%#$$X(!(SM7.>@.1NK,-#]6,YL?==\T=L:DPFO;;4UF$Q(PDT]8DV6/<2
M.6 D*2C 2JXR9'!,3?K00V=$FCDAMFAUP#P5B @M+FP2*WBN87,L;X#9C"%#
MU!)4MOPQ*%2$9 "07/E9D-RTDKQ."C+U&'8AA@'H0,# /7S9.#@=& WG]&W]
MK1]ZG\G.=@>P?,*M=?OF_P )OKIZ-O[6C[U/Y.,#V#YA3K]\W^$WUU01B$9$
M3W0G.?3$X[Y3C.>V"7?KYQQ@>P?,*=?:?R,1_H-5_HV_M:/O4_DXP/8/F%.O
MWS?X3?76I'5_ORV=.].J-LJU3A[$#(V:9&NA\H\UE-2IM?U[=+Q+64:'3+0A
MM@>&75A@G(V-.R>@4U\P4.0>&;!(O6-G%=R21NY1@BF(*H]\E:6.-8RQ5@@(
M<G)&,@ D FH+B5X55D!;+'=EF\JJK,6 W#)Z 8SV).#C%:N37E";I4[Q+!W'
M4M8@]9@[5E]<-WP*UR=C<8C(^'K]RS<Y6NQE;3;Q1HZBV:MR<Q&!U.0BQIRT
M"0+UP"5$X,G;B:3#)$#',S3& 3<DQ*N26>,1AV?EY:6-PN7#%4+;3UVUS>NK
M,&0JBR&/?S&)&%1]Y506P$8$X!P6ZD8;/JLUZ!YIIYO#3C;K:'6UIPG*5H<3
MA2%ISC';*5)SC.,X]F<9[XYQ=H'0@9'0Y S^7I5_)/ZIO\)OKJVSS;?J.8SY
MB<9Q&'YQG&,8SC/A7?KX[?\ _?;RAJJCW-U 8&#978/3_P!FE-6K'/IMIU;K
M=6X^$Q_Z5/CKRO\ )(>W66]L9]S&]RNV/K>S6.L_RY_YL>SGR[P#_P":3@CU
MGW"T[J>_6RMS7'U#_G:_Y0W[]W%/\FF:"!_(!7K1VQ[V/XL<^PU>IG&.V?U.
M,_YL<4KRSV'U[;+UMLR]5RSZ;K0&OZ=O)_3*[J'<Y&Q%H8.UW0=@0=OE*U#5
MIRT-H8!O]?\ 7,'!UV?'2Y,L1;%F8EPQ&+)V(M,BFAC=)W,TEN)^48PH.)98
MV179@F287VLSIT4L5P?)0DO'C=@T:[%EY6_<3@E%<,5 W8 900JMEF &<>;U
M"!+$D0@Y )YDH(\4<T0IG.%LDBE-(?'(:5CV*:>:<0XVK'LRE6,X]WG((*D@
M]""00>^1T.?RU?!R,CL>HJJ[8]['\6.8I5 ?C'FB>S'^/B?6_P#><4JO[8][
M'\6.*4[8]['\6.*5H3O'JOV#KK;I.LZ+KZGW(ID:J1$; 2US77+S:[CL"G[<
MM%9>K4:1'+B7J?$D:N3&V24.D1L)'D;++>+C6*&4U.]*WL8Y8.=+,\8/,8L(
M]\:1Q/ D@<@AN8W.#(H#$X5<$R#%66=T<HBJQ  "DX9G979<'MM&S#$] "3D
M &L^Z2>IQGJ6J\])FQ,=6K+6Y%@*3K89$@<I *L%Q3-A1(OQ[$,?%3MEKUN9
M@WZQ,VB*]6Q+22)UR5\> #'?6?H<BJ&+JZDAR O7H=A7)965&CWAU1MS$!=H
M#-M;7 G5C@*RM@J"3T[!NH \Q#$;2X  \Q.0-N.V/>Q_%CE&K%0=U.8Q^ENZ
M@/9C_P BFTOK8_81.<@NOM:X_ 2_1M7E^-_N+XN_%G7?S7=5V]-'ZW+07\"V
MKOQ(@^+7[6M_P$/T:UG@G[C.$?Q8T#\U6E3;R>O3TXI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE4SZRTY3X9@=W&<9\_+Q+C&4Y]GF^;A S_G8S[>^<Y3G&>WLSWSG"E=
M'I)3X&#^$'_Z.XI3TDI\#!_"#_\ 1W%*>DE/@8/X0?\ Z.XI3TDI\#!_"#_]
M'<4IZ24^!@_A!_\ H[BE/22GP,'\(/\ ]'<4IZ24^!@_A!_^CN*59S((214>
MN0K%:.7*C!!2BS$M$JD0XU\@F.$/4]$+R6, 0860$P1EQH5\HAUA"''W5*V#
M,,89AM)(P2,$@ D8/0D  D=2  >PK! /< _+Z\=L^W&>F?7UK$1M1ZX"<C'0
M]1:M$=A3).1AW1:S CN1,A-/L%3)\8MFN(4 9+$C#$290N6GSWQV'2ENN,MJ
M3N;B<[LS2G<%#9D<[@H(4-YNH4$A0<@ D#&:U$<8QA$&"2,*HP3W(Z="?6?7
MZZNU?H%4J9CLC5=>4*LR#\7&P;QU?BHV&,>A(5AL6'AW28V"&?7%1(K+(T;'
M*7D,%AIID5EIMM"<:O))( KR2.H8L [LP#,2689)PS$DENY)))R:R$13E552
M0 2% ) [#H.P]56=O4&MF@WH]K4.JVP"+$U;R 6ZQ ($>MK'G>AM#PR:WAER
MQ,^<O#4VM&9-OSE805COGOMSYR<F:7.PQYYCYV'NF=WP#ZU[?%6.7'C'+3&<
MXVKC(['MW'M[U>3:'5I,9X*1U[0Y ,D-4<0*;%QI0S\>LE\U8#S#\$XTZ&HP
MDDM0JTJ8R20\_EOTKJUJU$D@.1)("#G(=P<X ST/?  )[D#!.*R40Y!52#W!
M .?G'MZ_*2>YJUO:FUV0EQ!&I=7OH=LA%R=0]6X)U#MO+86,5:G$KKBDN60D
M=QQ@B<7C,F\RM;;A2D+4G.PFF'::484)TD?X .0G?X /4+\$>H5CEI]XG4DG
MRCJ3W/;N?6>]7W%.@DI2C%'IF$( 1%(3@(+"41;>6\HC4IQ"=D@(RTUE(>,8
M'3EM&<-XRA/;7F/]^_4[CYC\(]V[]S[>]9VK]ZO;'8=O9\GQ5AD[I#7,_4[1
M2'M<5*(K=TCYN*M E3=(I1<Q'67 :;(*_+U &$F&V[$R &-.J'/9<EA1VACU
MOL(2C&ZW$RNDG,9FC*E#(>8%*9V';)N4[,DJ""%).!UK4Q1D,NQ0&R&V@*2&
MQN!*X/FP-W7KZZCWJ48?#I^K0F(^."#$WKI$80<-]2&&&1[G&M##-,( 9:8'
M;0E#:$-8PEI"4I0UG&$XQ\5\:^NC<%DG)/BIX=Y/?)/$$&3U/?O[?7U'K^H>
M%O35>)0 ,?8^XW^+&-"N<#'L/;XJV;])*? P?P@__1W/LE?,Z>DE/@8/X0?_
M *.XI6(%42KFS4G9#=?40NQ3,&[6)F?*C(XB:E:V_C&'Z_)2KT$LXZ$>3A.'
M8HI]T!S&,86QGMS<2RA0@DD"*XD5 [!0X[.%!P&'J;&1[:UV)DMM7)&"=HR1
M["<9(^+M5>/5XD6938A:?4AK @0V/1.,#"LS" )*05+2 29)N&2:D0^54N3,
M&P]ADH]2C7D.$*RYG!=RNTNY7(.W<VW*C"G;G&0.@..W3MTK.U<[MHW=1G S
M@G)&>_4]3\=9!Z24^!@_A!_^CN:UFGI)3X&#^$'_ .CN*50QKDEX1.$"!9QZ
M8KVJ.?3GOXI[.>^/5^?9C/LQGO[4XQGV=_-PI5=Z24^!@_A!_P#H[BE8W9ZE
M"W8%B,N=*IUMC!3AI06/LX8<\"-)A^?D218$E84IADX7TB\CEMMI(8\]?HG$
M^<KONDCQG=&[QM@C<C,AP>X)4@D'UCMT'LK#*K##*&&0<, 1D=C@^L>HU3R=
M(K<XT:S,T*CR[,F_@B2:DXX ]N0(2]&D8?.05!NI+>P_#0[^'2,.+P[%1KN%
M>>"*IHLDBD%9'4CH-KL,#S# P>GPF[8^$WM-8*(>ZJ?E4'V?%\0^85EF')3&
M.V P<8Q[,8P>_P!L8][_ ,7<TK:K5/.2?J28[B!8QF,/[YP>_G.,>%=]N,>K
M\8SG]S.<8_=Y0U7]+=0^*RNS\O\ 8\O0?DJU9?;MG^ZK?Z9*\L_)+*+3K+>G
MAV1W>^]R_.],2XSV_P#@RUGC';"!G_.[XQWSWRGMWQC'G>[CY;X!_P#-)P1_
MV%IW_@K>N/J'_.U_RAOW[N*?S;H5>L/I)3X&#^$'_P"CN?8:O4])*? P?P@_
M_1W%*Q66I5=GFI-B=H=(F69M2ES#,K'@2#4NM28A"E2;9<&\@]2D5^!2I127
MLY3"1"<Y[1H>&=UDD7&V1UV_!P[#;\+X.#Y?A-VQ\)OOCG4HASE5.>^5!SV[
MY'7L._L'L%92E<FE*4I" 2E.,)2E)[V$I3C';"4XQ'8QC&,8QC&,8[8Q[,<T
MK:N?22GP,'\(/_T=Q2J$YR2["^<(%C^[A>W8YY7=7I/9C/<!/;&?KJQYV<?6
M3GBE5WI)3X&#^$'_ .CN*4])*? P?P@__1W%*QLZIPLG.AV>2I=./LT?&FPX
M%A-$#*G08B2[^L8L.6?A5R T:?WSXT%DA I7?/IVE]\\V#N%*!W"$AB@9@I8
M=F*@X)'J.,]NO2L%5)#%06 (!(&0#W /?!]8]=5$178^ ?DBH&J5:%)F7V"9
M@F):8CGY4D09L(8B2>#AV7#GQ@V61&'2E.N,C--CMJ2TA*,&=WVAF9@H(4,Q
M.T$Y(7). 3U..YZGK0*HR0H!.,D #..@SCO@=![*OGI)3X&#^$'_ .CN:UFH
M/ZFG)//3?O\ PH0+"<Z5VEYV4G/*5A/U$3G?*4Y 1A6<8]Q.5)QG[+'N\@NO
MM:X_ 3?1M7E^-_N+XN_%G7OS7=5<^FC];EH+^!;5WXD0?%K]K6_X"'Z-:SP5
MC]!O"6.WZ&-!Q\GN5:8J;>3UZ>G%*PC8]]A=8TN=O%@06[&08[3BQ0&<$2!Y
M9A3$?&QD>QE2$O'2<D4( (VMQMO+Y",N.-MX6M/F^+N*-.X,X=U/B751.]GI
MD,;M!:QB6ZNI[B>*TL[.UC)4/<WEW/!;0JS*G,E4NR(&8=OAS0;WB?6K#0]/
M,27-](ZB6X<QV]O###)<W5U<. Q2"UMH9KB9@K-RXVVJS$*8ZJM_W07,1S=T
MTN)7:],C&/-2D-L".L9U:>8#=,''MD8_$PJ6<%8:\)A^ +GDL'.-,N(RRI1"
M/*Z+Q/XASW]FG$7AW#I.E:A#<2)>Z?Q19ZM=:0\4$EQ%%KED]EIZISUCY/-T
MRXU)8KEHXF4J[2+Z#5=!X+AL[IM$XUFU+4;*2%&M;WAZYTVWU-9)4ADDTBZ2
M\OF?DEQ(8]1@T]I(%>16#@1M9U]0#B.FMGJ ^I9.5NUX6=S5_7&?-3DB9:B?
M"XF<1V<YPG#GI\/>K<>=YOH_18[^?CGMXI,/"%/%(Z*-SZ7%J/N+Z><#FZDF
MG\KT_P!%!P-XEW^B _J-OZJKP\/P?$IO#XZJ0$U&6Q.J^A]2(K)[OF^A^D]"
M=NS9Z3Y<[BW3%7;8N]8_74K-M'PYDC&5FFQ$_*9C%9(EC+#;K*FM4:HPX.4(
M:*D; 6-*J4MTAG B& W5IR.0MUN_Q;XEV?"5[J<=U83WEEHW#UCJEZUF>9?3
MZMKNL+I'#>@V-L5"2W6J30WK,\DR"!4@=E,<C.E+AW@6YXCM;%[>\AM;K4]:
MO-/M1=#EV<.GZ/IC:GKVKWD^2\5MIT4MF J1N9C),BD21HC\US8&Y5R@[=YT
MT%7X.0C9$YJ7K^P0+,N (#$=,9C[4"1#P*V5&);R*T97W)]ALW+;;B?#K44V
MTCBCQ":\1>)O#VVTG3;FSN[J._TOBFTUAM,EMK=[E+76K:2QTYD-PJ&%+C2V
MU.-;EDC91&QF3&IZ#P6MK(^@\:7&I7MO<V\#6>H<.W&F+?QS3"%[C2IX[R_5
MQ"6$K0ZBNGNT(9E;F 0MDE#VO$6;3U;V_8_!4^&F:L':)+!\BAT*%&)9PZM#
MTDZP&EY#6580EW([*G592A#7GJ2G/7X9XXL-9X!TCCW5?1] T_4-%AUF\%S=
MK);Z=#*FYEDNVC@$BKT"MRHV=F553<P!H:]PG>:7QCJ?!^G<_6;VRU6;2K8V
M]JR3WTL3E R6J23E"V"Q7F.$4%F8*"1;E[KJTNFJ/4R6@)P:;OH-)E<2$H;
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M8X3.E0>B+KLNFM8,?=WW0VMI0F8W8_\ )XNR@Y)B).X2I8M(6*[5'9J3I$>
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M2$NL8DF+7VSX'8GKX6/"G8.>JYK %CJ]IBEPU@AGC!4&Q[A0:G2&7@I$1>"
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M>?%G69)EYU*\^GWF<^D29W,Q((!+.VXLQ \S;NH)R5/P<5CT:#MREQ@#'7H
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MMUL" &5LY$_5B47<YRSA0'9@,5%]D#B+##[#7'N&.2.?P?@]"!_Z3= ,G &
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-2G%*<4IQ2G%*<4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g120909g37m21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g37m21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1KP4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &M2^:&@X0DE-! 0      %T< 5H  QLE1QP"   "'W@< E  "')R,3DU
M-C<V' (% #Q-:6-R;W-O9G0@5V]R9" M(#$R,#DP.5]W;W)D7S(T(#(R2G5N
M93(P,C$@0V%N9&5L(&5D:71S+F1O8W@ .$))300E       0\]^8W/R;$)MG
MPB5Y5N.2TSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              T$   ;:          $
M 0             &V@   T$                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   T$     4F=H=&QO;F<   ;:    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      05P    $   "@    3
M >   (Z    0.P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 3 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M]064]3R:SZMUK@XA[2+BPMH#'^QE&.VO93^?_GKQ+_G%U_\ \M\[3G]:N_\
M2B7_ #BZ_P#^6^=_[%7?^E$[V3W1Q/M0Z'U,%KCUK*+FL#)VU073.\L]/T_^
M@H7?5[/MN]7]LY;#%8#&$-9+&L8ZPL'Y]CFV/=_@?TG\R_8O%_\ G%U__P M
M\[_V*N_]*IQ]8?K >.KYQ_\ 0@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M05-687:!DZ&UTM/4UO R.;<C)"6"P1HT-D)'F/'_Q  = 0$   <! 0
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M5>'F9TE3KC'R'UYQ@@>DAFVMJ3K51#<:+69[\U?QT D(TRE:D.1B^OS^T,O
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M$XD1GDUWY,)B#CP$83:B;"8KK76DHVGL>>$WKIL[PR$Q>/QQ!G9FBCX01-2
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MVQGQ^K_53USM;>Z%!_I8!_$*=/#ZHSWP3OUAOSMC/C]7^JGKG:V]T*#_ $L
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MLZ?NIQGR+*+D?K$U\XDHB41*(E$2B)1$HB41*(E$2B)1$HB41;E>@S\\D_\
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M,#@^.1I:"[=M:YKPSIC)L:UY=V02F/7[[:.T\E$0/.T@Q^%IX.YP(W: <W-
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MT+N>A')Q:-=WA<@0>32&ZAP\9&NHUU&AL<[X;D4M@LXHPVS CD24TQ;?)79
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M&_UUNE8LH41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7<]^Q
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M=:ECKT*";>/H,49-WD;3V0/7EI8D,!RL(9DN,ABC=1H>;J^IA=P\DRI0VS7
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MYQT#6@N<3Y  "3^P+YV4J-W)6H*./J6+UVS((J]2I#)8LSR.U(9##$UTDCM
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M5W'UL3B:<=VQ#:ZQ0IU[HM6K4L=>+;8,YIMKQL<6,B,L;@_:R56#R\E_@O\
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MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+2_TZ?F?13X\HA]E9S7AY_\
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MZK$VQ'8AC=!.989Y)!$X3"8(\>N5QT"DU<FBBZ#[Q:;C\5?[1:.%Y&YV41)
MRKT..R/JC\GJV#TBXF;AVHUSL%)N"!)5<>^655B:UMS-I+B#X;6=,T[S,[1Y
M:!(>9U)DW:> 2=2"0:PX)[I-JF(Y+MB1LG06Z>/EX@C>^Z_.6)J=F6M";;H#
M*X33295\KHW&K/)-.9(Y'DV^P@G(@5-9 %7D!F.22$-!4\-G2^T!\:&"4I L
M@H!DF,P)R1@(\...IUCB.<($[DG#N2$K9XX*K%[ITA'.V1PW;71:2.>9VL#0
MXC:\2&1H\,R@-T=J3)IH-7+Q1A^.J^7NU7WK-*]BHJV9M7+>?AH5J[+KVFG>
M[YV+L5<36Y<IMA>R?K#I+TX(;NLEM7X:2Y8RL-'$'I4T[CLK'V-@4I%M\*U"
M/KRLJ&%W;)IG):W98FY 4V.%;*C<L;$2*TL4R625LL3S2GZ"VYK-2\M?S;OG
M9IJ\@$'=+]^XRM! U),FA.NJ]-O"?=*R-2DR2W:EHY&'K-1MWB:LRK,<C/6A
MZ("SD6P]<NV,W58ZN3T\[\BYSPX/G</!#],<HB^%HU#21;K+1>/&2D8%;9!L
MEV4?(X!TX<UE8%&5HJA;E4)@+M&1)]JT67:EG2C5O@W:ELV<&06G:L9N\)C'
M.8)FM(:=!&'L,@+2[>-C7-!Y]BHXOA3NBV6]1Q5J<BSCZ=JQ0K\25(WQ4YVU
M6XR/(TF7VNK=99DJ_4(+D;'.BL2N8UK([/1RP3"N3+V0HZX%2:2X&3T2"[.=
MQY':K9)%,#F*'FPA:1I)R;P866;BG(H@@,->#'AK-5F[68M&^.*N$&QV=W0A
MS]7L;,YO3:#: TM<YI>-ITV[6N#7:  M&F@H5L1W09;K,%!D;XM6\96S\E-G
M$<;6-IN@AM5K%Y@OB.O897DKS,@N".U!$^%[HHX_";Z!V@.24GCH>/#[.#<3
M7P8S#&/H;,CA$%&;R.-MY2(/20$E)EVT0?2&/DTW0MR;9#GQ;OUV;:Z[JRZ%
M@KV7L:T<V:-?MZ9A:S>P/:YS1(6L+F.&A(&NNW7=J%-#P5Q]?HU:,)?;QKVQ
M9+J+,]1FJ4#<HLR%:W?J,OOBQTMVG/TM:2U'%-9WO9&'R;F#S@N)VUB$I'0X
M\C'X?(":ZS5$2<E43Q,L,T91>)7?G 29^QL0 R+H/DDS:@]9LYQ:X*,L':1$
M8JZ@*LQ>V,AK'.)&USF;FD/+-7M+VN:S4'1_/73DT@AQDH]S3B*?(PXN\VEC
M+L[I&-JVLCCA:AV7SCNGMU&V^M5J9LQS-%M\+F/Z-IC;()JYFD6RN/DHUZU?
MG+% 9.'M\DDQ,@>GX@#=2E3-L+?+XQ4!ZJB9"28LAYT(_>J ;D\6S,JS77LG
M@IUVA+7?%J26EF@VNW1MZ0Z NZ-A?ND#6N:X[ [0$:@*SX@X&R&#CFN"Q5GQ
M<>T5[DUS&U)<@XL@F>,=2&0L37A#!;J3S&H9NCCL,<>6I%@JH+"$HB41;E>@
MS\\D_P#$A-/M+!J]G!?AKOU$G\4:Z=]"?^,J][ELE\NQ:ZZZR]?1M<UO3(><
M= OB=%?;*95UIW!?2EEO\>D^0TEQ7Z)3TWXCW-U_YIDUJ1K=BYS63FE-%QW9
M@$23-&)JR=R7;0340=.*1=B?9#"4A#^,&<AD2KHHP72$LEO_ ,XT9I9N5V>#
MA=!PCDVRPSQ#B#B.UA[,T5>OCY&4\)8SLYO79*KYH:MCHI*M5K()6NGD:1T<
MDCFQMD+&N8X/U&>\+<)T<[4KSVK&4BDO<0U>':XQ]"*W'!/=K]+%=N.DGB<*
MT+AK+'&#(^(2O:]ACT?.\M P4:R=$"DGG1>T;UK!I]+!L1C(8@_<+;">!QX=
MA%<ES=K.A(M0@N[-R$F@SPQ[P2,:,%%R&+Y.W^R?)32-B@I8R#K>7R6,HS7[
MMB*-K<6R>2P^]MK?<[$PB:RO6@>_[V>=\@9'T3KO[#\1!$^:>[EK'4\)B\MD
M8,=0K32N?F):T%:*@7W/NE>N^5[[5N9L?WT%>.-SINF;<)KQ-A861-A9B5R*
M7* ME"04X'A1PD"H+B;[9(B!MW;D>=,L##CP[,NQ3)%HJK(6T;/.5HN101>,
M711'RG\<9"Q5DF@HTZ LXB>QC9;$UBSTMZ/$SY(L;+5KS5V=&*\CH8+@JNMU
MF"Y%(Z.5D+O:B[GF+JW8Z]F]<R+JF<KU<K%5AK5#!CI<U7Q,<DD-NS#9D,IL
MQ":QCS;93MO=1G#9(7SBGLN-4'N!E,H<')B&;B%#,N% 'S*.Y$B.MPFV6.LG
MN=D43:SI(IFX</\ )J[>7:)W?#%&BPSP!P@=SO!Q=DA:I4VU\?8DL-@HS6HI
M+?0PY>Q@Y<O&-SZXC= UK(][(R\]%*U[91*U]561X'Q)IY#(/M9&LRN;.1K5
M)HZ1FGPM;B"+!R.VLM.DCL=))*(W2F,&>NZ)T'0O9:=.9]Q<U\(=[,),)B2C
M AC.]RQN$,#5PRN U/5>'?78R/O2USS_ #.N<K,Q:XEDY7&AE1<E,672>KLV
MMOC>,LK.S$0RX^&Y/)C>'[>1F@%@&<YL[.EJ%L'58A5:!),VQ(QLM@34X #&
MV22ZR_ 6&@DSEB'(S4:T67XEI8N&T*SA7;@&F0Q7=;(N2FT_[E ZO&]T%9T%
MVR'"5T4>/T>U<%>ZO0G91S-GQ612"71F+BX='&)D:-(1$&#-+.9D_>%&"C!H
M3\?-TT4F:62S 8Q*'EE'*3;%@MD]O,V(\R_&0,QL<%2K1N79K]N2O-+%>L6*
MX;CXF0R]-)!U9Q<7N#9)98:P#"\RMP^E@*DN!9E9W9*2Q<N9&C1@QM**U##-
MCJM6RY^2FELQ&)DYLL:QL;=T4$=BT\R-8(W7TDG%>#Q=F4-D9O*LA$3&;)1E
MK!D)C3\\C*-9%M<C2@EG=N?\4-TWBFP,6RMU7[[$4[%++MGDB9+MU%<<I\:9
M&[)!7AQU$3WIL2:,DD]N.L^GEX,M-!._?5-AQC&++QMB89V3L;)'5D:]K<KO
M=S_$X^.>U/DLB:V/@S3<C#%7HRVVW\'8PT$\$1;;ZNQLKLN&.#I)!6= Z1DM
MV)S"ZDYKQXBD*9%':LAG1S$J?*!80J%B@M=F,18P:&SM!]LAUD;PP$XK,IJS
M;/,!7A%A[$68D?;=-4$ARE[CN*KN1E@C;4QE<P589\BVQ=G;).Z7(Y'&NBQ#
M!7+IRU^/?)&9]#++-#4#6.<96>?E."\;BXIY'V\K:ZQ<GJ8IU6A7?%"R'%XS
M*LFS3S:;U;?'DV,E$)?T4->S=#GQ,;$ZK)3Q8@$3.FA1#91I7"%MMDWES4>(
MCI$X[SUU'[G%2L?8MI%X&T&F5<,QV V0$&A8798<_6R>)/\ -%I8T^-,G=K0
M3Q8BL'9!^)ZB^6>U#6C&5M"NV"U(^KTDDT#2)NEJPOKS%LT0Z,P[G^AD.Y_A
M\?;M5YLU:(Q;<V,BR&M3GM2'#4^MFQ4CCN]''!9?N@Z&W-'8@U@E(D;+M9@\
MIW?>*=SWG<]O/NN][/>]UVK]W=2V%[X64OAU7SMA>^-LNNV-[VZJV+ST&NF[
M0;MNNW=X]N[GIKV:@'3F0#R6IW[=SM@<&:G;N(+MNIT+MI+=VFFH:2-==%\\
MO)?X+_54S/OA^W]Q4J[%N2'F7[A_1\E/V'<5PCPCZ?\  >ZBC_,6+Z2<9_BV
MXC]R-_\ E;UQTX^2WP6^JN[%\VU&B)1$HB41*(E$2B)1$HB41*BWM'MC]Z+I
MQZ(/S5RGQLR[^Y(C7(G=U].L/^!T/E%Y=T^AW](,_NAR/R7'+:?6F5O=*(E$
M5)2:?P2%6;7F4UB42L\OE9I>320,!LZOAU]NS;QJ]:=_?'JOVK)=KL]5^OJJ
MHR*637HXY)-.W8QSM/;V@Z*5SV-^^<UNO9N<!^\A4EZ_NB?=JU+^L>'?C-3]
M5L^MY_@9/HJ7IHO58_?M^=/7]T3[M6I?UCP[\9IU6SZWG^!D^BG31>JQ^_;\
MZ>O[HGW:M2_K'AWXS3JMGUO/\#)]%.FB]5C]^WYT]?W1/NU:E_6/#OQFG5;/
MK>?X&3Z*=-%ZK'[]OSIZ_NB?=JU+^L>'?C-.JV?6\_P,GT4Z:+U6/W[?G3U_
M=$^[5J7]8\._&:=5L^MY_@9/HITT7JL?OV_.GK^Z)]VK4OZQX=^,TZK9];S_
M  ,GT4Z:+U6/W[?G3U_=$^[5J7]8\._&:=5L^MY_@9/HITT7JL?OV_.GK^Z)
M]VK4OZQX=^,TZK9];S_ R?13IHO58_?M^=/7]T3[M6I?UCP[\9IU6SZWG^!D
M^BG31>JQ^_;\Z>O[HGW:M2_K'AWXS3JMGUO/\#)]%.FB]5C]^WYT]?W1/NU:
ME_6/#OQFG5;/K>?X&3Z*=-%ZK'[]OSIZ_NB?=JU+^L>'?C-.JV?6\_P,GT4Z
M:+U6/W[?G3U_=$^[5J7]8\._&:=5L^MY_@9/HITT7JL?OV_.GK^Z)]VK4OZQ
MX=^,TZK9];S_  ,GT4Z:+U6/W[?G3U_=$^[5J7]8\._&:=5L^MY_@9/HITT7
MJL?OV_.GK^Z)]VK4OZQX=^,TZK9];S_ R?13IHO58_?M^=/7]T3[M6I?UCP[
M\9IU6SZWG^!D^BG31>JQ^_;\Z>O[HGW:M2_K'AWXS3JMGUO/\#)]%.FB]5C]
M^WYT]?W1/NU:E_6/#OQFG5;/K>?X&3Z*=-%ZK'[]OSKWC-TZ<-/FPL-MG698
MF\4[IH.&3N+/WSI6]NNR;9HU*JN%U+VM>_823RRZK=?54#7L-!+H)F@=I,3P
M![9+= HB6,G02,)\@>TGS JY=KVOY+VO\%45.M+_ $Z?F?13X\HA]E9S7AY_
M\$B_O#?]N5<R>BO_ !9T_=3C/D647)8-)/@Y!F5&.,VA!@O@Y:.<+89725P\
MG:34P4263SQOE@L@LFH@NEEFBLGFEGEC?% 2TAP.A!U!^OU*^=-:S/3L0VJL
MABL02-DBD;IJU[?8(<US2-6N8YKFO:2Q[2UQ!J%I*)@]ET?/BG#C.6C20*\5
MQ""VB"C$B)=M\X^V!!!C--BDHW?)H9LV#)A9-=WE>]T%5EU;JS!S][7 G>"W
M9H!J"TC;M:!IVZ: #F?%S5_'DLK8RM&]7>]V3KST^]S:E>)ABFK2,-..I5@B
M$32R5K#'%'#M=(=2USG.UKL IOR$E;B0@&>B"WJAS+N BL,>K+.CZH_U*NDW
MX8@&<8O\'HO8"0 @&>-%QY%I+V(]ZQ<)F6:2\S1-&=K6O:=Q);L.I<6]&0YI
M:==6R["T@@B0 @[AK[5,\;8BR:M6GFJUCKKK+ZKL5*][[CH1CY!-6FK/$HF@
MS3*DU:5CX)V9**&:*068VON(PE_+*[Z5,T6,K9%PZX\U*AKK7 MD25N^$WC@
M, 3'KQ/!R]%9QPRX:1V"O$E ",>NYN%")CVG6E5#[6KAH_<W:7@Q-W:;=K0X
M%FKAL<0R,^#MY-:&CE[D.3[I739*)D.1AM5I(;61@DP=>&PYTU?J52E8A=C@
M^:!U"W)%2Q$C75&TNDZM5;#'J/;&YMS EQ$.0!XS%2Y\L %,9,I"1 L$Y-R(
MR),"'SZ2KQQJ&P+R$I<<Z6D)!_8B<0(*HOB#Q@8>(O(M?;?M+=_A$-:[HPUI
M<]P<#OV: O< =Q.KM>9(<=:U'*]T_)SU9ZHR1%RQ3K0Y!V)K5Z;K-VU!:JRS
M7WT8ZPGMV'02/N2R]-:9,6R2RQ696R6)'[8G8P\=DC H-;$).P2%GFN,6BF<
M=)#FRX]TS9K1%4)G%,46#P2,(#K)!4\F!%@U(L[H/DL7%J FD#G/:X!SP X[
M6:$#;IX):6C3:TC1HT(!'/FL,BXGS,%Z[D(K$#)\A"VO;B%#'FC-#&Z%\4;L
M:ZH<=MAEK030[:K3%/#'/$6RM:\5 XY![D=(C$%9N[QP$NQI!GDW%@6JV1$0
M]B9%@4?N&HI%P6*)/(+$%E"955Z^<W ,<'3A=/%3!28SS';X9&PM+= T:%I8
MYI) !)!C9S.I.T ZCDKU_''%+VUVNRTNVK)!-%L@J1.,]:7'S0V)GQUVNL6&
MRXK'/,\YDF>:<(>]S00[YM-^;89IH))R=JJFB!;1E:SV*P\C<J#8>*+"F4@R
M?@'.4EN#Q !$X\ZD-RCV/)"F*01RP20Q3M#IY1_U#[T,)+&$N:--NXEI+RW:
MTM+RXM+06D$*$?&W$D88&WHW!E1E%W2X_&3&>K"*HKQW'34GNO&H*504I;AG
MEIMKQ-JOA#&Z4X'V?.04J'S<>:2O*10L&&&E2 8"7NR'QH4+"1_!NS+C'S!-
MP%&!13<:_LU\/:YL4'*3G%U;)?*#97M>) [PVAK0XM:[0,#6MTW @;0UH!TU
M&@YZJPK<1YBIDHLO!:9WP@K5*D%B>K4M&*&A7KU*09'8@EA:^M!5KLAE$8E8
M8FO#^DU>;A$N3FXGZHON9 P&LQ@(  6&-8['W ^0MP$0%0M%U,FY,8_M-'3@
M8*37OZJ[F&PYZZ=* T!2622*4YLS.T\+0!K6Z:-(<&L;'X8(^Z;@W4A^X!Q)
M ')>W8[H7$\[JY9<AKL@I4Z3X(J5-T-QM/&P8MLF29/!+WTD?!7#_P#Z@;+(
M)9'NJ,KMVM%.-][[9:8B[-9;=!8+?.PM^F#C6)9FWS+J'L!J9BP:Q3,*T,++
M/QP-1YF&&++*V'L&R:F6%X=8FY'?H6]A :'#F7 ;@-= 22!KH-3H!JK!O&?$
MC!7V9'8^J7]7G;3HBS%&ZPZT*[;/5>GZK%8>^6"H9#6KN>X011M)!E1+;NQ3
M,;5B!F1^-H\HFR218DPX)_F.Q8M1S)/((_=#%B,?6<,@XED2<@W@]P79C&#4
MJH]0:()X2F:1S-CG:MT  +6G0  >"2-6ZAK0XM(+@ '$Z!4+'%6<MT'8RU=%
MBDYL36PV*U.8P")D,334FDKNGIO?%6KQ3OJRPOLQ00QV'2LC:T6XJFL>2B)1
M%N5Z#/SR3_Q(33[2P:O9P7X:[]1)_%&NG?0G_C*O>Y;)?+L6NNNLO7T;7-;T
MR'G'0+XG17VRF5=:=P7TI9;_ !Z3Y#27%?HE/3?B/<W7_FF36I&MV+G-7!";
M3GL9A[^#QJ2%(\#*F5C92X(@_$/R*K@1XD<#WSP>Z;Y.PSACU=^,<8J-EEL<
M5%,<NSCC;S+&&QEN]%D;=2&U9@KBM#UF**>*$-G-ALL4<K'AEADFFV9I#VMU
M:W34D^U4XARU#&RXJC=GIU;%EUJP:DTU::9SZYJNAEEAD89*SHB-\#P6/<-7
M:Z "1"9E+P!-J;!2N3!#3)A@*9%Q!XJ-*,Q:2&+5(8U(,G:+MN/3;88-TV2*
MV#;!##%+!*R>..-KF>C1M0OK6J52S7DE,\D$]:":%\Y<7F9\<D;F.E+R7&1P
M+RXEQ<225:5\KDZD\=JKD;U6U%$((K->W/!8B@#!&((YHI&R,A# &")KA&&@
M-#=!HOK><S:X;U.7F,K]3UR=C7B+U1&/$WCFR]W5B_BSPSP+QG9U?PFS_N/"
M_"/_ %^][W]O4O>[']8ZV*%(6^AZMUD5*XL=7V[.@Z;H^DZ'9X'1;MFWP=NW
MDIN^^5ZMU+OGD.I]/UGJG7+'5NL[^DZQT'2=%T_2?=.FV=)TGA[MW->PALG8
MQ9B1&%=@3<F-+NUGY8<0EA]ZP*/G.:"KAX19N2"K=\Z<*-6RBSATFJJJHW0S
MSSRR2POC3BQ&)@DBFAQ>.AF@8V."6*C5CD@C8'!C(7LB#HF,#WAC6%H:'.
M!*J39[.6(IH)\SE9H;$CYK$,V0MR13RR.:Y\LT;Y7,ED>YC"][VN<XL;J3M&
MD%]D[%=)'D'4_FSE"4X-TI.BO*SRR4C3:MDF35,\FH0RP+X-F:"+1OB0Q<61
M:I)MT[8I88X6-Q.*8ZL]F+QS'TB\TW-HU6NJ&1[I7FLYL0,!?(YTCC$6ZO<7
MGPB2C\[FY&VV29C*2,OA@O,DR%M[+H9&V)@N-=*6V6LB8R)HG#PV-K6 !H 4
MJ%RN4@QI@,%DL@#AY"CBW/B19HD/&'&^':M@@88-'*+4FCA;/.V*3U)?#''/
M+&V-K996O7FI4[,T%BQ4JV)ZKBZM-/7AEEK..FKJ\DC'/A=R!W1EIU .NH"M
MH,CD*L%FM6O7*]:XT,MUX+,T,%I@! ;9AC>V.=H!(#96N !(TT*]Q>?SP^G9
M$]-Y@;1Q9J#L4B\F-DDK#UO N^863>OE\+,EO%H[OFMK=PK<>RNHGE=HAW=.
M#&8VJXNK8ZA7<9!*704Z\3C*WI-LI,<;3TC>FEVR??MZ630C>[6M8S.8N-V6
M\KDK3>B=!ML7K,[>A=T6Z+;+*X=&[H(=S--IZ&+4?<V:?)"<35LT-,&TQE3=
MC)&S9G(F:,B,)-#[1FWP:,VIMO@\Q1*MVK5--JV1?X.$T&V&#=+'%+&V%HNQ
MV/>^M*^A2?)3>^2I(ZI Y]621YDD?6>8RZ![Y"7N=$6%SR7D[B2H-R^69'9A
M9D\@R*ZQD=V)MVRV.Y'$P1QQVF"0-L,CC 8QDP>UC &- : %_1"=3<N@Q:E9
MG+";86+7!C&Y"1F7J \(Z1Q;N@[%%R]43:BG+?#!!P/0Q3:+(88)*HY)X8XV
MA%C<= ^62#'T87S3,LS/AJ5XG2V(W%[)Y',C:7S,>2YLKB7M<2X.!YJ$V7RM
MAD4=C)Y">."N^I R:[9E9#5>T,?6B:^5S8Z[V ,?"P"-S0&EI T5*U>KSU#+
MR7^"_P!53,^^'[?W%%V+<D/,OW#^CY*?L.XKA'A'T_X#W44?YBQ?23C/\6W$
M?N1O_P K>N.G'R6^"WU5W8OFVHT1*(E$2B)1$HB41*(E$2B)46]H]L?O1=./
M1!^:N4^-F7?W)$:Y$[NOIUA_P.A\HO+NGT._I!G]T.1^2XY;3ZTRM[I1%9'D
MOMK+0G';>N[\!^)934.HMB;*1%9Y98)DEX5$RLB08*YX7QSP2=K#\&ZN6%[9
M8IJ97QO:]K5<58>LVJ]<DM$\T41(TU D>&DC7EJ->7LJG*\QQ22 :EC'. /8
M2 3H5^0IO_D'N'E!M*4;DWI.CNPM@2TBY?D2YUZNZ39HK+**MPH-DKGDU!1T
M5@IX*(!#$FXT8TPP0:H888^WNFM5@J1,@KQ-BCC&C6M YZ<BYQ'WSG=KG'5S
MCS)6+/D?(XO<XEQ.NI).GM>UXE9?LX_F8?,Q^ZJZEU/E/G*=G'\S#YF/W434
M^4^<IV<?S,/F8_=1-3Y3YRG9Q_,P^9C]U$U/E/G*=G'\S#YF/W434^4^<IV<
M?S,/F8_=1-3Y3YRG9Q_,P^9C]U$U/E/G*=G'\S#YF/W434^4^<IV<?S,/F8_
M=1-3Y3YRG9Q_,P^9C]U$U/E/G*=G'\S#YF/W434^4^<IV<?S,/F8_=1-3Y3Y
MRG9Q_,P^9C]U$U/E/G*=G'\S#YF/W434^4^<IV<?S,/F8_=1-3Y3YRG9Q_,P
M^9C]U$U/E/G*=G'\S#YF/W434^4^<IV<?S,/F8_=1-3Y3YRG9Q_,P^9C]U$U
M/E/G*=G'\S#YF/W434^4^<KZHJJ-UDEV^>2"Z"F"R*R-[I*I*IY6S34343[.
M>&>&5K989XWMECE:V5KVO:UZ@0#V@'M',:\CVC]OC4"2>TD^VOT9_P!C(\U]
MO<J>(^R]<[JDYB=R7C?.0,7C<VD+UP3D!/7TN K$(Z&.%G:BSTP_C1 *>9-B
M;U55WF$7#L5E,\A_>JZQXKH0T[L4L#6QMM1O>Z-H#6MD8YH<YH   >' D#0
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MUP]>O.PU+$Q"09F&(RS8.UC[5)K8.]$E.O0'5)6SQ05VVK!G:^>[+-!TLLL
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M1*(E$2B)1$HB410R\E_@O]53,^^'[?W%%V+<D/,OW#^CY*?L.XKA'A'T_P"
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M20-KV*^*9K*-5KP? JA"QPQZ#2)VU8B=%%9)X^>NY,_*N .Q2%Y<FR'/+#Y
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MS+[LC(]IX--8:/''SWCTK#N;+')7 ;'6F!?&)H&NF%C<8W-D:YY=$.8;J/\
MHD>HAD( (T+7!VKG/:-#M=HW8!N!! T<2>?9J"-9K)N$G!IV2B4"C^Z1\*.[
M*(2R%:>VC)^0FK9=!)NS&:_C,VB6^]B!HV!;D='12429O)M7.8#-'S<T.+2<
M*KD[L]UY,/'$C+]]H?*ZN7MBVR31,K2M>S5[VOKQN+@V=S&]'+TC006-?J-)
M6!HQ0^" \ N'@O+VEKCH#N( !8"=S=''R#M:YQM=NS6W!5EH4Y.]=%3,C=QZ
M"D!6H0/J\UY&9H](GN5_)*%B);M$>+@JTCF3]CJV)P&8K1U[F-*L!I\,S3D+
M.*8B&MKF"6\ZPV.5K&ZR-,S@V5["UM2K(6QES]D8Z:1[=[6D> [1A>232>V+
M:=KG.T!#3JT$'I)!J0&ZD[0/&- X'70 '4A?RW^&]>Q]?)_EST5+Z_7M4*(E
M$2B)1%W/?L0/]R[F]_/[2_V=GU:^XU_MZ'ZJ?^.->UB?[.?]8W^ +<%TZ?F?
M13X\HA]E9S6K,_\ @D7]X;_MRKGKT5_XLZ?NIQGR+*+D[C38(\D =K)'BP\"
MN_03*/$+Y8JH-+Y_M\K*XMGN;?'*_9P4=8,7^;5/+-QBQ>72LW4Q5H:7 ..C
M=1N.NG+Q\_%[?B[=#IHOGAC8Z4M^K'D97P4GS,;8E9J'-C)T/A-CE=&#V&40
MS&($R"*0MV.N*#3UV#W)KE5XNS<P5M*M?OIL@]5O(PS-EB6&KRX;=RF/0N?$
MMV>+K%7NAZV*R62S!)0K@C@0?5&=&V:(D@QAT9DU)>T#<-XW$ O;ISUV\]2.
M:]^LW!T^+,&YSX9,0R_AILJV1_7ZL48LPG)P],V!G7:[8FR%Q$+P6N="V2TQ
MC9Y<A1X_AD\]3[(JLNQ5=+1_&1'VYN789-\<XOJTX?7;#<!2K%#KE)+9,731
M0052:CQ*"[9-1Q9D1<5F]1(:">>C0YW22#GMA<\@<F@;G3-\6FW5H&H)S>&O
MW*YA499>8GR/I]<N-MY$NC#J&!MVWQPBLZ%@-^?-8\-:QS(8JX<QG2".622/
MP?%*2!;-P9)K"),J :+-5RA^9/0N,@=Q<D[?-2*S@,2409BS8I@T:9()JY.7
M9U=-95=K9KXME+:CFZ-<(WZ$\WR.;KT>[0G1Q:T. :"!SUY]NHM9:7<WO50V
MI8AQ5]]6)T;IKV2EK"Y)0L33132259BR.O:KPQ1/C#NDDN/:Y[HS'U>HRH'A
M=X^>B@9BZK%B5.KA#A(]-46$B[1'>K>-ACZB8.[@3'K-P>D%B!4:P;&<&TF+
MJJNT<U'.0&<MI;BQKAH"X[S(\!Q+K.P/.TEK-K:O-OA .=XAX-[8H=RKKDL%
M2RQT,%JV^K:L7,FV&Z#8XK90JWGBIOJT@RIPH;%F&)EEK+]ISI6%SS5]RX;A
ML\;8#;R$<D@&[]!RZQ>2UDYP%/G<N?R-_&R3>)V=S20A"N$5%0)K*T&30K%G
M2BIA%%U9PN*B12(TW !F[F#)R:[<2X$-UD<UVP,Z3:'L))\9;6?4[ETK! +U
M=K*N\/D$F0CDZO-)D9KT]&9F/Z7*W*L[<?7P[,@V*.Q0D>^RULFY]>O"^I.+
M$'"AUI<^PCS";,BUHUD\=R5P:/ Q9'21.*&Y$D3B#HG#5SRI:?MI.9@[?Q1<
M./)-8V\*J#UFCZH8*D8;TCMH>';3K(7.#37+'$.9O87!TF\QM  :6M+ANU]B
MSPUW.\-4K'(RLI0YB*RVB99;TEJY4KV.%K&/MW&6,9)/C'W76,NR]:Q+#5;4
MAL1TI;!A>R2V<=$<5 L=>F39V**S3'*8]P$%*R^0QQHJ]B\Z##PJ*D@;+9%F
M;,AZDSX8XH):K-R+])*QXI<:[S0IM%1K=7.9T@Z3P0][FZED@  <.;1JQS7$
M:DZ<R O"HU>YQ4I2VK-O&'*[LH&4ZTF2N48C-1RU:&H!<8XV(HYN]URK;-:-
M[)IFQ]=L-KR.;XX%CQD<ZTACZ:$HV)F0?7DO9.<V#<P]D1.<NY5LW,8QDX!U
M&G\5>A\8B2CK@?*,7.9ID7;@!:3IL@VRNQA%U3HXS(YK7B.0'PG;S(7RZ![7
M-+"WHW,T?KR(:->W;0PPX!?@,3-E+&/KY2IA,E#(8H[,M^;*RW\Z88LA1?CY
MJ$U9N.GI20W=YM166TX&O8&GHIRO'^$@XS_ZA7(P)5+9#1^#"23?LVABQO%N
M'EYIPO&V3AIL!4#X4\DD::H*QP4^3&9,F>=EG@RT2VBUWA.U!<=-'RM!C+P
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M)BG#=';B1%X+FLEEVD"4EP,<1>'C5NU\>AU+ML>@?H#JTZ@$ %VNA<UO/5H
MT+AKJ01H1Y-<;=X\:R&B8# C4E/M5YS(9YLF$2Z'M,5,\(:1@4.TI)70AXZ6
M0;**R(,7VF8A<S9I)+, TLAI40T(OEFCVZ%S7M"Q)(&-(8V.*1CSH"\2/G:#
MH">1;$V1AUYLD!( +=:;F%HU/C)'+V #VZZ^/30@<P>U8NU=J5*(E$7<]^Q
M_P!R[F]_/[2_V=GU:^XU_MZ'ZJ?^.->UB?[.?]8W^ +<%TZ?F?13X\HA]E9S
M6K,_^"1?WAO^W*N>O17_ (LZ?NIQGR+*+D?K$U\XDHB=5O11$ZK>BB)1%#JM
M?RVM?^BB*%L;6Z^JUK=J_7?VK6]O^BUO[:: =@3_ ./V>1?U1%#JMZ+41.JW
MHM1-!Y/9_;Y4ZK>BU$//MY^WS3JM?RVM>B=G8HT3Z_7S!*(E$6Y7H,_/)/\
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M)1$HB41*(E$2B)1$HB41*(E$2B)1$HBU/\@]6<A=8\W7W+_57'(3RYC<[XO
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A1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g120909g42e26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g42e26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=64&AO=&]S:&]P(#,N,  X0DE-! 0
M    %SJ^648X0DE-! 0      %T< 5H  QLE1QP"   "'W@< E  "')R,3DU
M-C<V' (% #Q-:6-R;W-O9G0@5V]R9" M(#$R,#DP.5]W;W)D7S(T(#(R2G5N
M93(P,C$@0V%N9&5L(&5D:71S+F1O8W@ .$))300E       0\]^8W/R;$)MG
MPB5Y5N.2TSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              H(   =D          $
M 0             '9    H(                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   H(     4F=H=&QO;F<   =D    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      ,O@    $   "@    -@
M >   &5    ,H@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ -@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
MT^H]1Z@[J.43E7-#;K&-:RQS&AK'.8QK6,<UOT6JO]NS_P#N7D?]O6?^32S_
M /E#+_\ #%W_ )\>@+7C&/"-!LXDI2XCJ=SU3_;L_P#[EY'_ &]9_P"36E]7
MNI9XZEL=D66L=5:7,M>YXEC=['>\NV\+&6AT#_E1O_$W?]04W)&/!+0;%=AE
M+W(:GYAU:HZCU)X#WYEY<_W./JO&I_DM<&M3_;^H?]R\C_MZS_R:K5_S;/ZH
M_(I)_#'L&,0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M06F8*"VIR**QYE*3^<J?/D('K $7NO8%8\S#+M3$BDYM)NH1;1UN2!), JK
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M^)S_ )*?98\I?N#93YMN'UM44#].IRW9OT%S,,TF;'8YVNY8(QR6"5UD^O\
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M3I95=7/*][Y**97O7H:VPU%:9C,-I:CQVFV6&D#"&V64AMIM*1P"4-I"4@<
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M=.EDF[9LDHNX<+YXI(H((X745665SOC@FDDGCEFHIG>V.&&-\LKVM:]Z $G
M&2>  Z2>Y2I8@D^@^T8@!G^MI?&Y[!I0QQ)1N7Q T/D,;.L,\\TK/!1D4X=,
M'R%E4E4<E&ZZF."R2J.=\5$\\<9W&UM+4VXA3:TG"D+24J2>G!20".!!XCH.
M:@"% %)!!Z"#D'\=?,0Z?'[;5S"_2;77\&-<UU39_P#FB']XO_476 E^R'?O
MOU"K/=9FK>JE:?U!L??>RHEJ#4<6>379$[)9B(E%1[@>T>FB2;-R0S:-W!1V
MQ8)YV9LW*]\G+M!/L4LK6SOG?''*FZ\TPTMYY8;:;&5K()"1D#)QQ[?\=- %
M*4$I!*B<  $YST=SM_QCB(^2X\;H#ZH+;P+:\/C-5@]N+:(*2]^FV:LV>W6P
M-S)'4#49+N4RN1MF%:+O'UDF&;1EV.#=TY2=+)(YRB0PIT,)=272SSC0#QW.
MH)WG<TY(&20?>P,TPK3JTD)SIR1@:L$XZ3CH/:/:J$P+26UMGO$&$#@<BD2Z
M\X@^MKJM67:6+6=[*>$F$$C!$D\S;#Q9.4NPY5(2F2=-<%^]KU3)3!-LKEA%
M;[+7_4<2GK%N<3Q+;8"EJ XDA(()P#TB@"CT)*@3@:03Q/0,]'']?<!-4]?"
M20URNT?LW#5PV5[0LFLGEC?!7LE,<<>RMUXY64NDI=+/#++!;#"^:66>'NU4
M"@H92<@\1[X_7CM]P\#@U#/X_%^LBIKEFLIW!TXJM*(T0$IS6$L-C1FZG:'&
M1*$DR18.RD-L&:SC)HS7) RK3M;^S5TDHSSNN@GAFCFI*AQM95I4#I7NU=H!
M> K3G'$Z5)/#/ @U$Y R1T\ 2, D] '3GWR/?[AQTI# )I%,P*<CBQX+G*8L
M-F\;P)#'3;,W#RZ;A49)1N*B=KNPSY-JY4;/TK9-U,$%LNS['"]Z)<;5JTK0
MK2M3:L*!TN)QJ0<'@H9&1TBH<1TCZ>(.,'CVL=)Z.X>G':B>M9O.!<U-1:/O
M"PK7<4=3B9OD<FR+<'%F1J/1UT56S=.&_=&*!F51]EFT8V=/K7)(K6:W;X++
M)%NMH*$K4$J<6$(!Z5**5*T@#/'"2<G P/?%1X\< G S^7''&<#../1QJI@/
MBGR$DL9TG,8_JR2F8SR,GIC5VE2PW%BZ0GFP 10<&*18=@D]S79$VQ$JR1QP
M,)#4G2>:[IHJNT9/%T*2I4=*WFU.H2N.VEYY)/%MI044K5PX@A"NC/1T#(S$
M)60DZ3A1TI[>5<,I'=(R/'GCT"?P_ 3EN><31H/TX5Q>P2>S#5A8>2D,+"D3
M&R=?J72FT#@+ U)![S:$LC&?87, M;(2L@SQ<-,LV]\7K2Z\AGPTA)+Z2%MH
M=!2%J ;<SNW%E*5!M"\$)4YH!((!R"*F#;G'K3UIP>&#J[8&>DCMI&2 03@=
M,&C_  BY4RJ9:2U_'M+RLK+N1VOUMIZ4$-LQ%[SV -6AU^\DPU]F3P&LV;%G
M&C3D@B8=CGK!)ICD\;(]U,^Z(JG0T(>6I]L)CN!I]1/!MPZ<(4,9!.I.,9SD
M8J ;<)2 DDJ&I(TGKD\>(&>C@>/;P:Z<GX=;^AVF1G(*0Q>---2&L4;")0WV
MIJ0FN2=*)QU=<4RC8J=/I6Y/"6\MC;F0Q](%D;C;4PR<R >,04NIC%,R.MXQ
MDJ5OD^N04.C RL!1):"0E1;6$JUZ5%)TJ5VQ0L("\  ]!R./1VLY[8R.D9&:
M\U78O.U8+]RN.T**8HIK=I4[4HKG;++!/!3L>PR4SQQRRQPQO?+*V.5[6O:U
MZN<CHSQ[E29[O\=KQ>_W./12[%[9-56[1S9)OVGMZET5+)H]TVZV]U<[X]BG
M9>WNHWSOCVVWNI]E:F0,9(X]'O\ @[M1K?D-(8874R9.\4\4LE\E,FZN.%D<
M%L6^:U\KX6M9+%?+%#)2][88K98IWO;.]K7AJ3[89[F1T]SP]NGAX>'P9^CC
MX.-3%$X!-IV9;QZ'14])3CP0>/M!048Z?OG06+!24BD95NW03R468! 08J6)
M.4[9)-6(YVLIECBCG>TJW$-I*EK2E(4E!42  I:@E*<]&5*4 !VR1BF"?6@D
M\>&#G R3P]X GN8XYQ4M69/+IHJ]S+]J<9J)H*]J4[6LHE?&RN".=L>Q4S2O
MEC93'"^66%\L>RM;KM4V1T9&>G&>UW?R&G\?Q_'AJH>MM-;/V^7+ =;0LW+C
M ,:T+%1XI!.[ADQ(2(#$!N:MG"J&/;RDJE$<CHMGC?)X3-&QHQ@@X>.T4LI'
M7F6$A;KB4)42 2>!(2I9(QG("$J4<= !4>M!- %*R$C..X"<<0./O9(&<])Q
MTU74-P)Y6'#ZT;::MQ:D$[)70<')WK6-@BG=KM!B$[P2>0S 9&Y'[*W#E'&$
MW EB-IPE?-U$KF6J*RR=!4^(E.LNY3QSI0XLIP-2BI*$*4D)'K\@:/ZV*F#;
MA.G''N<!G/#K22 1D'&,Y[7OPUOP<Y5.HH3F"&G) HQ#%' DJ!L1C=MACUV<
MZQU@\>.M69&K;*2",]C98P=W(LHG8 UE%LPRY)-[AFE@,Z(%I1ODY4G4#UV[
M/6%S&]T[O46P5A&K5I!.*:%X)TG@<=''.<<4YR..1X>W72(<,>20Z4@(:MK5
M=P<ELAC\4AMQ<GA9L--I%*&9IZ%$0B3!Y$^C<S=N;1\LP<81@L5Q'&VZ4>)9
M-#KY@.=3)FQ2@N%T!*4*6O(4E2$((!4M)3J0,J!RH#*3J&0"1 I6#C2>G &.
MDCI .<'CPX=!!![H\O9X9)YY898Y89897QRQSQOCECEC?JOCEC>UKXY6O:]K
MVO:U[7\=K7]RKFH5MI2LF+ZE4^V.3K_2OL?^(&IZU?:_^;6O^Z:_T7:O;?[)
M5^"/Z0K/BY >\/NSR1[(]#35<PE>QG_P2_T35+:WL5VF^+]Y\G2:^>UCXK?-
M;]U<]3T#P#Z*\9ZUJ-*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I6<9T
M87P#>./Z(EO3"25O-K]@1OO#^FJO5WD(_HDV(^#'_*,VK1G3"_"CC/D8BWI=
M/J^Q^0GL-E_&"?\ [.W5\\>B/[/H/Q7MWE*\U:FKM%<!I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E;%/K,OFJ*>D>$?32LU[8/P?)MY')'Z%/*\_+7V3V[X>B>4&Z
M].KSV'73XMS/)CE84"7V+#\VU>@J^D>#]9KS%KDJ2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4J[1T>/+Y;CEKJ>1M+BOS"WY:03A,]E(>-^FV6RHP$OC'Q0_O(?*
M.9A&\QY^_<G=]A^+9QCWL=L7/='9+Y))_,O+M"YS?[*H2X3&+,H!,E_=+5_+
MY*M24Z3E/78SGI!':X_9/H:W=&S6T0W;JR;^A66T:@-5LA'!.1@\,X[A!SQ%
M7!O"CN__ /.#I3/_ +5!/]TJX;U*5]TK3_BQYM?1_./_ ()']U__ *K;ETHC
MG/'+#+HW^E+RQRM>V5K\4Q-[7M?QVO:^TKVO:]O<O:]NJ]O<IU*5]TK3_BQY
MM.<?_!(_NO\ _56F8US7<<(>9VL16A^('-_7/'GFILYV$F?%+;NC!\(9QK;)
M>Z3HMN3BXBRG,@50P<8*8$-K:P2&BXABTQ4DK$D'=YI((YI4'G\%XR)<!R3
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M7LO,).C"DM%V,J,P3QU--M1RVL'I+KBL*R<UN< ]+?#6E7KNE0"]2\8X*45
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ML$=7#IEB,QO I+BG$<ZYN%+<0V4J*@V$I*L[S0VHH2I24%2P<C(D2$:U<1@
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M*KFS9M9PHGACFM9NA92^5D4^Q8&2<#)QDXXG'1D]P9.!T#)P,DY5P=EE\?\
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M]5Z4R.Z/&*=5_BO^J]*9'='C%.J_Q7_5>E,CNCQBG5?XK_JO2F1W1XQ3JO\
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MF=CTC;)M%'0<3'(T["9MLKQXPQN\=7RI(E,H ;$=>Z2XAYM/.#K2Z@8RI6Z
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MH$N20\4E9&$AEQDI"@,A12X2%C!! X&KUCE@5&O5WNR+"'$7C:\;2OQ7+BZ
MF([8;WL]-MJ7FHZ'$.OP[V\N/<&PA49YIM88< Q4>B')_0%X1+=>E=:S"-Z[
M!\<I9J^+1E79%C,PFQF6;_U]LY?KF;+6;8-&WH]F,,/FZKR).0JN I%@NEGF
M]Q35F;E1]#C2FW$M"*\RE)<"G'"X^TX1O-V$H("24@H*>&,\>%[;N4'8PVN?
M9W[%<H%DA[#W+9^!;UWT2;G=9-RVQLM]6.JC-C1&@N,M,2WDK=@*BK$=+*TE
M3H"H:XYQQ<\\%-)=I)X3A^NYMK2=Z:!!MGO )>,DM50*.Z\ CIM(U8F55G0L
MD'B@)X87:CXJ:2(HO>\Q08R?J-$Y3/0K3K8)2TXTXPE+I24%EM+:4N+"3O$E
M*020E*@<Z3A6!;.<K=NF/1V[ELH[(M=ENUBO&R\2-?W8<F!(V>M$&R0V;K-5
M;I"KO'?C6V&])4VU;Y(?2[S:0PT\I I[-^8A>?:[F,+,PMHD5FL <PXL>9%K
MH-,"+[DV6Y)OS;,)WKO9!LJ^*JQ9N([XY6;-T\"?=ZN5^]]J;DU3C:T*0 IQ
MK=J4"0 3)5(*DCC@9.D#.1TYP,'"W7E.?O%CN=JE6IM,FZVARW2);4D(93(?
MV^E;</R6HICG2T7)*H#<8O$(2D/EU7_2J?R'.86:/OY*2UG*AIE/>[S=T9)0
MS:N,8(@7!K74<UP>#+/%8&8[Y9*#8TU>CW62#8?EF\>C3H4Z)679N*G/\J*B
MTM*N<%]!;>TE.IH-*226E9R$YZ!W%!0X'-R.5R)*FO3W[#<69*=KG-JK?(MF
MT*8,B&N79(-CFQEN*M,H/E3,%#S+F&V27'(\N)+C.+:7YAW_ +8"[GV![- <
M%80)O:/ @;IFU]C]W\A(B&^:+R72/*)Q2#1?.1G<\\<R68&(@6&5FZ%[M%'5
MW+MS:R'@^YK#8;PE*2!IRLIZ5KT(;25J[92A(X#AG-<]VTVDB;4WHW2':6K.
MWS.+%<:;YEOIK\9"DNW.<;=;K3 ,Z62"^8EMB,D(0="G"XXNB=4*U.E*5G&=
M&%\ WCC^B);TPDE;S:_8$;[P_IJKU=Y"/Z)-B/@Q_P HS:M&=,+\*.,^1B+>
MET^K['Y">PV7\8)_^SMU?/'HC^SZ#\5[=Y2O-6TH%-C>MIM%)_&LF>$AAAX9
M)0N1!M=VQQ)B'2;QG=VULHC=PWLNEA=5&RR=U,>O&V>/7UVZY<K='NUNG6R6
M'#%N$5^'(W*]V[N7VRVYH7I4$KT*.E12<'!P2*XG9[G+LMTM]W@[OGMLEL38
MN^07&A(CN)=:WC84@N)UI&4!22H9&>FJH1#DYN2"Q-C"(U*,60,1LH7MD&DL
MQ1>+ IB+3>)W5%9N^VH)"B-GZV1<*N@Y'OL\LL\T<,G3Z[O#3]C[!<YSEQEP
MBY(?L[]CDE+JFTR;>\I!P^$86I]DMI#$E*DNM  !1"&@WG[=MWM+:;<S;(,T
M-1(U\8V@B!32751+E'0ZC+!=U(##P>49$9:%M.*.HI"ENER+,.5FT <_$[%B
MB$0B!T,$D()LSCX)S@&50DZ2N)1V\:%"I1RZ?8KY-GP[)1]=F)=C!=QS)LW9
MX-LJ+VQ5GDVMZU357"?&D28LI;DJ2@R$JAD%E#:V&&$-ME&MM[2V%R$//%UQ
M:W"H7+/*#?8EW8O5O:MUME1XTV*AN'&<$=:9R2'G'42)$AQQU*M#K)4[NX[C
M+!9;;2VE-01YR0VD1$@@9$D.>#H[I\UHX:FJ,MFJG!3_ &E,A=53NG"[D_9F
MU'CVYA6]U,& L<W415[G[/.X;V3LS<B3)::>;>E7Z/M(\0]A*KE%U%H)!;4&
MXI6X\ZM@ @NO.J"DE6!9KVVOKT:+$>>96Q"V:E;*QP6 5)M4S0EXJ459<E[I
MIIE$A9R&66D*0K0">WR!W5AMYWKX0)[_ -H=J[7X2"1Q24=[,9&848-T4B4F
MD"8>Z@[$N2P:C1G4DZ?*8!P(9%P^=+IJYU3V7V>-A1='WS%,^]721<I8A%WF
MK"75*+,.*7P'MPR5//94EH;^4^I+2$J JKMCM0G:)VSL1N=]3;%:8MJA&=N$
MS9)90$/SIB8VID29 ;89.AQU0C18J%NN*055$L^56RU N8S,9 ,B;L=K\2:F
M?L23PFLD8:O-QTY"4#YM)\G@]N)6BP5BJLFR;N"@YHFF55>NDF[Q"B-B[0)
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MMQAA$5UJ2]S="]1:#3"]2UITCG!9B=:0&ZVQ)",<2++5JQTJYU_:T,<,]K1
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MA5E&",;UMM*[!]<B;;D%W..SBY/4XJ,.\76;T,>:SET/P J-H^Z;2),,#>8
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M &=NKYX]$?V?0?BO;O*5YKRGH [%8]JKDR0E<6#39JG&=6=RQ8T7+A6Y5?\
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M_+TNM/L29RX:8W.2M1SMD43U)JR)%A1;4<;NQFK;B*>.:[=;$E#P>+D,KRW
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M\4P+]HO(SS-N)[I144:9VK-1EN,*>"R$H+N!I64I+24+5E?K$*7J"4$X*E
MG@G&W6782Y7O9=>T#$]UJ+$>V@4EM<&<NW1G+';H%RE+F79I*X-L?GM28\6V
MB0$&=,:3&WB%;M8C46XT\BEYC&8D]6&1UD?E$&,6*R"?P<I!ESDHDI &!>N$
M%I(^C\RDBA&/R"]HHV2-24JS!E<,!#MG>]EITQ90<0A1"=2T+RMQM2"M:R$J
M(4HI<<*D+ZS"EJT*RD]NZMVP>W"[I MSRV(34RY6F094V[VF5:E3)T]Z)#6X
ME<YZ'=)RGH4LFVMB5<)+41Y/-G&LY[<PU]R*VR9C$FD9%LY:.!6OLPKM)>%0
M[)@'-"XU+;%HYKN//AI0D'B"FT6Q(](XX =6:*EWY,LX9.5"F#0MJ4\I"E$<
M0C2<MMX24I7E#22E1#>^ZY01A.HG4<G-:Z6;;?:27;[A/?;6RY%LJHBTKM%M
MW,:7'@7+G,*R0GF7WXUM5?D/S)T.&X&ER7I+ZFEJD):E]]I#DE=V\2P?DG[=
M^:N4*/E]F@V=D+#1IX^&G4Y:%)4@^B(M]'(>;D4=E4X0$-W8D3F['/E$[MKJ
MP+$OIU*(*N)WP3@!*REQU)6-VE:$*4E;@' =/1FP?V2V[#SS:7I#R'91?D/*
MOT5K0&&)DN-=KNT_<$O6V.]!M<J;#N-U1';<CQMY'D*26RKA=Z3W^QLL?6,.
MF1#/,YE(#Q/9L9#!&R! =!W"*N6PR$T1CYE>;,)A',6S=N545.(=ILC<FBV<
MW80+$E))*U)4"O4HOI2E((;P=YO0D[P.(P 23C U  4=V4VS92J6J4MI_5+,
MR6_?;?&B-I?8M*T+ZM/W9,*2NZM7*"EMMM\F4-&G?!"]Q)^N=*[#VE[#DVI$
M6)CTSF@*"!WTEF (=F\)7(BX\FN(BI$VUDDC'QA25,$7[H '?M@S4BOBJLV1
MP?W1D:8=?",*"4*6EM.MQ/'BA T(4K4I*"M()"2$@GB.-8NQ[*WS:'J6EM^/
M'@76YQ+3$>G7.&R77DOQX25Q;?(EMSYS-O-Q:;><B1GD1&GE@J;2'"F,-M(\
M@&S@L>&8*+/8B!9RU0S'MF1,@[[P2 8\,]^XP0"RMRN>9JBVQ1Z5=1I8ABV1
M9D^^&2:C9TFG-S>2"I8))0D+U)?23H4"=2"ES)20DZBC(PDE1!3PN4;*;9I<
MDRXP4ZY;8K=Q,F)?[<^YS.9'>EF7 >C7)Q4UI49,AV0[!6\&TMR"\I#B'@(L
MXXT<C%7F4%=,FF:6)RR60]QMG7]XO>;OI,0A/>#O@K-/8SEL1W(Q9,1G&\7>
M4L5S9.\LF.31#-7&8Q)6=T>("O6\X;T;PK+83Q<"=ZI:2G2>OX'4  :N7-A-
MN"X;2XTR4<["%,.;164P.JS\]^U\S+Z[J;>;V[.COQ3"#IN:MRL*:W84:W#=
M(<H2&$?)LD)%A@>CZ"3-\ML<.Q4&Q5$"]FPI&0J.90@M% +V.!WLFCC:1=ZF
M)5@P4?!DG.*..5@CS"$K&K"DD9WP2$HTZP%=> E*D@J1JPDI!4.UE'V3Y07Q
M"DM)FIY[$;2T\J]Q6RQ $)V[1D35.3TKMT-V%%=G06IO-VI+3*G8R' G(\XN
M7!5FZ(,ER#BZV%\!3_N<IB\;.4A2J*;9MW6S<+LR+!HHQ;789HK.&5L6S59E
MGDDDW4M:$GB,GCP/7$YQP SDY P,<2. ([1K1G7)3+K[3CZ]X-,=\MOAQ"TQ
M5)2TWO65J9?9;+3994A;C6&VU-+(2A5<C>02!H\1(-#YMJ_;.'SML^;E7R#Q
MNZ)VOB3=(.DE\5T7)'&]\7ZZ:F*KS&][.<U+7O:HA:P<A:\@J(.M6059U$'/
M2K/'N]O.!4R)\YMU+S<R4V\A;SB'42'DNH<D9$AQ+@6%AR0#I?6%:G1_U"KI
MKIO'[\BK9<B^>D%[=LZEGSI=VK;MRZSI;_N+YJ9_]YTY<.5?\W^=PX76RZU%
M5,LH$D]))\))Z>)Z>Z>/AR>DU1>D/R%:WWG7U]=A3KBG%#6M3B^N62>O<6MQ
M7'KEK4L]<I1/5J%4J4I2E*SC.C"^ ;QQ_1$MZ822MYM?L"-]X?TU5ZN\A']$
MFQ'P8_Y1FU:,Z87X4<9\C$6]+I]7V/R$]ALOXP3_ /9VZOGCT1_9]!^*]N\I
M7FK4U=HK@-*4I2E*4I2E*4I2E*4I2E*4I2E*4K8I]9E\U13TCPCZ:5FO;!^#
MY-O(Y(_0IY7GY:^R>W?#T3R@W7IU>>PZZ?%N9Y,<K"@2^Q8?FVKT%7TCP?K-
M>8M<E24I2E*4I2E*4I2E*4I2E*4I2E*4I2E9%O0O>\KM[RKH^AX"OEGE_P"R
M&Q_ J_*,NOL[T-'8SM)\8AY,A5>3K@M?25*4I2E6/>EEZ;C4/1F.0.M1L*<;
MJY#2L&E)V6OVQY.-1V)1=TY<LF)^=2.S N[9YE7+-[8& %B79$DDR<.7C@*Q
MS9/'F>L]B?NFITKW$9"B@N%.I3BP 2EM.0"!G"E$X!X *((JSDRTL82$ZUGM
M9("1W2<'Q</".&; E_JN'DA>]^KB1H^UNN_5;*;3R][6Z_<Z[]AC:]^KQWMC
MC:_CM:WBK/\ I-C>[9/B;'Y-)QXZLNJ3O>T>)9_*#CQ4]MP<D?DD:.^FL\_E
MIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R
M7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_E
MIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R
M7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_E
MIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R
M7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_E
MIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R
M7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_E
MIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R
M7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_E
MIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R
M7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_E
MIZ38WNR3_E^93JD[WM'R7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R
M7/VT]MP<D?DD:.^FL\_EIZ38WNR3_E^93JD[WM'R7/VURH?5<7(K%=+)UQ$T
MHLVQ4PNNDWGDY;+J)6RMV>"3A1J[314RQZ[8JYM7&.%[VRR2SM;L;O2;'XXF
MR,XX92VH>+2/#T^]VZB+D[WM'B6/RDUDT]%QTK>D^D\UL?.0H,1USM;7N0Q'
M9VI#Q)J7? \2^"UADACIQJ@RPDT/)N&KUDU+9C1)!J_9KLRH=A=1@J^UB[6A
M^U.I2X0XR[J++Z4Z0K3C*5)RHH6 0=.5 @Y"CQQ?QY*9 .!I4G&I.<D9[8X#
M(^CM]HGWGR ]X?=GDCV1Z&FJP4KV,_\ @E_HFL1M;V*[3?%^\^3I-?/:M];;
MK^*W[JYZGH'@'T5XSGH.:FQQ.9"ZCN,94<,KC\6+44HO@+'IEG(<>1S,L [L
MO@VL1<C&13/%ZBU5<96[:BPP5R40&"T6=0N*T!&4Z0 D'2,X"LA.1QZ>Z>YG
M(2 ,LY>ISMO%M4IDL;E$92TL,)DN1F'C*:BNRDM[]<=J0K>I;4X1K2T%:DL1
MT-5%C$QW?&8"';QM0AC #!/9@<8U0$"BS,F3(L-;*3U!RS49/73I0?B/UF58
MN"".28,PT$F(ZLS+MUW&%1"WTM@)!+:BXD)"0L*)W96"-)Z,-*X^M4 H8(!K
M-VZZ;6V^RPT6\O=1Y,B_1F&T1F)3;[[S5C5=TK:+3KBU,AFPR&5O)*8DIN/)
MA*:DHWB9[RY0\DW)RQQ5VS?$V3T/($4WFK8829C3:$E.3()*6HQ[%'+$>=QD
M,Y/DAAU!ND\QQDSEHT<68+MF^%3G<DJ*\@D%"O\ I-D)5J6M*P"@@+*G%D+(
M)5D](X5F3RA;>KEB8I3;KS3L6:D.[/VM]IF4F=+N,6X-L.6U;#,P3;K,?CS$
M(2ZD35(;7N%(14IM>0&\6+!J"1))8YB&0D*,<+0>-+2$&+!L8A$DP@LVO'E#
M@H:[;PJ+AS8]H\01,KLUVY7!RN:-XDI1)DC@#@@!():3J2D!"- )3J"3I0E0
M&,G()*E$UBT;9[8,QT04.I'-6XL2.I=H@KF1&(C=LMHAL25P53([#J+7;XLM
MEIY DK;4B0%KER0]- +DMN024P5D[7,^(%-.J7CDXE$ Y8^!<QJ2Q,..F)YY
M!#ERP$:&FY9B#&RT8=!HL7R#)(<H@@,LTF3+>2>OZY 3UZ=#:2M!2IM(<4IM
M14A*7%! 6"D:L<1I R,3;S:N/)UW!GG<>*U_^293:[;&DRH;EOG6Z,S=)CEH
MEF3#CQ;K)9AL7./+B):>2RA@I#(;B&R]^;Q;RV8C2D="QH'@=4C;K7A.$PZ5
MQ,.4$#H@(:"<D",<=@'9L4U@<;5;+,6;5)JJ@^Q"CQ8<L]&*Q=?D!QS*0@:M
M);W:%I2H)2D @HP2 V@XTIQA7  X36OVV.UK5RN;#T&)"B"8N [9G[5:[E;8
MLF*S;8R(VA^ Y"<EL(L\%2%--(2@MNB(S'C2'6#3Z*3S<L)! 18)J/33C<XL
M2BB1*&Q(Y,HY+4EQ$@=7C]C0=_,A3)VXC0U<C@QLB&=*,GC)>U[OB[9Y20MY
MM*$A(PESK I""L.'#G6Y3O!D(U'!">YTFL/;KSM7:8,./$:8 @W?>VYJ3:[=
M+NL&XH7&GN&$F5&=ND=AQR#'6^&DB(XIM;2N+KZ'(_%-S<B+1:T0CKU1:.LX
M=*4FJ:\4CF=FD3!PQ^'F.8TN1%8N+]HAUG34JJU=J/[I((W3RL^Q2SRF0])T
M!"22@(4D92D]:E"DKTE23DA *5XXX''!Z;JV[4;;BWFW05*YDW:K@EL.6^$=
M%NAVIZ-<U,29$9*E%%K2MJ26W"]I;1C+P3KJ;K;?&ZH8>%2F61-M.FTY*/=K
MQ1&0X04/%7\I:3V431S)G2Q>*F!R:WLK$2RZ#1@YBDH9HY/F$6-!FQ%--U7:
MD/H6%+;#H<.^;U:0DK#BG=>2A2<A87@ H4!J 4,'.?L.V&U=KEL7"?;6[LU>
M)+NT=N3-%ICVYVXM7BX75R<XN7;I3"%BY1;BI+;*[?/:27FK=*BMOH"Z4M]_
M[[46@MKKXDW41%LLH=D\@($B]L)9#KQT*X2<N0"[XB@('7L+"D5%EUV."2"2
M#OMB"5\*/.)!T$=*,:#NP582 E&00HJT\ DCCC "NBM=;VSVS4JSI!$A=K89
M-K+EFAOO<V:CF!$<2M<-QV0B.RKF\.05K4P A#;I4!5&#ZDJD9J12<\U)/3!
MAXZEDB(9"\VULUY$\S(+%W*+5J@U9M23M[=9NHFBW99]OPP:XV3NGA5NK4I2
ME*R5$ZUDCMK.=1P, *)R, #CP%:I--RGRY]QF-2'9,AU=RGO&.I USG"\J2X
ME#:6V6Y#KI4V0E#2BX$M#!2*V/(A)QX4?(GP,@U#%7YL8/>K(986</8XV"O#
MB/<]_P#]4EB.:R(*LLNLBFAEB02LDKGE@MBDT+P#I.%%02<'B4A)5X@H$]P=
M<>%0=M5R9B,3G83[<:0_+C,N*1Q6]!;BNRD[O_JI#+4Z(M:UH2C#R=*E:5:>
MCWC-V<JL[ABW=:*C=%9KWM>]TI+.\DL&B2J':.VIJ.LUT<&V&>%LE\EDL4K9
M74QM>&E62-*LC&04D$9Z!@CI/3CIQQJCS&;O%-<TD[U"FTK;W#N\0IXH#25(
MTZDJ=+B V" 5E:0D$J&8>JDJ@JJ@NDH@NBIFDLBMADDJBJGE?!1)5/.V.::F
M&5KXYX9XVRQRM>V5K7M4*MU)4A2D+24+0HI6A0*5(4DX4E23@I4D\%)(!!X$
M UQTJ6E*5G&=&%\ WCC^B);TPDE;S:_8$;[P_IJKU=Y"/Z)-B/@Q_P HS:M&
M=,+\*.,^1B+>ET^K['Y">PV7\8)_^SMU?/'HC^SZ#\5[=Y2O-6IJ[17 :4I2
ME*4I2E*4I2E*4I2E*4I2E*4I6Q3ZS+YJBGI'A'TTK->V#\'R;>1R1^A3RO/R
MU]D]N^'HGE!NO3J\]AUT^+<SR8Y6% E]BP_-M7H*OI'@_6:\Q:Y*DI2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*R+>A>]Y7;WE71]#P%?+/+_ -D-C^!5^49=?9WH
M:.QG:3XQ#R9"J\G7!:^DJ4I2E*^7AT_Q)^2Z6OEQW>[6==P&=9#65EL[YV:L
M&FF-=V;M$+7]Q-%+L\\L<,;6M?/-3._7GGE>_5MG@$VB'@8REPGWR75DD_QT
M5K\LYD._? >)(JS=6:JWI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4K)O\ J4XB^;](?L<<@Z628DN+,\S?M<,[V1=9,-B:J59Y
M+8>++)NHJIDEEU=EAVS.UKVMGE:^K;7@=3F20"1+:()QD9:=)QPX9X>*KVWD
M\X4,\-T>'_[#]G;S6>KR ]X?=GDCV1Z&FJYC*]C/_@E_HFJ6UO8KM-\7[SY.
MDU\]K'Q6^:W[JYZGH'@'T5XSU5)_LF[W7S:#]ZG>%D6 \=;LS.*L<;9#S;PU
M<^+C-AJ?>^7$;.>]1(]<NY[H%*D6MVEL7^'<-8NDM!O!X!*0=76C"LE6G3ZX
M@D%0.2,C'$8V1_: /6--G$=X:6&6!JEA5O;+,IV29L>WB.G<W-[>&._,,E>N
M,I]LM9> :JMJ+E,?U!#1L4!@5LUQTA*'+'&<E>A7BR)>?<?IN\&7Q9,\U,&R
MZ>ATP3B_=.6#EG*WBBR%\1V+9_69EJ9;"$IXA>O6%E)XN,+*<!)X$,:3UW$+
M/<P=@V9Y0I>S-KCVZ+#65QYDB6);<]V*XM,J\[&75V/AIE92VM&QZ8CIWA#C
M-R>4I!W :?FK/FO/^\2 I!N<;$/8Q)HZ2/HSLVF3,JG8AM2*C2I%;!#%PY<Q
MK_$M,D*Q<NG&:2\;8I-UV?;\5V4YG.E(3UV="D$[U65:FW6P5<!DHWI4@=HI
M3@I/1DCRK7?F?-T-S&WC N$%V8F[RP_(5+MVT%OCR7E)1K6[!ZN)?8WCBRE4
M%E+:VMX5LQQGS7LVD*\S6UHY<R]4R/>)D+SS/ ;86SWI!]\KMW(_**+$')Y[
M(H<J,5/]_$T<1Y6[FX95^UNNZFY^-9<+.5E0.=X< "0W(]J"5:F\%1Z01P!R
M1=M<JZ42^J3EA<<N?.&%A\W?#'-VMK;3M>M*VNIBGW)CDZV*8,TRP@,R"LQ%
M.H*EP(5S)/-HNP"&(T3-E!48N%3.9SH@A[*7ZT/E4)57V<S<"""T^ -1,FLX
M#QMT2&W&OF;JUR[H>9?,,94SE! 0I"EJ"2-6](U*W:VOMHTY6D)62E.>"N/
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MVM !PM1Z"1T)T)/#C@@G'3-NKN>G#7ON(E6Q-?1=GL_/1$?A#V=(\?-<6B3
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MS)=68B7VVPUE1R'<+0XM0PH)WH0DJ2A)$=\UIT 9!+97A*0%E!X] .G 4!D
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MMG_YHA_>+_U%UB)?LAW[[]0JSW69JWK7KO\ '?W/%[OBI4,#N"M.N_Q_E_\
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M(+%<T1O<KAI'RKK%P\CDKF5J9\A"RTEM+ZDZ6QD+;<)4&PV^ZE*%);9=4X$
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MSU/0/ /HKQGK6HTI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E9QG1A?
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MX@:GK5]K_P";6O\ NFO]%VKVW^R5?@C^D*SXN0'O#[L\D>R/0TU7,)7L9_\
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MI2E*4I2E*4I2E*4I2E9,7U*I]L<G7^E?8_\ $#4]:OM?_-K7_=-?Z+M7MO\
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MV40O>_WULMM- VMLT6[P7$%3B$(FQ@H%V%-"07XSJ?7#2LE32U#[:T4NC@K
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M/S!A[=/#(@:+NWQ9_GACF\>KYXVO;#/R'Y3A>D.K=<5P*UG)P.@#M)2..$@
M#)P*N4(0VG2A(2D=H=WNGMD^^<FJO51J>H0>  Y2'(1^2AQD@!%FRC,F&,L&
MI,60:JVZE&[U@]26:N4<[>YDDLEGA?[MJ@I*5 I4 I)Z00"".X0<@CPC\M6\
MN)%GQGH<Z-'F1)""T_%E,MR([S:O7-NLNI6VX@]M*TD'N5;XD_1,<"923<E7
M&CD0R[A3-59M%YI/8V,[/.]\\NYQ F3-AC)/KOU8H,FC=##&UK8)8VM:UL>J
MTV]2BKFZ4DDDZ5+2,GMA(4$CP  #M"N-S_0[\D-P?5(7LFF,XM14I-ONMX@L
M9)R=,:-/;CM))_J---H'#"1BI9\#OP#_ !2R#SJ;,]::DZC6_O'YZOVU9_8U
M<C_]G9G_ )#?_K&G@=^ ?XI9!YU-F>M-.HUO[Q^>K]M/L:N1_P#L[,_\AO\
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;J-'1W2&V4H25*P"I9!6L]<M2E9-3?4]9&O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g120909g44a52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g44a52.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2"84&AO=&]S:&]P(#,N,  X0DE-! 0
M    ('R^@Q8X0DE-! 0      %T< 5H  QLE1QP"   "'W@< E  "')R,3DU
M-C<V' (% #Q-:6-R;W-O9G0@5V]R9" M(#$R,#DP.5]W;W)D7S(T(#(R2G5N
M93(P,C$@0V%N9&5L(&5D:71S+F1O8W@ .$))300E       0\]^8W/R;$)MG
MPB5Y5N.2TSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              \@   =C          $
M 0             '8P   \@                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   \@     4F=H=&QO;F<   =C    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      6      $   "@    4@
M >   )G    5Y  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 4@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
MX;(OS;.H9#&Y-S0+K9(L?H ]W\I=%]5OJUU7ZQ6N]/)OQ\"AVVW(#WESG#W.
MIQ]S]KK-?TUK_91_PEGZ)4>C]#R.M=;?T['/IFVZVW)NY].H6.:7_P!?W,JH
M9_I[5TK<QO6^N8GU4Z,3B_5S!W-R:ZW%KKZJ3NR;;+ZMMOIY%OLJ_2?I?Z5?
M_.^Q)>DI^IW0,1K0^E^0X"#9=;;:XD?O>I8VG_MJFM1?]7N@_P#<*?)N\?\
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MW[)Z/CXACUH];(/C=9^DL_=_FO9C_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M/L(>1%\#Z5^P]=4> 8;H)/\ R4FV=K'\1E6(A1WO[9GE@R8!U#ZAN+H_)X7
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M2<].*V[*'Z 1G!H6M[)&?=<',02X?1BYR]/QFCP98[K0=CV"='"=GG\0Q<^
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MVV5<7CZ-!!-,I75JH2/@%C$%RB#1%MR76GHLHZ(CHB.B(Z(CHB.B(Z(JW/\
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M(>[6V.];*_$,L='P@*,+A\R1B"YF6-@O#"F%E$2!^87S]^LIAZD%A-A,%0&
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M&PC""E!,GU]5R(RK]S2 8$HGP1 4S*Y@#4?_ !<#,^9]RGVQ_CO[++=?NL6
M$AR1490L(K6)(8(WQ(J\*#XX,BGW9/[A\%['ZS/DFSCO[++Q6S[!AC06+R=A
M0BPX76FZ;*[I@?B*NQ)0<,@E^8^*1DX8,>0 _P ]$-&SD<6SG6E#G52;US8,
ME?Q";UVG\-NZ<>XU#493, F#.%%(?%!?MCX!8R!G\B<>/6",,7F"&?.??DMC
M:?8L-"Q]W?KJ#V<*0KU/MA*"] <27 SY)\04E\A_U%E/K$QZ]$G.FGYWI@Y3
M^-S>*UO&OU_$[%F\-C[<L1:QPW+U?#Y)S%37C]4JJE:;1L.0@B*1$_VP9&J9
M#J5E^*'O42Y(_3;X=N>:>/6^4U!@<=JEG84UJ^.]$I!EZH('[1(-*3(*[AAC
MF%*T,D9'R0B)1,ST8O663#WU04_GYFG+P]C4<I2N1FWV"="@+'7*:TVJ9N\%
M[PT8(G?(TH@P,17 @<Q\A>/60I-W+YDZ[$LJA5-KLFCX/-+%OI8=]N9D?Q/-
M5E$D,B8+; @RT,#X]!(73#ICU*"&8)R(EAE]M]&]]$Q6Q:;=P'^DHEMO'PPA
M _!R^L8-@U*>I7M)K6OS!6!+PPQGVB8CP-4G*7/;X8Z4=0>[Y>Q?A;ZB/&\X
M#DB<=I/.>JXEV,XD[@PQAVLSADL(X#1^1H#Q8W3C/*6"8LZETW9'5+QKSFO-
M0=9J'PAQO\]9+0)!]QFJ%G/G!?,7:5S5N/ O.&MV]*WG4\E9K-JL'[BAEL4V
MQ%G%;%K^662Z>PX7-TI1<H9>A+ZUQ)*@3642A,(JTL"7P.+4DY.$WS*[ @AQ
M_"8+D#4XVJD>7QHN?GZ"1DU"D)?EZ@B9M7(5T$]]ZJN!*N;G$15@*K Q\:!&
M0D4G,R?[[J%?;/>Y*-,Q,3,3'B8_$Q/]XG_*>MHCHB.B+ZU7\.M_R-/9/_T5
MY(_Z[.2NBXQ_Y'I[!=KNBRCHB.B(Z(CHB.B(Z(CHBJF?Q6\3/;EVI>)F)_QQ
MVJ//D8C\\?78\?N&8\SY_$^1\3^8GSXZA=G#$CF>S8K4%:M+#IOU5',OV^ \
M3$E$3/\ Q<1Y\Q$^"#P)Q^SS/F(CQ,?[8CR%<94F3W<:YG2A6C*7_P#KB1W$
MB[M*N"\"GQ/F)(BB(_=+ ]O,C$_^"<E(QXD0F?,S _C\S$=26,AD0*4K3&<Z
M-JXBK%SF[G-@SG"3G YA8S'>2&(EDD1>(\-/U*)(9\SY*9$_,3(^9F?/@?[Q
M$Q,"1F[ R+F748@$.94969PHU7?FQ<S(J7 D6<%8K7P<>\N;,S'M)LEI?[9B
M!DACU]HGQ^2]9.!@//\ X74_]W,T,Q@[%G$Y$SH6)1IL9LSS!YB<P")^VNDM
M60B&&3 ,A\>W[G"?K,3^9B1*)*(CS EY]O,1YF3&>LEF%'ZO*C-*E1\K>^ZZ
MR?3N^DQR;WF)Q7,'*.3RG"G:HN^7C>6XQ5_<.5OL'J1<Q'#.O6I)>5$VP=+(
M<A96DS2\ U3A0K8\F@L4OH <<&TF V$F[N.3+,432J?;G]E;ZX4X2XT[?]'J
M<+=MW&V$XZT6$T2RF+P;@R&W;O8JKE-;8N2-SO*J[!O&<L+AA'8S-H<;2,B7
MAL=BZJ(J#6>N\CF#R7&I<S.:DQKW$J_G6>RL4MAD )QE C&Z2XDC"+EI9K$R
MB2\$Q<*D@ADD1>ODF6D@V%?Q+ ^D?>.]E2EP>AXJBE< (T4D/HVFM-&N<1Y$
M%.<]_N=KU$0@WE#9(QF/>%BLI-O2K=,,N<TW\O3?,K=IPFN$H/FQ=J;!-")-
M3F EPK^0!M4VH6O'*)H^BOC.TE36N8U3)&/!57??9YIHN1\#CL3XLX>WF\9=
M441\7W=]HN4R0*6QCKE+[9GGPQP!]VY! Y<U;JI@D3-*RF_VI.;J4P[3J?9R
M4FN,[&(R5"Y5V'-9==Y?RDNO<NC2,_4W.6Z7S7<AWR^_K"#>;02M:F6)D1$J
MKOTY[RQ7JV?,,KU\V&.M(M+34*57[1FMB+$?%\T366^N-L_Z-JRA"8?8*&>%
M_O I=/@Y^_VY%3M5Y\Q^3S]&(SG(V>OM^\\H* 2IM6C4Q;UX\*X3_6$UU_6R
MT'BU@M;9MG8@B$H96@16II,M+YGOY5H.6 ^%D1W$U\/KNVX#6M6H4D[KB+.&
MR=ZS#!R%-=^C<3#:)I)S&'5M6X>D[7SPP*X^YRUAOBJ$_-=,=:C$>B:1?(7W
M57[;,8ZGE/=<0MZ:88S(+%0"'F;2JLPYX2/K%FY3F;"F0PWD9N)D(??:>E>:
M$]^1P9V#]6!U#K4(L.LL$L9:MR?LH$*.#5:&"4IPUV")1Y9(D<J\?%!S(KA8
M^ZXZLNE/M_":@X8_(E/LG8TO;9US#YO&9?!W#9F+2(++VW6CNTDXN#)5?&6'
MB*\</W5E99"Q$25CU17LQX$#)NG\ON29DRH/M@,UGV=OR==E*UK:\DHH<:;%
M1X?<+-Z(9\Y+K$M9%79ZK$'_ ! ==D^[VN2D1DAWSW7[+/K<NV<018O,/JC/
MJ,L;<H9)96'R;K5D1;C_ -S8?%IH+$4FN/2M[C\BX8$Z:YL=Y:IATWB/?JE+
M&U878CJG8W>XE+46(*OBLJ&LIK2F)6#+K5@W+OB5^0E)7E,8^O:" J0M55=9
M,>@Y<]]<$_6JW=/E"E:XJD;/VR]C6E8N'[DN()S[-J;;E+:58E"<K$XEIQ!"
M+8F'(X^M<'FV.&/*IS+YX4<>A2,,]F1.3FY-Q&.(1A;A69X^*P"U0O<4F2K+
MUQ#02H9)821-[Q_E%JVZGB[--M^(QU2&BB?0,W7>+[;Y7"JMC'6"38 V2(_(
M?J @MK K,$Y%RVE -[H7"*.6\<28ZY;=]NM>.OS P5FBF$XV\TF/ 66<0%\)
MBT7Y8UKHJ0M?H<*<MD!(<F_D_P ]5"-S/H")9]S11ZSNOYW67R.3JN? RH N
MIFBBB"X:(_&#"JMJK6)-$&,8<^Z980N$FI8HPWT^P5WN6_10_P"]CLGX6^H%
MHRL7R U''?<#@\8ZEQAW*8NNBSL.-L(7$U-3Y4KH&L'(W&MEX%1E-L+69UB"
M3=UVZM86:ERJB)N1PP*I2<Y<)<S]L_+NW<"]P6H'K'(VKIFTI2P39QFS8@@-
M^'W+3<YCA51VC3]CI+)U#+U9M WQ]J\:N1JVTIYD,X>H>M,&(& &0%)AA+L"
M"''\)HE/]O4FE#)]X\2P"(3D?6?VK )&%A/F)\Q!$4P<1 Q!$=C,N'D2YIE)
MG$YXDNC-,"N7,ER3GR)&"VQ,CR'GW/W&8GR*@&9*2'U6OT]H@? Q[% ^_P"V
M!\0,2.AH!)Y/*1R;KH^LL&;2+D8"@\K2;.D\L&!604R'X(@\RL8]1(",8\S,
MS,Q[0!E,1[>8\>/'YF?!# )8\C(T#/*>LC*CM.DSF11ASQY$2(<M3F/,?D'Q
M\K1'XXB3]6K;,24#!S$0YGEA3[1XF!A?[B*8\3$GHS'NSF9.,W:1#AG8":'4
MLT\'RH]6<9.7K)7=_P"%(*#X&[MRCV\3S!HDQ[213,?R5;_/L0C,^9_VP,#_
M +!B(CK0HV4NW0;DL15YA\?F?H.2I9?6O_Y63O\ ?_:2WS_YA'576&@Y#V7+
MT )A@ #)F9" B,3)$13$"(Q$3,S,S$1$1,S,^(B>BJESI6JAJ.(76<H/U?("
M#\HZ02Z5M_'QT%-^&2!=6"B'+^0X.W\IKF1@/3G$7DP(,A0S=NF+?$TV*CO.
M:VEM[!F2)4P,D<G(4?0"CUC]X0I:X!G]ICU'^\_ZLS,Q,K.(M(@'EH1.N'H4
M2FXJXFY$[B.4],X5XGUBYM_(W(&:HZYJ^%QH.!KK%MPK*Y99(&BG0H!)V[N0
M<*:]-*F,LD%>6G&VYX2?)M*AFY"KDE0E@77T3.P;L+XY[&.#,=P/Q_-?+[-D
MRJ;+W#\P)2A5_D/=*ZA%N,K7A0# TO4_6<=KV-84I>Q;\TQ4-LA(VDSO> 7$
MDDDGH,A+WQY!=?\ A ]2;A<M&-IT\;F\39O@QEL*[<A6PYB/Z9<KO%0^E2RA
M?SL6N0,7P0V0$Y")JGQZ*&G//>3P#PXS[;?^9N(='OU0AS9W?DK3,!D5(MN@
M9=<Q^3S5;,S9B8#U0RI+5&)Q(1,RN4][WUE'>@)Y [PF],64$K?U:NP$V*7?
M[P.$K]AYS7%X[M7O QP04FN?C1Z)CXX-<%(@N&* ADP(9F;J_P">ZUY3D>Q4
MCN/.Y#ASEVE7RG&?)VH;YC+,% 6=8S^/S2U!  !2P:S8=6,EL#Q#ZX>T$!%$
MPQ9%5EFJ.;U<[Y :)W <NX,%(18"53[G'J<E"_,$/QL.?/E1D0S*I@9@?7QX
MB()7W .&3MUF,,U@GA\=?D?V65%'CV 7,%1D0BLIE1A"_P B(MGTGQ,R,QXD
M??HE*U:K9:5-</1UAV-(PN2!*FIO*-9%,Q6M.K>X^XQ)$KW5[%\(A+%Q'B8@
M8B"_UY;WVP^Z.].3U]C]JC%:[_"K5(@8*,C[K-HM,+#H=)3/R%'MZ%/]Y.0]
M2.0A4@<3,QXE7[>X.V9.FVQZFE,5DCQEJ@B7D+$C(Q/RP7[XA7JV2,B-+O$1
M,@35Q'XGP<2$3U<-G^4H:==20!K/&662R*W'FFH./^]AOB&,$6,:5H8 F)@9
M O:!B)B/Q/DICQYF8&9ZF.,]]-Z).O?#X<MA0&JWZ=9UM8^J,-2@?)1,?;B7
MCS"X,2\1!P<C/K+9843Y\%$QYGJI7MD:[J*\EFQC,.DHG]+J+GW (]:E=BYD
MF>2"!B&1'C\^1\1'B9A?@?6.B%\NE*:X"75P"R]YHHB4^]6C G$P<QCZ[);[
M"<LF(8 K5,Q^8D5EX\^OD9B(Z/Z=4H<:XGV8&6#%A(8S2=LZEK;)^9N'J0R/
MDB8^$HCV]?)'Z3(?'/Y'V^-L1X\3[ 71'U$Z9Y#-YXTYIJLVW%XFVJ:*OM@9
M/S&E#[ +)S"B8GQ!NB#']L%^WW*%3'XF>IOWIJZJ'\@(JJ^!5'U&/]'\0I@S
MZ^?$>620L.0B1^,B8Q8#'B?]:>J_WU[538TEOND#DK]G.K9:QKE6'HCY#QX0
M2LB,A)%!BOPEMI:H'Y!-)R,+G^TQ[=,U*TET/L:'IW6@?F[U^#MVV?.XH !*
MV(.-(@(B(04P8A,+\>L1+(@YB"B/W>'))XLTZT$PVYSZ)0X'>\SKMJ+=*W8
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M$@/\>(CU'U  .1GR/F1,!B)CP)#,P=S5FF<VP?%F?D2,04(T?G.M6:3O.N=
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ML]$.\I[YCJQVA-@Y,9@)DEF:P.9 _$+D2F8AL3Y@0\E*XF1+T\R0^>B2#8:
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M^7I*DPM#D[2U+L,\I5Y&1B8(5G$D/XF1]&DPX@&1[@/YB1\Q_:.J 7>0U8#
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M.!CW<!B/JIBX!JYF0DV#!"+#(('R7XGWAO=4R:6SE*J]D^\#,2)%ZR:B7!0
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M78ZIKN$P]5[%/P[Z"1Q$I>AF*MC-EVA'EU.);#2?5G)]%STME9/XZ;J"53B
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M?]LS$SY\^9ZT S\\WP"Q$\GJWR<I=E49^J7AON/J_P#U",^V6 K!]Q._16(
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MP7I+5&PY4#(DI;,++_87K'DXCHFS^?3N,%^^2_9\DA)B/H,G[I8N?,B2Y]U
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MOR%S*[9NN[6F;)E]E?D(]61;G)"Y59 04IH4J0!0IUX15IX^L*0.<F>#S(Y
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M%.KD;=6;U9LN;F4T,@&+Q\_$?EK*&2L7T2P*=8?B-TB6#E4 DAOQS(QR&I7
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M/VE3O81^+W_='Y3$1,@<?B/6"+TDR*!B?:8(HB(]9CHKO;KTS'GU%D'/C]Q
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MD 5!>I01%(S,]5''QCO7E.DTF75GY,Q2T!A<^QP@2*05,Q*5SY\0)*F#-A3
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M(&FQ\MQ>H_?JY#H*\3%:E7V6LM$S:+H??UE3^%N L=#7G@?C^%7'[+L3/(_
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M1(B6DG;&6K$;/5RX.#,@(!:#O,1*P/TDH_,2HV'$ J/;R4K _!21>W$+%UP
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MI8?QD5M4@N'FD_D8!$+"@XSU[_SMBKY(LL@SL*\]T,J*B?K?\!XJA9MT=:Y
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M\<:;\]>N7(_<]JB+=-L%ZV</Q]IFT;,])0]BP:AF1=BC8,0<>!]A@YB)ZA<
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MK)L^:T3/*VPQI .6,Q633>9ZRE63F697810EF;> ])2SHSLSA\+>37MT\O\
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MQQVL<9,<<<<<1,4=I%%$8HHR3%%$28HB25:V^@%C-YX-^G'@^+>X71-IX;Y
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M7B$#*WLX+45,I1"1=J+S]:V)N]ZMKN9FPMK:QB)J]E'%![@[JL/X3N)C@;O
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MN*+/DA.?0I<[']8_ZG&[8:IC@[E]@P%&JO[:':MB@PCLI8>:/MTWK2C;-4X
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MQF&ICBDH2%0*.,PN.HXVA64'O42I551-4L6&5B(*6CWG(%G R#X3&#B0G(B
M-NN>W*PKYWJN.Q6/8JYCI?CCR*ODH.J7,A1R-SY<:SY7H6Y^#95K+NXLA@Z;
M!M-L598#5F5+SQ<RKSE-Q,!Z4?(!R+"DFWHLG%[.6OX+,8S&X'5+>7V%].;N
MU[%AU9S/8&BC[@E4]-L7;/Z?JMNVRQZY+.T:,[$8 JDC*4$181:@9B&$GPD&
MK,A@[2=]2:(1B[>SEF>?IBDQ<0<L,I!OW;'$/]8_0RA0S!L:1S,>!"9&2%T
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MTKD#0JE#>Z')G 7$FK9R,>S*Y?!Y/5:VLY*]R7<LUPUNUB<\0.O91..$;5?
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MU>P>M[]8V;"Z#:QMFD8V19G<;2P65NYC+,R0L:6P+53LC+(9"[O8?9<KG$7
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MEBO9W:LA:S&V[GF<EN.VYFXP#MY7+YZ[9R]V]9>9>_SY'+V[N29'RB),<ID
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M>QF%R=NQ6A>9V#("I2'$1N6YZ!B:M1?K+@"FB%I&)9^&M.9(IB/)F(K3I)@
MU!G3TDIKIMSO%5_?K6=SX\8</;]I>OY=BK&$KLX"U7[6Q]O][R)L\6G\N;#3
M.?\ 4?KM%69UE-N8CUOZ30@#$KX27D+QT#]4?ZC/!G@:S:\^'OIE<SXN\2P'
M]UB>*1F[7FZW6U!:".+]0\#L#9G]XL[UQ"%OV1PCTKX1?P#]%/$WBR,FPXSX
M\O(\.\#B=K0<.@%XL;>\6?\ N@)A'%;6&T (,5WN<8B'FA"I<KD,/A\ED)"
M*A0NO%[5^A2Y2#^&4#8\+(F--(@'DI(IGSY&2#KUT9D3>I8T!D&($Y>E<"_G
M/>]Z+Z>W\.O^?HU=D_\ T5Y(_P"NSDKKHN,?^1Z>P7:[HLHZ(CHB.B(Z(CHB
M.B(Z(JEG\6N,GVU=IL0(E_\ 7IMLS)Q!0$1QU?F3@)_:11XF!@H_,SX&)*?'
M68Z>_+7VP6X*GD?A1'_A^N?6Y_MTY)X+R%YSMC[=>3,3REJJV/EMF>)^;:M9
M>23209S",=@>4L+DV6)KQZ5+.[)%I+^:/<"" QH&-6P?+H3]TC$WS??9NKZ*
MQ?N96\<X]QI&2]?V1",%G*Z93%IU6S5QS*.68*C(&@NR)KGW'W42I@7@31&+
M(2>@["GQ/UP6/;UT^55N_B$^&[?ZKVP]T6$QWI@<CA]F[>]UM^#>5+9<-E;N
M[:<FV22(C1EL5=V&,>7LNO/V+EHJKEL,,:<NW,Z#'*M0&W9R?OV[G&795XL0
MA=NP"<C897I.MH*[8AA"U8MA*98L1"Y98?H $FK]JQ;/406P"+V'F-:2E(L^
M,FS<!CR$BNM';GS*<)0\:83,#1.YN>]*QN>2I3U8_$\?T:JJ]EWW) 96=ISU
MX&$(5C2RMC4/A17?6LLI5.I/0O(@%@[/,"6I:5:+/[CD'%:_;Y"V"=TURDPF
M:UPEQO29]W8J,9M64Y WRJ=9S/)U[-6UMF'Q[G-9[>H,QCTB#A%<,)<V9I-
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M+2S)AB X382,-O (O1WT/X?=O#?#?%7U;XQ90FY>%[C;W#@<%I+^ZXY>X+.
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MBL4.1;56PH;>,S7+]RZS$<4:T@K"X44HS(6]Y^S:LR50UE?S 8.KRZP@S=\
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MD&"+B)LK(7J,^4 16EC907>[VD1\T7]S#>B8B8RN6?(]\L5HS424,9FK5;&
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M.U>E6R6*V;CC8Y][.%<\%'+357L48.33D<?<$C%R?8D6JMH+!56*L*]%RO\
MJ];]]=?NN*A_W,=OV![G.!.6.S[D1U+"-WG#$G0]XN(!\ZER9@S3E^--[6E0
MB]:49U6/K9:X$J.SKUS+4YE8V3,59:>^A^1\H"Q!J1W.8Z]E08V?4-SXBWO<
M^-.4-5;I/*'&&Q9#4MWU;(M*WD<3LF"O+7>!0_ VM;J?A=O"YY+23EL-8IY#
M%/)+U/+)!#--F?I0D9"9K6LA+N"#,4P(QD)_&<EH46:1#?0JO;NE8"+(+$FP
MNHB'>K+!#]NZP8$;06;C>$^&+$8@YF3E&#$@2!E721IAK+!5_9UO<)CW,#(%
M=N,JX^E64_)2E#Q>238J:N+H%9*%LOW#8MGP_"ZPBI7LY%M>55RF#9'"CDF@
MEE-F8C7!E)['/7>CR<WBC+8?)<I\7XS8>.M#Y&UIVRZ_JHZ+NV=V? :.&*R6
M:&MF,UE\MKN2Q>:QM9->XW-YS,L,G6OL_AM52]4H5H8<J'!WD-0S%\LW4(D2
M)&K]/ME12K^I%E.R=_<EL&([!,37Q_$^L8#'X[8<WKV)R>+TW+[O[R&53Q^G
M)IQ^0?J.)&:M)5EU=T;!G8O7$Y4L73I ,+ NU)EI2+UF'T$YAL5(/-/S9R>9
MYZ<O90$/$*;65:KVHL5#=9E->$C]]52ITJ+]7IJ(9BTT6*<MR;-JEZ%^&$WV
M^&-(S #3S()S('(8?&][_*=_C3?MDXLQ?(>[Z'NNZ\>[+7PV-TG0\WHNW9C5
M-G_F7<<G0;G;RLEKS*N1HXVAH6)W"G:FC<0Y]O8<0EEH1E?O80P)F-,'T#YT
MI)@LQ.2 SB;Z95U/49S!06<WG)Y;0M7U:[DLQL!:7L6YYC%9#8<[F-C?1K[M
M.O-R>-KLSUJ\2Z%O)X6UE+=9$!#[N2L66,)[?F$3G2>5#G4%M6#D/5Q68DB3
MMZ?B21;;F*M*"_8H+J,$H5<=CF$6)KV#K?;4;N3QEI5\X&Q8KN.%4,@F2?7;
M\%-('"I." #5L)5E)P!,88-1Q)F7SU]LF:7NI+]A';76[J>[WC'C3-8NU<XX
MU/(-Y<YPILAI!7XPX[R5&UDL#:D0A@LW_9G:WQW1"%D2IVP[IJFO3:X$/.C4
ME.88XR;&9Q>39B( )YLY]1TG@U,5]*+CH+L:KFE95<.N9OD;=8O(KG2K5RBE
M=Q%;&-)Q+GU#&8G%5%"5,F5HK+8H*[*8I(=KDG=JSD@ [X6*RPMFZT^W8I"U
M@KE5HV,4465I2E>-LTD(D2%A.BZU3'@[[=9-[W\K7[$AS;BBMBI-*R^M760*
M6QKE."[?.PLW&JO2LV+EJ4,L.B9FO%FHL1L6EM!O%$UW*=5>W<295&,J3\V,
MS6H9JIG=D9C<!B\AE<#E:-^XU$9"RJP#5U*MJK\288)P+Z%*OY7\1$5,K^(+
MTC-V*/:'S$NH889&2YAXIR1V_*DAD,S6T7>M2%K(+TE&:HX3<FT'0(*?&!?$
M,]5P 0YZC/M(&I;":W!_N%9/-C3KF=.@5>/'XBE=5L;,P2&5<3CZMR_1> LL
MVVY+)U<;CJ]6K AX!^3N!%G(7#2FL@Y<+3ER!G(F[,U9G*A.,V<O.8F69=.=
M3++/KZ_*4*]A!]K/V\@ZZ>2V$?ENVAMM+(?.IA>ZWY)Q-98BS7>ZG=786UIU
MXK^'RL (),#$@]YL7%=:/-R^23MC]OYYS=2(T/8^(JG;%SSK&S\)9K:>X3=-
MSXOR7"G*0[!^FX+CS1M>RD1R.#Z(S%[)7]JKT<]BT0RO;K,M,K6195#&VPN5
MG!P<8"@:5)X3'-LU)^83D'><^W4;99&I<5\RX7C[:>XCBJUEMFXHPN*S&D<L
M[1J%BR[+<;XC>,;9UW,ZYR3KU%S<D.H[)CKKL6[-MKLU>Z%JN;&(-(M6F6,V
M. '/.<WK*561P[$,098OJ.U.B9C,9"N  %10$A7V_P!J]2:BX%-I8M5\B2A7
M^D*M--0F##8VL:@_<82N<EL:, \BQG.6KOF7JX6EI[*\C:!M^I6R; :W[2MF
M7XK)5<>N_;@5KJV;E,CJ5'O]B565%RL^\1KK5G398(,H)+S,M'H#1FG,59^K
M*$BCBF;;YJU[](#-\'\?[)VMZ/M&KXWC+8.9];Y%V_CVE@<]M5O6Z7*:*N.)
M][[_ 'FYLV?H-W?7<KD6T:-B\5>AG<I-'%L1,8\.O)7@+_ZL_JB^J?B.V:UN
MW@G@=R\+<,B(\W]O>+<V%A;^0S$,0M;IQP1$_N:\Q #RN5Z'\8?_ $[] O '
M!;,&SM_%?%KUXAOQ!\OZ]WLA;6MB(H9&(>2\\)BH0]WA)<LUDW:DGCUO,$>K
M+#8:/QR=A:[,,!EBDYJH=8,HB#8?PB9$!C!_!YF9]<<]M-IUYMV7G%-5?D0%
M#26J#'R9E[&DS,I-L3#%.-@,D8,F@H%#5FNTQCR33FICO>?XQ3EQ[!H.+XC^
M-8-%$RPR&LD0F(9"/<5NK(#YF*03ZY'Y-C5$T61)38_GI[24?49"GD,U<S&S
MV:H:UI]&Q>S+TV9M(*DN9(E^S!&U89?*RI=*"@)>4JJ*0GP01_&\0\>X9X7X
M'Q7Q%QF\"Z\+X/<K>_WVVBF196,)(@LP_P"^VMK0P6%WL@#%;6]I964 ,4<(
M7]/@W";]Q[BO#^"\,L8KQ?\ B5ZLKI=;&&7FM+6)O-$2PAL[.'S6MK:$B&SL
MH(XXB(8"0PR>0-4T' \T=XG- 3@^-M#UW/\ (69IJ1X0W7<9;$<#IV*)P2MN
M0V_8XPNF8&G6F;+KUI11693<V.O,G]._ >)^+>-^*_KSXIL(K/B?C&\V_#_"
MUUMGC'#O#EVCL[(VEVBCF(+3^VL.&W>T$$$45A<+S; QP<0)/WKZU\6N/ASA
M?AWZ0>'K:&.X>&;"ROOB"WL?V_WO'KQ#':&&W D8H!>+6^VT)BB$-K?+*R_;
M%<Q"*&W,/*^Y\_\ +O)/,W(ES[_?N7=[SG(>XW4-8RJG,9VPQU'!X\HF9C!Z
MEB2IZO@T3*QK8_'C*Q-1"/7K"(N1.HSHQ=Y,.3T:;5'GH2 R Z_=\]4C:ZS(
M0@)B?,1 $,E[C(_),B7B##YX FK:M0JF0CQ _P#A= &%)N]9X^LC@ SNTU"7
MI/"CBDWQ:F)? &15XK^%"&8X![L_)>T_XO:)$Q^[R$QI=SR$R7^MXB8]2&2@
MER'Y]H*(V-TD\VESQFN<51-Y5ZG4MR]!15;_ *N%].5^I;WRD )<^AW'\@8N
MXM8@N4LJ6DQ6]XDAAIOI%587]3R;!:7J,>H]<XP\V'.0/7$TE3$,ND(8#6>.
M-&P&NO1<PZMS/ZQL.#V[5\C=P6SZCG,3L^!S^.>ZK<PV=P>0J97%9"LQ,2=5
ME*W620M5 ,@BB(DR+S&@0V R>7\R+\JFI6JKZ0_8EWJXWO9[==6[B\%*,?O^
M%LAQGW':@D"0>$Y-QM"J\L\FO(K:K7.1<2VKM>#ORN %UVY1EQV*9+C?IOJO
M\Y!$JY8.,'=SSQ?JN@."SR]9VK"<DXB&6\="7X7=J2PF+C\!8#Y+%R*U=;)M
M7<,]5:ZI2Q!EBNA@A)>\3$IOD!,UYUI)*J$WU;/I-:/]0[0CWWCP,-K?=EHN
M G(<5;Z<U4X+F#4JWC(JXRY"L)"1LXZS\_VN!V%T%>UZX]%U3W8NUDZT&!+X
MYTWK^5J&)M0:A?/5V3!;CQ=M^YZ3M6MYWCK<-8RF3U;?M5O Q&3PF1Q&1@K6
M S-9H-"V$6U5F)'XSJ7$+K6T&:V(>6*'5B"X+$ .Y:I.-<Y&2ZN)'!P:O5QC
M082QR#I.#F/GDR$55Z_S'$BH!/R1M7$HD \CZRP!4KY ):/S'B/61ZM1(E]9
ME@6(I(4-'.(0$N:-_#%\C/#"J<W3LP[&Y2+&/S-'&9N*&5I+S<92W5*EB"Q5
MAV76MU=L#Z96BLL9969 NS5LG6+R92GJ3$@\P&.A_P#VF+#I)YH>\YC?0X9\
M\+6D1L&=H:I6$,6C)7#5CZ=:L=B<?"@=8%-9MA]>Q9A"8?" (@<V4!!3(E'5
M;/,O-GP <!SW&N"/\UE18--M#[:VQV.MVZ[0<.&==:C#6$$31A+[%5JW6F!9
MJBZ'8\'C*VO7,6()7]29@9AI!@Y)8^P!9B>15],][DO=LM7%TG5J6$<V,E6Q
MF///UGV:=M)9&]7G(V;6)(5UV"!T[*%G2$&VQM(;ZL;!P"S.P)>1)<CF"\R,
M ?1ZJ#'F6PUZXT]W3;V<G;52782QTTEW)%M@&& UK-T!CPN8*&0]WQ"3!)HM
M<*_,E"P@X$@MC6>((9CAU9ACA*!V I0YN[DC'N[OT?%SVZ[?DM3I\>5-@V39
ML=9V0,_CM;5E,EE<7E=IS%''8)*</A+#CA^2(45L?3LU5%]W:-M*O,)) S02
M<WG('F"'9@"0PQJ75E7H?=7HOI8]J'_ LX"XVXOV=%>AR7MN:K<Q\VVOCJ,;
M&_Y7&K#'Z]-V$LL.I:7@ETL!Z0SXFY!.9N(&!N>D:Y;UHV9YKC$?,7PH.6><
MZS7=/ 5W9O1]-?KU!]T:5:WIENNL8&$V<+D[ RY;HA<E%Y%E;?G&6*\2V0@I
MF9D0^Y],BIO=4A=AVW$X1YXI=N_F;]*RVUDG8QE9U*A;58BTZB%FO,)MN3*@
M@(K3\*1F:S/<XGPGG0^GL=<,IAT2X9=J[1A49G!V[]RO^H/JW))-:7KR5.L3
M78ZP;3$5&MME$0R1;%FJ'R)$9,I4:AR^<>GW1-3SU:#&T>-\6ZVROE,/CKV?
MR))L$BQC:&9N*-#9FJ0J-_Q4 %D?$,FH4_GU<:ROXWOT15@?XB7AAO(G%_%?
M<WK-H;N5X1V=.C;]DJ"8%L\;\IMI)P^:? K2LXQ6[4_MW^9%/OM),-2F?UHD
M5"^]X:K<!FV?QLJK2K(9C(E@,&!Y++6%C& P6MTL=;RER!G+'88K$5*%*Q%B
MY=L/;><Z&.,/DAC9<H2-66)FW,$!C(N0#F6.#FNG3J,^F#X4#/E1E,WM6V7B
M[CCNEXLCG_3MAVWB'7=GRD<O:]1L)KYV]KR,+:R=&F>1HVZE$[HVRQH7!J9*
MDJ[CW,KJL@#A,)3#.4B])\V+B0+2D!.%S#^VIIA7VWBDMN.Z:SL&4,..Z&3X
MNXNUG/V$\4Z5>O5PV31=5Q]^S=TRO?W6J!7]BV"G3!!V\[#*=PW!-99P"AL,
M$S!:HD^9,IC,,X>0SH0$B\R:G/[922<R^6N[;9R6S/M-RVQY^0#,V+%_(HM_
M=E630=8"W=>YK0OS7%S9@IBRQLKB8ELF=,V/=P3.@')W!#/BTR5H!I"BZ:;T
M[%\??3<XAUW+<85MUVC8<[@<OJFT%:^.WQ/LZMMS^^%MU/$6#]LE8LX$<CK3
MCL6A5CU9%AF#V.4*_)7TL?BG]2WUVXQ$/-_IMTX3P.SC,Q##".'W>. 2DT7
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M1BW>M;V;.T>"],F,H5;*_?[WE\:HH.Y<^9(T=542OQ8K8JSY.1*3AF8M1+(
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MR3$JTG0X]Z9\TQNP'D*ETJ[75VM!XH$T7E63B5R/[ON5F)L$52$H8P1@P\
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M$3(GIAA^*KI9DTW]@:%G)6&7; >DL8^Q+"< 1$5:ON$5P551"X]*ZQBNM8E
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MI[!=KNBRCHB.B(Z(CHB.B(Z(CHBJJ_Q5^2;CNW+M5--'$W"9SCM$266QE;*
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M7V"G,W#8NY131IL/]-I4:N+I17IHI8VAC:BV+KTL)K^*Q^/QF"Q[(0BC7J5
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M5%;E05R"IUR&[_&'3U5;U7+#GWZ]G:7PM5N83MUU6>7-NQEVTI.9)Z=X_?\
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M[XY;C]*[V\40-I'PRTMKS<X"+.SAAL["\"_W:_V=E#!=[<<2@LX"?2=W\?\
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M<N8YZBCL2WJ= # 3T(S9G=\,<<C1-IKC6F)A$$:!D5E[K(0<<B;?5292=<A
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MLK4]6YS[DJF)3Z 0C :ZW$-UR%S)?FN6).OX$?"Y+R4@#F.Q.6KX=74,0/\
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M[Z)@K4$HJY568#1M3U[7HHQ6,D"C]((/B%8>L+@@.$$T.$L)Z\OM1G-$4/\
MVBLY/[XZZ4RCW>_A/^[S*WBRN:[BNVO-Y=EC[E^4S,\G92_9:9 ;&/NW=%=<
M8TI^6)83YDR.&G$E$"+RF4R^>+/TFU?5Y-?/HTI3Y<MY+*7_  I'=ZH%K#N*
M[;H6F9A219R>*X#V.1CU_D25P8Q,#!?&4^AD,^8 8)Y1J="3K]]<9.74\YZ/
MU;?*>DEY?_BI/=Y'D@[B>VQ9E[3Y">3(]"F9B/'C0Q48Q'@B#X%B1Q$P(Q'3
MRY:5?!LB,@=6P5\^8Q.6K"APD5[H_A3N[V(*([BNV\(_$K@3Y+]1*?(L*?\
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MR3IO_FEK7_V\%BY_S_'_ -B_V_,_C^W1$3I.F3_?4=8G^\__ )AQ7]Y_O/\
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M\=[#V9]N.1T75-KV#>-:U,N*=4KX'!;5M@XP-HS&*QU3'UZ])VQ!A<.O-H0
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E5,14P6!QOWV2L6\A<^RQ=&K6^ZO6K-M_Q_+8>UQ&9$2UZ(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g120909g44i66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g44i66.jpg
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M$.;A%3]IX;ML,0_AL$E28MTW=E%F^W_9]KVW;V_[>TL>$\T'REXZ6E&KL8A
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M!IR(S.HN4.X!7;,J.=!\"[[42Y#$6Y'G3C%P/Q<6:+,S)5LHCD@1=X+47YH
M_FI?UK?HUJY]&34_X?6/_LT?["7\W?6[TR_ -8H^X(QEY%F+%06RC;N;Q5P
M9C%B0XRJ.:AUM0YCF[%4P'$E5&B+;!OF2%CGV2=W3%LJD^: /YJ7]:WZ-/HR
MJO\ P_L__9X_V$K+A^HBQYU<9N5+!GJ9UK.^M VJG:BKF:(RVQBTKGR:.*>&
M"47CG@'@/L?OEEE?)WX1X5:UL4>QO=7"_JC,B-[@;Q"9HGCZ*I@WZS8M^;4N
M(]H1VVY?M[[K</U%/&B+BUQ=H11:=DP7K$92$4F4'(]D^N.%U"+,S#0I=%T7
M8;N[N\G/TC=0\OLM;U<@5V=2B+;%TKO=%N7XEAOVZ0UOGZACNMQ%^+M.><Y=
M:D>JN[G:+^&YOY#'+<M715:7)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B+F)Y6^4?N;Y>&OUUJXH<=_#%Q&\J<E\HRZB\)O!KHKX@H_P!QU7VL3+(:
MS+77O@P3Y91C[[8U<>CN^[2WE'@_2=5474G>[G_B7*^8SKK&KO*N2*41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M15DXZ>Z3E-YS9_U3Z?HHOVA]S_%U9NB@E$2B*D&Q>7KG6VW)/#"\)6<0R/JY
MQUO*4LW#9@3G:VM!NR1,4O)W/>@1<E+-RK5GE'"[=B-$1CMMD%YPU$MGH-H4
M=NIGW;^G_#M^+\K+R(9S',E1VDY',(A%04(W'K>,39O-X_,+R\&.=X0P-*MB
MHMFHH?D?="(L^>&P#HD3# FP%B!O-3#I<'>4MX03;M[=>S[?E?\ R_I=7VHH
M*@?(#CIM39V\VLWCQ7%E%K:T6A-L&IX(#532?PW?4=D7:%'L+E,G!'73[9T/
M>QMW'/"HD\SC[A[L:,212,Q!AF46?V_\_&W^#?:_H7C/..>YF(6+2B%Y1IA/
M8LL31$1F1*@!40SAC+964NC,4DXO4L=@ Y8TOB<)R(\I$W@.(&2$7CD=EPR:
M..QG+(F[;OOU_O[;[OMU>[M]]EYW5ENZOTZM^7?8M\'MV.J;O,6F:BC7%U?<
MFM_",6RBV":V;>RW?V1S5334R3MC?/##*]\;4[+=S[/N1_+1K"/JC/ SK/WF
M!_.?"KB5JR%RL2B+;]TV?)WY_P#R9X\^L605BGCWX#^(_P #P'YS8E=,OX,'
MPQY+WN.]#ZO7M5R57Z%DHBVQ=*[W1;E^)8;]ND-;Y^H8[K<1?B[3GG.76I'J
MKNYVB_AN;^0QRW+5T56ER41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
MYB>5OE'[F^7AK]=:N*''?PQ<1O*G)?*,NHO";P:Z*^(*/]QU7VL3+(:S+77O
M@P3Y91C[[8U<>CN^[2WE'@_2=5474G>[G_B7*^8SKK&KO*N2*41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(M<>V$I0OS2B:5MJ
M[8AT95B^L6.,9&ZTW9+())7"FW([+U6(N7067--80DFXSUWC%IJ4GT'<O+0G
M81ELZE96//, ,4*+?OVO:^WV_%]OJZEL<HH)1$HB415DXZ>Z3E-YS9_U3Z?H
MHOVA]S_%U9NB@E$58>8W+;57!OCU-N3&ZDI4OKB .8JT.I0L.U.R/)68RT)"
MQ'@(MX3#MW&.)@^PR=W4((719V77PLKFGBCG/XS&V,M=BH5>C:>9I'!Y2< V
MBC.4N8F$G;V(/ML+[OLW4W6TI=N0T*TEJQS]%&X,7(/,7LS$!V9W;?V1-OU]
M3;NM%5OPH#I*VDF4RM!-^VF&0[Q1E*[:-A%I)D)MGBI89D=ML#QI<=VF..?@
M5W5VW?XXY=EWUK7JZOG>Y_\ C4/PF3] J%\U^)__ "OZD?TB_P"7/X3]TDWK
M9JR>0+?;MFQQ"8LFCG1D'7;,\8TYR>1S%J@KL#-)OB =YYN@EDL,+"G.>2['
ML%<KY7?.]S_\:A^$R?H$^:[$_P#Y7]2/Z13MEUA=$\^^(/+64\.3.ZX1)N/Z
MN@K2*020.CKTRTMM;9*X\3:-DH]*S+M:SAA#),S,VNJQ[-LZ;H?\4F\6Q2N?
M0>CRJ:\TW2S]7'WZ>1',[U9!&Y7D[$Q%J5NFAGB:-^24X9(]Q+8P8FV<6=6+
MQ1U1)\[K4U_!7;^.O42PG)<K224[,796;HPET,\$C2#TD72Q2<I#S1FX/N).
MRU=_C;<I?SB]V_6=,O\ >*VF^8;1?V)Z=_$]#] M,?GA:\^S/5'X]R?ZRGXV
MW*7\XO=OUG3+_>*?,-HO[$]._B>A^@3YX6O/LSU1^/<G^LJ?6VW-J;2Z?W4$
MQV5L><3_ !!LN+]PV,QE!J1V%7);L3L0N.L6>.[,[O;,&5G5V_9W7LT;]KWW
M8I][K=ZHS!83"XS /B,3CL6]DLJUAZ%.O4Z=HI,/T72]!&'2='TDG)S;\O.?
M+MS/O=!ZBSV>X.<8FS>:RF7:K#H1ZS9*_9N]CO-J@>FZ'LB63HNEZ*+I.3;G
MZ,.;?D';1K6H2U'2B+;]TV?)WY__ "9X\^L605BGCWX#^(_P/ ?G-B5TR_@P
M?#'DO>X[T/J]>U7)5?H62B+;%TKO=%N7XEAOVZ0UOGZACNMQ%^+M.><Y=:D>
MJN[G:+^&YOY#'+<M715:7)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M+F)Y6^4?N;Y>&OUUJXH<=_#%Q&\J<E\HRZB\)O!KHKX@H_W'5?:Q,LAK,M=>
M^#!/EE&/OMC5QZ.[[M+>4>#])U51=2=[N?\ B7*^8SKK&KO*N2*41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(M:.U1+R>\DX&I
M*A<.:#A&PH&L"3'F,7II\AK_ &EXS EW;XGP2D$E#DKR %91Y&A7(V.QU5)K
M=LC)68@JZ.OR^NIF?;M]KVO_ -NMOO+9=1?*41*(E$59..GNDY3><V?]4^GZ
M*+]H?<_Q=6;HH)1%HN_"1_@>>4'QWH/]H35]7;H?OEH>\N>9SJW]4=Q+?OJW
MG,2^7Q6>UB=*(NG3H0>1'U>_TW3]]:NYZ\<1X1="^]U1Z$)4'7G@OUQ[[3'I
M^LK.5L<M-4HBM]KKX/\ ZC/^AXI>NQ>M6?5/]R],^^S/RF$60,9X'>-/W'A_
M^=+K3S6EJU?2B+;]TV?)WY__ "9X\^L605BGCWX#^(_P/ ?G-B5TR_@P?#'D
MO>X[T/J]>U7)5?H62B+;%TKO=%N7XEAOVZ0UOGZACNMQ%^+M.><Y=:D>JN[G
M:+^&YOY#'+<M715:7)1$HB41*(E$2B+S#)L-'!CLU(2XP$&888JORQE^U%C&
M2>:F"."CM^^50:ML,UE$TL<UE<,<E%,,+7OEEC:Y%@*&\=*ND^U:[@U<Y2N!
M3E-E$-@1-9.\854023D=LTRV6-P2BKIJE@7[OB_)1RWPQ<7R63MD39_:^U]_
MVEGPDV&/-KO 9<899XY)X9.Q3]J1;6S6:MGR.%UV:JR5LE63QH\3Q[_NYM73
M=QC:Z2Z>>1%_(](0$6%N3DG.!XX%9W1Q=F#Q-D(%M<G*Z;5O9R0(+MVB%W#E
M9%NC95;&ZJZJ:*??**8XW(L"MO72&39P]QW'JN[-H!#2IT[ML*(W:MHO(TP2
MT>DB[BQ?LD0)U*41E4,84SQ'DTY$"S9.%\2X^[@H[/[3J2F)!@30R<C7K0@V
MP=/F.;ADY1=(8/1;UP-),\E4,U$\70\BT=,'S>^5E6CULX:KX)KHJ)XE!?KH
MB41*(E$2B)1%S$\K?*/W-\O#7ZZU<4.._ABXC>5.2^49=1>$W@UT5\04?[CJ
MOM8F60UF6NO?!@GRRC'WVQJX]'=]VEO*/!^DZJHNI.]W/_$N5\QG76-7>5<D
M4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7EG';I@%,/F+1V_>LA9!VS8L$
M$'3YZZ;M%EF[1DV=/![5P[<+88(MD')!B@LMG@FL\;)Y9+8$6KC4VS>9Q3 *
MTV"ML%L3O,]?#A#MCI]ZYCDK9E'VCFVS4ID2.:(UB7C(&+!S6PCP4BI&]>VQ
M(KR*.-I1L#+7N#]X7ULWY'=]^KKZ]O'[G4W^:M)Q_F&Z,)8<UON%M-9.[& R
M9 5M!>!,8G"#2(2:$@^>*CD>+&-$Y09\:8I"1K:UFQ*$0X5+\18AR?=YE"@[
M-VVV\75OOM^_C^V^WB5MZ*"41*(E$2B)1$HBU.G9)H7>/*<"](;W$:^VO )^
MPC*&N))+@!)(AGJ_D.:"HQB*A_9K&B0B>;&=:TCQ=HW6C1M=A!Y\<98LY'>9
MC'P H^+W7_LV[?MMU_T_?WVQ44%6;E5#MH3?7X0-JI_(!QC"9-7AIU&7;+ G
MA'\(U*6]^]$DI_JQC)$<3[H KF)<;"C%FV::<A27*+@DH^7*+?O^_7M[K,[J
MM8'1?(TS'T1\LD6V8S+F$1FV<DDH'=MEQD[FA:4QA[IYH(>*$WKL<&UI#$I#
M'IV84@\)?DS%D3H<=.G*^3C,F[;=6W7]KM>WV]_M;=;_ 'M]E</3J.UD-<+#
M-@,&0B;CUR3,>2?/<9"D965:(/+20PB..NK9(N)&\*IXM&10+XQ#LV9%N U]
MXTPA<9)U?O\ V-O^_NJ*^(Z,N;Y\E$9V2CAB68<EY+8P2B00G'(ZZ5OK+4V3
M;(:%,R"5$F">#*[9)?!T?(Y*NDUW":B**J;9$C^+W/\ %U;ZB@E$6B[\)'^!
MYY0?'>@_VA-7U=NA^^6A[RYYG.K?U1W$M^^K><Q+Y?%9[6)THBZ=.A!Y$?5[
M_3=/WUJ[GKQQ'A%T+[W5'H0E0=>>"_7'OM,>GZRLY6QRTU2B*WVNO@_^HS_H
M>*7KL7K5GU3_ '+TS[[,_*819 QG@=XT_<>'_P"=+K3S6EJU?2B+;]TV?)WY
M_P#R9X\^L605BGCWX#^(_P #P'YS8E=,OX,'PQY+WN.]#ZO7M5R57Z%DHBVQ
M=*[W1;E^)8;]ND-;Y^H8[K<1?B[3GG.76I'JKNYVB_AN;^0QRW+5T56ER41*
M(E$2B)1$HBHIM?J \&0:>Q]8$N?_ !.U)L\1C+(*1\?[XU C*-:SAAX>!>V+
MQ(U,QKE"01 XDK9Z +XLU420]1@032RP63M4X\+F)HPEBQ61DBD 9(Y(Z5DP
MD V8@,#&-Q(2%V(2%W9V=G9W9U(GD\;&91R7Z8&!$!@5F$2 Q=Q(2%S9Q(79
MV=G9G9V=GZU45_O[I2+2N.D1G4#X2"X3#Q3)6.P"W)J'NA>4V!:W1U-$I:;P
M4WO@!>*1>$-1[$8N)BX&9HO@L?),YVQ7&N+$_OUASG^Y\I^ 6OT2AZ[XOK_\
MQH]?_P"5![>_\=3'QIY><$(,NAJN,=1[B7M&THD8D%JZ!@]R:/:&FQ8\8>HM
M0 47&YJ[5D)Z3EC(\>W8!!0EJ\>M6N; !X\+&7Y7Y/"9F(#DDQ.2CCC$CD,Z
M-D0  9R(S(HF81$6=R)W9F9G=WV91'*8V0Q +],S-Q 1&U"1&9.PB(LQ[NY.
M[,S-N[N^S*TNV-YZ$( 9QK1WR:U1K>3/&Q2'FGBFQ(DSE4246SS%2#!HT7D@
MQV&E;%ID_;BGCKOL@!ZS0D[&DL&"HMW/5](:LMP0V:NF<_9K6(PF@L08B_+#
M-#(+''+%+'7()(S%V(# G$A=G9W9U1K.M]&TK$U2WJS3=6U6ED@L5K&;QL,\
M$\1.$D,T,MD9(Y(S9Q.,Q8A)G$F9V55Y"+X5G)M(I(GR2XZ,(V_@Q6,QZ 8S
MX2\B0>0O@^L0@^7$8X\VLI#B&<=8ZEB38.( Q.))6;-<K.WKE\JZ(._;YB-9
M_8GJ3\29+]67C\\'0OCUGI7_ .P8K[>__P#E>/=U.6AMJ:(U^+<P'\;K46R[
ME9J\OKT=A,H$R+! )>X]F @R6#"3$7<K+)O\7+A>0+8H$9"5+K*YCD%<K8Y^
M<NC=70123SZ7U####&<LTLN&R 1Q11BYR22&5=A  !G(R)V$19W=V9G7I#KK
M15F:*O7U=IF:>>0(888L[C))9II38(XHHPLN1R2&0@  SD1.PBSNZL9MV1$(
MEK:7242X?I%0HI1\*;"1C0R7-%$U4L1D9##'V6+5V9E3_)M'!*2V6-KD2C:]
MKVRM:K;5TJA3[?O*QGL+8>L$'>G%#D%UPD06D9<6;2 YR.)Q#0<CF4@>Q6.O
MSNR \<.N)5NA..DGD<7 $[BM=A SM0OF4<'RCU?>Z_=^UXG971T3M)SM:*&B
M)06]"R*,S.1Q"3B7;)NTP%&!SA)_8.V5;$RB9"P0:4'!GI%15FX?%6#]TL($
M=K@P1([;?T,_[]3*:Z*"41*(N8GE;Y1^YOEX:_76KBAQW\,7$;RIR7RC+J+P
MF\&NBOB"C_<=5]K$RR&LRUU[X,$^648^^V-7'H[ONTMY1X/TG55%U)WNY_XE
MROF,ZZQJ[RKDBE$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBJ%R'YAPWCI*
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MXI>NQ>M6?5/]R],^^S/RF$60,9X'>-/W'A_^=+K3S6EJU?2B+;]TV?)WY_\
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M08Y"N9*G(TS24Y"=AC(.0@=C<G(1J=[?;Q5_Z5\@O_D6N?XEU*>OU3^2L?\
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M>[=FEV:6:O\ ;+8IJWP[_O.S3[F&7?*YX8_T6R[MN3].KV99CK]D5:G2<_\
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M0WSK2[[S5KG]Q3\(VM?*+)><$OVS<!O SPT\C\-YJ"_K" I[^2LB4LW(),!
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ME$2B)1$HB41*(E$2B*LG'3W2<IO.;/\ JGT_11?M#[G^+JS=%!*(M%WX2/\
M \\H/CO0?[0FKZNW0_?+0]Y<\SG5OZH[B6_?5O.8E\U?C_&GLOWAJ>.L&[1X
MY(3^+W\#>3H7K-)X@S+-G[QFE/C!4&RBKYTS:KMQI;$HU?HD5&N(GMBN;)NK
MG*[(T52R;N[,,,FSM"4[L[BXB_0B)O(S$[.0\KLX[\VP[NV+:PN=B$69G=Y
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M->S=*(NSVGF]S77P?_49_P!#Q2]=B]8-]4_W+TS[[,_*81>V,\#O&G[CP_\
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MZACNMQ%^+M.><Y=8$]5=W.T7\-S?R&.6Y:NBJTN2B)1$HB41*(E$7R".IO\
M"0]0#SU>4GKOG%;)8'N'AOBNAYK$L+97NIDOA]SSB13SJHWV7 26,_91 $O
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MTC-28_6KIVQ#-1:7G9K2QS77O@P3Y91C[[8U1]'=]VEO*/!^DZJJ6I.]W/\
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M_3*#_P -Z)NWM-^7_-/Q;R_YS/)OZ90?^&]$W;VF_+_FGXMY?\YGDW],H/\
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M_3*#_P -Z)NWM-^7_-/Q;R_YS/)OZ90?^&]$W;VF_+_FGXMY?\YGDW],H/\
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MKEUEW]^T7SM:W<LG5O"7AWKJW3OZLTQ5S-NA3''TYI[61A*"F,LLXP"-2Y7
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M^,_>C@?*.]Z,K+<C">(L0V+J374@%E)-&)9((HG-3\H-$0KJ"N!^,FY$#RP
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M1UIYACCD$3(2,XQ%G$"?KV9G?9?I XE9Z_IC0VHL]BYZ]:_CJD4E>S;B&>M
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M.S..SLRBT\PL##-*S1\_(S2&S!TC.Q\C,^P\[.['MMS,[L^^[K_2.Y-O&';
M@6VKL@H_%-XJT%O2,YD[UV-:05PX=PALP<N2BJS-O#G3MTYBJ+?--./.'+A8
M1BS464RR#5K Q"%> 1)Y')AAC%B>9F:5R9A9G>5F9I'?K-F9BW9F1YYR=G>:
M5W%@9G>0W=FC?>-F=WW9HW=W!F^I=]QV6(2*1R&7G"LGEAXU*)*=>K$3<AD1
M1\;.&"#C+OW#\J6)+N7Y!ZOE_66=.W"RZN7].:F5_P"FO4(PB 8XP".,&V$
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M&X2C[!HZ=0.7ZGDJUAVY8(F'^+6<2YHFNVM(S#D<\5!*$P[\@[?@S.,9P;)
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MWUY:^$3?*$L>\5?";Q \LM2>E[:B3/;^VE$V:6>T=BYI#@[Z/#T\YM)<DV(
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M!@NM8S*M4RD_DVD*LW&JR]V,S[8F-BWB>)@HT9=8X.TX29%E3=L"C^ZHA64
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MEK0K50+C:(GD$8SIKLYNS:M+'W$S:J0XM?$*TC,!V!LDZRB[QX_'83J2A(S
MTLSHIFB*$"GLRA[=62*I$EW#2R<GJZ?&9.3&GACDDD>L&/,;\&]@[>4Q6(K2
M78XXI7QM.S<R;]C3R%//-%0OFU-BA$)+]Q&BJ^6Q465CS@11Q=EGDP?&V-JT
M='$Y?-6HJ$DLL#96]5HXD7MUXAKUZ\N2QH/>(9R./)I3Q(8PL04,'MH)W1'1
MMILE)$7#'3U9WJAY,X5"$Y%;PF0#\$)7XQG(UU[#,\\FEV+(CE>5XN,&C=W*
M4M=2Y">&"KAGYI;DF(<IL@$8AG(\?D,B53V%65RH]%CI8_7!F8^DDB9J+@YD
M$]?X>Q8RO8LV\ZW+#2CS8A!C3D*33\F3QF+:[[.Y"(9#ILI#)ZV.[QO%%-OD
M&-HPDKYMV ,=939>(L) XDB: .*&5'SL)://6RLIC F3^*" K$J:P:$PZ)A$
M<41P).,4"3=VW[[NHW[MTX+*29C'!?EJA4<K-ZNT<=GLN,QI79Z73Q3]!7>2
M&P5<I82>$.:$P/;8F5H:BQ$6#R98^&X=T1J8^R4LE7L.6,K]&O?[&FKM8M-'
M/6&R,-@6G-@G"0-_8NO)UG[Y&OOEO%/OYA7MF>X^5^+;WFLJE\'W:P_QIC_.
MX5$'-ORQN5'G";?]/3M<H[WUY:^$3?*$K)XJ^$WB!Y9:D]+VU!L# !)1+0P&
M1R>T."D%U\'T@L"*29PTQ19N'*+8?'PV-WY<N5<HHB S&RS)HN5?L\2102-\
M+)M/",1,Q$CY!??<N5S=MF=]F$>LB)VY1;J9R=MW9MW:T\13JW\C5IW;_K95
MF(VEN-4L7SC8(CD".&G6;I;-FR8#6JQ,449V)HFGGKP=)/'?<;TZ3!J6)0 3
MMH&K-C<K5!Q,4]BQ!HQ<#1LFU5$Y(K,"219XK#Y9&S.U&P\I#D1TBLW)Q64C
MESS=PW&^,J@V-)SZ-IAYR/E 7!VZF.$"YWYGY#%YF9PV+9P-G)GVWR_!P4LV
MLB.'KZCJ%E;>1*ICJ\N/GCB.""_I_'7BR4XV)2QN1HVM0!#/C0ANL,^/OP'<
M P@Z?&WW!7.^KR>X([LY60PM[#"TQU_DEK]ZW.R1"-!YF6DS22 D)(0=12S#
MV#%T6KL/E-T\VN:9XTE'HTP/& WR]#Z4\PRN0<CG&W1.Q%RB9$Q"Q/R;,#[.
MW/V^8F$6)QDIN$C^L,^I*6>*[C)<78R>&Y<-*%N\%&ME+%Z.]4"]-)CNB]:;
M(QR5O75G AMVAI48KEFKK^JG+#:OUQ5\G+F/^CX^>GYVL8\:/!CG_AV!](BN
MM_\  [?ZQ>;\EK/F686"UHJOT\JSNC]"1[<@)]GE-R<9DR<HCL<:^%11-S"T
M'$ID<6C<;'D9,J>8.UI+)W)PZ[#1X(&*ND1T,+DB6;86HY?B;_TEHVEJBG,[
MY:Q0OMD*5&/I,<TF* \A>QU&C#/>*W#(=^_);N25:52M8D"#%V9YW"N1RU\2
M\0>(^3T-D:XCI^IEL46)R>4FZ',%%GI(L1B\QE,I9JXH,?8ACQ6(BQ^.AO9+
M(7J<,EK.TZM5I;81U[DKWX@PYV!"283LJ2J"Y\-.6UVD0@XML^S.QG/=38NV
MF6#>9NT!(I9]I=XF.>AE3CO)M)6CEPP35$.&I"XWX9XJ2I4OU\]?>MF8;;80
M9L17"9[=#YJ0LAE&#*&%:N4VEY1@EJE;D*.]%(<0E7..6S?GVYV'(W\3<TIB
MAMZ<M8]]3'6U!;EKMC<LV@Y:4N"*3!127;@5]=P':KW@Q\(RXN:**P8W8Y:\
M4\C^/3+1%H7=C+5Y5[([2!@3[8:*9>*SL8L!N39Y>*)'(O 7/_C[:SB,2/Q%
M-X]V:5Y+'1EB8WM[<USHJ'2#8IX<F>1[.[-AL<T%>'L>WCVIO/&_8UZ[T)OV
M:'/C[W8F6H\H]GTH.G@Y[QX6\3+'$1\\UG#1XCUJ?&6:G1VKD_9F/R[Y%JDS
M=FXS&=D1?^6R]%EL7ZX8#)\Y>M63M]BVNCK#5@++:V<[@_N:9\VCCGZHHK5O
M\=>^W _\N>'7YIXQ:::7^N==_P#-/B;^>>84088XY9X8YYV3QRRQQR4O;+*V
M&-[VMEG?'&U\LK8V[N5[8VOE>UNY:U[]RU89!A(Q$B8!<A8C=G)@%W9G)Q'<
MG86W?86=WVV;K5U$[L+NS<SLSNPL[,Y.S=3;OLS;OU;N^S>-7#'<:8@5) 6[
M78,A1:R=_ (Z)1?PIDU/-3FS9%)0D.)G0UY9G<5&2HV.8RE+M764@\2F!N>(
M?-%9N]=[$4^"VGKUS%PPZLS$4&:LZ4Q-"*WIRK7RL&3UIE\SC-/7<ICO7TWH
M86_4Q#9P.>9\LV-OTW;'D$L-F?#=CB=F*E;(22Z=QQRXJOJ')7#KYR>7'RT-
M+XW&7LS5Q]WUH9K>5J6<D^)-AB;'=G4[0O=$XY8(?V">*H0@@_=*SU\@E%F(
M_P!F."PF-"K8ERZ.M,F#:.DI%-0P5RRLXV4W;JN3Q$$NO<,IBR;+NRS1FW]\
M?P)Q=R.U,>JK488.K5^:(9*&&HLV0OQ:,*K#A[F7U)CL=-5&764,,DV4MXN6
M5\<;5H)9\A7K0^-OBO>KR5X@T_!(>5GL>LSA<R=MWITSU0UB7)5L;@[UV.;H
M],22!%CZU\(^S1>>6.&G--)4,\)7 G#(-UBO@Y"E2(EQ@Y0LV<X+CGBS-;%P
MVQ6<8MU\5$<K*H8KKV24MDG992V/?Y:^Y6A+BLGD<7,THS8V_<H3#-$T$PRT
M[$E>1I86DE:&5CC=I(FED:,]P:0]N9\P4+<=^C2OQ/&45VI6MQE%(\L11V80
MF!XY7"-Y(W$V<)'C!S'8G =^5K(\*/*CU'\<&/18]68_4U^'#0'QAD?0656-
M..'@KUA\#I>EL>NE*NRRYFI1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB415NF/$'C5/];1[3\OU#&#6M8H:E
M$ACT16N3;CA1>;#)J%ESIOFR(-GE\9((V+-QIAJJY49OF4E)-UV^::B>*<]%
MDKT,YV8K,@3R!&!R-R\Q#$411L^XNWL"@B(79MQ*,79]V4J=*K)$,!P@40$9
MB#[[,4@R";]3L_LAED8MWV=C?=>)GP=XFJ.)2Z5T=#EG$U-R>1295>Q5?(F6
MFD<W;$Y2O_;$L[,VYH%R2WVV>#Q]F@Z[K;<Y*IM$RYYV^S^O77([1MV7*S1!
M& ;<K<HQ'4DC;J'K<3HTW8BW+:M"._*#,OGUOI[F_8X;R$9'ON^Y2#8 ^V_4
MQ#:LL[-LV\TC[<Q.Z\B3=/\ X;S%])R<CT#"R3^9$TS$B=WR-M5GK_Q#*HN]
MS0R8EFWBQN? 3J9C):Q%68L)DWE)Z\K;&52;M17ZCS&3B:,8[DHM$/*#>P?8
M>>.1M^87YG XHBC<MWB>,.C<>5MH%CJ)N;E6C=S?<G?FZWY3!]MGZN89#$V'
M9C8RYV+F??U"'!KB:39RAB]TG%U&\Q(NBYWLW)YLXS+/93&YPZ)BGC4PB\CA
M!69Q(!*[O(XN*<8R%DJ8P4Q?D"2[SY'*Y$7!QM2,\;,(]0.W*,9Q,),XNQBT
M4AQ[&Q-R/RNVS"S1?'TR8V> -C=R+K)GYG,#<A=B9P?G 3W!Q?F;F[;N[R#K
MSC;HG4Q].4:UU=%(2=0"/8TW>Q]EFPLU $!.M@3L.T:)K>!-!R@;3^LAN#5L
MV2209PP,BABEBBK97QFNV[ ='/8DE!R8W8RYMS$IS8G=^MR8K,Y;N[N[REOV
M^KTBJUX2YXH0C)A<&<6VV%VB%Q9NTS;0Q-LS=H!]I>0:XH\=9#8'8QJ>,O?8
MYLN6;?#Y7Q?HYM]ASR3Y32;'5LVSY'-^C+97V1Z1 B&3J.F"30>N_$KW&L+-
MOH,A=#FY;$C<\$=<NUUPPQ]%$'6S[/''N &VQB+NS$W,^\"IUBY>:$'Y)3G'
MMMM+(?/(74[;\Y^R)GW%W9G=NIMOQZLXA<:]*&F$BU;J2-P\X*\8V&$V"A9P
MZ'HE @6-.VC+,B2>^##\8Y'  !B.1M@Q%A0PP4,;LV+)N@G]6,E>M 06+,DH
M$[.0ER[.XD9L[["VY<YF;EVR(B(G=W=U"&E5KNQ0PA&0[[.V^[,XB#LV[OU<
M@"+-VA$6$69F9E_O,F/'9=Q"Y51.+!R4ADTGXW;RCT< !F:Y$N<.FM8R@:(#
MBA[7!1R^)$R#ENR8LVZ:B[ETNDBCAFIGCC>&-,(\C0DD(0".[5,S)V$0 9XR
M(B)]F819G=W?J9F=W2Z)'3M@ N1'5L"(BSN1$41L(BS=;N[NS,S=;OU+Y6OM
M4W4Q_,'Y<?4'LG]WJV"^:+ _[XQWX7#_ -:Q%ZT97_=UW\&F_P"A3[H3B!UC
M^-#Z<O\ 4G!CD*Q4V5"W6NYNVFW"H=MP6?A+\B/*D8XX#;;U/.!#<<3>BA^9
M3!DR:YDT&J;-^HX9]\WRD[F3TQ>:%K.6IET$K3PO%E#K$$HB0C(Q5K$).0L1
M<N[NP[N[,S]:F*]+-U7D>''VFZ6-XI&.@TS%&[L[@XS0R#RD[-S,S-S;,S[L
MIB':\Z\XP-%8XAQ$Y%+QZ*@6T5\1$>#$7*B)E%QNOEM3 (WM9@2TPZ;;A!Q'
M62^<$@XS:*<N:0:-8(#H@F%P;-LDI4I]($4AODJ3'(;R<[9642BD*9K!R5R&
MRSUCDG9II2KO&\TGLI7/=U[M'J%A &I6N0!8.5\<!"8-'T(C,SUW:<0B^EQM
M-SM&'4'*L:VKI/KK[M@A_76T.*/*^5QZ4'79V0.E^(UQTL*8.Y_*=JVBZ\\#
M:O'3;'73#9,UE4X"ZQ0D"6O 4D,N"0:,L5D6=VWI7MZ1J3!/7R./C.(&"-FR
M+E&.T,==Y&A.<HNG*"*.(YW!YC &$C?=]_F:#4$\9Q2T[IB9.1N])V,MY#FY
M'D&%I.B:60Y!A8FB$B=Q!MFVJ+[5-U,?S!^7'U![)_=ZJE\T6!_WQCOPN'_K
M4EZT97_=UW\&F_Z%T4=.[A+S!@'3C)Z^G'&+>D2G2O-F>3).(2'6,N$R/.)O
MM$ZA",Y)B(>BD7V01T8$DQ:!*R/@BKX>\:X*W6;JX8UK16I].4]5Y&U;SF*K
M5I-/5:X3SWJ\41SCDK$A1#(<C"4@QD)N#.Y,+L3MLZQUQ8TQJ/*:8PM;&X+*
MW[$.>N3RP5*-F>6.$\?7C&4PCC(AC(V<!-V87)G9GW9U.WXH/*C\W;<WU=2G
M_;*RW\WFBOLKT_\ C:E^F6OWSNM>_8;J7\37_P! IQ'0SG^)#0H RT5/\!FO
M61D7%DU>.<?<NFH>2,38V3 R)-S %2<@!29C(C*$C"R!X4&';/.T*-72S9HH
MA;DV0X7SV,C9DU+BWFRLE>:Z3:LM !STY:TU.Q%"&4&&K8IR5*Y5)ZL<,M;H
M^6$P$Y&*Z8<9Q=KUL93BTKEV@P\5J"@):,IR21UKT5J"]5FGDQ!3W*EZ*Y9"
M[5N23P6^DYK$<A!&0_Y(H=U")6#-QT_IS;#\7(%+8DL;Z.;MGOBRQ8,>QC#
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M*]JI)1:"#0E2M#0JS5;E&S'AXZ^$B#"/;IY"]7N28AJ4MN.W/V0<I'S-6?\
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MNK*.T^,9[)>M]JL.1&I;J.5RTY5[,$L9/.;D+N[;9$\A?47?W->%:ZY#YXR
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MIJ,[C"!=GO600]IS!FHX_P"&M>'L;$RGCT?*Z^3!DB6#!"4&X7"];@7$^4;
M!V<]ENW&S$NKCL/4TJ?:]",BA[';MMOM_P"KMMO_ &]7M;/MU;;N\7:JC?5X
M&)ZV@3ZT^U_$Q^N>%T2D64<#\3F,1@X5N5Z:87<"NM6+8&5?M9T "9=2"T]'
ME@Q."C@0O7V&N V6:<"0<E%^7[_7_&W?ZK9_:_B_X^-;H>+:NX5^,O'1;D.F
MNEO];1.HE=YI.< 23E/<*FOX]GLU-PG%_P#RRFOA-;F\5<([_P"!8*6RQ$?^
5'V;T7R^V[[=K=]O<WZE.U%!*(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g120909g45h32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g45h32.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1U<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '4"^=(@X0DE-! 0      &4< 5H  QLE1QP!6@ #&R5'' (   (?>!P"
M4  (<G(Q.34V-S8< @4 /$UI8W)O<V]F="!7;W)D("T@,3(P.3 Y7W=O<F1?
M,C0@,C)*=6YE,C R,2!#86YD96P@961I=',N9&]C>  X0DE-!"4      ! H
M+R&4\HPJ16NTNJQ FCU$.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              R(
M  9^          $                          0             &?@
M R(                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M R(     4F=H=&QO;F<   9^    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MN=0_Y1S/_#%W_GQZ$ST
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MW8^N ^D!E4)[7MFQ]?Q-?O6NE4RE9O-2'D;6=%Q DDD;C1Q<N>VW*?CM-O\
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M'3-H0AK0M3TW*:4U)LZ'M.DD2TNH0I<4J*U/L32X8(8<J-)JN+*#%4O:5O\
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M]:;N%ZJ8"A[9E:$VV=U<QN"FU:03>K@B^)$LOR,$@;)HL,%7BHR:IL: #GO
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M7F'76'FG&GF7%M.M.(4VXTZVK*'&W$+QA2%H6G*5H5C"DJQE*L8SC..708$
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MMD:OUS6M@;0K86SU[IOL>HH]0LLK=VK]>"X([JH [#J52G[#Z;ZC+V:#R.H
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M;$HK5KABAFCDD6K<4M4L,B,Q6&RJLT,C;+*H+(6'?I9QF0J0BQ:I6Z\!MVJ
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M<::<::<::VA>R/\ >B0_PCWG^O'\\>].'S]2?8FA_P W7N[S/7I>1_9K)_\
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M=Z<8S($*#LLBEBI7CARQS2(*HV8R4M8CVB;T.TKCE7E79CMR[;%2/$RD=Q#
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M2+S<T4T,L,JK+&Z+*V,8QCNQC&,8]S&,=V/BQR\))[R23Y2=]8\    ; =P
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M5>^%JMKF-+K5RG.&Y4VTEQ"X\ROR@DF;7,]AL?/)*2IYPJR %6$+-$DCGT"
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MY\)7P_\ U_\ 7Q?N<;#R#W-1W/\ /O[6_P!3Q:B@,Z:K)D38JZ6(@3X G -
MS8>;(&%@Y<7*;FC2@LA#<9EP"$"8RS*AS(KK4B-(:;>9<0XA*L09%=2K*&5@
M58$ @@C8@@[[@CN(.X([CN- 2#N#W^/?4.=>=>==?=<6Z\\M;KKKBLK<<<<5
ME:UN+5WJ6M:LY4M2LY4I6<YSG.<YY$   >H-OYM0W/?W^/Q^W]777E6<^[G\
M7&P\G_A]3R>WMX]-SXM^[R:Y\)7P_BXV'D'Z[_"=/U]W7'A9^'O^_C&>-AY/
MU[_Y^\]_CT!(\7=KGPE?#QL/(.[VM-1,(<,UHR)L5>*$ 9X"3@&@AH3+?'E!
M!<7*:G#2@V?$6U*A$($QAF5#EQW6WXTEIMYE:'$)5B#(C!E900P*L" 001L1
ML>[8CNVU$,000>\=^_C_  ZA[[[TEYV1(=<???<6\\\\XIUUUUU65N.NN+RI
M;CCB\Y6XM><J6O.5*SG.<YY$ *  -@-0UNA?4D%0L+:.M&^NC9#55F9T[481
M9QI:8LP^.]79<G C.Y3AMY\</(C)$UM"LKCH)0<N)QB2WE6I<9.HHXZ+<<[W
M+,H'J\B0UUYMOW)9@H;Q,5D [U($,6I;-6G7O6'&5XW/=L'GM3NB[[]S<L#,
M5(W"LC>)AON@*]S/WL_BYSW6TZ^>UU!?L_;V[_<^O+M'\N3W.?6OV38^OS?U
MC:^-G&GSX<6?QGXA_+%W4M36K\FF"U3R!QRCHEI?$BGCZWQD&3(<G,MD&JWY
MQ<<%HG/PB3,4JX,BL$'HLUJ+*D+9?2F0]:$7<OU?[4<QY1X]CR;]P)4@-R@;
M@@'?NU8S19E<56>:6V<2)>:O ]WK*\4CM*BS+0Z]FKB9H)T2PU=$G:*54D<J
MP%=*SJO;5R<K9T-M;,G;%HI;EGK%7E6FVP[A-H31TA55=UTFLQZR-6MT83G-
M5^?:8C>:Y%=DO/,RWHHF5<)%._(RSDS-'SJI=PYBY^3?K">4$D<W+S$<G>6!
MV4[90X<XBRK4;=7B'GXBOXHWZ&/ER&2BR<V(2U8Q_P#G22-*%=F->>5*4^0C
M7L,;,\BR&.O)#P73[U.G*Z&6'K]E]3_JCK3@48_;QPQ$*QVUVKI"%F0<\_$>
M%2WEW>I+F&W(47S6V?@2"<R(QE]U@M>VZKRAR RE09 .5GY"&"E@0?EJ$MMW
M<X)/CVIU."N/K-&H]:I>%/MU#LL#Y*"OU-[)M06I.M6:[')6D9\ICNNM-#&*
MXN0/8EB3F9)AHW39OXHZ()0S[%4&DQ$]^M6>->FR8XC$(; H5%-P1TZE$S;D
M=J<2V6%,R?&XCP3@GRZ9'=GNHPVY-'6LG9@Y0%3R,).8,'FBB9048[;F57/J
M,!ZO<1>XG@+C*P]6:.\F/AGIV9J&0CS':(+$+Y?$8FU#7GQ4]MD6>;/5K+%@
MD%NL9I4>5ME>FL>D[UF:Y;O#$P^Y0+7BQ'U9S>8Z4&55]]Z#8C4ZN+/8)2UQ
MI,!Z-(GRQBW7E,,IPZXA^'EZB$L&+K0S&-^=O\H/1<N_.Q4MN=MN\D;[]WDU
M@8\-Q;+@5S"S6CA;_;;??E8P+!I2-#=M2T7N=HD9)8FC>9ZY9BJ@,P>+GJ$[
MK7J3&4P]K>4)$Q@5NNN+#>5M%: 1MLPO6(%[DQEW8Y#)S+DQ7!R*+L X&%F9
MD<"2,BR!@;'G%I(Z0_5,5L(T+!0KRAY""C.>42;&1PQ<(HCE95;8,ZDCO*ZS
MC\/\=5\3<P;UZZU,GE%O98):PT^1EL8^#,2Q-E+4<\N42C&N)S%RK7M3)3GM
M5IK%>*2Q) [^()H+J:9)F:)463;26Y)9*Q0N^BP@ZP>3"ZC-F/#83EC@QC3T
MH5=Z6VXQ%1)DY<.014A&)C,F+%E2O;W98^< $[!90@?;D;=1S@$D/'[>[*I]
M%W:MZG!7':V;6'QL=@,CSGL]?,5ZL%SJX,;+(]=&NPQVW:OEL6"L8=R;<4#A
M9%DBCHY<HEOH%NF@9UHGR"XF17S7G(:7+8PDB\!@$!)"/(?7'EH(C!Y%N$Q,
M\!N1$PAUF*[AC*<JHOUD;E3(Q8%6W#,._E[F&YW#!6*[^/;<;[:UC*PY/"Y.
M6E-D)I+5=Z5OM$%BR/ES5(YJTZ.Y259Z\,PA20@/%RLL;<A&_I8W'M"-63E1
M9O%A0'LA\/9#:L$I7G8B2!AK* @(DG<NY,.#<"[<>CR1&9OFR;F8EZ7$>>CQ
MG&HBQ,$9!(VS.'8[GF+ ,H]%OS;;,W=OL=^_U-3+Q-GTQ]K&+E;@JW;M>_;^
M7R=HGL5:MZE")+?-VEH.S9*Y')6:4UY>MYI(F=(V23&K%8F(,$6S8#C(L61P
M7%C6BQ!L>,+8SX7G0?#1(3&ADO"[LXG1FFI6,XQW.^UCE,.X 4.P53NJAB #
MY0-]@?; W[SY3K&+>NK##76Y;6"O,;,$"V9A##9/_P!XAB#A(I__ *R*)!L-
MF&PUT^>C/_Z8*Y[X\>)GO(S,_P#98DS!")&]M[_P\6>E,Z,S_P#A,3$IE-)0
M_C#F!=SXV8]P'>Q/<#S >/Q ]X'J'O'?J3M5KUS8^82/_+R_Y..3KHT^;^9C
MFVE1?$LH$B@. =>XG;;8:ANCS-ILA> \2=,/029TJ0AO%W\+P^6=C2Y;S#A-
M[#CF'IZT9ENX6O"WE85GOB9)&!#.S G<@L2-_+L3MOY3XSW]_>=5I\ED;4;0
MVLA>LPM.UIHK%NQ-$UE]^>RT<DC(UA]SSS$&1MSNQW.I?Y)JRTXTUNG]D1^U
M^Z-_A]E_G6NW-WQ/[ @^HW]-M?4CS./I.<(_Z;_WARNL6_:]>^Q@?@BIG]MW
M'GM'H.^<>3[/7_Q:AKA'FBO3 B_B]B_QK)ZQ<<[!K@VG&FKF];3-7LZF)JN7
MF4W8!)3:1D)4+#9+-#%RR2:IK&/4I3@0!802W'9L_%CCI?BR(LHLD:J#,D28
M@Z.PQJ.6CS#9N$8\V*U:>##5[%^K5IR3)%V[,O>06+52TH$41J.5='2#K1(B
M(TSLV]X-\$O#TYR1K6;D$^>L5,==O9".M).*."3'2FI3O4RS22]O3FC>.2R(
M.JED>*!$6I4ZK]-;@/9DZ-*H[;$N):B->3 LA!)^JE8=#J1VN ZZR8V2B78A
MY.V2[*+A9Q3;0F*F!("'CCL^0.EAL1%<XN%G#1/'D69'HPVS)4A-:["^3O5K
MEFT\&'*5)8:,=29QX1I<W6)9JUUC26.QF)*/!K5\Y,C8L1M%D)Z8BNSK<H6(
ML1CKE"I22QGDDOP6,A)>KQL<5D1%U,E6Y;:9X9*M09<+IR7'749<O4T"OL7G
M;)W6<.M7(G88AZ"Y6J- UP3V=,.;)!+"3BPZ =5*@E+5KF(BSCX<4^/$Q'Y$
M:=BXY.*PZWXX\W+:?'8.KF)+>/@JR5I.UY*7+PX>.MB+(L1022U3&\%+*R&I
M+))6EG<+)'EYH.#^1\<9,!%3&4XBMX*.GD;-Y+<9HXF'!39Q[F?IFO+8A@MF
M6.QD<'&MZ**.[#6C>199,@4C19_U40Z>#U_/RQ!W=.,,';\8;MP.75M*.6.E
M.ZS&!M@S1EDK*[L-L9#RER5L7Q(V,V/L)ER+%AE2.1DR/$E;L<E^SE(PTG#L
M<#UL77:C9CN\0K3R(S$]C%QS5;G@Z6I%R*N(WF9I*T D>2"+')C.%[@NQ8RK
MB96$'%,E@6\Q93(U9L?PN]W%'!P5LW)6NTCDZ]R<.[YL)7C6"]:,<4=J?SN:
M_P"GJ&8FS(I[6,V(0M)TS2@LB\O3V9U01KG$X!7C[ZKU5F*C.EVYQU'C;F?%
MS(1&"J 7C2HDF$-)3#*<4R5HT>IF8Y(J->O?L+C1&T=YLJ8K5FLHQEUKT:4@
MK<E"M,DD,@>!XY$EE@E?#\)1S2R16\'*LU^W/C:KY5I$EQPP_7TZ=Q_"^.3'
M2R9 LO/D[L$D4\)BM1S1R106)JD#NF26I-8:5K1BMA=F[/F")R#\UTH0DGM1
MT,C0QY1Z9L\4J;0,7B+: KDWU3PQ8B6 !CS=S&(,'S=BLEEXP0=L<Y@V[.'P
MT=B(U4ZF&.MG<G%DY80F&GZO)G&/2L"/L3SSI9L2P8^8P5:U6^>'@N3>@IPJ
MTZN<STE646Y7GG>YPWAK&(AL%^(:O78<96._3:?PA'#6DJ5H;65K"S>M7++]
ML1ZC$OIJ-1X[$6OL,AFTL0B,0L,06P#&^J%0B?"LMSCNB73V23PYE%MLF(45
MQN"DV33&Q,>W_"O?DQE=\DS/:9K#%I(G@F,!LS&H)XI*>/83K5ZH2L:-,ROO
M*:T)<H.:<0)CX\K83&(L=94K#ECFCL0+8[+#VSLTL5_*(U=KAG>!1DK_ %41
M6+MECDZUJ=<RFL+IQIK:%[(_WHD/\(]Y_KQ_/'O3A\_4GV)H?\W7N[S/7I>1
M_9K)_P#3ZP_]J)[]'9G\D:__ "& \[KT/>E]AOK^5_*=K7G'IW],S.?P?$?D
MJIJR:AM W[O4&;/#8(UQVRA$'A\DZW5XTX.HC'P1B/V-Y2&@3,F)EUEPLXXR
MB A>9*GV,-^.;Z!DFLKC[S4Y&BMBG9-:5*S7'CL=2_4NM1=VLLLG*1  QE(Y
M C[\C<OQ"U7RF.6]$LU)KM86X7MK026L9DZZ-[KD+45X^96L,R"($N9(]N=;
MW/4SHE40I3DRM(LQ5;)UA8YQ9TW.BDAH.71[FV5J\1YOJ".C##6;4P!#'GZQ
ML\F!%+M7GXT;KD,4A=0Y]VSB4/#?*<2,PQ&8J15UK1/#/8CR.-,%V0'A:M+7
M(I/:L55NX>*U.*/9:U>V\Q6]T_L7"YBGQH?A<(V:P-V6PUB9)8*DN*RRV*";
M<:W:]I1?2E6NM1S]BI7>_P!KLW*,-96Q<->KO3 -L@:%)&T&;$L]NU>&L65;
M /+A44&=U]->V"2 RZWM(Z+QD)<41E))&;)> XV3GR'PY,)]N,U56WQE+4L2
MI/E8WIT<S8J?^BZPDR5FKE8UQ4-J.YA:LQ%C'\X:*M3QMB9/EQ".K,:;T^"(
M;E.-X<3)'>R&"K7M\Q=,6)J7,,[9B>F]+B&W6!J9((1/:O9FM"Y$7-+&RHG;
M70>DU5 < 7.U,+KMFD:+G>>Y]WGD+M920^CVDEL0?>:VYLBOYID>-?Y2JQ#>
MCXUN,BQ9HJ;(L$\.AT\B6W9XB%Z6R(\[/:IIQ)%V>+'118ZI#-DJ4&*DQML8
MBV,@S8M.VNKMEYI'BFC2M%.15:-&IPWX,BJ-)P_!3OGA.7M4N4EER=R>'$W[
M&:BRE)L[2\%K'F'./C:(8&%%FK3279JH>ZGDGUSI<@'J]"F1Z;F)8KGJZ'8W
M8=[.2HM.$RZ0@E=8XY^N["N4!D2_=(K08V>E&[ND /(%/-$UE] UZ!/';XTD
MK6Y(WR//4QV9DJ"3&UHWR$\>1:''R2I;Q5"4SC'2&>O62MCC:EBAZ^-D,RRR
M/2X&AM4XIDQHCN9+ )=ZO*VY$QT$N*6;*10R4\UE(E@;)J*MJX]O+"I!+8[+
M*'%=H)2MS.L2%VZ9JY;5:] UL;4Y O8XW6]RD66J Y<S<.T2[8^7;(UENQ!E
MF>+)@I1>:U8S$H0)*+D#G&6HL2+'OZ#9B+'<86Z RMFW->2?$RY;'I4NV(XL
M!AX&ECHM3QT3O%+#:2")J<"3S0JDJLS2.V/R"827)<#T<CX'J4Z^/>#,P87)
MR7L?5DEXES]D1/D5O9>=5FK3TWL2K=M/6@G+0<JQQQ)[K08UW2-:7X16Q^MA
M.P+C2:,.MD&D7BR6H8)EN[!N62HBFGV;Z>BE8<^FP*.7MHM9BW"(Y&3EB4ZU
ME*@XJE3KY7(Y?&6+DN7L8RAD,E+1DR6.ITIIT7%X[J9K]5L75>"2*_+DH*-A
M:]"PT:<Z*P^7S5+UG$XK#96M1APU?+9'%8F+(18S+9"_#7F\-91K-;'7ES%R
M.S%-C(<59R%9K.3JI*YC<KN*]>$UVH:FGP]6X\7J? &>#8F6>PV&_EFKZ0OT
M:L6PB4IAVGJVG11]<K4RRP15>"V&0Q5PR(S]>+S;T^DF9B\N+>0SD3YGOSAM
M1V3'3J5<9"<9'C&N48H<A6OC"9*6W;2I+/:M54:[8+K;@3&J8(&U;5<?@98\
M$0N 6M-362]<N9:R,K-ETH9*Q8Q=O&#B'$0TJ4EZ&M2J767&UE22G9DS!6>S
M&)W?K?2M$M @7.14TBS]WJT8N2@V\X115!CVFJ=8B4" @1LPN*37Y>W99BK&
MC)"V6)0</DQ#'7&)('Q; .QJW.-)*<\\9NF:MCKCUXY*-6)KTR\07ZL$LK3X
M:O.;28!(+U:O%0I]HL=G>6@XD>K+E31X#CNUX9^P+%:R>.2S+%D+=@4(7X9Q
MUV>&(5L_:KBK)Q'+9Q]BU-DK_9JHL1PY2-HDO04,W(%H(M4ANC"ZM'3&S4&C
M<J';1Q*6R>DP[>].CT\.$VYM<<_49L!D#)L$N3:+9/!VF*S#8+@H!EH!G8\#
M9R<P7PE-=8MV]JJ2T9H8VK(] 1O?GLX/"3)?CE:RE5$I4HK%-V=X+$D#6=:K
MQ'6Q=?G7&044Y!CUM-'?@E=+3Q9%YEQU:IQ)Q' V/DA2H]N27(Y*:MD(Q&EF
MI#92HUOZO<S][/XN;,OC'U1^'6H:VUNS3]Y3I7^+7;\Y%QYXEZ6_3"XA_?X[
M\DT-?0SH4]++ACZWDORO?U?7SG&NJ:<::<::L[ZU.A/ISZ^]5_6GZB*B\;%P
M9JR]6LP29YFNM'.JCJBY,54\EB3Y&\]'5XB=!F19X<HREI!,;+Q'C^*R>,RU
MO$RO)6*.DJA9Z\RL\$RJ25YU5D=60DE)(GCE0,RAPCNK8^_C8+XB9WE@L0%F
MKVJ[*D\7. )$]&DD4L,H"];7GCE@=DCD,?6PQ21X I7U)ATLN27UP^J+?<:*
MMU:H\>0"U[+?9:RK.4-NRD"8B7UHQW84ZF,QA><=^&D>YC9QQHNWHL4-_P#Y
M;S ?R!JKD?4+-]4GOUB? V5'<,O3('B+XB1G(\K,F4C0MY2L:#R*->?[$MZ8
MO2IWK\F=?_H/(_)HGTJ/W?\ ]GIX'RWTVH_>>;^V-/L2WIB]*G>OR9U_^@\?
M)HGTJ/W?_P!GIX'RWTVH_>>;^V-/L2WIB]*G>OR9U_\ H/'R:)]*C]W_ /9Z
M>!\M]-J/WGF_MC3[$MZ8O2IWK\F=?_H/'R:)]*C]W_\ 9Z>!\M]-J/WGF_MC
M3[$MZ8O2IWK\F=?_ *#Q\FB?2H_=_P#V>G@?+?3:C]YYO[8T^Q+>F+TJ=Z_)
MG7_Z#Q\FB?2H_=__ &>G@?+?3:C]YYO[8T^Q+>F+TJ=Z_)G7_P"@\?)HGTJ/
MW?\ ]GIX'RWTVH_>>;^V-/L2WIB]*G>OR9U_^@\?)HGTJ/W?_P!GIX'RWTVH
M_>>;^V-/L2WIB]*G>OR9U_\ H/'R:)]*C]W_ /9Z>!\M]-J/WGF_MC3[$MZ8
MO2IWK\F=?_H/'R:)]*C]W_\ 9Z>!\M]-J/WGF_MC3[$MZ8O2IWK\F=?_ *#Q
M\FB?2H_=_P#V>G@?+?3:C]YYO[8T^Q+>F+TJ=Z_)G7_Z#Q\FB?2H_=__ &>G
M@?+?3:C]YYO[8T^Q+>F+TJ=Z_)G7_P"@\?)HGTJ/W?\ ]GIX'RWTVH_>>;^V
M-/L2WIB]*G>OR9U_^@\?)HGTJ/W?_P!GIX'RWTVH_>>;^V-/L2WIB]*G>OR9
MU_\ H/'R:)]*C]W_ /9Z>!\M]-J/WGF_MC3[$MZ8O2IWK\F=?_H/'R:)]*C]
MW_\ 9Z>!\M]-J/WGF_MC3[$MZ8O2IWK\F=?_ *#Q\FB?2H_=_P#V>G@?+?3:
MC]YYO[8U% OU)KTF1"D*2<ZEM_F!3,AMR:,AC-?!I,UA"L97';)J!$_(\N8Q
MX.7L07UI3G.4)PKN5B#<:#E/)BDY_P!J9;DCH#_\R1PP,P]H2(?(P.VHC#9,
MD"3+UU0D<QKXHQS ;]_5O/?M0JVWB,E>51ZJ'Q:V,^F+I=TET>:@KVCM 4N'
M2:#7<OR$16G79A0T7FY2HE8K(8E*<GG#Y-:&\S"4YU;GB68T*,F./APXD?4K
M^0M9*P;-IPS\H1$1>2*&)22L4*#N1 26/C9W9Y)&:1W8YFE1@H1-% ')DD::
M>:5N>>Q,P56FGDV',_*J1HH"QPPQQP0I'!%'&EP*O<S][/XN66KS7SV^H']G
M[>WX9=H_ER>YSZU^R;'U^;^L;7QLXS^?#BS^,_$/Y9NZEF;*O*J4+:G0R+=*
MS*:;&$G $6/'EN,R#"HD-5D0.;(DH4:7D]D<.EE),")*;+>01VGX\SQ<A,AC
M4,#R#;E)0#?YK8<^VY W;8%B!W[ :L9I,T<372:*PN)ZQ5@G:E$B2LCVS'$;
MX@$\\22]M,$$MAX8Y5L]1&KI+M<8*UWU+2-)5N763N"U*L@=Y\=6Q+$]NT#Z
MDJSW29+@^JLC4Q\1JK)LE!LMI+TD#L"=#B/QE7(S6(R5RBK-X([9K+RN&C90
M0@^;6,R,=NL95 0O&7:-93MRAR@'?K=:V#XZDX5HRX^X+.+OU7:"E6CF7(0X
MXWLK++%X0GQT,2X\7<-D+]G%TLS-$C1')VJ$>\DZ?MESK3*%/"S&O9$W8;,/
MV*U,GB:_-*YN""%5Q#E#29&&Y+!6"7-CTKQ]2&R1TPFRS6<30,J&V,QB7_'B
M>\.2S+)N0A/.2FVS,-U8D1_*P03LFZ]PVJIYZMBP?09>>U>O09L235Z4L_A,
M38XQ/!//$9*MV29<66QT#P23A:)FIR1B :Z17KRXPL"-"CKRU"%Q:J%!QQ0
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MZ,?!%'6KP66B,L<V7R=E*6)Q[GGC$*69FFFL6"6[-3IVINJD*!3W@>G.[F(
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M7)[TR[JH+ V;4SJ7+%%<1J0BJH]<F\VN9!>A234QS,JRN6Z;/RXO!:<?6/\
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M<::<::<::<::VA>R/]Z)#_"/>?Z\?SQ[TX?/U)]B:'_-U[N\SUZ7D?V:R?\
MT^L/_:B>_1V9_)&O_P A@/.Z]#WI?8;Z_E?RG:UYQZ=_3,SG\'Q'Y*J:Q]<Z
M;KC^G&FG&FG&FG&FG&FG&FG&FG&FG&FN%>YG[V?Q<B!N0/*=M-9^>BWI$V1L
MSIIUK=@77?UA:?$FV;,N)KG6)#0;%&K>(-SL0QYL$U<=#V^R(01?A.F)WG.Q
MDEY)D)JHRXT+,:'&\9]*MV.+C[/QM0HS,KX_>65)C(V^*HGT16=5[M]ALH[M
MM]SN3]!^A:-FZ,^&")9%^5Y+N!&W?F,@?$1W>/;\.Y[]72^L(V]_^LZZ_P#_
M /BW2]__ (Q<Y[X1B^EF.][G_2-=2ZEOH\ONK\75GO61IRS:'H@^J$NO_M ]
MY[3W>^1UUIWIJ%S^DZ<<W=8IX]Q!(+,CD^EJ6)#:\%#I"IVR[S98V:G4*PI^
M486_(E#AA&\IV!/(7%#'010;2363'9 A4;[%2MD,921M&B'G9NX;>,4Y$*@
MS2L7/*J>A/,?5!]#W >J?4&K[>S1Z4MB]%_2'KG0^TMKE]M6\!DB4ES9K[4D
M%1V#3R)<?65">\@'S7:+2\>'!"ND66W'W79SXT?70#H>J@L?D[<=VY)8BA2%
M&V4!007Y>XRN"3Z-_&0"=@ "206-:",Q1JA8L1ZI]3?U![0UIW_57GO_ #2G
M^R/3?SO[MYN?!_["L_PIOZF#6+R'^67]X/PG6K_S;M6&KNM/=&FQ=W4>MW"H
M6[5\,G>K;L:BZXUY9+&:$7K8MIU74:C=;:*JS>*M+J+;Z UWK[8K%DM]>R8)
MR5C8.'9"$8=L9[T=>1HW1R$2*21U *1I*[HI;T7/XT8GE0A1WGN[]5%C+ $'
MO8D*-NXE0">_?NW)V'=WG4&U/T:=26X;5K:L5O4E\',[900ETJUV&E72#3RP
M8.#EV<R?A%X5<)O&!0NMP9)MW%<@FR,V$AM(@>1ERH<:1-->K0H[F6,]5MUB
MAT+*68(JL"P"EG8*.8J-_&0-R"QNS!=B-R1OL?4[SL/&VP!) WU+:>EGJ-ED
M'8 71FX;$GS%ZK8,P-JS83\<O2W<Y5 NPQJ36(9%VIEH_@2QAB3 BM28[B<J
M2V\EUEN?ME8#=YX4]%R$&5-U<=Q1O1=S@[@CU/%ZAU#D;<@*3L"WB/S(]7ZG
M_GXN_46UQT>=46V8P4E0="[6L 2R@[;8:W8X]'L;59L0VDURP6D\H%8Y YH*
M7E(%U<VV/@P)LB67*P\AA;,LHXW$5"6]5AY@\\0*,BLO.I96=U10R@[KZ)UW
MWVV!W/B.P1NWB1CW$]P\8'>=O*=@3_(?(=2@WTZ[^?@4PJQI#;CXS8SKK&O9
M[.N+B[$O+S(Z47<9J$AL,IJR/)$P9I3+8=<Q>1T25.QC,5AUU$YM5@7!GAWC
M[Y!UB;QC<#=QOZ$;D#<[=Y'EU#D?8'E;8G8=Q[S[7E_DU+5EU5LZES;(.N&O
M+O52%,P"5;X5BJAT++JV+1':EUG-ACDH$9P-BQ17FI0+)%,;!:.XV_ S(:6E
M69EGA<*4D1P_-R%6#!^4\K<I7??8]QVWV/<=CW:@58=Q!]PZN\(]'6_ZQ6#-
M9K^U:-86L5O46PMHZDHM]N,BPU&H[=A40A1KC=*$]5Q2+8-AM[$I#9R106-A
M3*Q)-0D$&(Z<8<Q8"[7=@S0LK<TT<4TB*%=HC()%23F/+N$<CG9%8 [$]PU6
M*,JG9CR[!F4$ A3L=_'L?'W[;C<=^Q&PHJ<U#U2O-U5,JE;PL8,J3GZJUJ91
M5]D3@%G>;FF!KE.U\\1$,+GQR#X0TVS61T5F2]YL*,OB6I ^>Q'N$FICF//
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M?#IZQWI#]'C5_P FXW]_'GB<<^RG,_=DFGG5]'7L.P7W$GPZ>L=Z0_1XU?\
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MUG$VL#^GC^I1E$)QCS]&$[/\KMCE;/[ I1*YU@>Q)EZBQ 29&1:U:XT[$@)
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MGVE9QG"V9,9YF5%?0W)C/,R&FW$V]N3%7JTU2W/3FK6(VBFB>Q%RNCC9AN)
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M8C+TE,->$H0X\%X_UI%[A^-IYR'11[!L+]I8_2-0K8W2EV7ENU[N6O:QSTG
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>3C33C33C33C33C33C33C33C33C33C33C33C37__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g120909g46g30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g46g30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1MB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &T:^:8(X0DE-! 0      %T< 5H  QLE1QP"   "'W@< E  "')R,3DU
M-C<V' (% #Q-:6-R;W-O9G0@5V]R9" M(#$R,#DP.5]W;W)D7S(T(#(R2G5N
M93(P,C$@0V%N9&5L(&5D:71S+F1O8W@ .$))300E       0\]^8W/R;$)MG
MPB5Y5N.2TSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              L<   97          $
M 0             &5P   L<                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   L<     4F=H=&QO;F<   97    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      0R0    $   "@    1@
M >   (-    0K0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 1@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MC!APW _N*I;D7BNX8IWY J>]@:PV0]OZ.BK8UKOU?0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% &6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M(C$7(T%1@9$8)#(S-$)AL? E<1DF4J&S-7-T@_'_Q  ; 0$  @,! 0
M         0,"! 4&!__$ #H1  (" 0,# @()! (#  (# 0$" Q$2  0A$R(Q
M!4%1\ 84(S)A<8&1H4*QP=$SX152\6)R%B1#!__:  P# 0 "$0,1 #\ _?QZ
M::/331Z::/331Z::/3339TMV120BRP0Q3+/*]CDE^?\ I1K/E[HK7)__ !1?
M^_\ LB^]D<?4RLU55^OX?A[U[:V=M"LS,'8J% ((KDDU7/S>FPNZ*8QTDL <
M3&M<]SY'O8R-C&JYSGR.D:UJ(W^U5?Z3V_W5/95M$ )Q!8FP!0Y))\ >]?O^
M%ZV!LD-DL_'@+B238XXNB1S_ '(U5.^\OKT+46])54N5+%"FD2OGE-+4BP%B
M^#9"&,:5$Q6?9)&U%9[N1'(KHU1WR;Z&+T'9F&$S[N2/<2(&:$=,,MGCL8%R
M*\\>XY!(&M@>F+CD6EH$@E0K D"PJE;!+#P>!7-U1,-:'\B&HH;BSK&8C/W*
M!%O$&6MEL6$'2P0PN)B#@+-C>;,R9#41H[5C= (]\4DTJ?2O"WO_ (_9B9KW
M,HC<HJB2!'=E'<%#1G(Y A0/A1YNNEMOHVLZIE/)&S@$@H"JAF95)(':#0%D
MD9'R!J)LU^6RT*25FZYKG^?POUBT8=S9W1Y=>X&5TJA3%@P0ML YBF-CB_8(
M6(*(B2-)?K2:-J<'T_UOTMX6G]::;T:,[E]M&TA652.1#-,XB7H)(X$3!E(0
ML':15UTMS]"GZAC].GEWY$"S,JQJKAJ+2(H\2%55B A+4K$CMY=K?R::DZX.
MH,[C,9>GU5F"MB3(;=4M9_CMJA*5]H#.=(^0PA)&B,.C:UH$#)IWBV!TD"02
M;4OJGH\^\?:^D/N=\-M!!/NY7:.%3'*+,NTN,F>)0"PD;I@C@XD'6L/HD8HH
MYMW-) NX$JP !')FAKJ12FATVK+MHNH&17"VTZ]/^1*^I+6.L&HL0YJS P.+
M+GN&Q32DPD2+'"D9B1P/DD&FB8XR>*&!K$FEE?'+'[[NY?T^  "=A)U5C,4C
M!#WL507TZO&F9CBE$$,>1JB'Z-K(&9I)PH1I+ BH(O!;)CBW)!-40MGVU,F8
M\G^O;>A6SQ_/Z"[)B")*/2)+!D569!(1[U$T,5J0ID[8?TG-G$*<XAQ"+&$Q
MBR?K]6+TW:+#')O-TVWD=UN+[-CTW571@XR M2>2*X\$\'GR>F;2&1EEW,@0
M$!7"@!^:-6I84;X*$<'D\78WFFUZ1?XT>TZ!F:?+:TA)?LH@Y22!0G(JMA;*
M0I9+YT>Y/FLD:L58U;[1-=_2Z6]AV<.X$>VG>:$!<I"5))(M@@$:_=' +#EK
M-8^-&?;;>.4I%,TB\D-B 2 0#QQ_W[#4ACW9WZ\'[48?[+F-^_Z/O^A'^R(Y
M8OL7[/@KE_T_8J*J*G])_:^M1E )Q)*Y$+E657Q>(JR*\?GXLZI,*><B .#E
M7!^-CP/?QXHZ]S7920R+!# Z=6JV%LGS2/[7)[1K*K7JY(FO5JR*WW=\$<K4
M^7LGJ%"VI8D*3S570\U?%GD"^+J^-1T!SW'C*N."0"1[^_@>+_4:U@+RU_5C
M_D80G%^[FOD#;*P:7XJOQDABEFFEC8]/;_3)*YZ?W_?]IZR=4S(B+%/;.LA[
M$,0%!(/N !SP-&B4>,_'@XGFP!SVCGG\J_'C5AVPA-D;30/'6UKHX)C@E25)
M1XB8_L@D7W^+7QS-_P#=R,<YBJCFHJN8Y$S;;RI&DS*1%(6"/8IBIIAYX(/!
M!Y'PUD(%-TQ8K606K6ZJ[_7V%UK=70DI[_\ )@]__P!+_P"OZ3V14^:_[JO]
M+_:(B_WZPP%^>/!_/G_-<7^WO/U=+^\U?A1NO-&@./?CS^XUGZDIB_\ P\/^
MZ-_VD]O=454_M'K_ -$]_P"E_M/]O=?=$GI@CR;^-CS^1^?CJ1MD]W)_*OPX
MY]^=:[]>8WV^(<#E5WLJ)]GNU/BJHYR?9_[/^WLJ*G_AZD1 U;5QY/N?T''Q
MY_R-9+M%/WI*XOV_^6/ZA[6/CIBXSI&[MY-0W5Y /.,KM$0%GE84I*V]"P<6
M6&R?\)Y?KE^Z4B!Z+]37/A5$B9\7>M[>[390_5?JF[.YZNV5YP5P,6X+,&B%
M@6,0K#@D!K)(()D;6,K9:1>YAR!58J4:_'<210RX%^^G<_;'M>QJ!"N:Y'_-
MZR2-6-4:WXHC$<Y7JKE=_7NQ$1J_[N]F^M3H"CW-8HT *(-^_M[?J1SI]4CH
MV[\#B@IR/L.:JQ^!JC=:\2;DYB*OZ@GM[JGNOW)[?_1?]:^W]_TB?VOLB^_]
M_P"TC;J?ZF\<4 23^7'M?PU)V:F\6;@^X![:/(H4>?-&E]_CJ$.P>555R*O1
M]E7L/N#12Y:BL'C)DCDF'=!&R.Q*A65X,<[R&+&]!II)&13NCB=];D3L>E?1
MZ?U62HW"0HRB:5B+"L&:XU-9D!>18 )%D ZS78QG$YL W )*C+D X]M +9LL
M0#1*DUR8+R'UVU(!L69:HCRMA3NFB/%(+*GAMX94^YDTKI8AOT)QWQ/!1K4-
ME5_VOB:.B2.G?>C;;9HZ'=.=U%+B\3*J@Q,MJ5'W\U-YD_9BBH);@2VPC#N
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M$$ @\^XHD 6+K6J<T^_DIR^ZW'FKJ[/%<\!3\!R=4ZV_CWL[6UM[<2_H[_\
ME[@VT)2]&)&,8)*CHQ:8>452!7P#!I&"+.QH<[&0COEE>YKE]>OV7K^SBABB
M:'<;8Q1)&A@9'0L""TSAJ8,6)D<$NHM@!1U8LM,H9%PQ &)Y\D,W( M;%4*/
M<./ZG?A;"DYACZZ+5 ?X.R[NGA BF&6%A*2?$,X9BR,DB>VOB>!6C/CCC^N!
M&M=*YOUN^Y^AO8YO4MU*=M)]>Z$"M*ZK#'C'F22**]2G=R2 6/L; &I8(7QS
M+%R2UY 9.+Q%G@_'PHI<:'B7(2$,B=*@\PZLDGA?%.QK'_9 ]\;U1&*YKV/5
MJO9(Q7,<GLJ*B?)&\IE*$C)6!"L&4D@A@"ILF[Y\$>2>+-FU"/\ V)-K=C%N
M2N)#8_TD$ 42P)NC=6T$_P#A!?\ _'A__EM]<8^3^9_OKSS?>;_]C_?\.-;'
MJ-8Z/331Z::/331Z::/331Z::/331Z::/331Z::/331Z::^.3W1?^G^W_P!_
M337 +S#Y<+H3-^?;V]U4X.Y-T59KZ^MJZ&SJJ\@:RL#*CI4H)%(?;D6>8L65
M95BZ Y*,RL&!#TM':! R319-"7[4,?"IT[5TPF!>7+K1S0E$D[XRI=%[IIED
M@D<$]S8[DQ* "6G%F,YACCB$Z0BE#QLX4$Q$122!RJQ1.S*!#6"![!;<^,;)
MIZ;&ZT;1:F?.#6--%I,3FT/*J=EBK+HXM1=Y \NXMZUEN;9PY753$)/ME;J3
M]*4(PJ6L"5RABV<;!RLI7IG;&0V\9^KF LHBE<,[*B;IR0J%T44VY*L$>2B;
MD)TF&:S2*0Y5EPW"O9AB:"(-*-K @B=H$C91KE!V;Q;Z;S_8]"Q+2,:89TZJ
M;3P1NNM0-!I-#A$#N<UMY.9SR[.N!SE"SFS\6VWT6E_=V0)MG)MK"MN HBP>
M?*9Q#<U1QNRI@L\4,)9T59(8I]Y!%N&::*<M(ZL1+(7D3<I%13K[=XW+3Q,Z
M=()(9'@?<2+&O<'ECVDQAC8.BO'$E"*/!%VLTY='M73^3%WA<I+0]-Y$_L_&
M]$1B;BJO[A]CG;CG6KV6,IFYFOT275U8'A4E.,Z"GAU6,S>:8%"73'UPVCTU
MGI$J]N+=NA+;N65  R0[K;%XHI TD@2  ""->JS,RQ&>9 K9-C$T8%<VQZDK
M-M&B@W!>2.7;N8W8XUFS@*\SRJ;$CR1=4]JJN49>3HC7]8HNC4[LKR\J 365
M%GB@;ZRLVV[ : R2NDT=[DZLV '.= EUN:H\F\!H6XJ\Q:FU-U56Y=;J/N2H
M,ZT>Z95AD!B>*1A!:[E)%8DR+*C/N6E@>8+)+-*HB:6-U,Q2.R1QOJBB:1I!
M( @ED4='"3$*#%*4V_;'MI28U5X9Y(@4,744!6U*\NWIGX;7Z$GI@&0K*FY_
M2*ZV!7PKER2[8P>M09+!X:TAU=76<L.=.2.<PRHM:GYZ,<2:'XR[1;;130EH
M4GC1!))LIY9(8TCB,@CO<M(0TKI4G51EBE:94VY57P&HL,MT%E8RG"$A%FW!
M)*EV6&,![LL3#B<:9FD<H9!-%/4]%SV4>8,854:=!JR]$RK-(]N?EUHM+6@R
M95OO46$-)E2+2H!)@DH8VEO:586$ =>Y\H:Z@F&Y#=G=*SF1I(D9H85D9RPD
M$C%Y&#R)(\I<XE5ZKAEQR:.(2@FF5;7,9AFS++U""V+8JU*BJL8KE+.32'H+
M+44Z6UC75U;?E2UQUB#6V%B773:#0CPD'14'W1A%L%',9%.5(9% <5+&XUKP
MFL9),V88X9%J439*R!NB8RL<)**SW*\:*02(P'9(E+*Q<V5U@*R4*R1K?]:,
MQ4V>6"VY5 ":4,U@BCVAI7K0O\G./*&?*P%\C8P1/XA6C/$$$A?,K+B&!CHR
MIT.%B=!8EHU!&RI70PL8]6ZF B+M]CDRJKX-&)<@3B66LW("D6H.!Q+-9 U+
M. D:MG8R.19SB"P Q0OBBFF)I"22UB^[6K-A]!<6-<UT<\E(>"7*LT9]7/4L
MG@FGE0.P)F'FNQUMOV(?J*KH9Q@8:^6!"ATFCC-M7< 6C0A7LGJ86RC%4^[U
M%CR4!B 5+.7:_ 9<6>)<R)@63$!#U QOG)%Q(/D!LG'FU3+D-H*"RR>I_@KL
M.*L$ E6<!]88LD5^/*),EM))&6))(P&&:U#D&DBG:9&3&L4RPPQ21$; "R1%
MT&;.:GR"E8V+ PE,75NH>D^89"O3 (MV4@3U%#(Q*D#"T-J5X.3$E>0I!'&7
M..7(+K* 76-EL(F%4#W#",HX00X)UBEC8=6I8344CQHI*9"QAV1_0C97L/$?
M+&!-&A$, +!5&-Q9ZAD!*E3C((UER1EDIF!Y"Y(X5I5-'"BM*P+D66<2,&R]
MR6 <%@"#BUB@00.!I'QU5J[.4XFP%RTF1_DXDS,&;LK(K3MK(\_7+-8:B701
M0@P::7327(J5PR%A09L@.92G6,Q,,>+RM&\JLAB8$A9"^<<JD@J5BCAA6%,.
M JM+;('$G< D/T\5'59WQ6U*8JCANZ,-')*9!2A@_P!B0<D,>(#-.0L5E,Z0
M^9'U]8D+F.%L0_JG#G%(GBFG_99.^.<,IC6O'>R-8UB;%,R18Y58R@X !*#M
M8(=6H,K $*01VL.+L^05//)I9Q= G(V*4AAQR"H%'(\"FKP0.?,1[4.OS>JL
M;6">LA=9@,,/-/;+..&:D"0_&$)L@T8[Y@1XC&$1$N=)(QZR#.>C)_6U 6F1
M(:=J<XQ1XH63D"W(<L5D)%.F(!8!Q9&LPXP#&UQ)1>0&/))I2+:R2#BMWPQ%
M :93M'&\N.O+AN&16D1LP:AU=V0PH6FG%;-&2;5#D! K(68&941%FB&VL#B6
M!U[XJZR>W8$:HZJLD74 Y#M&J D EE:4JK8!BDBA3B<2&-J0 -%\,@&(4AA8
M+!W "$EF)5#9 .-@/B2HTF:O6&TW/='H,U7':G0TE#=.KJ") B;@_25H)_Z5
M.6*,:% \NSN1Q:6.(::&%3BHTD)$$28T7-XV25KC&)'551<4<L7:]0O(I N+
M)QU"#0(HR4K3"JO(BR.47,!SD&*!F S\DL%'-UP.3VDU"^!Z/>V&"V>WT> T
M .LRY^CH;[*U"UI-ULM-@A" ;&/,5I&B+K!I;TJKE?G*G_(W5Z F5Y!5M&\@
MV>"7DVKHK;9YIEP+2JT$F6WD,N#Q)%$\[$1LG< HD+EP0^2L\R0RB98G:%%[
M3!(76->C*O6BDFDDBBX(EYE88FFQ6)4Q5P9*7J-S6G6W48LED@[".W+%PE'.
M1HC *8"T%_CTN-Z;)349$EO01SK>UD&7%CJ["X_3%TUH)4QS3V(T3]'H[66-
MP%BE:60/(=Q()AU(XH0615R1XHS)(S&/O"/(Z&E@D;%4G:;NS20*(HB@52HP
M93('#4&<L5 ;)0O8ZK9NAK!Q[)+(N.D,&";&'7268-0_]2.7]4$T*(V=! U)
M.L64XY<LTP!,[ U@>B201MV%V[W$RH)8S* TO2>9>H:9HV* /)21]4QE5D4%
M@5)).J'=?<A5Q)+$XK0!))( "XG(E@UD42:'&_:S5;)I6V?V10,!*E+<6Y(J
MML#%#DF<YA3V0D/C:CO::"*>(=K"6DR#O(A0FB-)BBM&1;L@C5+,X8Y!>44L
M@LJ,69"Y*%0X1L ^]9!OXVS!@0>" 6!X4FZ-? W6I4\?C08=[I:9&(VP7+BV
M\L7N"^:"OEM?XP!YCHRY3993'5Q$D$\L"L?#"L,LZ3#)%ZUO48W^K0S=W3ZS
M164D56FZ8FDP)01# 2 ,B,""0X3!E8V2 8*>VR> &!(4*.:X.+D\=M#$@&P0
M+B^N-JC1Z::/331Z::/331Z::J=Y5]E XU6\ZL;!MB\;0;.2IGAKZ8FV4H6"
MCLSYQI'C03K7*Y8(YX394CC60=1UD1T[4=T/3UA=YTE$A9H&$'2221A,"'R*
M1@DJL:.#E2EF4>:UU_2-LVX?<48U$<:.S2.%4+U%6^:)-L  MD6& -8G@-Y;
M^6NCW75TO..IHLU%D*:IJM>\\:2+^'.FL73%WHDI"L%GLA*24-H;$(_3C@$L
M9S('^P[YO _2+Z6^I[/?-L_2-]N!L]K$8O45$ ,,2RR$32,K,(6E6,VC2R8#
M%U; JA;ZI]'_ *.;,[*,^IQQ2ON6>7:!9!4V"'IQG &3IM(K!A0[G4H02S:1
M]3JM5H.84?3\BQLQE&&;/';V8)5*FD@6:6$6!R6<4@Z"?R<C#3BG3O$'(@>,
MY/KF(F;=ZOZCZAZ[]%MGZIMG@;<;%BB/N$;:S;M8@63,,TJ",,BO)-F"K9 $
MJ9&.6PVFSVWJLWINZ>ED92XA83K%)DI<C!BS2&,-$%49R!U)"'%60P;[#;*U
M9_,<_, O7T*AD* 648I<9HA4_P###!@3K%+.*]L\O[$\,,K(WBM0M\B,B'X,
M/JGIF^FACWOHY.Y6+HR1HX(PZ==(=%CE+%1D48AG&!:0E% W9(-WM8"(/4E;
M;KN.I&_3,?VBX*TP9U[0W,3"G4LH+1@"QH9W@U/>MSU%V^GAU& +O3$(90 (
M588JN(B_7A/($M8WV ,*J98%&!PS6A4JV!2CQO#2-BU>E_1_=^J[5(MQZ5+Z
MEL8YV7#:[:=IMA$6)%!T5HP+>1T[Y)2X.(#+5F\]5?93[B?TS=#8[IX8SG/)
M8W3A27[E8H<SBJEA$L:1A6HT6MI0=LY5XWV)=UA^7FUU+%'5XZ'G^&$]KLS.
M-*%J0],;4UT4Q) W\Q?1V9LH[!Y@JR*SMR%<]\Q$OJ=Q/M/HR(67TV79F198
M8=NJ1K+)M8WH2% .K9G8MRO9&9'!L-EYYO3]_P"ML5G]16:2_K$N[WCN4$Y0
M.\$<TI--A&$56X:0J@"*55:R\5TA/.^F!Z/7+KR[C=13#NKKQS;,VOAK?VRE
M(BE?8CAV R#$UM6KWBL@2&$IW^N:!3G>8]!]5;TSUB/U/?MNS];M!'(&.;A7
M$80H12])T0HN4:,,BMKEKM>L;)=_Z:=OM4@$>T)PDA)"L)50%70*S+WK(X8L
M<O"F[ N]MNS5LY1>4" O)[J I*NLJ9(1AXP;\6&6P%(<]2!SX@B:V=29&K\A
MT?$Y[7O0J%[_ +<OKL3>GMZC! 2[[I]C$A*O-)*(%E"30LR5$R-Q(+JB#3!;
M\-#Z4\3J))(TC$<4\C EB8F?IC[L3 @R8C%2Q^-"]1]K?'[J6GW_ "K7X"Q$
MI,P7J9='N^C5%E!35>8HZ<S/65PRQ+!K4G(LC/\ 'C<E'!]A0MA :)7?JD"3
M'?1X3Z1[7U'?;K9[OTWI)U=POUAX6<.8"(I).M(,!)1B,*E SX-BV0)KN[+U
M+T_:[/?[;=!Y)5B$>SVKIU.K)*)$ 4.0(HT3<B?N(&2%NT*,I$\O/-BTZ-<\
MNY[XP7BS#W-\$0NH(2US;)],$O[85;8A'1U.@2AK8%B(/9#$)-9V$T K'. $
ML"(]'U/UR<2;38>C@S;S?;R+97BZ")G90(Y5FBM4<$MY4OPJL!8UJ^B_1R':
MQ[_?^MHN&UA:81HZ2AH65T>6)HA+"[LP*J3DD<9ZBAFP4WM\0G=OKL+$%W2X
MEMS4JSC;\XVP&L)::V+E'+BJ([,91Y5"AJ"/]*M&A'BEC1 E:S_4_P!?%MYD
M]-V1WH7_ ,S(V4T4(#1A2TBX@B...1E90&95!)+*;"@Z\CZR^PEW4S^GH(]O
MF.@H7 M&%%LZ\C,FR;8'&NT \ZG6,['F-!5STXY=C47,4EE$:B-D9!8N)FD;
M^P8Z2.1KY$^2P)(V9Y?LOL[[6O>_TGIVZ;<1F.4%)8F9#7"K&BCRMCR>*"X*
M;L!2HU5MF$BN7Q4JH"@,<F#  UP1P#[401[D$ZKUL:XH3+Z30YK]E]] -]$7
M[+/V/J]R9R)8V*J/EEB@8XF-D+I'?KL<R9JJJ+'-L[O<;J#9SF J[A9)X[)<
M,0+/8JD758T"3C3*:XZFU2)]U"FX;[,,HJQ&%%@62.6)X%51%VQ Y@^JT4=:
M4I$X!?\ -D@J1/![/9(9&V&1S5$0B)(GO?.Z6/\ I6QR+ Z-BHB>R<39>HME
M(4V;S[EX0\JPY2.0$CR;I@I3O,1&[J!F5 *D8E>O/L^J1]LH@$A17(552S15
MR;H$!"#PP8CPM7(=3=Z*"N6J!@A%M"X"G2S62#_;$I@IO\<YS7I)++'*Y8U&
M6*5D8Z3,3YO3Z8TW(=U.G36<2(S2!FAD9DG17E;E5.<1LHH"&3@OB0&#+K4G
M@@9FD4!HT*XXA1&3&ZAE9K)+ -9(Y;R<KTW,KIM!3YP^TT]E87!8SI&V#BQI
MAF0*H8[_ -,9(H(V&,F,E6)/];Y60HKEG?\ "&)NSZ1)N=Y.=L>J&?=NX$V%
M[?:DNRA65$#, H 8#IJ7I"%"*,-]MH5<-"J(C1J51&!4MDQ<D6<.WNYQ!->"
M34-6X6LZ$B'GW5Q-5L.(4$)LL@H,GZ3_ +2%;)]J/B8K&N:,Q(9)GN3XN? G
MQ<OI_4!'LMNVQV<4:[C<QL9-U.AW"QJ025/4R =E5L+#(M4$%A@VC1JV9"QA
M0I  !D.62AF8*;!8\ %0*\@<%KZ0._KSH=.9H88I;"[00F&RA;/'+7PU,,;
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M$!@.#R/ KB*:/<.58$W=$6"O%W9KXWQ\"1J+^<TN\/Q, W:F4%SI5M"BTB&
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MTIW!64@#F,]58V+&-D*$.+"LLMN\<8CH,C%I,HJ+D%;U.GC]%!/O-I:L/?\
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MJ48Z*L7XS0-8LY(_ZD+97(+&+,LLQ$+99I(]2$32IN4.^_\ '@@Y2O),'#D
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M9Q\F10KJREE;L9) M%9(R VFR+565#)H1<O48O/-C(JJVML3I+:^<2*!7UA
M8Q].D-&X>%L"FPBUM7>%,B)A@MEG)*MC1 \@H3%PG>5/&21AE#.OWT5\?ND9
M,@  9%58T3.]91($,\LK@LY8*H-$V6<,22[,2EL5'%J:(MG!H<D$79U>]$K"
MB][7TCLZ*;2V$^>_EH;:8<2Q>?7F6\-+HJS.HI6BJ0-'+:%TLD)C: P6>U-6
MSK:-0)'.9( )PQDI5SZ*."(P<7D95<%0.I+C%;*I)*P(A) @,A-3<@$XAF!1
M79&D$<:2-%&I?!%D/35<8?K=G[;(:@L:JKK2.'!'WG4-!I\V:);Z#-&9K0 S
MZOEU94SSGDI:7=54J79S5]A46%:NAS-29;:&H+ACQ8IB4*QS_=#O(R01[;$%
MF(,PL@!J)C>.*)26>5F+QKM*C.C21M,HW#%((T FDD<R1E(I63M&-$B-QUI7
M1)5@C1TF#AP1,5BY;EFNT)58VVM5K*?? 2":+]:A *HK^K>/)<5L%Z+9V.>?
MJOU2:-DX01"S0"1_<#<BVHTI&(1#"SF]R%$>8<XI*YC@0"%.H5AE5%5F5Q<J
MB1&RF5$6F($Q2.U1^J%! D1@7,C++@QZBF4#E,BG:C[]7;G7!&TVN&&I^@5)
MV!SD&(N8[-E9F^JRWM;'9J1_/B5IE5HJ2&F(J(<EMFR7]9!"7>50 SW5ES]F
M+G-PAB?"%I)9>DL-J[6JQD3. 3$D2F54.W0ETZDSL\219KB(HU=Q$TDI S:1
MY(0O)9 H+JSNS%@RM(QC#K&@!,LC<UJM"5J=#I-ELZLK/"TV>'J*(S,9RLV&
M5N,X':5VDLIM+4$E-T0%Y;'G'!.(IX((EL8W57Z"0&)99LKJ0FW@V\1G4B0[
M;J(LV969(W$C]-5C+=3I)+($8AI99&EQ3%S$JJ@$[XNV)+]0*C *A6(HLJL4
M2-"TF+NJL&3%8R).)FQ,$-_JK'3U) ^5&#V._/((8G\5%FJ\H@(\P N8B/,A
M()6VLLS1(AG$N84CW3H\AZ9)++&SI$LBK,'AA19#(B),%$BJT)7JELD%R&0!
M@K% 0M4/;+':T%!"D1(KR$,.7+*;HD <@+Q5 7J1<G<U-KFLUJ8YB7CGBU5W
M26EE46=/>0U%M51'.DO1+ .N,I[A 99Y"@CQ*MPQJL#-'%(9(,W69E5V(,:Y
M]K*KW$Y#$J(_+=,+12\V !;(EB0:*0EXO>F5H\@Q#9"P#D5<V1W*#?% 7>IE
M9)(1I(V2E?IEP54Y4X;OJF_D@9IOU?F1/&CD%DKI1H6Q^Q<GW2/-=^M&UJ2^
ML:J,@ ,"R@<D%" 3V \D."<K4?=3GDZYX("@T2N5!P*57H,1R #EY '-5R>-
M*)Q@@LL [K2.N+D8^Q8Q'"R%%5];.&AWZXLR2.GC?(8(-))'&Y8D+;_S899(
M7^L%1RK.%M%8(S$'$,V952;%,0C'GSB:!HU/+FNEGY6N13$,%)84  >>2+(J
MB+IA'Z6RMS38Z^QBK*D99AI*X"+[3IB#'C3BV!9$*)-"Y\#I7O&8QT,C"F/D
MF=]2.DVD$:BBO4D!5LV)5555;.-5)Q:R4(-A@$- $D"R. *09+<E;]F %\,.
M"*!%79'MQR-,L;%B#DD_LDQN-*AC5C6#0CCC#"LC$#9" B*XN +V18TLICG_
M +,DC6/BC>V%EK[B1RC')HDS 5G9LI'8R.[N*(DD%AFC$=H!QEDS7@JHQ7C_
M -BH%T/NJ#RJ 'E$KV'WM-FQS64$V(>IUND"0T2RJJ+)P%3KG8 [C2!/IW5+
M$8>R"_*UDA WZU&=&5(IXE>2&.\I@\L6;32_5TA2***)E?(A4:691(6(:606
M$1D3$1=.RC"1I 0$+9#8]8UWNPR9%">'5%48,H9U:1BP*L5&"YAT_HF;BU(U
MEGJ3H!?.MDYF=+IM)5C415SGQ:S1U4T98E7KJZ[S]L'<$RRYU"#Z0J)\MD;7
MUI8EK''.+D&W70'0"E+DL,C3Q.61LXY8XY(74=%6,@6575 NX_H4FM>FKGK1
MEQBU@.(G\4'694+"F*L,PZLP,;*RDC54\%R '6=I7?\ 2ZS)9OJM=U+;[ZG'
MS T1-J>+701<XPQMIHADT! L!G,P"X-#1U6_J:JYE2K9:9F4FFNJ]G2F1$VT
M4FTV\@V@@DBW33[R83+/ND7,+MV>)>B[*CK']5>)&"3QR,9H9(L^J_3EB>1I
MED,/1==O6W"0EY6!8"FF28X)+(HD$;2PJ450))\[$-G"=/S/]JQJ*ZVGU<N9
MAOSL[G;Z:K#T%99LFS =J?=4]YC%V6EI<R!_*4K+*PL[ZJSU P)LIBE@Z$/6
MV[1[I8@"H89NFZ >-@CN%>,] -@H*G<9Q%"X,<C/&#C&%F2:,%W58UE=(Y$)
M!1\5>2-HI69 DS@E.FR!S*9 B.&>EAC8)8;.HO5HCL??P' V- ;25TX]L1;
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MQ$FZVDW4@E 9&205?NK42N2FP0"0>2"1QJN0.I9)!3!RKH]AEH F\035U9
M(YOS>[I:B*;+VF56P.(RUVT-Y8(9TL4HA(,K9P"19)'2?<@KXT1PI"21?%OU
M/8C416<[U'TW;>LP2P[E6BD=3'UT)1ZL-3!0%-MY-=X)!L$W9M-W-M)DF50S
MHS% P$B\\,>00#5!:/E?.H1*RS:6V$MJG1+:F-,^R-?JK@+(B$@N.5L12$K%
M\C65H:A$0C2N;-((CXHAC)!HI/#S^@>M[&92L6YW01@QW$$,3.RJT17(VN6$
M:!;8TP44JH$(]-#OX=W"8R4B.'*LTC1J54K:CN*Y2'(G'M#5?!8R&'FZZGL[
M P)Q,4EC'_(V)9P$PY4S%'0@>)KYI'(D4\I$8_QA56*4V(=SFMC9%+VEVNRV
MTQDC=$W&[MI^KVN55;0QY\1LIQ1@ 4LQJZW8/.:>>58XR00A,4:JV4:@L!);
M ,3P.H22S$#@^&&K/(06+5WE\&0 IT(]I*)8M<(5 2Z9HTTTE>SV9'/]OVP2
MRNCC5/FJ2HDB*J]W:%/4?3KBVYAWD^V"30RJ$E C(+))P#3%!B<1QCP%[11(
M#M9Y(UD#!7*1R)W(UA7HMSP%8<4P!HT"!4/Q6.MAWMH,7".7@S,Z8E8Z-I;;
MIVG:0YS7ELGB1T(T@DJ-'2&3ZO<)&DRL5\#4\EZ;/ZEM?I-"NX2/;^DI')W,
MCK.-P[ 1O*)$!B@:.1T["JJ8WZAH GLSP[*3TM&A<GU)9P9A:B$[<(.(U'#2
M!ZR++;#A1PXU8*DI(USP>C^R*QLH7(4'.,G[$]="1' D['?:]/\ 0TF4HAD;
MG*HL3Y&N^M51J>^W.Z<2R;=%*H00ZL0%9D/'%KR5H78R*\$D6?-2*>I3 <"A
MFN*N/(!921=&A1R-@G$ C2?1ESVC[0:.#ZBZN9ZSQ(QQ*LD'8U\BK*Q?D*K&
M_!L#HFJQWL^3XJD:IZSGBB0P%\2&Q,3MC57=*&%L0%R)/(+*0;LA,O3C3D]R
M9<<>"!\269K((:L@"2P)!TU[#*G@6HMI+^HHCX+)DPL)0ZE2CV"->1$9%$OS
M^231QS-4I_Q1[&.6-L3_ (+O)N5DC,*Y@@H0Y4A%9/NE6('E21VCD!N;%F,D
M)8 ?:$ @U:TK!:JZ%4U$\\ >YU?W@FDI+7FF>IZRR(L"\M5UU+9LL)7/L1"H
M!8W,A(:Y?L^AK%1E?.B/AF#CB>R5ZMD^/@_6MO/#ZA/+)&J)N99)4P4"-E+M
M15@.6\9J2&#DV![ZFX5E<LQL.3W UE?'( 4!N"6!JK_$:EY[OL:BI\4^/]JU
M/9?]2>R)[^R?^S_T1%_[^WQ_W3US%4@_B>1P35\\B^2..1R?8\ FK-11*D4&
M --X/%$,.23R" ?!Y]M-+4VX>>I;2[.;+(+5B2DS-@C=)/(C/;XL8Q&^_P Y
M7.1J(B?'V<CO_915];FVB;<S1P(0&D95&14*+\G*_ 'N?A5DZLB)O(+Q9Q /
MD-P5 6V&(Y'(/'PXU:&K(:76@$L1480$+,U%_M4;+!'(U%5/^OLY/?\ ^OKB
MN*=@?(9A^Q(UQ7^^U^<F_N=;WK'6.CTTT>FFCTTT>FFCTTT>FFCTTT>FFCTT
MT>FFCTTT>FFOCO\ ;_Q3_P"Z>FFN7MQ: #[S0B&R4PQM]I=&-F) U)+DNA*A
M9#25,*<% - :$41:N_C82S$0&%]@+,LSK"$/=50 +"W@EDN Y%WV@]V*L:&.
M2B^2,JUN+F%!QD944-)<9PC+' &SDI+J(CD<"Q(3'M4E;8$.MC$0^8N*;]:=
MLT8Y+PXR(B)PVMD+"8]C9"X7#0B0F?4\@0=Q@OW1Q&O;+!7,!0Y Q)"@@^23
M>1Y %'$98',V"1QFK8A@51@U42"S&@UJ:[3]XD@V3BM50!]$AFSV1!5< CEA
M-KGM@DFG>XLE('C$SCB2RO$#AC DB1I?LV8A\=C%, C)!B_64+J@<R*2K(58
ML6! LE%  LC*KI@#:_\ I1AD8J@R[@20 J8XT,@[<DD $UR10*@!B-,#J&=T
MHN9V^AQ-8A^_K<3([.+;6-S455S:,AG,CJ;-:N9S*YTAXL,)=X""^<0$^6%@
MSX8IT(SS&49.3!6)9%,*9URN$DJ2=YMP$E4H9!&7<$AH[HNVHBH5'>V 4N1B
M5/>A ,@JJ46Q(LDXHII^9H=1R2LWVMS7)EK)K?29^]J[*BUY.J+EMC\U355O
ML+; :38XAKR+8EUI0FGX_6D5A>=H"-F83!J 79PW)MLK%7A&XWI"/*9EZFXA
M%!$:%XX/K9@$9;%H8MG/*LKL\A>!XI#T0SN.C/)!$!<71$4<!Q,J/&%W#11H
M12==>I)'V5$A#M(%GCD86>J RF6H"8O74^FEY]DFQ6UE7<_OB9Q%Z#35'+\;
M: 9RC?2BFF6K*&H;5VECF (S:T?<6DM=;+ZK@Z]A$5TA$1,D+(KQ01N(TD.<
M'0$RQH"C3*1N7 *SQQAA&D;DJ2@+"8, <RQ&X812,K'<!I)S&QX[ ?JQH8(V
M&9B#R=Z=O>:;)()L50:"YONFU-_SF?FU1?&]1Z%F.190W8:_+:L5VAY^X\ZD
M@LX6U116[=RFPSMJ=3W-</9E"U^HYL^XBVP+@"!7B@BDFCW)FQ 9NH5VVVC;
M=.P52C[<0R3XR?6!,E%5Z&QVPW,:QL\LN(W#+MG41I<O2BC=)I2^T3-CVRDQ
MR&2,1X2'IO'>;DM%C-+51:^;FE!SW7[;/+G;L35LR,VDM\Q17UT5!47<%:?>
MC7;)9K*TT==6-/F:V&R*F)8!+&L#;52-E;%9)HI%$@AD;</&R[D!V8I*[X$K
MTPX(,@55B8HRLBZ>ZDFBE"-*2=O( )(01TY(UQC*R].(X^5R/:K%F3(N'>S4
MI;:DTF.01)QY8JZ!6SPL&G=9RR$P2Q"O>KUGG)%%ED9-&C4A&&?\&O69ZCWK
M&'C4%J(S'!8J4H%5*T H1R BFP;/*X@GF%BY+K[9, .[$*+R8KXQOWKP.0H(
M+?DNJF#2 Y;2?Q(5]<#CB$CD6RPWUA,Z.2R<RNK9I QD7],<@F4FK^T-%$M&
M,:YLAL26,R("T;VUDI&.F5" E S=QE^\2,&7D,&)H)J$AE:+J(&,<98A^FYB
MR46<I%CP/(Y#4>4]P-/O9DP*-64^8)@.M@31:PK]XVQ?$-7DQ+'9.*D"D=(I
MXP?Q+C80Z!97M;&TH=\R2)KBU(=E(#MD,5C#$K94IU%*X9<,JBB+%&JUCME8
M]625:B*D\ D9J05 K@9$XDFRBL6Q/%TY"U0F+W^U6WY-;&[7/YK#T]OT?(4V
M?,=L,X5,>HXPHL6VFWEI6\S6TD(NTLZ]]HQEJ3)E1[TT^5C[?K49ZSEA"&D5
MYXF:0PI+0Z;AOJXVXZUE698U0%,) $A"KU#LVDC@,<I:*0N(NMTU(-6Z,>*L
M+: /W<407+'-2=A$I='K1]5B;SF(,P>#J=;L='+HV9&YZEHILIC\7GL-H-.5
M0Q:&"4<NMK)@:ZLJ;6XL5& F!GO3S!Y*^L)FD*-*[HK3%'&Y/2'<7$87:MM>
MEDI8OMMTO+,PVULSHDV:1B'%XI1(SX+&-L&, 5VO<*L[RQ3\=J3PR",,")C&
MJ9/NKL@=HL&0TW(;%F9I#,9KX]"?=T-]D2]O77];K!QJ)TMS'JC"<Q;BCWHM
MA99BHJY7 +^I[2#_ **9LCF9XBNX$D 8YRI/&3@IC 26V+BCT64R%&#%+>,R
M$42'%!,L\+_6,UPB"%PCY49(S'T45Z#+C*\H)5Q3 $MV7K_ MX/)T;/;O)&9
MK/ZL#'7_ $C)V6.MG$W68T,[W<LLKE%LKF(=+Y8FIGZE&%6IUQ#%1*DMFLYF
M[#M-RP?I1N-PT3,T9CDS.W0L'88"BR.\JNDA#0E'!&1Q%!=XP$D 9&#,BLS(
MB22HJB;%RBDF,6) 2N"DM:H2OFRZ1R+31MYG<:S]P;H6;-K",>9F6+)?YW7C
M5&="#M<D\*32YB#Z;B .S%NJFD!'G.N$MQQ(XV)7Y31,$ZM;=79T"F3=2Q;C
M)1-(3!*'AZZ/)&P2:.2:5<88XY1(06A$DC/56*4K&W_*O?$CJ58JYJ1>HH()
MBXH'J,F%AF_S>ABI.@V=BN3T-+5Z;) 2LO=K7@&G'["O-)T+Z/&U$US;;&DQ
ME4";&979R<@6BHGYM1: .NE0DJXPFZO6>)I%G:$)&DZ3.=NB,TH*];I1QSNY
M>S,TKNXF8A"<\+'.<$14C%9G9]NA(<HRPJ)'4N8T<E,#A$DA8*\A<=/2"+I*
MSL<6W'Y/UJ!V\YX**+*),.-(-8WL48.CQTUS474UT53TP[DU>(N0M#0G7P)[
MKBU<*'=YVJG,#=N(7?:IM9EE4([@KNB#2AQ&T.XACC$ZLLN<71=RT<9EPCD1
MI, AEC3=PS1H[,Z8JT!CC9WB>W: M*T;1I(H$K0X?TW,#%QA_(WY-^0E9Y">
M/'A=@NNT&.NM;8Y?0="\@#@L=4E!Z6W6-U8VIIQ*"_CK,^^:D?5U41@0Y3[B
MVR]<[7&RQO:N,,K-O=ND<6V&X1I\(MS"DD2QJ _0@CW<<\_6*]?IM!(DG50"
M1U9BS[<<<<6QDG8OTYE1)!!/(LBI$S1M-($EAB*2N5,HW"F!8Y',,8X"=R^'
MYC69C/7\^QUVQV]UH]);640^I94@ 9]M8(!0_HY<0$@B:'-71E9/H:6>8@AZ
MCW2/+&"DD_539W4L,\KF*+H1%BRQ."9520DM$S".*UB K%LR#825X\,>.R*,
M A#8I&I='L2]F0D<9,H<@@.$"'($A;LGR)0ZC.9NN%#ARE 0 8""^HR53,)F
MFYAFH<6E/44!1,ZUMI%FRC*@>8$H:N_EIEL4#2M'!J*^(#&J+$$CQ"XH'++'
M'4?2Z@>.-254+'+@\)K'I%@ TTDRL)))6D>60N7;J/W2NY5G&=LQ=FD"EWSY
MR,A0$F,S_P &-KWZO2UM<4Y6UM3 &9 0TJ4O]L:4'XJA9)+I$AC#(%F6)XS&
M3N/C+@GD^<WO5Z@&^K02.H!>1F4ITP,&#\&.-:R+!AD&9E$11@*&M>6S&#3"
MGKDD@@K:GDW9 \GS[>#JUWKDZU]'IIH]--'IIH]--'IIJG'F57@6./RS+@HV
M*G'T+BC1 CYZZ0Z6(;V :I(\L<C'"FOB*C54FB18U^X:>/WC=W?H_MEW.[8,
MBR&-4E0,'(#HV2EE5@'7@Y1L,7X!(&NGZ9,\,DS(2&:,)8"MVDV]A@5HJ".:
M/- V>>>Y&=KS@M38A5[RI]7D%RX[KBXO;1!CPCH3::[D<2<O[3H8(3AIYFI$
M9+&2Q4?/%%*//N^M_1^.5MQN-JJC=2HJSQVR0R@-&N2PJ_2AFC1G :-%=J4,
M>T#7I=MNY5>%)3V;:5I$4)&N)<$,K4M%6.)LE@O)7$D50SL_B@_;"6EGE[/*
MQGM@0$;/O9(KWTP I)$=FH<P,#W:/]Z5D0\XGNDC71NA*F*<P:7Y)]+/H!-N
M)GDV,&W@FS B@D*1MT3E]NJ3%1U3*Q ='48AP96<8M[KT3Z5C9&*/<+,ZFV>
M1 Q+3-BO1D*Y?8")03$0;95!H$D)FDY'PLGG=4 ^KMR-Y#F I]-?6-=>6I1E
MD2(2"4YS;>TJ9V?KGQ20H,KW5MFXQBDA(I$\,_,E]$] /I04PO+ZF-I__<W4
MPW&XE28!ZZBR3QJQBF#JO%2LZ,1R=9[7U;UU/4A/UUCVAW1.WVT3QQQ,B,Q'
M,,1##IL#>*LI3AK4,(EY94T?.-0"XE^HT2AZRJ9_D62EK2SK.PLY/XTV[U<3
MRG2@T@P3X!B8GG_0=-6L1H-BH,[Y?+>B;%=KZDJ9;C<1P;A%^M[=5-R9J.IO
ME02,D4D8"A,HPS*5=) JZ[/JV\;>[:1C]6B9MO(?JNX6L(XP'6/:*S69PP,K
M2!<EC(&>+5JX/0\GT#=XC=,)%+LK:4C1U>=H:00.66O!NH5@HK"*O-(5YI=>
MV8*<^80DF9D@$Q@M6$Z>62L^P-Z2_K&PGVN[;:["29MPFWWG(BB80SR;9[F8
MR&*1SMMI&Z?9JP66XSG7B-GO]KZ?O]M+&LCQ(=O-,<N9"I!F1BJLJ#AI0K'#
MN$9=@"#1+Q'DTE1D.YC='YA>9O70V>>!)K;/.7%>'29_+B@"V@$--(+760>D
ML9&NLU.!5*PTJ1ME)!]D1L[OD7T3EW&SB]:'J.Q>"<-LH'8[8 ;:*!U[XH%
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MUEIQ?-EZJR_CNO3:/ 9?1(1RTN^QV8;L-D#?ZBSSX_/3*B2QL;/-R$R.&&L
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MRDB1F3HH12@A1LQ-ZE,LL6R&WCV\6TCW.[**IZ&W252Q7<$@B-I40=,1AW)
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M4 DDE$[Z0F^?)JXJTHZ$^A6L?47?^/Y<JI"RGO=%6 S2,I1XXU3(^'+/*>F
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M@8 (M(BXC)N)/*7D,F2L\OVDHPQ".6:T%WPO!5@;(-LS-;:C_H5IQW' W&Q
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M#(DQ"%2NW:,$6@W+E*)#,6").&BX3T2XV6[)T77IMGS'6XQ<XO*=ISK'6.>
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MW:!;!;9G- JHK)F#XKDE:USC9).=59/M^!%^P]QS=@#WUQ<QG!<MY2^0]SY
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MC$<H8K(X8*]QDXJP9;!=BM!$[R #B+%QOH-?@= 2.7D;K)W(Y$)Y!4I]35H
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M^QTM5A+F@'K18K,0C;SYZMK+"CG(6$,ZJ+S6AV'[W[8;EN*YD0WR/"5L$_\
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MN1&+*@8]0L[XK$?+>KVGT<.\V.VW$,Q$FYW+1S9%5BVH4A4S8@ %@&DMW55
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M/C*C$VE2"!E=')B<JD,850D=HS\V0P$JH5)9[RQ!^.M;ZNSDEAB"4-V2'Q<
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M:X(!!( ^!UJN3QR*(4D(; )4,!1]P2,@?NDM=$<0?4Y^[PL=Z7A\_8Z8&\U
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MBC<2)+@5)F#RVB A4+AS"3& P97RR7 JLLKO,\D2TY>E#.SXN4(M6%%V4,<
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M+M3NYD2PTZNXE0)"BR[C@*QS,2P,3UR$C !:)82T1<B]_A=E :+L/93*\71
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MV7TEVTCL1!]6DW;2#@Q%MN'C8$-&J2*429'=1TU>1@C$ '+3"T7-+[;Z#0V
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M0I<.5V&)_A*UPG4Z7:Q5GZF<(T9NCS$IMKI*JOC98?NNIH@*EV@-9_\ FEF
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MKZ_='9,FHV$^OTM;<7PM%M <A#FK"GK\V15D18T;]ND%R.SL_J[I-MMQTTW
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M]^_U<1R;I^IMU4;=-RN,;*PZ3Q,8RP:1ONVV(H$%E84'B;ST[(5@VHN'&6H
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MBI9/_61(8'AI$]GM]<DLA<D4C$5)H)9/M;!(V61?];H_A(G]JS^WH?LL. Q
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M_5K2PN:<6^KJW,9#,#YPM(3C3&7,Z?QXBAUUN34?XY8GQRR6H-92)406N@M
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M,XE$A=T*KTUR(#,H>P3C]RR,E8&B#C>0[?HDKQ33,I%&-0P*D]N8.0*D%2K
M$,#8)L T1KB?KN$T.,QV[LZ.<M\\,QEQ4*P".K=# %)-9O =\7QC?*S@BD66
M2.)DKYOT6$3+$/'!ZY>Z^BY]'V>[]1VL@BEE:6?IJSPR*K.6F!Z;@!G2-<B2
MF:("X18T5/H6V]6EWNZVT.X4,*6-L,6R+IB&)*,]J]A"2U=U479C V1O)&U
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M)8.YR+4?.)0?<'W46L_K,S<@A6!%@+9L 45YHD@ME=+9%V.!XJ*DF:T9(/6
M-,*8V)SXX&Q/<QJ-5(Y)U>WW:CF1S?"221KGQMD<SY(B+F_H7HD;?6$V:12J
M<A-$65^*'.).8XO%E*@DM0)8F&WDX!N=WH@D.;%'(^#CQRX-<$'$]O&G.=+<
MUT3 C8)600HUL,S"2IT5K6/6/XRD$3C*Q%7YJUD;6RO:B^R._P!7K97:;64L
MZDNS%<U<(02O +)B*/(MA1!"\\5K%9W-')3YXH  $BR,0#S5V"2/ ((XP?P
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M&3JY8H%B^+7I!\Y/2>@NNWF65PI:4.' 4+44N#%E81H6R41$C(\Q\FV)$;D
M11F+MC<!RB J"P"$L0"P5E))L $T+H$:Q#G$ B_"2G)<Z21L@\@S'?ZDB?\
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MV8.3YPQ1-((1(VFI'*[]9711)',]RK(UC%_U[/V?3C649.N+L'GN12@-.09
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MB,"[=G=R,BUF[(R+$"BU#52F='$Q= 9 SLV 4HC,YR".BHN9+E#$S$$ AD=
M1IT5ML)<\^)"<*7V"LJPDTE4';: 7,/+>KT"='<E9:RO$K3(89C6(RNL$"E2
M>O9(8UCK0FE%"E<A@Q"Y+<?4",0,KO(^"4<D!CYHWC9(8BSL(Y!MBS8-4;-V
M@6C8N%R5J4LQ#$-F5YP$OD6-L1!H(ZXFEN2A6OFJJZ>=D40$K:^%( [&9)BI
MI4*-CFGDF2""117HV$=ZQJUES9+S@2"K8L >YELBC3 @T S $JPX5JLZF"7"
M7$L8+',C+O6Z;I@A5R'A Q*DUDR V:UU-1LW\V!UW98.?W&SRQ4O2%?HL/\
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M:OOR7OF?$_[&33/6/WDE^Q$<Y5]FN7^GHY/=%L7U??J !,#B& M$/#$$C[M
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M/$]T,KGPSM:Z$B.6!\D;I.YF)O.O_P!551R*/"@#D$@_F?B=5*[*25-%@0>
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M%J;\'W'^/'[5JQTWBGR8\+R%JKP*VOZ/R<S%'CNITEG9>P!V>H^:P<IC!JW
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M=#3[6^SVQH</C\GD[#G3NA97$=#!Q%7GZ:H"V."Q]E$WZJA!9WS\_P#6IO\
MM7S^?O\ F=-_)_BA\;L?H"M #?=-)>XG.R50!)_/Q(J8'+^1^0\IJJK=;TO.
M*C5:QC>H8NN4BYZ'H=EJB<Z99U,F@60B$T9I9^)^17]N-8*;\37C7G]#@;ZK
MONF0MY\1R4ZOJRC.=VC+*UXIHKO1X.Q+T-MS8[<TZCSZ"S!MZC&:S*YR^!F^
MRTI2+.0FQ(:C6[A/Q7<$QH^!#M=[V_I(G)Z'D&-Y:+T37Y:Q'P6 XQLZ??9_
M"4\.?PN;C.H[[34%(3KSM&V[U-N%4U=0/HJ^LK018&GG4L>*'@5Q/PX2[@Y&
M^W?6V&?J\=25]W2\P'GR..IB2BJ[,UVGQ_.<EMM0+$X@>*6UZ9I][I2X:NJ0
MR\(D#25[3Y_/3?PWX]?'SF^8J<'2VVX0&"T\:+FNBLM-4S6917B+I1MAS7X*
MVB&^^!UG%"NO9$.O\D&_X#.J7.;,C3_O^>#_  =/KR6\).-^5=G#<=.*V@U@
M+R[4\HKR,GHH:)]?4Z?H_(^K_P Z(KJPY7:2BV_$\+9TLQ2DTRP#V5==4ER!
M8RCM?/[:#C40[#\?-4SQ/\N>!X3I.RONB>6@VIMMOU[KMI6'7=KNK_%9O !7
ME@+@,KD,Y2@U.9R.>K! <AD*B)&UR&S0E69)AA#4WR#\--3:_BOX3NE/MND=
M:[3K^@ZNYT#;_I6RMN17VDTE5J^;UO*Y<)'1WO(C.=55378VE'&S1^6PM-NZ
M@^2ZN1-8MEHM(3:J^?G\M+^?^QS\_@*=%A^+CQPNC#H=':=+TF.M)ZDZQYM<
M:&@?C3+2O\3K[PML;25X>2"UB$Z7AMT-77D,6IBKV:'/TN@HPJ4E;B.W:7_'
M^[^?V\:</'?QQ\,XP?SFVH[;66]QR[H1'1,Q;&T_(<N9.=+QWH'#Q*70IR[E
M//1M/4UV/Z9JC!C+N S4DZ0MEQ::.Q5Q0Y+Y_+4$W\_/YZ9R?BUXL#DUP^=Z
M5V+/9*?E/(N1VV;?_P &MKGM%2<372QXJXTN>ZEQK>T-Y=LKM==5EC ?62YD
MJ-X-K%G!M%55ET(U-_/^?STY>*^!G/\ F5#Y!<WU]DS6\Z[9SKFWCOF,V=<V
MA5X/X[\EXZ[G]1FM#?EO&/M]B?;:;I^EMKFI8+ ()H*L4!D"U2RJTO\ W[>?
MGVTP=/\ BJX'J02S^J=6[5TK8(?QTC/=-ZE;\CU.@R1?'*[I.2P ]32W'(G<
MSN8I\_V/:YFY"W&#UT6G_FFV5C$3J?C=O:CY^?[_ )ZF+._CYX5F6@K7DZUC
MPY/&@ARC3Y&B$*.\5^A[+J//CW4V6QM#GP2+K7;O0F;:&FJ*P"WAGABK J1T
M<DLK33 /_&)X]SDDU0NW[#1Y[7BL@ZMSVIVU /F^Y9VG[/N>Y4]-T40G(E7:
MU&<W74M2'&7A+;%6EIE;B'(ZNUOJ=L(RM-/.R_'CQHO*Y_+5VGZ/0Q9?!=8Y
MU4V8Q>%OB%SO9^S8ON6VBMJ?;X'5X[0?LZW"U-= !?YBTI),N5:4]G56+RXS
M!VGS\_OII9+\7W!<2_'-HM;UH:LR6=X_034*7F,@HM&_A7DA>^4O-[:SK0L"
M)%23472M9K01Z'!+CL2+B=#-E*W*@!4^8?1---O0_BQ\8=OK.K:$S6]!F)ZC
M7>0HMI4U-MS463./\E;FO/ZI8U6A#YS_ )]:S_Y1G(2\T/O];LZC($BST-/6
M"T(T5(.U-GY]Z\7\\^]ZVLS^.KQGJN@;CK%'TS2E:G6MO[#:W;$X$;9NZ-ML
M2G/M)U)NN;R!^SS>NT4"D74^>IM/4\O;KCK&UK^>#*>4)(U%_P"OYO\ OK)I
M/QYXS.>'G<_%+D._/I#NN:L+I5_K=2_(T#Z>Y(T6)-L[>IS7*\5A\/A@9*KG
M[65H^/PE'52Z-IVCLX3KVROK4QIK2TGXI_'OH;8=7J]YU+;]3-W6JZ-8=TU2
M\:W&RT<^ZP^ Y[<4QF?U7'KWC3<L[%\NYU6T@M-S"N+I)LK7WM-9B7A5K9V+
M34BZW\<W$M/SOH/,0;[:97*]-Z'GNCZBOJ:WDM_4S'YGC&(X36T ^1Z)RO<8
M&/+Q8SG^>+' ER4QE3IAUO*"QJ)80H0VIOQ^'CY_/4?:+\3GCGH<A_@"ZWKH
M..(U=+KK6H?=X/4%6MEG^7<=Y#52LTN^YSKM?F[@+(\0R3@]YB;_ #'30+@_
M3V5?MQ'7*1"M1\_ES?S_ /-9MM^*3QYW5W+H[74=&2X9N^W;.F*-!XQKX<Y6
M>1&P"Z)U3 TU=T7CFSJTREQOPY-?3V=D%8]#R=I8V8N7W=32ENJD:FSS^-?Q
MX^?\ZD;2_CC\;-C16.5T59IK#*6_3NN=4LLS%=BUU01<=JXA>^/^PI8HZNI"
M)K\R/@= =_CX-62$=3740=A#9OB%:(K4?YTQ.@?C0Y'U!N"=U7M7:>D= Q#=
MC6X[H?1I.#[381XK75>, TV"AH]3P^SY_/0__L/FKAEW!A&] KKZ,V]AVL1]
MW;S'M3=?)_?SJ?\ L_B%B.O)SHRLW'3.+:7E^0UO.<QK^*7&9S%W'S3?5^;K
MMASX@6_R&KS?^-W3,=DS(7!4 5UGK3.5-EE+BB,&^U[4:S<Y\-^+\GY_UCF&
M#!O*'$==RV8QES2Q6S2(L_F\?P['^/F?K<L04',6'&%SW#T3%FM9[HF>X:58
MSS2-G09C32+I/";EN@I.-4PFHZGCBN#\;U/$>=Z?![9V1V%9FM73<^I#;F31
M55;$:NI#'YIG9@; 51 '3/M8;&JL +"0)C34-W_XR>#:KE';^6=&Z/VG:Z'R
M2V&"V&X[+<[+)YSLBZKE(]4[GQ^,M\)A\;ELQ8Y2OH'L'*H\7%8G"%W4MV39
M.+EF8U-T;X^?-_GJQ'5/$GDW4N%8SQ[=%9XG!<W+Y@=SZ+(19J9^4FX\75%X
M6 >FV><V&+O*RL;3AB34FLRF@I2QF(LU?^U$,2.U&H)R'XQ/'7&8_3XNKLNB
M2UFOH.>YVXFFNLT).H7-?(_HOE+025XM+CZFEJY)>F]0TD)X]=4C5G^+-K*2
MM K5"_<F:?/[Z8O4OQCXRPR.R)YOK]N7T:2^VVLY6_9;R#,4G-+S?>2>'\J+
M9,IH\9SP[0U"TO5\:Z_QUGHZSHSZMUQ85&CJ]AEWQ4$+349\_P#Q#9&\RPF@
M\C=Y9Z;O9W1.U;G0;O/"\[W3):3MEQF+*]Y\81V+CU_0WXX?^%YTH?;TW-><
M:*NM4M'XL/#TEA)1)%?/'X?WKYXU-_/XCW_G_=ZO-E_"[CV0U^2V=&[3"V&*
M[ITCR"HJ]EC6Q4H^UZCS*SY-H:_^/&IAVQY4/*VQ/\'3CR02U]A&/,XX@>+]
M1TZC5?>C?BA\;NG[[I.^T=]TR(CIQO8[6YIJP[GXHH%MWCEA'(>C'UFEEYR3
MT::$_*S-FIZ&^W%YELW:BC3T5$"%'^@K3_&I4Z!X$\QV_2;+LE3T#L',>J66
MMFU*[GG6ES(5H*-9\GR'&M-D8 M/C-50S9/5X["Y>>V%L*@ZV$T=2%HL[<T=
M@((^!I_C6[<^$'&'<'\=^#!:?H6*9XQ08JO\?.J9O7U]3V##W6*Q9F#KK6LT
M1=*71W5G=XDJ[H=737>5MLUJ:>TM1K;.$CN8V!II@6/XY\Z?>YW9)Y4>8P/0
MJG)[_#WO1A.KY5^RVF8Z5I<WJ]+3V1]AS<\/'UT-IDZ3_'J[DE?S>OS$(\JT
M0H))1),K3Y^:T@V/XH?&62QH8<Q;]7Y_SZNIN'46EY!C]C6MP/1 _'/0?Y3R
M>;8F:+,Z'HD5C2WGM8W%ED=[E#=@5]I6MFN2BSIRFI))_<G]3YUT&S.#R>-L
M-I;9JFAJ[#H6G39[ F*8J5USI4SF=R3;.5A$\T8STSV3S]:D 3!A?KKF3?1^
MS,1-,U&FAS+BF/Y1<=FO,S);S&=TZD7U[:,MC(#!H]4;B<5@9H::*$(1P5.M
M'@J1[0B'FS(=)83J6L1$0X[35+K?\6O$+SG=3R:UZ'V:UYQ@M/0:KA6,O[+F
M>JS?CT;G':F"NK^;4FKY9=U5[2?P6SO\C+5]C#ZH/_B4P5'#],%35O$:?/YZ
M?N1_';P;%['G.[J2-<W0<S7E<U,L$N-H*>P.Y&'Y "T-C9YS(8G-Y^$FVD\E
M.CG:.&AK:.O,._@I0 :R.O)AL&FGU8^%_)+3L=WW$DO8)L[^_P!=HSX8[D%E
M(EAM.)Y+@=NV %:9Q#!F8?&5$P<;CGO@O7F'ODF'FC"A?/S\_P"=-0^-^,'Q
MS%RM)CHK#I/\305F5J@GNTU6ICAL?XDZCPOJ73S?XVD<DSN0ZZU*+>V%C9MB
MT2Z8R(*%]1*TOS^/G^^G=COQ^<?Q/4*WI]7J>GDS4VQAW]1CS[_/OR5;KW>.
M/_HM7%T/^IDPM4Z71<L'IX[48C4S CZ&BKKBC%I_MM!;)\_EI\_GJ'<'^)/Q
M]YL"T?(;SL-38UT' 0<MH R>2@W.2K/&K9ZO9\Q#%6NY"'6ZHJ(C9W]-I=%T
MFNV^LU-,3$MO?37 T5NC4V?[G]_.E3(_BE\=N?9W?Y/!W6ORE!MP'4M>"%DO
M'JRDQ.<FV8FX-RU58Z+A5U:[?-6%F '7%TO:CNJ"+GQ1JB!D,(P[HFHO]_C_
M )U=K@O%,AXZ<BP_%L'-;D9/!5<U73SWI 1%G+$38FVI+Y655=3T@$"FV!/Z
M--GZ6DSE$!^M39VEJ*4 "N&::E[TTUS(_(#XHX/OG0?"K37'CYC.N'Y[RLQ@
M?2+VYYQ0;$RLXE!R_N$UE7:BPLJLZ>+GL>TL\X457&RK2)H"ZPEX_P"\^"3T
MTUD\OK/LV5ZOQ6ARQGDGB?&^'GVN'D-\/>9YW?[5.V5][B1.:Y?9U5EA-['G
M>7IC7:Z44N6DJ\3)="Q";;058$%2.<T^?[_/G]]<VM:-^1_K0'D3B>GUG4+)
MSKZQ?<\U_P"'^I-PQ(E%Y8\R/Y#9\2U8O'\MD'"5_)J^PL;42BZOTVSO**6S
MMMV%0ZNGEAA::O!D,'Y*9OPNYAS_  \W4^4] T'FSM!-K;Y6@I2=WF.)[[S:
MZ==Z73#";/-:REKZPSF%V-=CWMA0'0!4QXMO C6)%)Z:?G\/8?A^GS\?>I\&
MQ_*]'>>28X)?48M=FPNS#B9J7GDU]G)\8%UJC Y/I_'C07W&\SR6VZ8)Q!UC
M=45%/U?H[]KJ"2X.C9JGN08*X&#_ (//_7SXU/P^?S_'_?MK:ZQN//5EYS0'
MQZU?F([D=CCKQ<'ONT\5N6]$F[DWHKQ/XOMN&S'C=8:E>5!9'^+?EO\ B+6<
MFIKJI,V)5QT*.W!R-C63I_W?(\?@?W_BM13O==YN>163\I<3R_;>6NJM+(C\
MG?--D"-A,KG>,T./YO>]AROCC3<&Z-!S^L)M>HG;[/X[GQ-6'K-+KR\O8[N;
M11TDE9D;@1\=./A\_O\ Z]N?-S#!NO/EFL&@Q!GF*=<16^4&YS0;+C%/6\=M
M_%=OC=7F7VUZ=HKCFU';4WDO%V)MZU<M86V?W*; 3-Y\3G,G/3[$XEI[>W^;
MO_7Z?J-78T&6\KX_$[Q$S%9U3NKNP;CH_!&^0_2(,_SMW4,WE=@"1:]@C(K7
M<W?B,G6YTPA:6&=V(6;-B#B-D(GLHGFRM1KFSTOM?Y*><Y_RWV.UU_5<&7A*
MGK?_ "&8 BXQXE4O<,M0\&O.#Z6^X;4\M+T$O-SXW2UZ]-Z89I5MKLC?4%'H
MJH0:N:FK( _U^)O\O\:6MOT/\D40Q;<%8^6\_C<_K/2PL)T;9<HL*KRBE9#R
M[D!F%BVV$R/CENMN[ED762NXCT=A:\?S_P#,.I\G7;/0"82:MFT33^_OX_$<
M?'V_DZD7=83SBTQ-1TCKG1/)V>3FOG-XU0,Q?%L16 XV7E,'CKS-_0M_F,=7
M<VOND:3)&=TU>Q"O%L+G2"9VM%M!I P8:"S.A?/[?/G^^G'\<_@;_P!?GIIX
MZT_(%M2<!6;C/^06S-@TOCIH?)VA[%Q+$0\YY[W.E\T.&3V,'B^8N&%9IN7T
M7&XNMWYFRHK#9U>9H<WS_9C;*HZ 1<S2-!_@_P!C7CY_321I;7\JN<Y_XV32
M;;R#FM]_Q>VUVJT3^<PZ"\Q_E"?H*8&DP70<-S+QZV!0'*Z#("QEUE/J@\9G
MKDT[:3;?J,%VW,SAM.+_  O]:_?SX^/OXUT"\U-#J?(OPB[5%QN?MM=MN<=;
MS.9O&\HS=E7[VXM.,=NQK.H,P%451WMEK:)*NKT%C3?P !Y>B;7,K1HRR?W*
MF=I[^WS^OS[ZI_V>[\_JKE-M=9C3>7!%[OO(/R6@S1=/AZZ0[G/-^>E[QOC;
M0)ALAX[;#=NJ^L1ST-@9K]9$/2"%U@$.PN69\L3+V+GY'M^_\_QJ/GY^?'[Z
M4*FQ_)79/K.H6^Q\A,Y>6W8Y<%9<[$Y-B+W"Y7E=S^-E^]-Z&#@I<C6:2ZM*
M#S(&$IZJ:PW\%=+IF2\Z11@[0V*1J>./Y_<_XK3/Y]TKSA.R^#&ZY+YX9?E%
M9INO5-KTOD?+TV';>@;\//<6.X^8[GW0_&W.](Y]Q.R,L^TBV >TYW:@C]$S
MP%?<],.Y2;GT(:5^/M\_A_GFJO29Y.7WFORWD6[\B+#1=7?J\>5^2FTS^BTW
M-N83S<.Q><T=M0>.4F&)FYV//2#;/)BU5H*;>6-NN\]P8[$HRC$"KQVG']O^
M_P"?Q'^M:WB\WK_J'-^BX:X\U-3S[ =XZ35<3E[-S0+)Z2YO==XB:"&O;V[(
MTW,<Y<P\('\B6A92NW6DH,S55-5H-)]=S!G0\AI1&G[>!XY]_P 3Y_+\N.=/
M?GEAY_;ZXP>0IMUYK4G*-)M.!5O6>C]9Y3@,!V;*[4_F_D2?Y&4F,'-Y9#4"
M\<$OJKAPX&O'RUMGJO57!E;S;:V ,GV 1^_GY_0?-^[Y^?[?W%\Z:V-JOR5R
M1<"=LX>K==O;',>(_5[W_C5S#GTE-SSMW['DQG^DUXLU)SG.MP@=9557'R-1
M-![:'/?S#;@>W!GTUBXV=#7L/C_UYY^?8^?&LZ#YM@>/V"TF0UWY#+WKM?:U
M9O<>>[3Q^3,DZ/J7_#VQDNL+R7>8+QUW<6-Q V[='-4Z,O"](X/;2"TE0=N:
MVG)NC+"*_'Y^?A7.GN?']Z^?D7KICVWON[V7B;VK2<!R?75ZG@]@-RBUKJ6A
M:/NZ2^JM?DJ7I.ER@Z8G?#[JOQ=!<W5Z]^'R&B,U+*.UH\=")I5$EKYU'S\_
M/XZYA4EE^475<SW![]EY04%MRKC7D)J>4?J\TH*NXZ_O<;Y&%C<+J]U6[OCH
M.JN9=%R*,9'YG^'QM[H:&9IE]$3;QR6$C4\6/8<7_DZF[F=?Y,[3SPXS?];"
M\GC;'G7>/,*75U]]S6NJO%K!\KM,7O\ ->.EIRW?5V,!;?D:K"D9=EV^3;Z*
MR786%^'KZZDM!\^&Q\_V^?GAQ1_CXD^_Z?\ 57SIL]$M/-+0=P[]@YL]VKKF
M!?U_DFDR9NAY%_%\PQ&<S_F3X]R#9JGQ^SXV7F=N;4<G?N=-0]=YCV+3RP4^
M9O=7OL;C=A!EK&I:?-?OS^A]O?3(TVI_(IR_EU1O=9TWR+<#O.2LNNTD6V2Y
M4->\A/KO,SDN-)K^*@%X"@K@>F7'C9KN@R9/,:)^JM]?84]59U%?;ZH4&$UI
MQ_\ /R_W7\ZA^BZ+YM=4"W/;_'4OMW6;+G07F+Q_F_1MWD<T+T.OYPWR%\$/
MW*1P-3AH\^3U,/FV?[6=C:RRQ%MJ2]%F#@K/.6FIK#Z-6I%>_'(]C[ _KS8]
M_P M=&<?H_-__P#5^];T%7:=!T7:F[,MW*2+3GUG7=MJ>-IJ,<+ID@S?6^<<
MN)V/3:',)TJQYH3L.:4:Z.2+$@W-9H#&EVEXUCJKG3=QY[MU_+J[@>J\NUXW
M8XV1_/-YVCC%TW?F=I3K%T%=U7>L1EO'"PT</,@<$S*+C9>D!\? M\_8;*TL
MMU)IP,[8T[4_/G^WR=6*\$N0]=P_DQV#2[C!:_-9ZWP7<P*NXNJ@\*K//O/R
M0>:?1:<8$@J-D<TUGSW8X[65[&*KI\WH*6PC7]4V!SFA-_L/WH _VUQ7S_X[
M_)9O! ,=M_']<T[8>)F)H0QN <1TW.MUT"VU/EOQBRZSDO+?6AZZXN+KJ?,L
M)E:S8<ROF4^;CM:S3=+N*V2K-RYH!;0GW'Q_UX_;Q\*'-:MOT?D'Y$0.B>3'
M!R^3[KM1'1>/^'_B!BO(5MT[-9WK?CWG>H^4/3.F;;H6\CJ+*NY[T>'B5ZG%
MMZ?,"7*;U2^H==4@_P ?M:8"%I[#WY)_+Q7Y_'Q\1J\/" /+'FGX]>\\,-QF
M]\?^L>/>CU7/.%7&4H#?(8J3BYUA1;3DY& >#35LW3_\$Y]J_P#@[:&4=$1>
MUUI@+*R&SUC<#"51K3BQ[^/P_/GYXU5,SI_Y2;I>)PU55WOG6<,QMH%DM%=Y
M+3]$-O\ KE?WK:4\EEVNIJ?%NMVH7,[;D4'/;7'5'7\KP@L;-V^MDU.SL=]5
M5NC%:>+^?['\N.?X-IO4>Z^?F;WNAQ]#J/*N+NVD"\Z;:;F9_)\=#QTD/F.@
MK;3Q]9XT7I'/H9-[-)RD@$Z0>KV.K.LKFQ(BV@-=J9Q*UKY^>#\_L7\?/G]-
M2#VWM_Y#=G?:W4<SSWDQA. 7'>>A"Y,Z+C>MSW6*7.!^.'C,1R)W^!B\*ZQT
MMW-;?KI7D)86C[' 1)-JQ*2AW%]G\U^U3DOGY^?VT^'@\<\^X)_'X5_CDC4A
M.;^4(2_/W0FOZ-HMV%VU>=5'-IL5E:+QWN<67^/"MUTNZD"+QC-K7YHGS'A_
MC(-'9;M\-"8XG'HL,$UE 2U'S[_'Y_"OQU%&S/\ ,:TYQC-=QMOFGLNMYWEW
MD3_-ZOR#\=\#4;[ =GMN08!@%=RCY\BI?HH+#9)=#!LI&WF'T%F&1345IH,W
M7PP1M/YTK=UZ9Y6^/.OU.5Z7W+RE!\?:#KW9",?UC.9OC]MV731">-GCWN^;
M"'2G\[&IK7B-1UB^[\)J=-5XMM3G;2DRN9VU[58L0UR-3QQ^7/YV?\5_]U+'
M8NK>9&C\"? _2\\F[A+U#JG$\1K.O='Y?F9+?2@;LGQ[%U%.'JL?E^/=-N1A
M]WTHJ,>2PKJ/-8_.68S(M@9+GRTS]DU&D'*WOY)BC,UV2^([Z;>C]9Y#G;/@
M0V4P&9Y_:\^T/X_,=L>FV#V6G/B+NJ-'\JY[?/0:BRU!-'C]4'+GEKF@I< '
M1SS_ (_[X^??35:,74?D+[+:<Y;LKWNV4;CND_\ $#$=EZISJPSY'&]9M? W
MS!S6R.O)]GR#EPIN)Q'7RN=4ALMCD9LK-9WZ_P"-F!T>CIJ:GG4WY_+]^0?Q
MK_KXZ=[_ "2_(#V?C_'?+3*A]R J>P[/27>3\9..Y*.R5V0R]-S'%YJ SM&?
MY5V:@S#];M:;KO0<^9TJABY/N,ALZ!;[=8X;+UA)C3]_F^/[?ESP=.HC8?D[
ML-=Y.#6NO[!SHRJ=W%@X]7PS6]2RP62&ZS5"<)M^%14W&J?.V=M-S![$MXLO
MT[K&X*KK;5WU]BF[?,TE% ^?GY_/4?/S\_YU:4KI/E@1^.F@OV8WR#H>SG="
MK\E=6;6':7KU)S1W99J4OJD&>A\?ZGI-Q138"*&W$RLW#J+M,&5.A9;3 :H,
M[8HU/O\ /S\\7JJ&?O/RO7G(^BZP2U[I!O\ G?C5G&\[REWB,=0Q]#VA/EIY
M.8C7Z6SCTG)@;N\ZW2^*>=Y;LLK1,J,_6V6IMLEH+WGMB5=0TK@U'S_UY^?P
MU:[GFE\Y'^!7D#H**QWFG[;%?WK^#MU^!N:GKM7@8Q\=%;C-INO<SX\3M=K4
MN7H=GS4K9\ZI![PK_%:.\;H!QIK>V?/S_P!Z?/S^G\_#QJNX'_I\=#L+W/XK
MI'FIF>$AUGDQ=<OZ!N>:8C%=\TIF9Y!PZRYI0[VOU/(X[.OJ)^U'=4!P3;?&
MY37[&HKS #9++-PUY%@_[]_G_KVU/ _$_P ?CX_3QQ1^.HK;Y2^:8O=><XK1
M[_K55Y";/L^'R-+QEV6YN-XWV7.3/"X_I3Z[4V ^;(UE'TK_ (TAV=AO*==7
M4ZS/T\$*RT0F"2ILB6GZ>W/[^?\ &EW)6OGQKCN83R4GDQO:+/67%]5O;3R/
MX3A:77X/R67EGD=!V&'D0@^ IVP<PI[.7FPE=K\W#;YBOMK8:DP._NJN]T8R
MM#7_ ,_2O\_$^Q U[O-IYY<>S_.(^M]:\H7\HVV3\(-7W;>09#FDO;,GK]YS
MWR)7O6"XI5 <VK()RJSI&2X,S:XFDRFJV>0QEQK+>G@9*6<>.TX_7G_%'^_[
M"QKJW^.GINR['X@<SZ/O-/HMI?Z.^[#].JUH.9KM)>YBI[;T:CPMA<"XP"LR
M:&2XBLSR/GS@4-*6UK2ZY919XII&HU=STTT>FFCTTT>FFCTTT>FFCTTT>FFC
MTTT>FFCTTT>FFCTTT>FFCTTT>FFCTTTG5=/448\PE+5UU0*0?96I U8$,!!/
M:7)Q%I;V4T(L44<I]K9EE6-D9(UQ!QQ)!94DI$TDCFFE'TTT>FFDRXI:?0UQ
M-/?U5;=U)C8VF5=N"-95Q;8I8R(FDA&13#3MCGBBFC26)Z,EBCD;[/8UR--*
M:)[?TGIIH]--'IIH]-->6,9&GQ8QK&_)SO9K4:BN>Y7O<J(B(KGO<YSG?[N<
MJN55557TTUZ]--'IIH]--)MQ35&AJSJ2_JJV\I;0>0.RJ+@$6RK+ 25/:44X
M V*84L>1/ZDAGBDC>G].:OIII11$1$1$]D1$1$3_ &1$_I$_\/337WTTT>FF
MC_?TTUX9&R-%1C&L15<Y4:B(BN>Y7O<J)_7R>]SG.=_NYRJJJJ^FFO?IIH]-
M-'III#TN8S6THK/+[#/4>KS-T.HEQG=)5 7E':B*]LBC6539P% '#K(QCUA)
M'EC^;&N^/R:BHTUXRV3RV'H*W*XK-T.0R]-"HU1G,Q45]#0U0[I'S.@KJBJ'
M%KP872R22NB&'B8LDCY%:KWN56FE_P!--'IIH]--'IIH]--'IIH]--)I-+3F
MV-;<&55<5;4S#HZ>T)"&GL:J.SCBALF5ILD3B066$,$,1S198D+CAB9.DC8V
M(C32EZ::/331Z::8N[Y?S3J(5?6],YYA^B5U2>RUJP-SE*'6!5MI&QT<=D +
M? 'P"'QQN=&PL>.,AK'.8DB-<J*TT]XXXXHV11,9'%$QL<<<;48R.-C4:QC&
M-1&M8UJ(UK6HB-1$1$1$]-->_332;<TM/HZBSS^@JJZ\HKL NJN:6W"&LJJV
MK#X'C'5UE7F1S"' &C2R#EB$PRCD02/AFC?&]S5::]U555T=:!34E<#3T]4&
M+75=55B#@5M;7A01C! 5X(L<0H80@T40XHH\4< \$;(HHV1L:U&FM_TTT>FF
MCTTT>FFCTTTPF<KYC'NY>HQ\ZPL?3)P?XN?HD>2H6;F:L^IL'\?+K6@)?2 _
M0QD'ZCSU@^EC8OK^MJ-1II^_[>FFFGM<%ANDT)&5Z)C<KO,P7*/.7G-GGZG3
MT),XDJ3"S$5%V(=7S2C3(DH\D@[GPR(CXW-<B+Z::6ZBHJ:"KKZ2BK*^EI:D
M,>NJJBI#'KJNLKPXF0" UX <<(H08L$;(1A1HHH((F-CBC:QJ(C32CZ::/33
:1Z::/331Z::/331Z::/331Z::/331Z::_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g120909g46q45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g46q45.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[21B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )$:^DH8X0DE-! 0      &4< 5H  QLE1QP!6@ #&R5'' (   (?>!P"
M4  (<G(Q.34V-S8< @4 /$UI8W)O<V]F="!7;W)D("T@,3(P.3 Y7W=O<F1?
M,C0@,C)*=6YE,C R,2!#86YD96P@961I=',N9&]C>  X0DE-!"4      ! H
M+R&4\HPJ16NTNJQ FCU$.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              N
M  =D          $                          0             '9
M N                       0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M N      4F=H=&QO;F<   =D    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M!E%049M1YE(Q4GQ2QP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( .P"70,!$0 "$0$#$0'_Q  ?  $   8# 0$
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MUE7 -/D6JM%WHLTGHQW8%4JX"MW@53UE84L4.;R)4)).OD753D\O8_C]!_\
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M2%1!R51[).2232(UBB95'TK$GQDX.2?XP.@Y5Y%J_P#ZF/R__G/Q<[B^E_\
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MA/1%U$_%(HM<&O)'1QLDVV@D+4,65F2[ MYIHXSOB;L^SD8#Y86 "LT9=>C
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MP2$C+F7YT,5/GR($:8_E]_+TEB.V^[EYW+CBLN+RHTDC *TCLH.0K.S*"/&
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M# B;9@%DN>L\7HGNTJ A"[#&NDR)%"3A;FP"]9*T.XT/)J*$L!*V%140(@W
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M\U!+$=,J<<NF"R^$1ECU=IO0V9;]\;:T]#MNP2H[5('7QN0U3-..V_;DN=M
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MT)Y9 "<U\(>#DB.S8G;R)(&>?B..I/+Q<_)MP>8Q5ZZ_T [8/3+# GP0]4.
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M! &>1SXST&/8!Y9!!#9QTE;G2/N,*/G:TW4UMV#545EXD,';9UY)EU@T8C6
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MA7P9_)G]7%0W0^8^Y6^3T'_D5]7/F1U__8$/G/;#YQL_Z-!_=K7KGW(?^%W
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ME*<>]S9CB#6!R%Z_D^9P?%?IZGQU8[SMOJ0_"?X50_<(/";^1Y4OTXVU]?\
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M1E[QA[633;'1M,ET^2($=\2;=&TVRNG:)&9X0]Q)RD9JIJ9V0WK4+05:L$(
MBS13J;4]!L%-&2G@-E<LU\V#'/PHJDX;A$(Y';5S>B+7AYB...MM)8PY &/0
MZ._+B)SN";]^X@Q^I<N\H; . =TSD$Y&UNAP","7CKB_3=1N%O8+(W\5X-1,
M-YIEO*UE?F_U?64O8HR,131R\2:H8V.42"\5 N^*!HZ.@=B-F0X<P3(Q7S0
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M@"'/&8)R!YJ7**Q6!&(A+?:)HK:H[O(S1VT1VLR@;G? /9J2"%PI#,Q!(!4
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M*?=*WBI?C*U5]"U/_N>/2KI'K=ORB?X=._I_YW]E/@4^Z5O%2_&5JKZ%J?\
MW/'I5TCUNWY1/\.G?T_\[^RGP*^B)_"7?%.C2F)#U^U&0:9=0XY"E:9K+<:4
MA*L94R^N$Y#F):<QCT5YC2X[^,9\VWD*\E8>E72>>(74^43S$_VF(_13OZ?^
M=_93X%;<'@V>+H%\3G7=P%VZK"]=]@]2MAW;[5P<F5(K%E &LO1AEYI_M@MT
MC#@/$8DH:: 391*17YF1ZLEIT8O$6CAVM:.VE2H5<R6\I81L<;E8 $H^  3M
M.58 ;@&&WP<G8VMR)U((PZ]0.A'+F/O]1XL@^/ S5\TE9=.*5YY>Z_PT;B^=
M;8O[X&.=>W'SQ/\ ;I??M7C'Q1]$_$OW0:S^L+BK9\LUHZ[,]<@6L":-E%-F
MMT-R+7 -1FB%;$([$A@6US]BU80?4B/K"0U:2!)56FF4#VFF9,./*4W+E-HP
MRAQ.5:K">U:;L\(L97M#(!SFC5\"([RP0L0 #@C)Y UV!P)9Z!.-=NM=&CE+
M"UTN2U.MS:W%9J9]:LK>](30'6_FG;3Y+E8%"21))B1PNT,+M#I72V189,1H
M6"AU,?'UWA9*W/;ES83%8?BV-_:+XQ%6GRAZ-PPY*JG"JC$V&-ULI39=R2W*
M0O,G-X>AY9AA1&!'DL;C>R$$RE=CY$V>S$8;;'C>3DY-<EA?N6M=O$EO916$
M*:*7N-2?B<WMSITJ7S:ZT L)Y8AQ1'(=,CTY)8H-#+K=%Q("7J?W:F]<J1JT
M1;Y=2I[Q*PU=Y>O1KY/;[5E./+I^M'L%+P.>/#A+A2.>*W.5%)TYYB@2Y,=(
ME4B2B'[6M5R1VD<08HIS&>R :8.Y[./:S@N%)WLW-/E>!U) %9NK:7P1I'#=
MMJLNF:7)<7VGEM#@:;B5+V[9M,T!^^=5MVNX+8W*7=QJLL<VELFCRM&MJSR)
M'V*PCB.C;UA/PZ^U6H-<>JY_-<L9(ENPE-@)5/;<JSI"FM#QN2NPD#T/QK R
MFYB:IEZ7&E#HZ\P'VIQO0XNP 55"MM;Y?R&1M)C"C=+MW!AO"Y(P, @T78[D
MK7E[%9+IT5D=.NS97UQ<<5SS1#ME.G&;2DA@[;6A"I6\5=4M=/W21M!&.R*3
M_,J=T_:]AA-2ZY$'FX53EOU^([N<A5X=C$57<+$%=QL<B.,LIL.NVD-=OVIZ
MN5RM%(("20B@X4B:DA+S!-B,#P<80E09RA=8[A3O889@6,1?8F-IP,C%6^V[
MF2A8EFL(H;J+3I6M(6XFFT^*_MM/XE2%M3OWC@O[NU.H3:*VI-86%A<0V;RQ
MVL32F62J"NT_JLS7#XJL!:_(LD\/:'\6$<_MC,<-;!]1U*^$@T1LZ69CN4PO
M>?XV(@Y=T#$C^:_F!DM+'/)&/JM.;0*XC5"Q$A##M1APD..R#M@(TAGVB16.
MW 9L8%:C5YNYXMA<V^FVM@U]-::@TE]"_$6RUU*WTSAU[6+1EN[I(VTJXU?T
MP16[:G:SW?>?9=O+ X@)JP1L#J^>KNF0&PZ\#4Q6Q>KZQ8'Q;.RX$D1$7)W&
M;V2;>:%&FH!">6/)U1&M)"-"($'*Z1+-U"$V2AL.BK@DLV2%)D0[1$CE1* H
M/;-(V%8@MN$(8C+!6RG0;=C!K7 -Y9<,6FLVEEV=C:\/Z?=M;KKEO):QF3BB
M[UVZ(@NE@FFN+P<.IJ$T<4\_>,TZZ9%'.D;6WQV=WIQ]AFQ%@A@O%U0H@P'8
MC6#:6867<T:L-5TGKB1/"9C*C)V!BTS;4%OL9_.1B8@P*<:@.QS$6EN\ DH4
M R>$$.Z7 /9IM,1 VE=XDW!\C:0JMMJWJ![E_H7KC6D%J-5!E2U2.^X@[+<=
M*L5L9]#::T9.S&L'4)-1M-5C?-NL<%M=I 8[F.E:^.ZSE]8T^(8*U.K[$D [
MH/+S93NVRBU6%ZM7:35K)9ID 7@, @0+"W313=?K=;MK4WUAHK(-M0VCP_E"
MK:&&,$HDQ5U9B)"0[+)M=V"X4*0B[45AS5MRX85KK*'@&XT#2XKBXTRPUJ2T
MU2&YEDDXCG;OXV&J2:=?ZA+%;BWLHH;X:;;K96-CJ22F19VO%A6]A-7RY72E
M5K17,#&$TUN-9; [?1#FTW3<DC6]D2R@2D-CRQ!J,V(ONKQ:JN.)JKC)()9+
M.&-G"D1D4488K/>(;9M&SPW$B=H&RLFY8]I( 66-=FXKN5F4L3CEM)).Y2=3
M6Q$$:Z4%OKQ]8M7XA:[DGL=;DN+;2^PN9T1;;5] MC807!L4GM;Z_M+NZN(E
MM9HQ P6ZBV1 8I8W7QQV.C4%5F041M@$@*Q9"LZF7=+5(RR4BE?8=:.US:U0
M=#P2,>2<3:::2"8(-A)TM<YL6VE]RL!"A [1E"M'!VC9]43$5F08.6W(<96J
M&N>YM?M;W%])V-R@X9TZ2()K$]F;>>QX=;5-0<I<QW &A&PXATU[:*=9+L:C
MIEQ:=L+25VI#L$;T,[2ZW7M-^U#,I%UF64Z.$MVJ9$'J)ZTUH-)1AQ^WCHA<
M@)1;P]ES%8?=]!#RI4N)$C0)D3&:+E[;LT2#&>TWL 6;;NAB#89@"5[0,!@D
M9!( 4@G5<:W7"#:5967#+6J2#5I+^[M[7O\ FC@:?0M#AG6"\U&"*YGM?1*U
MO>S#DC>7DBCBAD05U(\\?'C\_,*NLZYXI3BE.*4XI7"O@S^3/ZN*ANA\Q]RM
M\GH/_(KZN?,CK_\ L"'SGMA\XV?]&@_NUKUS[D/_  NX!^Y71O\ LXJPZ^,Q
M^'W5_P T:?WRL?/K?N"?0UK7]>?X"UKYT_E*_19H?W.)^M+ZL0/.]*^<*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2HT;[YC?UAC]JCD_2/YA^VJX_5#SK[]:WLX
MOWM'_H&?V:>>;[=3YS[M>K:>H7[%?<%1^155.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE>>G_  J5:U^(Q04+6M2&NJFN4M(4K.4MX5L;;RU80G.?).%*4I2L
M8\L95G*L^_G.>=B\)?[OE_I,GO(OW_P*TNH'Y<!_^-3^EJUI?15\7.59'E%8
M.#C.#CR^*OSG'E[V>32G%*<4IQ2G%*<4KGT<_%G\W&1TSS\E*XXI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5M)?P4%Q>.\>]VL+5AM?5HVM;>%9PA2
MV]KZMPVM2?/T5*1AQS"%9QG*<+7C&<>EGSXEQ?\ [OA.!GOV,9QSP89,UG:?
M\W/VMO?+6_MSKRMU3BE>>7NO\-&XOG6V+^^!CG7MQ\\3_;I??M7C'Q1]$_$O
MW0:S^L+BHU#UJW=1)<FLO-@9'2%1<>HA4%X(WT1,\I@O<9RBPW-8K"EPT0<&
MDQBV?9ERU>J>E"0Q-B.+M/IBOA8Y)N &"=SG>NQ<C&[#>;/(Y.B</KJ]K=7+
M7<D)@<Q 16@N8;?%M-<"[U28W5N=.T\F(0"[$=UAVD)A^5*LMU^K^K=>;81M
MP%=YL00;S1!$#5QTB<<"C FS+-?*O6*O),9P^U%EA)LTH@*:S-0]&%C"<HYZ
M*'!B'$WK2*.83"0[6,2B%B=H69Y$2/</&"6PP/(#)P"*Y#W/^'=$XC'$UGJT
ML=M=^A-K!P_=SW36MO9Z]?ZO8V%A)=$.(Y+666<6MT)1(EO#.]V%W0!AW*/:
M"ZA0J\J37&19R+)K!IT5.DV6_.WVYN5+3JSSYW7@\<?BTT?8+)9(;UK0!O$=
M\8@5)77@D.60C-#Y&<;>R&0N&!5BI+OVL@2 L6C 8(&:0;L2<@O)03R/:-YP
M7W-8K#M+&.WNDDL+QK::6^UEM8U7T,X:-W)=Z+#!>II45[?7L;ZD+358VMQ;
ML;.TCDF00OUTJO6&E;)WCL>C#+(_4*I6G:7"%31[4BSYC3+?%&1FB,Y.')T]
M=?&SG9,HT4E+AAQZ%QHA*P!%S!V)>*EI%)<31JYC1#%C:2_S0A=Q\%B0&SN<
M[%'(,RY&.$:=W/M,U[BO7-(@O9-,T_3FTJ*W>%9-0,<FI1PH)YDW33&T@E:1
M[NXE,5M &2.>\M#) )*Y'=4=2W>O5(D"/66O$5UYDE8H@]F3;,'RV-8]=3V*
MY58(]@R:^R%V?LRZ6^7$3 G*]HZO8V8T") "9EP;BVD,B(R,X.S<RKX98]E:
ML%0*&.XF5VQM)(# = 1N8.YOPWJ]GIDUI=WMA.;(3WR1"6_%Y<KH'!5YWCIT
M,(NKL7KS:[JFI21=A(>];"^5((H+0R14Y4^GVOK5:X54@;9,S4.B&9T^RQJI
MAH=%6=V99-?UB>D*F5/L48.S#K3MEM,JPPJ_!!-EA0DH8%.O199&A+.%W*"X
M;D,EMJX&Z62)"%YL%&S=)OV;=R@L"1G T_N7:/J&I0Z;!Q%=3;K5)IK^/3OE
M"&[UR_T:QF%HLD]ZEJ([%K[4)+N*SBL^^+6WGNK=F26>8R^K6MC%>JY2MR+I
MA1*G!;?&KPT=#-[+OCY#7.@"1,=2X<BR0Z_.&C#^R+B:DY9%I)#(-,N,%V:3
M:&,I#U]Z0L 4,A\ 2;$V-+)\KM2RIE@N \KL3MR CC/(;;TO<\T*YL=-N+%M
M5S<:79ZFEG;P1W6NZP\^B\'3SPZ7%)?1V4MO!=ZYJ=Y)L@[>WBTK5(6FN%@3
MO:T>YNO=$UC6#LP!LY^[V"N$ R9+T* ';JIL0;N^U:='E@9D,\1(./M-ZY@'
M7%.,N1%P[*TPTZI$1B<1QY[>**-RLQDD3!/@J$93+/$-I#$Y^5!B.8PV >F>
M-<5<$:1P_87<EGK[:M>64UKN:&&V73KNUN]4XATY);26.]GG=U71(;M^31M'
M?*BL%C6::XA'KEJK7=<M=GLILW;EPM<W>351TZ/""A[;8!\36K8+8E3DAK6R
M5.ZY=E7\DV*=<<B.R258]DF-$49,UP;?-M!&LCL[.1')L4[45V7LL2Q!6WF(
MEW"%N64Y[O"4;N?@7A[0K/4;^_N[K4S#H>JRZ=#+'%;6NIW<46A+::UITEKJ
M2W%WHK/K,XMG9XR]Q8 RB=6N;*"%2>GE:M-6UJ<*[ -T[[. =</>VYZO#T54
MQ).*OB7:)1YK!=PF<O;&:?!RQ!4.4B1]D#"%Q8SK U)^F.RC9(V:5TWHCY94
M"-O[3Y7%U8R H, Y]4!C) -.E=R^PU&PT&ZGUB[TT:O:6-X;J\LHETZXDO?1
M8'2-*F6[:XN]73T-A[.+L&$G?J!HXV2#OR4E^M6J*ZJ4HOLVY/>K3-AN/P(=
M-C"R4&!0-?ZXMDL5.AVZ?7"S-BF'MA?8PPN0#AP'&*\0-L-NKD,AD0;6!<YF
M=OFA "JA"QQQN5(DVMOS(4]3CP"<#F!8NN .'+%Y!<:]J;B.?6B\,.F)!<10
MZ/HNB:E);3)J4]E<)>RW>MK8J6M(H2EC/=HI+K:"L6>FVLYECM8R%N0VX,JK
MQ43(<135%S\B4%V9?-?%[>P J4RSRW*0'C4V#8)SGFEYM%G$PY),<TZV1=K[
MQA+/MG<JF0<*&?P99(VDVIVI,85 QY#&Y<L =U;*/N6:#-J&HVL?%%T8=-DN
M+60C2S<7KR6FNZOHUUJ:66G2Z@[:3;IIL5Y*<[P+^VADN( 1.T:O=0:4U3()
M\H6N%Q,V76TPO J]/$>S6!%B;E:(-PY])Q+D"AENAO@]D6((^TP^:'QW Q&<
MF4^9@R004ED@C#LSR,T9RB!=V_Y0^8\[4<;960@%@&!.0RD578]S'2ETR*\G
MN-2U2ZU#0)[J#3]-MMUZM^DG"%W%+I7:206VI1O::[>VC!)+NWC:UGD,K744
MEG:U OK!I,"^R%,V,-8&QQ9R 1M@8C.B.E HXWNH3.)1(BKM+#1RY!FDU^;$
MF-N.@H7LD9G(DBR[)EE:C:VZ<F<-CU3JQ!(5IPQ #XW%8P1T QZG&2<[Y'W"
MEE(EI=7EK>K#=207&I6L\T9GM8+KB>WDN(XCJSVR7,R:7:S1S!FLX<QIWM.O
M:2W/7G=.@*UKP&0MX:R%DC">PBVO*M6+%%&Q+'#L57/VB)>!MC]"?_\ "L50
M!'UV9;)^KMM%FMF!?02SF 14G'GMHXD,@D;!D,:(X&]60N)5;!'J%$3 \RW:
MX^E)K@_%/!=AHEM-J-K>W(@N-:GT73K"^C@BO8[VPN[^/5K>_P 3DQ)IUDFB
MW8GV*MRNO6@7:8;C;>(STTUW7+ '#'-J6".DT<I]-C^KUP<E^+8[1?+;1EF9
M.31$$W(IT1NO0[*R2%((Q28XAAD07)C78-FD7GL8D909GPQC08$>0SR-&7)8
M@%!@-X/(CU+%2&KE-SW*M%LKZVM+OB"]C[ZNM,TV,+8QAUOM0U?4M)-PXNI[
M-7TV,64=\D]L+B.Y@G5;:YFA:'4)+-[1TG4]>:6 VR&]8"ED/6+6:V+&0BQ(
M-8+AK;K U<#K-)S$,35&QH,^J'6BQ*?!C3(9D(_'SF(]-FAQUB:W2*"-PQ=V
M>/Y85PCJ\)D/9X8Y )"DD @J>9R17%N(.%--T7A.TU*,WL]]>7V@M'?3Q1PV
M%S::EH%UJ=TFE=G=RFZ@M+UHK"YGFB22.ZM2N8WDFM(NJG,2NMZX5\&?R9_5
MQ4-T/F/N5OD]!_Y%?5SYD=?_ -@0^<]L/G&S_HT']VM>N?<A_P"%W /W*Z-_
MV<58=?&8_#[J_P":-/[Y6/GUOW!/H:UK^O/\!:U\Z?RE?HLT/[G$_6E]6('G
M>E?.%.*4XI3BE.*4XI3BE.*4XI3BE.*4XI4:-]\QOZPQ^U1R?I'\P_;5<?JA
MYU]^M;V<7[VC_P! S^S3SS?;J?.?=KU;3U"_8K[@J/R*JIQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4KST?X5%_P"8U1/^576__<3;G.Q>$O\ =\O])D]Y%6EU
M#YN/M:^^:K'=1OL%SUWZFMW5'3_/7MRY[[^W65M9KKAC;>*+BRBO:;-9E'V_
MMFFKCBL9)_Q68U*ZF2JR8'8;QF/B5C.1=]IWQ<A!>=\B.+O,1=\]EOPQ\((#
M;; 3F43#U!QG.W%F,# SV>PMA\[-_J%W;?\ ZF2/4[3ZKQ$C-4?4.KO1(C0M
M/F3TY+P@PWUP++O0?LUJ>#>]O6O8)MAK?6EYVJ;69KT'3:-1C5G40+E:R=<@
MO.U* ^1LLUO9]6<$U/>:@))U')E[X7LC;3&.!8E)AE$L89INU)4F- V0^% ,
M; U".([<\QX.2&4%MQ\(%<C: ,X).!@$G# U=01TQ\.AL]O;-KV"'?2&(T)(
M:H4'<U0P1UG0K%J/-J-72'(O^Q@$ ]=1=ZP\ -4R3<MFB*9(@MU@B0-$+.'/
M0+9OM2(MQ'&PW!]SRPOMED64*L?RI)"J%/"#JJ&0$,%4*PILA':'<" %V@;0
M<8.>I'ACED C!Y=67'4OH-U]Z:[9UGM:R]B+?.1; -PKX*%51UXI5",US6A"
MM6$B:VK7TWB[T@3:#(\]!'B4#Y<XR%#^BTP<!R56@21%Y=]<WT4T*VZC8R.2
M[1R.C2@J$C;LU=E!!+' !/TIY$51&L95RQYKT'+.#N)/D)  Q@\R<9P1B_NH
M^FG3>]PNO38]0^[;#N&O=D6S?.L8G8NM5O&LS-&ZL[.VCK,4P=E1\Q8 K=!:
MJ#;Q?ST\F;'Z$G1WM5VB3 (R<O.V)KZ]B-SD,L<<L26\O82/VJO=0Q2G;NR3
M"'*1#:.^ 1(@.,56L49V8;+%6+*&7P=J,RY8K@[MOA$#"^<U6=&Z7= #MEV%
M'N-HK-3<ET37")=*#]CZ39<]>]EV/3]SN%LCMW:7;0 >]5D3;Q%5"0BD=W:$
MJ">.2-:F07MUAFV-TR7NH!8MBN_RR3$AMY$[=$F6-<Q[6*$HSL1\KW!1(K*H
M5:D1Q$L"0/%C(.TXR>> "!X^8QG;G.*M'3M$>'_9']< )PF<T0KQ+IZN^%!/
M8BE((;41N_J??MH;;@0!5Z-42JUB-K';]8K-:GP!]S'&&73A&EOG(=G,5:,/
MN27&HJ)'# !Q>=FIMY2L/>]TD41+('8F:)F()4KR#!2H.:%2(D#GR,7TRY8.
MA9\ X]21C'CSCD3BKAR^N/3N.HS0<6+5UM>JVVNPUBUSJ@+NZCUB%L4K'Z\=
M4+'1M=G=WG(S%MJXQVPV79S3X\S=28;%QU^;UA4;/.M<LC<#%LW5[@.%E3?#
M;*\S6\K-&#<72NXA#&-VVHA4J@8(ZNXVC8)V1@YW ^$^%W( 1M4C)QGJP!!.
M,@A I.329/KGX>05RQU9R; )GK;9NPX<:>B]D )&#HZ7KKI;JK=E> QI@B#B
MN[4BL]C+#>=+@[O*=C K]$KTR&$03.*BD(5:W6HML;#!52!B.]W!G$M]- 6*
MD[H2;9(YBG)HBX+8 P9V1#.3DDL,;E 7"J3SQ@Y8X# X(!"@'G6#Q7O9S_-[
M^><@'0>/EU\M8QZG'E-<<5%.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE;1_\
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M7'NDFQ?_ +8_B/\ T5ZG_P Y^/0R/_[IIGX^7XBG?'_X+C\5_P#M3W238O\
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M(LUQ."RQK&A4M*9)1$FYHT185?:-S<\L29#FI+!G+9!50>9W \N2^0\R%'0
MYQC;D5<Z#<O#T@R$63,'K45*BY#^=Y!25"W"@!L>74NO-0(5V/U@"1 3,*D!
MKWV%8O(NT$2KU+=]BBUV<W %Z^,3:S)ME-1.%S< $_*G#P;DS<R!C<$M\LVV
MQC95^6 G>&)< U.8_"Z DX^GP1@$#ECF6W>$3XE(V\ZF$7<W2@TSJBKW\OK8
MF @ZRTY5H8RL [U3:JP6UAU?M1S'\=C(RJR&CV+)VZVH8F$G70%O;8:H\+!!
M>*B6*/S:3%?H)7A#AVDF=M[1R/B6Y7'8G<-H6UB P&4^&3SD  G=%N .<!5
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MS\IF^'3O>#ZC'^ /W4]S)\.KY#?5/Z"=;_5[CT3U+U_>?E,WPZ=[P?48_P
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#O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g120909g66n88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g66n88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1RL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ')"^<Q(X0DE-! 0      $P< 5H  QLE1QP"   "   < E  "')R-3 Q
M.#4P' (% "M-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@0V%S=&QE("T@4RTQ
M(%-H96QL.$))300E       0H7P[6. 3J]R%!B7ZT[S85CA"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@             _@
M.$))300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              :@   /(
M          $                          0             #R    :@
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   :@
M    4F=H=&QO;F<   /(    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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ME=:=T?JY=/7:&]4QG/,EU@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MSN;6L&J0O]E;4ZE6BSNG,:U%"P<B^268D,14;DX6I5-0O)+TDRR"X<^R!3A
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M:JQ=@0NJ)ZD3EUF-+5X%YHS77S^"6:OQ4 U$Y:H1 10P BC*CWSET_8$]CS
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M/K.)VS!5<%D=66$-7IV%N8FE;FLQKI<O%(48<8]<A0L;MFDQ%H7@?MYR48S
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MQ(Y8+](F]:<U]T$A7BCA0EYEQG*AIRH?I'GVR+3+9:WD;^YH]IW]G1939E_
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MI#IL"*89;H,\(("QE6' R%204-_D&VU4W%NK=.$RV?P>6W+MA]L0FC<45L+
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MW_\ =U3+GY7D_/P_V=>G\G\,?N8_DYQW5UU]XTUY<GCSYS_5T][?Y^]<L?\
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MX](0@?K.O5?!+-#'*9^#(H8@Q@\<_66[ZN@_4<FJ,?AW:V-Y^7^*NL8_<_\
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M4Q!B&.^=="$*1:1B&-&K-4J60A%Y2@:$(QE:UK5A*4XSG.<8^WG9ML?^7*W
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MNM2NC>/*,+\]4L</80LC&3E8A.RQ#QXAL0J$J6-!E(4M*<J3C.,9SS$\4L1
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M(3$Q@,/2JCK)&I%B9:(LL0QF89ZSEX289!>Q[]H4;IC(L'8DE X;E1E0CMG
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M>45=H04L(66XK4NDJ]K>+KCV30QM.QXNKM*S+;'>QXT6.::-,YR,1GI%F=J
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MD+)N!'DABLP="3>6I9D#HHZ6X'(ZB1P#V/!(UY+=ROTO9KQB#J"N\3EF3J(
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M#RY$-8<+1E?JQ,;1*C)S%@648^V64'I+#A.0#P>"1VYX/&M'-<^R)TD FS$
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M')W#MX]?.7#QX[<'<N3E,5:\^K%B:W/)8L.9)I6ZG<@ D\ #L
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MKUZ[2B!9YT1FBA:8JPB660*C2%6"!BQ4@<'+ L3S0I/*T,#RQK-,L9E:*)G
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4&FG&FG&FG&FG&FG&FG&FG&FO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g120909g77p33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g77p33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &:Z^970X0DE-! 0      %H< 5H  QLE1QP"   "'C\< E  "')R,3DU
M-C<V' (% #E-:6-R;W-O9G0@4&]W97)0;VEN=" M($=L:6]M82!!17-?,3%&
M96(R,#(Q(%!A9V4@,3$Q+G!P='@X0DE-!"4      !!9_VC&[2>5;;0J6[%J
M;^:C.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0    >.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           %&@  "!0          0                         !
M          @4   %&@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   %&@    !29VAT;&]N9P  "!0    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !1H
M    4F=H=&QO;F<   @4     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      \V     0   *    !E   !X
MO6    \: !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M" !E * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P !
M @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"
M! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%
M!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C
M<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U2?(I
M2? H%^0ZIX:*K+ 1,L:"/ZO*']O?K^K9'E[!K_TD1$HX@VY\BE)\"JGVYVUS
MOL]_M ,; "02&^WW?2_/2^WNF/L^1\=@X_SD> ]E<0;<GP*8$ZZ'E#HN=<TN
M+'U$&-MC0#Q,B"Y3 D$3I.J:125F9%-FW8]K]X+F[7 RT&"YL'Z.JGN\BJ>%
MT?IN!M^Q8]=&P/#2P00+"QUH_M^A3_VTK8!DZ]_X)*<BNGK9 :WJ^/8]X(K+
ML=K@=MCW7.#*[ZW.<RIU6/\ 3]GIJ0Q/K)[P>I4.+@-L8I;M.YLNUR+=_P"C
M;9[/_/:L8O0^E8;Z[,7&KI=4ZQ]>P0 ZT-9<_;.W<]E;&?U%=UDZ^"-_RI3E
M45]7;GUV6=5INQG/<QV**6M)+6>]E=HL>_>RRMUGI_\ &+5W=H*IU=%Z73=Z
M]6-6RTW')+P-?5+;*C=_6V7W?]NJY!W<]DBICZ]6ON'M<&'4:.,;6<_3]S?:
MI2=PT/!_@J1Z'TDWOR#BU&ZRUF0^S:)-M4FF[_C*]SE=@[AKV/\ !!3$WU-)
M:YS06[=P) (WG;7.OY[OH*GDXW5[,UMM&<VC%!K)QC0'DA@M]9OK^I_VH]2G
M\S]']G_X2Q3LZ/TRW*?EV8U;\BT-;9:6^YP8YEM>[^I954[_ *U6K9!D:HJ<
M@5=?J<#D=0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$@43(2(Q!A1!42,R8:'1%4)Q!U(D,T.!D18T8G)3L?"2_]H # ,!  (1 Q$
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MF;F%:(.8ID-/\4''%J**EM3+6=$- MHV;UQPL\/,ERQ8-WKW;SW:8]KM&4A
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MODHR-,R$JK(Q+<@7KS4JKC'%KA2RJ=6^E4/E18V@S:/ '1\D,.RN #BVXO\
M;&ON+*VZAYF8[*U7 F$I@A\3K A#]1G9:0%['7M#81:2:\U5L= HU>QZ.<[U
MKL6*$IG"6I(5<K-9$I(TL6&#JF#@46X7RS+73?84L0W"S(1 :=66\+;Z2&#M
MQNI<56D-QJ0(=WX]MS+;S!9T *D*51B0WI7:(XT5&U=2Z@CU-OQPWK;B XWH
M;PFZRE/#YMXR8CL#^#'X7^,$[A(-2([?)[PXDMT[JVT]WU$"4U+.%#C+XS)J
MJU)@(^LJ7C^60MV&_1]HBLT*>G=B].?.N3*H57MZUG=/7C><=<;#Q\?'7$<5
M+Z3K>U=_2^F#<R=KG6V\5*U;DA<6B\@IW#9;8[FT%O<>WD#ROTU.Y.-R*<<$
M]T;Q<1$\>D4,U<7ALYPB4JCH4?)RP=@SDK)_&7;(#H02?WT^M<.TLFOC'@[\
MXW:*+NB:-L4'2F'F=/LZ=5DX-BHEERV5&RMV-:L2A#AGRF7%'J/N[*FQX/L#
M=>N0]=ZEBB%6XLHV0 P((%8[A/$'V&_O/C@9=\0*_#N\@>KX;(8/PGL^-N)X
M;=W_  .._"2(Q':VL3&CBS]NL<@4\V')>,5EK2 ;3:1V&;)5UE+8S&I>3Q!I
M(D8^BM(B=_?48@RQ9=8EF<>FN:,6Q^D%Z+DR5V%MKI3IYNMQR]M/?K=ZUY>E
MR*P<I-IJXHI6GY@%[5&5Q>LU$@\68W<%L"K848*QUHJ.1GT<^#HV3MQSQ&<%
MH@Y#YOK3+8G !Q!M-J:FDLCW >8,(QHOB? "^'/<S=EO(V<VF 3V&,V/._T9
M9;#?NY:WBAEF (/2#6."U6WD]5IQQB=19+*[NUU3%--Z)CJ6?)PW.7C$XRK0
MQI:JOF:@*RZEP%-AWHQW<VT JR\L:WFC,YT*KE6I]6$N.8=R WKT0"2%$_T4
M5\K/1BD12(I$4B*1%(BD12(I$D"?UE/M=Y_LC2)7I$4B*1%(BD2:9>/1X@J_
M&BUSA%B-?/& 5JX:-')AZV:JK-1;=T_508MER"^";1)P\71:(J+8J.%4T<<\
M\>J 64%@H) +$$A03Y8@ D@#SH D_0;@^Q\;_3[_ *3_ # <$LL^$EAG'MQ$
M3;;_  E[OD&X-M<+,'G\I@4^WKJT#HV/2]SOZ<AQPG6,EC4NV?%XW%8[J=A&
MX6!%H#',[/$-=EI9.1$>QG@PB[^RZC7TBSIF)71G8RT49MM26U8US9+U_+5L
M6N1ZZ7=VO+V,2PJ07"NIG[1 \FALL7VL]%I=Z48H]B+6'[KC2,&< !- :7D2
MA+*O($Z:@MN)7/X7IH9-#>)1@X<\?4P0-1VQ3BJ?SP?P^/=;.N7N215TT2X'
MR'!&-E^=L * L6RW$J"P#*IF,S.*[3*^SY/^A%5.&==,0JW'!6HY0N'(* ?Z
MD.I&O18EC1R+ KPT9Q>[\YL]W_W#;&[N7;*$>?'RYQP=: '/P#OEN?1[CWXM
M/A - <31/7^B(20V!K1Q!]>\4"!1MKEL;'A=-:/';65XKM+MRS0;FZ(;*V8Z
M$Z>PUQ\H7<&&2DV+X!LT\6:":/D],PNEY.&+<FU:KNY;A<3<59LC)- P<DJ3
MH4TAL@W: 4BI2WN9IOMR*[>-8+)Q6TGAL"NOGWDW[<WU6$V=^MM#Q.7X%QU?
M"L$ME\/H280U2/6VD$T/LN+1HYI[-G%-E1;>.T),9G,#E$O$Q<@3A<GTAI\A
M#8@A@/<!'T>E(Y><[3S,QH[V#MEO3>B+3E,EO,TMDTNZ7@O4^-0BU6UULZBQ
M,G(#N=A@U9[5/%UV:EORR]8*:Y"M@I30866,74G1*FJOBH\[! 9^0,TYLSB\
M^$HWCP\\8X&>0*5B2H>!R$D7U4(@)S7\WU'/8UQ/:[$:SB>MY.+ H/96!EVO
M,SMI"5DTD,D#=VS*:Q%=&&+FA[*^G!Z1CY6 U5J,&L4+<UJVUWU/A6M<]R%B
M$>NWB55$4+LUV V!28-=E/7<&1AH>5 XLK"Y BJ=;*NG(DL3O\RG@2!O/8G'
MS\(%&M':DV"N\D0[:KG:W$N%XCM"Q_0;E?8$"DD&D$19ZYTOIMR[UC-M?[+C
MPX$1>/V3^2; A\VWZF;&2'7$]#L!,A A,]73.EODWTZ0TBC#;$RGR1V;$M1S
M;D9 6ZNVEF<*"$KLKQ2I2ZIBRNTVR,@5HWD/SM%M:IZE92O"M"497 !WLLK6
M@AD=0"!UQ\(-MO;,2XBHH4@Q*2@"FKO@R_A$^)C1D:2:.'R4SXGX5&]6QN)#
MS,/1S<CYF7@T4F)YX-BSYD6;Y.)&_P \&:ZOQ*J.'I6/19BN+0K+?UGI.'DO
ML#MX=KWO85L.C6MKUIMQKQ6/(&P;LEW6P%21QQ<JVL?[K5%84%?[N(8D+KZD
M^=>/6UQLGX2DK-=X:LO+[[.)0Z.\*&R(O,T-4:WU3\4PW/K[:3_9D*03E#ES
M&38^(RR(QG)E\6X=R\2D:^1&G[U++%:ZVKI"ICW<.TKMG4O7WK;]G'MH%-OH
MTZFRNQ]^U;<=JH,X&RN5J<N17M,K<%3PZOR WL$*57Z[!)!GSBXLX_O>$<:#
M';4UBY[?VYRC7A SAW#8I%N-\20+D@4E*B-B.];[/X<CD-X2ASI!@]$S"4OY
MYGL*-,L(HB*/"0MG)9N:];!?%MZ>V.CKC8X.?W,SGTU@JL@:D6TY:V9Q!(:N
ML5&JQNX60L0NLUHL2\.V[7;L:IU>/8E7*-65I'T=BP90!H@?7U]CAA1SC6W[
M_P /3W% "T:;X;N.BV^9$1*\=42DVOS;;569 1*.(8EQ$NLM.81 ',&<C<\-
MO_X^K18J,;)110UB:$(/.Q2S+T[&[J839*YG3?E45>F6):O>TR8HQ!WS:R%1
MF?-<U8\P.+D3K^;[.)N%9JO%AWD*5/#8-AM]'$$$5&O1&Q_;N?Z4N#V:3G8_
M"3PN[#V>BJWV5.^'?2TQV"BX;W:+I3:3:WC9J4X+M;VQNV6Q./7UE6]\<;HY
M]Y/NX]WLM\GGUU4YV952=TU9>174=[W4ESK6=_7T >?K/2I9FJJ9_#M6C,-:
MTQ4%O'T\D^)T962612(I$4B*1%(BD3UW*]VZ?QF+=PYOWK8_%ML<,U/;:]^]
MV**)X]VW9V7OWNWMO;LM?^Y$]#FJG2"_W#;U=)S9^Q_;^8YJIT@O]PV]72-G
M[']OYCFJG2"_W#;U=(V?L?V_F.:J=(+_ '#;U=(V?L?V_F.:J=(+_<-O5TC9
M^Q_;^8YJIT@O]PV]72-G[']OYCFJG2"_W#;U=(V?L?V_F.:J=(+_ '#;U=(V
M?L?V_F.:J=(+_<-O5TC9^Q_;^8YJIT@O]PV]72-G[']OYCFJG2"_W#;U=(V?
ML?V_F.:J=(+_ '#;U=(V?L?V_F.:J=(+_<-O5TC9^Q_;^8YJIT@O]PV]72-G
M[']OYCFJG2"_W#;U=(V?L?V_F.:J=(+_ '#;U=(V?L?V_F.:J=(+_<-O5TC9
M^Q_;^8YJIT@O]PV]72-G[']OYDPP2S4'K8W%E$^U1K?OJ(M[86['2&79>]G6
M5^W+L[MO9^U>UK]ENV]D;_0_M_,I\U4Z07^X;>KI&S]C^W\QS53I!?[AMZND
M;/V/[?S'-5.D%_N&WJZ1L_8_M_,<U4Z07^X;>KI&S]C^W\QS53I!?[AMZND;
M/V/[?S'-5.D%_N&WJZ1L_8_M_,<U4Z07^X;>KI&S]C^W\SQ*G+(W1Q4%%L;K
MJV02M=!M\]6^&:EL;?\ -_K[B>>7M_NQO2-_H?V_F>7FJG2"_P!PV]72-G['
M]OYCFJG2"_W#;U=(V?L?V_F.:J=(+_<-O5TC9^Q_;^8YJIT@O]PV]72-G[']
MOYCFJG2"_P!PV]72-G[']OYCFJG2"_W#;U=(V?L?V_F.:J=(+_<-O5TC9^Q_
M;^9XKG+67P;W%%K+*)*+88?$-NW))'-+!3+_ /R_U8YKI6OV_P!^=NSM[+]B
M-_H?V_G7[[GEYJIT@O\ <-O5TC9^Q_;^9AD B$)U5%F<(UOKU*$0\<].$1\:
MC8D>+"L'DE.DI,<59#VSG!NUL1/&"9-=)#!-&SAXM\4FFG?'#&RVVRYS9:[6
M6$*"[DLQ"*$79/DZ554;\Z G% 4:5-#9.AQ V22?&_J23,SYJIT@O]PV]75<
M[L_8_M_,<U4Z07^X;>KI&S]C^W\S#F\3A;6?%=IM]?)I;'.1(' RTUQ$C_TC
M?0R-%SQ\'&5B=W-W')AQJ3GB:++#/%+)X1565Q4S30NE8;;#4M)=NRMC6K7L
M\!8ZJK.%]N15%4GWT-?><T.1;AZB I;T[X@D@;W[ DG7ZS,>:J=(+_<-O5U7
M.[/V/[?S'-5.D%_N&WJZ1L_8_M_,\6)OO*J(8BBUU4<4\U,?B&W;CBM=2R=[
M_P#-_P#[72S[/\MZ1O\ 0_M_,\O-5.D%_N&WJZ1L_8_M_,<U4Z07^X;>KI&S
M]C^W\QS53I!?[AMZND;/V/[?S'-5.D%_N&WJZ1L_8_M_,<U4Z07^X;>KI&S]
MC^W\QS53I!?[AMZND;/V/[?S'-5.D%_N&WJZ1L_8_M_,EC"6>',?^EE,^^4=
MY_,1;W[G;9+YF?:ZMV9X]GSK6[;6[;=E[TC?Z']OYE3FJG2"_P!PV]72-G['
M]OYCFJG2"_W#;U=(V?L?V_F.:J=(+_<-O5TC9^Q_;^8YJIT@O]PV]72-G[']
MOYCFJG2"_P!PV]72-G[']OYCFJG2"_W#;U=(V?L?V_F.:J=(+_<-O5TC9^Q_
M;^9XD#EG**:Z(HMFDKC;-/.R#;LRQO\ JO;_ )ND;_0_M_,\O-5.D%_N&WJZ
M1L_8_M_,<U4Z07^X;>KI&S]C^W\QS53I!?[AMZND;/V/[?S'-5.D%_N&WJZ1
ML_8_M_,PP_$(3*93!9Q(M>I&9AK)Z>(:^DK\2/7-0]W* 3F,R-4"0R<_*&%C
M@%VL,*))9V1>M_B?CT\\VS;-*Q;;$2RM79:[@HM0$A; C!TY#V/%@&7?D'V]
MS.$ E6*;*[*D\=C8T='?C8\'[S,^:J=(+_<-O5U7.[/V/[?S/&L;^3HJKK"B
MV"2*>:JN=T&W9@FGC?//*_\ S?ZL<;7O?^_V>SVTC?Z']OYF*SR,1#:4*D^N
MMAP/],8+-0C^.RN*GAK)^&/@BB&38@+),U'=TW#1VAGDFJGE^O&_LO:]K7M.
MJVRFQ+:G:NVM@];H2&1E.PRD>00?(,XP# JR<E((((4@@^X()\@_K,J1(8MT
MDD$ 9-!!!/!%%%%JT32123QM@FDDG@ZQP333PQMAAAAC;'#&UL<;6M:UJA[^
M\[L_8_M_,\G-5.D%_N&WJZ1L_8_M_,<U4Z07^X;>KI&S]C^W\QS53I!?[AMZ
MND;/V/[?S'-5.D%_N&WJZ1L_8_M_,<U4Z07^X;>KI&S]C^W\SRHD<UE<$[C2
M2-L[]EU5D4,4L/9>_;GEBYSRM;V=GLQROVWM[*1O]#^W\RE2=BD12(I$4B*1
M%(BD12(I$4B*1%(BD12(I$4B*1%(BD22<^C%_P#4:?SC>D2M2(I$T+Q+\1<
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M!8YBI?%==#T</ISY55F0]]&+C56)2;K^ZP>^P%DIJKHJMMLL*J78!-*@V2/
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M'SO!LB^<9-V[A%%QEBYP63P[U'"?IV9;AV65VO4*B;*BQK86TUW*5+!20%L
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ML"%TL5ZZ[:[$Y!7KM4.C<75'4Z.BK*""-C:D,8HX<$Z((8J0=;#*=$;!(/\
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M(I$4B*1%(BD3"MDS5KK;74^V*^9."3* PJ4S5X.:*)I.G[6+ GYUPR;*K?\
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MI@#WNIK9V/*@#B>1++R " <MZV2-; !)\ ZR%?B\X;4349 I[9CQ![+Q.M)
M!=!$#!\$XC^Y"[^/ZJ/O90$&$(T&!; /C7@*+&318>,+FL$A35UF_=-&Z\1@
MY95V[#@5M<K!N*L&QU#WJ$8AV:I&#V*JDJOJ(T"0[M>P.8)(0C7D:<D(=C8
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M?L^,602Q2P]E[]N>6+C*]K>SL[;8W]M[>RD2E2(I$4B<S<3'%+!>%EOI,AL
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M&Z*;G)?'%3).R>=V/<:+5M"ABJV#1.OSUM7O>C[<M_KK7ZR%B<U*[ULJ=_\
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MYMV7,WXH2@LOGW$OEIDL("#\<\GQHL+%MW;]O=CT/DWU8]94/<ZUJ6)"@L=
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M("J#=Z1G"T*P4(F#1!!@.2..WY-\Y6:8UV]4-G,=D*&5U_."1SP*L'?IK1?
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M/3'QVQL;I_3,#_3=;>FV=*ONMRE^),I<+JB5YMF6+L<8=;]_;UY-E;5KW'1
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M0QXW^E2(Y/\ O0QXW^E2(Y/^]#'C?Z5(CD_[T,>-_I4B.3_O0QXW^E2(Y/\
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M\MQ$#M"Z:F.EM=(7X;IKO@A+MK0&3S_-4C$YW'(DV!XL0FTM:M14961/?+9
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M!>=1# @EC66*@1F!+4+8&4,I7B]:L&)9M\N8T?&^+[&M:[ U)Q>;)V/O*/\
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MJT)78UV-CXG*^QT9'9\K%+/2@I5JE8.16>ZY>H^?S&16RQVQG+ *[V>A0P(
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M2/B+UF0B9?<.O-9FSSQ2 :VVD8BCYZZ=%8@T&1I%&7^K5TO$-Z8]MC!GR:<
M6=\+_P 9PJ^:%528EW-<>ZY4'=MI5P !82Y[>=K[.!=0-*CW%>&]U N:ML;%
MXFQ4)]*.5/N!KU9@GQ";=CD^XDH#K R8-[/V!QXGXQ (\Z@;7;BHN Q/@HX;
M=@2M$$+EV^.'V'18,$*%,"SOY;/\,7+H\30 14S(CEG#:!Q:'JP[;E5::NF*
M]KBTT<K7ZCEU(6*8V598S*.(U5L!06=40@A8X>]5)+-D\4!7F HQJ6/@N@4
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MJNM-/#26,KZ&]%AR"L5G;6L0T%F#?BN2$4IR QLAN)!=]^H C]0/!(W,;?\
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M9*7:O'**M%-]^.Q>BVREV4JS5NR%E)!*L5(V"0#H[&P#[@&39%< .JL 00&
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M 1K4PR%<-/#OK>8D]AZ_T9J6&3TPZ-/",TC.OHL&E+AQ)'2C^196/,1:)-#
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MU?8Q6QLI<9%J:YQ4UQ?,^:8WE@;E>CL TVJ%5*EKLWVIK&L&V4'G8'K-A+!
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M.-FU#_RPBG9L"II.*@Z8'8&_/HR)?;TJG$A)E)GL9T&1^$MU]IB"Q=W&(O\
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M6#:^-A5W99Q\!SC-3YK6P9"Y=HPUL<*ZO70KJ.0H%K,%K/J2*V-Z1985J#W
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LQPPPQM;'##&UL<<;6M:UK6M:LOO[R<_=(BD12(I$4B*1%(BD12(I$4B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g120909g90h66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g90h66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %MR^6%(X0DE-!"4      !                      .$))300Z
M  $+    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    4 $, 80!N &\ ;@ @ %0
M4P U #$ ,  P "  <P!E '( :0!E ',       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              -(   '6P
M   !                          $             !UL   -(
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   -(     %)G
M:'1L;VYG   '6P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   #2     !29VAT;&]N9P  !UL    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M5V=WAY>GM\?_V@ , P$  A$#$0 _ /54'*RZ,2KU;W;&%S6SYN.W_P R1DT
M\I"KU4;Z.=E=2P[L?TQD/QS<T%MK6D$-)<UVP_O_ *)[?Y'TU7&2PLJV]3<P
MOWDDURXDN:?HO#O3:R/9_P"DU9&-U1]5C+WT6[A#6.9+/I%_O;#?^*_\$3NH
MZJ]VYQQMS0178&.W-W#7;N+OY&Y3#A&@(W[W_P!PQ'B.M';R_P"[:=6138',
M9U6QP:SU-&_FM@O=NV^H_P"E^\K6-U;"95MMRC:\'5Y803VW;&!RGZ'5'5V,
ML=C/W,<T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 0T"6P,!$0 "$0$#$0'_Q  >  $  @(# 0$!
M        !@<%" ,$"0(!"O_$ %H0  $$ P$   0# @@(" <-"04" P0&  $'
M"!$2$Q0)%187(1@B,3-8=I*R(T%7>)>VU=@*)#4W4Y:XT24R459QE=8F-$)5
M@I&4L<'3U-?P.&%S=WF!A:CQ_\0 ' $!  (# 0$!              4& @,$
M!P$(_\0 5A$  @(" @(! @,#!@<,!@8+ @,!!  %!A$2$Q0'(14B,18C020R
M45:5\#-A<8&AT=,74E15D926L=+4U=8V0E>2M<$()D-R=G<E-#=$1663QN'C
M\?_:  P# 0 "$0,1 #\ _OXQC&,8QC&,8QC&,8QC&,8QC&,92OH3M(KS_P G
MLW3B8UTZZ(_+X(2M1I28DZS6(T0C"PP."]MB4I+\N7*2MQ3464XS#8E24QW=
M,*1NP\5X\_E&\IZ9+AK"_P!K+%PPEBZ=2NHWV++!\@B1!83 Q+ @F$ 28^7>
M5GE_)J_$=!=WCTE:*OZ55:2V0MMZY9<"*U1)2)S!M8<3,BMD@L6,\"@)C*!_
MAL#U>6#7HW5"DLF:I;&:+<>8RSS;!*LVQ%Z&4TB'(&$B7$I?AL%H1U&MBD+>
MB28["T,K<4XBT?[G;OVUK\2_$P*O>HELJ&Y76DDW*,ZUVP584B7Q,@PD,K3,
M/F!8!E$G P,U*/J:F>!VN9_A+!LZZ_&KV6B9;$;%'8#M4:UU9UF*Y1YK&PJT
M/[B)-9@,P$E,C?')>S(ZE:>U5I-?4%WQ_HNZ N8HEJ=H\K00:8_-$LZA1-CM
M?^$/M_M-NS-_X+ZGW'\?Y$UG><?G2TN/7)M18_'M3&TA<)E?Q>[#J_IDI8?N
M_P %Y>SQ7_.Z\/MW-KX_R6-]?Y-1BG-;]G-S^$RR70WY<_%1:]\!"E^F.G>'
MK\F_S?+S^_4<;?ISST[;(M$1V;G6[C,-RZTQ7/U0,T5W8(,O<"0&=BJ?TN.1
M^_UN"Q%D?2=ES4JBQ$OOI4WK[/#N511/93Q_;? 76"X5OX3O3%5B_:-B#\>B
M5ZOWI&/8@OHSD1F)S&.<</+8!J8Y+IIV3+3:(4OGH^1\Q+)2=8@\^P=[8E0K
M/Q)C8E:X(XZS(.^AN%L] ;Y4YUJ@IZ*Y-T+34-V49LS^;*5\B0RX^G]I;-+<
M^#: [BTDUN*2VF+M:TIWJCBO)"U<[N-'M)U(K]TW_AN^/Z(CN;$%X]S6B.YF
MQ$2F(B9DXB)G-Q<PXL.WC0%R#41N2;"(UTWD?*^1/VBM(>?VLS/VBO,P^9F(
MA<S,1.NCWNB@VH#U5_E!&D$[#RZ[UZLOM7F\"JQ7+ #+6  %D6X29BJ)*_*'
M'S*API<IB.[,,L_9MLNO*:CR+8/TVV=*UI!WBMDFKNM=:N"6MUKKENK915M6
M HOKG"8]\#7AKX BA=<O81",$84TOJIJ-A4WY<?=JWW-#M*=$QVNT11I6ZMB
MY4JGL:]E<OGXTG9E-<C ";9'UP)3(B>R1COO$Z_?(7+SG5*(*Z%/=BQXU1FV
M08P:W+G)0N!!=BN/IW&GD$NLJ'P)6V9LY+\=41A[4AGYZC7XQR*UK&;FMI-D
M[5*$S.^NHXJ\ KN&L$X'\ZE2)0UH>2U2)0PA\2ZNMGEO&*FV7HK6^U2-PTE@
MO7-NH"U+&Q$I5*Y.)!KHD94H_%C8()6)>8]XBP>G//54L+M3LO9N= [-'-IK
MDH$2M R*4A&5(87J'.B.OI=@_!,F/M<B6EF(WMYM+CZ5*UK-]7A_*KU2+U/C
M^VLTRKS;"RFDXTLKQ)1[%L$9%GW ^@7)'/C/0SUG-;YQP^A<+7W>2Z:K>"U%
M)E1]]"WKLS %"FK(X)7V8'9L@5QY1$G$_;(?7/8/$+!U#L7+7;:&!$N,M07S
M9HX<"P09:-H:Y-M$D5)7/^HB/19J-!+6Z0;B('E5H83MQ._GSOM\"Y'5TN@W
M44;%E/()8-:O7K6&64'[H72!P0OJ2V2Y^31A4LEJ(DOMUUD;2^HW%[F^Y'H"
MV%:H_C0K.U9M6JJJM@(3++QUSEWE :IL?&V!.%<)?,#]X^^2\1Z=\\GJ[*M@
MGLW.YE=@G!5:FE46<:W'AG3BW4!ADI+[[3T>25VQ)6/2\TA,MF),?84MB'*<
M:X7\.Y55MA1?Q_;+MLK/N+1--TDRM6B)L."1&1($^00V1*9 C6)1!,""DJW.
M.'VZ;-A6Y+IFTU6J])KXO(@%VK<R-5#((A(&6)$Y3!#$,%;#&9!9D-ZY6LM6
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&8(%*?E(*;D.J=VP:GQFM
MJ^'\1AK;?TV]?#6OXJ?COX?'X[_?^_>\8S.XQC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,T*]>\3[?WR_<*K= )#J30Z%8I
M74#W0R; :Q-0KR!;4FCP6Z--(1I!W<1_4IUY4IC8E*"B5O./*BN17?3>!\BX
MYQC5\FM[1+=CL]G4#35=4DK%26ZVU/>R9.R6HQK>8^ Q %#YE,P,#YP8^3_4
M3C'*.6[;BE+4/3J]3J;K-[<W+PK715M*@S&J4.J:Y9VY6?L,I8/QXA\$122Y
M66J-I\@^JQ=<].<X1*#=<$]O)<XZE$NL7]*\_;5TL1T2OS[C!?JSQI"!RR5>
MB/E7Y\=/Y=*=%0V65IGREQM7>CSOA+K?#=L06-$_CB=MI6:XYO;28T[]5:7K
MVC=&O,MA-M@(%13[@%S"*)4$%E!O?3OGU:GSG2PROR.MREVFWR]H$:_3][RO
MN:;=DDZ!6H%,OI+*P;@CTL*NH1*',(,W^\]<RN5!OOITY:!K, ;TGLRKA4'V
MR$":HB W5PHW4MUF'(?=@.?>0Y#7VLY$>3\$:<^E]-25;\OY5N=?M-9PZM2:
M3':CC\4+XDIBX3:B[8=ZQ(Q$6QZV 7FN3#[]>7<3$>M</T>RU&VYS:O(%2-U
MR7\1UQBY39=4^!51["%9D2I]JC'UM@&=1Y>/4Q,^7-7Y-UKN-/[CR>E<EI3U
M<L_LWH!<IWHC8Q,0[SY5:N(F>02S77(3=@FD4CV=10\P3.E,NQBY*#(8A:VN
M1OV>[O-'QO8<;WFQWFQ&W2^GVJ0GC":CSK;6+E!ZE25N&356KVE[+"WJ A.N
MEH&R>@CPJCQ_D'*==ROC^KX]K"IW_J9N+-CEK[M==K3S1VB&M\*9*BXU\)#U
MUF5W,&0LN48+B9.;+OWF7U?;[X169!E;"Q!]2U[J86QP;USD/SO?.(!B)(B[
MATEP?$MC%X%PDNI*$GR##\YEM3'U3+JD.RH;6<PX10UBHKV4U#9PJUI;%1FM
MV]C;?B[:Y@SV;&&G0+7.9,2E0J(5D4%XUXB17.;;A/U V.V;-JJ^XM//J6_K
M7$[335M/^"JM+8'KU<H7L!VE=4%#WF\#:(R'G:F8EDEZ!YC[C.B^M:%6N5!'
M@O4>Q4#JM#NT6TU,<W.&C[;S^<6J:P\A^(1&;%CPQ4FMV6J-#D2H:XT)F0[)
MB.R.35\QXVL^#;.YN[ V--H-II-GKCI7VRIS:.T6B]%@ -+O<VPE$"N#8 ,@
MV$$ P0[-OP;E+%_4+4TM!5*KO>2:??ZG:+OZ],-2G8Z=UG7S6,UN1\=-6P^2
M9(+-@2"A,C61QZW>+>OS.G]@KA('=;MR[M'8D=*79ZGV"B480$@3S$4FMJVU
MZS4&TVR=8:EME:0DFN2EP)33<5MEN%MZ:E/70^H6A7IM#;39UVNW7'M!.GBE
M>T&SV;[#55V)$J-NGM*5!=6]Y1-D+80T"DY*6>*YSEV'TSY$W>\CI/J[/::'
MDW)(W<WM?R/5:JM52VPM\AL*=[4W]BVYKY"8JG2,DL 0$13Y-RQ>G>2^C6GG
M7N@=!HX,E<.R=-K%@Y9.F$*QHD3!!W:>ZMY9>5*0H'N.H>;6U%)28#OSK>4T
MU\9>MNQ&FYQJ:6U^FS6[*RK7\?T]VKNEK5<E2;-B+\0,( .K/G#:T$:18,1
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M]%/7:TEZG< ,F_T8B='":7'%#9*M62NPT2)2)I!46'))#7F$2A>MPIDKBU_
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M]A3(;*UK=+=;896L2(+:T9 F**53)Q)#U)"$S,1R<A[%3NUT*J]"J+DR,+N
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MGP$.9$2M+3B8*8D%F43 ?SYB1B>X'_UI_0?X]9]-Z5S,,<H)B1&8-@#,$?\
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M4E+=_33CF\O?B#V[FG8;K@U-^=;N+=.-O04KU)1MY$B._"P^WDX_-T0(V)<
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MAB M5V1VR8]<]Q)!-6OJ:Y^NW-9FCW/%]P?$-UR/CKMH%%RKRZ%%CQ8J%-L
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MZV*4U[5I0MCG-,5J4H"8UC#F! %K")(S(I@1$8DBF8B(F9S6YRJZF/>U:4)
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M'FB) :8\Y&:<>;C//Q9+F]);=7IM?PVE7QUK>4>_R2U<Y0[E2EA4NGM@VZE
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MML3-9[U%\VG!6K)D<-.W,00]$N9V-\:?\_/&?_Z9/%/]>EY4^?\ _HUR#_\
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MT7JRU65R(^Z&Z$CSI6O4=<;F6 5<>AVX#!.W%WT"(-H'@0PRDT=51_3]4K#
MG\L7#8S9<M^$S:&?!'C'RG6^K\U)] \3=7"=AI97IW(YEUX-THP"7TZ'$JG3
M>1LW,.3FU)H/TR0\.0.MS,T-9:\",P]K1&^SQC*AYW^ X(I%@\O_ %_0Y7=
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MS0$;I=P]N&WUZ6OMW*M.^VUI?@[Q=W2@HPI&T92<09??+OYKW7I;O6;!2.@
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M!99JHJOU-6VJ%/M/L#!.6*5Q<[_>+F]SWSK9%C(P<WTN'+LUKC+CJ3'4(JU
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M(Y.'J3"R[M$PB*&@/MDRF8+RF9SX>S?3%MMFP=5$*\J?9.V:!&H(0,K:XF#
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MKX\CN*\8L5&Z]_'-$Z@^O1JNI-U-!E1U7608ZVLRN=>4FC7BPXHJ()75@SA
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M;O06J^O7J%UKU0=I>FMI++"UTD W14-#C=&XLV+@O(PL.=*Y-0P1,DLM').
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MG8:]+62I3;=5J -L#)RL28(Q)^$27C$]]1,_I$Y,LL&0^,8QC&,8SSC]%?B
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MEX^J\YFQ"Y +HE*8*S/S\8"A%;O!.DP+TD4P''EF96.KT%=X/BRJRSNW*(L
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MZ4QTI@2FAT9N1#2F(Z]%3J*\E;&DQGG8^M-_!EUQOY5;8S/XQC&,U?\ '_\
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ME"=:2G6M:UK&,VEQC&,8QC&,95'4.?GK?H"<IUN>IEWIRSDJMDG!T(N&EOF
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ME(6VT,:FN,L)VMNTZS8ZBS0K:3?!;571<LV*>UIDDV4)NKKK:+J95B;;JPQ
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M_6 G_>:QC))C&,8QC&,8QC&,8QC&,8QC&,8QC&:E>NO^1^!?YVOG7_7N-_\
M5C']_P"_^7-M<8QC&,8QC&,8QC&,8QC&,8QC&4AV2MV:9*YU=*6)*'+)0KDS
M.<#BRP40\5JY:'(&V8>MX_)@C7M/1MQEMM.S8R]+;^9M>U:VG=AT-NHL=I0V
M#TUJFRH$J+#T6'BBXE@MJ-@:H-</B<%$D*S^T]3'65SD%2X9ZG8:]#[-O6;
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M+5;>JU@WHQ#DBRJ8FY0AH$MK45'Y_MQ;FFV?)GK^$S_DZ_\ G,9LY_".O_\
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M+$QER76XL=.]+ESY:DHAC8+6_K3I\B-#8TIY]&ML9XI/?BA70KSB/U[G-/X
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M5QC&,92G?.3/]FI0&JQ2L0+)"]@X%TY,^7"7.2J/QKN7/.MSQ;+;;K+C4D_
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M"PNV[H/!XGF>YV.?;9E^>M1(P?XM"CU&;/(&9,C4C3EH8<9MS[YYQC(1QO\
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M$5+:VK4CB&_=:I5SH.JKOWBUZ+]I;5ZZ7 3184V@6P92 UWMEBX9YJ0TU0R
M+K=8YIQQ%2]97L46VZ^@.QL:^HQ3-GZ#%,K :9L6</85FLJ%ME?@ZPE;I7+!
M[Q]E]7>>:L-.$9O5Z;._3L^&,+CPIT:6*Q)TXU'K[3*H,24MS>D%']L/N_'Z
M+6HTU:G/EAR?I[:?".576UE+TFP7\M3'5VV*SD)8M=<K4E##"(^Z1@A'^<4F
MN(C]X/>F[S[A]%-IS.0:QOPW*1836MHL6%M=:"F(RI;)+[6"D"+^:/@WN?W9
M]9\#W_E9N 5)/VT "C"K0Y55*,62K[U+E.6$[6 TR,X*.%&41+(6K)Y@*Q-=
MB%EJ$D69PR#*@RX[/-:XONJS4)&C:LF^E%V(KU+OY BI6NV%G#ZR2EE-%RL5
M@EBQ$0])*<T&K,NRIRW0V5/<6PJ501>*A,V;M#]XR;ENA68$HM/&%W;%&V%8
M&DNQ)5W@U"F*8 Y!WMW-'^<VWJ5=M0.XU.FCB\TK,K9T ^TJ0('I(K%)($2H
MT+"(3&'HGV6S!09!6B?!E/S6(,A$O-0\=VX[:CI;=&S0O;!J%I7<JVA* >V4
MP^4J0ZRQ2R%GL]"'-B5, 5DP9#-I<GTI:;8;VG?J;'7ZU-AMAM*W3(?.NF'R
MCW.L(JJ<P"7*_DV$*F'*8304<,S&0?1W"YQF-6==6H,>UR#,.M*JKUM +/Q[
M/-GR1#=<>A12,G2S"#,.4&<C179"-$V?M&W7''6/J[F<2Y*NN=S\$VAT1KLN
M1=&C:BJ=-:@?-L6&H.J\UV!8@S$)])>9","7CH5S+BS; 4OQ_4A?.RNE- MA
M3FV%YKCK12):W'!68LK96D%D<>\)7!3,CY<;7I7SZ\/*%6>S\V='!9PX85F-
M6X,XQ!(%]S4BH;ZTRMZT^16-(M0FT_,J2]!F,M?,[&>0C[/$.4BU*2X_MQ;8
M6YR%E1L03%(]<O8,2$=BJ'*)D_H M64]"8S/P>:\1-+[ <ETA)K-2A[1V-60
M4ZS[?CK,H9U!NE#A4/ZF2F"/9 41(1G:N1&BD\((Z52B9<8=@5B>.@V(9)EQ
M; 3D2X8\0ZRU(4O4Z9-@3H3#.M;4N;"EP]?\9CO-(Y7<=WM9*K-C4;%*'5FW
M%.94<"SJI &->)$$1ZUK:MA%WU"V S^80E/6CDW'K+VU:^ZUC[*;2J+4*N(-
M@6WFU::Y )S/M8U+E"'ZRU3%_P \"&.C&[[Q*9)D1(O5J#(DQ 92RR6FK0)6
MI@ $9ER2Q9WY9.THA#XD";-DO*WK3<")(G;_ .*-+>UL/C'(E@##TFT$#LII
M@14GQ!VK! "$#^3[L:QJU@,?JTP5_A"@9UAROC+#-8;[4D:ZK[K!B]7F0J5A
M8=BP7[SH5)6IK3*9Z%2S;_@QDHZ0OT?P(W]_^4]EYL0_*Q!,^2W%N 1W4 *&
MD,Q2A.9O4SX1X4)^1'2\^[M*-)D1W=;4T^TM>Q_$^3UO5[^/[=7O>FJGSH61
M]MBP!&A*^U_G8P1.1$>YGP*/U$HC4CF7$K/M^/R32.]%=]M_KV54O36K&*[#
MV]-_(I1F$&9=1'F$_H8S/.YZ%X8TFLK=ZWSYI-SW\*K]2TB4;/*_.-5Y:1R5
M2=*?4T>W^3/IUK2HY-*X3^FY"%MIQCBO)"FY Z+:3.OCN[U2?/QH^/\ *B73
M =#!5OY0,S_.3,,'L9B9R+E_%@BC)<AU QLO_P!0\K]>/ES\GX<PCMGYY&W_
M "8XC[@_M1='$C&=YGU:B=@"$['STY'L(439CU2E$(OPW'V8KLS<.>EA>E*T
M]%<WMJ5!E)W].; DQ9K'S1Y+*U\VXTFRT-E-3:UCJV'TZMX%']CBO;7[%2<=
M1XG'1 P)_,M@&LNB$HCJTF_U7(JK[FHM!<K5[UO7L<O[A-BFSUN\)B9\ES/B
M:F1^5JC!H=@8S-BY$Y,XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC(W6OYLS_ %@)_P!YK&,DF,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,9^;WI.MJ5O24IUO:E;WK6M:UKX[WO>_W:UK7[][W^[6L?K^F)F(B9F>H
MC[S,_I$?TSF,02%$ER1T,M#>EIBI<>9@SXSDZ-'EM:VQ*^FVMQQE+B'$.QGU
MM_37\4+1M2=Z^.Z4O3 .8A@KDY@2:HX49!/Y@[F(@NIB8,8GN/O$]9HAZ'2:
M5V%DR%P1"IH$T 8/Y&=#)2,%$P0%,=3]ICN,TQC>)>)FD6<=9[5;;U97F0,:
M*:58 E6L=)16H=DCU5^#&YB(I<%TH*5;#4ULI:!9F81DR&MSURH[#3&O02^H
MG(JTTW4J5'6TQ*R9UOBV+M38S<93.Z+3W#]@T4OBC67*:3JZU ,^J ,I+/-@
M^F7&;,7E7MAL-K=,:BUVOEU:%W6127>&@:@T=?6**Q7G8VFC8O(LM<9Q+B8
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7&,8QC&,8QC&,8QC&,8QC&,8QC&,9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g120909g96s82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g96s82.jpg
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M+S&E6XA\(BX/36LKU;'X_)87)/F+^(/=BQ*S9G'@B<T.43N:T,PL><5<=DL
ME/4-46S[W"WA]?QFH7T7Q(AEL[IBH>Y=HY.BV-IY$563C.^,N&D(4VD1F$ @
MB70D-,$)%@*R*PMJY-\BU]$DQ),PQE-+'R3?2%:-O4*E*<*)DC2 E:YN(^R%
M'&]4L!_K=B&$)04R1<;L700+8<AX\\;;?"(6G XC @U'ELZ^9M2I%L' U7%8
M*F.U?O2ZN(I.4<2L1WG&(X@KVB/+8,MK+PAX5UN)!,V;)9<N$QV(]ZZ\;0A!
M*]C(Y:S.O4JQZ>8X;SD/D9HN\W,:N-FW+%GV^9W6%AX_#O%D;$[J$R+1N2)&
ME0J,()%M^4M)!B,]2468868BVXF ,UHO8M'IQ%B"'?6Z,EU1Q3CB.#4^+&)H
M R#3T]@\[6QQSS$*7ON?'"G6*<<)$A.J]V<)[#YF*%X2BW;M8\!P^?)<3X\.
M\C<+2>.9RV)->$&!"-[VBNE@<8IRC"4;#582CO-FZ,K29W[-]6A?)1#../DH
MN1J:DH7R'LC^I?8J8L,$4C>F-&8M C$JT5H_:%Q2[2K$JG1.Q:)4[)%H2A,>
M ./:6XZ5-6<&,_Q.Q^/KQRVF<3F#Y?3T[4W'6RN)JSMQJRL,-C=4NU^@L5[#
M"=^B.XW9S +&-YU!PEL:=XH8?05VX9\=G<AC X[,Q!%IGQ^1/&O*PP7FX^L5
M#=, P7)MT@FFSL(HY/,E53-18E<PZ<*D)+8HE#&D=CD"<X:@E(-3H6]DEG&
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M\3=+";M)F:KUIVI/=U@?&V3L3-(V91I4T/[6@>6Q3H.P^O0.:4I8D-V#?\X
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M7*8C (T2">O2O I<LXQ>,Z9!R9ICFS>CWC%BO=1X/(U'&3'ZHQE_4%,P)1(
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M.[B:#SY]IO)HQVMVL>).L->CH"U1DAY >,G8)38="A2Z*=J(HG=WI5@.3G8
MV9B/)H\N\69W??:)C7,1GJN)KI0VF."F$R)%*XV86O7HM(7QO-+.2JQ@1*2
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M%8G8!MX74]*(D@XT*@I((K91)IFA]0L>]31S.'G3GD89;&RQXYN,EZ-ZK*G
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M_<\>^N+^^5#URO\ K$]Y<S]Z<GZA:_5)] 9W^Q4M_#CQ^YX]]<7]\J'KE?\
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MX.\C])X#VLG?^X@?&ME^X)GY;Q\.'"OY7T_4LM[/3R8./'X.\C])X#VLG?\
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MX.\C])X#VLG?^X@?&ME^X)GY;Q\.'"OY7T_4LM[/3R8./'X.\C])X#VLG?\
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M^Q9=Z^X+_?=K[^KF,_Q.2X&9Q$OIVF$3")A$PB81,(F$6QQ*6/D'D#?*8VJ
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M<>7Q\,/A Z;#/%:@S6,/;P0'C,>.R=BC> ?(#8K3,UBP25V!CVYCLP>[;Z?
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M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB]:$HLY4468'K
M$(.A:Z=ZZ=;%K6_K#O6]?5O_ );R6;NS=G?]:C%F=V9_\]BDHHHLDL)10 @+
;!KH"$.NC6M?_ -WO].][Z=[W]>][WE%5U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g120909g98k04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g98k04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1J 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &F2^9U8X0DE-! 0      !<< @   @  ' )0  M0971E($AA;FQO;@ X
M0DE-!"4      !#]I6B(9L\8>(^>]R?; 1Z).$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0&CZ7(         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      -!    !@             ""   !((    & $0
M4P!0 #  .  V     0                         !              2"
M   ""                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ""     !29VAT;&]N9P  !((    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   @@     4F=H=&QO
M;F<   2"     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    #.$))300,     ! <     0   *    !(   !X   AP   !   !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !( * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5,YS6-+WD-:T$N<3
M  '))3H+J]]SYM)8ZO8:-(!DS9N'Z3W-.SZ22EQDXQ( M82X@ ;AJ7#>P?VV
M>]J;[7CD^UVX'80YH+FD6'97#VC;](*(P,8/#PWW!S7@R[EC?29^=^;64S>G
MXC6M:*Q#!6UO)(%)WT:G_1N24H]0Q6@DN<  YQ]C^&N]%_YO^D3NSL9N[<XC
M9OGVN_P8FW\W\U0/2>G%I:<=FT@MB/S7/^T.;_V]^E2=TOI[]V^ACO4]3?(Y
M]8 9$_\ ';?>DIJY&#A9&:[).3DUW/ IBI[V-$,=>&@-;^X_U?\ C$+]G]/>
MYME67EL>^NEC7,LL$@MV8[B-NW\U]C]WY_\ /*QG862U[;<"G'<27V7^J#N<
M\5?9Z37MAN[9^A?ZG^!6,<O,Q\BNB[$QZG,LPZB16Z =CW15;ZFU_P!G^C5^
MXI80G(>DC;:]6.>2,31!WJZT=%F!@N; S\P2T.#W76,T+O2_.#6>^S\W_,1+
M,'IC18ZW*NMK+1ZE1N<\$8YJ#W^FR;'/:ZFO[1_US?\ SJP*>JV-IK<S%QF$
MTT_1K<(#LES=C8M_FVN_2M_X5+(Z_E&B\NHQGCTLLEKF/+2&W,K<U[?5_P +
M_A$W*)8JX^M[?U:_[Y9]YQ5>NW%MT=Y_3\"MI8[+R23 GU7N+#2WU"-S?YKV
M_I7M_/4&].P2&5G-S"\.:&DV6 [GM=8SEOL]GYOT*UD7]7O&0Z:,=Q-F7+G,
M>3+,=AG6W_"-_1V_\&I5]3L-]9^S8V[U<:'>FZ03CN>U[3ZGTZ_YJO\ X).C
MCR2XJ_1W^R,O^Z3]YQW6N_#MU=IF)@CTKOM62X!K0QIML#CZCW['V@1<[U++
M/\)^C_1IL'$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT7+\E65,?9)<:C<FD;RQ=G>=)APWW')RXY)R>/%3'4U._<WX(G<D (]Z-IW
M.8,R.U Z ,879PV"\,UZS2%S@L6T.(MDK/3MHDK%'U>(:R[ZQV>.+$6.<<OD
M6I5U92=BR PEGICBO(-1.BZ.J10X&\OK:N2-L,E3.^)C&1MC=(XL;'&[>C8
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M)C?TUY*3Q7DBLTXCO&<_'UBUL&MUM57A*Q-/&LU(%:M4J])RX/4VKUX@<S)
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MJBN].W=)F=*HMDTT$U%A.<B1"IE$"@ :)D\.'N\1P7$9UVO1[]&584F/92:
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M/;@G@?B4NBVN:,K[?>;G3U-:ZDL--!5W%SJ"9CV0U%0VFC,;'8,I,KF@M;Q
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MRSWE.6:3+/U,22.Z4*?;_AQ41=.W;U3G*P"XF*55VLNJ5,![DT2F!),.Y,A
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M3W]-$F6XV501.Y4(%$Q:<#.G;IZMQ4Q_7SB N'BRZXE 1X$(*@E3* $(!2
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M5M?1RN9&(Y&DB..9SW'+@,-!*UK9%K5B/D&]&) 31BGN-G,0Q8I\8IBC-OA
MQ3 @(& 0$! 0$0$!X\=;?M%92"TVP&JI@1;J($&>($$4T601O<"%I>\4-:;O
M=2*.J(^^5<<BGE(P:J7!R&8P>CK5E^4**8FX%H0Y1*8N)\3%,4P"4Q3%ID>
ME, \! 0$! 0$ $!#@.L/V5$'2TA!!!OM\((X@@U\F"#T@K-=KP(U;&"""+!I
M\$$8((ML.00>((Z0O7(7D#[>?LS9:_@[+2U=]#5?YO6/Z;UYN_>GTC^<NH/J
MXEYVN_I![WOL25'X8!IK7NHV;_#U=Y HZ&[D]I_YO6_SD%C&PKRO,'_7,_\
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M'P58O-%(OMEUP=39=M%;BT<I$0L6=1*Z4!#JSH5+@@80;B1<ZXBC_>*],@B
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M.3O(/VP?90S5_#6&O=F[YNLO@73OU<JA>^]3H?X=U+]9&L/PQY+V^O[%./\
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M-EA]02G_  ^BAD=8^7JY_D3M(V\V6'U#)_\ #Z*.1U^G/^KBO':1MYML'O\
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MX3:G.3,8 !0G X%$Y!$H' Q./.*8 YNVN=WMY][0>04ZZBV,#&SNQ^_N!_\
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MT[%.^?ID<.>\YYOY@NO/UGK/63C@#F.)#_M[[OX_UXY[QX<1_/C]X\  /M
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M]4!X=YNS-ADB'[__  !;$^/_ )PU<RW?LS'?R>YRMY^;LREA(X>WV">/M*T
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M1(]4TX<QV6N <"!D)C%(4QSF I2@)C&,(%*4I0XB8PCP    $1$1   .(ZE
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MB >,0T1?1LY;/$2N&CA!TW.)@(NV5371.)#&(<"JI&,0PD.4Q#<##S3%,4>
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M2E  *4         UI$DDDDDDDDDG))/$DD\22><K?@         &  .   X
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MSJ'QCCXRAS&.<XT>#$QCF$3&,(]'Q$1,(B(^Z/?K+AKW6@  U/>  , =E.P
M.&.;FPL+.SG0I))TK9B222>Q&<2>)*T#<HDV6:;PLMMEW/6U$24$G3] DVYQ
M QI3NB*"*( D0$D^8D'- .<! ,/RPCKJK9&2[9_8R222ZZ%Q)R23=Z\DG@!Q
M)SP7(FV8!NT>_@  !EI  Z ++;P!\0 'IA;PN36*H79_C43JBH4[RY&3+S"E
MZ$G;":**8"7O/Q.4ZG./Q-Q.)0^5*77.6USN]O/O:#R"G73FQCO=V/W]P\X5
M*O?K6JVFFB)HB@6X;8\'7NT2%QLM&2<STUU4+(M'3UH@(^W@R:I,&A;K!U^;
MBX.Z%0CT48],+3'2X%CT4F/_ &1,B($4YM6K9BU;,F3=%HS9H(M6C5LD1!NV
M;-TRHH-VZ*92IHHHI$(FDDF4I$R%*0I0* !HB^^B)HB:(FB+B/Q?%8O319&B
MDF#1R,<F_5608J/@1.+0CU9NBX<(M#N.C*Y5007631$YTD5#@4AB*D>V;;=D
M;%>3[_D'(#RFK)61A/-:U&U*8"0+ )VV]O\ (-D8.EQQ;0I:?1<3T@JNPE[A
M.V^;CFR81[)PU1=22KXBN^[;D>-7+10ZB9'3=9N<Z)Q26(1=,R1CI*%^634*
M!A$AP[R& #!WAHBUZX^V26^K5"WT:4RZR:1-MPYC';NYE\?TTE7L;;%>'VF0
MBUF434F9:U0BF1[.XR+*,KW-N(5>'>5]HRCH6'BG:*<B0BL9@/!LEA#!+##"
M60I67>19K\$7>65>I\%)PZ=PM5DL<8K$U]I J4Y!Q5R3R*$>W<UYY#+KQY!<
MQ*L>H,:4BQ;9S%OX3&EXB92R2]OD&&XK<NW=V:?;P#29FEBYQO(F>R+:KPM<
MKR+E0! #$B8.,: !0YC4@\X3$5K]$31$T1-$5>9C=3@R$RBOAAY="JY)0(D
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M"@OZM%KP$CSH!]!,)F4>6A)*("ZV2C1D^_8FJU1DK-=I*,K3B(!) &,D@#)
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B.<2YSG.+G$DDDDDDD\22>))XDJN: &M &    .8#',O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g120909g99c98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g99c98.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X>$\:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P-" W.2XQ
M-C0U-S L(#(P,C O,3$O,3@M,34Z-3$Z-#8@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.FEL
M;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C
M(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @
M(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z
M9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/F<Y.6,Y.#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SID97-C<FEP=&EO;CX*
M(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z(" @(" @(" @(" @(" @
M9SDY>C,S+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @($1E;'1A)B-X
M03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q,2U&96(M,C R,2 P.3HS-SHQ
M-"8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q,2U&96(M,C R,2 P,#HP
M-SHQ-"8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU
M<W1R871O<B!697)S:6]N.B @(" R-2XR+C F(WA!.T=R87!H:6,@='EP93H@
M(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03L@(" @(" @(" @5')A9&5';W1H:6,M3&EG:'0F(WA!.R @(" @(" @("!4
M<F%D94=O=&AI8RU";VQD)B-X03L@(" @(" @(" @5')A9&5';W1H:6,F(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE
M(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @
M0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @
M("!G.3EC.3@N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @1&5L=&$F
M(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#$Q+49E8BTR,#(Q(#$P.C(P
M.C0Y)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#$Q+49E8BTR,#(Q(# P
M.C4P.C0Y)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL
M;'5S=')A=&]R(%9E<G-I;VXZ(" @(#(U+C(N,"8C>$$[1W)A<&AI8R!T>7!E
M.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@
M8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K
M<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R @(" @(" @("!4<F%D94=O=&AI8RU,:6=H="8C>$$[(" @(" @(" @
M(%1R861E1V]T:&EC+4)O;&0F(WA!.R @(" @(" @("!4<F%D94=O=&AI8RU"
M;VQD5'=O)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S
M96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[
M(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N
M/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q+3 R+3$Q5#$P.C(P
M.C4S*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO
M9&EF>41A=&4^,C R,2TP,BTQ,50Q,#HR,#HU,RLP-3HS,#PO>&UP.DUO9&EF
M>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3 R+3$Q5#$P
M.C(P.C4S*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B R-2XR("A7:6YD;W=S*3PO
M>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @
M(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @
M(" @(" \>&UP1TEM9SIH96EG:'0^,3$V/"]X;7!'26UG.FAE:6=H=#X*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z
M9F]R;6%T/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO
M-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-
M04$T46ML3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))04%!04%104(O
M*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)1
M64I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"
M351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA5
M4D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G061!14%!=T52
M)B-X03M!04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&
M07=)1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#
M07=11D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)
M4DEX459%1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG
M=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*
M4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP
M86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K
M-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)
M0T%1241"455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y
M)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!3
M3F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z
M:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U
M8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5
M-'%L,G4V9F,S=&MI5WI)2C1:)B-X03LT3&U-4T5Q:D=#5EI/1$UO66=.>'!7
M:'DS1$U23R])9VHU:'!Z-'I+3S--14@U1S!J,$QY:'%';5AN<4=A2F]J64IA
M4TU#-60U15)&)B-X03M";U(X2W)X4%)T-B]:0G%4:S5T5D=9-69X5S0K1%-Y
M9V5E,T18-"](-U-D4$E0;7$S4THY4'5R87AM4S%7,5I)6G P6&UO:G)/1U)%
M)B-X03LK3U)O-G5/3SE"5W9836<V,T5F<4)/.3AH-3=F1&\T;S!/5TE(0U)%
M.$YC>C5B.'5V5C%N<&9N9E4U-W@Q=C=M>DM44$I!.#=815-G)B-X03M3>6]6
M45)&5E9V5&I2>%1D87-+13E1>GE964%B03=E6#0S3F5A65ES.'EF55)U92]V
M2%1Y1BM7+TY%;GEP-2M"<DAR65=P53!E931F)B-X03MI05=O9RM&9G-H:'4Q
M4S5(>&)B6D0X>F<O;2]94'@K<',O3%HK:R]T4#0O6#%2369K+U=Z65A%5C-C
M43-C.#$S2&-U:W-K<&IM5DE")B-X03M#5FQB:GE7<F9'04%12T%$24A6431G
M44-"5F1.=#<O67I';&YW;7E#5$LO9G17+S-Q56YL8GIY8G5:-'184T=%>44R
M-D-E-%I556AL)B-X03LO=3)"2F]/3D8U.&$W-%)Q34Y#-#<K-&9J-T=*,"MF
M:4I%='9E9E!P.'1R<G%R-E)O2&UU,U<K:3%$54ER-7)I,&5+2T-3961K16I(
M)B-X03LT97=:54-M:&%P8RM/47DV:D-30D564CAR<CAF0FYI,"MA25!%94MX
M-3%F-#DU46$K4F1B4DE3<C(S3T]&:TUB4WDK;4=95#AO,#12)B-X03MX.%E:
M1$]R36]!<'=!,S8U861:1&9N>C=H-65F358Y<E5.1DU6>35D-3@Y=5A),SEG
M4G9L-WED<65N86QB6%4P<U%3145U16MD,F]9)B-X03MY;F],5DDQ.4QM9E9!
M;T]*,D$R<FQE9E92;D5G9FIZ.2]2='=A5U5*06XX8F-U43(V+UEH+TQF;"]W
M07EA6')';C)T>F53>3).=D$W)B-X03MY>$DX>E<V.%572TYE5&A1>%HR9"M0
M-T\S641*6C@K3V-#44YY9DLK+W=$54=';G=:251I0V)I0C4Q,T0Y2B]!44YL
M*UAF;5-X*TLP)B-X03MV-%EP0F)#3EI),F%):55T1U<O=30Q<7 Y33%F-V)!
M,%!J;',Y9&IL>D(U+W(X+S).5U!16DEC<$0V9G0R.'9,;GI+8C)V;&9Z0F(R
M)B-X03M&>$$Q>$1C4"MK63<K,5)P2E5126QX-C=22#18-%8V,4-N8S<Y0FQ%
M=%)J36=A23E.2#568F9(5%I"16EW9E9X1"]46%-(:SAR965P)B-X03LW:6%:
M.6)&=4I(:UI)-%I::7%",4Q+2T5!9D,O0F1G0GA"-VLU26%J0T%"=S,X=G@K
M,6ED3FY*2C0V*V8T-3$X4&5N2&Q(4F18,'E+)B-X03LX3W$S2UA.>F13<DIZ
M4FYE9U=*639%>69%86-+5DYC;S%/5T5Y3T550BMT>4Y,:&Y!2&I.:VXY04-F
M-6EU53=&6%EQ-T9867$W1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1E9S,#!5351Y>D]S8U593%!)-4-Q;TA5:VY91$9"24<U641Q+S4Q*U9,2UIO
M8E)*=%%:5%%Y)B-X03M204I&-S!:>4-F;U=M5DA+2%9:=3)C3411=5AU5V%6
M*V1V;&$W;5='.&EN<T]2;TI806MJ2'I+2&M0.$%G8U)L0TU88E='4F\S1FXY
M)B-X03MT8S(Y>D%L>&)Y3$Y"2T]58W%%37)!.7=2;&],=&]Y0D9J:W%9<&1I
M<5=E65!-1FYO=&PY66XK3U)Z>&=H0BM*,B]G0C-/65=U,3!.)B-X03M.1&EL
M>C9$=F-R4V%35V561#1L-69Q+VUZ5SE5:V(Q8FAO;T0P=#1I55%$=TY.,BMN
M3THQ6&%M9DUD>E5E-&-V,G96869167-1,D9N)B-X03MV2U0Q24YE+VIM=6-X
M3W1(.#,V,W!K:3A*,FYT>#EQ,VQ*6F%E>$\V+U)M>3!N875F0V1J>%(W:BM.
M;D,Q2%HK3$M.>%(W=SE2,%!7)B-X03LW4%=,1F)Q,DY$.6U722]A4G9!+W=/
M9'9O=%I$55$T;R]%9'IY=7$P<W--*T=8.7%96FQU33=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T98)B-X03M9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$X52]/
M:GIF8UA'<"\T9'1:0W1P86A7=D]*<#9K<D1K1DY/<6]#4' K5UDK4U<Y4$TY
M)B-X03MS-G-M6&A$:T]B0G1*.'9Z86AB+T%&:%1*-F%Y3VMG:6E-:D1J2'I!
M5597<E P0S%'5G5T=V%1-4DX6#9,-E=I9DU(;%9.27,T-VM8)B-X03LP9'HV
M:FA&:59A34YI5TQF13%/3DM9:TTY5F]V0VIX8U8W<V\O2GIZ:&,R3W-*;U9X
M25<P*RM*14-S9&\U-E9(2#)F;U(T,'EZ2$MJ)B-X03M4;61J-G=X;C1:*VLX
M=DEV8SAY2'%867$X=C$W;G(K<S-5=C%K4G<R-U!$8F]W<4-S4E5':'%.,C5%
M+VAN138V.59M:V5+:$=W4&A8)B-X03LS+W-E<3!N*T0T;VER2C-0>%%+95=O
M<%!46DQL+U-K67(V:E)O;T)%66MO955T2VUV.79B355D;D$Q56I2.&@S6"]/
M8V<V,&DW1R]V)B-X03M09E@X,750>7$W>%)Y+U=/4WEQ5T-2<'EC8U)5,55S
M=$U-97I#441X8RLT8B]+=VE7=4%*1F-M:SAR.')O46TU35,Q645Y;TDS*T5H
M)B-X03M13TIF<7I%53,W-$(R8F-Q-'$Y-&\O2RMV4DHQ=%)U<CEX=CE(4DTO
M3%IB471C<V=S<GE7=7!&;TA,2455:T]546EJ=G5'.&9(33-S)B-X03LK.4YN
M:G542$IT>3@V2%4Y6$4Q=C<O1DQB,5$S*WDK-W5E;#4R8GI#,E-33TM.<$I'
M0U)O0WIS9&=!0E5K-$-10EI41TI*;V,S:U=R)B-X03LK8G1D.'HS16\P,BM/
M;39:1DM9:U)(5T]6,31-+TYI5U(R2C1F65A/87HV>DIN2C14=W@O2#1P-U!4
M9&Y99$Q%94I(:GE%6#-G8FIB)B-X03MK4C$U;$QR2S,X>C9:271Z86%Z3$="
M2#9W3'5P:F5I<U-!:E--2"MZ5&1A*S(R55$X5T<X6E8Q+T<K-VQ:6C9F2T]'
M5TU(9757-"MZ)B-X03MB.&)V4R]);FTY4$UU;$Y,26]J=G)9:$QU3F9S,4Y3
M<G(W3E0W-C5V.4)R4$AH6BMO8S-L93%U>G9Y=5-H=D-83#E42F-Z;E9U>%8R
M)B-X03M+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6.'EE9C%K
M6'IR<DEK<4<K=%-%5B]L2G%V.$%W=$UX2F-Y.%(R:B]!2#@O)B-X03ME:B],
M+VM"=%0P=$Y3=DPY9%!H:V5I2S9+4UEV5&Q:6F%V2D5G1%!#55AK=S,W*TI%
M5S=49&UN2D1J;$QH+U9V=GI(8W%8,S5D;3$P)B-X03M8571883EF-G)94#9A
M9W=+5VM,>%%V17=-53!Q8TA-+S)G>$%!<C%02$5X,G1/5',S:&A+9D9T2'DU
M-T-U=FUK6&Q*2FXX,#9/<U Y)B-X03LV8C(S-$AW26Q5,2MJ0DAM-&UJ0D]A
M1F9Z:#DW-FQZ3&4W9&ER=VDU1$,U;$1F841T6#4Q>GDW3#E2.3<S,%!P0W9P
M5FY"93,P5G),)B-X03M+.%)M25-.;S1X25,W14%!9W1(46(Y835B<&--8VMX
M06MI*U9#.2]M1W90:TU)1U%&,34Q*V=P,6(K5#1,:C!V478X03%056LT17)(
M)B-X03M'46DK<3!19&@V=DU6;T0Y;6TY2S5S<V9:35HQ=WIU>C-$8C%66CE6
M+UHQ<3-#;C)G63-C86]D-3=R+VTQ.79W4UA6=%!/;C,P;&UZ)B-X03ML-4E1
M;VQ02&E!-55&9TYZ54%N63DX,75Q=V5&37=U>4]F=B]!0C%C,T)L.%-!;#!+
M,U1&9'13=$94-UIM:D,P-C%,:6U2,'=*>5)R)B-X03MN>$0W,E=C:F=L9F-8
M=5=E;E!"<%0U=5-:+TLR<DQ$6#%$8515039N-$159F1M3G)!5&AL6#@P=5HR
M8U%.4FIV;'A$-S-H3V<K6%DY)B-X03M8=&)T;S=S4EAL=6IY>#)X445/<V$X
M:CA26E0O04U#<F4Y0G9N2C1-07E!-RMO9%!X*S$Y03%E<T]'56)J8U-A=G5V
M-&9E4C5752MH)B-X03LO3$PQ,FXY1%5U85=Z5%)Z:W=%15!A>4EK+T91-35!
M2SE6-W13;$(Q>DQ(6G0S5756.4\T:2]V,C<S6'DW8S1A=4@Q5EAQ+VY!;5!4
M)B-X03MY,S=V3DTO>55J;"]3=7%01U-B5EE556MI;%=,:W!55D\Y03)8.6EG
M.&-U-FY&.7!Y4$1G1#E6+V\S970U,&)X<G-69&ER<U9D:7)S)B-X03M69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F539FY,-4AU<#4O=T1%;6YX1U@T06UO
M>$E+<T%G;W-T3S0T-TXT57(T-5)L:C%E9C=9)B-X03LP2FMF1FHX9C%V3V)$
M>FPU;W-,55=L<G%5>3)O2S!T,TEK:D%7;T-H2D%Y.%1Y3E9P43EX<TUR16DV
M6$AR8S!"46MA*V8S='DK8R]-)B-X03MS<V,X56PU>6EU031M:CE+3&E6:VI3
M2FQ#.$M!8TEK04$R5VQ2430X4EI(6%II0T-E9FM09"MH;G8U3RM28F\S:65:
M3E%I36-%45 V)B-X03M0:F-53'-W;UIA2#EK02]$-#EC<WAX-G4Q-T@P2G9X
M6D0S9G)E>#5E.4<W1EAK=FYN4EI.3S%Q5UI6+S!A.%EY>$XR-4AD,2MH:CDR
M)B-X03MC1C(Q;WII>D4O=WHS2#98<BMY.5--;4E$*TM/,S9K:G1,=31T3&A,
M:3-B:$UL940P0G!5161W9DA.6FEY>7AY16\W14]D:WAI631:)B-X03MC:UAA
M*UED671966]93&IG:TI":BM"0U)2=5E(27%72SAJ6&E44W5:1U!8-6]!0TUQ
M03AH-RLW;&94:S%4,&U/6DI)-2LO,V9G;U<V)B-X03MV3&TW9$AU2#5U:4Q%
M<E5!4$9"4F$P07)19'IV;5!L>7EM45I'-D9F2G1X-#1W1D1V=&M0:T12<$PS
M5U5U,E@O045A>5!Q37@V1U0Y)B-X03MH4C=G+T8Y1V)F<TQ32$IM17HY34XO
M:C O5S8W=&)5:4=,:"]I;#DS5C9P;F-V2G5)0D9$=40Q1TMV369-2&M8>E)P
M9W56.')3:#E.)B-X03MU;60S<W8S66QI36DX6#E*,T911UAB-%="<'1V;6@Q
M1V=Y=W9W=G!05&%X-W8R4%8V4'185#5A+TU$,7@O:3-O,7ES1#E)<$Q.4#!N
M)B-X03LX,DPR-E5(;&%,>55T4$US36%G<DES=DUQ<3AM679'<%DP2F%M*S)9
M*U!$<35(=3DY1')F-DA+>F%J<S=(2"MD-41I4%%I=DQ9;74W)B-X03MO.4HX
M<BM7-V)19%!.=D=W;'5*;DTQ,V-C46YQ4TXQ;V\R5E(P04=B>E-A65E9,3%0
M379,-B]7>3%%*TDW4D=W2&-%-'I+8THR2W5X)B-X03M6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9I,G(O04I:95,Y5FUA96%W14TW;7)3
M5S=.1E4Y-G%P-&(K4$A)2$=#)B-X03LT3V)S-T)K3FU/+VQS=#!N.')V2E=M
M>D-E3W=%.'EM<79C<S!O0D@K4S-W9FAI35E#-'5Z8T5$66IV-3=S<D%!04%&
M04]G>6)N3WA6)B-X03LR2V]05G1*<W16<S)T3'1/56)B<5)S>7-/:DMF2$UF
M5F%71V5(0DUB3C)$55-X4S1O.#-M*W(O;#ER9&Y)>E=I+UAB9CEL:V](02]Y
M)B-X03MK4#A!0W5C9'%U=W,R32MJ,7@X=69Y+U4Y3G K,7-5>#9V4V9X,5-9
M841R:&9G3E!U968X=F]Y5G Y,F$W.&IN=75#5B]W0E5U8BMA)B-X03MX5F9&
M2#5H4$Y'+TPS5TQT,64Y2#%+,S<X<4=1:C)59%!P>EHV5'-(3FM.>CE%9G0K
M6#8S0C%082M/07%0<5 R4%-.3C R>C V>E,P)B-X03MT1311<#DU4&1M4&-N
M3W@P*VYH:&=)449!4$TU<S!S:VI+4C-23UA.5'-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9103$W4G9R3GIB1SAI)B-X03M383!E3T\T5C(T0EAM1EDQ<3%!4S-T
M;'9G>F]'=&DQ95!#>4PS2% T<49R-7,X=%A333A7<%%C5D-L=E5C4FUJ<#9G
M3DI/4#=/+S,K)B-X03M">55T3FMJ>FE73616:FQY:U!X=7(S1W4V4F)4=W=4
M6$M*2D]N<5)N8W)W3F%->F=&5D)O849I2S5'3T=20DE(2FY,3D5':5A,<BMH
M)B-X03M-<VI,<4YS>7A*-G-H5V%.=4M';$=.1#!.4G9J-$TO-7 K4T)N:"]/
M2'I7,C-M3%)B<&]K=')T2C5*;VI02$A(5FXY3E96:5-O1E9.)B-X03M*1BM%
M-RLR37-%-#AX5F)):FYH2W%.,DPO2'I1.%!N1'DS36])=E9J-4]9-E1*2D-A
M<4=,16E654E596UW3$AA;W!7=51/;'E$<"ML)B-X03MJ2%8T>C$K93,S*S5'
M5W5T-E)D,T17,79D>%-80VUN<$)H>4Y%5C9Q1#EP94QQ95,W6EA,1$])<VI:
M<VIM:$DP1'8X06HY84YY='-D)B-X03MI<G-69&EQ5S9J<4%S9S%:5%)%.5=A
M5U9K:FEJ4W1!6&-Q,4]2<GA!0G)L;5!(>$YC.&=I:V8X06HW4B\K<FQA9CAJ
M,B]W0WEB36XX)B-X03MJ4'5L.'8R=4XK9G@O=T$V4'HO63<O2#)J+SA!5GET
M4"M2-V8Y:S)0-4=F9$PU9G18."]J+VY2*V8W2&8T*S!F+W$U5VXO23EV*WEB
M)B-X03M(.&I0=6PX=C)R*V9X+WIO+U X05DW+T@R:B\Y6$LP+S5(="\R5%DO
M:UHY,'9L*S%F>BM0*V1(-2]S9"]J-U(O*W)L868X:C(O=T-Y)B-X03MB2#AJ
M4'5L.'8R<BMF>"]Z;R]0.6IV.$%(,FHO05!6>710.$%K93,O04=462]K6CDP
M=FPK,69Z*U K9$@U+W-D+VHW4B]W1'$U5VXO)B-X03M!0U!B+W-M>"])>C=P
M9DPY<2]N.&8X-E!Z+UDW+T@R:B]W1%9Y=% K4C=F.6LR4#5'9F1,-69T6#@O
M:B]!2C!F;BMX3V)/.79B,C)3)B-X03LU<S-G;G0U3C!L:G5/4VUM>#-%1UDX
M.%EI84YG*S<Y<FM1>4=1<U52-R\R2S,K-6XK4TPO04I(9CEE36I593@O3#ER
M2S5D=RMF-TAF)B-X03LW;68U278X06MD+S$T>'%0969L*S%B;#-$-2]S9"]U
M6B]K:2\U2&8Y94UA:C-N-69T5S5D=RMF-TAF-VUF-4EV*U(S+T%&-'AQ4&5F
M)B-X03ML*S%B;#-$-2]S9"]U6B]K:2\U2&8Y94UA:C-N-69T5S5D=RMF-TAF
M-VUF-4EV.$%K9"\Q-'AQ4&5F;"LQ8FPS1#4O<UA+,G)Q86U+)B-X03M&=EEZ
M;BM%07AQ4&5F;"LQ8FPS1#4O<UAE<G%V+TQ.0B]W06HS+S9O-#%(=E!Y+V%T
M>3=H."\R3SE85F8K5V%$+VME+R]62$=O.34K)B-X03M8-U9U6&-0;BMX,W$V
M<B]Y>E%F.&HS+S9O-#%(=E!Y+V%T>3=H."\R3SE85F8K5V%$+VME+W=$,5)X
M<5!E9FPK,6)L,T0U+W-9,4HU)B-X03M&4CE2:S%$9WDS57-J>7E0.6%*0DQL
M='5,5S=+049K6D)19%!F9DUW87HP.%!4,V9T8U X:T],:38K+SEN;E@W5D$O
M;'9:;&0T;35H)B-X03M1<5-I-TMU=D9),%%H;'1X=6=H1E!M9DA*9FYZ*T(W
M+T%/;#5S4#50:BM$-W9,>51"+TMK<&AI:&E$5S925V=S5SE'-UI3.$MH9V=C
M)B-X03LK9U1695I)<%0S>6]A;F5Z=G9F3'(X,C<X='11,C)R;C K4U@R+S5C
M,CA#8U96;5E/.'%Y3F1$:TI(84HK5S%S0G,P0S R<#%Y,E=U)B-X03M*+W,Y
M+W=$4S@R;5!:.%(Y+U S9C!F2D4V1#5(:C!4549V<E--=DMK4F=66F)T;E5)
M,4-A1#9U2V)I=3(R-7E/8E=E2DAH4&8S9G1:)B-X03LT3D5-575+4&184#EI
M,F9Y2W-Q3V]$4D=35#%3.&0Q4F<S2V1Q0W1S9'8X05,S,BM8=E9'<W(K>C-F
M,'8V2T1O9V8W9C8S;"]32W)P)B-X03M8:W=A6&9W,W1T2%=71D%G5G)N-%=!
M:%=%8W5.=7)':7!7;&%6,W=:3E9X>$E0,V5D+WIM5TQ30T5G4CDO;%AD-4UG
M.5A69BM7840O)B-X03M!2DAV+W="56-X2VHS;C5F=&-U-61W*V8W2&5R<78X
M07EZ468X:C,O04]Q3TY2-WHX=C)R8W4T9E Y:G96,5@O04I:;U K4C<O=T16
M)B-X03M(1V\Y-2M8-U9U6&-0;BMX8DQE,W1V1UIR;3)15S9#<W)X4VPR5E)U
M5S1S:V113SE$6#)/15%",D(S45I%8FMB350O3D%K84)Q;$13)B-X03MS9&M$
M+W=!:C5->G5Z=C=Y4"MD.7=C1'14*S9L+VTO93AH=%DU-'A(3D)4,5=0=W-7
M555Q4T%!1U!5.%0Q1V(R4D(R3'IM3TI&16,S)B-X03M84VE727I5<$E'26,Q
M<5139TY34&@R,C9$=C=9>#).3&M&:2MR3&)J>4QO4W4U4SDQ05%Y3W-6<7@P
M-C1.5U!%1W165&QU5RM%54\S)B-X03MF34=/<VXS4C@O54A94S!'4&]:*UAO
M4#9K269+=FQU1S%L3B]Q9'I:<TQJ:&$S56QN4#9C.%!P<30T>&Q">%EL*SAN
M5#EN97579FUC)B-X03MH4'!I1'1U3TEB2#AE5%8K57A!97%5:'9S944W:74V
M=C O0G$R.'8K4GA&8TYD83=0.$)%85-R6GEO<V-R1G="24M35G%Q8V=V24AR
M)B-X03LT67EZ-7)&44@K;4-X,"MN;S--+S95."].3$Y1,')Y,T)A>5,R975'
M.&Y51#!O4'%K<UA-,5%%8VU.1F]'62\W2#-'6%%Y6D-A34M()B-X03MV1%)K
M=S1H1S1Z-&HO5DE36$UH>$A9<3EW+TM4+VQ$,"]W0TTX=C9X;D]D<"]W0C<X
M03E8,E0O8T0S;&UE83DR5'-69&ER<U9D:7)S)B-X03M69&ER<U9D:7)S5F1I
M<59496)02S!%:S!5*W,R355L<WIX,T-08W=Q,&)X>&U:,6-&=FA+4DM864AO
M;W(P>%9E9DUV;'=',D(Q5WIR)B-X03ME978Y54@Q:4PY.3E5<CE9.5 T=FHY
M2&EF57 Y;G941E=+-C5Q5FQQ*V]H=$,X,S)C3C5.1D)"<&1P1F9X.$I,9U V
M.&AA2D]F371!)B-X03LV8V%!,4(S2$A->E0U<V-10DM.-VTK+VPP8TQ5-$UK
M:51#5D=H6&1D-S)R84EV;C(Y84LX5%AD3W9D3F%D879B1DI636-5>DQ01W)P
M)B-X03M%;TQ$:54V-T55,D\K5&YK,#EB4FQD9F(X,D5-97!V955A<V9+.2MN
M9"M/<64V0VPP8GI68FPW=$QQ,&QU1U,R161W,#1J34Q.2$MH)B-X03M"54-.
M;&-56E9/,4MD45-C8DQ/2FI%1&U/97IL66]317!%.&ED="]X4V%09%=Q6$UD
M<3AY3&-Z2SAK34)90U(P:DMH,E9A,4E5>4QY)B-X03M)-E9(:FQ,8S)T>F)T
M8U!B3$MJ6$53<DI*0T="9%5K3$)'6F5O1$9';V4Y1#19<7%9<3=&6%EQ:$Y8
M+S0U5C<O04U92F8K24A*-'9Q)B-X03M(=EE:4'!0=5EZ*UE7;C-D+W!7;S)L
M<$=:8G%30S-K:6A8-V)R1$TU:S1$.6]Q2$<S=FU:;UII36]K.')0,FAW=3!-
M6FYJ;$=03V@Y)B-X03MH955W*UA036]4,#5D1G9M5'0O;S!X<#%04VDQ-BM/
M8G,U.&9-4VHX=S@Y2$)L<6I#6'E,52]L>GI->4-/4%)R-5EW83 K<E1D4EAT
M)B-X03MX4&HT;D--*U!N>%(K65=E;GEK54E3<C-&3DQ39CAY3%,Q:'1)9$]U
M:&)7-E!(1D4R;FAG1FM"-4%K>%9916UP1%9"3S5Y:55D4$EK)B-X03MM47,O
M,'8R=#A*-G%)045442]O+W-6>'%V-7%'4TM35S%V-6UG1"MJ>G1(*T9N:4U0
M4%I"56A4=%AV=C0U2'<Y3E=X:G8U*V1S=D<Q)B-X03MD-VE2<BMJ-58S3VDQ
M5#@P63<Q-S<V;&5T9$]N07E'>5ED0GA"-')'<7-62%1K0TU4:C!X2$1C82]R
M9G173V)69S-5<B]Q+W-3-U9R)B-X03M8>B]Q>7=,<4=N,S!Y,G=):$@Q4FMP
M54MP*WA'=&1K2%A,<U5S14PT5$58-2]T86,P9%1K<FEJ23$O4B]9;#,K1F9.
M2"]6;G9V*VMA)B-X03MB+VUN3&9Z3TPK9$@U:&\O2UIF-6MV:UAF-%8X,&8X
M059N=G8K:V%B+VUN2#AZ:2]N4BM96#AP;"]M4RM297DO;&YP="]P+VQ72T<Y
M)B-X03MG93-M85=345)31&DT5FIT5E1U3VYF3V8W47E2;&Q*:6)E;3=.>'EH
M:$%K2TQ+<W=N4&1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9E)B-X03MC-B\K
M4EAL5%A*-35B=2LQ2D),2F1Y<$9$3D5Q4DYF>4Y*8V-!65=*-4=75VY-=%%/
M,4]I.%97-'9Y23AK>#9666%2-G5O4'!.9S$R)B-X03MY,DPS5$Y'+S$P37)Q
M5%1N1W%Q-4%%3$I7<#4X*U165E$R:V8X-#EE4TY+,4Q38BLR=3E33#9-62]Q
M,$Q4>"MM-GA4:3922E%S4VPQ)B-X03M&>41.,2LP9C51<6A65FXO04-%.&XS
M2&QI5'DS8S-U<%0V83$V,F]W3$I017I15$]J;U9H+V1C46XW,'-624Y7,TYD
M-G%O3S,O=T-C)B-X03MC4$I&=61/360Y<4HO4FQS,6Y!<VHR<VE.1SEX2F-K
M>7$Q=599.#5M;V8R9&ET2$%B1E5,6B\X04]-=FMQ3%,U-T]E+W8R:W9,3DQ+
M)B-X03LW:V=E3D5O='A&9$TX4U-P8TUN2U=!9D-864-P-VMN1E=5*U5V>6DX
M<6569%AT9%4P>')L<')/=VLP,C-J;F1*23%I;757=6U99D%')B-X03LU.#-+
M,35F6C)P:7).<U9D:7)S5E%M<TU&,&TX<6%6:&M!.7E624%(=51L;4PV:#<R
M1U0V5#=L831T3%<U54QC47!-<6UQ:5)1=T(X)B-X03M254A)>&M2>4Q)>$(U
M<5 V23!R+T%*66]0*U)39C!W*TQ,=DQ(=S0Y=V0K:4Y++S59;U K4E-F,'@X
M5UAE5CA/4&-(9F]J4W8K5TM$)B-X03LO:U5N.4UF1FPS;&9$:C-",S9),'(O
M;&EG+S5&2B]42'A:9#58=S0Y=V0K:4Y++S59;U K4E-F,'@X5UAE5CA/4&-(
M9F]J4W8K5TM$)B-X03LO:U5N.4UF1FPS;&9$:C-"-&@U-B]097<X=F5A8B]2
M3$AY>&$S365N>65J2F-41E5,>4%$;%)643!!3W<S,S8U;#0X8W!#*TET3352
M)B-X03M"<FA#4E(O.#5*4WE/230O2T9I>G1S1D0O=T18=DHK0V8U>%EI8V8U
M;U9,:B]N23930FQ6=DMM;DYZ54]P4U-O;S-4+T%(6#%W1$-F)B-X03LU>%-:
M4D@X255F.$%O6EDO.5-L668X2"]!3F4X4&=Y+VY&2$A(*V%(9CE$3$@O<55R
M1"]G+W=$<C-J-$UV-7A8:FHO3D1V.$%O6EDO)B-X03LY4VQ99CA(+T%.93AF
M0FPO3TLX8V8U;V0O=T)$3$@O<55R1"]!25 O04LY-"M$3"MC5C0T+W=!,$\O
M-D=74#A!,4M6:"]W04@O=T)E)B-X03LX9D)L+T]+.&-F-6]D+S!-<V8X07%5
M<D0O9R\K=F509WDO;D9E3U X,$TV+TM8.#%D4#A!4%=T6&5K,U!L-C)S6F],
M63-C8W-F1U)7)B-X03M66D5J6E-#:6M'<V=P;$]A36]#*TES.%IJ23AG.54O
M4D=L9CAS54@O04-+5"MM62]I>3=Y,BM(2'5$=C!2<%@O04-X468X:6LO<&HT
M)B-X03MS=3AR-&-E-$\O4D=L9CA!3$9"+WE+5"MM4&EY-WEV:'@W9S<Y16%6
M+W=!<U5(+TEP4#99*TQ,=DLK2$AU1'8P4G!8+T%#>%%F.&EK)B-X03LO<&HT
M<W4X<C1C931/+U)';&8X04Q&0B]Y2U0K;5!I>3=Y=FAX-V<W.45A5B]W07-5
M2"])<% V62M,3'9+*TA(=41V,%)P6"]!0WA1)B-X03MF.&EK+W!J-'-U.'(T
M8V4T3R]21VQF.$%,1D(O>4M4*VU0:7DW>79H>#=G-SE%858O=T%S54@O27!0
M-EDK3$QV2RM(2'5$=C!2<%@O)B-X03M!0WA19CAI:R]P:C1S=3AR-&-E-$\O
M4D=L9CA!3$9"+WE+5"MM4&EY-WEV:'@W9S<Y16%6+W=!<U5(+TEP4#99*TQ,
M=DLK2$AU1'8P)B-X03M2<%@O04-X468X:6LO<&HT<W4X<C1C931,:S!Z5%DS
M5U),4T9(43%6,6I114AX0D%X3U-2-FQ20U!C151K1V)S5F1I<G-69&ER<U9D
M)B-X03MI<C1P+TYD1V8X>E!-4W%+:S,P=C8X,FU(-D$T950V:6M,3VUN<SAA
M36MS;$)6,4(K,$XY*U%59TMF,E-0=$-P-D1*.#!C;5@O;%9C)B-X03LV.5!,
M<D=L-EEM:S-*=DE9<G$X=$Y:5U)O-5ER0GIC55AH4D-/4V=-<FYO9D%%:79+
M0G-49G=:63=.<RMM<V90<VQW3'EB4E!+<50R)B-X03ML>F-71G5Y,C%Y,'-B
M5S X2TLP4U)C-5924V\Y2&)O94Y/56E+,4YX-S5.;%,X:VDX<5$K8CE73GI!
M3$AY>F1Y-E9W55A6+U,V=497)B-X03LS:EA456II5T)P<"M.5D1X<G<K2C9&
M2VMG1U4K160K+SEQ23A2-VLV='1$.#8V:G!Y-FI&;U!K>4-*5$Q*04=T>D9)
M<7A*8WA64E-F)B-X03MS<V)D-5508VM.,$1C66U546%U4U%*9'=38E5R5'IB
M9C9$.6%V4$I8;#-43$A716IG='15=$E926IA+U=X1DEK.&=6-V@Q6#!66G1L
M)B-X03M$3%5T=#!-9UEG.'IS>&]K8V=W=68X<5!0<T=M5#9P3'!Q:E0W5D1*
M4&-,8S)R<7%I05A&9FAL2B]U:4-01V](6&),=D=J9%<Q*TA*)B-X03MI3U=-
M2'-8+T%$:3,O=T-403%$+T%,6DTS+U548C5J87(V9FDS64]B-FIZ6'55-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ)B-X03LW1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6&=8;F8X:V)R6&9.1W!A>G!/<'<O5G13:SEC;5,S=5I3<FM$
M:W%V17)X=79)5D@Y;&-Z;UI$)B-X03M%045F84A':T%462LT<V)0+T].6&U!
M:VLV=D-39'E483-V.$$Q4WEZ>"],-U%X.% S+TEU+W=#:&%D9B]!3W)V1"\P
M:3-V.$$Q4W@X)B-X03MF.%=%94=0=T,R,R]!1&I:-6A9,6)726U.04MM,794
M<T)11"LV-T1"-"]L.6]4-&9V*U)A+W=#:&%D9B]!3W)V1"\P:3-V.$$Q4W<K
M)B-X03M0*TQ#4$1(-$)B8B]!2GAS.'=S871R151'9T9483-P,D%O0B]D9&AG
M.&9Y*S!*.% S+TER<'8X06Y(1'I,3R]/8E=O-5@T<6Y*-V$K)B-X03M9.%55
M2V]Q675I<6]!.7-F1TAD.6]89SAZ.&DV9B]N2$1Z3E!+,# K='AY>79U,&HR
M,3AZ2'1U5$982'AH,V9A1DU032])<E K:&%D)B-X03MF+S9U.% X03!I,W8O
M5DQ$-"\T<TDX369G1FYV-5 X03555"M2=&-V3EAV-S5R=5-E,4YP1D1"85A)
M041Y2DEZ37IO3G@V44%!1U4U)B-X03MP.%ER8C5H<WAG4DXW+TEV5V8P;F)F
M>50O=T134% X03@P6FIE1V9,-6AT-'@U+TEU+U-D="]*4"]W0DDX+SA!>E)J
M-%HX=FU&-'@U)B-X03LO274O4V1T+TI0.$$Y23@O+TY'4&AN>2M96&I(;CAI
M-SE*,C,X:R\O045J>B]W1$Y'4&AN>2M96&I(;CAI-SE*,C,X:R]W1#!J>B\X
M)B-X03LP62M'9DPU:&5-969Y3'8P;F)F>50O.$%34% O04TP62M'9DPU:&5-
M969Y3'8P;F)F>50O05!34% O>E)J-%HX=FU&-'@U+TEU+U-D)B-X03MT+TI0
M+W="23@O.$%Z4FHT6CAV;48T>#4O274O4V1T+TI0.$$Y23@O+TY'4&AN>2M9
M6&I(;CAI-SE*,C,X:R\O045J>B]W1$Y'4&AN)B-X03MY*UE8:DAN.&DW.4HR
M,SAK+W=$,&IZ+S@P62M'9DPU:&5-969Y3'8P;F)F>50O.$%34% O04TP62M'
M9DPU:&5-969Y3'8P;F)F>50O)B-X03M!4%-04"]Z4FHT6CAV;48T>#4O274O
M4V1T+TI0+W="23@O.$%Z4FHT6CAV;48T>#4O271R<61M6%)'6C1M:U!&4%9J
M:VE$365I9W5Q)B-X03MG:RM'4&AL94U)<DE-,UEQ-T9867$W1EA9<6A.6$9D
M2G92+WA23"]X03501CE1.3=$2CE*.7HU2"].:EAT6FLO3518=E9V<F<R.6YC
M)B-X03LO5C=E0DI74D920E)%5E9)0W)24U14=C=M=5HK2TDT43!42G-S564O
M,65(;DI*95A2:49"2"LK9%-E5R]J,DA8=T]754=&:THY-5AJ)B-X03LP>3ET
M9%5B6'9-5B]P:E%F5E!Q3C-';'AC46=4>3!L85I9,6,W4F)Q=DYA;G5C:D]X
M5D)L2'):3$QB8GE0-69V<FTT9S O>EAR=# Y)B-X03MQ:S!-,&-7;#9H27E8
M55%#<C9N0D-Y0G!',VI+,55B1G$P>6]Z235G9DU-*T5D-5%.;C5.,$\T,4=7
M>6LO34,W=$A6;5<Q5S4P*SAI)B-X03MK=596,&E$47AV27!9;6(Q275&95A*
M1'0T4TUZ6#!O168V5'HQ-S=Z1VM:;&4T=D9J56]R3UAL0VAP1DQ)0V$Y5U93
M5CA2;#%"<754)B-X03MP8B]Z2$-O85<T=DDQ6C)J1$\X<6=V2%1M=34K,'9)
M5DAA=4Y"8FLV5R\X04U52TI*3F-8:V-C:%I59#-L54U53DA!2D\U53EF1$=G
M)B-X03MT>55V,#%R2"],9&-F.&I8+W)H-%%J:5!E.6DO-7AI,6Y6-2]/;7!7
M53DW3DYA3G!S:WAG:VM:,#E22C165C9-5'5&9&@Y3UEU<6E/)B-X03M(-'0R
M1U)*9E,R64QK<48O9E=L:%DS1CEE4W)"85=K5'HS37IF6E-/3E-Z<V9:5D9C
M5EEW,S5S95%&=31,3U161$AD,TTQ=&)X5SAL)B-X03MV8W!*-G0T6D)!:DDP
M45I#>&AE=DMN2#EQ;%)65E8Q1#@P4$EU;EAD>EHS=7%#0S9T1$U*;U=H;C55
M=&]:3&E:;$%J*TY%:FAE<DI6)B-X03MA:FI8;'1I<6Y9+VUV-4%V.4UU9%5T
M3E8Y5W=T0F)'968P3&=!0SEL.4-!<4=J0F9L3#A"-&<X5T)$54E/2W!L<2]N
M:GEF;S98:F%L)B-X03MR3FYB3EE!1S=H85I$3D=7:4UY2UEL2FLU4$5H9%9#
M,5E#;T=+<UDX>&$O;S)O-F]W,&IZ=' Y<G%$>%%W8619<G%54W$Y=W1Y,W%C
M)B-X03LT5DPX>5%!9V]/=%%2;5IP.#)/24%L1SEZ9F9Y-D]&<4U'4U)*:$MT
M:%AD9#<S.$5U,#=Z>F-M.6LK="ME3D(K<E<X.$IN0FYH44=!)B-X03LX2FY%
M8G1(1W-G355Y1&UR158R<4=Y8S4V971O>75V="MB0T=053-V2TY74&QE+U0X
M9F%N+VPO>FPU8DTP*W!4*UID4&94.5IM03!7)B-X03M*<C!&>55!3'AH2G94
M2WEF=E4U4DM0:'%!9#EZ:C5:>$U99T1C8S-*>%%M2E-*3WA/>4\P<CAZ9DE'
M<5)Y>3)7=3)J4G=1>#-->GE0)B-X03LV2W!&3DM915IJ3'=P*SE89U(Q0DE"
M<'E7=$1E-C@O37HX=C=/.71,3S4X=U=35%AY4WDR-V5S<E)'3T)M4U(S;%=S
M8UE6;S)7<G-+)B-X03MS<$$S0GA65'10>E@O3%,V331H.#!A65!Q.&]H:V%3
M-FEI5756-41G6D=54T%J;WE62%AF631Q:5 K5FHO;#574F8X049':V-O<6U5
M)B-X03MF6#=A<6=':#5F=DYT>E1&5U)9<6A.655.<$XV0TMJ,$I$.4E1:UI:
M:2MO93EH:RMK*S5&-5=Z9&ER<U9D:7)S5F1I<44Q9B]!235.)B-X03LW+WAG
M;"\T9V-N:2MO93EH:RMK*S4X8F9M<DI-;C5M95EX1S5J3%@P9TI"2SDK*V)(
M1#E!8V))9E574'I35$Q%+T9J2#9D3T5W66=Y)B-X03MJ-THW+T8T:6Y16DU)
M2EI"*UA7<%,R*W!85'!R<F%(9&E*<#1,-'AX4U9A2TM11F55,#A#:&U6>6EI
M:E9R-&=:1$M.=59P>&YZ6C=P)B-X03M6-7(R:U=L,41"*UI&<6I83V]44$Q%
M.&1J8U1V=TU534XQ-C%X3E)F5FA#.$%S=$8R,S1E;SAD2D%0.$%#,D-X+T5K
M,VQF56(K-C V)B-X03M44G)J>B]A,D=M85,U9E0W6EE),FMK9$QX2&HT=F-I
M,&HT=$Q':V\O9D5+4'1C4E=K-4%!,W<X,DE*-5=Y-2]-=FU$571#=$=U+WI*
M)B-X03LP<E1,-C--<S='2T9%=4II<VQZ2D%Z:T]%54]K83!#4F]3<VY&=W@T
M:#9U14$O4U=D;BMC>"M45V905G1";S)P86XU,#!G;44X-#=9)B-X03M'13-L
M;DAQ;'-7:VXY15)W33=*1D]4>#55-55!<FLK1T\T05 Y:4QL,4E3:GIR;R]M
M5%=R9#E3.'=E871"=6)V5&\R-5%,3TEB=#8R)B-X03LV>D)204E9=5150WA!
M0F9T8DAU8VY#44=W0EEZ0E!-:#5N;#=3.6DO-7AB+T%02F=A:"\R>5IV*V]M
M,WI',5@P+T9U=V,S,4AM=F-P)B-X03M1=C=','8W1S1S8GE*6C=3-VEE0S5H
M8C=,>'E+5F14-TUP<&ER15<O2FXX=&UV66(V5%(O5G9)6C0W<&)I4S5U<$AA
M845+23-K6C53)B-X03M:3U!$.75O,UDO=$Y65FEM<C9.*U5+96-R:GES+VQE
M939V:$,Q.7%$<DAE=6M.;3EP2F)&<DI)+U5:;$99;V93=#%64E9E4'A204MQ
M)B-X03MX:E9F3E U06%&9#8U-4E0;')52D9U6DEB3%9&:FM):&,V8T9A0W1X
M2F1O,%-+=S-A<3E#6DYT.%5P6"]!27HO04]C9CE:,#-4,S%4)B-X03MY6G%I
M4$ET<&%E:$<W=4LR;'59270T-W5/4U9);S%:160P1%!2=4E,0G=&55):-G8K
M4F<P=E9V3U=H95A.56AU=DQK,6AQ53!%.&I5)B-X03MU-3=Q42]6;%!R5%AA
M,%=:*U1/1D1$.6MS<$MS<75U9%HO24M+,5%76&LS56)Y865Z:W993%=6-55I
M6DY.*W-W2UIJ2F-T=V%.3$-4)B-X03MJ5D,T56YI0WI-=4M&.%@U9V9K;S$Y
M-5 X=3)8;$<O5V5Z=C1Z;S!6,C5H1FY*9#-95U-2:4QI85)M.5)!+T)W461U
M9WA3=G-03B\U)B-X03M*,F9L=E8O35AL+WEP<4)0;"LR,#9.<F4U;6QH2'!8
M3C9T-6)+:&$T;31Q=#-%<VI-1C-05&MP3TMO1U1Z3"]Z:GI$3E!(3#50,6E/
M)B-X03LV.'%W;$I#2GE'=&=,=W%W:FLK=F=S-EAD,&%-<')89%110VEQ9F53
M3D4O24QZ-61$4F1..'!8<TU5155U<7$X.'-Q,C9T8T="2%9:)B-X03M)3'55
M8S)#>"]U>'-N16<X5S5,:7).-R]!4$E4.'5,>E5R,U5(=$HP;#%#84LV=6]X
M8U-34DY02$LX<E,K;DU:1C530U)O,C(K1E-E)B-X03M(06MK<4AO;4MO5%8O
M=T1J:S-V+T%"9VPO=T-)2$HT=G%(=EE:4'!0=5)E45IU>%8R2W5X5C)+=7A6
M6E V4&]3979X.4AI9E8U,#0X)B-X03MA9D9Y<C)P:$8S<V<Q5S=Y=GI4+T%-
M<60O4S<O04ME*W(O<$AG=DPV>CE3.69H5#1053EB.3E8:E-N<69&4VYT;6)(
M:CAV="]2=#AN)B-X03M'3F5F,F9P,U-J+W)(-R]L>"\W;#)(,2M8*WE88CAC
M3'8K<V9V*UA(+W5862MV>2\R4S=F:FAD+S%J.2]Y-"\Y>3=(,2M8*WE88CAC
M)B-X03M,=CA!<D@W+T%*8V8K-61J-B],+T%'4S=F:FAD+W="62]F.$%,:B\S
M3'-F6#5F-TID=GAW=2\V>"LO-6-F*S5D:C8O3"]:3'0K3T8S)B-X03LO5U S
M+TQJ+T%.>3=(,2M8*WE88CAC3'8K<V9V*UA(+T%,;#)0<CAV.6MU,S0T5U9E
M4F8X065R9&8T331E=GA8-C,Y4B]2,W%C2R]$)B-X03MY<#A81W8P6EAK=BM+
M=CA!6DUO*U8O-T9L+SA!=5,O-68O.$%P>'EV,"\P9CEK>3E8.4PO04=,=CEY
M6"]!0R\O05!4:FHV9C90*WE8)B-X03LQ9C!V.6DW+T%(2F8X=CA!+W="3T]0
M<"]O+S=*9E8O4R]W0FDW+V-L+W=!=B]W1# T-"MN*VHO<VPY6#E,+UEU+W="
M>5@O3"]!4#A!)B-X03M4:FHV9C90*WE8,68P=CA!67!8<G8V3'!99G W;%0V
M-48K:E!R,S9-+W="-W0O4CE$,68Y,R]A-&-0:38P>#E0.4@O6DPV=C98*WA4
M)B-X03M4+V-L+W=!=B]W1# T-"MN*VHO<VPY6#E,+UEO5TMN-E-U4%,K<V9P
M3#!O9G)F1#E(978V3EI043E3;G@X3UAQ8TLW9F%P,W@Y4#A!)B-X03M2+S)3
M*W(K;"]S558O=5,O-68X02]P>'@Y4#A!4B\R4RMR*VPO<UAF-VMV*U@O.$$V
M8V-F5"]2+S)3*W(K;"]S6&8W:W8K6"]!4#9C)B-X03MC9E0O045F.6MV<2]P
M9C=&2V1(+T%%4#9Q9F]B*SDK<'=E;CE4+U)F3#9J5B]Q,5!4,SE#=E P+S)F
M=%4W-"MN*VHO<VPY6#E,+UEP)B-X03MT+W53+W=#6"]W1#9C8V94+U(O,E,K
M<BML+W-89C=K=BM8+R]!2V-C9E0O4B]W0FMV<2]P9C=&6DI8-&8P:CEB*W$X
M:'DY6#9V-E9E)B-X03LS<65H.%A(>#5F1#0T4B]2<2]J*VQ"+W!86'<O42\O
M6CPO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL
M<SX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IB-3$Q,V(X
M-RUF831A+38X-#<M.3<S,2TT8F5E83(T-6$V.3(\+WAM<$U-.DEN<W1A;F-E
M240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z8C4Q,3-B
M.#<M9F$T82TV.#0W+3DW,S$M-&)E96$R-#5A-CDR/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP
M34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.F9E,SEE-60W+3 R
M.3@M9#,T9BTY.60Q+6(S,3@U8S@W,3@Y83PO<W12968Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#IF93,Y935D
M-RTP,CDX+60S-&8M.3ED,2UB,S$X-6,X-S$X.6$\+W-T4F5F.F1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I
M9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N
M0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @
M(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW-6(V,F8V,"UB
M-C$R+3$P-#DM8F)A,RTW9C4W.68P9#@R,C$\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#(M,3%4,#DZ
M,38Z,C(K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(U+C(@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IB-3$Q,V(X-RUF831A+38X-#<M
M.3<S,2TT8F5E83(T-6$V.3(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#(M,3%4,3 Z,C Z-3,K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(U+C(@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-
M.DAI<W1O<GD^"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL
M93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(" @
M(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R871O
M<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @(" @(" @(#QX;7!4
M4&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L
M94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P
M87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*
M(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @
M(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C4Y-2XR-S4U.#4\+W-T1&EM
M.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C@T,2XX.#DX,# \+W-T1&EM.F@^
M"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*
M(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!4
M4&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E1R861E1V]T:&EC+4)O;&0\+W-T
M1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A
M;6EL>3Y4<F%D92!';W1H:6,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO
M<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S
M:6]N4W1R:6YG/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O
M;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M
M93Y41T)?7U]?+E!&0CL@5$="7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M
M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$YA;64^5')A9&5';W1H:6,M0F]L9%1W;SPO<W1&
M;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M
M:6QY/E1R861E($=O=&AI8SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0@3F\N(#(\+W-T1FYT.F9O
M;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP
M92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.G9E<G-I;VY3=')I;F<^,# Q+C P,3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&
M;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I
M;&5.86UE/E1'0C)?7U\N4$9".R!41T(R7U]?+E!&33PO<W1&;G0Z9F]N=$9I
M;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4<F%D94=O=&AI8RU,:6=H=#PO
M<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%M:6QY/E1R861E($=O=&AI8SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/DQI9VAT/"]S=$9N=#IF;VYT
M1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@
M,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT
M.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE
M3F%M93Y41TQ?7U]?+E!&0CL@5$=,7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE
M3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX
M;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y"
M;&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H
M1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO
M>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P
M5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^5VAI=&4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y";&%C:SPO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,# N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!2960\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0TU92R!996QL;W<\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--
M64L@1W)E96X\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!#>6%N/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+($)L=64\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0TU92R!-86=E;G1A/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3$U($T],3 P(%D].3 @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,34N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^.3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STP($T].3 @63TX-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXX
M-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-
M/3@P(%D].34@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C@P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.34N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TU,"!9
M/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TS-2!9/3@U
M($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XS-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@U+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU($T],"!9/3DP($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-2XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^.3 N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(P($T],"!9/3$P,"!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C(P+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3<U($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3@U($T],3 @63TQ,# @2STQ,#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STY,"!-/3,P(%D].34@2STS,#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^.3 N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,S N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXS,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3<U($T],"!9/3<U($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^-S4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C<U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STX,"!-/3$P(%D]-#4@2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXX,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C0U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STW,"!-/3$U(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C<P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$U+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M.#4@33TU,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-
M/3DU(%D]-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XY-2XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C4N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3$P
M,"!9/3(U($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXR-2XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<U($T]
M,3 P(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C<U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T],3 P
M(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4P
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,U($T],3 P(%D]
M,S4@2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,S4N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,S4N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,3 N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,"!-/3$P,"!9
M/34P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-3 N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TY-2!9/3(P
M($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XY-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C(P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STR-2!-/3(U(%D]-# @2STP
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXR-2XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XR-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C0P+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STT,"!-/30U(%D]-3 @2STU/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXT,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XT-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C4P+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C4N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/34P(%D]-C @2STR-3PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXV,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR-2XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34U($T]-C @63TV-2!+/30P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU-2XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XV,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C8U+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C0P+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],C4@33TT,"!9/38U($L],#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,C4N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M-# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXV-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],S @33TU,"!9/3<U($L],3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,P+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4P
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^-S4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STS-2!-/38P(%D].# @2STR-3PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,S4N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXX,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR-2XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/30P($T]-C4@63TY,"!+/3,U/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXT,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XV-2XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C,U+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,]-# @33TW,"!9/3$P,"!+/34P/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXT,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXU,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/34P($T]-S @63TX,"!+/3<P/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C@P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C<P+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @
M(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1W)A
M>7,\+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG
M<F]U<%1Y<&4^,3PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],3 P/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3DP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C@Y+CDY.30P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],"!-/3 @63TP($L].# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^-SDN.3DX.# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP
M($T],"!9/3 @2STW,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXV.2XY.3DW,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D]
M,"!+/38P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P
M,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C4Y+CDY.3$P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-3 N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STT,#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXS.2XY.3DT,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3,P/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C(Y+CDY.#@P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D,],"!-/3 @63TP($L],C \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,3DN.3DY-S P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STP($T],"!9/3 @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXY+CDY.3$P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @
M63TP($L]-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXT+CDY.#@P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<$YA;64^0G)I9VAT<SPO>&UP1SIG<F]U<$YA;64^"B @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R;W5P5'EP93X*
M(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],3 P(%D]
M,3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TW-2!9/3$P
M,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-S4N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TQ,"!9/3DU($L]
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XQ,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDU+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX-2!-/3$P(%D],3 P($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3DP(%D],"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XY,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/38P($T].3 @63TP($L],#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,S$P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# S,3 P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI3=V%T8VA'<F]U<',^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@
M4$1&(&QI8G)A<GD@,34N,# \+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M /<")@,!$0 "$0$#$0'_Q  ?  $  00# 0$!            !P8("0H#! 4"
M 0O_Q !5$  !! ("  $'"00%" 8'"0$% @,$!@$'  @1"1(3%!46UQ@A5E=8
MEI>8U!<9U=8*&B(Q62,W079WMM'8)#8Y46&W,C0X0G-UM24F)S-$4F)QLX'_
MQ  = 0$   <! 0               0(#! 4&!P@)_\0 7A$  00! @,"!PH&
M# H)! ,! @$#! 4 !A$2$R$',105%D%6E987(E%25%5AT]76"",R5Z+2-E-Q
M@9&2DY2QT=3P)#,U0D-R<W6ALR5%8G:RM+6VP30W=((F@^'Q_]H # ,!  (1
M Q$ /P#?XXQCC&.,9:UW"V)<=7Z>9M%%,J!'5;&U<"5/3!&$,Y%6&]A YB)Z
MN6A3XF,3!TN1&R]AC$AC#GI8SK+R4.)W30537W-^4*SC^$QDJ;J2C2NO-?CX
ME9)D1SXV'&G/Q;S8'P\7 6W"8D*JBZ'VCW-E1:;2?525B2_'-#%YJ-,/?B)E
MM$C26^"0TZW^-8<,.+@XPXN("$T0DI#8^SMOC^S=BUIKZ5%*,HZ:W;951I9&
M**;&D]M0+XP"K$N:6<88*M1GT.LC)$3)B,*RR\M]UII].);>0J*:A=T=$N+4
M#9)>T"NIY]@TX^KK-$[6+)F VPA$P1@J$\+G@YO\0H(J0_BUQUU>:B9UQ-I*
M=QM\1[-K.[KJQX(XL/ZA:MABP7'9! ,@0-%%@FUDA'X24R$3_&#0_4;;5RMM
MRFU;8&Z[.7NL>D12=TTCMK4PC76P:K;4S(S)(W32 ,>!'&=>96X]#89PQ97V
MTJ&S'"8[,E;,G(Z[HJ^# ;FU>G83%<=D;-=J.BO7[:JFP5;,F8U@U)=E.L6R
M((N$7%# E1YM&7N!"#%]GFH+*PLG8%OJ>=)LPJVW[/2^H=/1Z:W@6". +\FM
M>B-1&)%/N1-B*#/-$5AQ7V>-1.I=RF]RV7M/1M,:\W*6U( )Z0M&P9\D33:+
M;'9AT-;QP6)B0U;P9)>(JHI'_+,Q9<5*_5T8QYJUK<Y9Z?C:?B:*LM0VNGV+
MV4SJ.%5M _86<%&XTB [(<X2@2644T-GWI. YMQ+WHB)E[J65J2;KRJTU3ZE
MD:>B/Z7GV[QQZVJL"=E1;%B*WQC8Q7U1M6W_ 'PMN-HO G<JJN4AIOL?=+9:
M=24B_EB;EZ%[?[*:9MBJ:,K\&G;#+:9JZB+9PM%*H>)AFY$-^'.&QJZ1@Q\V
M%,A,[T8=:(4>_P!0:2KH,.]LJMAD:QZATCJ&"E@]+<L*IC4$U&5C,&PHLR"!
MP7&GBELNGX+PJWO(3F%C]-ZTL["?IZKMY#Y6K&H]:Z:L%K6(;5;<R--0"?&5
M(;D(3\9#;)IUD(;S0^&(:.[1E1H:O3WKI@[&S8]OHEEK)K6],$WIRO1[%KZV
M$R(HY:HU*'"Y[E4M9475+4BQD!44H!L1&(H1%),D9<O$-#KJ;#W-;!Y:8X%E
M#F1K>P?K$EG$M(+++\:$=BZ\V,Z$P]-A+$:?-F3$:<1]QDF6P5Q1%<BG:I6L
M^/ L:J;"DTM;'M5AA,J+!]Z/*L K&6'5@3WV*^>,QV.$B+,>;6.V^+SCG+0B
M3[=[J^HJGP"FDKTQ9AVWJ;HYZL#[)KXM.E7^ZUHQ:QT0:2C65%?>&,B88C$@
MG.+C6VIAER-):C8$S'5![.^8C;K.HZPH;M#8:D&8[$M6&PJZZ9'@O&ZR<-90
MO$^X_P #+;#JDW'0P4^>V*"[3>4KK+^E[4)S.HJW2Q06IU/(=<M[.#)L&6V7
MPG)#)@8S4;C?=D,(+LI6S$/!W27T8/<F(9@@A('4EW,;:-; V9K=6IV"]-CS
MQIO4#,:7?9<RVS#L>IY#BXA 3ZI.8(.J)SBL.%#9<\YQ]%%SL_..[)?E7M;'
MHH]53VZ7A1[ VGHU\1MU;806XQ3DD/N-/\;9M"C#3+CCA#L@K7:[26Y+46/$
MT]:2=0R;B[I5T^,BM;>9E:=%MRV=<L'905_@S#;T?EN@\2ON2&FVP7=20![L
M4ZYV35M<H])LU@D[*J@NX91--4:J$0@Z?;R]'GP6!-ILXJ3:S=5/ #6+8-JR
MR.14"#B8P]/S)CLK2NSNPKXEU+LK&'%"HFO0$5N/93FI+K<!BR:<-^%#?"#'
MFQ9498+LU&>>ZZK9"UP&2(G:?66<VBA5=9.EG=P&+'9V35U[T5EVQD5;K0QY
M\Y@Y\J!+B2DL&(*O+'::1P">XP%>(+WJU06V/)I+L=\<#]X+W51MS>L-/EIF
M'-<CRI*QJFTP>=E7@$!?C@3:0%A*@F(1IZ"AMM,?! >N3&1V:WC%2%B)@[(\
M%K9SU>,6>"MQK9UAF)R[!V,%=)E"<J.LJ(Q))R.+JJJGRG4"6-VJZ?D7)UA
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M1E=N4(/#+Y*6*VHNAX:KJRN02KR?!T:3ARNMJ7K>5 WAKP/ W/"M%IV-N 7
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M,)/ *]EQQPY")'XG0D(VH.HT)LN0IM R*:%(KH^J)_@HUA5-5PU5"V_71D<
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ML,BD7L5V9'HZQ\H1,.3&V&>8<N>4&'Q28#2J(R)3]?\ %0T!:KE.TZD./LQ
M)LZ5$BEK"*JA,F,J67MB'*3+5(DQ_P#HTC,&")9/O(ER!JD,S$LNX::0F6Y+
M6Z-L;1W3/@K$]^)?.MM2)D:ND2&*Y2NI54XIN![P^4S'&82.$PHBX@EPBB.+
M-==I-/1Q]<+.DU,:?I-EYZ%6S+B)$EW2!IBOOV4::<_&M\^1-.M F6Y:$;"N
M!QF2LC=7T&[W63KC;!=!O96:7T78""(L^%*<=EN:^F3GL8]YZ^E65NLC$/N9
M?L02/C+$J,N22A1LEV_,G=#['>UZ=H>QCTUQ)=DZ1FO(V\TX1.%2NO'_ /7P
MD]\0QT,N.;$#WC@*;[0>$CL]Q_\ "-_!YJ^U"FF:CT[#8A=H5;&)Z.^R(,CJ
M5B.WOXILMN$')9-BC=9/<V<:=1J+(=\#)"C[44>1'F1V)<1]F5%E,M2(TF.Z
MAZ/(COH2ZR^P\VI3;K+K:DN-.MJ4AQ"DJ2K*<XSSZ$@8. #C9BXVX(FVX!(8
M&!HA"8$*J)"0JBB2*J*BHJ*J+GR"=:<8<<9>;-EYDS:=:= FW&G&R4'&W&S1
M" P)%$P)$(2145$5%3.;DV28XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQFLGY?C
M9LN1=-!Z;8D+;@B:Q8=FE8B59]'+EV$JJK )#R/'PRL<S6+(W&5C&,X24EXS
MG.,I\W6;]U>..SYD$G5^E27@'^#A+;]U<\*?A?WKAVFD-,@:BU&@3;V0VBKP
MN.39"U\,S3NW8&!.%M4ZHDAS?O3->/FNYXRQQC)^>W.']M5VVQ*1)1;!E*KF
MNSJYUJ];JMDJ G5<73QD:L#%KXTR*>L]/C+9ESX=M7*&RYDJ4,6P]B&N)<*^
MG$)H'OT;%HMRW$@%E&"3AX45.,$ZJA;HJJJ>;;;RU-&\*A6+=4:6+%7"II:O
M6',KYU;'T^&FY3"Q&X;$J.4ZM!1<>:L5<8<<<<84"Y:M]^H=@EZXM>NS%#IT
M2'7-<$+D7@5JS%W+(^>+; !Q*Y:YUC,1QH%J1ZV$%A1<&(,#BH4"(%A.^KR"
MKY0H1B$CEFV38(@-J9(!$I<2N"@FI%LF^XB*;"(HB"G3BW):U;K%:2PI9-36
MMMPJ1ZSDLP9\A9QRY%S$:A6#LV2#$03YD6/%89;8C1VF6XK1<!R"D2'Z$N6U
MSEVHFLJ&3BQ$0M9M6[U4FA;[I0[,N!MLK-GF7WUK](]#APQ(2"EOP0T/%Q\>
M'GK<SFF;Q.-M-KMLVA=?.2D6ZJ2^=41!%/H%/IS$6>H)5I4T52^VVC5$-CRW
MT4RD2W;*4+[KTDS5>(FFFHT5I$Z"S'#SJN1;REF!QQC-WSR5VS9>T>C.DYY*
M0N26J TMK>>M:\N*2S1C,T)7V\K5XJSE%39 85YWSX5E6,9SC&,YW>J=5V"P
MJKNH(32_N-DHC^APY]4OP?[UR^[*-+//FKDBM8DTCRJNZH%3*=BPQWW55VKA
MAHN_7??S;*N0SF1SLV.,8XQGRI24)4M><)2A.5*5G/AA*4XSG.<Y_P!&,8QG
M.<_]W(*J"BD2H@BBJJJNR(B)NJJOF1$ZJN11%541$55541$3O55Z(B?2JYJA
M$]A3)>V2VT%-)FSI]X*W'+$E:TH?>GF))3#3BTX\]"/%_"/[./[*<8PG&,8Q
MC'PPEZLDO:[G:U4$DRI.I9VH5;>(A%UV58/3N U'<A%5<X=A_)3HG1$SZT1M
M.,-Z0AZ50UCL,44.FXVQ%2;"/#:C*8BNPJ7XO?KWJJJN^^=ZO;9+UV>-EQQT
M"3'AT>71I0Z4I]48C"?=)RXI!W*%(=8GC"<Z.3A+87A.) YEE[#T.1,C/W-1
MKN?42HC[,.*^RQII_3+\1]7%9EQW#F2&)1J*B;4J%-D,S8Q-DB([$;;<1R.]
M(9<H6.D(=E'DLNR7VG7KYJ^9DM"".QGP"*P]'!"0A<CRHC#D5]'$55"29AP/
M-LN-^$!O4L"BCH:@1Y&*/>IUZB9<<=3F=+G8IV%P)'FX_P G'1[G1O-<;\7<
M^N/^./\ )M\QE7J9^K'30MQ6G?)K4TG4S"F9CX2_)33R%%=X?R&A\GV=C#WZ
M^$.[_D!F0L*%FP*](Y#C:WM"Q0N\(BO@[+"W2I(;W_*<+QT[N)>]3D-[?E%G
MTY:@D.+88M=K\\>FS@E@R:RM@9,Y0W[Q5VQ,2(6(P(+AE;;P#U9Q#WK*76I>
M5IRRMC'I9BO*V,Q;,5%5+BI=5A5DTI]JW8J(>-ZBW:=C(Q5UJ-D#E5R3%SGH
MX$A216R:3F2A43GG:YVRL8\E:N>,Z*D2N.$BEXMLJTVGN9/FJX)!8<T2#EJ!
ML[*AHXO!4,';A&&4=,+#0)4LB4IA:P8>?DX9L$FKCR@LI@BE&4N*Q=89:;FS
MJP]Z23*ESY+2V_6\M-9:+KV7'FN3RKHK[\R;IV?:HXXZC5L]219L*<DL15#)
M-1QYTA;HD-3>?D2G@(/"% ,<_HZ,]%"&DV0TS&BW<2N5MMKCKFK:1%E1/!E)
M%%%HWH;'BM%#A::98:,2Y*$7-+VXZ:D%E6,$B=%.!SPDDT-)9$R,I.;!9V(I
MZ'(=@$V(OJA..S :8S"?:R.PIM.&G<H<;GD:\<LG9ZW%8,EFSK[2!,"%,\ >
M5+/5C>KB=CNN19S3'(FM-Q0:6,Z"Q$44X#43&1G1P06X:5D]8[L";7S(IRHW
MAC:+ TZYIM ?;"1%<>5Z*Z<@W$?;/PE4)>,.(2\N/=ZS&%P!&:6\0A K(7LP
M&,5LBY$;$HV,JL"="L#<$,->,P/2U2+(::@R0+V&Y,B*\^_CS7>63.I*9F%%
M@KIUR5'K+B?<U;,ZX5UGG64*DBR8]L,:NAN6,7F4;#S817JLT!]YAQQQ.$TN
MG**T=E/S/'@1WY]9#J[!V)6"VZK4&5;2&'JXGYLD(,A MG6S-]JP!3:;=!L%
MW#.SC<%I0Q(>COOP[#* DP3UHA3I4(QA!N^2;Z8G1WH:HZHLTC-D*%R%L.(;
M6*=F1E(4B:ZG%9.T"[%IYQIQUBW?K)E8Y=QI3T:>@V.J'M46$EIR.K1,R)DA
MTH3I-& E!.0RHJ,DT2GY&5).-@XVV]6M3XL\*E^.R_#4H- UI^$PX#R.(ZQ&
M8;24V)BI)+%EQ"16!5?*L6Q2=F@%XQ*,AV:=717RQ5V3(D3)TVC "U=CSWU/
M94IV87BD\2BK[SCCKY!ER7E>5RW?"QM]73+F+/9F,B<FS+3#LZ<;SKLB3)TS
M53JAJ4Z3BD3DBP8F(_.=<,S=EMF^I*3Y[75=IJ+5R(;L9T@8KTOPAQ :;;98
M8OK")8N1VT!$0&8;L56HC8"(-QS%E!060SK6RS@[/Z.<BOD!Y[U$%!D3LV!F
M6,=;"AX0;"VA7L*-(87)9@,NY\XL_AEQ3F,8<3E.$T;Z[K;M1EI52XEJL:LC
M/2/&K;\$QKJ^-7\3<!:MIYHGFXK;B\5@ZC9J:(A"HH-6GJI]5Q,%8QY-?SY\
MAJ/XN-F4!3IK\U4.7X>ZVX+1R#!-H@*8H*JHJB[YK/)AV=XKHVR5R0YE:JI?
MR*(:<Y\<,C#8L42;;3C/]V,D_:[V?#YLY=S\WCXYS]&OP+[ER=V9W%0Z:DM'
MJJ6,=%7HW#LH,&8 (GFWF^'N+MLBJ?P[JOB/\**K")KRMLFQ04MM/QB>7;\N
M3!E2XI$J^?:*D,/A1 _<S)%SV!GFK'&,<8RR+RB&W)VG>J&QS :4N%8;6U"U
MX!E-K4V['DVYU<,K(CNHSAQF7%K+1Z5"?:SAQF8Q'=0I.4>=CE';7J1[3'9U
M>2HKBM3;$6J6&X)<) Y9$K4AP"14(76X S'&B'WPN@!(J;;IWS\&71<?6_;'
MI>#.9%^LISD:EL63%"!QJE!'XC3@+N+C+UJ=<R^V2*)L.. 2*B[+J&<^:V?:
MS)));)G$C&PC#@V(V[L$&@',90Z]EL>R@S6S.'XJE>*G7,N5MAG*7?[/F27E
M8\%)1S/OW[S\J[E+';$KN$D-T$,E%@4DP9/&VJ]2+B@@.Q=.%PNNZ)FJQ=*Q
MXL'3,$9;Q!IFP6P8<( 0I1K M8"MO(G0!X+5QS<.O$T"=REDA#NP4EBW*N9*
MMNR2H_8=BV-7/8UH*5SU&;:",(D7K)F3#8?G&:=)?'QU*&P90 IA;Y)39MM!
M%YM.:8ULX%FMJ_ (Y#-W-O(/@MC(@\IVP>:?DU\MQH#=EU;AL-JK#3D*1N4C
M:4@OD*:Q*[-&G*1**+:@U#DZ9J]+VGAU1$M/"6*B*_$A6T%I]QN/ O&FY+B)
M*D-643A;B(4 BB@2T8SM@BU;=8VWV3"5)UD49*08GIG\,%'&=CG=CX:EK^=Q
ME"IQUX;G+/BK$5AMWYWE*YB4U&\EC0V*1FN.ADI)9;4SX7R2[EW:"XNR**<V
M63&X]>6"%^4JIF>/1D4Z;5M-X:^C>K89PY+W+;XX@GI>OTOQL#^29)'KPE;.
M+MSG"#\A$R)^:YFYYM=>2YVW-VEU2KHXQ*<EF=6FR6M9#[Z_.??$BHP\M659
MQG/CAB%7S, ''5_[Z0RO'.5I7GGT3_!_U*]J'L[@LRG%<E:?E/T1F2JIG'C-
MLR("KO\ YK4*4S$!?.D9?.BY\=/PN-%Q](=L5I)A,BS!U= BZJ:;;1$;;F3'
M9,.U1-D_+?LX,F>X/^:LU-MA443(MSMN>8L<8QQC'&,<8QQC'&,<8QQC'&,<
M8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M'&,<8S4;\NRQ*:[BT]Y_"O02= 4U<)6<9\WT+=XV6RZA.?[O%,I#ZE)Q\^/2
M8SG']K&<ZC>HJ3 7X8X;?QW4SYS?A9@X/:76$>_ >CZQ6E\W"EK>B2)YNCB&
MJIYM]_/UPM\PN>8,]BO5\W;#P:KUH7-.6*Q%( 0&&&L+E$"I8G):ACQ\*.WC
M*WI,N4\TPRVG'BIQ:<?-_?R81(R$ 12(E01%$W525=D1$^%5Z9<PX<JQEQ8$
M&.[+FS9#,6)%8!7'I$F0X+3++0#NIN.N&( *=5)43,E^Z?)O-:7LG3&H$=P0
M;&;[/[$E:TN+M?!19@?6=F#7&C4BTP!9%L^XFX/5P_:BPN9Z5L!A9"N/,YPQ
MZRK$7)OUG).$"O(12G>4?"**C1H8 :(J'[_@(U14][U%>[?IW+5'8BFEYW9C
M6O:E9FRM>W3E%9%#A@Y&HI\6SJ*J>TP^,TDLRA3+&0P[Q##W>A$'O>->72?8
M_JKU3T>&V2/!=J+Q<=HT.PF:;%II#KO;:S7CENK5BR L89F_/%IM>3@9F*5?
MQ+CNS(\G,'#;*U8?0YR23$B,"Z@RG#=;(@0%CF(D8EPD*.;J/39>J;HNV8_6
MW9]V?Z4C7;,7M!M;._J)DJL;K'M%64"'+LH,U8<V*-P<IZ$G@ZMR"YH$Z#BL
M\(*J&A9*<OR8,$1;PKMCW)(K^EQG4^J]G]K[6FTIM2:5[WO6:$#H(@(BRX18
MSI:=774B?$F.D$&&B&&(*IK$.'/J^*T0Q4GE%A(@2G75!/Q?'Q(+:)Q>^(E%
M>'JBKLJ(F^V^>/L';CV499VICAZ88[.Z_7NH-0NU2*E7XR*>W$IX\5)^TZ7(
M=A$D?_"&#? 7N!E70::>Q-3,1$RY6!ZY+D#$E_$)R8TTS+<B8=5B,N4RP[(9
M:DJ9\Q3[3+[S3;N5(;=<1C"U8A=MUVWVWZ;]^WFW[^O[^>>7>6CCB,J9,H9\
MHG1$7%;XEX%<$2,1-1V4Q$R%"W1")$15ZW&29N!^0^CRF>E#SDC"L,R]QWR1
M!\[Q\,Q4C:K%7E'C\WF^O1IF,^'S>?A?^GQYN%'_ /1?_P!SFW\ ?_.^?23\
M%0'![+C(]^%S4UN;6^^W+1BO;7;Z.:#O=TWW\^^9A>9C/2F.,8XQGEFVW70I
M=ICQ].X+(-L^']_I5Q'DM^'_ (^?E/ARRLA,ZZ>#>_,.%*%OA_*XR8<0-OIX
ME3;Z<NH1 $V(3FW ,J.1[]W +H*6_P!'"B[YJ%\^!F?8;'&,<8R9-4U/3=E:
M-JVMMDGK)V&X/2$:'T,K=,&&WTS,D''5C94; _,%34-*$/87F3B4K*,X] OQ
MZ'H:B[/+ENR+7.NYNC'(YQ4K0B:8G:B2P!T9"RC<*&\TD18Q!'01<XE>YY*.
MW*+?2]66VM*PX*:3TC%U.#PR%G')OXE(L(FU92.(#):<60CZ&\I*&W*Y2(6_
M,3:Y27T[ISFX]):N [9)$X>X:27OJ3DND*%3@@)FOF#H!Y8&4=]8=6;2$FLK
M9EOCY$'",J<9<<QEGG8I'X/NGB[0NS?1-7KN9-C]H&G)^J$L7]-K!E5M8W4S
M[2J<*L>L^:9625TALFI#D1Z+P*IMD?XM.9,]L]R.C-<ZJGZ1C17M&WD.@6"S
M>I+8G3SL8D"P 9[4#E@,%9K!B;(2&W^)$$Q%>/(ENVI](#6*LQK_ '38[D<L
MMF!BFQI;5!^GQT!"CKC$D]%)%IBHT[U-Y4-"(C6<9DXDY6EY"6E9SH>I="]F
ML)JE;TKVBV^H;.XN*V",*?H:UT^T-;-,VGK-B9.?5F3X.ZK BP"HKW.54<%
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MG<7:"SG]ME'VCQF6CT2M$W:.:B\)C#7LQ@TW,B+SG"=0@<1XFT(%'<0+F%L
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MQ#C8?C?HKC<OB_I)CWDN'U=$?O'6?XAQL/QOT5QN7Q?TDQ[R7#ZNB/WCK/\
M$.-A^-^BN-R^+^DF/>2X?5T1^\=9_B'&P_&_17&Y?%_23'O)</JZ(_>.L_Q#
MC8?C?HKC<OB_I)CWDN'U=$?O'6?XAQL/QOT5QN7Q?TDQ[R7#ZNB/WCK/\0XV
M'XWZ*XW+XOZ28]Y+A]71'[QUG^(<;#\;]%<;E\7]),>\EP^KHC]XZS_$.-A^
M-^BN-R^+^DF>B*,V*;,;CD:=,#Q5)<RN>\9"3&VU)1E2$98A2W9"LNJQA&,H
M1G"<YPI?@G&<X@J)YEW_ 'E3"*N_4=OIW1<JKD,FQQC'&,<8QQC'&,<8QQC'
M&,LKWAUJN6\]XU:SSK\6H6N:/JVU  DJF20SMPFW&_$&AMN:EPK-5[ $8K<R
ME0XPUUYM.2<B2XXTWF-%2[ZST/3FKZ_36G)L-JL8L[:RNH4J2%@$A(#=?5M$
M] )MR'-BR"EMV+CCR"2\D0025#/;@YGJG1-EJK5$"<[;R*FFJJ*?$BG6'%*Q
M<LK=X6+$7&IT"9%&$[6--L$0ISS,B%%!OBXX<U[UT[*ZA;U^<!0]4[$L]=T;
M8.N,\=<K0=$@HE7@["(V37=O2Y"JA1\Q&:KLJ(&N-0PT*>E8'1$#3*D_VV,_
M:ZLTA?%:QI3EW4PY>I(FK6G:^%%?E',=JF8=M 5')S(L&4L')%?.4GQ#G&KT
M=%Z'K=/HW6VG1IY45N@N9\/2TO1;S-E/EQXC<!JX>FT]BA-U[YR02$;4:RKD
M".;G(;1F2J=0KO8F@-P'[+V@P*A4:6&["=>*W0(IC-@)!EUR[U.L7$(S%57L
M@2BGJ^8F6E+Z)Z#7K B%$PVN&1?=SAO&U.J*&+#T;SW+()&E=5S+0XZ169"2
MZZ=,KY!&DKPIA!E1VX2BK2Q^!]P]T<:%$XLI<Z0U',FZ[2.W5.1M8Z.@U#<E
M9;\985I7P;**+:PUB2%*')<GH8NI)4X[3?"K;QKLG6D]1[9/W_JV_OF!$?7(
M:ATE[88&/+D^U"FV]:TN\4:E6$7C,'#*XHT5>7G4RG)$=]+X,>I4=S&&\-3A
MKJ"WI>ZJQCR#MI%G8C4RB .2Q17%C6V5C%?V=XD-Y^L$5 1,>&2ZB&/52E<[
M/+!W5]%;E)CA31JFL*XB XYSW]0TE9:559,83E(*MLQ[4R0R,#0XK*\"].'K
M]5^K5QT[9*DFZUNNS6M7U2T5.L[$C[IV]:YYM@\0'^B<":IL2D437 ^:'@,8
MLPX:Y.2\8ACWA/H8T?SL3ZUUK7W\2<M=+EM%<SH4Z95%IZAA-1RBLN\0R;R)
MO9V[K<ATEAO/"THL&Z+_ !&>RT]!:#LM-S*[QI#B/)15\^O@W(:GU%8.R1EO
M-<)1:";PU-*R[&:!)K+"O(4EMHH_" [Y(NQ-8[NJF]#.\=$P->VEZ]ZY$4&X
MU/8)XU66X)2LDY\VLV\64$!3>9T5F*3D0# -UF"^ZVRR]"G*=D+]4Q%5<:<G
M::CZ;U*[:PAK+:1:5\ZJBQIA.LS&6FYD!YF1(C<IPC9!V/)$G 12(76M@3CS
M-S1ZHK]52=5:4:IYYVM-&J+*ON)<J"+3\%]YV#8L2(T:5S6Q!\VI,0@:,A$2
M:=XC7@@/L#UQ[=[CKQ"J&K?3;7$-:E" W%C+]<]4U$-L9@K/GV<N2I5=KY9>
MQH)*&H4,KS%F+Q0H[,204D (\I:&5[1I;5NA*"4U.CP;"$<>]DR41ZKK[N=(
MJ28;:A,,V$N6PE2ZRXCSTLX;!R'>,&0E$"*2:EJ_1?:)J2&]7RK&MGMRM/1H
MJDQ;V>GZZ-="^Z[/D/UD*)(6Y:?;6.Q#"=(;C,\LWSB X2 M<7?JYLFQP.QK
M$&35TO;7VWU[O-9S)*348:#ZO;UTFR-EE(%.YBSW,U4I[+98Q+:E>?%]-(B^
MF<]%C*[6=1$=TF;@3>&DHM55LS@9;7BD7)6ZQ%817TXVA\.8YQ%RR#8^$#X4
MXLI:Z#NYK.M :. AZ@U%H^U@J;[J<,:B&F2:,A4CDK;JK D>#B',$^)OB-OB
M+A\5_K1O"+8X%5'0]=2]:C.Y@WM*U=)-J,Q;C,$3;4NPF*C+JB:G(A/F12IT
M]N.><M*(Y&'$&1L0F'77W8ER.L--G$=FNN6S=N]V?/:*6N"%'.O;?;@I$CSF
MYRSP=&.]RVB.,D)3:<-X^8:(*';GHC5 3&8#+=.Y2L=I3&O!LW)\D+%R.[8+
M,DU[E>E>;128_->%N4L] >:;8;Y0*1$WY&I.G-YH;RJ^; 5TS$I@+<PVB[+F
M;OV^6F37-D13L$2J'IV>C]G5*D*%G'8-TD1/:+4Z8VV5&-*G)S*77OM?UMF/
MA4:5*CG8R=/O65.WINA8;;2H.,Z^CE^VJVUB"/QA<KQ/E$TVJL/$C2\"6^GN
MS>TJC\$DQ(DENLBZE9JKMW5.HY#CBW;<MJ.K6FW4\35AJQ*)JR)OG"ZXB2&!
M5U.85\FAJ28UKI/4VO;"N$X=I.NZA5C#@U]V2/63! H0Z:J%(>8BNOQ52([F
M6'7(S"W&_-4IIO.<IQS?4UC'M]17EK%1Q(UC;3YL='A$'49DR7'FT< 2,1-
M-.(4,D1=T0E3KG4=)U<FDTOIZGF*T4NKIJZ!))@B-E7XL5IEU6C(&R)M3!>
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MO5=@=\[NO.EZ&7#M7"NT2@6Z/K@+1:,2;;E5YZ[6Z'&S9;)<"0Q\?**M^UH
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M1+[8_:_[\]@OY=X\C^TOT T-ZLTM_:L>7/93^<G7_K/5W]AQ\ICHE]L?M?\
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M,O-&B$#C3H*#C9BO11,"421>BHJIE:,^]%D,28[ALOQWFGV'6U43:=:,7&W
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M$;)!5%]6F=MM-V>NGS96QQJC+JTH^W8 9C,IV?!AB=DFM8#IK&8L-;955AL
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M4^HO#YO_ ,1"7^[4OG>^P+_+E[_NIG_S89YS_"._R!I[_?#_ /Y)S,E78/\
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M4#:MW)2:MKO<%/LV+7Z"XY+3ZM6ZZ-ALBV#DRO&@XF>NS,V8,=K[ ]TA'B6
M,]$N==N-2=(@R :-/3 +M;/=:?LIMM0SX:P>* C#4V7+><)XXS<J/(?:2&4*
M3%E$Z+1N19 N5\NOG(U):D&TKK!:G0ZEJH%-J2MG>,$"S60] A0V&A8"4Y#D
MQH[JSAG1I<,62>!J9&)NRA65>3L5Z,#J-21F>V=D^O;AA'NEKR2JO%=A "5J
M8)ZVU\.GR==O[.[&6^X5P.ILL<R,)-UK9VM@(.7#EP<2\TI#$IT8+%C84G7H
M.D-5#'7PZV!);%5*9A$Q;VKK8VPTVDH$"7(W8C<YE9E-<2I+;@.\'C%2 7GW
MWG V6PUMH]9(^+Z<UAR+B&_8"_25#+ITQWFL[&RAQU1^5R7Q@WM)$BN-FUS%
MJT R8CL,-N<!KLKU_*UV*.C:I@"Y+9W:<M;;&NJRJ<W"L0_=<"C.M61%K8;4
M@2-NVM Y$2[6%O)=HV#K1Z5(%A(3LT;2&J6)9O'>.O L6E;12MIG+5R([IUV
MQ%8:P25%>>KKB0T^,U!4;+P98P ])<&25K?2,B$# 4#3#@R[YQ1"FA*Z+4QC
M4[-4234G@BI'8LZ2,\P4%3XJOPI)9FQ%:+WQ7:?0TNR(+7"MVTL,C$[K+2'F
MT>C66&2A6]>J(K\*4T:/)D#G\C*8?1ZX&GP7VWI$!F4X6$2BH:3:O:*U,W#5
MB!,@L/FS7 LANRLX;C+D!+QP7 *-&4'11ZPBKRY#3HD(.D",/@Q(&]8U]I)R
M:#]C"L9##;UF?@[E55S6GVK%=/MFTX,J6ALDK%9+3F1G6C0C9%PGXYR(QT]%
M[&Z&6,'PG:=*"$1U0CU]H["U'JZQ2/".%T4T1'K&FR3 ^;[QDJ5M*._826)A
M,?&N#,K$:9@N8@PKH]):G1YYQ+ )+3T\Y2QG+VZB#N<C4I-.H]&:)UOP1FQI
M"&*SP,NG7DWQM\B.ZY9MZUTDK#315IQ7F:X8@2F].T4PTX(VE1>85B2\#3GA
MKU9>B<Q[F/,A8"YP.^$2&FH)WUM#6^P@6IQM!J,*KOT^J1Q5B6S41]>F3)Z:
M]4!K[,HQ LIGWJ90:"6 U$)/B*U(PJQ27I4.3/FS76]FTS36]5)O'K2>Y-&?
M-)Z(A3W98-M>%3WA(([L./X"2QY,6.XR#\P/\$ 0<!IML5U+5U]2W,73[-17
MM02KJ\&)BC7M0W#>\"K6# Y+4V3X> R8LN2V\4>$2+,<(VC===)+;N;=FDXX
MQCC&.,8XR(]Z?NI_3F]S%_\ 5H__ ,!G_P#S3SYHG^67^L7]*Y]7&_\ %M_Z
M@_\ A3.?DN3XXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,8XQEOKG7JHD]^FMZV<75[01=I]&KM1BFZJ/(D
MZ44J!:UDY-@!G)ZI3L*65]X837B/C09,90AIU4M_*VTQ]I354]G2\?34-Z;"
M9&?92YYQYKK+-BS/8@LA%DQFD 7 8\$<+\:;@&CY"C8[$IZ@NCZY_5TG5<YB
M!.>*MJH5>W*@,O/UC]=(L'SF193JN$TY(\,:'\2#1@L825P]Q0(';Z<7$1#7
M[J[?;!E%!;""=ELUTO%Q-&67L<:WF5&O30EO#GA\0@&-/T>9) F1)G",O%AY
M6 I[$1K9EU_7R#1)U"LEE),64(%+8/EO0])1]-,/"W)@2(KKC4B.-DV$J._'
MWX6'6'4%3+5![.+*,VO@&HDBOK%F1"<&'(;YK$W6<G5,A@G(MC&ELMO1I)5;
MIQ),>2B<4AE]I21L>:F=.;+2YNFI O9H>%G6TL[D^3"T\R'L%E!&MD7"_P V
MH1Y[5Y?CN5(PS:_89(+<H=U0-<@>\%<D"S<V3)5+8:_B6+>H!?IWW/&X1O!6
M9$^/(BPY4>I@583R:*M$TG,%"\)9DU[E<KR.)%E@]&; $FK>S>;6.Z:-B\CM
M>)'92RWXU=)C3)L23=65NY7 \-J0+7R1L/!7XMFW:"RK2RX1L2G3/*^ZM]8/
MDXQCL5P\!L/K@6JU87.%ULF$*N@J@LZN#*LLTI:K-@B7EY.+R\P': @("V'7
M!HEG)"1A&+UIK+RM.*:19,3ER)TU]IZ6S)823/2,CH0VV8,/DL-^#)PD^4J4
MZA"CSY<H57+:$T+Y&!+;67$F<R- @1W6(3\6042N66K)SG7Y\[GR'/"E4ACC
M$B-$)$S''G%MZ.B]*[.UQ=;Y<=BW^D;'*7W*WR=BA4(_7;IY\6:VJN 4%INP
M;"!A4>LC'B4(75PM7$)S+E)+RIT@DZ3?)4M2ZBIK:NK*^IJ[*I9K-A8B.6D6
M77;&VJ2Y*L-U422Y93'A9<>FR)LA>6VK -BTC(LUM*Z8O*6SMK*YMZNZ?MMS
M?F-5$N'9\3;@K#BI(=N)D1NKA,$\TQ!BP(R<QQ))NF\3Y/W2\TO-\QQC'&,<
M8QQC'&,<8QQC'&,<8QQC'&,<8S#OY8[_ #3:B_VB$O\ =J9SO?8%_ER]_P!U
M,_\ FPSSG^$=_D#3W^^'_P#R3F9*NP?^83=_^R'97^YAKG(M*_LGTY_OZG_]
M0CYVK5_[$M4?]W;O_P!,E9B<\IW_ .Q/UD_^?Z]_\IC_ #N'8W_]Q-8__BVO
M_KD7//W;I_\ :_1'_P";3?\ MZ;F#O6E@&UFZAR)O+^*_*05KME7%;]-,:J]
MO"D:G9WX3/BGTL]@ :(O06\J3A<M#*<K3C.58]'W$1Z972&8_#X4"L2X:&7"
MVLV!(:G0A<+9>%HI4=D751%5&U)415Z9Y8HYC$&TC/2N)(;B2(<Y6QXW!@6,
M9ZOG$T.Z<3H1)3Q-"JHBN(*+T7)5M=#)V&.&JJ) O&S* ,Q7%B'",2-'V13'
M)DPY3+C0RLYR+"LCSHHPT+CAXKJ"):ML50K6HAO+Y](C"P;-F(4B:HO>)[1Y
M9:/HRX9U%B@-Q["OLV&A-R((OL$\4AP5:8EE.8F.1N&+S]@L:E^8$6O0V/'E
M0PD)8Q/ V%W6$XY)K+*ID/$#4TBCR!8",V0O2(8P'X3<GBEI'Z)B@[CLDZ 3
MW9.MU0!B8J(:[3MO)J&]"$,NN2'H58$V%;!NU$5..O/,@JS&F2I$R0J605"A
MJFE(]1BTT_#;<9TZU GR7S5Q(5$D9P7'R1!1R8_$0HT)I$01*3,-L!;'@:1U
MQ&V2I2:C4LYUJ1JAVPKHD9M&BGZA62T3482(R:@1YBA*GO*1$01(+;IFZ:N.
MJTVKKX>AL(XRU4CA;U)\,]M*531E*!S%H66':8U@*]@ 9IO*,)0X_8I0FKQX
M,YI",$95-L9#$=F#-&.R*55&(IT9CF#(&E"P>L9+:$C#NH;E_P *E-QM^X8@
M/S3<:)2Y(6$1KB5UIY!K7,L!KI<GE'&*_<K6*N*ZJ+(8TS1,>"1')6R(BG,-
MB #3HHG/<K9KR +3K!.1AK6PSP]E&#XLFBP8ATT#B$I^PZP)L-8AQTSL-Y?,
MN2P!\L/!(1)>R>R!CIF2AN'4+:DY:8;3F;B*T_#>=,+-TXT>2XTU4S'XDUPU
M:WX8Z-RHK#LE5 4C))-6P>X50@XB5<#1S'HTZ.RVY5,MRI45MYZX@QYD%H$=
MX>.23D27)9B(CA>%^" CCC'$BBYPB*9#;$9T X-M"D/Z,1/>I)!.R(C(K7$L
M@^9SU]+CZHQK\M7:^/"33*=T)A$R<_3T$ VW)E"G+&V]$&DB*^4Q(^J!=AHH
MZE5H;)I:@U>MP:%CRI8>FE:,2I3TAN/Y/JZRRU?N2E4 ?2(0N/,,CV29+TB3
M-ALYI5'3JWTNP1BE<=.3Y(2F*\*B1#ALQG9*:F1E]YW3K41$(V"FB3;+SQ=+
M7T71U)KE6J&QY6D'9U6;?KIM$Z!5#1[&^A>[KTVLL<)^RY!\IK=&M451B4^3
MDR=:R8;;4>1"=*MSD)J6KFI+&7-GU#>HT;G*,N,K;LZ/%\F7].5JHQ&91\(K
M-OXX6:38L@%P!D1@XC!-*M&G#2U7"@5MRYI8GH"'#E(ZU7R9::LCZGM1*3*?
M5AR8_2I2I7B9/&=*XT(@;*R!=%.K>3&BW-;6!EB1HYRQXHAUC9GL(+1FRY7:
M[FJ=,QZ1,UM(#B6W4"8VQ(VP5EW]9NP:IZYFP2SB7A1,>]-J5L?4J6\4C#4B
M1/&D8J?PF39*PS1I=Z@*Q;MQ??5%?*I.K2.-RCLWE^"MQE%]ET6Y;:5I0J28
M(GI4IOBF6%YX)&JADR-0+I_3(5;M*<:.))'"Y"X60=&35?S/"W):%'>:)VEZ
MMKSKS7]4U(W;X=73=KKJ:RE1C1Z[NP7YY:4%VU'R2='ORI$8"H89JM)@U*9D
M?$01+FR;+"S,J.B*.O)MKJN5=SHT!R;XNKKV&P\4:M1P6F&Y-$?)%T $Y2/Q
MYMBY.;1T^4Q'9(TC@2F]85]-HV'I^NE63<!+2TT]-D,#,M%:-Z0Y&U"'.5DW
M2;AJQ)@5C5>ZK+:/2)+X@LDPX&8VM(C25'W):[!4)]3)TBJ:XFVFKUM1B/;(
MQ&\$XB:Y5:\\]*(GH%BF!3QD7=#\:,0GP9@,(55*A5YYR76@>7A/ZCLJ"#%G
MM3F;&=;MPILM(YP3:K6367-EB+;,9R(W(C1WJ^*9M-.-R9+*-N2A1N9)P<^-
MI>JU+/F5KU>_5U]([80(2R0G@]:OMI"@0R)Q^6U,=BRI3%G+;;>=;<BQ9"FU
M#(G(46LM5ZOZZNT+3=HVBB8()WW.Q(;K98Q+"!R4W73%J=9G)E$#M4'- K:_
M;-?AHLSWF"PDV&@V. R9B.3"47EA=W6K!L]00J7ER&:Q*EP28CA(?9;MBA"3
M:@U&FO%*@C!M)!M>!R'%BVD1THYHVR>9.@H=&%4:;GWR.1G[9+ELAD27(L=Y
MVE&>0O(;TN RD6R*PJ(K;GAT5I)E1.:&2T3CX)V2%"ZEB*7DXR9!'#$;]ILX
M6(Q?I*IQJ%'%WN91(%A;A$XTV,39("*J.6Q"K]71+R26EJ78$$8A&)(S9ZY?
ML/!CCR8T<TIVWG_%8<J,Z3]8W9N15<9-LV2:D3GA-V7,5ODHI-Q59<9.9VI[
M/(]8LL9,65)#QV['C>-S5V4T$>U<JFIB-/@X#Z/1X#) U#@H?/7A<EB\V\WC
M\YU+.08XQCC&.,8XQCC(CWI^ZG].;W,7_P!6C_\ P&?_ /-//FB?Y9?ZQ?TK
MGU<;_P 6W_J#_P"%,Y^2Y/CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,9B,\I=<K2O<71G1B>PFP^L^J=TVGLM/VMLK5U
MLC4&V,(U#UUM%_I,-%R=BR)$,2S8V/;94%$6PJSLAT#I.78B7FE,F%$V)>]4
M1-D[]]R1%Z?N?!F-DWY12Z"_* ^3SK%6[57C;NBP&MNH>N-M'8>M;E3Z%V7M
M'=.G;6#!=SW>/# 2:AKHT&*8ZUWFOUJUG*_+DKVB48K0^9%@S6V7]_\ _O\
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M=55/^"IW[KO]&4+3/*N[ZW#9Z24US ZIT73ML%[;WB$N>^C]UI$:^]:JEV_
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MB-W;'U,^:O4@^6)#WBYQBJ"9S+(!J+"9=R1?6E")L8>,CDJILO[PK_"B+_\
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M.,8XQCC&.,8XQCC&.,8XQCC&8YMM6/L&5[4E:5J(O>%,5VJ:*L+<"%/H,?6
MB >OUMC;!G;(A6?PLY)@M3PDB*"9I#4DPR6B-NY5$_R*W>LT432K&B6;&^8K
M>*7.U+$5UQNT.Y?=C5<$ZINH<A_X$R3$^2)R2LB".3#BC[_WR#QG4,W5\C7T
MBLT[(M5&%7:4F"RT]4MT4=J7;V+=P[=-SO\ #GQD5T4FXHU8N21?;0MVMA):
M:USVMV<+KYX3954XP0S%O)REV&Q2[0Y/(/I[56[3HVMDP]7KY8J:(,PFQ\.H
MUZJBY)0X\.@"W9C#Y1V:,O+;1%,]*BOPTGQV>96QK&+$;AHVT*Z)@7[TQF1-
ME,,1V2<5UR?+FO S&%UUX6R%D6WK*FU]>,0Y4><M;)>X+6563)KLY7GB37MA
MIQB$_&@PY#\EX6T:;KH<!@WY1,LL$X)/DZQ75([?7NRD=)K,TBKUJL["20#V
M4W.G6=:(]TA;&NNNV:R+Q #DLUDB5=J+96M1[VR.'6B:2?J4(_%,"'WY.,L=
M!UL-K421[&;+F57*D1(S;4-%*O<J:ZU*8\KLAI)C3"3E8F%6$Z]";:&>Y%..
M^(#E:OM%M9SVF%DU<"%!N.=&FRG79Q"-FU<V=.,&/R8S_@3\@J\9$$+466)[
MCQU[4P),<R.0.I_8^Z=@HIPC:=?(I@Q5=IURJ<YC)1+9$/<7+$E UY)>/'<(
M21#82,ZJQC&T!#7M):(,>,H<]Z;%ZWTE7:6.,U"M5L'DEV%?.;)&=VI%>D3=
MX58,T:!\I)BD1Y5D1^2BN&:.CPY?0&M+/5[<IZ?3I6,+#K;*O=%7T1Z-9+,1
M&"&0 $Z<9(H$LU@4BR>>J- "LEQ4OI:VW)GLB8I\W:YG9VO[;J AL>JGYY"E
M%Z[;"46\"AQ$IKYNF0__ +J5RHQSK-2FB#)&0Z>FXC%A^'TPITE=YJ&!7EI%
MB>W21Z:U@7S51.BMM6,>7!9.N?=:9M%L7/\ #I<XXI3FWX[0I%;XV'>'F-@E
MCIFPLAUK)KG;^3>5%CIUZZ@2W7JV3#GOA:1V7GZA*UO:OAUX2AKW8TEXRE.H
M$AGB1IXUOLYS7.JXXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9B8\JG<[%J.NZ
MCVI0B#H&ZY-637[IF%G+,J15CL&!8Y@R0ZWE*WF$EJH+E1VW%*2PYZRIK",R
M'LK[CV*5T2^EWM)9M#*KO!X=HD=U.(!FQ7'8C;P"O035B<^!JFRFG A;\ [>
M?.WNSEZ=AZ>OZITHEGX3-IRDM$K;AP);34UQ@R'92!)%>PX EN@%QJ.W&7%E
MGYP[/0>.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9:]W _S-Q/]L?73_P _
M]:\W/07[(#_W!JS_ -KW&:)VC?L;:_[RZ,_]W4F:M7]*W_Z[]*/]5=Z__5]6
M\V'LW_Q5M_M(?_ADY<ZK_+@_ZLC^EG-;O=*)]$UOIG3L&-*A0%4T!NZ^O(8=
M1&LM\VZ&9L]2FNR\(0F? J^F"M!$A83ZY#0 \6V%*'*C.6LNV[O<3A>D2Y1$
M*ES3AL)NF[;$8U;=3AWZ$Y+%XC5.I@+"%_BQVUI_=MMEE-T10%]SHJ(;CH\8
MKO\ YR P30BG5 )753\LLDFI:KLF[>JHHJ1FUD%,U%?S(*@VJWV(;6Q<G59-
M$4]LP*<-EW6!P@+KO8UQI)6CQ7Y#!*VV;=MZ#U>%9RD!^"%MW9+<.R(11PTE
M, ;[339.$DD54(Y@ ;D1OL-/"\J(J-MQ&2<4!5%.J#1/Q455$59<46S,D%%:
M78G!52V1!;=,"!-]S)]Q!0E14'@VSK:QZ/ZT4D..="$X^V;6^?VS;:R;'6"!
M(<!NEFM/4L4;#/3A):BRQ$:T7ILZ$+21EEOB3U*L$"!<^OTR+ C%D-S+%XBX
MQ6,T@16G (%1#X?"GB T$Q>0E;94#%";94' 4FIB*4'6R8BMHFR\TU)XQ)"1
M>'=&00A51)M40W$4543<X@)$<CJ@QKK^8N_:(V]K@QGUIW5(V)O+6DESQ<F"
MI3UKIU"V=58&5>&&0MLK=D%W<PE:E>@)ZI$J@(846,9G7#Z<B;$D!T222PY"
M>8TY3KT9Q?A)IQLFA^$9);[H([4VU5QAYM>O*1'VOA'WX-NBGT&)"X7?LK*;
M;;EO7G6CLCV!Z]:JWKG5]4$&]4WDG1Z]NXA815CFU^7$-4#?6NP&O3\H+8P$
M;V3>*[LO8Q# I_TI9XQ3@UB 314BJ2GGJ-A A3I,-)#IA)9%YR(+9-H:*+T-
M\WP0VS7B9..P/$FPH+I :%S11*D63(CM2.4 DTXK8OJ2$HJA-R&Q;+A(4V<%
MUQ=EW52 2%4X5WN)#^4N['RJPHC7=&Z110M45.O5O,815]I,5&C.S3T3-9.-
M,L;71%!DI16.3C"J_"7$ICZBYQ]%0>DMMRX-@6GX".(+DR6K\EQQS<G(ZNO(
M@%S W6,JF*"HJ1KNZB "<U$54*Y&TE*&XL,<MH!'9 =0&]R3@+9'=A551404
MV#WQ*@;[*E1ZM[S]UCP,#8J!UYI=\@1MNZBUV,M@Z@;2*,S;3)=TW+I^A\OA
MM@1PSJMEG.O5#..0FH:-AS",0Q%JMH!ARBQ+<DFGJ0,P>G.L+X+)?)I7HXJ+
M:)*1V;[]E3_$!->#=5Y""H*XV9"A9,U/FD(DW&;-.<RTAHVZ2*2\E0C[HYP_
MC2C 2IMS%7B03$2X<D\!V3\I[JB!<#<+JB;I]>TE4XX*]OL4;L#1LZ^!C]1=
M.00$C8+57MFUJX!F(%)Z;Z4ML60NQQQ-E9.W7)YBPU"U008FW.OT])5H%LA=
M.6XILISH3O/,I5H9HVV<<VC4GK26TJ<"DVH,\"@ZVIG4&19LH:I$4!8!!<_%
MR Y:(S#$5(A=%P=@ALG^4B%Q.<:$V:"EME:[T[^U(.CV"T:7H,(+O?7VIZS%
MN\RLWD+9K5J316O*]UNC(IYAN\0A1P=)A:Q4\2<L(JSUN/L^$7-!A@E3"1L*
M^.FA255MJ6^1PGI)JRCC)MMR9C[D]>:*LJ0$BR-D0";<6.H"9%OQ+;#.D-)Q
M&RVB2&F@1Q1<0S98;&,G 7,1"1>5NO$ABCJ*0H/<E1;<[[7;?&H.W%:K&K)@
M.N;#G:Q4736FITJIZOTC3=T6^]C))^:8GV>PJN=]W#MD/"L9I)T35GW78 0<
M'1&="#14L:F9ARJQQR2AN,I(4.9PHY(F.Q&F20! 6VT:8BQB(!X"=38C(]^-
M2G>GN2&9@BTJ"XK7%PHJ@TPV^9BI$2F7&X\\B$7$@*JH*)LHH.-:%KN[D[E6
MM>"JR4,7BY2*=#JE6#,8+F;#.V##$3Z8/$PQJI3DTC8HY\/[/'LX5-5(GLPW
M&&YF'&$9Y9#(LN/DX(LM(ZKCAKP@",$0ND2EML+:@7$2]-A5=]NN8Q&S4Q;0
M54SX$ 4ZJ2N(*@B(F^ZDA#LG?UV[\HU2<I5E*L9PI.<I5C/S9QG&?#.,X_[\
M9^;/*W?DF5FQKJ\3+1*I<"L%2=JA"2QV4#$L8+3F0P&KS+J<**0.5*3F"&J0
M^?82DA*U-P!4&9*E*:;C/9115]D6T>)P1:4A!#)>$5(W$9 ??;=3=(0%/\XE
M1$WW3)^6:DH(*J:(I**)NO"(*9+TWZ""*2_ B*J]V47RMDF5P%UGL.Q7N!J\
M-2K-.V.4(H#CZ,@-.:M4PNZSE]D4P#?9:(N$Y#?AF+ Q'];E+6TU'9===:0N
MB<AAMDI)O-C'$>,GN-%;0-]N)315'A3SEOLG>J[94%IPG$:%LU=5>%&^%>-2
M7N1!VWW7S)MNOFRA^5LIXXQCC&.,9G#_ *.W_P!J/J3_ %"W+_Y<G.:AKG]C
MTC_;Q?\ G#F<T[_E1K_9O?\ ++/Z*O.'9T3'&,<8QQC+5.U/;.L=5QFL$3M<
M[2W)?=T[#5K'56I]-C*H2O=QLT6H6B^E\Q5WFX4*I#A8*HTX\8*3S%I@82B,
MQ%AM3)DIEA3(HBKOYD3JJKW)YOW?WD15R#/WHG79.Q>D&L9%>W .LG?"L&;1
MKI)JCQ0*-9M#!K#\$1O&$9/P3=+.6<^Y*I%:AAQ-J8GVT9/BNRXHM,8M)9'A
M78EW3WJHB]>_==NGPYT=$>55ZT=B-LQ=*T$=LAN^+[&]A^L90<<#5:$BO7GK
M?4YUSM!XSB'<B,M%'MX8=,3K\W B3YA>?%FP# D ^/(8BO[_ -_[_P#SD%%4
M[_@0OWEVV_IRN=_>4!U_UVVQ"UQ;]/[_ #56B$]+A=@;UK%+KKFF-7&.P=^S
MK750RRFK!<Z]:K+,,VI42.9:U;3]@*J,0H)EV; Q,]M&&10=TWW3S].NZ[)N
MO<B[=/AV^C*+V=Y57JWJK:/8_59O&Q31#JWIEW<&S+/5:K#,4^3*9M=8I;FI
M:>44=B2[/MMFP7:GC9X2*.:K8<C8HH<W;!IN$:&BW]_[_P!__G((*KM]*[?T
M]?W.B_P91;_E9]<L2LT%/6;M7)[+1]FG=8E.IL6O:;=W0(EUK3X3?1:V2BN=
MUHTU(IJ=5V,#8!Y$=M>:3*SB\*O00[IM;L-ED>'Z4VVWXNNW>J?!OWHJ=W_#
M+BK-WOTF"ZAZ^[HB6K3;M5;7AZ6=UX/$QJ^$LITCOVV5*D:]$$';S8ZE3J@\
MJRW,1!LA6YVX!7*RVT1E%#3;$3"G6.%=U'N5-]_WD55[OW/-W^;)3U)V4U=M
MWK=4>UD$F_2]0VO6:=M/&=A+%UW-4I;(E\V5*6N:T4(U^#!!CHDR61-P#A.M
M.P(RS LV1"NQB3[(*FR[>?NZ9XEQ[I=0M>)2Y?.S^A*:A5F#4S"[-MBD!4>]
M=@J@&]A@&5D#4=*29"D6JLW!F*K.%XK%A"G7,(&$X<IYC9?@7X>[S=V_\/3*
M'=\H#U9 R]TM;2VC5M%#M'[_ ,=;3EBW9:Z5K^O6K8ZM6:^V_ANC$25G7@R+
M34MC"EO.3FA).-($V&1)%,AA[1:6W_>QLO3IONFZ;?!NJ?TIE3'^T/2^@[5O
M@&R[]Z]U/<M>UM%N6QPY?9%&%7L+JNM#I-JC6&U0))=HM J0,(<DV?$T@TU"
M'@RV3RU-#)J);ER4R4<5F"<ATH<=YZ0S&(R5EI^0+0/NMMJO"+CHL,BX2)N2
M-@B[\*9:A!BA+>L&XK0S9++$5^6+8H^\Q&-XX[#CJ)Q&VR;[Y- JJ@DZXHHB
MDN4!?MI^3FJ;D2K;*V5U4K;YB]3]0P@MLNNNA#\S8C9FO[7*42-'(E([OO-&
M.WVJWDD*;PF;#(7.OEI:&7;"-<EY-K4NH&'$=:N;%MU"$T,93J%Q!!&L%5]]
MUX:\0A)ONB1Q%K\E$1,2[I/3DAHF7J*M=:4"%0*&TH\!V!6Q;>]]ZA69G.54
MVWE$3V_&JKD=A^R?DZ@$@D8O;NE>O:]"]CK_ -7Z44W/)UEK5F;LVI9#W"PI
MU:_-/K1,!9FWM!F$\K V>.(2R)&0)$*?;E2CFIM0O-SVG;JS<;M.#QB#DQ\Q
MF<MEN.*R.(UYB^#M-,$I;J;+8-FI  BD6M*:;9=KWF:&J;=JN8M:;4&.)0>9
M(=DGX-PMHC2>%/.R!0=D;?=-UOA<,B62+%OGJ'UKJE_L.MI^BV[&HM;T&Z75
M=AZ@UV7L9[5UNK=.V0.F%K=9:Q7!TC5QW806'9X9HL/CUDG91XE;<8M9!\2?
M;6-S;6Z1TM+*;8)$ FXR2Y#K_) N!#1OF$7"I\MM'"_*/E@AJO .US64-/2K
M)*IJH-:LUP792PXK4?GFBFH*XK0#Q""N.JV'Y *XXH"BF>]>ZSM?3(/9][DM
M1V30,*W:L5+5V-DT<Q2TFM<98FVB3.9VCD1(S*IR$$:G;Y<R&=P.;S- &Y;[
M.7X$IUN>??75I&C1+*UGSHL-$2+'E2GGVF-@1L5 '#)$(6Q1L25%(6T0!5 Z
M93KM.451*E3:NFKJ^7/55E2(D-F.](W-7"0S; 24"=572!%0"=57"%352SZO
MO<SKM3J5?+0*V[J6X&*55;18FJ? V]K,%/.3:WI=[L"D"DW:K0&K%?>(ZC3%
MV%@S:"XBOBJ+.8NYHG JJ7BS>)S-;*NW1>O=T7X=OZ>G3S],MQ+>5RZ25ZZL
M46Q;1#A)X[<!#2&Q3T^R46+2]27(?U]-]B\3K]9YEOBQ&*@5KE=-4JOV<"T=
MB&]GBRM.A-+?#&Y0UD4 E3?;S;IW[JFZ)TV^E4Z?!UR]2_=A-#ZKIU4V%LO<
MNL*%0[W.%C*3<[=>:V J]P)' 1&T!!]8.DR,8:>G&:X(*&Q$07)E/DQD"5,@
MMOL,K7AD-E^!<H1?=7I^VSMF0OM!H-+&AY\ 7NE[]K%(RWJPD4/*J@V!>UX-
M936I<ZUMNU6(P4S&=?L[+]>;2HPP]"0QLO3HO7NZ=_[F0UI_RD77C<%<1L5@
MZ&U]J'&M-I;0F['V;LC4-:B"JYJ7?MIZ^'BY$!&V 5.L5 K9JE.,U[8:8SE(
MG"9P<=)-0;5.S7F7]_X,<*_ N_3HB+YTWV_=^C*9VUY6CH]JH-/,1]O@=II9
MT&1[) XNH[!3+<JZ:P$;":UD4F4XD]:A0 P7'V9)9,T1DO&?BP:Q:Y3ZFU5X
MDTPQPK\"IU1.O395\RY<(YW@Z:LA:+9'NU77MJO[/MIJAZZ-N[?H;8N\7*ME
MF -@K=7G+.XC&BP4W+@B2D2 X^N"0(C(DCT;Q. B2QLO7HO3JO1>B?"OP9P6
MKO1TNHR;JJY=KNO%6QK>WPM?[ P>V_1!:Z5>2,FT1(=/M#<PXTL'9GGJ1<LX
M"$4QR*&*I8I3D=$4,0>CL;+\"_P9ZQ[N7U(J]N+T&Q]FM#@[Q7ZZ4MYRHD]J
MTF'8Q%5"4"-M8M8R(=\TB?#"#]82V-AR2;["(;=)4NT9>]BLO36V-EVWV7;X
M=NF3!4=CZ_O[]EBT:ZU:X2*:5'@K8S63HTVNMFBM:!7,8)-X'29'LPC/J5GK
MEFB0Y?HI#X(\(*MMJA$8CSK(;*G>FW]]OZ45,K3C&.,8XQF&[RSO^9C4G^T^
M3_NH7YW_ /!\_9#>_P"Y@_\ /,9YL_"8_8SI[_?I_P#I\G,R/. 9Z3QQC'&,
M<8QQC'&,<8QQC'&,<8QQC'&,<8QQC+7NX'^9N)_MCZZ?^?\ K7FYZ"_9 ?\
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MQC'&,<8RQ#NUUPW%N<KUCVIU]LFM NX>K6ZBNUJN(W'$M+VM[?!M&I=BZCL
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M2W1W_$9O_P"34U\9./)OM#]&*_VAB?4X]U'LT](;#U!._7Q^Z6Z._P"(S?\
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(!-UQYYSA_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g120909g99i99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g99i99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &?R^9E(X0DE-! 0      $(< 5H  QLE1QP"   "'C\< E  "')R,3DU
M-C<V' (% "%-:6-R;W-O9G0@5V]R9" M($=R87!H:6,@,3$R+F1O8W@X0DE-
M!"4      ! $H4LF.D&-V52IGS> .^ZD.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M @.__C4  @ ".$))300F       .             #^    X0DE-! T
M  0    >.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             #    !IX          0
M                       !              :>   #
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   #      !29VAT;&]N
M9P  !IX    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   P      4F=H=&QO;F<   :>     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    (.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( /8"'@,!$0 "$0$#$0'_Q  >  $  @,!  ,!
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M?2]H?I;5?B546(UHU'_<+56"M0YM#L4>Q05LJ3>:EL;49P!=/H%J'>FK*Q:
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M:B5.8Y E1U1;-BMFVR((8EZZ_P!3IEQ$<1'$1Q$Y+]H^SI/85OKVEM(5^#M
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M#\2QQ$<1'$1Q$<1*TFNSM;%=IZ;U0C4/:%@M%IUD?V@6V)7:I@KJ;78X3/3
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M>N[-A5"IT#5FLM.JUV*V\9KH2N$+)7U0-5;()R3=_(%<SR5,JA>;;8P[RAC
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MQ$<1'$3DGUE>LXKQ .[#(JOZ/H&DJDR)<L<L!KS7-(OELM9Z$'M#5DLE@
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MAZ8]\>(T\\VVY*D>R_)]B.A:DJ??^-%DR/::PISV([[OI]MIQ20!.2 2 ,G
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MU#Z1-FF:QC2H4IZ@Y ["3LW8+;,D)G:.0$]'3K:E%2W,7M"@.QP23[2.1(&
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MAH KM%[>VSFB@PBA\A%V4[L%C9[SCZHSMG:%I0,1([AS^/7*7%J.I^KFMI9
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MOW$L<1(&VUUOUENZX:MN>PXQ\G+U 0/&*B)A6,H' _6CL2%%2;*0!CT9R88
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MV0ADA7H+JR!RTMP$6 D0<PVER=(*K$AI<K,I3J,D@@(HA""003*AHF"9Z?\
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MAA 69/D2'A:(\=$%3"8[.$;K.T-=;8+;-7>UBH]2L;"=M=F>)6H[E2S)WJ
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MZ0'<8 V,ZEZ;ZXK.,2?MX25R-CJDSH,-,TEB)"5-G0X>)&9,EEM:)71SQ!M
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M9!,K?:G'NT.O!HYY.SJ5J""U+Q3-F3LY,W?8 @I680Q<6%)97 ?='$"LQV'
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MB&UM6#V%="9JDU@WK:_SZ50@Y Q;^XNRB;,B)L.\)'.P(VJJ)K8T1':1(,K
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MZS:46VA>:?-3E:$JRG-QOF,IRI.,Y3G"[&A>,X\_+.%H0K'Z%)3GSQA+/O\
MP9-)_P!R,S_3*]?ZS<1.>.Q&[!"QL.E.^'WOY]N>:OM2H5YU9NF1-61J\:QN
MTJN;#?(S3S,C7Y4JUE^WP1LH389@<+](,H:,,NDFA23S^GO^1P/:?EW9EN@
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#B?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
